Clustering O 0 4.786250792676583e-05
of O 0 6.3334514379675966e-06
missense O 0 3.095160354860127e-05
mutations O 0 4.042895511702227e-07
in O 0 5.993947382876286e-08
the O 0 9.191587651002919e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.6865205907379277e-05
in O 0 1.933625526362448e-08
a O 0 1.3475421667408227e-08
sporadic B-Disease 0 3.1271167699742364e-06
T I-Disease 1 0.9999997615814209
- I-Disease 1 0.9998559951782227
cell I-Disease 1 0.9999608993530273
leukaemia I-Disease 1 0.999995231628418
. O 0 1.9424364836595487e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9983238577842712
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.957868319863337e-08
is O 0 4.871267389461309e-09
a O 0 1.1748899630958931e-08
recessive B-Disease 0 4.703725267063419e-07
multi I-Disease 1 0.9948827028274536
- I-Disease 1 0.9999986886978149
system I-Disease 1 0.8248783946037292
disorder I-Disease 0 0.022421792149543762
caused O 0 6.358473569889611e-08
by O 0 1.106839064846099e-09
mutations O 0 2.4915616236853566e-09
in O 0 1.551661688026229e-09
the O 0 9.718467808284004e-09
ATM O 0 1.2913092177768704e-06
gene O 0 3.806404080819448e-08
at O 0 5.1966974723427484e-08
11q22 O 0 1.0224825928162318e-06
- O 0 6.74328362038068e-07
q23 O 0 5.378925834520487e-06
( O 0 1.0977470310535864e-07
ref O 0 2.7080352083430625e-05
. O 0 2.6957387433412805e-08
3 O 0 2.705941710701154e-07
) O 0 3.4944051208185556e-08
. O 0 2.0619889085082832e-07

The O 0 1.7963609479920706e-06
risk O 0 1.7755883163772523e-06
of O 0 6.223298214536044e-07
cancer B-Disease 1 0.6307635307312012
, O 0 3.9825540198989984e-08
especially O 0 5.005371122024371e-07
lymphoid B-Disease 1 0.7737855911254883
neoplasias I-Disease 1 0.999701201915741
, O 0 3.7071746561423424e-08
is O 0 3.1007985068498556e-09
substantially O 0 3.687601690671727e-07
elevated O 1 0.5752539038658142
in O 0 1.4775831402857875e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.20707975327968597
and O 0 1.1164555502318763e-07
has O 0 4.263529085335449e-09
long O 0 7.785599720477876e-09
been O 0 2.006445232183296e-09
associated O 0 1.4588981578356197e-08
with O 0 3.957241290208913e-08
chromosomal O 1 0.9999604225158691
instability O 1 1.0
. O 0 8.186941704479977e-05

By O 0 1.012270104183699e-06
analysing O 0 1.5890273061813787e-05
tumour B-Disease 1 0.9995554089546204
DNA O 0 1.8067828477796866e-06
from O 0 1.745626221349994e-08
patients O 0 1.1059196225460255e-08
with O 0 1.7972215937689384e-09
sporadic B-Disease 0 8.777655239100568e-06
T I-Disease 1 0.999987006187439
- I-Disease 0 0.006168424617499113
cell I-Disease 0 0.0009716067579574883
prolymphocytic I-Disease 0 0.00021523446775972843
leukaemia I-Disease 1 0.6726896166801453
( O 0 5.023025551054161e-08
T B-Disease 0 4.90623751829844e-05
- I-Disease 0 2.8473382371885236e-06
PLL I-Disease 0 0.00015717677888460457
) O 0 3.3720408687543113e-09
, O 0 8.274818608100531e-10
a O 0 3.427410355527627e-09
rare O 0 5.01896515459066e-08
clonal B-Disease 0 6.601552513529896e-07
malignancy I-Disease 0 4.569724751490867e-06
with O 0 1.7233576787845095e-09
similarities O 0 1.585873832254947e-08
to O 0 6.373502614565041e-09
a O 0 6.220734860562516e-08
mature B-Disease 0 1.6765976624810719e-06
T I-Disease 0 0.20038965344429016
- I-Disease 0 0.00015070874360390007
cell I-Disease 0 0.000222762071643956
leukaemia I-Disease 0 0.004336059093475342
seen O 0 3.073912679951718e-08
in O 0 4.3766816837376155e-09
A B-Disease 1 0.9741787314414978
- I-Disease 1 0.9794788956642151
T I-Disease 1 1.0
, O 0 1.5141521814143744e-08
we O 0 2.29374541582672e-09
demonstrate O 0 1.878653677067632e-09
a O 0 1.666504045871875e-09
high O 0 1.2236605506643627e-08
frequency O 0 7.77163844389861e-09
of O 0 8.522200722893558e-09
ATM O 0 7.613557500008028e-07
mutations O 0 2.6593468760438554e-08
in O 0 7.146978475702781e-08
T B-Disease 0 0.0015434096567332745
- I-Disease 0 0.00011211354285478592
PLL I-Disease 0 0.2483566850423813
. O 0 4.289042408345267e-06

In O 0 1.0996830042131478e-06
marked O 0 1.1218405688850908e-06
contrast O 0 5.384670203056885e-07
to O 0 2.4695530953522393e-08
the O 0 4.0805609557992284e-08
ATM O 0 2.680562829482369e-06
mutation O 0 1.219871403890238e-08
pattern O 0 3.447218688279463e-08
in O 0 2.301174184538013e-08
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
, O 0 2.198842707912263e-08
the O 0 8.852243382762026e-09
most O 0 1.2739616028767387e-09
frequent O 0 2.75081490919149e-09
nucleotide O 0 2.8329216750222486e-09
changes O 0 9.137978151940729e-10
in O 0 5.248320111839178e-10
this O 0 2.284650468808991e-09
leukaemia B-Disease 0 0.00031750331982038915
were O 0 3.048962184948323e-07
missense O 0 1.337890626018634e-05
mutations O 0 1.1174787459822255e-06
. O 0 1.3074070466245757e-06

These O 0 8.454366025034687e-07
clustered O 0 2.130475650119479e-06
in O 0 1.1227655249967938e-08
the O 0 6.722842282869124e-09
region O 0 1.1157845314357928e-08
corresponding O 0 4.692504163017475e-09
to O 0 4.219946170280764e-09
the O 0 2.5429491401496307e-08
kinase O 0 2.899795106259262e-07
domain O 0 1.2100136004278284e-08
, O 0 4.556255372989426e-10
which O 0 1.8685643310423217e-10
is O 0 6.492391069201631e-10
highly O 0 1.4373790158117572e-08
conserved O 0 1.7028941812213816e-08
in O 0 1.5968059097204446e-09
ATM O 0 7.53076562887145e-07
- O 0 5.892483301295215e-08
related O 0 5.884820630797094e-09
proteins O 0 9.555098934299622e-10
in O 0 8.02468202998341e-10
mouse O 0 3.195181008663894e-08
, O 0 1.0799543481709861e-09
yeast O 0 6.456214691752393e-07
and O 0 1.3936848120010836e-07
Drosophila O 0 9.334667993243784e-06
. O 0 1.6796640238680993e-06

The O 0 1.2642237834370462e-06
resulting O 0 3.931141066004784e-07
amino O 0 2.0388641530644236e-07
- O 0 1.365738313552356e-07
acid O 0 1.7414095054846257e-08
substitutions O 0 3.170285722831068e-08
are O 0 8.514105531709504e-10
predicted O 0 3.2540825145588315e-08
to O 0 4.096607497672267e-09
interfere O 0 6.963730925235723e-08
with O 0 7.235140042638477e-09
ATP O 0 2.0221950762788765e-05
binding O 0 7.539447466342608e-08
or O 0 3.2452625475798413e-08
substrate O 0 6.593630814677454e-07
recognition O 0 4.719636592653842e-07
. O 0 5.553824280468689e-07

Two O 0 1.903103111544624e-06
of O 0 1.3409884331849753e-06
seventeen O 0 3.8598991523031145e-06
mutated O 0 4.393270955915796e-06
T B-Disease 0 3.98058291466441e-05
- I-Disease 0 3.5251298413641052e-06
PLL I-Disease 0 2.5495319277979434e-05
samples O 0 1.4506238876776933e-08
had O 0 7.989071626468558e-09
a O 0 3.2418705497860856e-09
previously O 0 3.158733008490344e-08
reported O 0 4.185583080129618e-08
A B-Disease 1 0.9994578957557678
- I-Disease 1 0.9978680610656738
T I-Disease 1 0.9999998807907104
allele O 0 7.294841907423688e-06
. O 0 1.2040505907862098e-06

In O 0 7.419833423227828e-07
contrast O 0 4.428875115536357e-07
, O 0 2.6750560877530916e-08
no O 0 8.76325678689227e-09
mutations O 0 6.684037767712425e-09
were O 0 2.3879629384992995e-09
detected O 0 1.6538672653609865e-08
in O 0 8.784791227789412e-10
the O 0 2.160078782509345e-09
p53 O 0 5.169202843546827e-09
gene O 0 9.84337944487379e-10
, O 0 1.1358777807224385e-10
suggesting O 0 1.7043750855094686e-09
that O 0 2.914051777658244e-10
this O 0 7.029438364725138e-09
tumour B-Disease 1 1.0
suppressor O 0 0.228651762008667
is O 0 3.5291534139503256e-09
not O 0 3.8694111803572184e-10
frequently O 0 1.6411837444607613e-09
altered O 0 1.3074460625261963e-08
in O 0 3.219293720491123e-09
this O 0 1.4442080420451475e-08
leukaemia B-Disease 1 0.9340389966964722
. O 0 1.971689471247373e-06

Occasional O 0 2.550811223045457e-05
missense O 0 4.303977402742021e-05
mutations O 0 6.363059128489112e-07
in O 0 7.049016659266272e-08
ATM O 0 4.7680918214609846e-05
were O 0 1.3888910643800045e-07
also O 0 2.1523314686078265e-08
found O 0 4.80503858923953e-09
in O 0 6.678914754587595e-09
tumour B-Disease 1 0.9992068409919739
DNA O 0 2.999037178597064e-07
from O 0 8.932672379557971e-09
patients O 0 5.272845271520055e-09
with O 0 2.739672710916352e-09
B B-Disease 0 0.00010995129559887573
- I-Disease 0 0.00022994040045887232
cell I-Disease 0 0.3790533244609833
non I-Disease 0 0.00011078218813054264
- I-Disease 0 0.0018473222153261304
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 0.43946805596351624
( O 0 2.547177402334455e-08
B B-Disease 0 8.006707616914355e-07
- I-Disease 0 1.422816495733059e-07
NHL I-Disease 0 5.187082479096716e-07
) O 0 1.8054605588346817e-09
and O 0 1.506994529165695e-09
a O 0 9.048851445925266e-09
B B-Disease 0 2.9753998660453362e-06
- I-Disease 0 1.7778097571863327e-06
NHL I-Disease 0 0.0003632363223005086
cell O 0 0.0002302967186551541
line O 0 1.1765552699216641e-05
. O 0 1.2656930721277604e-06

The O 0 5.579156550084008e-07
evidence O 0 3.95227857552527e-07
of O 0 8.913835358725919e-08
a O 0 1.274159000530517e-08
significant O 0 1.2573465824061714e-08
proportion O 0 1.057068743648415e-08
of O 0 2.065290516384266e-08
loss O 0 1.1117228950752178e-06
- O 0 3.207734607713064e-06
of O 0 1.6082896081570652e-06
- O 0 1.097937115446257e-06
function O 0 1.4536531978137646e-09
mutations O 0 3.9062061918393454e-10
and O 0 2.138482030344946e-10
a O 0 8.480895430373891e-10
complete O 0 2.3043892127816434e-08
absence O 0 4.7374356881846325e-07
of O 0 4.1108796722255647e-07
the O 0 3.954109928372418e-08
normal O 0 1.0756131985090178e-08
copy O 0 1.3111395524845193e-08
of O 0 9.610632289991372e-09
ATM O 0 3.659124274690839e-07
in O 0 9.573579706767532e-10
the O 0 1.2478847954966454e-09
majority O 0 8.697046971484212e-10
of O 0 2.314617830734278e-08
mutated O 0 3.982595899287844e-06
tumours B-Disease 1 0.9999986886978149
establishes O 0 1.2255908359293244e-06
somatic O 0 1.9928852452721912e-06
inactivation O 0 2.8778481464541983e-06
of O 0 1.6603941332959948e-08
this O 0 1.1867947735666462e-09
gene O 0 2.2241626318475483e-09
in O 0 3.155369576735012e-10
the O 0 6.388813922342251e-09
pathogenesis O 0 0.00031805166509002447
of O 0 1.3976368791190907e-06
sporadic B-Disease 0 0.2056553065776825
T I-Disease 1 0.9999998807907104
- I-Disease 0 0.001147414674051106
PLL I-Disease 0 0.00038916789344511926
and O 0 1.0210658096809766e-08
suggests O 0 5.2856941046286465e-09
that O 0 2.879245175613221e-10
ATM O 0 1.1060887317171364e-07
acts O 0 5.4134972060637665e-09
as O 0 1.6763589627544206e-08
a O 0 2.1482144063611486e-07
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.005449995864182711
. O 0 3.0752726161153987e-06

As O 0 1.1345038046783884e-06
constitutional O 0 8.558544095649268e-07
DNA O 0 5.050337676948402e-07
was O 0 3.6373787537513635e-08
not O 0 3.589879782328609e-10
available O 0 2.2972832525169906e-09
, O 0 1.4054613028946505e-09
a O 0 2.1099531011259387e-08
putative O 0 0.15374070405960083
hereditary O 1 1.0
predisposition O 1 1.0
to O 0 0.1136406734585762
T B-Disease 1 1.0
- I-Disease 1 0.999997615814209
PLL I-Disease 1 0.9996891021728516
will O 0 1.2773662128040542e-08
require O 0 3.863284803173883e-09
further O 0 6.1416720598117536e-09
investigation O 0 3.5964696110113437e-08
. O 0 1.208957023379753e-08
. O 0 1.0771020697575295e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00021881921566091478
kinase O 0 7.652372914890293e-06
is O 0 4.237448170130165e-09
involved O 0 3.437696127761569e-09
in O 0 5.285812343380769e-10
the O 0 1.5946328701943457e-09
modulation O 0 1.425473072913519e-07
of O 0 2.0139687251230498e-08
the O 0 6.939519892057433e-08
Ca2 O 0 6.6419252107152715e-06
+ O 0 3.466588395895087e-06
homeostasis O 0 2.541493131502648e-06
in O 0 4.0356681552111695e-08
skeletal O 0 1.7205957192345522e-05
muscle O 0 7.510392606491223e-06
cells O 0 1.1060566976084374e-05
. O 0 1.4973661563999485e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.16938599944114685
DM B-Disease 1 1.0
) O 0 6.390851581272727e-07
, O 0 1.7029657684020094e-08
the O 0 1.004262184522986e-08
most O 0 1.3818420185884861e-08
prevalent O 1 0.9283910393714905
muscular B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
in O 0 4.003315368095173e-08
adults O 0 1.4235054024425153e-08
, O 0 2.010505983918165e-09
is O 0 8.259649075803566e-10
caused O 0 5.829390659073397e-08
by O 0 1.1363167295996845e-08
( O 0 7.690159264939211e-08
CTG O 0 0.00016229521133936942
) O 0 9.031074554854968e-09
n O 0 4.569418621258592e-08
- O 0 5.5964552103660026e-08
repeat O 0 1.7547730379874338e-08
expansion O 0 1.3391840525400767e-08
in O 0 5.438124950352119e-10
a O 0 4.678327725216036e-10
gene O 0 2.579609859054699e-10
encoding O 0 1.8171237847752764e-09
a O 0 3.2268183680628226e-09
protein O 0 3.262783465629582e-08
kinase O 0 2.8860941370112414e-07
( O 0 3.063424003357795e-08
DM B-Disease 1 1.0
protein O 0 2.0264512841094984e-06
kinase O 0 4.874067371929414e-07
; O 0 4.414594023671725e-09
DMPK O 0 1.690641511231661e-05
) O 0 9.196694517044079e-10
and O 0 4.507813844423225e-10
involves O 0 1.7648148498139449e-09
changes O 0 2.084694195048087e-09
in O 0 2.75453215792254e-09
cytoarchitecture O 0 6.249967441362969e-07
and O 0 1.936083471321126e-08
ion O 0 2.7586643227550667e-06
homeostasis O 0 4.4400909246178344e-05
. O 0 1.804004000405257e-06

To O 0 5.15897227160167e-07
obtain O 0 5.405983074524556e-07
clues O 0 6.92381263434072e-07
to O 0 1.0865769617396381e-08
the O 0 1.5199683289779387e-08
normal O 0 2.2533535926072545e-08
biological O 0 1.5476213377496606e-07
role O 0 6.835752230927028e-08
of O 0 2.0752379725763603e-07
DMPK O 1 0.9999971389770508
in O 0 7.218849873424915e-08
cellular O 0 6.043102303010528e-07
ion O 0 2.4050052616075845e-07
homeostasis O 0 1.0354197002016008e-06
, O 0 5.908078914984571e-09
we O 0 1.9991106547934123e-09
have O 0 5.999923891053527e-10
compared O 0 4.86246731767892e-09
the O 0 1.1619553319519582e-08
resting O 0 6.217052259671618e-07
[ O 0 6.337152314017658e-08
Ca2 O 0 5.273813741268896e-08
+ O 0 1.1581430925389213e-08
] O 0 6.705669353124222e-09
i O 0 2.8276312402653048e-09
, O 0 2.7110605427260737e-10
the O 0 1.5405736686346927e-09
amplitude O 0 2.6716703516171947e-08
and O 0 3.835158413068029e-09
shape O 0 8.868267542538888e-08
of O 0 8.397060469178541e-08
depolarization O 0 2.1054158878541784e-06
- O 0 1.8159453247790225e-06
induced O 0 6.170734195620753e-06
Ca2 O 0 1.7530186369185685e-06
+ O 0 1.6499988930718246e-07
transients O 0 9.577002657579214e-08
, O 0 5.694043569981488e-10
and O 0 5.582579398755172e-10
the O 0 4.091921912419139e-09
content O 0 1.9137610607344868e-08
of O 0 5.2097583136401227e-08
ATP O 0 1.3703788681596052e-05
- O 0 8.681440704094712e-07
driven O 0 2.6831639843294397e-07
ion O 0 3.527096623656689e-07
pumps O 0 5.621573677672131e-07
in O 0 1.6696452220799074e-08
cultured O 0 8.525681209903269e-07
skeletal O 0 1.6945725747063989e-06
muscle O 0 6.593530343934617e-08
cells O 0 7.779443222943883e-08
of O 0 3.889088873165747e-08
wild O 0 1.209400295465457e-07
- O 0 7.596667472853369e-08
type O 0 2.5023365424203803e-07
and O 0 2.3182258246379206e-07
DMPK O 0 0.0034314654767513275
[ O 0 5.868592438673659e-07
- O 0 8.865171139404993e-07
/ O 0 1.0463055332365911e-05
- O 0 1.2924999282404315e-05
] O 0 3.11409371533955e-06
knockout O 0 0.00041129448800347745
mice O 0 1.2666542943406967e-06
. O 0 1.1887441786484487e-07

In O 0 8.927835551730823e-06
vitro O 0 3.0483268346870318e-05
- O 0 6.818485871917801e-06
differentiated O 0 8.197713214030955e-06
DMPK O 0 0.0008739361655898392
[ O 0 8.086021807685029e-07
- O 0 6.066690048101009e-07
/ O 0 2.7828712063637795e-06
- O 0 1.1839171065730625e-06
] O 0 2.98650746799467e-07
myotubes O 0 5.298986138768669e-07
exhibit O 0 5.054449747632361e-09
a O 0 3.978885221300743e-09
higher O 0 3.049072105909545e-08
resting O 0 9.18623356938042e-07
[ O 0 1.1766339724772479e-07
Ca2 O 0 2.2682223743686336e-07
+ O 0 7.616107922103765e-08
] O 0 2.5671649694913867e-08
i O 0 7.958745662506317e-09
than O 0 8.738166856758767e-10
do O 0 1.2715679620356468e-09
wild O 0 5.023485627475566e-08
- O 0 3.866655617912329e-08
type O 0 5.5417299194004954e-08
myotubes O 0 2.813972514559282e-06
because O 0 3.436633866371608e-09
of O 0 6.516040151893776e-09
an O 0 4.800327912946045e-10
altered O 0 5.031998817628391e-09
open O 0 3.933894987540043e-09
probability O 0 1.345137889963155e-09
of O 0 6.017507381272935e-09
voltage O 0 8.696712825440045e-07
- O 0 3.739031058103137e-07
dependent O 0 6.846777722557817e-08
l O 0 7.52532471892664e-08
- O 0 5.385077272990202e-08
type O 0 3.0916581295059586e-08
Ca2 O 0 1.13798186873737e-07
+ O 0 9.266128131457663e-08
and O 0 2.9711779703234242e-08
Na O 0 8.301403795485385e-06
+ O 0 6.233408385014627e-07
channels O 0 5.560257250181166e-07
. O 0 1.3451005997922039e-07

The O 0 4.4599975808523595e-05
mutant O 0 0.00013541564112529159
myotubes O 0 0.0001525527477497235
exhibit O 0 2.3589065278883936e-07
smaller O 0 1.251850534345067e-07
and O 0 3.193060749140386e-08
slower O 0 2.1312234821380116e-06
Ca2 O 0 2.300903361174278e-06
+ O 0 1.1307606939681136e-07
responses O 0 3.017729621745957e-09
upon O 0 4.4779344676726396e-09
triggering O 0 2.523453446201529e-08
by O 0 1.1835576962937466e-09
acetylcholine O 0 6.004302122164518e-08
or O 0 5.5627378259259785e-09
high O 0 7.510784172382046e-08
external O 0 3.546129221376759e-07
K O 0 1.3941503311798442e-06
+ O 0 1.5447576515725814e-06
. O 0 1.905720665718036e-07

In O 0 3.2049959486357693e-07
addition O 0 1.1476314654146336e-07
, O 0 1.9872240741847236e-08
we O 0 1.1510271624715074e-09
observed O 0 1.2802168214420817e-09
that O 0 1.933815468868616e-10
these O 0 3.5373348694633933e-09
Ca2 O 0 1.8337188976147445e-06
+ O 0 8.197660008590901e-07
transients O 0 1.429375942052502e-07
partially O 0 8.128296258291812e-09
result O 0 7.716334238239142e-10
from O 0 8.256010874951869e-10
an O 0 1.8768009368841376e-10
influx O 0 3.575415519208036e-09
of O 0 5.672907033016372e-09
extracellular O 0 3.6511693224383635e-08
Ca2 O 0 4.671145958923262e-08
+ O 0 1.450950470882617e-08
through O 0 1.678405747718159e-09
the O 0 2.788969277744968e-09
l O 0 2.846844004977811e-08
- O 0 6.065642565999951e-08
type O 0 9.265968969884852e-08
Ca2 O 0 1.6551647377127665e-06
+ O 0 1.7273574712817208e-06
channel O 0 1.0767195135485963e-06
. O 0 1.543389771541115e-07

Neither O 0 2.7614421924226917e-05
the O 0 6.674943620055274e-07
content O 0 1.504953672792908e-07
nor O 0 9.964510638837965e-08
the O 0 1.3963290967922148e-08
activity O 0 1.4849309337705563e-08
of O 0 1.2037079955007357e-07
Na O 0 1.578521005285438e-05
+ O 0 4.226021417252923e-07
/ O 0 2.880072713651316e-07
K O 0 3.89821707358351e-07
+ O 0 3.330330287099059e-07
ATPase O 0 4.31883137252953e-07
and O 0 3.569530093727735e-08
sarcoplasmic O 0 2.7342632165527903e-05
reticulum O 0 2.5358027414768003e-05
Ca2 O 0 1.6609252497801208e-06
+ O 0 3.790089806443575e-07
- O 0 2.426703247238038e-07
ATPase O 0 1.7055783985142625e-07
are O 0 7.500327026122022e-10
affected O 0 3.764640599257518e-09
by O 0 9.314731208576177e-09
DMPK O 0 0.0016925603849813342
absence O 0 2.499376751075033e-05
. O 0 5.0909220590256155e-06

In O 0 4.4804485810345795e-07
conclusion O 0 2.8830132237089856e-07
, O 0 2.1694772200930856e-08
our O 0 1.923436698803016e-08
data O 0 7.495311038496766e-09
suggest O 0 7.773654608911329e-09
that O 0 2.2406323463286526e-09
DMPK O 1 0.8894376754760742
is O 0 6.449689671228498e-09
involved O 0 3.2423033147210845e-09
in O 0 9.721540239482351e-10
modulating O 0 8.635647219534803e-08
the O 0 5.743807651725774e-09
initial O 0 4.740361436716967e-09
events O 0 8.996136058314619e-10
of O 0 3.2012854589424933e-09
excitation O 0 9.766802122612717e-07
- O 0 4.712274403573247e-06
contraction O 0 2.399223149041063e-07
coupling O 0 3.061053064357111e-07
in O 0 1.4215194354960659e-08
skeletal O 0 6.523903721245006e-06
muscle O 0 3.6293127436692885e-07
. O 0 1.1789152409846793e-07
. O 0 6.975840847189829e-07

Constitutional O 0 0.0003679512010421604
RB1 O 1 0.9999394416809082
- O 0 0.0001472852163715288
gene O 0 1.380363414682506e-07
mutations O 0 2.0335777506375052e-08
in O 0 1.2662410009411929e-09
patients O 0 2.626915929226925e-08
with O 0 9.511246901183767e-09
isolated O 0 1.564738340675831e-05
unilateral B-Disease 0 0.0005108107579872012
retinoblastoma I-Disease 1 1.0
. O 0 0.00028567505069077015

In O 0 1.1549849432412884e-06
most O 0 6.169982214032643e-08
patients O 0 4.783816365261373e-08
with O 0 3.495230105343694e-09
isolated O 0 6.430161647585919e-07
unilateral B-Disease 0 6.6590118876774795e-06
retinoblastoma I-Disease 1 0.9999997615814209
, O 0 3.9795745010451355e-07
tumor B-Disease 0 3.723354893736541e-05
development O 0 5.593968310790842e-08
is O 0 1.0247215298520018e-09
initiated O 0 1.3640709672912976e-09
by O 0 1.4471238096724903e-10
somatic O 0 7.402454116345325e-08
inactivation O 0 4.7302575012508896e-07
of O 0 7.333814000531902e-09
both O 0 1.3576960666839e-09
alleles O 0 1.188233067495048e-09
of O 0 7.3767143504710475e-09
the O 0 1.0066943190167876e-07
RB1 O 0 0.000886287831235677
gene O 0 5.659422299686412e-07
. O 0 5.373820499698923e-07

However O 0 4.027260160910373e-07
, O 0 1.6098312016765703e-08
some O 0 1.1394784005247516e-09
of O 0 6.1775873305691675e-09
these O 0 5.186228335674059e-09
patients O 0 5.518602961274155e-07
can O 0 2.0224412367042532e-08
transmit O 0 1.5238850210153032e-05
retinoblastoma B-Disease 1 0.9999545812606812
predisposition O 1 0.9142910242080688
to O 0 3.2695805884941365e-07
their O 0 6.331715098895074e-07
offspring O 0 0.00014247790386434644
. O 0 1.8819217757481965e-06

To O 0 2.9219867769825214e-07
determine O 0 6.630367721527364e-08
the O 0 1.8715232030785955e-08
frequency O 0 5.0436085530236596e-08
and O 0 1.834949081569448e-09
nature O 0 9.598010386469014e-09
of O 0 2.7470308694432788e-08
constitutional O 0 2.9280950002430473e-06
RB1 O 1 0.9999781847000122
- O 0 2.1467553779075388e-06
gene O 0 7.644775479320742e-09
mutations O 0 2.053689662773195e-09
in O 0 2.1517013171212795e-10
patients O 0 3.3790070741446243e-09
with O 0 2.4013409039014277e-09
isolated O 0 8.244261948675558e-07
unilateral B-Disease 0 3.8551570469280705e-06
retinoblastoma I-Disease 1 0.9999995231628418
, O 0 1.3316883951119962e-07
we O 0 6.211864356231445e-09
analyzed O 0 5.800307345538158e-09
DNA O 0 2.6206302905507073e-08
from O 0 4.903895511887413e-09
peripheral O 0 7.271483354998054e-06
blood O 0 2.9136998591638985e-07
and O 0 6.062646917825987e-08
from O 0 4.647134517199447e-07
tumor B-Disease 1 0.7633963823318481
tissue O 0 0.00046191594447009265
. O 0 2.2323590656014858e-06

The O 0 2.159451014449587e-06
analysis O 0 5.577251727117982e-07
of O 0 1.6850146948854672e-06
tumors B-Disease 1 1.0
from O 0 2.2644961461537605e-07
54 O 0 3.378867745595926e-07
( O 0 6.223438653307767e-09
71 O 0 7.480461050590748e-08
% O 0 1.7399677254559265e-09
) O 0 7.445806748940242e-10
of O 0 1.657650550157541e-08
76 O 0 5.989799092276371e-07
informative O 0 2.196105874929799e-08
patients O 0 1.1785348696946585e-08
showed O 0 2.659416464823039e-09
loss O 0 1.8758365527560272e-08
of O 0 1.7694662801659433e-07
constitutional O 0 4.9309892347082496e-05
heterozygosity O 1 0.9999997615814209
( O 0 0.00014636902778875083
LOH O 1 1.0
) O 0 1.889386993525477e-07
at O 0 6.737877242812829e-07
intragenic O 0 1.0669033144949935e-05
loci O 0 1.603385840098781e-06
. O 0 4.044530328428664e-07

Three O 0 2.232925453427015e-06
of O 0 1.1756609410440433e-06
13 O 0 2.076533746731002e-06
uninformative O 0 0.22130410373210907
patients O 0 3.733096309588291e-05
had O 0 4.5631000489265716e-07
constitutional O 0 1.4990622503319173e-06
deletions O 0 2.908532587753143e-05
. O 0 2.384654180787038e-06

For O 0 2.4829155336192343e-06
39 O 0 3.65223581866303e-06
randomly O 0 3.9777114579919726e-07
selected O 0 1.1749793884519022e-06
tumors B-Disease 1 1.0
, O 0 6.755370804967242e-07
SSCP O 1 0.9999998807907104
, O 0 4.943452950101346e-06
hetero O 0 0.014256948605179787
- O 0 3.3816829727584263e-06
duplex O 0 1.0869758853004896e-06
analysis O 0 3.096123801782369e-09
, O 0 3.7217157133895284e-10
sequencing O 0 7.255758660562606e-09
, O 0 7.108688082624326e-10
and O 0 1.279867656300837e-09
Southern O 0 2.2776255548251356e-07
blot O 0 1.6991069742289255e-06
analysis O 0 1.3102195772773939e-08
were O 0 2.065198900780274e-09
used O 0 3.801889025822902e-09
to O 0 5.085898369117103e-09
identify O 0 1.0797864291589576e-07
mutations O 0 6.800067922085873e-07
. O 0 1.425597019988345e-06

Mutations O 0 2.7472281090012984e-06
were O 0 4.76358536616317e-07
detected O 0 5.055050564806152e-07
in O 0 2.9176307592138073e-08
21 O 0 1.7286365050495078e-07
( O 0 1.1520600473602371e-08
91 O 0 1.3877352955660172e-07
% O 0 4.084413252058994e-09
) O 0 3.862511199770324e-09
of O 0 1.9590667932334327e-07
23 O 0 0.000354802148649469
tumors B-Disease 1 1.0
with O 0 0.12447897344827652
LOH O 1 1.0
. O 0 0.0002638388250488788

In O 0 4.085372893314343e-06
6 O 0 1.7955884459297522e-06
( O 0 2.939964360848535e-08
38 O 0 1.1380610231981336e-07
% O 0 5.960927307313568e-09
) O 0 4.182381108108757e-09
of O 0 1.2498129819960013e-07
16 O 0 3.367949102539569e-05
tumors B-Disease 1 1.0
without O 1 0.7109670639038086
LOH O 1 1.0
, O 0 1.9426604325190056e-08
one O 0 1.104306646126929e-09
mutation O 0 8.204522061738828e-10
was O 0 3.458319852711611e-09
detected O 0 2.6695501365026075e-09
, O 0 7.578916383366163e-10
and O 0 2.6824940047021073e-09
in O 0 5.597306174109917e-09
9 O 0 9.654915089640781e-08
( O 0 5.709445360935206e-09
56 O 0 1.5684445742181197e-08
% O 0 7.293913251160689e-10
) O 0 8.479408286632406e-10
of O 0 3.670685799761486e-08
the O 0 1.3957746887172107e-06
tumors B-Disease 1 1.0
without O 1 0.9489806890487671
LOH O 1 1.0
, O 0 1.2163816620613943e-08
both O 0 2.6767084104761807e-09
mutations O 0 6.5885621403083405e-09
were O 0 1.5812677389703822e-08
found O 0 7.146297065219187e-08
. O 0 5.168387247067585e-07

Thus O 0 2.2068986709200544e-06
, O 0 8.328980527494423e-08
a O 0 9.558220881444868e-09
total O 0 9.915891441281133e-10
of O 0 4.004244935629231e-09
45 O 0 6.962586507341939e-09
mutations O 0 1.859619680466551e-09
were O 0 2.941539012368821e-09
identified O 0 1.7261974960547377e-08
in O 0 6.3629594926339905e-09
tumors B-Disease 1 1.0
of O 0 2.9978447855683044e-05
36 O 0 5.083880023448728e-05
patients O 0 6.549455429194495e-05
. O 0 1.0903678457907517e-06

Thirty O 0 3.382426803000271e-05
- O 0 3.396725787752075e-06
nine O 0 1.2484669298373774e-07
of O 0 1.5510352113778936e-08
the O 0 6.725394907647342e-09
mutations O 0 8.182865052219768e-09
- O 0 2.3248471592296482e-08
including O 0 1.997414678100995e-09
34 O 0 1.569539875845294e-08
small O 0 2.577447144602729e-09
mutations O 0 2.408786059504564e-09
, O 0 2.136827603749225e-09
2 O 0 4.1327897548626424e-08
large O 0 1.2166809781888333e-08
structural O 0 1.8920586626336444e-06
alterations O 0 1.6335417967638932e-05
, O 0 2.5352781207743647e-08
and O 0 4.4541959454136304e-08
hypermethylation O 1 0.9514862298965454
in O 0 1.8794722222992277e-07
3 O 0 7.793462827976327e-06
tumors O 1 1.0
- O 0 3.926314548152732e-06
were O 0 7.867913431880424e-09
not O 0 5.033032879353527e-10
detected O 0 1.0731501021155054e-08
in O 0 4.3809059158128605e-10
the O 0 1.6104169109354416e-09
corresponding O 0 3.662776038027005e-08
peripheral O 0 0.0001804913772502914
blood O 0 1.2060191920681973e-06
DNA O 0 6.075118562876014e-06
. O 0 6.555153504450573e-07

In O 0 3.5574632875068346e-06
6 O 0 1.7850300082500326e-06
( O 0 2.2867311599839013e-08
17 O 0 2.6266803843100206e-08
% O 0 1.6645630429579228e-09
) O 0 7.888074637918407e-10
of O 0 7.445441596587443e-09
the O 0 1.0407537942569434e-08
36 O 0 6.610542868656921e-08
patients O 0 2.1937948346817393e-08
, O 0 1.3721446201486742e-09
a O 0 5.258744106839686e-09
mutation O 0 5.270100800203181e-09
was O 0 6.393558038553238e-08
detected O 0 2.1073025990858696e-08
in O 0 1.4201474440866946e-09
constitutional O 0 8.034656495681247e-09
DNA O 0 5.800995950266952e-08
, O 0 4.1045364329583833e-10
and O 0 8.117168603938296e-10
1 O 0 6.871474944603051e-09
of O 0 4.105086492955934e-09
these O 0 1.1612281136663682e-09
mutations O 0 2.8747524360994703e-09
is O 0 5.448777540273397e-10
known O 0 1.5983538936836794e-09
to O 0 4.97318186631901e-10
be O 0 8.711939503136534e-10
associated O 0 1.172532648752167e-08
with O 0 3.149436711424869e-09
reduced O 0 2.5103272491833195e-06
expressivity O 0 0.0006227143458090723
. O 0 1.6016801964724436e-06

The O 0 6.180194418448082e-07
presence O 0 7.844690941283261e-08
of O 0 7.120363676449415e-08
a O 0 1.6584159823196387e-08
constitutional O 0 4.1350290302943904e-08
mutation O 0 6.116958051194388e-09
was O 0 3.2369029678847028e-09
not O 0 5.287483645366464e-11
associated O 0 4.155074617706589e-10
with O 0 1.1739749450345727e-10
an O 0 3.1398506017410455e-10
early O 0 8.078963276147988e-08
age O 0 5.186468499118746e-08
at O 0 1.1924969101073657e-07
treatment O 0 1.3373140745898127e-06
. O 0 8.980265988611791e-07

In O 0 1.4962170098442584e-06
1 O 0 1.5872528820182197e-06
patient O 0 1.96143309949548e-06
, O 0 9.781047793921971e-08
somatic O 0 0.0028522303327918053
mosaicism O 1 0.9999979734420776
was O 0 1.6583073829679051e-06
demonstrated O 0 2.0482298523916143e-08
by O 0 1.6176010531054885e-10
molecular O 0 3.2801472649168772e-09
analysis O 0 8.683174179680009e-10
of O 0 1.4745749066236158e-09
DNA O 0 2.8341768043560478e-08
and O 0 8.660121508796692e-09
RNA O 0 1.3438585710900952e-06
from O 0 5.6369284351376336e-08
peripheral O 0 0.00039200327591970563
blood O 0 7.160703262343304e-06
. O 0 2.8726274194923462e-06

In O 0 2.5710760382935405e-06
2 O 0 3.347638312334311e-06
patients O 0 1.600967181047963e-07
without O 0 1.4568293238426122e-08
a O 0 7.681022928807124e-09
detectable O 0 4.5665046854992397e-07
mutation O 0 3.525481773181127e-08
in O 0 5.765969479654132e-09
peripheral O 0 0.0003436303813941777
blood O 0 1.2103272410968202e-06
, O 0 4.355133143008061e-08
mosaicism O 1 0.9065766334533691
was O 0 6.187808025970298e-07
suggested O 0 1.2146428751691474e-08
because O 0 1.3272268839514823e-09
1 O 0 9.054738292491038e-09
of O 0 9.34993948931151e-09
the O 0 3.394531589151484e-08
patients O 0 3.9936248867888935e-06
showed O 0 1.8193393316323636e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.4928348264220404e-06
the O 0 2.180313174449111e-07
other O 0 9.996068861539698e-09
later O 0 1.4541745940732653e-07
developed O 0 2.038196498688194e-06
bilateral B-Disease 0 5.8601708587957546e-05
retinoblastoma I-Disease 1 0.9999135732650757
. O 0 2.536779902584385e-05

In O 0 7.831368975530495e-07
conclusion O 0 1.2721916391456034e-06
, O 0 8.77699548595956e-08
our O 0 4.9610505925556936e-08
results O 0 1.0017827456465511e-08
emphasize O 0 6.881367653477355e-08
that O 0 1.0562056784735319e-09
the O 0 1.0690987650718853e-08
manifestation O 0 4.178658127784729e-05
and O 0 1.9093791081559175e-07
transmissibility O 1 0.8039699792861938
of O 0 6.617669896513689e-07
retinoblastoma B-Disease 0 0.0005546865868382156
depend O 0 1.50620152794545e-07
on O 0 2.1038367492565158e-08
the O 0 1.845253505550204e-09
nature O 0 2.0605719353028462e-09
of O 0 4.104601103449568e-09
the O 0 1.470648158807819e-09
first O 0 7.162201387522771e-10
mutation O 0 4.1380784909783586e-10
, O 0 2.0509798026591142e-10
its O 0 3.217769384278313e-10
time O 0 1.2378573721605335e-09
in O 0 3.668099712861306e-10
development O 0 2.4933681785910267e-09
, O 0 2.2478653660673587e-10
and O 0 5.837896832616707e-10
the O 0 7.950457514560583e-10
number O 0 1.9954145280554059e-10
and O 0 3.1569530323238837e-10
types O 0 6.022077059242292e-09
of O 0 1.3005491794615409e-08
cells O 0 2.8224599546433637e-08
that O 0 5.645465761539015e-10
are O 0 3.676589033219102e-10
affected O 0 7.857431150171124e-09
. O 0 2.703905899181791e-08
. O 0 5.255277528704028e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 0 0.014152035117149353
the I-Disease 0 1.328828147961758e-05
fifth I-Disease 0 4.886286478722468e-05
component I-Disease 0 3.0754838462598855e-06
of I-Disease 0 3.282001728166506e-07
complement I-Disease 0 2.2319377421808895e-06
in O 0 3.6882875065202825e-07
man O 0 1.7626327462494373e-05
. O 0 2.03860486180929e-06

I O 0 0.04545813053846359
. O 0 8.363348752027377e-05

Clinical O 0 0.00020215584663674235
, O 0 1.535243768557848e-06
immunochemical O 0 0.220125213265419
, O 0 3.397842363028758e-07
and O 0 1.537519267458265e-07
family O 0 4.845213084081479e-07
studies O 0 2.8847239263996016e-07
. O 0 5.376086278374714e-07

The O 0 1.829713255574461e-06
first O 0 3.294275643384026e-07
recognized O 0 2.391073223861895e-07
human O 0 2.898053423905367e-07
kindred O 0 0.005243627354502678
with O 0 2.1107585723711964e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999877214431763
the I-Disease 0 0.00023955569486133754
fifth I-Disease 0 2.453640991006978e-05
component I-Disease 0 1.2078205600118963e-06
of I-Disease 0 1.7716376987664262e-07
complement I-Disease 0 3.700855586430407e-06
( O 0 8.156741387210786e-06
C5 O 1 1.0
) O 0 4.822982901941941e-08
is O 0 3.002298853971297e-08
described O 0 3.3301839152954926e-07
. O 0 3.8693715964654984e-07

The O 0 1.676285501162056e-05
proband O 0 0.00027174106799066067
, O 0 2.254914903687677e-07
a O 0 7.612970875925384e-08
20 O 0 7.170299909375899e-08
- O 0 1.6765451960054634e-07
year O 0 3.475189558344027e-08
- O 0 7.57610393975483e-07
old O 0 6.579196565326129e-07
black O 0 1.0029911123865531e-08
female O 0 1.6072010389223124e-09
with O 0 3.4904068524355125e-09
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 1.0
age O 0 0.00036726013058796525
11 O 0 5.468940571518033e-07
, O 0 1.3360001993589776e-08
lacked O 0 4.405883373692632e-06
serum O 0 1.5979994714143686e-05
hemolytic O 1 0.999997615814209
complement O 0 2.335893896088237e-06
activity O 0 8.775170101671392e-08
, O 0 2.1221244761449043e-09
even O 0 6.192699686380365e-09
during O 0 1.1817045475481791e-07
remission O 0 9.071447493624873e-06
. O 0 7.528317382821115e-07

C5 O 1 0.9999998807907104
was O 0 0.000127515391795896
undetectable O 0 7.750062650302425e-05
in O 0 3.864355235805306e-08
her O 0 7.55527818085966e-09
serum O 0 1.2290725237562583e-07
by O 0 9.635625630721734e-10
both O 0 1.3690867106674887e-08
immunodiffusion O 0 8.913878991734236e-05
and O 0 8.922286838242144e-07
hemolytic O 1 1.0
assays O 1 0.9844059944152832
. O 0 2.3681648599449545e-05

Other O 0 3.260600465182506e-07
complement O 0 1.9461805322862347e-07
components O 0 2.7459105922389426e-07
were O 0 1.2064462318051028e-08
normal O 0 4.474783654728753e-09
during O 0 1.1205277594683594e-08
remission O 0 3.2812133099469065e-07
of O 0 6.016752251980506e-08
lupus O 1 0.9605665802955627
, O 0 5.0296023346163565e-08
but O 0 2.2591461146248548e-08
C1 O 0 1.5072049791342579e-05
, O 0 2.601094450938035e-08
C4 O 0 6.972866685828194e-05
, O 0 1.1210151917850908e-08
C2 O 0 2.9179816465330077e-06
, O 0 9.044727633522598e-09
and O 0 1.0734780175880587e-07
C3 O 1 0.9999972581863403
levels O 0 2.9086572794767562e-06
fell O 0 0.0004123894323129207
during O 0 2.0211666651448468e-06
exacerbations O 1 0.9995352029800415
. O 0 1.2014551430183928e-05

A O 0 4.250799247529358e-05
younger O 0 9.850627066043671e-06
half O 0 7.708528642069723e-07
- O 0 2.9612995149363996e-06
sister O 0 3.7842673918930814e-06
, O 0 3.5848952251171795e-08
who O 0 5.3594703786075115e-08
had O 0 5.966275296032109e-08
no O 0 3.0603697354081305e-08
underlying O 1 0.8340106010437012
disease O 1 0.9999920129776001
, O 0 4.185615409824095e-08
was O 0 6.939869763300521e-07
also O 0 7.245773758768337e-09
found O 0 1.8952270863792364e-09
to O 0 5.673599812183738e-09
lack O 0 2.06451859412482e-05
immunochemically O 1 0.9997162222862244
detectable O 1 0.9755771160125732
C5 O 1 0.9999979734420776
. O 0 5.900383712287294e-06

By O 0 2.1434452719404362e-06
hemolytic O 1 0.9999982118606567
assay O 0 0.0006939869490452111
, O 0 1.8166762174587348e-06
she O 0 1.0014545637204719e-07
exhibited O 0 7.235915688852401e-08
1 O 0 1.6672684921559267e-07
- O 0 2.1377201164796134e-07
2 O 0 8.73172751880702e-08
% O 0 2.1205870393004034e-09
of O 0 8.672916607110892e-09
the O 0 1.7343955605042538e-08
normal O 0 4.094158043699281e-07
serum O 0 1.4369684322446119e-05
C5 O 0 0.009187709540128708
level O 0 3.9428588394230246e-08
and O 0 1.3220676775560491e-09
normal O 0 1.8157241266081314e-09
concentrations O 0 8.047125632515417e-09
of O 0 2.6307203082609476e-09
other O 0 1.1505355557162034e-09
complement O 0 5.0586670852226234e-08
components O 0 2.3135951323638437e-06
. O 0 1.0562504257904948e-06

C5 O 1 0.9999493360519409
levels O 0 2.747691723925527e-06
of O 0 2.3706020613190049e-07
other O 0 1.4349383015144213e-08
family O 0 1.7046977163204247e-08
members O 0 3.2455685361476583e-10
were O 0 8.864403655550745e-10
either O 0 1.712319064317569e-09
normal O 0 8.200348844411565e-09
or O 0 1.7291161835686353e-09
approximately O 0 4.2677006373281756e-10
half O 0 2.1989630116792114e-09
- O 0 8.443421961601416e-09
normal O 0 1.6602951236066588e-09
, O 0 2.3770238555265166e-10
consistent O 0 3.7737417635241854e-09
with O 0 8.575760657159037e-10
autosomal O 0 2.946808876913565e-07
codominant O 0 2.4631376618344802e-06
inheritance O 0 4.752621762804665e-08
of O 0 1.5670211794827082e-08
the O 0 5.188506690956274e-08
gene O 0 7.488525852750172e-07
determining O 0 1.1533566066646017e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 5.459854219225235e-05

Normal O 0 0.00013473314174916595
hemolytic O 1 0.9999998807907104
titers O 1 0.9655319452285767
were O 0 3.973104412580142e-06
restored O 0 1.587573206052184e-05
to O 0 5.565223659687035e-08
both O 0 1.8239241228457104e-07
homozygous O 0 8.003364928299561e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.8189253751188517e-05
C5D B-Disease 1 1.0
) O 0 1.0767980995751714e-07
sera O 0 1.0926021332124947e-07
by O 0 3.435832451881282e-10
addition O 0 2.742474913830506e-09
of O 0 4.1711821552326e-08
highly O 0 9.889453167488682e-07
purified O 0 6.7641076384461485e-06
human O 0 2.0484405922616133e-06
C5 O 1 0.7725624442100525
. O 0 3.0962785331212217e-06

In O 0 1.8911712231783895e-06
specific O 0 1.5616138853147277e-06
C5 O 1 0.9994773268699646
titrations O 0 5.958163092145696e-05
, O 0 3.8814931713204714e-08
however O 0 1.6441140004985755e-08
, O 0 3.358574307554818e-09
it O 0 9.248092291969101e-10
was O 0 1.1186464199397506e-08
noted O 0 1.5011250020791067e-09
that O 0 6.060649898609327e-11
when O 0 2.7906707500413575e-10
limited O 0 1.053139908613332e-09
amounts O 0 5.161399752040552e-09
of O 0 2.736811843817577e-08
C5 O 0 0.016466662287712097
were O 0 2.85801871058311e-08
assayed O 0 1.0439850228749492e-07
in O 0 9.529800282237488e-10
the O 0 1.0964235075405782e-09
presence O 0 2.8509394844888902e-09
of O 0 1.4545359583451045e-08
low O 0 6.337840545711515e-07
dilutions O 0 7.48684979043901e-05
of O 0 1.0200501066037759e-07
either O 0 2.4390095632043085e-07
C5D B-Disease 1 1.0
serum O 0 2.8570650556503097e-06
, O 0 7.620202246982899e-09
curving O 0 5.0876280965894694e-08
rather O 0 2.686129096929335e-09
than O 0 4.825278510089959e-10
linear O 0 3.7082972248470014e-09
dose O 0 1.5043639223222272e-07
- O 0 5.593083329813453e-08
response O 0 1.0262281691097996e-08
plots O 0 3.601686771048662e-08
were O 0 2.8357112213939217e-09
consistently O 0 8.998920719704984e-09
obtained O 0 1.554048889573778e-09
, O 0 6.011929287730311e-10
suggesting O 0 7.174866034631577e-09
some O 0 1.6300900629317994e-09
inhibitory O 0 3.377598432052764e-07
effect O 0 3.0672103434881137e-07
. O 0 7.696452826166933e-07

Further O 0 1.1331533187330933e-06
studies O 0 1.28854338754536e-07
suggested O 0 3.38477548211813e-08
that O 0 1.291269535741435e-09
low O 0 6.514550818792486e-07
dilutions O 1 0.9244046807289124
of O 0 0.0002999341522809118
C5D B-Disease 1 1.0
serum O 0 3.860963261104189e-05
contain O 0 2.4041971968813414e-08
a O 0 1.2028893436877297e-08
factor O 0 7.234560062130413e-09
( O 0 9.444787174572866e-10
or O 0 8.080527913456592e-10
factors O 0 6.27878504744217e-09
) O 0 1.1345835382314817e-09
interfering O 0 1.5409328923965404e-08
at O 0 3.148379557060821e-09
some O 0 3.184250918497611e-10
step O 0 9.73832214867798e-09
in O 0 8.411687457687833e-10
the O 0 1.070651833856573e-08
hemolytic O 1 0.9902778267860413
assay O 0 1.4064714378037024e-05
of O 0 7.499912317143753e-05
C5 O 1 1.0
, O 0 8.280743202249141e-09
rather O 0 5.406996628209981e-09
than O 0 1.3814829280534013e-09
a O 0 1.3710779178666144e-08
true O 0 7.727695674475399e-07
C5 O 1 0.9999375343322754
inhibitor O 0 1.2715882803604472e-05
or O 0 2.5895761268657225e-07
inactivator O 0 3.892713721143082e-05
. O 0 5.457134761854832e-07

Of O 0 2.6792183689394733e-06
clinical O 0 2.9048622309346683e-05
interest O 0 1.1932887389320967e-07
are O 0 2.0114725440834036e-09
( O 0 1.47691681107176e-09
a O 0 3.127652581369489e-09
) O 0 1.0420662110988133e-09
the O 0 2.2699906399026304e-09
documentation O 0 1.2606345478616277e-07
of O 0 2.3488675537919335e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 0.004250403493642807
vasculitis B-Disease 1 1.0
, O 0 1.0024317816714756e-05
and O 0 0.05908036231994629
arthritis B-Disease 1 1.0
in O 0 8.506363883498125e-06
an O 0 5.4088353351744445e-08
individual O 0 3.6025593175281756e-08
lacking O 0 0.0029830276034772396
C5 O 1 0.9999995231628418
( O 0 2.405311860798065e-08
and O 0 6.70694833004859e-09
its O 0 4.994639368760545e-09
biologic O 0 2.3126115138438763e-06
functions O 0 3.1417930479449296e-09
) O 0 3.075135424079889e-10
, O 0 2.099024842827646e-10
and O 0 7.505378540884067e-10
( O 0 1.2396482729215563e-09
b O 0 3.6364074418315795e-08
) O 0 1.6293129068145618e-09
a O 0 5.145299741826648e-09
remarkable O 0 2.8599927759387356e-08
propensity O 0 4.4421742018130317e-07
to O 0 2.066315119009232e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.3375461566388367e-08
the O 0 1.5255098517741317e-08
proband O 0 1.3881285667594057e-06
, O 0 8.400656281715158e-10
even O 0 1.4139200921192696e-09
during O 0 3.7556180387809945e-09
periods O 0 6.655975681724158e-08
of O 0 3.4402034998493036e-08
low O 0 3.059807056615682e-07
- O 0 3.097891720926782e-08
dose O 0 5.2995670074551526e-08
or O 0 7.1340782170636885e-09
alternate O 0 7.444080551977095e-08
- O 0 1.7610018687719275e-07
day O 0 7.221122189093876e-08
corticosteroid O 0 1.8058122805086896e-05
therapy O 0 4.26934493589215e-05
. O 0 5.653940888805664e-07

Other O 0 3.22133502095312e-07
observations O 0 2.0186459437354642e-07
indicate O 0 3.2454604337317505e-08
that O 0 3.265371750771351e-09
the O 0 5.570363725837524e-08
C5D B-Disease 1 1.0
state O 0 1.553314810109896e-08
is O 0 2.4919559749037035e-09
compatible O 0 7.990599470986126e-08
with O 0 1.0887110102331121e-09
normal O 0 5.501079414216292e-08
coagulation O 0 5.920512649026932e-07
function O 0 2.6233746286408177e-09
and O 0 1.4545130655463367e-09
the O 0 1.937042970467928e-09
capacity O 0 5.001150604755367e-09
to O 0 4.158414501631569e-09
mount O 0 6.770444542780751e-06
a O 0 8.668459940963658e-07
neutrophilic O 1 0.9131911993026733
leukocytosis O 0 0.020949868485331535
during O 0 6.695302545267623e-06
pyogenic B-Disease 1 0.7448036670684814
infection I-Disease 0 5.496213270816952e-05
. O 0 1.675357594876914e-07
. O 0 9.336600896858727e-07

Susceptibility O 0 0.0009353297064080834
to O 0 1.8620627088239416e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.06318700313568115
twins O 0 0.1282413750886917
: O 0 1.2096629475877307e-08
the O 0 1.2152824524491734e-08
role O 0 3.590547592580151e-08
of O 0 5.1891205998799705e-08
genes O 0 6.99792366276597e-08
, O 0 2.2634505825180895e-08
HLA O 0 0.0001386515941703692
, O 0 1.1423470169802385e-08
and O 0 2.6236159911263712e-08
the O 0 1.0841056763410961e-07
environment O 0 1.9658882592921145e-06
. O 0 3.5891034144697187e-07

OBJECTIVE O 0 6.181354547152296e-05
To O 0 1.4727099539868505e-07
determine O 0 5.183986218071368e-08
the O 0 1.742299815532533e-08
relative O 0 2.317312919331016e-07
effects O 0 1.1809897841885686e-06
of O 0 1.6396833757426066e-07
genetic O 0 1.8958156715598307e-06
and O 0 7.1082983943426825e-09
environmental O 0 3.5350975480241686e-08
factors O 0 4.105760176287276e-09
in O 0 2.2680388678253394e-09
susceptibility O 0 4.236458607920213e-06
to O 0 2.0463651253521675e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9999997615814209
AS B-Disease 1 1.0
) O 0 8.19537774532364e-07
. O 0 4.895842380392423e-07

METHODS O 0 7.554456533398479e-05
Twins O 0 0.000267981318756938
with O 0 1.2577356756082736e-07
AS B-Disease 1 0.9985815286636353
were O 0 3.118106306487789e-08
identified O 0 9.875579465301598e-09
from O 0 2.477515526067009e-09
the O 0 6.473759750491581e-09
Royal O 0 2.195052047682111e-06
National O 0 3.302388051906746e-07
Hospital O 0 0.00016376705025322735
for O 0 1.0777247183568761e-07
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 6.354987999657169e-05
. O 0 5.600775693892501e-06

Clinical O 0 0.00019407359650358558
and O 0 7.026826551737031e-07
radiographic O 0 0.0004694237431976944
examinations O 0 5.9648700698744506e-06
were O 0 5.455376239638099e-08
performed O 0 7.723140349469304e-09
to O 0 1.5175456447025226e-09
establish O 0 2.0379420817562277e-08
diagnoses O 1 0.9830804467201233
, O 0 1.9291283592792752e-07
and O 0 2.616650363052031e-07
disease O 1 0.9977520108222961
severity O 1 0.9947547912597656
was O 0 3.1438562473340426e-06
assessed O 0 1.681129901953682e-08
using O 0 1.4739224285520436e-09
a O 0 1.6337566854929264e-09
combination O 0 3.568903750306163e-08
of O 0 8.062830403332555e-08
validated O 0 1.2059996379321092e-06
scoring O 0 1.3783405847789254e-06
systems O 0 0.00036173794069327414
. O 0 1.9318820250191493e-06

HLA O 0 0.0015562708722427487
typing O 0 1.8261958757648245e-05
for O 0 9.198050179293205e-07
HLA O 0 2.630696508276742e-05
- O 0 2.7077383037976688e-06
B27 O 0 7.3390187935729045e-06
, O 0 6.837381505420126e-08
HLA O 0 4.567167707136832e-06
- O 0 3.064838836053241e-07
B60 O 0 9.259729267796502e-07
, O 0 6.4053464754465494e-09
and O 0 2.4175463408937503e-08
HLA O 0 0.00030126277124509215
- O 0 9.687352758191992e-06
DR1 O 0 0.002066061133518815
was O 0 1.1194916105239372e-08
performed O 0 6.563010135351988e-10
by O 0 9.675308471068789e-11
polymerase O 0 1.4875594445129536e-07
chain O 0 1.6984341044690154e-08
reaction O 0 2.5804280934238477e-09
with O 0 3.0564289987822235e-10
sequence O 0 2.6167281674815968e-09
- O 0 3.780296964350782e-09
specific O 0 1.1836435165335502e-09
primers O 0 8.603834800169352e-08
, O 0 3.207452303755076e-09
and O 0 5.98399507723002e-09
zygosity O 0 4.099716079508653e-06
was O 0 1.6933951485498255e-07
assessed O 0 1.3174472712762508e-07
using O 0 1.1019741208428968e-07
microsatellite O 0 2.155250149371568e-05
markers O 0 2.4394894353463314e-06
. O 0 1.078020318345807e-06

Genetic O 0 2.4861545171006583e-05
and O 0 1.295245795063238e-07
environmental O 0 1.489951841904258e-07
variance O 0 5.50452199377105e-08
components O 0 2.595066916910582e-07
were O 0 9.467337136470633e-09
assessed O 0 2.441541013809001e-08
with O 0 1.4929359970494716e-09
the O 0 2.1417660533984417e-08
program O 0 4.1430496366956504e-08
Mx O 0 2.2302559443687642e-07
, O 0 3.1716734794073886e-10
using O 0 4.469680736640669e-10
data O 0 3.3094305074143904e-10
from O 0 1.9607314383218721e-10
this O 0 3.926544853150027e-11
and O 0 3.2352345802344473e-10
previous O 0 3.307829121723671e-09
studies O 0 1.5131756958552955e-09
of O 0 1.0680736295398674e-08
twins O 0 1.0046013585451874e-06
with O 0 6.818017084242456e-08
AS B-Disease 1 0.9999994039535522
. O 0 1.104469265555963e-05

RESULTS O 0 7.322114925045753e-06
Six O 0 2.135139766323846e-06
of O 0 9.510321774541808e-07
8 O 0 4.651134531741263e-06
monozygotic O 0 0.00429535610601306
( O 0 2.615537596284412e-06
MZ O 1 0.9999532699584961
) O 0 8.356430214462307e-08
twin O 0 1.907080331875477e-06
pairs O 0 2.1535223382329605e-08
were O 0 2.8514957506331484e-08
disease O 0 2.406478870398132e-06
concordant O 0 6.372025382006541e-06
, O 0 5.01014429943325e-09
compared O 0 4.258937202905599e-09
with O 0 1.3128504949833086e-09
4 O 0 1.2410606586854556e-07
of O 0 1.3601298576304544e-07
15 O 0 1.2908361668451107e-07
B27 O 0 1.4153395113680745e-06
- O 0 1.693813374004094e-07
positive O 0 9.275903600780566e-09
dizygotic O 0 5.703130227630027e-06
( O 0 4.352774496396705e-08
DZ O 0 6.728420703439042e-05
) O 0 1.164464613623295e-08
twin O 0 2.4615803795313695e-07
pairs O 0 4.886062665576674e-09
( O 0 3.475492782456513e-09
27 O 0 1.297744223194286e-08
% O 0 1.6379814171685325e-09
) O 0 1.0894026791774536e-09
and O 0 2.8589115519395136e-09
4 O 0 5.587112283933493e-08
of O 0 9.621714269769654e-08
32 O 0 1.2942483635924873e-06
DZ O 0 0.0011953924549743533
twin O 0 1.578810724822688e-06
pairs O 0 1.342316746644201e-08
overall O 0 6.61999308704253e-08
( O 0 6.557432818965481e-09
12 O 0 5.348696419105181e-08
. O 0 6.760892290458287e-09
5 O 0 4.514322782256386e-08
% O 0 9.640043430181322e-09
) O 0 1.7942426211448037e-08
. O 0 3.178738836595585e-07

Nonsignificant O 0 0.003263544524088502
increases O 0 1.8977004856424173e-06
in O 0 2.643890795184234e-08
similarity O 0 9.618484142492889e-08
with O 0 3.679165416770047e-09
regard O 0 9.575724391197582e-08
to O 0 1.065749710704722e-08
age O 0 5.5442885837919675e-08
at O 0 6.142681741039269e-08
disease O 0 9.288295586884487e-06
onset O 1 0.8888677954673767
and O 0 1.3827172296032586e-08
all O 0 9.68480406982053e-10
of O 0 1.0102446879045601e-08
the O 0 2.937514942402686e-08
disease O 0 1.5213047845463734e-05
severity O 0 2.4996272713906365e-06
scores O 0 2.8300391363700328e-08
assessed O 0 6.096493088136867e-09
were O 0 1.6961443360941075e-09
noted O 0 4.763836880528061e-09
in O 0 3.2261104898623216e-09
disease O 0 3.9506434404756874e-05
- O 0 4.407715550769353e-06
concordant O 0 0.0017302681226283312
MZ O 1 0.9999724626541138
twins O 0 1.4698332961415872e-05
compared O 0 2.476924692018656e-07
with O 0 1.326413183733166e-07
concordant O 0 0.3585115969181061
DZ O 1 0.9999998807907104
twins O 1 0.9619815349578857
. O 0 6.461414159275591e-05

HLA O 1 0.8509824275970459
- O 0 0.00013663982099387795
B27 O 0 1.62679953064071e-05
and O 0 4.374096818082762e-08
B60 O 0 5.651596097777656e-07
were O 0 1.8083278208180786e-09
associated O 0 2.231905327221284e-09
with O 0 4.0356717967426903e-10
the O 0 9.940095857530196e-09
disease O 0 0.02578822337090969
in O 0 6.211864356231445e-09
probands O 0 0.00014021247625350952
, O 0 2.541052257498677e-09
and O 0 7.78326403327867e-10
the O 0 3.983144480912415e-09
rate O 0 1.564614038329637e-08
of O 0 8.90946623144373e-08
disease O 0 0.009654218330979347
concordance O 0 6.231104634935036e-05
was O 0 1.5072733958731988e-06
significantly O 0 6.362294158179793e-08
increased O 0 2.9743986829089408e-08
among O 0 4.7365411148803105e-08
DZ O 0 0.0003974742430727929
twin O 0 1.5054201867314987e-06
pairs O 0 1.1307666802906624e-08
in O 0 5.027068095131426e-09
which O 0 1.2027877582809765e-09
the O 0 1.6034601202363774e-08
co O 0 6.049514240658027e-07
- O 0 1.8650806055120484e-07
twin O 0 1.5869410390223493e-06
was O 0 4.1149505136672815e-08
positive O 0 9.734417716344979e-10
for O 0 2.6714754852719125e-09
both O 0 2.1206568945331128e-08
B27 O 0 1.3796944585919846e-05
and O 0 1.0637918421707582e-06
DR1 O 0 0.07429739087820053
. O 0 3.5325099361216417e-06

Additive O 0 1.1877523320436012e-05
genetic O 0 1.430962356607779e-06
effects O 0 5.025057703278435e-07
were O 0 1.8404179513709096e-08
estimated O 0 3.228270983868242e-09
to O 0 1.2034119256654208e-09
contribute O 0 4.222731941894153e-09
97 O 0 2.419452016511059e-07
% O 0 2.6013213805242685e-09
of O 0 5.099672684139023e-09
the O 0 5.787245349608838e-09
population O 0 4.181006929560027e-10
variance O 0 1.560807838529854e-08
. O 0 7.580152328046097e-08

CONCLUSION O 0 6.948292866582051e-05
Susceptibility O 0 0.0003896746493410319
to O 0 1.0156427379115485e-06
AS B-Disease 1 0.9999998807907104
is O 0 8.365200443449794e-08
largely O 0 1.2176263908258989e-07
genetically O 0 2.8420911846183117e-08
determined O 0 9.07122910120961e-09
, O 0 1.5678546239072944e-09
and O 0 1.269147453797359e-09
the O 0 3.3148777056624112e-09
environmental O 0 5.089083643383674e-08
trigger O 0 3.224346656338639e-08
for O 0 1.3318777192239395e-09
the O 0 2.4333445480806404e-08
disease O 0 0.004702978767454624
is O 0 3.3379226493934766e-08
probably O 0 2.0204345219099196e-06
ubiquitous O 0 2.6642099328455515e-05
. O 0 1.7375231209371123e-06

HLA O 0 0.18808671832084656
- O 0 3.382020440767519e-05
B27 O 0 4.1368148231413215e-06
accounts O 0 6.776992300672191e-09
for O 0 2.044653335531166e-09
a O 0 4.8458295154318876e-09
minority O 0 8.95023788416438e-09
of O 0 2.422970446502859e-08
the O 0 4.23336281585307e-08
overall O 0 1.939436344855494e-07
genetic O 0 9.217245633408311e-07
susceptibility O 0 5.228695044934284e-06
to O 0 1.0678581219281114e-07
AS B-Disease 1 0.9999998807907104
. O 0 1.6218888049479574e-05

Cell O 0 0.00031430908711627126
cycle O 0 7.384836408164119e-06
- O 0 1.7453336340622627e-06
dependent O 0 2.548754878262116e-07
colocalization O 0 9.298629265686031e-06
of O 0 1.7785156103400368e-07
BARD1 O 1 0.9999759197235107
and O 0 1.6920650125484826e-07
BRCA1 O 0 1.6015810899716598e-07
proteins O 0 3.1683435874896304e-09
in O 0 1.945143823789408e-09
discrete O 0 1.219491565507269e-07
nuclear O 0 4.83499343317817e-06
domains O 0 7.706183851041715e-07
. O 0 7.210784929156944e-07

Germ O 1 0.9999289512634277
- O 0 0.00027979345759376884
line O 0 2.0497909645200707e-06
mutations O 0 5.974804651032173e-08
of O 0 6.233895533114264e-08
the O 0 8.932488526625093e-08
BRCA1 O 0 1.317554392699094e-06
gene O 0 9.701285108576485e-08
predispose O 0 6.167323931549618e-07
women O 0 1.3692217359917436e-09
to O 0 1.9021695329968225e-09
early O 0 5.350795618142001e-06
- O 0 0.009498733095824718
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.9999939203262329
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 5.606944242231293e-09
compromising O 0 2.358006696567827e-07
the O 0 1.431139118324154e-08
genes O 0 1.4496668754304665e-08
presumptive O 0 6.739625860063825e-06
function O 0 7.180424255182061e-09
as O 0 6.124406315421993e-09
a O 0 5.27749648426834e-08
tumor B-Disease 0 9.193732694257051e-05
suppressor O 0 0.0004192855558358133
. O 0 2.534544137233752e-06

Although O 0 2.570350488895201e-06
the O 0 5.903530109208077e-07
biochemical O 0 1.5248896488628816e-05
properties O 0 2.1127716536284424e-06
of O 0 6.551047704306256e-07
BRCA1 O 0 2.0028728613397107e-06
polypeptides O 0 1.929787174503872e-07
are O 0 2.3883170441330037e-10
not O 0 3.0708741105556214e-10
understood O 0 1.3230597062374727e-08
, O 0 6.290961085397839e-10
their O 0 7.284070013824362e-10
expression O 0 7.881882702065468e-09
pattern O 0 1.711849684227218e-08
and O 0 6.014639009066514e-09
subcellular O 0 2.0270156255719485e-06
localization O 0 4.0196996451413725e-06
suggest O 0 2.7731424268040428e-08
a O 0 1.2725294595838932e-08
role O 0 5.304097783209727e-08
in O 0 1.7626760495659255e-08
cell O 0 3.2238298445008695e-05
- O 0 1.387609813718882e-06
cycle O 0 2.1868477517728024e-07
regulation O 0 8.719675861357246e-07
. O 0 3.1979982395569095e-07

When O 0 5.9090439208375756e-06
resting O 0 0.00019069149857386947
cells O 0 8.890588105714414e-07
are O 0 5.437484684733818e-09
induced O 0 1.4945998145776684e-06
to O 0 1.9804470952067277e-08
proliferate O 0 7.605683549627429e-07
, O 0 1.5782847029299774e-08
the O 0 2.868230986052822e-08
steady O 0 6.447945679610712e-07
- O 0 7.398445944772902e-08
state O 0 1.5896980398721894e-09
levels O 0 3.6044751627883898e-09
of O 0 4.491569338682666e-09
BRCA1 O 0 6.291204446284837e-09
increase O 0 6.238088379184603e-10
in O 0 2.0335377826086187e-09
late O 0 6.775914584977727e-07
G1 O 0 1.274381133953284e-06
and O 0 2.3608357491156085e-09
reach O 0 3.6780778422951244e-09
a O 0 1.5088122973239138e-09
maximum O 0 8.082196245595696e-09
during O 0 6.815117359337819e-08
S O 0 4.640218321583234e-06
phase O 0 7.150194505811669e-06
. O 0 9.22964829896955e-07

Moreover O 0 1.2624776900338475e-05
, O 0 3.3610052696531056e-07
in O 0 6.422194331889841e-08
S O 0 1.95550310309045e-05
phase O 0 1.0213296263827942e-05
cells O 0 1.5336809155996889e-06
, O 0 1.1829083490511039e-08
BRCA1 O 0 1.1918227471596765e-07
polypeptides O 0 1.1268325295077375e-07
are O 0 2.1770867331127874e-09
hyperphosphorylated O 0 1.9166088804922765e-06
and O 0 1.737839205873115e-08
accumulate O 0 2.7102470312456717e-07
into O 0 8.260885664412854e-08
discrete O 0 4.209473445371259e-07
subnuclear O 0 1.125931794376811e-05
foci O 0 1.2172854439995717e-05
termed O 0 4.104887921130285e-06
" O 0 1.179481500912516e-06
BRCA1 O 0 2.5532172003295273e-06
nuclear O 0 1.7641834347159602e-05
dots O 0 7.1669746830593795e-06
. O 0 7.923538873910729e-07

" O 0 0.00015934008115436882
BRCA1 O 0 0.00018107244977727532
associates O 0 3.6549918149830773e-05
in O 0 3.627692635177482e-08
vivo O 0 4.752413644837361e-07
with O 0 5.6285349714357835e-09
a O 0 9.377053089565379e-08
structurally O 0 4.182996053714305e-05
related O 0 2.4924479475885164e-06
protein O 0 4.737823928735452e-06
termed O 0 2.1348882000893354e-05
BARD1 O 1 0.9855969548225403
. O 0 2.9037128115305677e-06

Here O 0 1.020285071717808e-05
we O 0 1.7030573928877857e-07
show O 0 2.1162646746120117e-08
that O 0 1.4800186631802603e-09
the O 0 1.0296651531405132e-08
steady O 0 3.237528858335281e-07
- O 0 1.2702395224550855e-07
state O 0 9.871242712122807e-10
levels O 0 5.269668257312787e-09
of O 0 1.1254842391394959e-08
BARD1 O 0 0.19081975519657135
, O 0 1.7716882405593992e-09
unlike O 0 4.734939551553907e-09
those O 0 9.658074340279654e-10
of O 0 1.424015927398159e-08
BRCA1 O 0 8.157732622748881e-08
, O 0 2.175945201798868e-09
remain O 0 8.371900506176644e-09
relatively O 0 9.008777723806816e-09
constant O 0 1.868687427020177e-08
during O 0 8.106129456564304e-08
cell O 0 1.2613311355380574e-06
cycle O 0 1.636441879782069e-07
progression O 0 4.0825466385285836e-07
. O 0 1.5713034429154504e-07

However O 0 9.372059139423072e-06
, O 0 1.1262916359555675e-06
immunostaining O 0 0.00015267047274392098
revealed O 0 2.272553501825314e-06
that O 0 5.0346510960253e-08
BARD1 O 1 0.9997931122779846
resides O 0 7.798123988322914e-06
within O 0 1.9598161316025653e-07
BRCA1 O 0 8.3291064356672e-07
nuclear O 0 3.720134145623888e-06
dots O 0 1.1378114805893347e-07
during O 0 9.243674270464908e-08
S O 0 1.6062509757830412e-06
phase O 0 1.0754141612778767e-06
of O 0 4.1320962651525406e-08
the O 0 7.4105179770356244e-09
cell O 0 6.304468058715429e-08
cycle O 0 1.7086422277046154e-09
, O 0 9.892536095845728e-11
but O 0 1.5501640249215853e-10
not O 0 3.189259412117451e-10
during O 0 1.971661411914738e-08
the O 0 5.739890340805687e-08
G1 O 0 8.434833034698386e-06
phase O 0 3.939238922612276e-06
. O 0 6.225773745427432e-07

Nevertheless O 0 0.00010765493789222091
, O 0 1.7779115069060936e-06
BARD1 O 0 0.1812378615140915
polypeptides O 0 4.609722054738086e-06
are O 0 5.733190810985889e-09
found O 0 5.3581494796617335e-09
exclusively O 0 7.0293983966962514e-09
in O 0 1.0634262359587865e-09
the O 0 5.487662768643986e-09
nuclear O 0 3.078519057453377e-07
fractions O 0 3.3919619113476074e-08
of O 0 1.2168364094122808e-08
both O 0 3.068264309291635e-09
G1 O 0 2.2947019715502393e-06
- O 0 1.0404843919786799e-07
and O 0 2.0727055627389745e-08
S O 0 1.4557715076080058e-05
- O 0 9.77585045802698e-07
phase O 0 2.7048345145885833e-06
cells O 0 8.3388664506856e-07
. O 0 2.2882828432102542e-07

Therefore O 0 2.7099677026853897e-06
, O 0 1.0174618836344962e-07
progression O 0 6.190069257172581e-07
to O 0 2.290236267299406e-08
S O 0 6.3647253227827605e-06
phase O 0 1.0481825256647426e-06
is O 0 3.165311346364774e-09
accompanied O 0 4.654796548209106e-09
by O 0 2.808162591350083e-10
the O 0 2.463407700048492e-09
aggregation O 0 1.9165225850770184e-08
of O 0 1.5659635366205293e-08
nuclear O 0 1.2633158803510014e-05
BARD1 O 0 0.0015289504081010818
polypeptides O 0 2.5055173864529934e-06
into O 0 3.333482254674891e-07
BRCA1 O 0 7.115489779607742e-07
nuclear O 0 8.673250704305246e-06
dots O 0 5.426647021522513e-06
. O 0 6.706068234052509e-07

This O 0 5.501173063748865e-07
cell O 0 6.806531018810347e-06
cycle O 0 3.2877346711757127e-07
- O 0 1.2831503681809409e-07
dependent O 0 7.494342213476557e-08
colocalization O 0 5.251247330306796e-06
of O 0 1.5047957901970221e-07
BARD1 O 1 0.9996814727783203
and O 0 1.0302903064030033e-07
BRCA1 O 0 8.074341906194604e-08
indicates O 0 5.907176969799366e-09
a O 0 5.021471238819686e-09
role O 0 2.2787155273817916e-08
for O 0 4.010185961078605e-08
BARD1 O 1 0.9999704360961914
in O 0 1.3073417903797235e-07
BRCA1 O 0 3.278659050920396e-06
- O 0 2.5829660899034934e-06
mediated O 0 0.0010060578351840377
tumor B-Disease 1 0.7758088111877441
suppression O 0 0.026764748618006706
. O 0 3.725008127730689e-06

Ethnic O 0 4.411088411870878e-06
differences O 0 2.4167500214389293e-06
in O 0 2.6268514830007916e-07
the O 0 3.317365440125286e-07
HFE O 0 0.01805919222533703
codon O 0 6.812057108618319e-06
282 O 0 9.919273907144088e-06
( O 0 9.144871455646353e-07
Cys O 1 0.821781575679779
/ O 0 0.0004189192259218544
Tyr O 0 0.002655538497492671
) O 0 5.750162017648108e-07
polymorphism O 0 5.41432382306084e-06
. O 0 7.968361614985042e-07

Recent O 0 2.056514858850278e-06
studies O 0 1.6372817412957374e-07
have O 0 9.43150713084151e-09
shown O 0 3.343970078617531e-08
that O 0 6.765912985429168e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9988040924072266
HH B-Disease 1 1.0
) O 0 6.440029665100155e-08
is O 0 3.181551022635176e-09
likely O 0 1.0696046714997465e-08
to O 0 1.1389242882131612e-09
be O 0 9.905984921232402e-10
caused O 0 3.884159482936411e-08
by O 0 2.768458573498833e-09
homozygosity O 0 2.5055794594663894e-06
for O 0 3.806329473832193e-09
a O 0 1.4259402547622813e-08
Cys282Tyr O 0 2.5085539618885377e-06
mutation O 0 9.533532185912463e-09
in O 0 2.327827708370478e-09
the O 0 3.5656377406212414e-08
HFE O 1 0.6006360650062561
gene O 0 5.663028446178942e-07
located O 0 2.2026630119853507e-07
4 O 0 8.489989795634756e-07
. O 0 5.337211632649996e-07

5 O 0 0.00012160171172581613
Mb O 0 0.0009511706884950399
telomeric O 0 0.0002010442258324474
to O 0 1.4800724557062495e-06
HLA O 0 0.0008468153537251055
- O 0 1.472998883400578e-05
A O 0 6.581463821930811e-06
. O 0 1.7830886918090982e-06

Population O 0 3.063652087575974e-08
studies O 0 2.269476695460071e-08
of O 0 5.7606710512914105e-09
this O 0 1.0112621851021686e-09
polymorphism O 0 2.9113325084040298e-08
are O 0 1.4552503646569903e-10
facilitated O 0 8.637686121915067e-09
by O 0 3.165774586921799e-10
the O 0 1.671250138279845e-09
fact O 0 2.7166935367972656e-09
that O 0 5.20921583646583e-10
the O 0 7.855363470810062e-09
Cys282Tyr O 0 9.218158993462566e-06
mutation O 0 4.43664482929762e-08
creates O 0 9.754424468155776e-08
a O 0 6.287835674356756e-08
Rsal O 0 1.5557450751657598e-05
restriction O 0 4.3882030809072603e-07
site O 0 6.38070616787445e-07
. O 0 1.6207845021654066e-07

We O 0 1.4275888133852277e-06
have O 0 7.097367671349275e-08
studied O 0 2.7261506829745485e-07
the O 0 3.447941665513099e-08
codon O 0 2.2004311972523283e-07
282 O 0 1.6720549638193916e-06
( O 0 2.517612927022128e-07
Cys O 1 0.9926134347915649
/ O 0 0.0004547182470560074
Tyr O 0 0.0010729740606620908
) O 0 2.5154955451966998e-08
polymorphism O 0 1.0340583855850127e-07
in O 0 8.56458015618955e-10
different O 0 3.1590852156426763e-10
ethnic O 0 2.565342605009846e-09
groups O 0 4.1034113884563794e-09
. O 0 6.205495139965933e-08

In O 0 3.868028670694912e-07
agreement O 0 2.0439530601379374e-07
with O 0 6.756328829737868e-09
previous O 0 7.949039115828782e-08
observations O 0 2.4571474455115094e-07
the O 0 7.081425934529761e-08
Tyr O 0 4.9087644583778456e-05
allele O 0 1.856784024312219e-07
appeared O 0 2.872780768825578e-08
to O 0 1.0208744960493732e-09
be O 0 1.2744548749665796e-09
rare O 0 4.423361943395321e-08
or O 0 2.5348912302547433e-08
absent O 0 7.526838317062357e-07
in O 0 7.776190358299573e-09
Asiatic O 0 5.43435589861474e-07
( O 0 2.8096214244044404e-09
Indian O 0 6.675580266346515e-08
, O 0 1.0705088371310012e-08
Chinese O 0 1.2851477038111625e-07
) O 0 1.1133292510123738e-08
populations O 0 7.171147586859661e-08
. O 0 5.860862870576966e-07

The O 0 2.3683294330112403e-06
highest O 0 1.4902815337336506e-06
allele O 0 1.0875830014356325e-07
frequency O 0 9.386215538143006e-08
( O 0 3.964000239164989e-09
7 O 0 2.103708318657027e-08
. O 0 1.0377344539236333e-09
5 O 0 7.272828561610822e-09
% O 0 1.4002436987681222e-09
) O 0 1.5399038710839363e-09
was O 0 3.01275058234296e-08
found O 0 1.5761067118091887e-08
in O 0 4.968711664332659e-08
Swedes O 0 2.1465859390445985e-05
. O 0 3.519701294862898e-06

Saamis O 0 0.0017263931222259998
( O 0 7.473329333151923e-07
2 O 0 4.729319300622592e-07
% O 0 9.644677945175317e-09
) O 0 2.8908520022241646e-09
and O 0 5.386040058397157e-09
Mordvinians O 0 1.7310781913693063e-05
( O 0 1.990528097906008e-08
1 O 0 6.331389101887908e-08
. O 0 1.5918795170932754e-09
8 O 0 9.299836456477806e-09
% O 0 4.116312291024826e-10
) O 0 2.949335220492344e-10
had O 0 2.0903161424001837e-09
significantly O 0 6.299297083955935e-09
lower O 0 2.6981767931033573e-08
frequencies O 0 1.670008131782197e-08
of O 0 7.1444947735699316e-09
the O 0 2.339129423489794e-08
Tyr O 0 1.5799396351212636e-05
allele O 0 9.703317118692212e-07
. O 0 6.159982604003744e-07

Comparisons O 0 2.8304873467277503e-06
with O 0 4.559232991141471e-08
allele O 0 1.6285936510485044e-07
frequencies O 0 8.174569643415452e-08
based O 0 2.7009315672898992e-08
on O 0 1.7375276328834843e-08
prevalence O 0 7.295728465805951e-08
estimates O 0 2.7373443955980292e-08
of O 0 2.0812593959362857e-07
HH B-Disease 1 1.0
showed O 0 4.454676343357278e-07
some O 0 5.813420855815821e-09
disagreements O 0 1.2500348134381056e-07
with O 0 1.9082562197070274e-09
the O 0 4.203422054871453e-09
RFLP O 0 2.7258778345640167e-07
data O 0 4.9283968017732604e-09
, O 0 1.940822613732962e-09
particularly O 0 2.3584334485349245e-08
in O 0 5.127559887796451e-08
Finns O 0 2.361361293878872e-05
. O 0 1.9955286916228943e-06

The O 0 4.592994628183078e-06
newly O 0 1.1857740901177749e-05
described O 0 3.0883456929586828e-06
HFE O 1 0.9864773750305176
marker O 0 7.645808182132896e-06
provides O 0 6.731788460001553e-08
a O 0 3.8707121952086254e-09
new O 0 3.6729319585759868e-09
approach O 0 1.0804122929641835e-08
to O 0 8.081144087235259e-10
the O 0 1.125522341993701e-09
screening O 0 7.848010241673364e-09
of O 0 1.4020616667664854e-08
HH B-Disease 1 0.9725059866905212
as O 0 2.533127130277535e-08
well O 0 2.7139177571910977e-09
as O 0 8.017919661540418e-10
studies O 0 2.7648794365120466e-10
of O 0 5.879163267330512e-10
the O 0 9.334824024875843e-10
relationship O 0 8.961717590239004e-09
between O 0 1.5194059344025845e-08
the O 0 1.4588431440643035e-07
HFE O 1 0.9999470710754395
Tyr O 0 0.0007746310438960791
allele O 0 1.3237935547749657e-07
and O 0 8.655662853129797e-09
different O 0 3.6659631774682566e-08
disorders O 1 0.9733873009681702
including O 0 1.649139630899299e-05
cancer B-Disease 1 1.0

Autosomal B-Disease 1 0.9999961853027344
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999997615814209
associated O 0 1.7714411342240055e-06
with O 0 4.5788411284775066e-08
a O 0 1.1056795301556122e-07
missense O 0 1.235136096511269e-06
mutation O 0 6.054257539744867e-08
encoding O 0 7.724152055743616e-07
Gly23 O 0 8.07378746685572e-05
- O 0 5.767979928350542e-06
- O 0 6.036505055817543e-06
> O 0 1.1778216503444128e-05
Val O 0 2.083605431835167e-05
in O 0 1.1320058490582596e-07
neurophysin O 0 0.00015313659969251603
II O 1 1.0
. O 0 1.653899198572617e-05

Autosomal B-Disease 1 0.9999716281890869
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.00013605941785499454
ADNDI B-Disease 1 1.0
) O 0 1.318050379950364e-07
is O 0 9.064277328718617e-09
an O 0 8.838679121936366e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.09027089178562164
by O 0 6.82621461578492e-08
progressive O 1 0.9998500347137451
degeneration O 1 1.0
of O 0 0.0036556704435497522
the O 0 1.4918721717549488e-05
magnocellular O 1 0.9997327923774719
neurons O 0 2.265265948153683e-06
of O 0 5.180947368899069e-07
the O 0 2.1601638309221016e-06
hypothalamus O 0 0.00011117786925751716
leading O 0 5.615912414214108e-06
to O 0 1.9023953967689522e-08
decreased O 0 1.858644225194439e-07
ability O 0 4.7721425033842024e-08
to O 0 1.2671645066575365e-08
produce O 0 7.33244647221909e-08
the O 0 9.484511309665322e-08
hormone O 0 6.068501079425914e-07
arginine O 0 6.215528856046149e-07
vasopressin O 0 2.4993937586259563e-06
( O 0 6.300032140416079e-08
AVP O 0 2.012994264077861e-05
) O 0 6.312722433676754e-08
. O 0 2.8591344403139374e-07

Affected O 0 1.8234665049021714e-06
individuals O 0 1.3161707279607526e-08
are O 0 1.5832285482630937e-09
not O 0 3.7231802085813115e-09
symptomatic O 0 0.0029376517049968243
at O 0 1.0051229537566542e-07
birth O 0 3.7860864665617555e-08
, O 0 9.802890721388735e-10
but O 0 7.108688082624326e-10
usually O 0 1.4268489501034765e-08
develop O 0 9.114171916735359e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 1.0
at O 0 0.0001041042705764994
1 O 0 8.758448529988527e-06
- O 0 1.7562686480232514e-05
6 O 0 3.487004869384691e-05
yr O 0 0.003494169795885682
of O 0 2.390252404893545e-07
age O 0 5.743547148995276e-07
. O 0 4.62369627030057e-07

The O 0 1.648949364607688e-06
genetic O 0 1.0616088275128277e-06
locus O 0 4.2414859535711e-07
of O 0 6.138055397286735e-08
the O 0 7.08889871248175e-08
disease O 0 0.118021160364151
is O 0 4.605819370340214e-08
the O 0 3.2788483395052026e-07
AVP O 1 0.9999243021011353
- O 0 0.0004463938530534506
neurophysin O 1 0.9996542930603027
II O 1 1.0
( O 0 1.439831521565793e-06
NPII O 1 0.9979027509689331
) O 0 4.844082912569547e-09
gene O 0 2.6488966575755057e-09
, O 0 3.119352276481635e-10
and O 0 7.007320279583951e-10
mutations O 0 4.691313559845867e-09
that O 0 9.045861282253043e-10
cause O 0 3.485329943941906e-05
ADNDI B-Disease 1 1.0
have O 0 1.645199354527449e-08
been O 0 1.6145565995273614e-09
found O 0 2.1849105857896234e-10
in O 0 5.82706938256905e-11
both O 0 2.391060960338365e-10
the O 0 2.159551204528043e-09
signal O 0 1.8241468069390976e-07
peptide O 0 9.599918371350213e-08
of O 0 6.750226333451792e-08
the O 0 2.674684651537973e-07
prepro O 0 0.0009300235542468727
- O 0 0.00014499106328003109
AVP O 1 0.9972230195999146
- O 0 7.344958430621773e-05
NPII O 1 0.5189123153686523
precursor O 0 7.308357453439385e-06
and O 0 6.074580483073078e-08
within O 0 2.707172939153679e-07
NPII O 1 0.6946825981140137
itself O 0 3.0424898795899935e-06
. O 0 1.2473308288463159e-06

An O 0 9.943245231625042e-07
affected O 0 9.6481005584792e-07
girl O 0 1.0550866136327386e-06
who O 0 3.834143669223522e-08
presented O 0 1.3083345606901275e-07
at O 0 9.685089708000305e-08
9 O 0 4.308501289074229e-08
months O 0 7.227829890155135e-09
of O 0 3.015895444491434e-08
age O 0 3.5815602927868895e-08
and O 0 4.331016878467153e-09
her O 0 1.1916124753597046e-09
similarly O 0 2.5595365826802663e-09
affected O 0 3.5468943337946257e-09
younger O 0 2.307380668753467e-07
brother O 0 1.5725325965831871e-06
and O 0 1.736249011230484e-08
father O 0 8.115084142445994e-07
were O 0 1.5999285452039658e-08
all O 0 7.225441911451469e-10
found O 0 6.342877889586873e-10
to O 0 2.002246562993193e-10
have O 0 5.427141513969502e-10
a O 0 8.546797047870314e-09
novel O 0 1.3938203835550667e-07
missense O 0 2.3892769718258933e-07
mutation O 0 1.4519138780144658e-08
( O 0 5.5999116455041076e-09
G1758 O 0 1.6363417216780363e-06
- O 0 6.934531029401114e-07
- O 0 1.0449526826050715e-06
> O 0 8.061674634518567e-07
T O 0 2.6990861101694463e-07
) O 0 7.058912343538282e-10
encoding O 0 3.84250276042053e-09
the O 0 1.8480078578519965e-09
amino O 0 2.498547813090113e-09
acid O 0 3.7436169719740064e-09
substitution O 0 3.1018885238154326e-08
Gly23 O 0 4.20119431510102e-06
- O 0 1.311199184783618e-06
- O 0 2.3728146061330335e-06
> O 0 1.0590550118649844e-05
Val O 0 1.92422085092403e-05
within O 0 1.1426562878114055e-06
NPII O 0 0.003557562595233321
. O 0 2.5851741156657226e-06

The O 0 1.280278183912742e-06
mutation O 0 3.6204386333338334e-07
was O 0 2.1571921138274774e-07
confirmed O 0 4.8777224037621636e-08
by O 0 6.153808129738536e-09
restriction O 0 1.2530244930530898e-07
endonuclease O 0 4.830430498259375e-06
analysis O 0 4.089436345111608e-07
. O 0 6.102499128246563e-07

A O 0 0.0001896474277600646
T1 O 1 0.9903197884559631
- O 0 1.2113839147787075e-05
weighted O 0 2.7934916602134763e-07
magnetic O 0 4.344629758179508e-07
resonance O 0 5.800840767733462e-07
imaging O 0 2.5828280740824994e-06
of O 0 3.425468548812205e-07
the O 0 4.160640855843667e-06
fathers O 0 0.14691728353500366
pituitary O 1 0.813424289226532
gland O 0 8.754916052566841e-05
demonstrates O 0 1.048914555212832e-06
an O 0 4.927553831635123e-08
attenuated O 0 2.699832657526713e-05
posterior O 0 5.1141400035703555e-05
pituitary O 0 0.003332678461447358
bright O 0 0.00047998418449424207
spot O 0 0.00037219247315078974
. O 0 9.333661182608921e-06

This O 0 3.868127862460824e-07
mutation O 0 3.832433606021368e-07
may O 0 5.000141811706271e-08
be O 0 4.157311828123511e-09
valuable O 0 1.3885031080462795e-07
for O 0 2.6064070901554715e-09
developing O 0 2.2012555334072204e-08
models O 0 1.1927910215092652e-08
of O 0 1.1424837254025988e-07
dominantly B-Disease 1 0.9999396800994873
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 1.0309547349152126e-07
as O 0 3.147887284171702e-09
the O 0 1.009908934257453e-09
early O 0 7.4115780179795365e-09
age O 0 5.408603009904311e-10
of O 0 1.7956659492668336e-09
onset O 1 0.6938715577125549
of O 0 5.941496965533588e-07
symptoms O 0 0.0540960356593132
suggests O 0 5.9160875309771654e-08
that O 0 8.950911539740147e-11
this O 0 9.163019648594783e-11
mutation O 0 9.806612188967279e-10
may O 0 1.251197701002127e-09
be O 0 1.157932527640071e-09
particularly O 0 3.0159931441176013e-08
deleterious O 0 2.422097793441935e-07
to O 0 1.4903987377579142e-08
the O 0 1.3375712626384484e-07
magnocellular O 0 0.0018923085881397128
neuron O 0 8.949044968176167e-06
. O 0 1.2652138536850543e-07
. O 0 5.061041861154081e-07

Frequent O 0 1.5373330825241283e-05
inactivation O 0 0.0006234420579858124
of O 0 5.5356849770760164e-05
PTEN O 1 1.0
/ O 1 0.9999998807907104
MMAC1 O 1 1.0
in O 0 1.2396085367072374e-06
primary O 1 0.96739262342453
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1334673874662258e-05

Sporadic B-Disease 1 0.9996389150619507
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 6.668213700322667e-06
the O 0 9.454799254626778e-08
most O 0 4.151020860376775e-09
common O 0 7.436701565666226e-08
male B-Disease 0 5.3358167662054257e-08
cancer I-Disease 0 1.4209238543116953e-05
in O 0 2.2535673327439554e-09
the O 0 2.0679907564158384e-08
Western O 0 2.9418848498607986e-05
world O 0 7.865696716180537e-08
, O 0 9.770838582667807e-10
yet O 0 1.479967925988035e-09
many O 0 1.3379292118642638e-10
of O 0 1.640313773698665e-09
the O 0 1.943067262644149e-09
major O 0 2.2741609484455694e-08
genetic O 0 2.825918166138308e-08
events O 0 6.151751885674628e-10
involved O 0 3.762642697413554e-10
in O 0 1.9942997253608041e-10
the O 0 7.897257847666594e-10
progression O 0 1.08390089792465e-07
of O 0 1.3393373521353169e-08
this O 0 2.1555843776610573e-09
often O 0 8.774668458499946e-08
fatal O 0 0.007576330099254847
cancer B-Disease 1 0.9891389012336731
remain O 0 9.229480610883911e-07
to O 0 2.0487689766923722e-08
be O 0 1.1478788053409517e-07
elucidated O 0 0.008165998384356499
. O 0 1.951731974259019e-06

Numerous O 0 1.113051075662952e-05
cytogenetic O 0 0.0005362352239899337
and O 0 6.341286962197046e-07
allelotype O 0 0.00020117730309721082
studies O 0 3.963987182942219e-08
have O 0 2.1492045920723513e-09
reported O 0 5.266031166684115e-09
frequent O 0 2.6261945507144446e-08
loss O 0 1.0078102832267177e-06
of O 0 1.5683997844462283e-05
heterozygosity O 1 1.0
on O 0 3.2846288377186283e-05
chromosomal O 0 1.2495986084104516e-05
arm O 0 5.380093716667034e-05
10q O 0 8.79160415934166e-06
in O 0 4.626845395705459e-08
sporadic B-Disease 1 0.9556521773338318
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.5310727475443855e-05

Deletion O 0 1.9091046851826832e-05
mapping O 0 9.329025942861335e-07
studies O 0 4.696983424423706e-08
have O 0 6.696594390120936e-09
unambiguously O 0 5.145106030113311e-08
identified O 0 1.1801679633549611e-08
a O 0 7.944155555605903e-09
region O 0 4.328648728346707e-08
of O 0 2.208601017628098e-07
chromosome O 0 4.5069671728015237e-07
10q23 O 0 6.433265298255719e-07
to O 0 1.223501189251408e-09
be O 0 7.324472139913496e-10
the O 0 3.1034610437075116e-09
minimal O 0 2.7341047825757414e-07
area O 0 7.69560273283787e-08
of O 0 7.98671422330699e-08
loss O 0 4.268122665962437e-06
. O 0 3.009738293258124e-06

A O 0 1.032399359246483e-05
new O 0 1.4235279195418116e-06
tumor B-Disease 0 8.020235327421688e-06
suppressor O 0 1.0225537153019104e-05
gene O 0 1.153434681100407e-07
, O 0 5.73170666484657e-08
PTEN O 1 0.9999935626983643
/ O 1 0.9066171050071716
MMAC1 O 1 1.0
, O 0 2.4207398041653505e-07
was O 0 9.610853339836467e-07
isolated O 0 3.2880168987503566e-07
recently O 0 4.0170526460769906e-08
at O 0 2.8552602504561264e-09
this O 0 1.273526006873027e-10
region O 0 4.330248604134113e-09
of O 0 1.820607842262234e-08
chromosome O 0 6.829548482301107e-08
10q23 O 0 2.2993167192453257e-07
and O 0 7.875416430103144e-10
found O 0 3.624548994274335e-10
to O 0 1.6001099056861534e-10
be O 0 2.201979848459601e-10
inactivated O 0 2.6031791833247553e-08
by O 0 2.2986013092918256e-10
mutation O 0 2.081118610774979e-09
in O 0 3.2498321811402775e-09
three O 0 4.4231049400877964e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9219856262207031
lines O 0 1.5544433153991122e-06
. O 0 3.3296632295787276e-07

We O 0 1.106772106140852e-05
screened O 0 3.8002661312930286e-05
80 O 0 1.4587790246878285e-05
prostate B-Disease 1 0.9999986886978149
tumors I-Disease 1 1.0
by O 0 6.41643964627292e-08
microsatellite O 0 1.607692138350103e-05
analysis O 0 2.167252155516053e-08
and O 0 6.393470197707529e-09
found O 0 6.054948542555394e-09
chromosome O 0 1.3055970526920646e-08
10q23 O 0 1.7262246387872437e-07
to O 0 2.442876567698704e-09
be O 0 4.404249409617478e-09
deleted O 0 6.429180388067834e-08
in O 0 6.176656519585322e-09
23 O 0 4.778582152198396e-08
cases O 0 3.6455119811762415e-08
. O 0 2.167019204080134e-07

We O 0 5.984774134049076e-07
then O 0 9.956342239547666e-08
proceeded O 0 3.827764771813236e-08
with O 0 3.788885594158131e-10
sequence O 0 8.678207041867836e-10
analysis O 0 9.791100152867216e-10
of O 0 6.375265648728146e-09
the O 0 2.0447791015953953e-08
entire O 0 1.3327471606316976e-06
PTEN O 1 0.9999998807907104
/ O 0 0.47119760513305664
MMAC1 O 1 0.9998871088027954
coding O 0 3.5374084745853906e-06
region O 0 3.0368028092198074e-08
and O 0 2.795189413262733e-09
tested O 0 1.1630285179364819e-08
for O 0 1.3567148515747363e-09
homozygous O 0 1.3683191468771838e-08
deletion O 0 1.0899956492949059e-08
with O 0 7.516007816121828e-10
new O 0 2.1025691410159197e-08
intragenic O 0 2.202050200139638e-05
markers O 0 1.043943171907813e-07
in O 0 5.192223873073942e-10
these O 0 4.4211725946929903e-10
23 O 0 3.8969210081063466e-09
cases O 0 7.890542663702149e-10
with O 0 1.7655454875864507e-09
10q23 O 0 3.1023823794384953e-06
loss O 0 2.533620772737777e-06
of O 0 1.5512947356910445e-05
heterozygosity O 1 0.9999963045120239
. O 0 2.5597004423616454e-05

The O 0 4.298757971810119e-07
identification O 0 1.5646534734514717e-07
of O 0 2.2944911393096845e-07
the O 0 2.46457972252756e-07
second O 0 2.7743649297917727e-06
mutational O 0 0.00042408984154462814
event O 0 1.8102704757438914e-07
in O 0 5.9383782335942215e-09
10 O 0 9.049421656470713e-09
( O 0 2.4175956792049647e-09
43 O 0 1.0601949185229387e-07
% O 0 3.0983407839357824e-08
) O 0 2.4631677320030576e-07
tumors B-Disease 1 1.0
establishes O 0 0.009997615590691566
PTEN O 1 1.0
/ O 0 0.03250407427549362
MMAC1 O 0 0.47654008865356445
as O 0 3.2824207352177837e-08
a O 0 8.400339979175442e-09
main O 0 4.752005722252761e-08
inactivation O 0 1.2628498780031805e-07
target O 0 8.04945887722397e-09
of O 0 1.4624390587414382e-08
10q O 0 1.0891467354667839e-06
loss O 0 3.880298322656017e-07
in O 0 3.52947147064242e-08
sporadic B-Disease 1 0.9846218824386597
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.65108393857372e-07
. O 0 4.981332608622324e-07

Risk O 0 5.7738361647352576e-05
reversals O 0 6.0305075749056414e-05
in O 0 8.123309669372247e-08
predictive O 0 4.991956643607409e-07
testing O 0 3.7116396356395853e-07
for O 0 4.622620224381535e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.218994384544203e-05

The O 0 1.191150545309938e-06
first O 0 1.1222906692864854e-07
predictive O 0 4.960303385814768e-07
testing O 0 1.6965407212410355e-07
for O 0 1.2751114297770982e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.066827384325734e-07
HD B-Disease 1 0.9969039559364319
) O 0 7.88258969208755e-09
was O 0 1.9676230422760455e-08
based O 0 2.2698478652216636e-09
on O 0 2.2392820930861035e-09
analysis O 0 1.6695614890593902e-09
of O 0 2.899129158961955e-09
linked O 0 5.1587058180757595e-08
polymorphic O 0 2.2586361581033998e-07
DNA O 0 3.2210894573836413e-07
markers O 0 2.25305267775866e-08
to O 0 3.4543629068295445e-10
estimate O 0 1.4954866234262454e-09
the O 0 2.1458621546344148e-09
likelihood O 0 4.468031633564351e-08
of O 0 7.927719991585036e-08
inheriting O 0 2.1441741182570695e-07
the O 0 2.9516119326444823e-08
mutation O 0 2.243507069010775e-08
for O 0 2.622435246735222e-08
HD B-Disease 0 0.00038701281300745904
. O 0 1.7085736772060045e-06

Limits O 0 2.194336275351816e-06
to O 0 3.261532910414644e-08
accuracy O 0 9.691778757314751e-08
included O 0 1.6400329982957373e-08
recombination O 0 2.678129362720938e-08
between O 0 4.265074515785727e-09
the O 0 2.25713780999115e-09
DNA O 0 8.03614668143382e-08
markers O 0 1.9565156605949596e-08
and O 0 1.0066780742334913e-09
the O 0 3.917952628995636e-09
mutation O 0 9.646848653233064e-09
, O 0 2.7045439221495826e-09
pedigree O 0 1.187717515449549e-07
structure O 0 4.673337983263082e-08
, O 0 1.0593126376079454e-09
and O 0 7.931342804745611e-10
whether O 0 5.440594086358885e-10
DNA O 0 1.1712630865190476e-08
samples O 0 9.170734172059269e-10
were O 0 8.235125359412621e-10
available O 0 6.581164058161448e-09
from O 0 2.6831504129631867e-08
family O 0 1.8209348695563676e-07
members O 0 4.3229061219562936e-08
. O 0 5.005705361327273e-07

With O 0 7.992123585154332e-08
direct O 0 1.7454738099331735e-07
tests O 0 3.730447062366693e-08
for O 0 6.614349068456704e-09
the O 0 2.3409818084019207e-08
HD B-Disease 0 0.0003115482977591455
mutation O 0 3.264096903876634e-08
, O 0 4.250659380033994e-09
we O 0 1.2474279387220122e-09
have O 0 4.757551019807238e-10
assessed O 0 9.308656068185428e-09
the O 0 3.150668392848388e-09
accuracy O 0 4.0331595840825685e-08
of O 0 4.22268353617028e-09
results O 0 7.325813289327243e-10
obtained O 0 2.233821794206392e-09
by O 0 2.980813096353785e-10
linkage O 0 2.7010603531607558e-08
approaches O 0 2.480542882210557e-08
when O 0 1.7888119874243102e-09
requested O 0 8.99976182466844e-09
to O 0 1.0386690396657627e-09
do O 0 3.5031971767907066e-10
so O 0 3.436068374274015e-10
by O 0 3.5236763507029423e-10
the O 0 3.6414862236711087e-09
test O 0 2.5718698282162222e-08
individuals O 0 6.098993310388323e-09
. O 0 2.1583197451491287e-07

For O 0 4.2911230480058293e-07
six O 0 5.843918415848748e-08
such O 0 2.3312403119035707e-09
individuals O 0 4.227153904690084e-10
, O 0 1.512892811028621e-09
there O 0 2.75231082369487e-09
was O 0 5.4239080782281235e-08
significant O 0 1.4717377538886467e-08
disparity O 0 1.0408992068278167e-07
between O 0 7.804213275619531e-09
the O 0 2.00212628698182e-08
tests O 0 7.049943917536439e-08
. O 0 1.3240523344393296e-07

Three O 0 3.3676096791168675e-06
went O 0 1.9063601257585105e-06
from O 0 3.6036794881511014e-08
a O 0 8.260141903804197e-09
decreased O 0 2.123911357898578e-08
risk O 0 3.080968014046448e-08
to O 0 2.1188160115315213e-09
an O 0 5.543944192609729e-10
increased O 0 5.094743293909687e-09
risk O 0 4.046273360813757e-08
, O 0 1.148732997613422e-09
while O 0 3.8602704366397234e-10
in O 0 1.4450056429193836e-10
another O 0 5.817466508517555e-10
three O 0 5.032332328624989e-10
the O 0 1.3112189112263195e-09
risk O 0 4.822237897883497e-08
was O 0 9.899836328486344e-08
decreased O 0 1.850347786103157e-07
. O 0 3.013480807112501e-07

Knowledge O 0 3.3817010262282565e-05
of O 0 3.1650160963181406e-06
the O 0 3.1528287536275457e-07
potential O 0 2.799182254875632e-07
reasons O 0 3.523344105360593e-08
for O 0 1.3500524032039607e-09
these O 0 3.8483241593390005e-10
changes O 0 1.0534573213760723e-09
in O 0 7.763485965206485e-10
results O 0 9.87736448188059e-10
and O 0 9.122166355624017e-10
impact O 0 6.5778760216517185e-09
of O 0 9.948574408724653e-09
these O 0 2.0534156597307174e-09
risk O 0 4.839505507447939e-08
reversals O 0 5.772711801910191e-07
on O 0 6.357039339377479e-09
both O 0 5.64665036950629e-10
patients O 0 7.827916981284488e-09
and O 0 4.955326815547778e-09
the O 0 3.3743717153811303e-08
counseling O 0 3.349396422436257e-07
team O 0 7.708409022200158e-09
can O 0 7.973282034612339e-10
assist O 0 1.397235038780309e-08
in O 0 1.873911914529458e-09
the O 0 3.5204403836530673e-09
development O 0 1.9101507930940897e-08
of O 0 6.748575920312305e-09
strategies O 0 2.6573793832085357e-08
for O 0 1.2332337373521796e-09
the O 0 3.596975606257047e-09
prevention O 0 1.1137012734252494e-07
and O 0 6.116254724908288e-10
, O 0 1.4447851248711174e-10
where O 0 1.4781474655389815e-10
necessary O 0 1.3328942394252863e-09
, O 0 4.755555393920474e-10
management O 0 5.043452322439634e-09
of O 0 2.7910180833146114e-09
a O 0 5.585595985735381e-09
risk O 0 5.3026511181997193e-08
reversal O 0 6.900333460180264e-08
in O 0 9.156629343642919e-10
any O 0 1.155521123230585e-09
predictive O 0 1.1209210448726026e-08
testing O 0 9.465188632873378e-09
program O 0 1.1882858252931783e-08
. O 0 7.090761755534913e-09
. O 0 6.592838985852723e-08

A O 0 2.0063898773514666e-05
novel O 0 5.145428985997569e-06
common O 0 1.8005766833084635e-06
missense O 0 1.0591175851004664e-05
mutation O 0 3.5886995419787127e-07
G301C O 0 5.25262930750614e-06
in O 0 2.4804814202639136e-08
the O 0 5.3448214742957134e-08
N O 0 1.3501994544640183e-06
- O 0 4.6428377231677587e-07
acetylgalactosamine O 0 1.0731002475949936e-05
- O 0 3.146106735130161e-07
6 O 0 2.1029464392086084e-07
- O 0 3.2442139286104066e-07
sulfate O 0 2.755611603788566e-06
sulfatase O 0 7.855961302993819e-05
gene O 0 2.1116504456131224e-07
in O 0 5.3036728786537424e-08
mucopolysaccharidosis B-Disease 0 0.0002724222431425005
IVA I-Disease 1 0.9999567270278931
. O 0 2.655686330399476e-05

Mucopolysaccharidosis B-Disease 1 0.9998835325241089
IVA I-Disease 1 1.0
( O 0 0.0023291625548154116
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 8.40992072426161e-07
is O 0 3.248637625574702e-08
an O 0 1.7432107313197776e-08
autosomal B-Disease 0 0.2731471657752991
recessive I-Disease 1 0.9999974966049194
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.02073727734386921
by O 0 1.5759511029500572e-07
a O 0 4.041575266455766e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 9.309944744018139e-07
N O 0 2.4797474907245487e-05
- O 0 8.85544613993261e-06
acetylgalactosamine O 0 0.00020365091040730476
- O 0 1.1798595096479403e-06
6 O 0 7.109086368473072e-07
- O 0 9.251502888218965e-07
sulfate O 0 4.169674502918497e-05
sulfatase O 0 0.24588394165039062
( O 0 2.734683732796839e-07
GALNS O 0 0.022958602756261826
) O 0 1.5811869502613263e-07
. O 0 2.377897345695601e-07

In O 0 3.5587763136391004e-07
previous O 0 1.4488313127003494e-07
studies O 0 3.765345724104918e-08
, O 0 4.818263565908865e-09
we O 0 7.864969231441421e-10
have O 0 2.717122360440527e-10
found O 0 6.329040624919458e-10
two O 0 6.76493971951686e-10
common O 0 2.0629560282259263e-08
mutations O 0 3.3765989115863704e-08
in O 0 4.754278748464458e-09
Caucasians O 0 1.4324821222544415e-06
and O 0 4.6097039074766144e-08
Japanese O 0 0.0001048235862981528
, O 0 5.6270454962259464e-08
respectively O 0 3.265766395088576e-07
. O 0 9.5613029316155e-07

To O 0 6.649713100159715e-07
characterize O 0 7.899953743617516e-06
the O 0 6.274884754020604e-07
mutational O 0 0.20413757860660553
spectrum O 0 3.207857662346214e-05
in O 0 4.360416916426857e-09
various O 0 8.276223595338195e-10
ethnic O 0 4.956987598170315e-10
groups O 0 5.114580980958294e-11
, O 0 9.851375964986531e-11
mutations O 0 4.2498787822253803e-10
in O 0 4.592261848568313e-10
the O 0 7.203016405554763e-09
GALNS O 0 0.07722433656454086
gene O 0 3.3179219371959334e-08
in O 0 5.2236557301910125e-09
Colombian O 0 3.6807507513003657e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 1 0.5288466811180115
were O 0 4.437270817447825e-08
investigated O 0 6.769191429611965e-08
, O 0 2.9244096033664846e-09
and O 0 2.52980369985778e-09
genetic O 0 4.7796302027336424e-08
backgrounds O 0 6.334744284686167e-09
were O 0 2.8722257905400284e-09
extensively O 0 3.1126969890493683e-09
analyzed O 0 1.649424485883344e-09
to O 0 5.001529190806764e-10
identify O 0 1.243133596062762e-09
racial O 0 6.513116157513821e-10
origin O 0 1.2432853635502283e-09
, O 0 7.30031535223219e-10
based O 0 2.963252976329045e-09
on O 0 5.665662605736088e-09
mitochondrial O 0 4.998442104664491e-09
DNA O 0 1.5020223287365297e-08
( O 0 1.1923878551201028e-09
mtDNA O 0 1.325413734321046e-08
) O 0 6.105417948987224e-09
lineages O 0 3.862970743284677e-07
. O 0 6.817014650550846e-07

Three O 0 4.149561391386669e-06
novel O 0 3.87700492865406e-06
missense O 0 5.943179530731868e-06
mutations O 0 2.361584989785115e-07
never O 0 1.897161752140164e-07
identified O 0 4.857371393995891e-08
previously O 0 8.772593673711526e-08
in O 0 1.3201424398090467e-09
other O 0 4.4086512218655116e-10
populations O 0 1.1267832222827678e-09
and O 0 1.0348644163826748e-09
found O 0 1.392073678552208e-09
in O 0 1.354220069416101e-09
16 O 0 1.497288337759528e-08
out O 0 4.268288833486622e-09
of O 0 3.2436659580525884e-08
19 O 0 1.5843961875816603e-07
Colombian O 0 4.916780198982451e-06
MPS B-Disease 1 0.9999972581863403
IVA I-Disease 1 1.0
unrelated O 0 1.0428252608107869e-06
alleles O 0 1.0121328664070006e-08
account O 0 2.7857420814569878e-09
for O 0 1.0444904496864638e-08
84 O 0 2.330375764358905e-06
. O 0 1.5995676676539006e-06

2 O 0 4.227870249451371e-06
% O 0 2.429217360599978e-08
of O 0 2.3476532717836562e-08
the O 0 1.5466216751747197e-08
alleles O 0 1.3902170081792065e-08
in O 0 2.040200675068604e-09
this O 0 2.803358434277925e-09
study O 0 3.695455674801451e-08
. O 0 2.011577748817217e-07

The O 0 1.3519863387045916e-05
G301C O 0 9.041823795996606e-05
and O 0 6.348644774334389e-07
S162F O 0 4.2738006413856056e-06
mutations O 0 5.510593936719488e-08
account O 0 1.0240127856775416e-08
for O 0 2.726131675956367e-08
68 O 0 7.0056685217423365e-06
. O 0 5.467529263114557e-06

4 O 0 1.7219679648405872e-05
% O 0 4.5276888727130427e-07
and O 0 2.464739736751653e-07
10 O 0 8.781488531894865e-07
. O 0 1.576199110786547e-06

5 O 0 1.1521565284056123e-06
% O 0 3.1130316102689903e-08
of O 0 2.0831528502185392e-08
mutations O 0 9.511645693294213e-09
, O 0 3.962572048266111e-09
respectively O 0 1.4335815201604873e-08
, O 0 2.5033466410917526e-09
whereas O 0 2.2816948330728337e-08
the O 0 4.1548407381242214e-08
remaining O 0 2.3835514184611384e-06
F69V O 0 0.0006389267509803176
is O 0 2.990723668716555e-09
limited O 0 2.5199362596595165e-09
to O 0 8.762868763945164e-10
a O 0 9.054392791085775e-09
single O 0 4.1999701494432884e-08
allele O 0 1.634615358625524e-07
. O 0 2.6827723331734887e-07

The O 0 3.594273039198015e-06
skewed O 0 3.0813730518275406e-06
prevalence O 0 5.247107310424326e-06
of O 0 3.677785400668654e-07
G301C O 0 8.648289622215088e-06
in O 0 7.543470736948166e-09
only O 0 1.874641109012032e-09
Colombian O 0 5.390606006017151e-08
patients O 0 4.712975254506091e-08
and O 0 4.205226389331074e-09
haplotype O 0 1.6612389686088136e-07
analysis O 0 3.088238553772271e-09
by O 0 1.57132348799216e-10
restriction O 0 2.09130512907052e-09
fragment O 0 7.90752618939905e-09
length O 0 2.483003358477731e-09
polymorphisms O 0 3.5109469109784186e-08
in O 0 1.8167495285936752e-09
the O 0 2.4833124001588658e-08
GALNS O 0 0.0007084709359332919
gene O 0 1.6211362918738814e-08
suggest O 0 4.011981413754029e-09
that O 0 7.927697942555767e-10
G301C O 0 3.603150844355696e-07
originated O 0 5.042242534614161e-08
from O 0 3.6400764624744397e-09
a O 0 7.336919960465593e-09
common O 0 1.4211715892997745e-07
ancestor O 0 2.5527580874040723e-05
. O 0 1.5962364159349818e-06

Investigation O 0 4.540047939372016e-06
of O 0 5.554311428568326e-07
the O 0 4.548635956780345e-08
genetic O 0 3.6142939308092537e-08
background O 0 2.313177871471339e-09
by O 0 1.188248388572788e-10
means O 0 3.389140967868798e-09
of O 0 1.0337364741985766e-08
mtDNA O 0 1.6998374263721416e-08
lineages O 0 4.8324095835994285e-09
indicate O 0 5.743410746994471e-10
that O 0 2.862991788088465e-10
all O 0 1.70746616845463e-09
our O 0 2.7941249314267225e-08
patients O 0 7.830698223187937e-08
are O 0 6.324382684219643e-10
probably O 0 4.748816095911934e-08
of O 0 1.3482291194577556e-07
native O 0 3.1609576467417355e-07
American O 0 1.5751892306070658e-06
descent O 0 5.479136962094344e-05

Low O 0 1.5210494893835858e-05
frequency O 0 1.5517534848186187e-06
of O 0 5.239439246906841e-07
BRCA1 O 0 1.5204981309580035e-06
germline O 0 2.0351665170892375e-06
mutations O 0 1.7974898014472274e-08
in O 0 2.4127864151068934e-09
45 O 0 5.425387783475344e-08
German O 1 0.9999940395355225
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.8323936476226663e-06
. O 0 8.874949912751617e-07

In O 0 5.565838705479109e-07
this O 0 1.2688115447190285e-08
study O 0 7.131955470640605e-09
we O 0 1.0788673288075756e-09
investigated O 0 7.019041348144128e-09
45 O 0 2.3199216769853592e-08
German O 1 0.6101567149162292
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.6407256825677905e-08
for O 0 2.9057058981152295e-09
germline O 0 3.940528472412552e-07
mutations O 0 4.3058374643578645e-09
in O 0 2.1489874324487346e-09
the O 0 2.6944329434286374e-08
BRCA1 O 0 1.2662484323300305e-06
gene O 0 3.626527416145109e-07
. O 0 3.28777872482533e-07

We O 0 1.1754344768633018e-06
identified O 0 5.735003014706308e-07
four O 0 7.280632274841992e-08
germline O 0 1.9756382698687958e-06
mutations O 0 5.1467157646811756e-08
in O 0 1.1679546219056647e-08
three O 0 8.037970644636516e-08
breast B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999974966049194
families O 0 5.2719634879849764e-08
and O 0 1.8048796235348163e-08
in O 0 2.0922239940546206e-08
one O 0 1.8736930087470682e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 4.781190000358038e-06
. O 0 1.478275168942389e-09
among O 0 2.84290174734636e-10
these O 0 1.2700476781368764e-10
were O 0 4.678791798440329e-10
one O 0 4.911550055552993e-10
frameshift O 0 3.2387077908424544e-08
mutation O 0 7.508356159036111e-10
, O 0 3.159175698819183e-10
one O 0 6.105508321141428e-10
nonsense O 0 5.023102289669623e-08
mutation O 0 4.6118033836251016e-09
, O 0 1.3467218451523877e-09
one O 0 1.1400980159947949e-09
novel O 0 5.3204715300125827e-08
splice O 0 5.181663595976715e-07
site O 0 1.1268718402845934e-08
mutation O 0 1.5015746424040799e-09
, O 0 9.408092083162956e-10
and O 0 3.117087699067156e-09
one O 0 4.0313825167004325e-08
missense O 0 8.641200111014768e-06
mutation O 0 1.5664467127862736e-06
. O 0 1.56711303134216e-06

The O 0 4.685311978391837e-06
missense O 0 9.479350410401821e-06
mutation O 0 3.6825235838477965e-07
was O 0 7.839005320420256e-07
also O 0 2.0684284507410666e-08
found O 0 8.75401884314897e-09
in O 0 2.599110793255477e-08
2 O 0 2.313098775630351e-06
. O 0 1.6971215472949552e-06

8 O 0 3.1881183986115502e-06
% O 0 2.5931489844310818e-08
of O 0 1.7656237361052263e-08
the O 0 9.986502291781107e-09
general O 0 2.262324017010542e-08
population O 0 5.788832191377935e-10
, O 0 6.685794140537382e-10
suggesting O 0 1.4367779188617646e-09
that O 0 1.9377588422742065e-10
it O 0 2.857067360473309e-10
is O 0 5.26516441556879e-10
not O 0 1.3181347124913145e-09
disease O 0 1.229301574312558e-06
associated O 0 4.440861118837347e-07
. O 0 1.4810834727541078e-06

The O 0 6.685723406008037e-07
average O 0 6.836925336983768e-08
age O 0 2.0788979426811238e-08
of O 0 2.646191354926941e-08
disease O 0 0.3090718984603882
onset O 1 1.0
in O 0 8.665545436770117e-08
those O 0 1.3103146123683018e-08
families O 0 1.2117110870235592e-08
harbouring O 0 2.4349756131414324e-06
causative O 0 3.4553389127722767e-07
mutations O 0 3.524285219214107e-08
was O 0 1.9752323510147107e-07
between O 0 1.1368829433422434e-07
32 O 0 2.377503506068024e-06
. O 0 1.76075275248877e-06

3 O 0 3.914461194653995e-05
and O 0 2.5792885480768746e-06
37 O 0 2.6070852982229553e-05
. O 0 7.034395821392536e-06

4 O 0 1.4634286344517022e-05
years O 0 3.8483543107759033e-07
, O 0 1.6666415803001655e-08
whereas O 0 4.300274625279599e-08
the O 0 4.78617145915905e-08
family O 0 2.664104385985411e-07
harbouring O 0 6.429023869714001e-06
the O 0 7.229294141097853e-08
missense O 0 4.5148914296078146e-07
mutation O 0 1.986841091650149e-08
had O 0 1.5117107565743026e-08
an O 0 5.128611424431995e-10
average O 0 1.4679634174896705e-09
age O 0 2.2285744361028037e-09
of O 0 1.4014708504817008e-08
onset O 1 0.9946796298027039
of O 0 0.00021111522801220417
51 O 0 5.657988367602229e-05
. O 0 2.083269919239683e-06

2 O 0 0.00017114492948167026
years O 0 1.4971339624025859e-05
. O 0 8.431953574472573e-06

These O 0 4.673596833981719e-07
findings O 0 3.219182076463767e-07
show O 0 2.1920799397889823e-08
that O 0 1.2656591330539868e-09
BRCA1 O 0 9.679955326191703e-08
is O 0 1.8481031149875093e-09
implicated O 0 4.6714934143210485e-08
in O 0 2.3198230003629305e-09
a O 0 3.346169785700681e-09
small O 0 1.2161073259520094e-09
fraction O 0 5.922791146417694e-09
of O 0 3.5125552244608116e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.0789217458627718e-08
suggesting O 0 6.353645609635805e-09
the O 0 2.2757564721587187e-09
involvement O 0 1.1548364931002197e-08
of O 0 9.13348685571691e-09
another O 0 2.5739899101040464e-08
susceptibility O 0 1.5799673747096676e-06
gene O 0 1.473041493227356e-07
( O 0 1.0731872635005857e-07
s O 0 1.808764682209585e-05
) O 0 2.7021428650186863e-06

Paternal O 0 0.004810165613889694
transmission O 1 0.7639512419700623
of O 1 0.9980301260948181
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999924898147583

We O 0 7.143992775127117e-07
report O 0 5.747164522063031e-08
a O 0 1.5714929801902144e-08
rare O 0 3.93690697819693e-08
case O 0 1.0559245566810205e-07
of O 0 1.5123099501579418e-06
paternally O 1 1.0
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 1.0
DM B-Disease 1 1.0
) O 0 3.842685327981599e-05
. O 0 1.0350789125368465e-05

The O 0 1.1450778401922435e-05
proband O 0 0.00015492340025957674
is O 0 8.444279586683479e-08
a O 0 3.7690679022261975e-08
23 O 0 1.2121668646614125e-07
year O 0 2.4481112248508907e-08
old O 0 0.0001719778956612572
, O 0 0.00012221258657518774
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 4.2049214243888855e-05
who O 0 6.642753191954398e-07
suffers O 1 0.9994832277297974
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999996423721313

He O 0 1.5035894875836675e-06
presented O 0 1.0369533356424654e-06
with O 0 1.7639331417740323e-07
respiratory O 1 1.0
and O 0 2.300354935869109e-06
feeding O 0 2.0705083443317562e-05
difficulties O 0 0.0002779716160148382
at O 0 3.331449761390104e-06
birth O 0 1.2838169823226053e-05
. O 0 2.553740841904073e-06

His O 0 2.9579481633845717e-05
two O 0 5.945742032054113e-06
sibs O 1 0.9997351765632629
suffer O 0 3.7082238122820854e-05
from O 0 6.253461606320343e-07
childhood O 1 0.559857189655304
onset O 1 1.0
DM B-Disease 1 1.0
. O 1 0.5300280451774597

Their O 0 5.004969807487214e-07
late O 0 6.839495199528756e-06
father O 0 1.8857143686545896e-06
had O 0 5.394987567797216e-08
the O 0 4.389271612836865e-09
adult O 0 2.606665772120209e-09
type O 0 8.9979250716965e-09
of O 0 9.368150699629041e-08
DM B-Disease 1 1.0
, O 0 8.08277036412619e-08
with O 0 1.4861296193657836e-08
onset O 1 0.999998927116394
around O 0 3.353167983277672e-07
30 O 0 1.8125128065094032e-07
years O 0 1.003217207085072e-07
. O 0 2.36957589550002e-07

Only O 0 2.9122165301487257e-07
six O 0 2.1765481861280023e-08
other O 0 3.879298549058774e-10
cases O 0 8.377966653760893e-10
of O 0 3.8246614764148035e-09
paternal O 0 7.790155905240681e-06
transmission O 1 0.8755039572715759
of O 1 0.976834237575531
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0004791953251697123
been O 0 3.738004465958511e-07
reported O 0 7.674319135730912e-08
recently O 0 1.883609996866653e-07
. O 0 1.9856103961046756e-07

We O 0 1.3034022003921564e-06
review O 0 4.041754095851502e-07
the O 0 3.165989426179294e-08
sex O 0 5.199599417693435e-09
related O 0 1.3760031336573775e-08
effects O 0 1.0748753709322045e-07
on O 0 3.036119267108006e-08
transmission O 0 6.980978469073307e-06
of O 0 2.7587313525145873e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9962015748023987

Decreased O 0 1.0231253327219747e-05
fertility O 0 8.214633453462739e-06
of O 0 3.818984950498816e-08
males O 0 1.7637649118995569e-09
with O 0 1.0989883447720672e-09
adult O 0 8.208944279886055e-08
onset O 1 0.9999167919158936
DM B-Disease 1 1.0
and O 0 4.475460855246638e-07
contraction O 0 3.83481363996907e-07
of O 0 4.911929707418494e-08
the O 0 1.3618957517280705e-08
repeat O 0 1.860844633938541e-08
upon O 0 2.8674800311989657e-09
male O 0 1.3521088693124739e-09
transmission O 0 1.251297843118948e-09
contribute O 0 1.0934553956731818e-10
to O 0 1.2623387057875135e-10
the O 0 8.844610044356216e-10
almost O 0 1.0651536319628008e-09
absent O 0 7.978442795320007e-09
occurrence O 0 3.174688956164573e-09
of O 0 5.209526587890423e-09
paternal O 0 6.479777994172764e-07
transmission O 0 7.378789632639382e-06
of O 0 6.105390639277175e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.16161960363388062

Also O 0 2.118342081303126e-06
the O 0 2.7480484732222976e-07
fathers O 0 7.762292284496652e-07
of O 0 1.932892530476238e-07
the O 0 2.7480379571898084e-07
reported O 0 8.976670073934656e-07
congenitally O 1 0.9761273264884949
affected O 0 1.4888041732774582e-07
children O 0 2.4005361254353375e-08
showed O 0 8.257274863865405e-09
, O 0 3.170942841634883e-09
on O 0 1.0130387195772528e-08
average O 0 2.359166906273913e-08
, O 0 1.2561576667735608e-08
shorter O 0 2.28591488848906e-05
CTG O 1 0.9984033703804016
repeat O 0 4.064035692863399e-06
lengths O 0 2.1120483779668575e-06
and O 0 1.0580666343074085e-09
hence O 0 9.506603504405575e-09
less O 0 6.465454838178175e-09
severe O 0 9.345729267806746e-06
clinical O 0 0.0001083099195966497
symptoms O 0 0.00138535862788558
than O 0 7.883957486853888e-09
the O 0 1.4771428524795738e-08
mothers O 0 6.915944261720597e-09
of O 0 2.633621987158108e-09
children O 0 2.798000720005689e-09
with O 0 7.652656819345793e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9999738931655884

We O 0 7.227556579891825e-07
conclude O 0 8.776272579780198e-07
that O 0 9.838485581781242e-09
paternal O 0 3.22017240250716e-06
transmission O 0 0.00011701793118845671
of O 0 0.001643775380216539
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.00035242081503383815
rare O 0 3.49653305420361e-07
and O 0 1.4521734925665442e-09
preferentially O 0 1.7170219690498811e-09
occurs O 0 1.6978848882409636e-10
with O 0 1.1474010630507792e-10
onset O 0 0.00037391591467894614
of O 0 0.021180324256420135
DM B-Disease 1 1.0
past O 0 1.0250483683194034e-05
30 O 0 2.8185006328840245e-08
years O 0 2.1859161147830264e-09
in O 0 3.3007874211676835e-10
the O 0 1.0899992020085847e-09
father O 0 3.926250968788736e-08
. O 0 1.5024548716269237e-08
. O 0 1.4738579068307445e-07

The O 0 1.1297725905023981e-05
RB1 O 0 0.001464568660594523
gene O 0 5.279389370116405e-07
mutation O 0 4.9973959193039263e-08
in O 0 5.7951319298865656e-09
a O 0 2.4592402780854172e-08
child O 0 2.74562779623011e-07
with O 0 3.928064415958943e-07
ectopic B-Disease 1 0.9999998807907104
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00026819680351763964

The O 0 1.1710546459653415e-05
RB1 O 0 0.0009652103763073683
gene O 0 3.705733035985759e-07
mutation O 0 8.241497084782168e-08
was O 0 1.1048490478060558e-07
investigated O 0 8.817786323334076e-08
in O 0 5.75942982194988e-09
a O 0 1.6102578825893943e-08
child O 0 2.1226503577054245e-07
with O 0 1.7140003194526798e-07
ectopic B-Disease 1 0.9999861717224121
intracranial I-Disease 1 0.9999996423721313
retinoblastoma I-Disease 0 0.0071183377876877785
using O 0 2.7619410758461527e-08
DNA O 0 4.447760915127219e-08
obtained O 0 2.7082502906949912e-09
from O 0 2.023655909511035e-09
both O 0 2.7811339897709786e-09
the O 0 7.565621729099803e-08
pineal B-Disease 1 0.9998049139976501
and I-Disease 0 6.356488029268803e-06
retinal I-Disease 1 1.0
tumours I-Disease 1 1.0
of O 0 0.0871424525976181
the O 0 1.826295192586258e-05
patient O 0 0.0013935904717072845
. O 0 2.483976686562528e-06

A O 0 1.6831480024848133e-05
nonsense O 0 2.5930734409485012e-05
mutation O 0 4.965850735061395e-07
in O 0 1.1606157812593665e-07
exon O 0 1.116627458941366e-06
17 O 0 7.964398207604972e-08
( O 0 1.0529998206720848e-08
codon O 0 6.476306424474387e-08
556 O 0 1.852060336204886e-07
) O 0 6.416755571336807e-09
of O 0 2.8921824934968754e-08
the O 0 1.5964967303716548e-07
RB1 O 0 0.05326710641384125
gene O 0 1.1272119593286334e-07
was O 0 4.5156923533795634e-08
found O 0 1.5018696286617228e-09
to O 0 4.0582651128495684e-10
be O 0 4.874248227260125e-10
present O 0 1.0148295537248941e-08
homozygously O 0 0.014452578499913216
in O 0 9.804353773290586e-09
both O 0 5.530470748027483e-09
the O 0 4.933026787057315e-08
retinal B-Disease 0 0.005135504528880119
and I-Disease 0 4.7459005259042897e-07
the I-Disease 0 2.0046378267579712e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 9.074440458789468e-05

The O 0 6.966938599362038e-07
same O 0 4.9173664251611626e-08
mutation O 0 3.9783177641083967e-08
was O 0 9.42291578098775e-08
present O 0 2.4960197464451994e-08
heterozygously O 0 2.066961496893782e-05
in O 0 6.210371328307929e-09
the O 0 5.1353188368352676e-09
DNA O 0 2.0536202072207743e-08
from O 0 8.007954854782895e-10
the O 0 9.221214347654438e-10
constitutional O 0 1.1552417689131289e-08
cells O 0 9.711500936759876e-09
of O 0 4.142479248514519e-09
the O 0 5.4323638920550366e-09
patient O 0 3.352151054514252e-07
, O 0 4.731833591620216e-09
proving O 0 4.506571826823347e-07
it O 0 5.056008944848145e-10
to O 0 9.784080212682511e-10
be O 0 1.889538525645662e-09
of O 0 6.914601868857062e-08
germline O 0 8.3145951066399e-06
origin O 0 3.204794438715908e-07
. O 0 7.246259769999597e-07

The O 0 4.682925975885155e-07
initial O 0 1.9969286313425982e-07
mutation O 0 8.584787281051831e-08
was O 0 1.1047963255350624e-07
shown O 0 2.3692621198279085e-09
to O 0 9.748742924031717e-10
have O 0 4.827349631142397e-10
occurred O 0 1.9252388128165876e-08
in O 0 1.5669008313068389e-09
the O 0 1.0117680915300298e-08
paternally O 0 1.4657211977464613e-06
derived O 0 4.958033628099656e-07
RB1 O 0 0.000283628236502409
allele O 0 1.4962969316911767e-06
. O 0 1.089345118998608e-06

The O 0 1.1569550224521663e-06
mutation O 0 1.399729541162742e-07
is O 0 7.890155195866555e-09
in O 0 2.482505978562699e-09
an O 0 7.011277114443715e-10
area O 0 8.117652328110125e-09
of O 0 1.6276365144562988e-08
the O 0 5.204630504351826e-09
gene O 0 1.0523608651169525e-09
that O 0 2.0175501547203822e-10
encodes O 0 2.37867592289831e-09
the O 0 1.0033119890451303e-09
protein O 0 6.055560497486567e-09
- O 0 5.284404025474032e-09
binding O 0 3.3389271347772365e-09
region O 0 2.452378211614814e-08
known O 0 1.7799071372337494e-07
as O 0 1.94796623276261e-08
the O 0 5.253653867498542e-08
pocket O 0 0.0001786381471902132
region O 0 7.022499204367705e-08
and O 0 1.84294002281149e-08
has O 0 3.2099740643332098e-09
been O 0 1.2071199595453663e-09
detected O 0 3.4955833783101298e-09
in O 0 1.5660993335497864e-10
other O 0 2.3458382458763083e-10
cases O 0 1.7875262381394919e-09
of O 0 9.445138715591384e-08
retinoblastoma B-Disease 1 0.9532105922698975
. O 0 1.0068572464660974e-06
. O 0 3.1619570108887274e-06

Low O 0 2.144521386071574e-05
levels O 0 2.992597387674323e-07
of O 0 1.0447977416561116e-07
beta O 0 4.61097926063303e-07
hexosaminidase O 0 7.170502158260206e-06
A O 0 1.5042103029827558e-07
in O 0 3.6755809507127424e-09
healthy O 0 5.974757577575929e-09
individuals O 0 1.2733025744893212e-10
with O 0 1.1548777489878148e-09
apparent O 0 0.006009579636156559
deficiency O 1 1.0
of O 0 7.738114072708413e-05
this O 0 1.4726622055150074e-07
enzyme O 0 9.464629329158925e-07
. O 0 1.3989195224439754e-07

Appreciable O 0 0.00017758300236891955
beta O 0 5.181254164199345e-05
hexosaminidase O 0 0.000117067938845139
A O 0 4.140887995163212e-06
( O 0 1.1709485647770634e-07
hex O 0 4.1205175875802524e-06
A O 0 6.268712127166509e-07
) O 0 9.118361177229417e-09
activity O 0 1.7081511316519027e-08
has O 0 4.382813667547225e-09
been O 0 2.5056394736822085e-09
detected O 0 3.150844207766568e-08
in O 0 6.96750124262735e-09
cultured O 0 2.0341692561487434e-06
skin O 0 4.989696390111931e-05
fibroblasts O 0 1.6439860701211728e-05
and O 0 6.084036158426898e-06
melanoma B-Disease 1 1.0
tissue O 1 0.9820172190666199
from O 0 3.4938929616146197e-07
healthy O 0 1.4252312041662663e-07
individuals O 0 1.704042601469169e-10
previously O 0 3.313254737236093e-08
reported O 0 5.2064472733093226e-09
as O 0 8.245629068426297e-09
having O 0 8.237583415393601e-08
deficiency B-Disease 1 0.9966354966163635
of I-Disease 0 3.190182178514078e-05
hex I-Disease 0 1.0791643944685347e-05
A I-Disease 0 1.5335696446072689e-07
activity O 0 4.570863243458234e-09
indistinguishable O 0 5.972660588327017e-09
from O 0 3.407053805748461e-10
that O 0 7.327682211011322e-11
of O 0 1.737205490570659e-09
patients O 0 4.999331437716137e-08
with O 0 8.171231797859946e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.3512374607671518e-05
TSD B-Disease 1 1.0
) O 0 6.531297458423069e-07
. O 0 8.691149560036138e-07

Identification O 0 1.8656727434063214e-06
and O 0 7.26098051018198e-07
quantitation O 1 0.8909138441085815
of O 0 5.128204429638572e-05
hex O 0 0.0001692694640951231
A O 0 2.1730486423621187e-06
, O 0 2.435573343007036e-08
amounting O 0 9.273677648025114e-08
to O 0 4.867313307954646e-08
3 O 0 1.8532206240706728e-06
. O 0 1.3828433793605655e-06

5 O 0 2.212537219747901e-05
% O 0 3.0002379389770795e-06
- O 0 1.158739087259164e-05
6 O 0 6.342966116790194e-06
. O 0 2.8397992082318524e-06

9 O 0 4.785797500517219e-06
% O 0 5.445978246143568e-08
of O 0 5.0624311853653126e-08
total O 0 2.6805007991015373e-08
beta O 0 5.181940423426568e-07
hexosaminidase O 0 2.2711385554430308e-06
activity O 0 1.4932357572661203e-08
, O 0 2.2267390153984934e-09
has O 0 6.241028249753811e-10
been O 0 4.5956793925938655e-10
obtained O 0 1.4258090264007706e-09
by O 0 2.4017028366074555e-09
cellulose O 0 8.894447091734037e-06
acetate O 0 4.078840447618859e-06
gel O 0 1.408234652444662e-06
electrophoresis O 0 1.873249971140467e-06
, O 0 1.1869701666000765e-07
DEAE O 0 0.009285305626690388
- O 0 4.539900601230329e-06
cellulose O 0 9.349420906801242e-06
ion O 0 3.072154868277721e-07
- O 0 1.1449574799371476e-07
exchange O 0 6.609004543634e-08
chromatography O 0 1.4039207485438965e-07
, O 0 8.505296023031406e-09
radial O 0 4.2093691376976494e-07
immunodiffusion O 0 1.6370242519769818e-05
, O 0 6.056117030084351e-08
and O 0 2.2184234182986984e-07
radioimmunoassay O 0 0.0005023620906285942
. O 0 6.589044460270088e-06

Previous O 0 3.080217356909998e-05
family O 0 5.834117473568767e-07
studies O 0 1.752284539691118e-08
suggested O 0 7.349721720117941e-09
that O 0 1.0544920492350229e-10
these O 0 1.129203050509453e-10
individuals O 0 1.395326770792238e-10
may O 0 4.656021790339082e-09
be O 0 3.0640068260368025e-09
compound O 0 4.131805440010794e-07
heterozygotes O 0 1.1251798781586331e-07
for O 0 1.424303119890169e-09
the O 0 3.37103767122926e-09
common O 0 1.02465598672552e-07
mutant O 0 6.464593980126665e-07
TSD B-Disease 0 3.0082204830250703e-05
gene O 0 1.4601229558763862e-08
and O 0 3.305142382004078e-09
a O 0 1.0112162662778701e-08
rare O 0 2.4324427272404137e-07
( O 0 7.6083395583737e-08
allelic O 0 6.153755748528056e-06
) O 0 1.0320486154569153e-07
mutant O 0 1.99784017240745e-06
gene O 0 6.226699724720675e-07
. O 0 1.2918401353090303e-06

Thus O 0 2.4663322619744577e-06
, O 0 7.092929621421717e-08
the O 0 2.3915195157542257e-08
postulated O 0 6.571721087311744e-07
rate O 0 8.622973979299786e-08
mutant O 0 6.399927343636591e-08
gene O 0 5.0878972146506385e-09
appears O 0 6.4747478489834975e-09
to O 0 4.786750995577904e-10
code O 0 8.66543781175011e-10
for O 0 6.438710120626467e-10
the O 0 1.0552814178055314e-09
expression O 0 3.878960264103171e-09
of O 0 5.526442414804933e-09
low O 0 5.1723414884463637e-08
amounts O 0 5.483728582333924e-09
of O 0 2.5897582744960346e-08
hex O 0 1.7429135823476827e-06
A O 0 1.0278342870151391e-06
. O 0 7.725352588749956e-07

Heterozygotes O 0 8.081775740720332e-05
for O 0 1.7840196164797817e-07
the O 0 1.963110207725549e-07
rare O 0 2.4563021270296304e-06
mutant O 0 1.8485518467059592e-06
may O 0 1.565357266031242e-08
be O 0 1.51391754688035e-09
indistinguishable O 0 8.215647540055215e-08
from O 0 6.6582335200848775e-09
heterozygotes O 0 2.1387927517935168e-07
for O 0 3.265901105109492e-09
the O 0 1.749612721368976e-08
common O 0 1.1865318811032921e-05
TSD B-Disease 1 0.9999957084655762
mutant O 0 2.294686419190839e-05
. O 0 7.10458664343605e-07

However O 0 2.1737077986472286e-06
, O 0 1.5200602376808092e-07
direct O 0 4.2260256805093377e-07
visualization O 0 6.81224773870781e-05
and O 0 3.395425949292985e-07
quantitation O 1 0.999927282333374
of O 0 9.372649947181344e-05
hex O 0 2.7578289518714882e-05
A O 0 2.2273566457897687e-07
by O 0 1.3771996876243975e-09
the O 0 3.3842315616539054e-09
methods O 0 6.416341591375385e-08
described O 0 1.9959951913506302e-08
may O 0 4.7343435838342884e-09
prevent O 0 1.3763969519686725e-08
false O 0 9.909300757726669e-08
- O 0 6.011980246967141e-08
positive O 0 1.8727648321004153e-09
prenatal O 0 2.0143190226917795e-07
diagnosis O 0 2.374720679654274e-06
of O 0 6.20488606273284e-07
TSD B-Disease 1 0.9999998807907104
in O 0 1.778661555817962e-07
fetuses O 0 4.2318006876485015e-07
having O 0 2.0543568624020736e-08
the O 0 1.2231938129048103e-08
incomplete O 0 4.6282931975838437e-07
hex B-Disease 0 4.73026648251107e-06
A I-Disease 0 1.2083158935638494e-06
deficiency I-Disease 1 0.5470466017723083
of O 0 1.2026596323266858e-06
the O 0 1.9085071301105927e-07
type O 0 2.0839256649196614e-06
described O 0 1.436279291056053e-07
in O 0 6.249726958174051e-09
the O 0 3.198876186161215e-08
four O 0 1.0796957639058746e-07
healthy O 0 8.591779305788805e-07
individuals O 0 2.5121735802713374e-07

The O 0 2.512029641366098e-05
tumor B-Disease 0 0.00011066888691857457
suppressor O 0 5.848592263646424e-05
gene O 0 1.524044705547567e-06
Smad4 O 0 0.0005461504915729165
/ O 0 3.9227568777278066e-05
Dpc4 O 0 3.8803638744866475e-05
is O 0 3.903080081357757e-09
required O 0 1.26004440215155e-09
for O 0 8.282824981442616e-10
gastrulation O 0 7.424313821502437e-07
and O 0 2.365933893244687e-09
later O 0 1.8293238923661193e-08
for O 0 1.9484001079206337e-09
anterior O 0 3.7687659215634994e-08
development O 0 8.026052711329612e-08
of O 0 2.415785900211631e-07
the O 0 4.4893451445204846e-07
mouse O 0 1.03415732155554e-05
embryo O 0 1.6738290469220374e-06
. O 0 3.910556642949814e-07

Mutations O 0 5.559225883189356e-06
in O 0 3.911832493486145e-07
the O 0 6.644007726208656e-07
SMAD4 O 1 0.9999994039535522
/ O 1 0.9879399538040161
DPC4 O 1 0.9999853372573853
tumor B-Disease 0 6.166189996292815e-05
suppressor O 0 4.004158199677477e-06
gene O 0 1.5123511332149064e-08
, O 0 1.3144692001532121e-09
a O 0 9.182185678469068e-09
key O 0 2.192955435020849e-06
signal O 0 1.9593951947172172e-05
transducer O 0 2.7809451239591e-06
in O 0 1.3631042072859145e-08
most O 0 1.3196346237975831e-08
TGFbeta O 0 3.629919592640363e-05
- O 0 3.4699843354246696e-07
related O 0 7.639269483661337e-08
pathways O 0 1.6674736968980142e-07
, O 0 2.55062165832598e-10
are O 0 2.7671464078449226e-11
involved O 0 3.386929070536837e-10
in O 0 2.6276650300083304e-10
50 O 0 1.341888711259287e-09
% O 0 1.4387853131125894e-09
of O 0 6.054061714166892e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.6120075088110752e-05

Homozygous O 0 0.00043738901149481535
Smad4 O 0 0.06861933320760727
mutant O 0 0.00011321710189804435
mice O 0 5.533223884413019e-06
die O 0 2.402406153123593e-06
before O 0 8.472785566482344e-07
day O 0 1.3711951396544464e-06
7 O 0 3.978504082624568e-06
. O 0 2.0567972569551785e-06

5 O 0 2.882359149225522e-05
of O 0 4.4054800127923954e-06
embryogenesis O 0 0.0008478831732645631
. O 0 1.689042619545944e-05

Mutant O 0 8.054585487116128e-05
embryos O 0 3.461840606178157e-06
have O 0 1.873008592667702e-08
reduced O 0 1.0294004226807374e-07
size O 0 2.5779501200418053e-08
, O 0 8.211195279272943e-09
fail O 0 3.048354528800701e-07
to O 0 3.762029265885758e-08
gastrulate O 0 0.00025363086024299264
or O 0 9.942451129063556e-08
express O 0 3.140261028988789e-08
a O 0 8.471038093205152e-09
mesodermal O 0 2.9451416594383772e-06
marker O 0 5.720342528547917e-07
, O 0 1.3374381602204721e-08
and O 0 3.77512563431992e-08
show O 0 1.3971155965464277e-07
abnormal O 0 3.851559711165464e-07
visceral O 0 0.00010370043310103938
endoderm O 1 0.9945863485336304
development O 0 2.5750985514605418e-05
. O 0 1.7451606026952504e-06

Growth B-Disease 1 0.9999997615814209
retardation I-Disease 1 1.0
of O 0 0.0026261801831424236
the O 0 0.00010476712486706674
Smad4 O 1 1.0
- O 0 0.12937107682228088
deficient O 0 2.8591462978511117e-05
embryos O 0 3.962989225669844e-08
results O 0 8.566899967199504e-10
from O 0 1.1378799014138963e-09
reduced O 0 4.032251865737635e-08
cell O 0 1.1039364835596643e-06
proliferation O 0 1.9688286556629464e-07
rather O 0 4.041705192747713e-09
than O 0 7.220647413319625e-10
increased O 0 2.805638565916979e-08
apoptosis O 0 5.9029162002843805e-06
. O 0 3.880069243678008e-07

Aggregation O 0 3.402673246455379e-05
of O 0 5.1479614739946555e-06
mutant O 0 1.9379995137569495e-05
Smad4 O 0 0.0014205706538632512
ES O 0 6.975579162826762e-05
cells O 0 9.685311397333862e-08
with O 0 4.879729953444212e-09
wild O 0 2.3057879161569872e-07
- O 0 2.2677508582091832e-07
type O 0 1.0588494205876486e-06
tetraploid O 0 0.001377121894620359
morulae O 0 0.0024915719404816628
rescues O 0 4.8005855205701664e-05
the O 0 1.2672318234763225e-06
gastrulation B-Disease 0 0.0011075320653617382
defect I-Disease 0 0.00019600577070377767
. O 0 3.2385742088081315e-06

These O 0 4.311732197948004e-07
results O 0 9.897758701526982e-08
indicate O 0 4.281059418076438e-08
that O 0 4.384510976507272e-09
Smad4 O 0 2.11416572710732e-05
is O 0 5.483205889333931e-09
initially O 0 5.321767915233977e-09
required O 0 3.708196250062912e-10
for O 0 2.704408363918276e-10
the O 0 1.1485862261295665e-09
differentiation O 0 3.073713372714337e-08
of O 0 2.7082206699446942e-08
the O 0 3.1826754565145166e-08
visceral O 0 2.8791769182134885e-06
endoderm O 0 0.00013836671132594347
and O 0 1.3138280685609516e-08
that O 0 1.17613596639643e-09
the O 0 8.936591910924108e-09
gastrulation B-Disease 0 7.01001554261893e-05
defect I-Disease 0 3.8028956623747945e-06
in O 0 1.0533091732156663e-08
the O 0 3.18123696274597e-08
epiblast O 0 0.0016563358949497342
is O 0 1.337142219171028e-08
secondary O 0 9.23618443948726e-08
and O 0 7.866757911756395e-09
non O 0 3.267423664965463e-07
- O 0 1.0268643563904334e-05
cell O 0 4.0068964153761044e-05
autonomous O 0 7.178112468864128e-07
. O 0 4.809654114978912e-07

Rescued O 0 0.001186205423437059
embryos O 0 4.735755283036269e-05
show O 0 7.161422104218218e-07
severe O 0 1.163766864920035e-05
anterior O 0 1.569373853271827e-05
truncations O 1 0.9999774694442749
, O 0 6.59897807508969e-07
indicating O 0 7.921324822746101e-07
a O 0 1.3048754965439002e-07
second O 0 4.0185472016673884e-07
important O 0 9.785861720956746e-08
role O 0 1.2607426924660103e-07
for O 0 4.854592816627701e-08
Smad4 O 1 0.6542818546295166
in O 0 1.3414087618457415e-07
anterior O 0 3.158208301101695e-06
patterning O 0 0.0004437519528437406
during O 0 1.7049153029802255e-05
embryogenesis O 0 0.0004700219433289021
. O 0 4.547371190710692e-06

Prevalence O 0 0.00010981224477291107
of O 0 1.109416098188376e-05
p16 O 0 3.75526215066202e-05
and O 0 1.4349842558658565e-06
CDK4 O 1 0.9981299042701721
germline O 0 0.00021147404913790524
mutations O 0 3.707472160385805e-07
in O 0 4.3452590858805706e-08
48 O 0 3.932077561330516e-06
melanoma B-Disease 1 1.0
- O 1 0.9990379810333252
prone O 0 0.061467912048101425
families O 0 1.7941097496532166e-07
in O 0 4.356545346695384e-08
France O 0 9.967036476155045e-07
. O 0 2.0760585357493255e-06

The O 0 8.94210006663343e-06
French O 0 7.437848398694769e-05
Familial B-Disease 1 0.9997658133506775
Melanoma I-Disease 1 1.0
Study O 0 1.0740996003733017e-05
Group O 0 8.273609068965015e-07
. O 0 5.920580292695377e-07

Germline O 0 0.0006306036375463009
mutations O 0 1.621145997887652e-06
in O 0 4.8647706307747285e-08
the O 0 4.7234145483798784e-08
p16 O 0 1.4644161865362548e-06
and O 0 6.09904233783709e-08
CDK4 O 1 0.9999270439147949
genes O 0 7.297969517594538e-08
have O 0 1.3508766327774424e-09
been O 0 1.3493161032940293e-09
reported O 0 8.496504610988609e-10
in O 0 2.2937923782606617e-10
a O 0 2.7539333036230573e-09
subset O 0 1.9585915111974828e-08
of O 0 4.863768410245939e-08
melanoma B-Disease 1 0.9999979734420776
pedigrees O 0 2.914910965046147e-06
, O 0 2.8382436401130917e-09
but O 0 5.105548206429944e-10
their O 0 7.863529272178482e-10
prevalence O 0 4.8947587316661156e-08
is O 0 5.341381226209307e-10
not O 0 5.180965656492731e-10
well O 0 7.512887201244212e-09
known O 0 1.1517100517721701e-07
. O 0 2.804788721277873e-07

We O 0 8.829017019706953e-07
searched O 0 5.171533530301531e-07
for O 0 1.0237394043599579e-08
such O 0 1.76987224875802e-08
germline O 0 8.555804924981203e-06
mutations O 0 1.195547412180531e-07
in O 0 3.059914277514508e-08
48 O 0 1.118372097153042e-06
French O 0 0.016091516241431236
melanoma B-Disease 1 1.0
- O 1 0.9997119307518005
prone O 0 0.0002207100624218583
families O 0 8.666201978257959e-09
selected O 0 2.17681273007031e-09
according O 0 2.3726706710469614e-10
to O 0 8.606797496923946e-10
two O 0 1.5068163383702426e-09
major O 0 3.618329103005635e-08
criteria O 0 1.9748494395344096e-08
families O 0 2.413679478507902e-09
with O 0 5.907466738008793e-10
at O 0 1.19397922659914e-08
least O 0 1.650834469124618e-09
three O 0 1.6287723392238718e-09
affected O 0 1.6188798079852518e-09
members O 0 5.8713855999315e-10
( O 0 1.3864164261079281e-09
n O 0 1.5079844928322927e-08
= O 0 1.1215925965757378e-08
20 O 0 2.964112288950105e-09
) O 0 1.8354767705730524e-10
or O 0 5.420438542458328e-10
families O 0 2.63790378429718e-10
with O 0 6.647186967523311e-11
two O 0 3.823499850064138e-10
affected O 0 1.037425700900485e-09
members O 0 2.9419303104738503e-10
, O 0 6.195460811042608e-10
one O 0 4.47924780599962e-10
of O 0 2.186716807628386e-09
them O 0 5.163209304548388e-10
affected O 0 9.892390240295867e-10
before O 0 5.954529758156468e-09
the O 0 4.15846956869359e-09
age O 0 4.9870525486994666e-09
of O 0 7.929743972567849e-09
50 O 0 6.357427473346888e-09
( O 0 1.888853962128678e-09
n O 0 7.803796719940692e-09
= O 0 2.092275863674331e-08
28 O 0 1.2572122898291127e-08
) O 0 8.511004678801726e-10
, O 0 5.544515402355898e-10
and O 0 9.27621757185193e-10
one O 0 1.3734801074249958e-09
additional O 0 7.356790732160334e-09
minor O 0 4.845906005357392e-07
criterion O 0 8.262722258223221e-05
. O 0 1.6504283166796085e-06

Sixteen O 0 2.3836470063542947e-05
different O 0 6.520978104163078e-07
p16 O 0 6.094581749493955e-06
germline O 0 5.015375791117549e-06
mutations O 0 4.052297697398899e-08
were O 0 1.0258406568652845e-08
found O 0 2.6558579779845104e-09
in O 0 1.9037629250817645e-09
21 O 0 2.6068162739534273e-08
families O 0 4.55266135901411e-09
, O 0 1.8066937945704353e-09
while O 0 3.449084573503569e-09
one O 0 5.270442304805556e-09
germline O 0 3.879273435813957e-07
mutation O 0 1.3088857997445302e-08
, O 0 2.576955537847425e-09
Arg24His O 0 2.7093346943729557e-05
, O 0 1.527274129387024e-08
was O 0 1.2580476038692723e-07
detected O 0 7.700506898800086e-08
in O 0 5.018867099693125e-09
the O 0 1.0290137453239367e-07
CDK4 O 1 0.6599398851394653
gene O 0 1.5050183037601528e-06
. O 0 7.264000601026055e-07

The O 0 7.527620482505881e-07
frequency O 0 5.24923677858169e-07
of O 0 1.4345174292884622e-07
p16 O 0 2.819687097144197e-07
gene O 0 1.452645115307405e-08
mutation O 0 7.769133780755055e-09
in O 0 1.9410668627983796e-09
our O 0 4.5392476444305885e-09
sample O 0 1.1531851029644713e-09
( O 0 7.724152983890065e-10
44 O 0 5.1238715492729625e-09
% O 0 1.2864709297844001e-09
) O 0 6.513550809827962e-10
is O 0 4.5430911810306895e-10
among O 0 1.4161872785578566e-09
the O 0 2.724799275100054e-09
highest O 0 3.537660475672055e-08
rates O 0 4.849833423747896e-09
yet O 0 1.2894064704838115e-09
reported O 0 8.425335984441062e-10
and O 0 9.129302869226308e-10
the O 0 5.392104540646869e-09
CDK4 O 0 6.226876394066494e-06
mutation O 0 1.140746164196571e-09
is O 0 1.9078985613596444e-10
the O 0 5.179839890345761e-10
second O 0 2.9798994383156696e-09
mutation O 0 1.593702281255105e-09
detected O 0 7.502248600133044e-09
in O 0 1.0753050672107634e-09
this O 0 1.960205331386078e-09
gene O 0 9.788232802065977e-08
worldwide O 0 1.1113289843933671e-07
. O 0 6.747548582097807e-07

In O 0 1.811009383345663e-06
summary O 0 5.007604158890899e-06
, O 0 1.8640457710716873e-07
our O 0 6.191863377580376e-08
results O 0 1.3105469598428954e-08
show O 0 6.336823066277475e-09
frequent O 0 4.246234919236258e-09
involvement O 0 1.741044108882761e-08
of O 0 9.38746502754384e-09
the O 0 9.280504364994613e-09
p16 O 0 1.5112792084437388e-07
gene O 0 1.1710776348650143e-08
in O 0 1.956529604996149e-09
familial B-Disease 0 1.258039083040785e-05
melanoma I-Disease 1 1.0
and O 0 8.980302368399862e-08
confirm O 0 5.6303740336716146e-08
the O 0 5.127530755544285e-08
role O 0 7.650642430689913e-08
of O 0 2.836113708326593e-07
the O 0 4.3959687445749296e-07
CDK4 O 1 0.9751282334327698
gene O 0 7.391844292214955e-08
as O 0 1.951346639827989e-08
a O 0 1.9357814551312913e-07
melanoma B-Disease 1 1.0
- O 1 0.886875331401825
predisposing O 0 0.2394569367170334
gene O 0 1.0795881735248258e-06
. O 0 2.011030915127776e-07
. O 0 9.99522058009461e-07

Progression O 0 0.00028115909663029015
of O 0 2.014167512243148e-05
somatic O 0 0.2638845443725586
CTG O 0 0.37722915410995483
repeat O 0 1.6608840951448656e-06
length O 0 6.85480117113002e-08
heterogeneity O 0 4.5864109665672004e-07
in O 0 2.5763706723580526e-09
the O 0 5.30087884698105e-09
blood O 0 8.688699182357595e-08
cells O 0 5.855041536051431e-07
of O 0 4.570213150145719e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999998807907104
. O 0 5.24264105479233e-05

The O 0 8.71180475314759e-07
genetic O 0 7.753916975161701e-07
basis O 0 4.4367382656673726e-07
of O 0 9.277547178498935e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9761909246444702
DM B-Disease 1 1.0
) O 0 1.2260311166301108e-07
is O 0 4.687190191532409e-09
the O 0 3.6216967203017703e-09
expansion O 0 9.16720992449882e-08
of O 0 4.398735953259347e-08
an O 0 8.598171064022608e-09
unstable O 0 1.8087335774907842e-05
CTG O 0 0.0005537948454730213
repeat O 0 5.451682909551891e-07
in O 0 6.72000943779949e-09
the O 0 5.664301028218688e-09
34 O 0 8.477944390961056e-08
UTR O 0 0.009410962462425232
of O 0 3.9969336285139434e-07
the O 0 5.088700731903373e-07
DM B-Disease 1 1.0
protein O 0 1.6291386373268324e-06
kinase O 0 5.135331662131648e-07
gene O 0 1.4368882972348729e-08
on O 0 2.5621165633538112e-08
chromosome O 0 6.266188989911825e-08
19 O 0 3.8252255762927234e-07
. O 0 1.1336873058098718e-06

One O 0 1.0176137266171281e-06
of O 0 1.7512563488253363e-07
the O 0 5.143222026049443e-08
principal O 0 2.11836933772247e-07
features O 0 2.735298565426092e-08
of O 0 2.288864919819389e-08
the O 0 1.1785038367406742e-07
DM B-Disease 1 1.0
mutation O 0 9.932991673622382e-08
is O 0 2.9111977273288403e-09
an O 0 5.580332862464843e-10
extraordinarily O 0 6.445203126759225e-08
high O 0 6.994133627813426e-08
level O 0 3.4351153033185255e-08
of O 0 3.460763053908522e-08
somatic O 0 6.4299556470359676e-06
mosaicism O 0 9.235328616341576e-05
, O 0 2.281158373307335e-09
due O 0 1.0185644327975751e-08
to O 0 1.0677757567023605e-09
an O 0 4.182123536367044e-10
extremely O 0 7.605971852342464e-09
high O 0 9.7134451593206e-09
degree O 0 5.311528639140306e-08
of O 0 2.2575177283101766e-08
somatic O 0 2.1863672827748815e-06
instability O 0 2.6856548629439203e-07
both O 0 3.202219822640018e-09
within O 0 8.393773676118599e-09
and O 0 2.8958464515227433e-09
between O 0 4.356069283062425e-09
different O 0 1.024950702088745e-08
tissues O 0 3.484021362964995e-06
. O 0 7.010668241491658e-07

This O 0 2.734266217885306e-06
instability O 0 0.00012266254634596407
appears O 0 1.0732605915109161e-06
to O 0 1.6865445928715417e-08
be O 0 6.789218520708573e-09
biased O 0 5.997240748456534e-08
towards O 0 2.8353881020848348e-08
further O 0 5.079151321751851e-09
expansion O 0 4.0450540694791925e-08
and O 0 1.3307452917388218e-09
continuous O 0 6.554643938727622e-09
throughout O 0 1.0944198880480371e-09
the O 0 6.982983635772655e-10
life O 0 1.3363921080866703e-09
of O 0 6.360068582900169e-10
an O 0 7.076541436168426e-11
individual O 0 6.97560550988463e-11
, O 0 1.0115316917413963e-10
features O 0 5.491261334533704e-10
that O 0 5.822003296129807e-11
could O 0 7.580622796155012e-10
be O 0 3.972051021428058e-10
associated O 0 2.655482944646792e-09
with O 0 1.0525855742571366e-09
the O 0 3.232178968914923e-08
progressive O 0 2.3647723992326064e-06
nature O 0 2.933036213903506e-08
of O 0 7.629105880369025e-08
the O 0 6.035430146766885e-07
disease O 1 0.6889268159866333
. O 0 1.8406132085146965e-06

Although O 0 1.0828321137523744e-06
increasing O 0 2.1325480759060156e-07
measured O 0 1.1841549252267214e-07
allele O 0 3.106986667944511e-08
size O 0 5.857921259178056e-09
between O 0 7.55755635850619e-09
patients O 0 5.251800416772312e-08
clearly O 0 1.331980037377889e-08
correlates O 0 2.6890781157362653e-08
with O 0 1.8193908879471365e-10
an O 0 1.0934678856822089e-10
increased O 0 9.062025574380073e-10
severity O 0 4.0863952222025546e-07
of O 0 7.226329756804262e-08
symptoms O 0 6.989905159571208e-06
and O 0 4.8367159166673446e-09
an O 0 2.421212397241135e-10
earlier O 0 4.979275325389665e-10
age O 0 2.338792493006281e-10
of O 0 1.0565279762175805e-09
onset O 0 4.290629931347212e-06
, O 0 6.521955198124374e-10
this O 0 4.6703016454152646e-11
correlation O 0 1.682555761384208e-10
is O 0 3.441720866637077e-11
not O 0 2.6078268017259987e-11
precise O 0 4.661228736324574e-09
and O 0 1.214864764342849e-09
measured O 0 2.577157154348697e-09
allele O 0 1.062558374620437e-09
length O 0 3.7963943100294273e-10
cannot O 0 5.052452345388758e-10
be O 0 2.1984462861279752e-10
used O 0 1.1589710302573053e-09
as O 0 1.1775052044527001e-09
an O 0 1.5399206909627594e-10
accurate O 0 4.83229243286587e-08
predictor O 0 5.440744530460506e-07
of O 0 5.295586191778057e-08
age O 0 6.470071411968092e-08
of O 0 5.105865170662582e-07
onset O 1 0.9998070597648621
. O 0 4.550264748104382e-06

In O 0 8.571989269512414e-07
order O 0 2.447878273414972e-07
to O 0 2.5375952006356783e-08
further O 0 5.17355545071041e-08
characterize O 0 5.74138937281532e-07
the O 0 6.865006696443743e-08
dynamics O 0 3.2777620617707726e-06
of O 0 5.6134599617507774e-06
DM B-Disease 1 1.0
CTG O 1 0.9999980926513672
repeat O 0 4.083491603523726e-06
somatic O 0 4.704731509264093e-06
instability O 0 7.351069939431909e-07
, O 0 3.670194148597261e-09
we O 0 9.156996272352558e-10
have O 0 2.241575813854979e-10
studied O 0 2.2931199161746463e-09
repeat O 0 1.827725526482027e-09
length O 0 2.0122772892428031e-10
changes O 0 2.450799840847395e-10
over O 0 3.4962815975703165e-10
time O 0 5.438146044589587e-10
in O 0 1.7415083819471988e-09
111 O 0 4.135986273468006e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 4.14035866924678e-06
with O 0 1.3498463458105903e-09
varying O 0 1.8861907591372074e-08
clinical O 0 1.3260253126645694e-06
severity O 0 0.0004871182609349489
and O 0 2.27876898861723e-06
CTG O 0 0.0009892648085951805
repeat O 0 2.2328801208004734e-07
size O 0 6.818586584245168e-09
over O 0 1.4522343327882936e-09
time O 0 6.509713323943345e-10
intervals O 0 1.8590629036197015e-09
of O 0 5.6539062320837274e-09
1 O 0 1.2651437941713084e-07
- O 0 3.17112665015884e-07
7 O 0 2.2436147162352427e-07
years O 0 8.418099639584398e-08
. O 0 2.2229322382827377e-07

We O 0 5.791741841676412e-07
have O 0 1.1442181424570208e-08
found O 0 2.603286919367065e-09
a O 0 3.5084348759539807e-09
direct O 0 3.231710365980689e-08
progression O 0 8.670882607475505e-07
of O 0 1.3783008512291417e-07
the O 0 4.123624464114073e-08
size O 0 3.414434246451492e-08
heterogeneity O 0 1.0077432932575903e-07
over O 0 5.184646045819363e-09
time O 0 8.290095276919374e-10
related O 0 2.608013360827499e-09
to O 0 3.1503140096589277e-09
initial O 0 1.1223549023497981e-07
CTG O 0 2.8041091354680248e-05
repeat O 0 4.617236371018407e-08
size O 0 3.251605429355209e-09
and O 0 7.730711626408038e-10
the O 0 1.0292738883421748e-09
time O 0 9.32660171315547e-10
interval O 0 4.1927963323473705e-09
and O 0 1.2356917711286997e-09
always O 0 3.0788576133033985e-09
biased O 0 9.071575490793293e-09
towards O 0 2.114735409008972e-08
further O 0 1.454117093402374e-08
expansion O 0 5.123244477545086e-07
. O 0 4.125198529436602e-07

Attempts O 0 2.567734736658167e-05
to O 0 2.3019848072181048e-07
mathematically O 0 8.437499445790309e-07
model O 0 1.5311569256937219e-07
the O 0 4.71106993416015e-08
dynamics O 0 1.445833504476468e-06
have O 0 2.9224816344708415e-08
proved O 0 1.0962548913084902e-05
only O 0 6.237818261922712e-09
partially O 0 6.431854870925235e-08
successful O 0 2.5365695321966086e-08
suggesting O 0 2.043269331508668e-09
that O 0 6.407722963341911e-11
individual O 0 6.333095159405389e-11
specific O 0 5.662170177167525e-10
genetic O 0 1.686229467168232e-08
and O 0 5.830588456490204e-09
/ O 0 3.6221313166606706e-06
or O 0 3.917655888585614e-08
environmental O 0 1.9817777285879856e-07
factors O 0 9.209689011413502e-09
also O 0 1.347747136115629e-09
play O 0 2.8486131231630907e-09
a O 0 3.1603946126779192e-09
role O 0 3.063131970293398e-08
in O 0 3.492359468282302e-08
somatic O 0 4.5607102947542444e-05
mosaicism O 0 0.034859709441661835
. O 0 1.97923171185721e-07
. O 0 5.452447453535569e-07

Aspartylglucosaminuria B-Disease 1 0.9999995231628418
among O 0 2.1058351194369607e-05
Palestinian O 0 3.572275454644114e-05
Arabs O 0 5.30940160388127e-05
. O 0 6.666872195637552e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.8159152865409851
AGU B-Disease 1 1.0
) O 0 1.1084854349974194e-06
is O 0 2.7839057281653368e-08
a O 0 6.369409533135695e-08
rare O 0 2.99506718874909e-05
disorder B-Disease 1 0.9999991655349731
of I-Disease 1 0.6143749356269836
glycoprotein I-Disease 1 0.9999994039535522
metabolism I-Disease 0 0.00015018742124084383
caused O 0 8.218829350425949e-08
by O 0 1.6934097457621533e-09
the O 0 8.032775156152638e-08
deficiency B-Disease 1 0.979662299156189
of I-Disease 0 3.922451924154302e-06
the I-Disease 0 1.6677280427757069e-06
lysosomal I-Disease 0 0.02179788053035736
enzyme I-Disease 0 5.654393930853985e-07
aspartylglucosaminidase I-Disease 0 5.668568064720603e-06
( O 0 3.48448843112692e-08
AGA O 0 0.001095629995688796
) O 0 9.507404996611513e-08
. O 0 5.340093593986239e-07

AGU B-Disease 1 1.0
is O 0 6.291042154771276e-06
inherited O 0 0.3299751579761505
as O 0 2.6350812731834594e-07
an O 0 1.655615733398008e-08
autosomal O 0 0.00010900226334342733
recessive O 0 9.65199142228812e-05
trait O 0 4.820628419111017e-06
and O 0 1.2423805095806983e-08
occurs O 0 4.14825063188573e-09
with O 0 7.618207176207648e-10
a O 0 4.710097201154895e-09
high O 0 4.673449893743964e-07
frequency O 0 1.2218838207900262e-07
in O 0 6.026328769337397e-09
Finland O 0 3.5553423316514454e-08
because O 0 3.6874341358128504e-09
of O 0 4.470691195024301e-08
a O 0 3.776278845180059e-07
founder O 0 2.7657803002512082e-05
effect O 0 1.7057765262507019e-06
. O 0 1.4790156228627893e-06

While O 0 1.3018144500165363e-06
very O 0 1.6328516494468204e-07
few O 0 1.2202883681311505e-07
patients O 0 2.660247844232799e-07
with O 0 4.18180867711726e-08
AGU B-Disease 1 1.0
have O 0 4.380212885735091e-07
been O 0 2.3144234972960476e-08
reported O 0 2.551279854046129e-09
from O 0 1.270687777221724e-09
non O 0 1.5040836132129698e-08
- O 0 4.1787153293171286e-08
Finnish O 0 2.1773645642042538e-07
origin O 0 1.05710098452505e-08
, O 0 3.3547074007600486e-09
we O 0 3.1462605853960213e-09
diagnosed O 0 8.512491149303969e-06
the O 0 4.7725336571602384e-08
disorder O 0 0.00010116079647559673
in O 0 5.839325023515585e-09
8 O 0 2.1633617564020824e-08
patients O 0 8.056431965997035e-09
originating O 0 1.2447001651594292e-08
from O 0 4.008355869444813e-09
3 O 0 1.952940031912931e-08
unrelated O 0 2.193786485804594e-08
families O 0 1.174683239568708e-09
, O 0 4.1334163869422014e-10
all O 0 3.7722142076646037e-10
Palestinian O 0 2.823267486462555e-08
Arabs O 0 3.349645183448047e-08
from O 0 4.10006295581411e-09
the O 0 3.471325671355885e-09
region O 0 9.979780557500817e-09
of O 0 7.494084997006212e-08
Jerusalem O 0 1.7428406863473356e-05
. O 0 1.921898501677788e-06

The O 0 1.576999125063594e-06
clinical O 0 4.8402704123873264e-05
diagnosis O 1 0.9999997615814209
of O 1 0.9999884366989136
AGU B-Disease 1 1.0
is O 0 3.481444082353846e-06
often O 0 1.7569096399938644e-08
difficult O 0 4.560511612794471e-08
, O 0 8.247700300501037e-10
in O 0 4.6343659465541975e-10
particular O 0 3.0901239345126896e-09
early O 0 7.006751445715054e-08
in O 0 1.0735794475635885e-09
the O 0 1.710706465374301e-09
course O 0 2.3740492238744082e-08
of O 0 4.413937659819567e-09
the O 0 4.791055108199771e-09
disease O 0 3.757824015337974e-05
, O 0 1.1536911426190954e-09
and O 0 1.7436054822184133e-09
most O 0 3.484958766009072e-09
of O 0 8.468909840075867e-08
the O 0 1.4055068220386602e-07
patients O 0 6.798783829253807e-07
are O 0 1.5903924843740924e-09
diagnosed O 0 6.069265623409592e-07
after O 0 3.567733131148998e-08
the O 0 1.0448850673583365e-08
age O 0 3.5813144450003165e-08
of O 0 6.228975024669126e-08
5 O 0 2.491839268259355e-07
years O 0 3.242596164909628e-07
. O 0 6.586390668417152e-07

However O 0 2.55824079431477e-06
, O 0 1.492701073857461e-07
since O 0 3.9701461673757876e-08
these O 0 5.7826330390753355e-09
patients O 0 1.7328851242837118e-07
excrete O 0 2.894048805046623e-07
early O 0 3.7504086947137694e-08
large O 0 4.153127175499094e-09
amounts O 0 3.5127871722551163e-09
of O 0 1.6147360781815223e-08
aspartylglucosamine O 0 5.2384380069270264e-06
in O 0 2.27076157877093e-09
urine O 0 4.073497983370089e-09
, O 0 4.434457523405655e-10
biochemical O 0 4.006409071166672e-08
screening O 0 1.291713669360206e-08
is O 0 5.605422792598347e-10
easy O 0 4.0944359014361e-09
by O 0 6.5316901887158e-10
urine O 0 5.349920684238896e-08
chromatography O 0 6.070214908504568e-07
. O 0 8.05081370458538e-08
. O 0 4.586585475863103e-07

Detection O 0 0.00011834296310553327
of O 0 2.2953017833060585e-06
heterozygous O 0 2.920075701240421e-07
carriers O 0 8.344962054707139e-08
of O 0 1.2843831598274846e-07
the O 0 1.4816570228504133e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.225582521641627e-06
ATM O 0 2.091995884256903e-05
) O 0 3.505003842718679e-09
gene O 0 1.4157767180833503e-09
by O 0 4.979787693315529e-10
G2 O 0 4.3128355173394084e-05
phase O 0 5.186802809475921e-06
chromosomal O 0 7.625273610756267e-06
radiosensitivity O 0 3.4555469028418884e-05
of O 0 5.389401849242859e-07
peripheral O 1 0.984423816204071
blood O 0 4.573728801915422e-05
lymphocytes O 0 2.7894133381778374e-05
. O 0 3.8064661112002796e-06

In O 0 5.44021422683727e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.99998939037323
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.225213494166383e-08
patients O 0 9.611314055746334e-08
, O 0 1.338963828700912e-09
mutations O 0 1.2890990497282928e-09
in O 0 8.123085537548036e-10
a O 0 1.3291421296912631e-09
single O 0 1.4774831358366214e-09
gene O 0 2.2643216190942894e-09
, O 0 4.938058295600456e-10
ATM O 0 6.683383730887726e-07
, O 0 5.431718963500032e-10
result O 0 2.2523640730298666e-09
in O 0 5.493999033490127e-09
an O 0 6.984188871683727e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.101356374988427e-07
embraces O 0 2.9997980277585157e-07
a O 0 6.972527000215223e-09
variety O 0 1.4977882045741353e-08
of O 0 5.473427933111452e-08
clinical O 0 6.276887233980233e-06
features O 0 6.350740591187787e-07
and O 0 6.686488518425904e-08
manifests O 0 9.402714908901544e-07
extreme O 0 0.00016859022434800863
radiosensitivity O 0 0.0040695155039429665
and O 0 7.065249718607447e-08
a O 0 6.131444507673223e-08
strong O 0 1.7543420938181953e-07
pre O 0 0.0006623980589210987
- O 0 3.1874511478235945e-05
disposition O 0 3.4745178709272295e-05
to O 0 1.6263415147932392e-07
malignancy B-Disease 1 0.9979590177536011
. O 0 2.1203875348874135e-06

Heterozygotes O 0 8.460344542982057e-05
for O 0 4.949330900672066e-07
the O 0 3.8009235936442565e-07
ATM O 0 9.033263268065639e-06
gene O 0 3.134922721415023e-08
have O 0 1.8255862377358767e-09
no O 0 2.7795907797667496e-09
clinical O 0 1.384183718755594e-07
expression O 0 4.1859184563008967e-08
of O 0 6.330374731078336e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 8.819854713237874e-08
may O 0 5.1555190339058754e-08
be O 0 1.5070584780119134e-08
cancer B-Disease 0 7.45029974495992e-05
prone O 0 2.0817257961880387e-07
with O 0 1.3922968333801578e-09
a O 0 2.32627552776421e-08
moderate O 0 2.677885049706674e-06
increase O 0 1.564172436019362e-08
in O 0 1.7575766619870592e-08
in O 0 5.714187167882301e-08
vitro O 0 4.752567747345893e-06
radiosensitivity O 0 2.7108750145998783e-05
. O 0 8.391518235839612e-07

We O 0 3.85861449103686e-06
performed O 0 1.703984935375047e-06
a O 0 2.3940987148307613e-07
blind O 0 1.5660672261219588e-06
chromosomal O 0 2.313294231726104e-07
analysis O 0 9.207109741282693e-08
on O 0 1.816136006027591e-07
G2 O 0 8.810214785626158e-05
- O 0 2.7022514359487104e-07
phase O 0 2.597867592157854e-07
lymphocytes O 0 6.24318872155527e-08
from O 0 9.738303496931167e-09
7 O 0 2.2089228224331237e-08
unrelated O 0 1.3596381620573084e-07
A B-Disease 1 0.9984336495399475
- I-Disease 1 0.9998587369918823
T I-Disease 1 1.0
patients O 0 1.789496855053585e-05
, O 0 3.362274014762079e-08
13 O 0 3.8550354020117084e-08
obligate O 0 2.0482616491790395e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0001263968151761219
( O 0 1.8915443433797918e-08
parents O 0 3.2925833171049135e-09
of O 0 4.980769130469298e-09
the O 0 4.720295709859101e-09
patients O 0 8.107888582742362e-09
) O 0 7.90642162851185e-10
, O 0 7.834126680705822e-10
and O 0 2.513326657904713e-09
14 O 0 2.6872681857526004e-08
normal O 0 3.3463756210494466e-08
controls O 0 5.292859839300945e-08
following O 0 1.1151080059335072e-08
X O 0 6.407494197446795e-07
- O 0 7.212257457922533e-08
irradiation O 0 1.6119271606385155e-07
with O 0 5.096862043529882e-09
1 O 0 2.2354646489475272e-07
Gy O 0 3.250768713769503e-05
in O 0 1.191762577512634e-09
order O 0 1.2225261913911822e-09
to O 0 6.519641493341055e-10
evaluate O 0 5.934031044318999e-09
this O 0 1.2183594133574616e-09
cytogenetic O 0 1.9103717363577744e-07
method O 0 1.587253706247793e-08
as O 0 1.7356321935224628e-09
a O 0 2.27748464531885e-09
tool O 0 3.841529760961748e-08
for O 0 1.8525887490739024e-09
detection O 0 1.0308086757504498e-06
of O 0 4.0832634340404184e-07
ATM O 0 0.0001548876753076911
carriers O 0 2.1828523131262045e-06
. O 0 1.4351704749060445e-06

Both O 0 2.9226239348645322e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 1 0.9999877214431763
and O 0 1.6835787164382054e-06
heterozygotes O 0 5.191046875552274e-05
showed O 0 1.0782305537304637e-07
significantly O 0 4.539769449252162e-08
increased O 0 9.328741334968527e-09
levels O 0 1.4403841674948126e-08
of O 0 4.0885073104846015e-08
radiation O 1 0.9992538094520569
- O 0 3.395133899175562e-05
induced O 0 0.000154580338858068
chromatid O 0 0.0002188321523135528
damage O 0 1.4615295640396653e-06
relative O 0 1.9712240373337409e-07
to O 0 2.2223645146368654e-09
that O 0 7.624909037495797e-10
of O 0 1.6850464135131915e-08
normal O 0 1.2376507640965428e-07
controls O 0 8.815421210783825e-07
. O 0 2.766795432762592e-07

These O 0 5.621257628263265e-07
results O 0 1.4699863015721348e-07
show O 0 2.6955998322364394e-08
that O 0 2.1261110649817283e-09
the O 0 2.5093617850302508e-08
G2 O 1 0.9085063338279724
- O 0 2.575296775830793e-06
phase O 0 2.323563194295275e-06
chromosomal O 0 7.4914834158335e-07
radiosensitivity O 0 1.5796571233295253e-06
assay O 0 3.055895803072417e-08
can O 0 1.632846219346007e-10
be O 0 1.0353654739114759e-10
used O 0 3.933600389860459e-10
for O 0 2.7697827365003036e-10
the O 0 1.073985012034484e-09
detection O 0 7.351322324211651e-07
of O 0 4.363531331819104e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.00017130491323769093
. O 0 2.1049943370599067e-06

In O 0 2.1077994460938498e-07
combination O 0 3.5748109894484514e-07
with O 0 5.349775289431591e-09
molecular O 0 2.2698668544762768e-07
genetic O 0 5.828212223946139e-08
analyses O 0 1.3193175441017502e-08
, O 0 3.3829325452039427e-10
this O 0 2.1906482183808862e-10
test O 0 1.0427786634181757e-08
may O 0 1.3068619519884805e-09
be O 0 2.1995073817837607e-10
of O 0 1.5179277834675986e-09
value O 0 1.1402023769591096e-09
in O 0 1.764423468442189e-10
studies O 0 3.2134395144822747e-10
of O 0 7.553200287446771e-10
familial B-Disease 0 8.794339123596728e-08
and I-Disease 0 1.387522985396572e-08
sporadic I-Disease 0 3.0681248972541653e-06
cancers I-Disease 1 0.653416633605957
aimed O 0 1.1124451475552632e-06
at O 0 5.6742301524081995e-08
determination O 0 2.7015962800192028e-08
of O 0 7.444389993338518e-09
the O 0 5.338176123359517e-09
potential O 0 1.1738282346129836e-08
involvement O 0 2.7286182202601594e-08
of O 0 3.296556627674363e-08
ATM O 0 1.7746891899150796e-05
mutations O 0 5.5349794081394066e-08
in O 0 6.889533388232394e-09
tumor B-Disease 0 1.229932331625605e-05
risk O 0 1.5231830730044749e-07
or O 0 2.0938687228522213e-08
development O 0 1.6346137954315054e-07
. O 0 5.657328472352674e-08
. O 0 2.875291897908028e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 9.428522389498539e-07
identification O 0 1.559403983719676e-07
and O 0 1.991052123173631e-08
detection O 0 5.148137279320508e-05
of O 0 7.2157354225055315e-06
founder O 1 0.9999408721923828
- O 0 1.146185695688473e-05
effect O 0 5.4728015896898796e-08
mutations O 0 7.484268316204634e-09
in O 0 1.0946494821695296e-09
the O 0 6.49899822846578e-09
ATM O 0 1.3777359981759218e-06
gene O 0 1.4305877371612041e-08
in O 0 1.4210089771538037e-09
ethnic O 0 7.75961073173903e-09
populations O 0 7.35791587658241e-08
. O 0 3.328793241053063e-07

To O 0 3.656243166005879e-07
facilitate O 0 3.107775512489752e-07
the O 0 3.1969488389904654e-08
evaluation O 0 2.767827140814916e-07
of O 0 5.233781052993436e-07
ATM O 0 0.0042212167754769325
heterozygotes O 0 2.8019062483508606e-06
for O 0 6.768944071922078e-09
susceptibility O 0 5.861483032276738e-07
to O 0 1.4069042597597559e-09
other O 0 1.7144694552939654e-09
diseases O 1 0.679581880569458
, O 0 2.536500565142319e-09
such O 0 1.8033276205642323e-08
as O 0 6.31551392871188e-06
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999970197677612
, O 0 5.1588830984883316e-08
we O 0 5.728808094573878e-09
have O 0 1.5399271857674535e-09
attempted O 0 8.272269269582466e-08
to O 0 2.150734035311075e-09
define O 0 1.091023182908657e-08
the O 0 5.782522904951293e-09
most O 0 1.2495569023940334e-09
common O 0 4.087569394073398e-09
mutations O 0 1.21153709287114e-09
and O 0 4.982115830998168e-10
their O 0 5.915810619150363e-10
frequencies O 0 2.4998838554779468e-08
in O 0 2.6498984340150855e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999927282333374
telangiectasia I-Disease 1 1.0
( O 0 0.10894119739532471
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.392538280242661e-07
homozygotes O 0 2.8747651867888635e-06
from O 0 2.023857526012307e-08
10 O 0 1.4575297413443877e-08
ethnic O 0 1.8818354874383658e-08
populations O 0 8.037496002089028e-08
. O 0 2.1835550967352901e-07

Both O 0 3.639554790879629e-07
genomic O 0 1.5985459640432964e-06
mutations O 0 7.937736512531046e-08
and O 0 4.1988705845597e-09
their O 0 6.33662944338198e-09
effects O 0 2.633262511153589e-06
on O 0 3.0743763090868015e-07
cDNA O 0 2.328063601453323e-06
were O 0 2.99179241380898e-08
characterized O 0 6.445861231441086e-07
. O 0 6.560693464052747e-07

Protein O 0 1.5022999832581263e-05
- O 0 3.3946919302252354e-06
truncation O 0 6.1310752244025934e-06
testing O 0 1.8859755357425456e-07
of O 0 4.901934147483189e-08
the O 0 3.342407950412962e-08
entire O 0 1.170092289726199e-07
ATM O 0 1.3643432339449646e-06
cDNA O 0 4.323326834310137e-07
detected O 0 2.0451340176919075e-08
92 O 0 4.94441501075471e-08
( O 0 4.841607559313843e-09
66 O 0 1.5100040684501437e-07
% O 0 6.206854141765916e-09
) O 0 4.754251659022657e-09
truncating O 0 4.993265747543774e-07
mutations O 0 3.7769048333302635e-08
in O 0 2.078580862985291e-08
140 O 0 4.2014926293632016e-07
mutant O 0 1.4594263575418154e-06
alleles O 0 3.3936260024347575e-07
screened O 0 2.863543841158389e-06
. O 0 4.7168691708066035e-07

The O 0 5.106710432301043e-06
haplotyping O 0 0.00050960952648893
of O 0 6.37686753179878e-07
patients O 0 2.400651339939941e-07
with O 0 2.15680584503275e-09
identical O 0 4.067359071768806e-08
mutations O 0 1.440095687144094e-08
indicates O 0 3.2617503364917866e-08
that O 0 6.182228062812101e-10
almost O 0 5.920461343400518e-10
all O 0 2.514504715556143e-10
of O 0 8.400624640358956e-10
these O 0 1.4316944851877622e-10
represent O 0 1.0238575265386629e-10
common O 0 2.3533277548892784e-09
ancestry O 0 1.2913287106286475e-09
and O 0 5.987668694196202e-10
that O 0 1.0078187590023546e-10
very O 0 2.576277413623984e-09
few O 0 9.267592027129012e-09
spontaneously O 0 5.8413665016132654e-08
recurring O 0 8.850489621181623e-07
ATM O 0 2.612391472212039e-05
mutations O 0 2.1835570862549503e-07
exist O 0 3.90650512827051e-07
. O 0 1.3897340522817103e-06

Assays O 0 4.361117316875607e-05
requiring O 0 1.8190183936894755e-06
minimal O 0 1.5657834637750057e-06
amounts O 0 1.1176594227890746e-07
of O 0 6.749544212425462e-08
genomic O 0 3.0509343673656986e-07
DNA O 0 1.0355366697467616e-07
were O 0 5.7031437350474334e-09
designed O 0 2.0890338348067417e-08
to O 0 8.318098432269494e-10
allow O 0 3.523651592729493e-09
rapid O 0 1.2789524816980702e-07
screening O 0 1.391773594150436e-07
for O 0 2.277002586481558e-09
common O 0 2.7585926432038832e-08
ethnic O 0 2.364992113257358e-08
mutations O 0 1.4871991993459233e-07
. O 0 3.774208323648054e-07

These O 0 4.497375414302951e-07
rapid O 0 3.7616960071318317e-06
assays O 0 4.2039118852699175e-06
detected O 0 4.7211355536092015e-07
mutations O 0 5.20999670072797e-08
in O 0 4.69506433731226e-09
76 O 0 1.1134528676848277e-07
% O 0 5.656894064287599e-09
of O 0 4.8450655043552615e-08
Costa O 0 6.16138095210772e-07
Rican O 0 9.89387672234443e-07
patients O 0 1.1780397102256757e-07
( O 0 2.445291302777264e-09
3 O 0 1.3217582583990861e-08
) O 0 4.385286300756519e-10
, O 0 2.5107618761843753e-10
50 O 0 1.1212797357273985e-09
% O 0 2.6239838080144295e-10
of O 0 2.7210083075601688e-09
Norwegian O 0 3.55775142679704e-07
patients O 0 2.5407580039882305e-08
( O 0 2.6707620559562883e-09
1 O 0 4.465143632614854e-08
) O 0 1.7302446142508643e-09
, O 0 9.80915682013972e-10
25 O 0 3.009584359503492e-09
% O 0 2.6750127113395195e-10
of O 0 5.274555459067187e-09
Polish O 0 1.4035156709724106e-05
patients O 0 4.543095712961076e-07
( O 0 6.46037623397433e-09
4 O 0 5.353820142772747e-08
) O 0 8.276065943668698e-10
, O 0 5.885468223887358e-10
and O 0 1.194652932134943e-09
14 O 0 6.598710911021044e-09
% O 0 9.578930981746225e-10
of O 0 1.0202170663831112e-08
Italian O 0 1.9394303762965137e-06
patients O 0 1.926706971744352e-07
( O 0 5.254062518389446e-09
1 O 0 4.151038623945169e-08
) O 0 1.3213919958232623e-09
, O 0 1.0976937137030518e-09
as O 0 4.4991059766630315e-09
well O 0 5.253490975576369e-09
as O 0 3.858549479929252e-09
in O 0 8.909458171224571e-10
patients O 0 7.261933721025571e-09
of O 0 1.988881059844516e-08
Amish O 0 6.717864948768693e-07
/ O 0 7.267964292623219e-07
Mennonite O 0 2.2084693682700163e-06
and O 0 7.800749557418385e-08
Irish O 0 9.33168678329821e-07
English O 0 1.1148398471050314e-06
backgrounds O 0 1.2376074209896615e-06
. O 0 4.869663143836078e-07

Additional O 0 7.252364753185248e-07
mutations O 0 1.4198101894180581e-07
were O 0 1.2840275509518051e-08
observed O 0 1.2751996791848796e-08
in O 0 3.157587080693247e-09
Japanese O 0 1.3515057162294397e-06
, O 0 1.1452442549853004e-08
Utah O 0 6.80155949339678e-07
Mormon O 0 4.675005698118184e-07
, O 0 3.049315022707333e-09
and O 0 3.5642693241300094e-09
African O 0 5.99709224502476e-08
American O 0 3.6118618140790204e-07
patients O 0 1.189022441394627e-06
. O 0 1.1329772178214625e-06

These O 0 5.510793243956869e-07
assays O 0 2.318600536455051e-06
should O 0 4.131567976628503e-08
facilitate O 0 5.26814361023753e-08
screening O 0 1.9377132787212759e-07
for O 0 4.2161829583164945e-08
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 6.63819519104436e-05
in O 0 6.691015297377589e-09
the O 0 4.240553241885436e-09
populations O 0 1.8404556767492863e-09
studied O 0 1.3340751614521196e-08
. O 0 8.572037302201352e-09
. O 0 1.722963247630105e-07

The O 0 2.230136851721909e-05
von B-Disease 1 0.9993101358413696
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999982118606567
Lindau I-Disease 1 0.9999994039535522
tumor I-Disease 0 0.02666778676211834
suppressor O 0 1.76091562025249e-05
gene O 0 1.0933939087465205e-08
is O 0 3.8772274280063357e-10
required O 0 8.942606100070805e-10
for O 0 3.875839205136344e-09
cell O 0 2.0931683764047193e-07
cycle O 0 1.653413050917152e-08
exit O 0 1.562484719386248e-08
upon O 0 1.4025911987403106e-08
serum O 0 3.025904504738719e-07
withdrawal O 0 6.295798016253684e-07
. O 0 8.582729265071976e-07

The O 0 6.887709332659142e-06
inactivation O 0 9.777440573088825e-05
of O 0 1.7979480162466643e-06
the O 0 8.402032563026296e-07
von B-Disease 1 0.9984007477760315
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999996423721313
Lindau I-Disease 1 1.0
( I-Disease 0 5.498495738720521e-06
VHL I-Disease 1 1.0
) I-Disease 0 5.438770585897146e-06
tumor I-Disease 1 0.9999711513519287
suppressor O 1 0.9998828172683716
gene O 0 1.7625000054977136e-06
predisposes O 0 7.987008757481817e-06
affected O 0 7.482484853937876e-09
individuals O 0 1.6595724794399302e-10
to O 0 9.17934450672675e-10
the O 0 5.5980994062565514e-08
human O 1 0.9931235909461975
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.3349354510694411e-08
is O 0 2.8834162835167376e-10
associated O 0 9.140819767772257e-10
with O 0 1.2550889216811356e-09
sporadic B-Disease 0 0.0006522521143779159
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 5.172634337213822e-05
RCC B-Disease 1 1.0
) O 0 1.202189537252707e-06
and O 0 3.827119144261815e-06
brain B-Disease 1 0.9997557997703552
hemangioblastomas I-Disease 0 0.21021568775177002
. O 0 2.3381137452815892e-06

VHL O 1 0.9998927116394043
- O 0 0.0004629222967196256
negative O 0 1.0215585461992305e-05
786 O 0 0.00026214931858703494
- O 0 0.0001973744365386665
0 O 0 5.529837380890967e-06
RCC B-Disease 1 0.9999995231628418
cells O 0 1.7631053196964785e-05
are O 0 3.375388502036003e-08
tumorigenic O 0 0.06787283718585968
in O 0 6.75228619684276e-08
nude O 0 1.682731465280085e-07
mice O 0 3.112532809268487e-08
which O 0 7.157640036226098e-10
is O 0 1.491837209322e-09
suppressed O 0 7.183604822103007e-08
by O 0 3.706663642688568e-09
the O 0 6.646752126471256e-08
reintroduction O 0 8.749524567974731e-06
of O 0 1.4281389439929626e-06
VHL B-Disease 1 0.9999934434890747
. O 0 9.10145536181517e-06

Remarkably O 0 8.661288302391768e-05
, O 0 7.130040557967732e-08
this O 0 1.9614618818053486e-09
occurs O 0 7.3235257858073055e-09
without O 0 6.822345799406548e-09
affecting O 0 4.972140921211121e-09
the O 0 1.5020186205916275e-09
growth O 0 2.213489169733407e-09
rate O 0 6.173864974812204e-09
and O 0 3.1360036789607193e-09
cell O 0 6.141440849205537e-07
cycle O 0 2.1543522521483283e-08
profile O 0 3.080766752816544e-09
of O 0 2.8206394997454254e-09
these O 0 1.0928721261294072e-09
cells O 0 2.047264935356452e-08
in O 0 6.293244592114888e-09
culture O 0 1.6801610058791994e-07
. O 0 1.499076489608342e-07

The O 0 1.2020900612697005e-05
786 O 0 6.806818419136107e-05
- O 0 7.490785264963051e-06
0 O 0 4.186238129477715e-07
cell O 0 5.926856374571798e-07
line O 0 2.9475816631929774e-07
, O 0 3.0343345613914607e-09
like O 0 4.659860053379816e-09
many O 0 5.450693230102388e-09
cancer B-Disease 0 0.013993358239531517
cells O 0 2.690248379622062e-07
, O 0 4.216558657788028e-09
fails O 0 8.4060665983543e-08
to O 0 8.37955305144078e-09
exit O 0 3.3401525456611125e-07
the O 0 2.4493351347132375e-08
cell O 0 1.6186682216812187e-07
cycle O 0 7.909411792184073e-09
upon O 0 4.474766779338779e-09
serum O 0 2.669452783266024e-07
withdrawal O 0 3.790885045873438e-07
. O 0 8.931685897550778e-07

Here O 0 2.152115712306113e-06
, O 0 5.00124812674585e-08
it O 0 2.6871234126701893e-09
is O 0 8.180208177499537e-10
shown O 0 8.77434180868164e-10
that O 0 1.8166031179323028e-10
reintroduction O 0 2.3327098119807488e-07
of O 0 2.629948880894517e-08
the O 0 2.6601076896781706e-08
wild O 0 2.3717235819731286e-07
- O 0 1.1633894558826796e-07
type O 0 2.758482935405482e-07
VHL B-Disease 1 0.9999735355377197
gene O 0 3.842285138944135e-07
restores O 0 3.5852215205522953e-06
the O 0 2.5802915359918188e-08
ability O 0 7.640478827397601e-08
of O 0 2.1917387584835524e-06
VHL O 1 1.0
- O 1 0.999954104423523
negative O 0 1.500335565651767e-05
RCC B-Disease 1 1.0
cancer I-Disease 1 0.9144508838653564
cells O 0 1.0561219454530146e-07
to O 0 5.537299951896557e-09
exit O 0 1.2477694610879553e-07
the O 0 2.0157443714197143e-08
cell O 0 2.1970238606172643e-07
cycle O 0 1.3679225752127877e-08
and O 0 4.842420242567869e-09
enter O 0 1.9528923189682246e-07
G0 O 0 0.089927539229393
/ O 0 4.477303082239814e-05
quiescence O 0 2.019075327552855e-05
in O 0 3.597766351504106e-08
low O 0 1.3016705224799807e-06
serum O 0 3.2370951430493733e-06
. O 0 6.66015353090188e-07

Both O 0 3.5560966352932155e-05
VHL O 1 0.9999997615814209
- O 0 0.0017281542532145977
positive O 0 6.173891620164795e-07
and O 0 9.87482621894742e-07
VHL O 1 1.0
- O 1 0.999563992023468
negative O 0 2.991826249854057e-06
RCC B-Disease 1 0.9999998807907104
cells O 0 1.5226312370941741e-06
exit O 0 2.2053239945307723e-07
the O 0 3.131168213599267e-09
cell O 0 2.1144973771924924e-08
cycle O 0 9.578894344386413e-10
by O 0 1.1457871457176694e-10
contact O 0 2.0221982310886233e-08
inhibition O 0 7.805778636793548e-07
. O 0 5.770581310571288e-07

The O 0 1.6338019122486003e-05
cyclin O 0 0.00012982393673155457
- O 0 9.15368309506448e-06
dependent O 0 2.097783863064251e-06
kinase O 0 5.9885701375606e-06
inhibitor O 0 1.2782053318005637e-06
, O 0 1.006018290894417e-08
p27 O 0 2.421038516331464e-06
, O 0 5.82823167505353e-09
accumulates O 0 4.195614522473079e-08
upon O 0 4.32990177046122e-09
serum O 0 3.354401911792593e-08
withdrawal O 0 2.459371728491533e-08
, O 0 1.3413360422376286e-09
only O 0 4.0442019177966415e-10
in O 0 1.780957187280663e-10
the O 0 4.306771328455028e-10
presence O 0 2.088618389350927e-09
of O 0 2.1624707358114392e-08
VHL B-Disease 1 0.9999997615814209
, O 0 1.6917866219046118e-08
as O 0 3.598382258829247e-09
a O 0 1.9114689830956877e-09
result O 0 1.6672258018601838e-09
of O 0 7.854374040050516e-09
the O 0 1.1824594636777874e-08
stabilization O 0 1.0645062502590008e-06
of O 0 8.572071124035574e-07
the O 0 9.404669754076167e-07
protein O 0 3.6556193663273007e-06
. O 0 4.941342126585369e-07

We O 0 4.6282931975838437e-07
propose O 0 2.1782307157991454e-07
that O 0 6.554606635233995e-09
the O 0 1.021295670255995e-08
loss O 0 1.6129359892147477e-07
of O 0 4.694171593655483e-07
wild O 0 5.6321955526073e-06
- O 0 5.34015441644442e-07
type O 0 7.997710440577066e-07
VHL B-Disease 1 0.9999997615814209
gene O 0 9.672056222598258e-08
results O 0 3.864766284777943e-09
in O 0 1.1065647287367142e-09
a O 0 5.388649970683446e-09
specific O 0 8.472464685382874e-08
cellular O 0 4.583531335811131e-05
defect O 0 6.833653060311917e-06
in O 0 2.7637010902026304e-08
serum O 0 2.33406917686807e-05
- O 0 1.0425804248370696e-05
dependent O 0 1.4538015591369913e-07
growth O 0 1.8532187340269957e-08
control O 0 5.080926968048516e-08
, O 0 1.2540551930229071e-09
which O 0 6.899471549637326e-10
may O 0 5.271899805592284e-09
initiate O 0 1.6241685329987376e-07
tumor B-Disease 0 4.3113309402542654e-06
formation O 0 1.2559788729049615e-06
. O 0 1.6243169511653832e-06

This O 0 3.815810600826808e-07
is O 0 8.635680615043384e-08
corrected O 0 4.239039412823331e-07
by O 0 4.945242437770503e-09
the O 0 3.694045958013703e-08
reintroduction O 0 3.6237415770301595e-06
of O 0 1.8638112919688865e-07
wild O 0 6.156358836051368e-07
- O 0 5.075077069705003e-07
type O 0 1.994440481212223e-06
VHL B-Disease 1 1.0
, O 0 8.208534723053162e-07
implicating O 0 0.48008838295936584
VHL B-Disease 1 1.0
as O 0 1.554375012347009e-05
the O 0 4.3852242015418597e-07
first O 0 9.16647593385278e-08
tumor B-Disease 0 1.1994767191936262e-05
suppressor O 0 4.24470090365503e-06
involved O 0 1.0365678093648967e-08
in O 0 1.1514443842841615e-09
the O 0 5.750439679985675e-09
regulation O 0 5.592123031306073e-08
of O 0 2.257733200394796e-08
cell O 0 1.8099873955179646e-07
cycle O 0 5.76612313452074e-09
exit O 0 4.7800652325236115e-09
, O 0 1.1855272319394317e-10
which O 0 4.193832087162619e-11
is O 0 8.334578166513396e-11
consistent O 0 2.0542068046580653e-09
with O 0 3.544356752538391e-10
its O 0 7.377277899678347e-09
gatekeeper O 0 3.7119336866453523e-06
function O 0 4.026239786014685e-09
in O 0 2.1943962202897183e-09
the O 0 2.5312822060641338e-08
kidney O 0 0.00016936052998062223
. O 0 5.89089879099447e-08
. O 0 4.293226822937868e-07

Piebaldism B-Disease 1 1.0
with O 0 0.0005878617521375418
deafness B-Disease 1 1.0
: O 0 3.708908025146229e-07
molecular O 0 3.8954777892286074e-07
evidence O 0 6.660966533900137e-08
for O 0 4.588306623531935e-09
an O 0 6.473994229594382e-09
expanded O 0 9.058177056431305e-06
syndrome O 1 1.0
. O 0 1.6287987818941474e-05

In O 0 1.7547648667459725e-06
a O 0 5.126137239130912e-07
South O 0 6.239772005756095e-07
African O 0 8.72788135097835e-08
girl O 0 8.001534723689474e-08
of O 0 7.50167856722328e-08
Xhosa O 1 0.5742380023002625
stock O 0 2.0398346123329247e-07
with O 0 2.5900135369738564e-09
severe O 1 0.6789150238037109
piebaldism B-Disease 1 0.9999990463256836
and O 0 5.855590643477626e-05
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.0005390273290686309
identified O 0 1.2497700652147614e-07
a O 0 1.24282601987602e-08
novel O 0 2.6396028474096056e-08
missense O 0 1.0129502214795139e-07
substitution O 0 1.51686123217587e-07
at O 0 7.580600680512362e-08
a O 0 1.3284711108951797e-08
highly O 0 4.451733204291486e-08
conserved O 0 3.125942527049119e-08
residue O 0 4.994175384354094e-08
in O 0 1.5335521741377534e-09
the O 0 3.879788934568751e-09
intracellular O 0 4.317929125363662e-08
kinase O 0 9.309511739274967e-08
domain O 0 1.0020388074849507e-08
of O 0 6.920984674252395e-09
the O 0 3.045259688860824e-08
KIT O 0 6.712136382702738e-05
proto O 0 0.00012439166312105954
- O 0 5.446369414130459e-06
oncogene O 0 1.8147047740058042e-05
, O 0 8.706416565473774e-08
R796G O 0 9.480181688559242e-06
. O 0 1.3519376125259441e-06

Though O 0 1.9263063222751953e-05
auditory B-Disease 0 0.004292534664273262
anomalies I-Disease 0 0.00011799095227615908
have O 0 3.660624514623123e-08
been O 0 2.3861657538759573e-08
observed O 0 2.3946414628994717e-08
in O 0 5.482494458419751e-09
mice O 0 5.2334915068286136e-08
with O 0 1.592827092444793e-09
dominant O 0 0.00013570570445153862
white O 0 1.9606175555964e-05
spotting O 0 0.0003597289032768458
( O 0 1.0334861144656315e-06
W O 0 0.16439983248710632
) O 0 6.286669851363058e-09
due O 0 5.005628622711811e-08
to O 0 8.237627469043218e-09
KIT O 0 0.4974563419818878
mutations O 0 1.7429866829843377e-06
, O 0 2.0329241579020163e-06
deafness B-Disease 1 1.0
is O 0 1.1045750625271467e-07
not O 0 4.282380228204374e-09
typical O 0 9.919720156403855e-08
in O 0 1.060687981890851e-08
human O 0 1.618101919120818e-07
piebaldism B-Disease 0 7.046905375318602e-05
. O 0 1.2901620038974215e-06

Thus O 0 1.3005042092117947e-06
, O 0 2.4056651781734217e-08
the O 0 1.1894785600929936e-08
occurrence O 0 1.8828448844487866e-07
of O 0 2.5365574401803315e-05
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 1.02827843875275e-05
this O 0 4.964713795629905e-08
patient O 0 1.044731561705703e-06
extends O 0 1.291950724180424e-07
considerably O 0 1.3503587581453758e-07
the O 0 5.0335917656241236e-09
phenotypic O 0 2.2016166667526704e-08
range O 0 4.3107039715550854e-08
of O 0 4.0005975421308904e-08
piebaldism B-Disease 0 2.55904114965233e-06
due O 0 5.189833274243938e-08
to O 0 7.408270441544573e-09
KIT O 0 3.8001497159712017e-05
gene O 0 1.495553014763118e-08
mutation O 0 1.715732222962174e-09
in O 0 3.347100097084166e-10
humans O 0 7.578688787646115e-09
and O 0 3.80589382231733e-09
tightens O 0 3.0333384870573354e-07
the O 0 3.1406006684164822e-09
clinical O 0 6.184981771184539e-08
similarity O 0 3.2182146725290295e-08
between O 0 1.8259076028925847e-08
piebaldism B-Disease 0 9.97636561805848e-06
and O 0 1.3281942212728381e-09
the O 0 6.140778996410745e-10
various O 0 1.1423181289771378e-09
forms O 0 1.2430986906508679e-08
of O 0 2.394903276581317e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.117376427828276e-06
. O 0 2.527529659346328e-06

Cycloheximide O 0 0.0008165669278241694
facilitates O 0 6.285177278186893e-06
the O 0 1.5091102056885575e-07
identification O 0 2.73920193194499e-07
of O 0 1.9389665339986095e-07
aberrant O 0 1.9582985260058194e-06
transcripts O 0 6.73816657581483e-07
resulting O 0 5.7174904810608496e-08
from O 0 1.2682478178760448e-08
a O 0 1.0292115604215724e-08
novel O 0 1.3835857259891782e-07
splice O 0 9.779349966265727e-06
- O 0 7.012687888163782e-07
site O 0 2.2499479612747564e-08
mutation O 0 2.9141420387901462e-09
in O 0 1.2662144666109043e-09
COL17A1 O 0 0.002680462785065174
in O 0 7.322324524494661e-09
a O 0 1.1999812699059476e-08
patient O 0 1.1393185417318819e-07
with O 0 1.8714766625294033e-08
generalized O 1 0.5542744994163513
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
. O 0 0.00043892834219150245

Patients O 0 2.4489705538144335e-05
with O 0 6.077524972170067e-07
generalized O 0 0.02518889680504799
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 6.19264756096527e-06
show O 0 4.250742691169762e-08
decreased O 0 1.8126039336152644e-08
expression O 0 7.752895214707678e-09
of O 0 1.8989911865219256e-08
type O 0 1.91738013199938e-06
XVII O 1 1.0
collagen O 1 0.9948480129241943
, O 0 4.371837007965951e-07
a O 0 2.419629652194999e-07
transmembrane O 0 6.342127676361997e-07
hemidesmosomal O 0 1.446056899112591e-06
protein O 0 3.317301633387615e-08
encoded O 0 9.91304016650929e-09
by O 0 4.719053592339151e-09
COL17A1 O 0 0.0003555358271114528
. O 0 2.4254454729089048e-06

This O 0 3.0170178888511145e-07
report O 0 5.9204559477166185e-08
documents O 0 1.1917249764792359e-07
a O 0 6.7493502342586e-08
novel O 0 8.435777658633015e-07
splice O 0 5.728031828766689e-05
- O 0 5.019156105845468e-06
site O 0 1.1758487516999594e-07
mutation O 0 7.2288774966011715e-09
in O 0 2.83847079174393e-09
COL17A1 O 0 0.1574263572692871
in O 0 9.983188498097206e-09
a O 0 1.2651408809460918e-08
patient O 0 1.2247561187450628e-07
with O 0 1.2693320172729727e-08
generalized O 0 0.2696191966533661
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 3.3504699104014435e-07
and O 0 1.905464053209016e-08
applies O 0 1.557227591320043e-08
a O 0 5.02317654138551e-09
new O 0 2.2156436685349945e-09
methodology O 0 1.2069525823221738e-08
to O 0 5.78829095765343e-10
define O 0 4.009556242579038e-09
and O 0 2.153307754326761e-09
characterize O 0 6.879189129449514e-08
the O 0 2.1015186035810984e-08
resulting O 0 1.6497753563271544e-07
mRNA O 0 1.6254651882263715e-06
splice O 0 6.0811007642769255e-06
variants O 0 8.429593663095147e-07
. O 0 4.6772888140367286e-07

Mutational O 0 0.0009052114910446107
analysis O 0 3.7283955407474423e-06
of O 0 3.6350252230477054e-06
COL17A1 O 0 0.39344096183776855
identified O 0 1.3938392839918379e-06
a O 0 2.6839444444703986e-07
maternally O 0 1.6731379446355277e-06
inherited O 0 2.4460761778755113e-05
G O 0 0.0004938797792419791
- O 0 4.083031672053039e-05
to O 0 6.090731403673999e-07
- O 0 5.799219070468098e-05
T O 0 0.0001762177562341094
transversion O 0 2.0071363906026818e-05
at O 0 4.386344798490427e-08
the O 0 4.231488048844767e-09
- O 0 2.046308544834119e-08
1 O 0 2.4744849724811502e-08
position O 0 9.883648033337522e-08
of O 0 8.470541956739908e-08
exon O 0 1.8104257151208003e-06
32 O 0 4.622690994438017e-07
. O 0 4.3507577629497973e-07

This O 0 2.695083765047457e-07
acceptor O 0 1.7194948043197655e-07
splice O 0 1.2596081433002837e-05
- O 0 7.834700568309927e-07
site O 0 4.2921868725898094e-08
mutation O 0 3.3549567568513794e-09
led O 0 7.213107888759396e-09
to O 0 1.2867850118780666e-09
the O 0 5.484648735176734e-09
formation O 0 2.1709431052840955e-07
of O 0 1.895573404908646e-06
aberrant O 0 3.2608727451588493e-06
transcripts O 0 2.0235030717685731e-07
present O 0 5.930341995252775e-09
at O 0 1.6382102785428287e-08
extremely O 0 7.390209333379971e-08
low O 0 1.4701968211738858e-06
levels O 0 8.229666832448856e-07
. O 0 1.0628294830894447e-06

Based O 0 1.1105689736723434e-05
on O 0 1.4601280327042332e-06
our O 0 2.0225191121880925e-07
recent O 0 3.864458619773359e-08
finding O 0 9.976339754302899e-08
that O 0 1.0943161043996952e-08
cycloheximide O 0 8.643557521281764e-05
stabilized O 0 0.0018409532494843006
mutant O 0 1.968007745745126e-05
COL17A1 O 0 0.4422890841960907
transcripts O 0 4.104564652607223e-07
in O 0 2.252922737255858e-09
keratinocytes O 0 1.9117223359899072e-07
homozygous O 0 1.9028780329222172e-08
for O 0 1.7376030614357774e-09
a O 0 6.552656639513543e-09
frameshift O 0 4.861180968873668e-07
mutation O 0 9.50966771995354e-09
, O 0 1.585280240412601e-09
the O 0 2.6302988676008e-09
effects O 0 3.636352516878105e-07
of O 0 3.9119666439546563e-07
the O 0 3.7703986777160026e-07
splice O 0 1.1663044460874517e-05
- O 0 2.102886327293163e-07
site O 0 7.943792290632246e-09
mutation O 0 4.5657200242743556e-10
on O 0 1.7012895536794304e-09
splicing O 0 5.2107719028526844e-08
of O 0 1.364136714698816e-08
COL17A1 O 0 0.0004346673667896539
transcripts O 0 4.097970247585181e-07
were O 0 6.62860788480657e-09
determined O 0 5.1057749139715725e-09
using O 0 9.128019229365236e-09
reverse O 0 2.029741779097094e-07
transcriptase O 0 5.523826303033275e-07
polymerase O 0 8.8306762791035e-07
chain O 0 6.612497571722997e-08
reaction O 0 8.0392394963269e-09
of O 0 1.2298166041091463e-08
total O 0 3.0112381477209738e-09
RNA O 0 1.7073993774374685e-07
from O 0 4.557414001737925e-09
keratinocytes O 0 2.5097813249885803e-07
incubated O 0 2.511205821065232e-07
for O 0 1.1351534823234033e-08
2 O 0 3.800028309797199e-07
. O 0 6.442720632549026e-07

5 O 0 1.3451149243337568e-05
h O 0 3.7937597880954854e-06
in O 0 4.6147889065650816e-08
the O 0 1.4822173710626885e-08
presence O 0 2.4527196273993468e-08
or O 0 3.673914861224148e-08
absence O 0 1.2292066458030604e-06
of O 0 9.324268148702686e-07
10 O 0 6.421202556339267e-07
microg O 0 3.427969932090491e-05
cycloheximide O 0 1.2909021279483568e-05
per O 0 2.403285748187045e-07
ml O 0 4.441574674274307e-06
. O 0 1.434857040294446e-06

Using O 0 5.939213565397949e-07
this O 0 1.315059083850656e-08
approach O 0 2.872195068448491e-07
, O 0 8.750480340324884e-09
an O 0 4.461353064755258e-09
abnormally O 0 2.9193518003012286e-07
spliced O 0 9.3206847395777e-07
transcript O 0 4.031360276712803e-07
was O 0 2.5849516305243014e-08
identified O 0 2.042034319416075e-09
that O 0 1.6830981053317373e-10
contains O 0 6.330694302114637e-10
an O 0 6.946346831071537e-10
extra O 0 1.5948769416240793e-08
264 O 0 3.689251215632794e-08
bases O 0 4.003338105462717e-08
upstream O 0 5.892595922318833e-08
from O 0 2.1949908557417075e-09
exon O 0 1.4640941792265494e-08
32 O 0 3.0358049407652743e-09
, O 0 2.0361216879205557e-10
resulting O 0 1.3932265341409789e-09
in O 0 9.656969668370152e-10
a O 0 4.8098347527059104e-09
premature O 0 8.978967258599369e-08
termination O 0 1.0426582548461738e-06
codon O 0 2.0824565183374943e-07
27 O 0 2.6078907922055805e-07
bp O 0 5.895327603866463e-07
downstream O 0 1.6532624158571707e-07
from O 0 1.2493025280946313e-08
the O 0 9.249600196881147e-08
cryptic O 0 1.1025456842617132e-05
splice O 0 4.361974060884677e-05
site O 0 3.4319207316002576e-06
. O 0 8.864392953000788e-07

Three O 0 1.3835821164320805e-06
other O 0 5.208883635532402e-08
splice O 0 2.8308086257311516e-06
variants O 0 1.1415503564649043e-07
, O 0 4.3160826024291055e-09
including O 0 1.6980348238604392e-09
one O 0 6.961759502210896e-10
derived O 0 1.1780023179142063e-08
from O 0 9.346587503955561e-09
the O 0 5.732425645277317e-09
skipping O 0 4.7537461966840056e-08
of O 0 2.0812306544826242e-08
exon O 0 1.0765208457996778e-07
32 O 0 1.7106421168477937e-08
, O 0 1.4077901067111043e-09
were O 0 3.791388536455997e-09
also O 0 1.536296068138654e-08
identified O 0 1.7235515770153143e-07
. O 0 7.762869813632278e-07

These O 0 2.4384186758652504e-07
results O 0 3.8049449813115643e-08
indicate O 0 3.6832044969514754e-08
the O 0 3.1985099013809304e-08
usefulness O 0 1.8962458625537693e-06
of O 0 2.5464979103162477e-07
cycloheximide O 0 0.00033247112878598273
treatment O 0 8.920856089389417e-06
in O 0 3.412642168854063e-09
evaluating O 0 8.444420274145159e-09
the O 0 1.4716696750127767e-09
abnormal O 0 4.286229149386145e-09
processing O 0 2.0517800791708396e-08
of O 0 8.54319548437843e-09
mRNA O 0 8.915450422364302e-08
due O 0 3.785227065122854e-08
to O 0 1.4244451840284e-08
splice O 0 7.498669674532721e-06
- O 0 2.3007447680356563e-07
site O 0 1.2621088174569195e-08
mutations O 0 5.383294920946469e-10
, O 0 3.2087296708560586e-10
because O 0 1.4636215572849665e-09
( O 0 8.069873658200777e-09
i O 0 1.2296318629978487e-07
) O 0 3.136954918048218e-09
aberrant O 0 2.503949581011966e-08
splicing O 0 4.292489919066611e-08
often O 0 2.962658174343602e-10
generates O 0 3.1294594693420663e-10
a O 0 3.213525279210927e-10
premature O 0 8.122841066438014e-09
termination O 0 1.185611466780756e-07
codon O 0 5.2504486092175284e-08
, O 0 3.6346861076452797e-09
( O 0 2.625446970938583e-09
ii O 0 0.0019677155651152134
) O 0 3.0738993572754225e-09
transcripts O 0 1.9607893975148727e-08
with O 0 2.1901552793579526e-10
premature O 0 6.005413411003246e-08
termination O 0 1.3505446077033412e-06
codons O 0 1.6784120759893995e-07
can O 0 2.8765676507447324e-09
occur O 0 4.089503402582295e-09
at O 0 1.8141671276339366e-08
low O 0 9.885042828727819e-08
or O 0 8.56259241288626e-09
undetectable O 0 2.542537629324215e-07
levels O 0 6.3922755977330326e-09
due O 0 1.1798664267814729e-08
to O 0 3.134568604679089e-09
nonsense O 0 2.3524297887433931e-07
- O 0 3.405276771673016e-08
mediated O 0 8.586309974134565e-08
mRNA O 0 2.1044748166332283e-08
decay O 0 1.95389038282201e-08
, O 0 3.1861344118588875e-10
and O 0 4.3392750503912225e-10
( O 0 2.0166315284342318e-09
iii O 1 0.6208213567733765
) O 0 8.542787810483787e-09
the O 0 5.572762695749134e-09
levels O 0 8.070982104868563e-09
of O 0 2.1560984109214587e-09
these O 0 3.622696864713504e-10
transcripts O 0 8.771451120992424e-09
can O 0 9.713602838745672e-11
be O 0 1.8913406951703848e-10
increased O 0 2.5986235385744294e-09
by O 0 6.330601820536685e-09
cycloheximide O 0 3.2535222999285907e-05
. O 0 1.4016653722137562e-06

A O 0 9.668100574344862e-06
deletion O 0 2.366001808695728e-06
mutation O 0 1.7047895539690217e-07
in O 0 4.11721146065247e-08
COL17A1 O 0 0.2980562448501587
in O 0 1.4875872089703535e-08
five O 0 1.7848016398147593e-08
Austrian O 0 7.505943244723312e-07
families O 0 1.456462594973118e-08
with O 0 1.0678698814103882e-08
generalized O 0 0.0007117927889339626
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
represents O 0 1.0151527476409683e-06
propagation O 0 3.620888037403347e-06
of O 0 1.0404664863017388e-07
an O 0 1.2207232558125725e-08
ancestral O 0 1.6158902553797816e-06
allele O 0 1.9176421517386188e-07
. O 0 1.3993010838930786e-07

Patients O 0 1.7827667761594057e-05
with O 0 3.3850602676466224e-07
generalized O 0 0.16000518202781677
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 3.253589682117308e-07
a O 0 2.9679721791353586e-08
usually O 0 1.650300163191787e-08
nonlethal O 0 2.3455215796275297e-06
form O 0 1.0072205469668916e-07
of O 0 8.702182640263345e-06
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999997615814209
, O 0 4.369319128727511e-08
have O 0 2.083485828308085e-09
generalized O 0 4.805334583579679e-07
blistering B-Disease 0 0.00011631772940745577
, O 0 8.609585506746953e-07
nail B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
, O 0 1.78541595232673e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.00010920763452304527
and O 0 0.0002663089835550636
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.0011427804129198194

Skin B-Disease 1 1.0
fragility I-Disease 1 0.9999997615814209
in O 0 2.864978512207017e-07
most O 0 5.741616959653584e-09
cases O 0 3.771770007432451e-09
is O 0 3.6265268565927045e-10
due O 0 5.436375349887612e-09
to O 0 1.2144198979768817e-09
mutations O 0 2.6005773090531648e-09
in O 0 8.628741055005662e-10
the O 0 3.877850929256965e-09
gene O 0 7.304692850595984e-09
encoding O 0 8.706864207397302e-08
type O 0 1.8592855894894456e-06
XVII O 1 1.0
collagen O 1 0.9997791647911072
( O 0 1.2558396520034876e-05
COL17A1 O 1 0.9999740123748779
) O 0 8.032819209802256e-07
. O 0 7.197957643256814e-07

Recently O 0 2.2337701011565514e-05
, O 0 8.814304663928851e-08
we O 0 1.037635932732428e-08
reported O 0 1.3161884027113047e-08
five O 0 4.499252082013072e-09
Austrian O 0 2.2687717660119233e-07
families O 0 9.265930245305753e-09
with O 0 5.9138285379845e-09
generalized O 0 0.00019199120288249105
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 1.5800813343957998e-05
share O 0 2.16310240830353e-07
the O 0 5.221307475267167e-08
same O 0 9.661086153300857e-08
COL17A1 O 1 0.7716994881629944
mutation O 0 3.454954139670008e-06
. O 0 1.1268201660641353e-06

Affected O 0 1.5503128452110104e-06
individuals O 0 1.6578688644131034e-08
in O 0 1.3117824160246983e-08
three O 0 5.612122766507355e-09
families O 0 1.8677386304233323e-09
are O 0 3.977100038188297e-10
homozygous O 0 4.30816227137143e-09
for O 0 2.0545203316402194e-09
4003delTC O 0 3.562158212844224e-07
, O 0 1.878943889366269e-09
whereas O 0 8.794754258190096e-09
those O 0 4.346765614116066e-09
in O 0 1.2467666898885454e-09
two O 0 9.7961805334279e-10
others O 0 3.1330562588749444e-09
are O 0 1.3297658529864975e-09
compound O 0 5.434216063804342e-07
heterozygotes O 0 3.941456270695198e-06
. O 0 7.07187552961841e-07

To O 0 4.602280512244761e-07
determine O 0 6.605992552977114e-08
if O 0 7.588264239188902e-09
the O 0 5.0315187571925435e-09
occurrence O 0 2.1140618144954715e-08
of O 0 3.683415172872628e-08
4003delTC O 0 9.460451906306844e-07
in O 0 1.279638173201647e-09
these O 0 5.71813929539644e-10
unrelated O 0 5.5708917479080355e-09
families O 0 3.935236303487244e-10
signifies O 0 2.401061571788432e-09
propagation O 0 9.829916791659343e-08
of O 0 2.4843167523158627e-08
an O 0 2.812581056943486e-09
ancestral O 0 8.616101609959514e-08
allele O 0 6.010487219043625e-09
or O 0 2.552369871011706e-09
a O 0 1.9663136896497235e-08
mutational O 0 1.145631631516153e-05
hot O 0 1.0351322089263704e-05
spot O 0 8.495229621985345e-07
, O 0 3.6832870087266656e-09
haplotypes O 0 6.678254749203916e-08
were O 0 4.546603982191755e-09
determined O 0 1.0989155363461123e-08
for O 0 6.5959429029760486e-09
polymorphisms O 0 4.4305394908406015e-07
both O 0 1.5654379126317508e-08
within O 0 1.8613030761116534e-07
and O 0 5.992461069581623e-07
flanking O 0 0.03681204095482826
COL17A1 O 1 0.9999988079071045
. O 0 2.5011555408127606e-05

Five O 0 1.3320049220055807e-05
intragenic O 0 0.00010825963545357808
polymorphisms O 0 2.828199285431765e-06
were O 0 4.750211246573599e-08
chosen O 0 9.069815121165448e-08
based O 0 8.149940811108536e-08
on O 0 1.8655752853646845e-07
their O 0 1.3659585818004416e-07
informativeness O 0 0.000802883121650666
. O 0 1.1892594784512767e-06

One O 0 7.344538630604802e-07
of O 0 1.3552327970955957e-07
these O 0 5.665337976523688e-09
, O 0 2.6632438476781317e-09
not O 0 3.799494885381449e-10
previously O 0 9.52053902381067e-09
reported O 0 2.9930977696324135e-09
, O 0 1.9358683545078748e-09
was O 0 5.1484342122876114e-08
2988 O 0 1.4976360489526996e-06
A O 0 8.28643464956258e-08
or O 0 1.1492596208029227e-08
C O 0 9.348539720122062e-07
that O 0 2.265457821337691e-09
introduces O 0 2.6239113992687635e-08
a O 0 4.620317461956347e-09
new O 0 6.236818617111339e-09
restriction O 0 2.1211787881725286e-08
site O 0 1.677823924239874e-08
for O 0 2.679349186962554e-09
Eco0109 O 0 1.8704937474467442e-06
I O 0 5.64686706638895e-06
. O 0 9.287959983339533e-07

All O 0 1.0391906926088268e-06
the O 0 3.523539646721474e-07
4003delTC O 0 3.796166538450052e-06
alleles O 0 1.1125717946924851e-07
showed O 0 2.0920083443343174e-08
the O 0 5.420337068073877e-09
same O 0 5.3389093146449795e-09
haplotype O 0 5.212089035921963e-07
for O 0 6.57446497243086e-09
these O 0 3.5112399654479987e-09
five O 0 2.715451685730841e-08
polymorphic O 0 1.469706262469117e-06
markers O 0 2.9308662305993494e-06
. O 0 5.458820737658243e-07

Fourteen O 0 0.0001571400644024834
microsatellite O 0 0.0002782136725727469
polymorphisms O 0 3.5228179058321984e-06
were O 0 6.188085421854339e-08
selected O 0 2.010330568680274e-08
based O 0 1.536618476905005e-08
on O 0 1.5622761750933023e-08
their O 0 7.259718159957629e-09
high O 0 5.552876132242091e-07
heterozygosity O 0 0.0002505209413357079
and O 0 1.8280402969139686e-08
their O 0 5.009169523617629e-09
location O 0 9.808341872030724e-08
within O 0 8.841464449460545e-08
10q23 O 0 7.822434781701304e-06
- O 0 1.2218062011015718e-06
q25 O 0 1.2410584531608038e-05
near O 0 6.03554963163333e-06
COL17A1 O 0 0.020074302330613136
. O 0 2.2838078166387277e-06

Three O 0 2.6945260742650134e-06
families O 0 2.2007648681210412e-07
shared O 0 1.2041964509990066e-06
microsatellite O 0 4.242727663950063e-05
polymorphisms O 0 3.323766804896877e-06
covering O 0 6.297756272033439e-07
at O 0 2.0090297425667814e-07
most O 0 9.00760976918491e-09
19 O 0 1.412295613789638e-08
cM O 0 2.3064560039642856e-08
, O 0 2.3473654131578314e-09
whereas O 0 1.3029824330601514e-08
the O 0 3.70278598893492e-08
others O 0 3.981627472171567e-08
shared O 0 3.35403704809778e-08
smaller O 0 4.2956163071039555e-09
regions O 0 2.020840161875981e-09
consistent O 0 1.3042405377916566e-08
with O 0 2.482577032836275e-09
cross O 0 3.2682495998415106e-07
- O 0 8.975985110737383e-07
over O 0 4.949092691219903e-09
events O 0 4.5222209310580297e-10
during O 0 1.5203386327655721e-09
passage O 0 1.2565596341218566e-09
of O 0 2.406654042719225e-10
this O 0 7.89183232652313e-11
mutation O 0 3.4377334312551966e-10
through O 0 6.761856630177476e-10
several O 0 2.6266389063778206e-09
generations O 0 1.4983061191742308e-07
. O 0 2.1806208394536952e-07

These O 0 4.722306528037734e-07
results O 0 7.379433952792169e-08
indicate O 0 3.8174697181148076e-08
that O 0 2.8948412555962477e-09
4003delTC O 0 5.276037882140372e-07
occurs O 0 7.987365435724314e-09
on O 0 5.095103006169666e-09
a O 0 1.854759568153952e-09
single O 0 3.401120940438318e-09
ancestral O 0 2.007560766514871e-07
allele O 0 7.106308430593344e-08
. O 0 2.063916326733306e-08
. O 0 1.6967074145668448e-07

The O 0 2.3046301066642627e-05
haptoglobin O 0 0.001390741323120892
- O 0 2.4599459720775485e-05
gene O 0 2.811081571962859e-07
deletion O 0 3.184521801813389e-07
responsible O 0 6.699956855982236e-08
for O 0 1.1684252854138322e-07
anhaptoglobinemia B-Disease 0 0.003057229332625866
. O 0 6.545167252625106e-06

We O 0 1.1775977100114687e-06
have O 0 3.2613215239507554e-08
found O 0 1.4720465735251764e-08
an O 0 1.8751991071042085e-09
allelic O 0 3.4539681337264483e-07
deletion O 0 3.4244854418830073e-07
of O 0 1.0386740001422368e-07
the O 0 1.932029931595025e-07
haptoglobin O 0 0.0007396627916023135
( O 0 5.9161440191246584e-08
Hp O 0 5.477500621964282e-07
) O 0 5.492898580428118e-09
gene O 0 3.848759533298107e-09
from O 0 1.3759237083021958e-09
an O 0 8.266441975379735e-10
individual O 0 1.969792329248321e-09
with O 0 1.604989918746469e-08
anhaptoglobinemia B-Disease 0 0.0008750911219976842
. O 0 4.2178826333838515e-06

The O 0 5.650702860293677e-06
Hp O 0 6.728650987497531e-06
gene O 0 1.336136961072043e-07
cluster O 0 1.1954813317061053e-07
consists O 0 3.1436830028042095e-08
of O 0 5.795842028533116e-08
coding O 0 9.93829644357902e-07
regions O 0 2.371162111103331e-08
of O 0 1.1132934929491967e-07
the O 0 8.874614110254697e-08
alpha O 0 2.728233710058703e-07
chain O 0 1.06153192902525e-08
and O 0 7.28016646966978e-10
beta O 0 1.6663237900615968e-08
chain O 0 3.9773464521886126e-08
of O 0 7.656055345250934e-09
the O 0 1.9571949394503463e-08
haptoglobin O 0 2.019663725150167e-06
gene O 0 1.5146115472930433e-08
( O 0 1.6037713379546403e-09
Hp O 0 2.8718163846974676e-08
) O 0 4.0845435367309335e-10
and O 0 7.409030056138022e-10
of O 0 9.355736629856892e-09
the O 0 2.110959229639775e-08
alpha O 0 1.0719066523279253e-07
chain O 0 2.9112268151720855e-08
and O 0 2.3927042569482637e-09
beta O 0 2.3453123887406946e-08
chain O 0 3.8490842513283496e-08
of O 0 1.511860681091548e-08
the O 0 3.4256345315952785e-08
haptoglobin O 0 3.5644557101477403e-06
- O 0 6.464742341449892e-08
related O 0 1.0210619905137719e-08
gene O 0 8.068672840977342e-09
( O 0 1.4360956868131325e-09
Hpr O 0 9.006768095787265e-07
) O 0 3.6617542331640607e-09
, O 0 3.21494919575116e-09
in O 0 4.844693091143881e-09
tandem O 0 6.699209507132764e-07
from O 0 3.446534790896294e-08
the O 0 6.462350654601323e-08
5 O 0 3.0245598736655666e-07
side O 0 1.4924661400073091e-06
. O 0 7.573301559204992e-07

Southern O 0 2.559598215157166e-05
blot O 0 6.180864875204861e-05
and O 0 1.4263066816511127e-07
PCR O 0 5.882118330191588e-06
analyses O 0 2.2464494975338312e-07
have O 0 3.0122664362863816e-09
indicated O 0 3.998368303115285e-09
that O 0 1.5341160286563849e-10
the O 0 9.42952382843032e-10
individual O 0 2.1823823304067957e-10
with O 0 5.320547336040704e-10
anhaptoglobinemia B-Disease 0 5.5519458328490146e-06
was O 0 7.181905914421804e-08
homozygous O 0 4.816435250631912e-09
for O 0 4.4756437445059305e-10
the O 0 1.8451444816491858e-09
gene O 0 1.3429639622586365e-09
deletion O 0 3.881817089990136e-09
and O 0 2.738929083534458e-10
that O 0 3.784492164093933e-11
the O 0 5.620753862345396e-10
gene O 0 2.1486143975124605e-09
deletion O 0 1.3089556105683187e-08
was O 0 1.484979161858746e-08
included O 0 2.151903544245215e-09
at O 0 3.7499492400172585e-09
least O 0 3.5877784076987496e-10
from O 0 6.497767324198378e-10
the O 0 3.429391659537373e-09
promoter O 0 2.5786687274376163e-06
region O 0 1.1417179734962701e-07
of O 0 5.308956474436854e-07
Hp O 0 2.000451786443591e-05
to O 0 4.888386584411819e-08
Hpr O 0 2.0465215129661374e-05
alpha O 0 2.3081290123627696e-07
but O 0 2.3022090900326475e-09
not O 0 8.402131213003372e-10
to O 0 7.107118893401321e-09
Hpr O 0 9.44390740187373e-06
beta O 0 9.845432487054495e-07
( O 0 6.372556526912376e-08
Hpdel O 0 2.5072549760807306e-05
) O 0 1.140403469435114e-07
. O 0 2.573401616245974e-07

In O 0 4.105660877939954e-07
addition O 0 8.881640667368629e-08
, O 0 1.8395475365196035e-08
we O 0 4.0703214132520316e-09
found O 0 2.467593018806724e-09
seven O 0 3.0073465939750577e-09
individuals O 0 1.8876249174848425e-10
with O 0 1.1181999770570883e-09
hypohaptoglobinemia B-Disease 0 0.0030527086928486824
in O 0 2.097062079542411e-08
three O 0 6.2885168183868245e-09
families O 0 1.582863284887992e-09
, O 0 8.015228480928727e-10
and O 0 1.7116627004654106e-09
the O 0 6.55020793161043e-09
genotypes O 0 4.002185960416682e-07
of O 0 8.057096323454971e-08
six O 0 3.75102366945157e-08
of O 0 6.917345274359832e-08
the O 0 2.3990347486346764e-08
seven O 0 5.61734880832887e-09
individuals O 0 1.1644611663808035e-10
were O 0 1.7902729299024145e-09
found O 0 1.6501797706069965e-09
to O 0 1.6057025709059758e-09
be O 0 3.445239826760371e-08
Hp2 O 1 0.9715666174888611
/ O 0 0.43765389919281006
Hpdel O 0 0.4464867413043976
. O 0 3.087815457547549e-06

The O 0 5.880755452380981e-06
phenotypes O 0 1.2601512025867123e-05
and O 0 3.161059964895685e-07
genotypes O 0 1.147632792708464e-05
in O 0 2.9763336684140995e-08
one O 0 7.796596257492183e-09
of O 0 7.282962233290391e-09
these O 0 1.1562134583087413e-09
three O 0 1.405984217939249e-09
families O 0 1.0028413655049917e-09
showed O 0 7.851928551794174e-10
the O 0 1.648402414566874e-09
father O 0 7.189060369228173e-08
to O 0 8.084185765255825e-09
be O 0 4.426906841104028e-08
hypohaptoglobinemic B-Disease 0 0.00014311171253211796
( O 0 7.152842584901009e-08
Hp2 O 0 2.5277531676692888e-05
) O 0 1.0057228827520248e-08
and O 0 3.820456484504575e-08
Hp2 O 0 0.0001358211738988757
/ O 0 8.602818525105249e-06
Hpdel O 0 0.00016809020598884672
, O 0 1.8707915216964466e-08
the O 0 2.3379385538646602e-08
mother O 0 6.143760344912153e-08
to O 0 5.538894676249129e-09
be O 0 1.0414031414995861e-08
Hp2 O 0 3.0108090868452564e-05
- O 0 6.305430702013837e-07
1 O 0 1.260950739379041e-07
and O 0 2.3803654158882637e-08
Hp1 O 0 3.3403575798729435e-05
/ O 0 1.2608933275259915e-06
Hp2 O 0 1.3679658877663314e-05
, O 0 2.782391650413274e-09
one O 0 1.503621005483069e-09
of O 0 5.062032570890551e-09
the O 0 5.664452018550037e-09
two O 0 1.414141248545775e-09
children O 0 1.0106528947062543e-09
to O 0 1.0565199826118032e-09
be O 0 8.179073418546068e-09
hypohaptoglobinemic B-Disease 0 9.623614459997043e-06
( O 0 3.214668709006219e-08
Hp2 O 0 1.693910962785594e-05
) O 0 9.500821462893327e-09
and O 0 3.2343123734790424e-08
Hp2 O 0 0.000413945788750425
/ O 0 2.052970557997469e-05
Hpdel O 0 0.00011269428068771958
, O 0 6.2406386724944696e-09
and O 0 1.9682975249679657e-09
the O 0 3.8731200469044325e-09
other O 0 9.109994980605052e-10
child O 0 2.8614863811782243e-09
to O 0 7.698002790768044e-10
be O 0 5.138003356108811e-09
Hp1 O 0 3.7722686101915315e-05
and O 0 2.0299083303143561e-07
Hp1 O 0 0.38576871156692505
/ O 0 0.0025632288306951523
Hpdel O 0 0.0005183331668376923
, O 0 9.526824662486888e-09
showing O 0 7.1978938365191425e-09
an O 0 1.3756823458166423e-09
anomalous O 0 2.4885952143449686e-07
inheritance O 0 2.243093604192836e-06
of O 0 2.128743290086277e-06
Hp O 0 0.000637430464848876
phenotypes O 0 1.1087910024798475e-05
in O 0 2.2666430510298596e-08
the O 0 7.951647518211757e-08
child O 0 1.664580366877999e-07
with O 0 1.104743603264069e-07
Hp1 O 0 0.004678439814597368
. O 0 9.726332791615278e-06

The O 0 5.241126200417057e-05
Hp2 O 1 0.727990448474884
/ O 0 0.002350525464862585
Hpdel O 0 0.0002817035128828138
individuals O 0 1.567696905624416e-08
had O 0 3.11093018012798e-08
an O 0 2.7884641262687637e-09
extremely O 0 9.580546844745186e-08
low O 0 1.4356029396367376e-06
level O 0 4.2699687696767796e-07
of O 0 2.5516931145830313e-07
Hp O 0 1.2359821539575933e-06
( O 0 1.3979708057831886e-08
mean O 0 4.485707094659119e-08
+ O 0 9.127430899980027e-08
/ O 0 1.4675855197765486e-07
- O 0 1.2471068089325854e-07
SD O 0 1.6228459571721032e-06
= O 0 4.8166764798907025e-08
0 O 0 2.3905345258867783e-08
. O 0 3.6930931646139697e-09
049 O 0 1.1070402479163022e-06
+ O 0 5.982467854437346e-08
/ O 0 7.139947655332435e-08
- O 0 4.643005624416219e-08
0 O 0 2.6165896116481235e-08
. O 0 4.396091934921742e-09
043 O 0 1.5654611615900649e-06
mg O 0 4.1065146660912433e-07
/ O 0 6.782930483950622e-08
ml O 0 2.9041116178518678e-08
; O 0 3.1188898130807274e-09
n O 0 1.09629239020137e-08
= O 0 1.473605681923118e-08
6 O 0 1.3205209370426019e-08
) O 0 3.903584400166693e-10
, O 0 1.6969395333354953e-10
compared O 0 4.47455988927814e-10
with O 0 3.202242637723174e-10
the O 0 4.603305292505411e-09
level O 0 2.5161961403341593e-08
( O 0 7.741409735473326e-10
1 O 0 6.350422854239923e-09
. O 0 8.030867637565109e-10
64 O 0 1.4163689776580668e-08
+ O 0 2.842709179162739e-08
/ O 0 3.843574702955266e-08
- O 0 4.0537354806247095e-08
1 O 0 2.449437630502871e-08
. O 0 5.2140798345590156e-09
07 O 0 1.1908081631872847e-07
mg O 0 2.1026978913596395e-07
/ O 0 5.026149807463298e-08
ml O 0 1.8621548747432826e-08
) O 0 4.263128461357013e-10
obtained O 0 2.068139437483296e-09
from O 0 8.743339385830495e-09
52 O 0 1.0837355546300387e-07
healthy O 0 6.409492669945394e-08
volunteers O 0 4.855389335034488e-08
having O 0 3.448750618417762e-08
phenotype O 0 4.3216985545768694e-07
Hp2 O 0 6.0467673392849974e-06
, O 0 5.789784651710761e-09
whereas O 0 8.469746681782908e-09
the O 0 1.8765879516990935e-08
serum O 0 6.730042514391243e-07
Hp O 0 4.6295380684568954e-07
level O 0 4.231974415347395e-08
of O 0 7.70558639118235e-09
an O 0 5.081978726728664e-10
individual O 0 2.0284544877124944e-10
with O 0 4.321747681945709e-10
Hp1 O 0 8.144957064359915e-06
/ O 0 4.173214165348327e-06
Hpdel O 0 0.00020201884035486728
was O 0 1.762336864885583e-06
0 O 0 6.404036412277492e-07
. O 0 4.921363938592549e-07

50 O 0 5.378340574679896e-06
mg O 0 7.217015991045628e-06
/ O 0 1.1166615649926825e-06
ml O 0 3.076754921949032e-07
, O 0 6.767833848897453e-09
which O 0 1.8086175890275058e-09
was O 0 2.043835500842306e-08
approximately O 0 1.957619621961726e-09
half O 0 2.7167195160160418e-09
the O 0 1.4753710475545745e-09
level O 0 4.12053466902762e-08
of O 0 3.254430325227986e-08
Hp O 0 3.062156963551388e-07
in O 0 1.1569287750035073e-08
control O 0 1.9974353904217423e-07
sera O 0 1.7881873759506561e-07
from O 0 4.380740659115645e-09
the O 0 1.581629760494252e-08
Hp1 O 0 2.0053996649949113e-06
phenotype O 0 7.47678043921951e-08
( O 0 3.2585218967540186e-09
1 O 0 1.647337732890719e-08
. O 0 3.222943023573066e-09
26 O 0 2.3571473661831988e-08
+ O 0 3.001938253532899e-08
/ O 0 5.6432106987358566e-08
- O 0 4.632461525488907e-08
0 O 0 8.086020741870925e-09
. O 0 7.331628082418717e-10
33 O 0 1.8975429227907625e-08
mg O 0 7.778270827429878e-08
/ O 0 4.3541362515497894e-08
ml O 0 2.2572939073484122e-08
; O 0 2.077937377720218e-09
n O 0 1.6928840551599933e-08
= O 0 2.1397285721036496e-08
9 O 0 8.510001592298977e-09
) O 0 7.767914089740202e-10
, O 0 7.545496449878897e-10
showing O 0 3.6642902045969095e-09
a O 0 4.088115179712304e-09
gene O 0 1.3313857571972676e-08
- O 0 9.802862166452542e-08
dosage O 0 9.985551514546387e-07
effect O 0 5.650146022162517e-07
. O 0 6.568819799213088e-07

The O 0 1.9281567347206874e-06
other O 0 1.0035081032810922e-07
allele O 0 1.7045456957021088e-07
( O 0 3.040802099008033e-08
Hp2 O 0 6.52969265502179e-06
) O 0 3.891335698114062e-09
of O 0 8.637357495899778e-09
individuals O 0 1.302077334841556e-09
with O 0 1.0249664228467736e-08
Hp2 O 1 0.9873741269111633
/ O 0 0.022298384457826614
Hpdel O 0 0.17873646318912506
was O 0 2.1735866084782174e-07
found O 0 1.6930737922749017e-09
to O 0 4.905483241834929e-10
have O 0 2.8734406520847244e-10
, O 0 8.589609579168211e-10
in O 0 7.058104101176355e-10
all O 0 6.322525281099445e-10
exons O 0 1.0291726937339263e-07
, O 0 4.200470526960487e-10
no O 0 3.4774338963927676e-10
mutation O 0 5.290108906486068e-10
, O 0 3.1265476319042307e-10
by O 0 4.3908102154155415e-10
DNA O 0 1.7691810683118092e-07
sequencing O 0 1.714900918159401e-06
. O 0 5.040387236476818e-07

On O 0 2.5876211111608427e-06
the O 0 5.86611967889894e-08
basis O 0 2.5389363500494255e-08
of O 0 3.512112201065065e-08
the O 0 6.33118135695554e-09
present O 0 2.3977664298513446e-09
study O 0 1.2232305168780044e-09
, O 0 2.211378163918809e-10
the O 0 1.1387505383098073e-09
mechanism O 0 8.62623110720051e-08
of O 0 6.190505530412338e-08
anhaptoglobinemia B-Disease 0 1.0814598681463394e-05
and O 0 5.1783013432782354e-09
the O 0 6.753056780439692e-09
mechanism O 0 1.1068654259815958e-07
of O 0 1.5183166723886643e-08
anomalous O 0 2.557435152539256e-07
inheritance O 0 7.32727301056002e-07
of O 0 5.79083632601396e-07
Hp O 0 1.6052330465754494e-05
phenotypes O 0 2.8066078812116757e-06
were O 0 5.796461266527331e-08
well O 0 9.282066315563497e-08
explained O 0 5.480604272634082e-07
. O 0 3.9138623719736643e-07

However O 0 8.702047580300132e-07
, O 0 3.7307032130229345e-08
the O 0 3.853741858961257e-08
mechanism O 0 1.650280296416895e-06
of O 0 1.422337732037704e-06
hypohaptoglobinemia B-Disease 1 0.89445561170578
remains O 0 0.0001586248545208946
unknown O 0 4.224141230224632e-05

ATM O 0 0.0005468003218993545
mutations O 0 2.788085566862719e-06
and O 0 1.995087899331338e-07
phenotypes O 0 4.2551913793431595e-05
in O 0 3.4503971164667746e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 0.001666342606768012
in O 0 6.590927625893528e-08
the O 0 3.338674048336543e-08
British O 0 3.53342613834684e-07
Isles O 0 1.9811968741123565e-06
: O 0 1.5201885972260243e-08
expression O 0 1.9221824132387155e-08
of O 0 2.2827656209756242e-08
mutant O 0 1.9072844281708967e-07
ATM O 0 6.380474815159687e-07
and O 0 2.1824833051908854e-09
the O 0 2.8154794051715726e-09
risk O 0 2.5660584768161243e-08
of O 0 4.280471443962597e-07
leukemia B-Disease 1 1.0
, O 1 0.8011166453361511
lymphoma B-Disease 1 1.0
, O 0 0.02426546812057495
and O 0 0.02526000514626503
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4624729374190792e-05

We O 0 9.29256771087239e-07
report O 0 5.702744232394252e-08
the O 0 2.007751653820833e-08
spectrum O 0 4.1037975506696966e-07
of O 0 9.800375977420117e-08
59 O 0 5.334250090527348e-07
ATM O 0 2.79477285403118e-06
mutations O 0 2.7739782026969806e-08
observed O 0 3.2145461403843e-08
in O 0 4.3869473387303515e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999527931213379
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.657416827873021e-08
patients O 0 2.486602568296803e-07
in O 0 8.037583931752579e-09
the O 0 6.364733451391658e-08
British O 0 2.8188339911139337e-06
Isles O 0 6.990603287704289e-05
. O 0 2.239626610389678e-06

Of O 0 1.7882684915093705e-05
51 O 0 1.2740803867927752e-05
ATM O 0 3.786548040807247e-05
mutations O 0 1.925547792325233e-07
identified O 0 4.2477438455534866e-08
in O 0 3.662802061654702e-09
families O 0 2.8038076305136883e-09
native O 0 2.673697929722607e-09
to O 0 5.195215369013795e-10
the O 0 1.116725645289307e-08
British O 0 6.771244329684123e-07
Isles O 0 4.627843736670911e-06
, O 0 8.141112672888084e-09
11 O 0 2.0479172135878798e-08
were O 0 1.3096824069691593e-08
founder O 0 1.3151365010344307e-06
mutations O 0 6.02205441069259e-09
, O 0 2.155247091906176e-09
and O 0 7.582245942217014e-09
2 O 0 2.3807791649232968e-07
of O 0 7.332194229547895e-08
these O 0 1.2592642484321459e-08
11 O 0 1.1814363887197032e-07
conferred O 0 2.579419060566579e-07
a O 0 1.3304743973208133e-08
milder O 0 3.0662879453302594e-06
clinical O 0 6.201271389727481e-07
phenotype O 0 4.896607919135931e-08
with O 0 4.2065717575923145e-10
respect O 0 4.300469758078407e-09
to O 0 5.898237898094294e-09
both O 0 2.359682724772938e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 0.4594086706638336
cellular O 0 0.0006643906235694885
features O 0 1.341973529633833e-06
. O 0 4.6194207925509545e-07

We O 0 4.6289727606563247e-07
report O 0 4.310030021770217e-08
, O 0 8.289656072690832e-09
in O 0 4.193548175379647e-09
two O 0 1.759102552512104e-08
A B-Disease 1 0.9998801946640015
- I-Disease 1 0.9994112253189087
T I-Disease 1 1.0
families O 0 6.443101341346846e-08
, O 0 5.010545311989745e-09
an O 0 3.198679321414488e-09
ATM O 0 4.477082597986737e-07
mutation O 0 6.365338478531157e-09
( O 0 3.266748649366491e-09
7271T O 0 7.382150215562433e-07
- O 0 9.793225217435975e-07
- O 0 1.4690125453853398e-06
> O 0 2.2201429601409473e-06
G O 0 3.250682084399159e-06
) O 0 1.3405354604145714e-09
that O 0 1.1506007951966879e-10
may O 0 5.22195953145399e-10
be O 0 1.1871202632018907e-10
associated O 0 3.05098890596156e-10
with O 0 5.0915036076126796e-11
an O 0 2.0956795326876332e-11
increased O 0 7.387891409749159e-10
risk O 0 1.411670869089221e-08
of O 0 2.6108895667675824e-07
breast B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9144402146339417
in O 0 4.695870359228138e-09
both O 0 8.847416133050956e-09
homozygotes O 0 2.6125560452783247e-06
and O 0 1.0630698099589608e-08
heterozygotes O 0 2.2909773633728037e-07
( O 0 2.0963291103015536e-09
relative O 0 8.872972045992356e-08
risk O 0 1.4746916576768854e-07
12 O 0 2.3645773339353582e-08
. O 0 1.774102753593354e-09
7 O 0 1.9761982272825662e-08
; O 0 4.509252082840476e-09
P O 0 8.816606396067073e-07
= O 0 5.951364556722183e-08
. O 0 3.393565206621929e-09
0025 O 0 7.261604082486883e-07
) O 0 5.307067008075705e-10
, O 0 2.42844605535808e-10
although O 0 4.947806608868177e-10
there O 0 4.5620118793721076e-10
is O 0 3.576696161466941e-10
a O 0 1.8765085041394514e-09
less O 0 3.5783218610419e-09
severe O 0 0.0009002570295706391
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 2.59501263144557e-07
in O 0 5.929954860484088e-10
terms O 0 7.532425794209985e-10
of O 0 1.1928495968760444e-09
the O 0 1.5842707146163093e-09
degree O 0 1.813560572827555e-07
of O 0 3.817834794972441e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.000125919483252801

This O 0 9.312332736044482e-07
mutation O 0 4.196734835204552e-07
( O 0 5.932562530119867e-08
7271T O 0 3.2132211345015094e-06
- O 0 8.306133736368793e-07
- O 0 6.69155383548059e-07
> O 0 7.955369483170216e-07
G O 0 9.925679478328675e-07
) O 0 2.191660852801647e-09
also O 0 5.728946761429654e-10
allows O 0 4.207920123455722e-10
expression O 0 1.5154053567556502e-09
of O 0 3.324223118994496e-09
full O 0 1.7559180776061112e-08
- O 0 4.7476660824941064e-08
length O 0 9.63954693844471e-09
ATM O 0 1.710778292363102e-07
protein O 0 3.774180523663517e-09
at O 0 1.573441710256418e-09
a O 0 5.69423841412231e-10
level O 0 3.4930307535319116e-09
comparable O 0 1.3820475430748047e-08
with O 0 6.77072231614062e-10
that O 0 4.975952427876962e-10
in O 0 3.183560304265143e-09
unaffected O 0 7.735777671769029e-07
individuals O 0 1.4058024966345783e-08
. O 0 2.7715830697161437e-07

In O 0 4.368319537206844e-07
addition O 0 6.836481958316654e-08
, O 0 1.7229870863388896e-08
we O 0 2.691709077851101e-09
have O 0 3.9740818968958536e-10
studied O 0 9.144381252212952e-09
18 O 0 2.869916215786361e-08
A B-Disease 1 0.9999904632568359
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.006632920354604721
, O 0 9.216647001153433e-09
in O 0 9.340451745387668e-10
15 O 0 3.9934295870125425e-09
families O 0 1.0056916410761119e-09
, O 0 8.116348704234611e-10
who O 0 3.5007412524379333e-09
developed O 0 3.0345011055032955e-06
leukemia B-Disease 1 1.0
, O 0 0.010606696829199791
lymphoma B-Disease 1 1.0
, O 0 0.0004278379201423377
preleukemic O 1 0.999944806098938
T O 1 0.970295250415802
- O 0 9.193032383336686e-06
cell O 0 2.487321353328298e-06
proliferation O 0 1.1502758070491836e-06
, O 0 1.1237032415678527e-09
or O 0 1.802867330980007e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.431389243109152e-05
mostly O 0 1.05269293726451e-07
in O 0 3.283178529045472e-08
childhood O 0 2.237866101495456e-05
. O 0 1.5522656440225546e-06

A O 0 1.1142023140564561e-05
wide O 0 9.628063253330765e-07
variety O 0 1.5943180642352672e-07
of O 0 4.7513530887499655e-08
ATM O 0 2.080629428746761e-06
mutation O 0 6.780082273394328e-09
types O 0 7.007390667723712e-09
, O 0 8.301487830486565e-10
including O 0 2.5752655563593407e-09
missense O 0 1.1581582839426119e-06
mutations O 0 3.243962964916136e-08
and O 0 1.9984026877750694e-08
in O 0 2.4128659958932985e-08
- O 0 3.2877662192731805e-07
frame O 0 4.4613301497520297e-07
deletions O 0 1.1561482438082749e-07
, O 0 1.8462463780011262e-09
were O 0 1.970378527005323e-09
seen O 0 9.454200977643268e-09
in O 0 2.501284734890419e-09
these O 0 6.941608621247042e-09
patients O 0 1.2493893564169412e-06
. O 0 5.692777449439745e-07

We O 0 4.851066023547901e-06
also O 0 1.9012423990716343e-07
show O 0 1.216024436700991e-08
that O 0 3.2570285357635953e-10
25 O 0 2.653569142196943e-09
% O 0 1.1663178201004598e-09
of O 0 2.2114058140232373e-08
all O 0 9.500062958522904e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.522044724173611e-06
carried O 0 2.9316993277461734e-08
in O 0 5.032478878064239e-09
- O 0 8.191957334702238e-08
frame O 0 9.231887077021383e-08
deletions O 0 2.9296813863766147e-08
or O 0 3.3549631961449222e-09
missense O 0 4.623581517648745e-08
mutations O 0 2.9958733271939764e-09
, O 0 4.360631300492912e-10
many O 0 2.3259538739495156e-10
of O 0 5.543354664183653e-09
which O 0 1.28725630155202e-09
were O 0 2.17361395549176e-09
also O 0 6.74983402504381e-10
associated O 0 1.6116337153704308e-09
with O 0 5.413329229320141e-10
expression O 0 2.0896713692764024e-08
of O 0 1.033575358633243e-07
mutant O 0 1.4261871683629579e-06
ATM O 0 9.538493941363413e-06
protein O 0 8.38202424802148e-07
. O 0 2.8794767104045604e-07

The O 0 1.2527869330369867e-05
DMPK O 1 0.7453821301460266
gene O 0 5.609713753074175e-06
of O 0 8.236992243837449e-07
severely O 1 0.9989342093467712
affected O 1 0.5919246673583984
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999997615814209
is O 0 3.984355601005518e-07
hypermethylated O 0 5.95834462728817e-05
proximal O 0 0.00010313771053915843
to O 0 4.8969720722880083e-08
the O 0 2.8863860279670916e-07
largely O 0 1.1360824601069908e-06
expanded O 0 2.015175141423242e-06
CTG O 0 0.000564931018743664
repeat O 0 6.608452167711221e-06
. O 0 1.5874678638283513e-06

Using O 0 9.439585483050905e-06
methylation O 0 1.9368690118426457e-05
- O 0 7.239605565700913e-06
sensitive O 0 1.055978373187827e-06
restriction O 0 2.6762656091250392e-08
enzymes O 0 7.067268548155425e-09
, O 0 5.967647487281624e-10
we O 0 5.126234992047785e-10
characterized O 0 9.808899470442611e-09
the O 0 5.03463848389174e-09
methylation O 0 1.686457729022095e-08
pattern O 0 1.855400988404199e-08
on O 0 5.1418855839813205e-09
the O 0 2.356687511806399e-09
5 O 0 6.66095134604916e-09
side O 0 1.891890732963475e-08
of O 0 5.7942173725678003e-08
the O 0 3.79164788455455e-07
CTG O 0 0.0952703133225441
repeat O 0 2.1736612154654722e-07
in O 0 3.456130714951655e-09
the O 0 7.0776287053320175e-09
DMPK O 0 3.683432805701159e-05
gene O 0 4.46765469064303e-09
of O 0 1.224023993273704e-09
normal O 0 1.4300440831505057e-09
individuals O 0 9.335068829052773e-11
and O 0 1.5882826165380948e-09
of O 0 3.2436659580525884e-08
patients O 0 1.9840595086861867e-06
affected O 0 1.1412781475428346e-07
with O 0 5.161285230315116e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 5.412038603935798e-07
showing O 0 6.150185072328895e-08
expansions O 0 3.904530956333474e-07
of O 0 9.182749494129894e-08
the O 0 6.728964763169643e-08
repetitive O 0 1.4458887562796008e-06
sequence O 0 1.1678525879688095e-07
. O 0 9.107188958523693e-08

The O 0 6.399148333002813e-06
gene O 0 1.0848001466001733e-06
segment O 0 6.029999326528923e-07
analyzed O 0 7.259084355837331e-08
corresponds O 0 4.8337486902028104e-08
to O 0 1.6532489155451913e-08
the O 0 2.0706968939521175e-07
genomic O 0 9.589241017238237e-06
SacI O 0 0.0007017566240392625
- O 0 1.287421127926791e-06
HindIII O 0 4.413865553942742e-06
fragment O 0 1.1332306826261629e-07
carrying O 0 5.285515314312761e-08
exons O 0 4.565167444070539e-07
11 O 0 1.5414480003528297e-07
- O 0 7.2786184546203e-07
15 O 0 6.113135100349609e-07
. O 0 7.966552857396891e-07

There O 0 6.103103942223242e-07
is O 0 6.321204892856258e-08
constitutive O 0 2.160884832846932e-06
methylation O 0 1.0769783784780884e-06
in O 0 9.885005169962824e-08
intron O 0 8.726584201212972e-05
12 O 0 2.620511168061057e-07
at O 0 5.7614979454001514e-08
restriction O 0 8.263482342840689e-09
sites O 0 2.778069774223013e-09
of O 0 3.3253646503084155e-09
SacII O 0 1.4912425285729114e-06
and O 0 1.0772414071880121e-08
HhaI O 0 2.6117463676200714e-06
, O 0 6.98414615030174e-09
localized O 0 1.5043281109683448e-07
1 O 0 9.238898002195128e-08
, O 0 4.861864688621154e-09
159 O 0 6.423958609502733e-08
- O 0 3.7386780604720116e-07
1 O 0 2.2966234780597006e-07
, O 0 1.3952615951495773e-08
232 O 0 1.1034505575935327e-07
bp O 0 4.954280257152277e-07
upstream O 0 8.596354916790006e-08
of O 0 1.9641957393901066e-08
the O 0 4.4856559355821446e-08
CTG O 0 1.5007806723588146e-05
repeat O 0 1.0906865099968854e-07
, O 0 7.925777811834678e-10
whereas O 0 1.510171210306055e-09
most O 0 6.604651270336603e-10
, O 0 1.4237863665833572e-10
if O 0 8.176460203346281e-11
not O 0 5.4294166385027154e-11
all O 0 1.0767287755841792e-10
, O 0 2.2844139080380188e-10
of O 0 1.7069190505480947e-09
the O 0 3.2311540110185888e-09
other O 0 8.324828049133259e-10
sites O 0 6.079666992064858e-09
of O 0 1.6914027511916174e-08
SacII O 0 5.004978902434232e-06
, O 0 1.1799158983194502e-08
HhaI O 0 9.022655831358861e-06
, O 0 8.734304834945306e-09
and O 0 2.582714131449393e-08
HpaII O 0 0.0004241434799041599
in O 0 5.188939500300194e-09
this O 0 8.693780140234253e-10
region O 0 1.355337087005637e-08
are O 0 1.5392284113957544e-09
unmethylated O 0 1.3155657143215649e-05
, O 0 3.7019651788483543e-09
in O 0 1.1494015739188512e-09
normal O 0 5.000024838608397e-09
individuals O 0 2.6351279491798607e-10
and O 0 1.0257187321727201e-09
most O 0 1.5177916701247796e-09
of O 0 3.261532910414644e-08
the O 0 1.8050161543214926e-07
patients O 0 2.696001274671289e-06
. O 0 5.5392933973053e-07

In O 0 3.143752280720946e-07
a O 0 2.607601956583494e-08
number O 0 5.296633798224093e-09
of O 0 4.711213819064142e-08
young O 0 1.6760944276938972e-07
and O 0 2.8795886564125794e-08
severely O 0 0.0001831589761422947
affected O 0 5.426795013363517e-08
patients O 0 1.1997724413959077e-07
, O 0 8.023396391720894e-10
however O 0 2.3902457790825338e-09
, O 0 5.435771277539914e-10
complete O 0 6.002834229690279e-09
methylation O 0 1.3129863418726018e-08
of O 0 2.3461657061574215e-09
these O 0 7.362569998115021e-10
restriction O 0 2.588255609836665e-09
sites O 0 2.4726154457255234e-09
was O 0 2.6540651898443457e-09
found O 0 3.7852523893100454e-10
in O 0 4.695796529397001e-10
the O 0 6.0190226136569436e-09
mutated O 0 4.944863007949607e-07
allele O 0 8.912574571695586e-07
. O 0 8.081981945906591e-07

In O 0 4.7148452608780644e-07
most O 0 1.7223594994675295e-08
of O 0 9.230263664505856e-09
these O 0 1.303026464505308e-09
patients O 0 1.646144198730326e-08
, O 0 4.1173092713009396e-10
the O 0 1.3460362824346817e-09
onset O 1 0.943658709526062
of O 0 1.1769098819058854e-05
the O 0 1.0002401722886134e-05
disease O 1 1.0
was O 1 0.8832098841667175
congenital O 1 1.0
. O 0 4.819874811801128e-05

Preliminary O 0 1.8986338545801118e-05
in O 0 2.89010949927615e-06
vivo O 0 0.00010275427484884858
footprinting O 0 0.0025311580393463373
data O 0 2.9638940191034635e-07
gave O 0 8.839221976586487e-08
evidence O 0 4.416314425270684e-08
for O 0 5.561910043638818e-09
protein O 0 3.5212547544460904e-08
- O 0 4.8285148324112015e-08
DNA O 0 5.512654155381824e-08
contact O 0 1.8167503057497925e-08
in O 0 3.4355327471757846e-09
normal O 0 1.749245726045956e-08
genes O 0 1.4000467452035537e-08
at O 0 1.3503724360930391e-08
an O 0 1.8232549914287688e-09
Sp1 O 0 2.5780122996366117e-06
consensus O 0 4.442199497134425e-07
binding O 0 1.2151785711012053e-07
site O 0 1.7415413822163828e-07
upstream O 0 4.9207724117650287e-08
of O 0 5.1817692359179546e-09
the O 0 2.4784904795183138e-08
CTG O 0 1.207653713208856e-05
repeat O 0 5.113818346558219e-08
and O 0 1.097296031815631e-09
for O 0 2.0936588573938764e-10
a O 0 1.973570890045906e-10
significant O 0 6.805186969494059e-10
reduction O 0 1.6354972487420127e-08
of O 0 6.822840514786321e-09
this O 0 2.412039734611682e-10
interaction O 0 1.5637002803714495e-09
in O 0 3.03678804325358e-10
cells O 0 8.952487640101481e-10
with O 0 2.5073115805795965e-10
a O 0 2.4484194227625267e-08
hypermethylated O 0 1.3980627045384608e-05
DMPK O 0 0.001378941466100514
gene O 0 1.738294201913959e-07
. O 0 5.116013213068982e-08
. O 0 3.2430105534331233e-07

The O 0 0.0001626695302547887
hemochromatosis B-Disease 1 1.0
gene O 0 3.232291874155635e-06
product O 0 2.9962924941173696e-07
complexes O 0 3.629202183219604e-07
with O 0 6.228592752677287e-09
the O 0 1.0340288270072051e-07
transferrin O 0 0.3962589502334595
receptor O 0 9.036417054630874e-07
and O 0 2.5267718584132126e-08
lowers O 0 3.0437212217293563e-07
its O 0 2.7457252027573986e-09
affinity O 0 8.135368823047884e-09
for O 0 2.070539295573326e-09
ligand O 0 2.630320921070961e-07
binding O 0 2.235434664044078e-07
. O 0 3.260961136675178e-07

We O 0 1.3906355889048427e-06
recently O 0 4.650113680781942e-07
reported O 0 3.7951672027247696e-08
the O 0 9.456003979835259e-09
positional O 0 5.17270518685109e-06
cloning O 0 6.214461336639943e-07
of O 0 3.245720492373039e-08
a O 0 9.072821605116133e-09
candidate O 0 4.693267285915681e-08
gene O 0 9.813918211420969e-08
for O 0 1.4172276507906645e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999998807907104
HFE O 1 1.0
. O 0 1.671678364800755e-05

The O 0 1.1461935400802759e-06
gene O 0 3.51131532738691e-08
product O 0 3.235071588392202e-08
, O 0 4.3619228229374585e-09
a O 0 6.458355628069512e-09
member O 0 1.2978876640090675e-08
of O 0 8.434717813088355e-08
the O 0 2.601283881631389e-07
major O 0 1.126585812016856e-05
histocompatibility O 1 0.9999349117279053
complex O 0 1.333410637016641e-05
class O 0 1.0562710173189771e-07
I O 0 2.2198349824975594e-07
- O 0 5.7069875936122116e-08
like O 0 2.533106391311435e-09
family O 0 8.784293292762868e-09
, O 0 8.768386017266039e-10
was O 0 1.4873887010935505e-08
found O 0 1.4779989454538622e-09
to O 0 1.110954994665292e-09
have O 0 1.0959322338521815e-09
a O 0 1.1519809106630419e-08
mutation O 0 2.0185835225561277e-08
, O 0 2.0999278760314155e-08
Cys O 0 9.510271047474816e-05
- O 0 4.2742817640828434e-06
282 O 0 3.621077894422342e-06
- O 0 5.628737653751159e-06
- O 0 1.4357070767800906e-06
> O 0 2.8636502520384965e-06
Tyr O 0 3.2556676160311326e-05
( O 0 1.5819948018247487e-08
C282Y O 0 1.4741220866199e-07
) O 0 5.770389721604374e-10
, O 0 5.619853471472425e-10
in O 0 8.371162096842966e-10
85 O 0 2.2052057957466786e-08
% O 0 3.4910858648373733e-09
of O 0 2.9676550994395257e-08
patient O 0 1.628517225071846e-06
chromosomes O 0 1.3254284567665309e-06
. O 0 1.2090513337170705e-06

This O 0 6.409602519852342e-07
mutation O 0 5.134176035426208e-07
eliminates O 0 2.053291154879844e-06
the O 0 5.580721662568067e-08
ability O 0 1.0572465214409021e-07
of O 0 6.495567959063919e-07
HFE O 1 0.9999954700469971
to O 0 3.4490997791181144e-07
associate O 0 3.3656926916592056e-06
with O 0 5.140858405638937e-08
beta2 O 0 0.006999945733696222
- O 0 8.384462853427976e-05
microglobulin O 0 0.03270544856786728
( O 0 1.196505650113977e-07
beta2m O 0 3.1591684091836214e-05
) O 0 7.7336359538549e-09
and O 0 1.0487145374327156e-08
prevents O 0 1.9776582860231429e-07
cell O 0 1.7495649444754235e-05
- O 0 8.71889426434791e-07
surface O 0 8.441918453172548e-07
expression O 0 6.879923262204102e-07
. O 0 6.148525812932348e-07

A O 0 1.0677480531740002e-05
second O 0 8.610809345555026e-07
mutation O 0 1.795841519935948e-08
that O 0 1.3960834710502468e-09
has O 0 1.6086424414751832e-09
no O 0 3.0074382983968917e-09
effect O 0 2.1501158187220426e-08
on O 0 4.992974922402027e-08
beta2m O 0 4.476768026506761e-06
association O 0 2.1935605332146224e-08
, O 0 6.110264738623528e-09
H63D O 0 0.0394490510225296
, O 0 3.486416133569037e-08
was O 0 9.727168759354754e-08
found O 0 2.6777757788920553e-09
in O 0 1.1618971340610074e-09
eight O 0 2.306771662574647e-09
out O 0 8.609391533020982e-10
of O 0 9.642102227758187e-09
nine O 0 3.209375520896174e-08
patients O 0 5.1761510633241414e-08
heterozygous O 0 5.8959321869167525e-09
for O 0 2.9948337143537174e-09
the O 0 1.278563530604515e-07
C282Y O 0 2.9444729079841636e-05
mutant O 0 6.514820142911049e-06
. O 0 1.3917326668888563e-06

In O 0 2.7426602855484816e-07
this O 0 1.0495730506931977e-08
report O 0 1.2280398919983782e-08
, O 0 6.970612087542349e-09
we O 0 5.1260218292270565e-09
demonstrate O 0 5.1087095442881036e-08
in O 0 2.3360309242548283e-08
cultured O 0 1.6364105022148578e-06
293 O 0 5.748582907472155e-07
cells O 0 3.4236498436257534e-07
overexpressing O 0 1.3484837836585939e-05
wild O 0 4.1935905414902663e-07
- O 0 2.3785005964782613e-07
type O 0 3.1549524237561855e-07
or O 0 9.062551953320508e-08
mutant O 0 4.33621835327358e-07
HFE O 0 1.928894744196441e-05
proteins O 0 7.92508225710975e-10
that O 0 1.2939982418913587e-10
both O 0 6.733490987009816e-10
the O 0 5.366044941723658e-09
wild O 0 2.0192331362522964e-07
- O 0 1.7931039053564746e-07
type O 0 4.185351940577675e-07
and O 0 2.0322849536569265e-07
H63D O 1 0.982371985912323
HFE O 0 0.11437590420246124
proteins O 0 1.0972358133187754e-08
form O 0 7.2005299500688125e-09
stable O 0 1.54869766788579e-07
complexes O 0 1.1157871426803467e-07
with O 0 4.262155073320173e-09
the O 0 7.922142941652055e-08
transferrin O 0 0.0003032508247997612
receptor O 0 8.668303053127602e-07
( O 0 1.9190538935731638e-08
TfR O 0 1.0285217285854742e-05
) O 0 5.258305435518196e-08
. O 0 2.3692955153364892e-07

The O 0 1.826880543376319e-05
C282Y O 0 6.997859600232914e-05
mutation O 0 6.327006190076645e-07
nearly O 0 4.871213832302601e-08
completely O 0 1.0363942237745505e-07
prevents O 0 3.07621164097327e-08
the O 0 1.2058112730528592e-08
association O 0 9.796484512492043e-09
of O 0 4.5446384433489584e-08
the O 0 1.285940953721365e-07
mutant O 0 1.6391218196076807e-06
HFE O 0 0.0016402197070419788
protein O 0 7.916825950360362e-08
with O 0 5.220329057920026e-09
the O 0 1.958610909014169e-07
TfR O 0 0.027472078800201416
. O 0 4.005742994195316e-06

Studies O 0 7.274958534253528e-06
on O 0 1.911714662128361e-06
cell O 0 6.9053353399795014e-06
- O 0 9.547862873660051e-07
associated O 0 2.159876402174632e-07
transferrin O 0 0.00025500377523712814
at O 0 1.3503895957001077e-07
37 O 0 4.1847130205496796e-08
degrees O 0 2.7890672527064453e-07
C O 0 2.81760918596774e-07
suggest O 0 9.566410774652923e-09
that O 0 8.716710131473349e-10
the O 0 2.5590985330836702e-08
overexpressed O 0 3.33881939695857e-06
wild O 0 5.080384539724037e-07
- O 0 3.375971857622062e-07
type O 0 3.28435021401674e-07
HFE O 1 0.7153540849685669
protein O 0 2.2594862869596e-08
decreases O 0 1.626856649394881e-09
the O 0 2.0522554489144085e-10
affinity O 0 2.625867523420311e-09
of O 0 3.826200689616144e-09
the O 0 2.124328624120153e-08
TfR O 0 1.4864554032101296e-05
for O 0 8.528985517841647e-08
transferrin O 0 8.47579212859273e-05
. O 0 8.731691991670232e-07

The O 0 5.5349879403365776e-05
overexpressed O 0 0.005637558177113533
H63D O 1 0.9973822236061096
protein O 0 3.7429876442729437e-07
does O 0 4.247417528802089e-09
not O 0 3.508600354695801e-10
have O 0 1.1298622454303242e-10
this O 0 8.438455489923058e-11
effect O 0 1.257206894145213e-09
, O 0 3.480924437582189e-10
providing O 0 1.2766931956065264e-09
the O 0 7.331139584287882e-10
first O 0 8.366166093232152e-10
direct O 0 1.9570558507098212e-09
evidence O 0 3.968433581746922e-09
for O 0 1.5798711228143247e-09
a O 0 3.6720495533160147e-09
functional O 0 5.427685323411424e-08
consequence O 0 1.3576040203133743e-07
of O 0 7.520144862382949e-08
the O 0 3.869696456604288e-07
H63D O 0 0.0032455746550112963
mutation O 0 1.0199319149251096e-06
. O 0 6.3338893596665e-07

Addition O 0 1.7174803588204668e-06
of O 0 1.4248928437154973e-06
soluble O 0 1.8291608284926042e-05
wild O 0 3.930547791242134e-06
- O 0 2.480951025063405e-06
type O 0 1.5044793144625146e-05
HFE O 1 1.0
/ O 1 0.9999984502792358
beta2m O 0 0.15690453350543976
heterodimers O 0 0.00011162435112055391
to O 0 4.359737459935786e-08
cultured O 0 9.709621053843875e-07
cells O 0 3.131761161512259e-08
also O 0 1.2458302167672741e-09
decreased O 0 3.0855065169532736e-09
the O 0 2.4651045649193293e-09
apparent O 0 1.1348107165076726e-07
affinity O 0 5.1414176027719805e-08
of O 0 3.764383649240699e-08
the O 0 1.6354068321788873e-08
TfR O 0 8.43563270791492e-07
for O 0 9.587027838264817e-10
its O 0 1.096586710325198e-09
ligand O 0 2.5762149746810792e-08
under O 0 3.7579702905077284e-08
steady O 0 2.5740249043337826e-07
- O 0 3.836784756572342e-08
state O 0 1.0919345427851113e-09
conditions O 0 1.3391765030235092e-08
, O 0 8.788075822607766e-10
both O 0 6.706126209898855e-10
in O 0 7.692953496452049e-10
293 O 0 1.6070545783009038e-08
cells O 0 1.3832633705135322e-08
and O 0 4.98784213931458e-09
in O 0 2.2635152419070437e-08
HeLa O 0 0.0013462859205901623
cells O 0 2.0644890810217476e-06
. O 0 3.5536686482373625e-07

Furthermore O 0 3.5484467844071332e-06
, O 0 1.295072991069901e-07
at O 0 7.95383243712422e-08
4 O 0 2.314679647952289e-08
degrees O 0 1.2613681121820264e-07
C O 0 7.524635066147312e-07
, O 0 3.241264590059245e-09
the O 0 8.101952886363506e-09
added O 0 4.055336688679745e-08
soluble O 0 2.736087196808512e-07
complex O 0 1.8136557855541469e-07
of O 0 6.427341503467687e-08
HFE O 1 0.999923825263977
/ O 0 3.967912925872952e-05
beta2m O 0 4.1120501919067465e-06
inhibited O 0 6.652408757190642e-08
binding O 0 8.137681639652783e-09
of O 0 2.1402142280635417e-08
transferrin O 0 1.3247890819911845e-05
to O 0 9.057643524101877e-08
HeLa O 0 0.0010109366849064827
cell O 0 4.3617937990347855e-06
TfR O 0 5.8564664868754335e-06
in O 0 9.044623716647493e-09
a O 0 1.494024814974182e-08
concentration O 0 2.022184617089806e-06
- O 0 5.153041797711921e-07
dependent O 0 1.1525935406098142e-07
manner O 0 7.688390155635716e-07
. O 0 7.630006848557969e-07

Scatchard O 0 0.0011267372174188495
plots O 0 1.563263140269555e-05
of O 0 3.944051343296451e-07
these O 0 1.1453753501200481e-08
data O 0 1.623785195192795e-08
indicate O 0 6.699302890211811e-09
that O 0 1.4564562889063382e-09
the O 0 3.336401732667582e-08
added O 0 1.6937956104357e-07
heterodimer O 0 8.883875125320628e-06
substantially O 0 1.1780633712987765e-07
reduced O 0 2.6650743834011337e-08
the O 0 5.76544145758362e-09
affinity O 0 1.3340395454974896e-08
of O 0 2.8881805391733906e-08
TfR O 0 2.0826519175898284e-05
for O 0 2.2729992110726016e-07
transferrin O 0 0.00033095694379881024
. O 0 2.618854750835453e-06

These O 0 5.3803432820132e-07
results O 0 2.3503621093823313e-07
establish O 0 2.2302687341380079e-07
a O 0 4.287073096520544e-08
molecular O 0 3.4270405535608006e-07
link O 0 8.186566446966026e-07
between O 0 2.5272137804677186e-07
HFE O 1 0.9999998807907104
and O 0 8.99440863122436e-07
a O 0 2.6669769681575417e-07
key O 0 2.48204901254212e-06
protein O 0 2.3548105687609677e-08
involved O 0 2.270098997669834e-09
in O 0 1.500217727823383e-09
iron O 0 5.467523806146346e-05
transport O 0 2.792335749290942e-07
, O 0 6.0127347545346765e-09
the O 0 1.3876526594458483e-08
TfR O 0 0.0009485752088949084
, O 0 9.088270580548397e-09
and O 0 2.5659006031020226e-09
raise O 0 5.913693090775496e-09
the O 0 3.1553653023763673e-09
possibility O 0 1.6409247294291163e-08
that O 0 3.754011823620118e-10
alterations O 0 6.969683852275921e-08
in O 0 5.451906703868303e-10
this O 0 1.3336819149056822e-10
regulatory O 0 1.6637798694318917e-08
mechanism O 0 1.9504273751635992e-08
may O 0 3.3992855197340077e-09
play O 0 3.347867760794543e-09
a O 0 2.8381190730897288e-09
role O 0 1.3702962320394363e-08
in O 0 1.8848376193147942e-09
the O 0 1.5111515594412595e-08
pathogenesis O 1 0.9999998807907104
of O 1 0.999263346195221
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.014166624285280704
. O 0 5.642695214191917e-06

Genomic O 0 2.206370118074119e-05
organization O 0 5.98206895574549e-07
of O 0 1.6749197584431386e-06
the O 0 4.472329692362109e-06
UBE3A O 1 1.0
/ O 1 0.999864935874939
E6 O 1 0.9999932050704956
- O 0 5.031890032114461e-05
AP O 0 1.2872718798462301e-05
gene O 0 3.4696064687977923e-08
and O 0 4.767636951896748e-09
related O 0 2.1868895316856651e-07
pseudogenes O 0 0.00014590611681342125
. O 0 2.7419355319580063e-06

The O 0 3.658891000668518e-05
UBE3A O 0 0.002692999318242073
gene O 0 2.357478933845414e-06
encodes O 0 7.169286959651799e-07
the O 0 4.192750679976598e-07
E6 O 0 0.003839287208393216
- O 0 3.948330777348019e-05
AP O 0 0.0003088629455305636
ubiquitin O 0 1.3974122339277528e-05
- O 0 1.1227193681406789e-06
protein O 0 2.4996356984274826e-08
ligase O 0 7.468457141612816e-08
and O 0 7.00215307958274e-09
has O 0 5.476077369337418e-09
recently O 0 9.113075627453782e-09
been O 0 8.719686084290856e-10
shown O 0 4.626028726750775e-10
to O 0 1.8405986457192824e-10
be O 0 6.947221131703429e-10
mutated O 0 5.494409265338618e-07
in O 0 3.171439857396763e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9999825954437256
who O 0 3.7443624023580924e-07
lack O 0 3.6769683902093675e-06
15q11 O 0 5.959209011052735e-05
- O 0 4.803539013664704e-06
q13 O 0 3.5947252854384715e-06
deletions O 0 2.6476712378098455e-07
or O 0 3.483119570546478e-08
chromosome O 0 1.996555454297777e-07
15 O 0 1.7862548418179358e-07
paternal O 0 0.00017292618576902896
uniparental B-Disease 1 0.9999996423721313
disomy I-Disease 1 0.9999059438705444
. O 0 5.6398133892798796e-05

Previous O 0 9.172225691145286e-05
UBE3A O 0 0.011820713989436626
cDNA O 0 3.374115112819709e-05
analysis O 0 2.0356699792500876e-07
has O 0 1.3226610029448693e-08
shown O 0 5.4329238885486575e-09
a O 0 8.881009705419274e-09
coding O 0 3.3697222079354106e-07
region O 0 5.065860619879459e-08
of O 0 6.849677447462454e-08
approximately O 0 5.747164522063031e-08
2 O 0 1.0833857686520787e-06
. O 0 5.415203077063779e-07

6 O 0 8.039008389459923e-05
kb O 0 4.9699461669661105e-05
and O 0 1.9184908239822107e-07
a O 0 3.0092994052210997e-07
3 O 0 2.3227744350151625e-06
- O 0 5.11985717821517e-06
untranslated O 1 0.9999979734420776
region O 0 2.2157539660838665e-06
( O 0 9.584787363792202e-08
UTR O 1 0.9999806880950928
) O 0 1.0084465706938772e-08
of O 0 3.751209831648339e-08
< O 0 3.329402886720345e-07
50 O 0 3.059009756611886e-08
bp O 0 5.4435894014659425e-08
, O 0 5.604930963798438e-10
whereas O 0 2.3771291601804023e-09
Northern O 0 1.1952119294278418e-08
analysis O 0 6.000201668854288e-09
has O 0 6.331600799214243e-10
indicated O 0 2.1881436662596343e-09
mRNA O 0 5.956324322653472e-09
sizes O 0 4.5422181571552755e-09
of O 0 2.6188665458448668e-08
5 O 0 2.8619419367714727e-07
- O 0 2.118511702065007e-06
8 O 0 2.3747707018628716e-06
kb O 0 5.5713368055876344e-05
. O 0 1.2499768899942865e-06

We O 0 2.0341226445452776e-06
have O 0 4.5388777181187834e-08
analyzed O 0 4.696643074453277e-08
additional O 0 2.9751587860005202e-08
cDNA O 0 3.35400386575202e-06
clones O 0 1.1356328286638018e-06
and O 0 3.3329146109650765e-09
provide O 0 2.0593693417225722e-09
evidence O 0 6.510673333792738e-09
for O 0 1.4503798162479598e-09
an O 0 1.0325557076029668e-09
additional O 0 8.682780716640082e-09
0 O 0 1.4615280008456466e-07
. O 0 2.228191675612834e-07

5 O 0 1.85103253897978e-05
kb O 0 6.128910899860784e-05
of O 0 2.0912598301947583e-06
5 O 0 3.287864501544391e-06
- O 0 5.538450295716757e-06
UTR O 1 0.9998395442962646
and O 0 1.4949890214666084e-07
> O 0 1.0745520739874337e-06
2 O 0 4.427515136740112e-07
kb O 0 2.4608227704447927e-06
of O 0 3.9416522668034304e-07
3 O 0 2.5947032554540783e-05
- O 0 0.00014462940453086048
UTR O 1 0.9999992847442627
. O 0 1.0913313417404424e-05

We O 0 5.64867036700889e-07
have O 0 1.5835826872034886e-08
established O 0 3.826596994827014e-08
the O 0 5.129640712198125e-09
genomic O 0 4.769003325577614e-08
organization O 0 3.815735283296817e-09
of O 0 2.1547631234852815e-08
UBE3A O 1 0.6732800602912903
and O 0 4.435933931290492e-08
the O 0 9.68604574325127e-09
sequence O 0 7.72427544148968e-09
of O 0 3.677013538094798e-08
intron O 0 4.479169365367852e-05
- O 0 4.066280325787375e-06
exon O 0 2.200908738814178e-06
borders O 0 2.2032449464859383e-07
. O 0 3.7179421497057774e-07

We O 0 2.7604564820649102e-06
have O 0 7.908615629048654e-08
also O 0 5.996691498921791e-08
mapped O 0 1.8961542025408562e-07
two O 0 9.376083909273802e-09
highly O 0 3.8740228802680576e-08
homologous O 0 3.226505995712614e-08
processed O 0 5.9079571457232305e-08
pseudogenes O 0 4.752771758376184e-07
, O 0 1.2019490291947932e-08
UBE3AP1 O 0 0.15158338844776154
and O 0 1.085212417706316e-07
UBE3AP2 O 1 0.9986376166343689
, O 0 1.034789942622183e-08
to O 0 2.993451708732664e-09
chromosomes O 0 1.3646051399973658e-08
2 O 0 2.1553139717411796e-08
and O 0 4.683732068855306e-09
21 O 0 2.571781720916988e-08
, O 0 2.1547950090905488e-09
respectively O 0 8.203602241962926e-09
, O 0 2.217618089161988e-09
and O 0 3.989965247086502e-09
determined O 0 2.0797466859789893e-08
their O 0 1.4008614712679446e-08
genomic O 0 5.877997182324179e-07
organization O 0 1.2636388646569685e-07
. O 0 4.826608801522525e-07

These O 0 2.8199019652674906e-07
results O 0 6.293510779187272e-08
will O 0 1.8786321387409544e-09
form O 0 3.495496780914209e-09
the O 0 2.962947887041878e-09
basis O 0 3.981094121030537e-09
for O 0 2.9331506667951146e-10
studies O 0 4.8007947617279e-10
of O 0 9.419205415639453e-10
mutation O 0 1.1781701170221481e-09
and O 0 3.968751105531965e-09
imprinting O 0 4.197337602818152e-06
of O 0 1.0517088412598241e-05
UBE3A O 1 0.9999997615814209
. O 0 1.680275636317674e-05

Mutation O 0 1.1144339623569977e-05
spectrum O 0 1.7130902051576413e-05
and O 0 2.908835767811979e-07
genotype O 0 1.2901305126433726e-05
- O 0 1.2260035191502539e-06
phenotype O 0 3.890351081281551e-07
analyses O 0 3.1642265696518734e-08
in O 0 3.1264357769344997e-09
Cowden B-Disease 1 0.9940388202667236
disease I-Disease 0 0.22579997777938843
and O 0 7.41643077617482e-07
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.89888508986769e-07
two O 0 8.032926643863902e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 0.9999998807907104
with O 0 2.2552412701770663e-05
germline O 1 0.9999988079071045
PTEN O 1 0.9999998807907104
mutation O 0 4.309645009925589e-05
. O 0 6.474091605923604e-06

The O 0 5.013994450564496e-05
tumour B-Disease 1 1.0
suppressor O 1 0.8447136282920837
gene O 0 2.4184599169529974e-05
PTEN O 1 0.9979974627494812
, O 0 1.315127349243994e-07
which O 0 5.4379441394303285e-08
maps O 0 4.3779701286439376e-07
to O 0 1.665750772872343e-07
10q23 O 0 0.00017063033010344952
. O 0 7.019685654086061e-06

3 O 0 7.17338207323337e-06
and O 0 1.5272848941094708e-07
encodes O 0 4.8421274101428935e-08
a O 0 7.980696103970786e-09
403 O 0 8.973758625074879e-09
amino O 0 3.8788421363733505e-09
acid O 0 6.918028816471633e-09
dual O 0 4.1035388420596064e-08
specificity O 0 2.428981531465979e-07
phosphatase O 0 3.2556828955421224e-05
( O 0 3.48567148478196e-08
protein O 0 6.825342069305407e-08
tyrosine O 0 7.876460728084567e-08
phosphatase O 0 3.315689127703081e-07
; O 0 1.3347362104454419e-09
PTPase O 0 4.617579918431147e-07
) O 0 1.0768771430136326e-09
, O 0 6.939990249144046e-10
was O 0 6.3164056207654085e-09
shown O 0 1.182817510603229e-09
recently O 0 6.493880988500678e-09
to O 0 5.942840108907887e-10
play O 0 6.825365161944319e-09
a O 0 6.719855338843672e-09
broad O 0 1.3138085819264234e-07
role O 0 1.1175016823017359e-07
in O 0 2.147247180062095e-08
human O 0 2.717175107136427e-07
malignancy B-Disease 1 0.9997639060020447
. O 0 3.974385435867589e-06

Somatic O 1 0.5754875540733337
PTEN O 1 0.996753990650177
deletions O 0 1.1136137800349388e-05
and O 0 8.756394009878932e-08
mutations O 0 2.369900542475989e-08
were O 0 3.5485117066968996e-09
observed O 0 7.396043777418981e-09
in O 0 3.1153819524121218e-09
sporadic B-Disease 0 1.8722066670306958e-05
breast I-Disease 1 0.9999996423721313
, I-Disease 0 2.5029760308825644e-07
brain I-Disease 1 0.7903716564178467
, I-Disease 0 8.459320355314048e-08
prostate I-Disease 1 1.0
and I-Disease 1 0.7593971490859985
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999125003814697
lines O 0 8.93088497377903e-07
and O 0 4.322195046313482e-09
in O 0 5.903726951750343e-10
several O 0 2.649553687561479e-09
primary O 0 6.144815074549115e-07
tumours B-Disease 1 0.9999969005584717
such O 0 1.2728862408550867e-08
as O 0 3.5029986520385137e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999979734420776
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.1404711753129959

In O 0 4.1368519987372565e-07
addition O 0 1.7876830327168136e-07
, O 0 1.141796417414298e-07
PTEN O 1 0.9979673027992249
was O 0 7.839924478503235e-07
identified O 0 1.3259827014167058e-08
as O 0 2.351075334416919e-09
the O 0 1.3388591346696899e-09
susceptibility O 0 1.1355859186323869e-07
gene O 0 8.123398842485585e-09
for O 0 3.784452751176559e-09
two O 0 1.74900975480341e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 9.230598720932903e-07
CD B-Disease 0 0.0007247690809890628
; O 0 6.391113629433676e-07
MIM O 1 0.8076121211051941
158350 O 0 2.5776786060305312e-05
) O 0 1.9620465252501162e-08
and O 0 3.772447954020208e-08
Bannayan B-Disease 0 0.0011039678938686848
- I-Disease 0 0.00046134873991832137
Zonana I-Disease 1 0.9999860525131226
( I-Disease 0 1.558201347506838e-06
BZS I-Disease 1 0.9733539819717407
) I-Disease 0 9.211096596573043e-08
or I-Disease 0 7.33046050527264e-08
Ruvalcaba I-Disease 0 0.00011341786739649251
- I-Disease 0 4.426651230460266e-06
Riley I-Disease 0 1.9962479200330563e-05
- I-Disease 0 0.00023720675380900502
Smith I-Disease 1 0.6436260938644409
syndrome I-Disease 1 1.0
( O 0 4.521114533417858e-06
MIM O 1 0.9999899864196777
153480 O 0 0.0011706666555255651
) O 0 3.445667573487299e-07
. O 0 7.535248300882813e-07

Constitutive O 0 3.5350451071280986e-05
DNA O 0 7.467426712537417e-06
from O 0 3.01207620623245e-07
37 O 0 1.198988229589304e-06
CD B-Disease 0 8.787965271039866e-06
families O 0 6.650442685440794e-08
and O 0 3.2453986165137394e-08
seven O 0 2.4997555669870053e-07
BZS B-Disease 1 0.9996546506881714
families O 0 9.008986978642497e-08
was O 0 1.8202801754796383e-07
screened O 0 1.5389890961614583e-07
for O 0 4.5751658461767875e-08
germline O 0 7.16720605851151e-05
PTEN O 1 0.6274113655090332
mutations O 0 7.036159786366625e-06
. O 0 1.9503775092744036e-06

PTEN O 0 0.022676341235637665
mutations O 0 1.168587459687842e-06
were O 0 1.0978516939985639e-07
identified O 0 3.7662005070160376e-08
in O 0 4.751531612612325e-09
30 O 0 1.3261192144398137e-08
of O 0 3.4922464919873164e-08
37 O 0 2.087477071199828e-07
( O 0 5.0542952045873335e-09
81 O 0 1.0275819306571066e-07
% O 0 2.4985096214180658e-09
) O 0 7.8860590280172e-10
CD B-Disease 0 1.9095539016689145e-07
families O 0 1.7348974479247659e-09
, O 0 4.945334697303849e-10
including O 0 1.068415356186847e-09
missense O 0 1.9349840840732213e-07
and O 0 1.6652370149472517e-08
nonsense O 0 8.086160505627049e-07
point O 0 7.956668923725374e-08
mutations O 0 1.7804078211725027e-09
, O 0 3.499757705860418e-10
deletions O 0 2.0689297386411454e-08
, O 0 1.786391146119115e-09
insertions O 0 1.128878324152538e-07
, O 0 3.1617151119434084e-09
a O 0 1.4217199861832341e-08
deletion O 0 6.059225370336208e-07
/ O 0 1.295889774155512e-06
insertion O 0 7.430632535943005e-07
and O 0 1.2584855824115948e-07
splice O 0 5.5910295486683026e-05
site O 0 1.0042996336778742e-06
mutations O 0 2.40739609580487e-07
. O 0 3.0083467095209926e-07

These O 0 2.821502675942611e-07
mutations O 0 1.4100903911185014e-07
were O 0 2.3254504100123086e-08
scattered O 0 5.0665754258716333e-08
over O 0 2.3599094234327822e-08
the O 0 1.3138456544936616e-08
entire O 0 2.3769988644062323e-08
length O 0 1.2319107511871152e-08
of O 0 2.4255228936453932e-08
PTEN O 0 2.9842276489944197e-05
, O 0 1.9962986819166417e-09
with O 0 3.4149516547898884e-10
the O 0 3.096407352742858e-09
exception O 0 8.695475450792856e-09
of O 0 8.860047806535931e-09
the O 0 6.4788117093428355e-09
first O 0 8.404442475296037e-09
, O 0 3.838832363101119e-09
fourth O 0 2.5580351348253316e-07
and O 0 7.362183396253386e-08
last O 0 7.941316084725258e-07
exons O 0 6.163056241348386e-05
. O 0 3.0812554996373365e-06

A O 0 7.713683589827269e-05
hot O 0 0.0001420186017639935
spot O 0 6.0129259509267285e-06
for O 0 5.399094860081277e-08
PTEN O 0 0.00011115188681287691
mutation O 0 4.267916509093084e-08
in O 0 1.463834475856629e-08
CD B-Disease 0 2.768457989077433e-06
was O 0 3.514364550483151e-07
identified O 0 2.3099957502381585e-08
in O 0 4.298247091583107e-09
exon O 0 3.307048146439229e-08
5 O 0 3.953950056256872e-09
that O 0 8.536948231663288e-11
contains O 0 1.2068737120785045e-09
the O 0 6.436196464676414e-09
PTPase O 0 4.529625130089698e-06
core O 0 5.542352710108389e-07
motif O 0 2.990531200453006e-08
, O 0 5.90109294762442e-10
with O 0 3.0057623057189176e-10
13 O 0 2.0115885845939374e-08
of O 0 6.124104601212821e-08
30 O 0 7.424272041589575e-08
( O 0 8.824225794512586e-09
43 O 0 5.247044398970502e-08
% O 0 3.5435745449063916e-09
) O 0 2.389261233304296e-09
CD B-Disease 0 3.087672268975439e-07
mutations O 0 4.796074648538706e-09
identified O 0 7.0181314093531455e-09
in O 0 1.4871439635300021e-09
this O 0 6.483459991102336e-09
exon O 0 2.150663021893706e-06
. O 0 4.193230438431783e-07

Seven O 0 6.226532150321873e-06
of O 0 1.3454460940920399e-06
30 O 0 1.7849129108071793e-07
( O 0 1.1608433325704937e-08
23 O 0 3.052691610605507e-08
% O 0 1.5850384338378376e-09
) O 0 7.060675932812899e-10
were O 0 1.3077471328060142e-09
within O 0 6.291420273640824e-09
the O 0 1.1779258457522701e-08
core O 0 1.0762498448002589e-07
motif O 0 1.3005591270598416e-08
, O 0 2.7763519261370107e-10
the O 0 3.7712000189316086e-10
majority O 0 1.986892178562627e-10
( O 0 2.137576643468364e-10
five O 0 9.083137020304832e-10
of O 0 2.167805268626921e-09
seven O 0 4.446028434301752e-09
) O 0 6.357958048930357e-10
of O 0 1.712743724624488e-09
which O 0 7.221294673342982e-10
were O 0 5.927073942757488e-09
missense O 0 1.2777346114489774e-07
mutations O 0 9.043519710871806e-09
, O 0 1.5201906400363896e-09
possibly O 0 2.8139831798057457e-08
pointing O 0 1.0197894084740255e-07
to O 0 5.945518743999401e-09
the O 0 1.273427674419736e-08
functional O 0 5.159808225130291e-08
significance O 0 3.499240719406771e-08
of O 0 1.8182999994564852e-08
this O 0 5.958460835842061e-09
region O 0 2.2613690475736803e-07
. O 0 6.299767960626923e-07

Germline O 0 0.016001179814338684
PTEN O 0 0.006457799579948187
mutations O 0 9.753547374202753e-07
were O 0 1.2037276064802427e-07
identified O 0 5.156276472462196e-08
in O 0 8.99857699465656e-09
four O 0 6.7258310032514146e-09
of O 0 3.849921270671075e-08
seven O 0 9.31169665818743e-08
( O 0 1.5868209857217153e-08
57 O 0 1.9141852192205988e-07
% O 0 2.1139490158361696e-08
) O 0 6.553309361834181e-08
BZS B-Disease 1 0.9901158213615417
families O 0 1.8557643954864034e-07
studied O 0 1.5965043758114916e-06
. O 0 1.0687765552575001e-06

Interestingly O 0 9.76253068074584e-06
, O 0 6.09183459232554e-08
none O 0 7.019151837539539e-08
of O 0 1.5303154299317612e-08
these O 0 2.368656604190278e-09
mutations O 0 1.4702900230645355e-08
was O 0 3.3687317824160345e-08
observed O 0 6.497969273766557e-09
in O 0 4.834483924298638e-09
the O 0 6.05682117793549e-08
PTPase O 0 0.0035337728913873434
core O 0 0.00013740874419454485
motif O 0 7.136501153581776e-06
. O 0 5.823455921927234e-07

It O 0 1.90086538509604e-07
is O 0 1.0801423755424366e-08
also O 0 3.6540446224364587e-09
worthy O 0 9.957120283843324e-08
of O 0 2.5543535286942642e-08
note O 0 1.3417101207835458e-08
that O 0 2.9344093821492834e-10
a O 0 3.6230165534334446e-09
single O 0 1.2450611208691953e-08
nonsense O 0 1.4712303197939036e-07
point O 0 3.238534773686297e-08
mutation O 0 1.563059237597031e-09
, O 0 1.749385081240007e-09
R233X O 0 3.700541526541201e-07
, O 0 6.615169301227297e-09
was O 0 3.138536541769099e-08
observed O 0 4.7942640968301475e-09
in O 0 1.519897874224796e-09
the O 0 5.450370821336037e-09
germline O 0 2.086704853354604e-07
DNA O 0 4.67078926646991e-08
from O 0 1.088713119656859e-09
two O 0 1.0467835487304455e-09
unrelated O 0 6.067772062579024e-08
CD B-Disease 0 5.002063062420348e-06
families O 0 3.2210518696729196e-08
and O 0 3.72663500058934e-08
one O 0 2.2893676998592127e-07
BZS B-Disease 1 0.9999997615814209
family O 0 3.0309231078717858e-05
. O 0 2.528903905840707e-06

Genotype O 0 0.00019712655921466649
- O 0 1.2316002539591864e-05
phenotype O 0 7.969759963089018e-07
studies O 0 1.1217808015828723e-08
were O 0 1.5809382691855944e-09
not O 0 5.832120897331095e-10
performed O 0 5.352847498585334e-09
on O 0 2.7627826693077395e-09
this O 0 3.11311726397534e-10
small O 0 1.9194226208441023e-09
group O 0 1.7791518258647443e-09
of O 0 1.152411073235271e-07
BZS B-Disease 1 1.0
families O 0 5.065694949735189e-06
. O 0 1.5460428812730242e-06

However O 0 3.720726681422093e-06
, O 0 2.777605629944446e-07
genotype O 0 3.5479222333378857e-06
- O 0 6.633795237576123e-07
phenotype O 0 2.460052428432391e-07
analysis O 0 1.9419491792405097e-08
inthe O 0 3.833808364106517e-07
group O 0 5.039855643929059e-09
of O 0 2.9233348186608055e-08
CD B-Disease 0 8.020493987714872e-05
families O 0 3.1098505104409924e-08
revealed O 0 2.1235994296375793e-08
two O 0 5.954594595181106e-10
possible O 0 3.6112877133120946e-09
associations O 0 5.728356677892066e-10
worthy O 0 9.42712219398345e-08
of O 0 2.0532128885975e-08
follow O 0 3.044167939947329e-08
- O 0 4.201432091122115e-07
up O 0 1.5746763892821036e-08
in O 0 2.6604309866229414e-09
independent O 0 9.097810504954396e-09
analyses O 0 1.2877032418145973e-07
. O 0 2.0802909261874447e-07

The O 0 2.823273007379612e-06
first O 0 5.225412564868748e-07
was O 0 3.3025642665052146e-07
an O 0 3.4794325198816978e-09
association O 0 8.08793299000854e-09
noted O 0 1.0165885910851102e-08
in O 0 2.168963231241605e-09
the O 0 5.141601366887016e-09
group O 0 1.6288219661930725e-09
of O 0 1.9108505000531295e-08
CD B-Disease 0 0.020965395495295525
families O 0 3.867408082669499e-08
with O 0 1.1644218034234655e-07
breast B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 6.838418630650267e-05

A O 0 5.199967290536733e-06
correlation O 0 4.3534970473046997e-07
was O 0 1.645024383378768e-07
observed O 0 8.323910449803407e-09
between O 0 3.481384291958989e-09
the O 0 6.866391455417897e-09
presence O 0 3.397232362090108e-08
/ O 0 4.493933829508023e-06
absence O 0 1.1979630016867304e-06
of O 0 2.582207514478796e-07
a O 0 1.1554030976412832e-07
PTEN O 0 3.3462656574556604e-05
mutation O 0 3.1558589075331156e-09
and O 0 7.165603665981735e-10
the O 0 1.1974634617217816e-09
type O 0 3.830320949305133e-08
of O 0 5.520292347682698e-07
breast O 1 0.9026561975479126
involvement O 0 2.88375867967261e-05
( O 0 4.559085198252433e-07
unaffected O 0 0.00041798900929279625
versus O 1 0.5968198180198669
benign O 1 0.9999923706054688
versus O 1 0.9986658096313477
malignant O 1 0.9999994039535522
) O 0 3.713409739702911e-07
. O 0 7.922118356873398e-07

Specifically O 0 7.920086204649124e-07
and O 0 1.9604229350989044e-08
more O 0 5.15573972403871e-10
directly O 0 2.0350277019076657e-09
, O 0 4.376003726047628e-10
an O 0 2.4336857529227984e-10
association O 0 6.682355113696303e-09
was O 0 5.4994639953065416e-08
also O 0 7.710787564008115e-10
observed O 0 4.422463228959117e-10
between O 0 4.591920454988241e-10
the O 0 8.049285682432128e-10
presence O 0 3.2305746966443394e-09
of O 0 2.8842388033467614e-08
a O 0 3.0586136290366994e-07
PTEN O 1 0.9999343156814575
mutation O 0 7.832832693566161e-07
and O 0 3.100279400314321e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.126326919300482e-05

Secondly O 0 0.0002072165661957115
, O 0 6.099351139710052e-07
there O 0 5.269128067197926e-08
appeared O 0 1.378010381358763e-07
to O 0 3.215390842470356e-09
be O 0 1.4907790557572298e-09
an O 0 1.9111847660013837e-09
interdependent O 0 9.291061360272579e-07
association O 0 2.2793415155319963e-08
between O 0 1.5086834892485967e-08
mutations O 0 4.36398011061101e-08
upstream O 0 2.2900751162069355e-07
and O 0 3.9181249356090575e-09
within O 0 1.1933736665525885e-08
the O 0 5.258094759597043e-08
PTPase O 0 3.021408338099718e-05
core O 0 2.8700014809146523e-06
motif O 0 1.2569047669330757e-07
, O 0 2.6348732085068605e-09
the O 0 4.084101501433679e-09
core O 0 2.356150048399286e-07
motif O 0 2.4298845602288566e-08
containing O 0 7.121607747961889e-10
the O 0 4.2126740984471667e-10
majority O 0 5.106969847012977e-10
of O 0 3.89406817902227e-09
missense O 0 1.0249589621480482e-07
mutations O 0 3.6573706285736307e-09
, O 0 1.4493233280177265e-09
and O 0 1.045877495720049e-09
the O 0 1.0694719776438433e-08
involvement O 0 1.323802223396342e-07
of O 0 3.3096672069632405e-08
all O 0 4.369941741799721e-09
major O 0 9.791164501393723e-08
organ O 0 5.87512222409714e-05
systems O 1 0.9367247223854065
( O 0 7.202661436167546e-07
central O 0 0.00014889838348608464
nervous O 0 0.00012875102402176708
system O 0 0.00015044814790599048
, O 0 9.929864290825208e-07
thyroid O 1 1.0
, O 0 6.742750429111766e-06
breast O 1 1.0
, O 0 2.1050700524938293e-05
skin O 1 1.0
and O 1 0.9845795631408691
gastrointestinal O 1 1.0
tract O 1 0.9999997615814209
) O 0 1.2077052815584466e-06
. O 0 2.68836083705537e-06

However O 0 1.3477371112458059e-06
, O 0 1.6520512957640676e-08
these O 0 1.9251531480080075e-09
observations O 0 2.249904973439243e-08
would O 0 2.7319029261008154e-09
need O 0 2.915988117635493e-09
to O 0 1.2119300007995548e-09
be O 0 5.727788243703458e-10
confirmed O 0 2.6698250277235047e-09
by O 0 4.296089317623597e-10
studying O 0 2.5412461024387767e-09
a O 0 7.226199638665776e-10
larger O 0 9.73081726307612e-10
number O 0 1.0612418721578365e-09
of O 0 2.8602382684539407e-08
CD B-Disease 0 2.3343049178947695e-05
families O 0 2.2418396383727668e-07
. O 0 4.85980422126886e-07

Molecular O 0 0.01786569133400917
defects O 1 0.9998656511306763
leading O 0 8.875746061676182e-06
to O 0 8.786240357494535e-08
human O 0 6.731255552949733e-07
complement B-Disease 1 0.733027994632721
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.194562267111905e-08
an O 0 4.344875570438944e-09
African O 0 1.9442506271616367e-08
- O 0 2.1132238714471896e-07
American O 0 2.132424015144352e-07
family O 0 3.129564447590383e-07
. O 0 2.8437270316317154e-07

Complement B-Disease 0 0.0013160788221284747
component I-Disease 1 0.9999997615814209
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.692882379866205e-06
C6D B-Disease 1 0.9997677206993103
) O 0 1.484093559156463e-07
was O 0 1.3098293720759102e-06
diagnosed O 0 4.30145837526652e-06
in O 0 1.2273256189132553e-08
a O 0 2.8813026631269167e-08
16 O 0 1.1528661048032518e-07
- O 0 1.4236348988561076e-07
year O 0 3.791766545191422e-08
- O 0 2.7399781288295344e-07
old O 0 1.2509486850831308e-06
African O 0 2.276478880958166e-07
- O 0 2.9856019523322175e-07
American O 0 9.076733142876492e-09
male O 0 4.153951405072576e-09
with O 0 5.643821410217242e-09
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00015942730533424765

The O 0 2.5359802293678513e-06
patients O 0 3.412316573303542e-06
father O 0 2.8144047519162996e-06
and O 0 8.111681637501533e-08
two O 0 9.242616272331361e-08
brothers O 0 0.00573408417403698
also O 0 2.063920874206815e-07
had O 0 4.993217999071931e-07
C6D B-Disease 1 0.9999874830245972
, O 0 1.3508515195326254e-08
but O 0 3.0676672313489917e-09
gave O 0 1.1471811944829824e-08
no O 0 2.6870721203664516e-09
history O 0 1.3769563267373996e-08
of O 0 2.5712420637091782e-08
meningitis B-Disease 1 0.999987006187439
or O 0 2.6446707579452777e-07
other O 0 1.3556866917951993e-07
neisserial B-Disease 0 0.040082238614559174
infection I-Disease 0 0.11119052022695541
. O 0 1.0345439477532636e-05

By O 0 2.9048547389720625e-07
using O 0 2.41864910321965e-07
exon O 0 1.5566566844427143e-06
- O 0 1.3909576068726892e-07
specific O 0 9.438418047125197e-09
polymerase O 0 8.990531910058053e-07
chain O 0 1.3052712688477186e-07
reaction O 0 1.3460522474417758e-08
( O 0 6.113668682417028e-09
PCR O 0 3.8661252688143577e-07
) O 0 6.883662084788966e-09
/ O 0 1.1403903243945024e-07
single O 0 7.427203740917321e-08
- O 0 1.7388413198204944e-07
strand O 0 6.112061612384423e-08
conformation O 0 3.7070524427917917e-09
polymorphism O 0 2.6713633527464253e-09
as O 0 2.885776895222847e-10
a O 0 3.3728109194441913e-10
screening O 0 1.7063722657084668e-09
step O 0 2.22301754781995e-09
and O 0 3.3876332294902056e-10
nucleotide O 0 2.7085809151117246e-09
sequencing O 0 4.648603724177747e-09
of O 0 1.8906274323882144e-09
target O 0 2.4704199574898666e-08
exons O 0 2.2049118797440315e-07
, O 0 1.7027115273293703e-09
we O 0 7.241473531927056e-10
determined O 0 1.2808640814654382e-09
that O 0 1.779598968187912e-10
the O 0 3.531436032488955e-09
proband O 0 1.2545699519250775e-06
was O 0 4.76831196749572e-08
a O 0 6.861691659310054e-09
compound O 0 9.173121640060344e-08
heterozygote O 0 1.0731745305747609e-06
for O 0 1.6379821943246498e-08
two O 0 6.898556392798127e-08
C6 O 0 0.1017150729894638
gene O 0 1.432286694580398e-06
mutations O 0 1.019555611492251e-06
. O 0 1.0782321169244824e-06

The O 0 1.693015406090126e-06
first O 0 2.6174490130870254e-07
, O 0 2.9876808582685044e-08
1195delC O 0 1.4773493148823036e-06
located O 0 6.715937672652217e-08
in O 0 5.341170172812326e-09
exon O 0 8.451127797570734e-08
7 O 0 1.4863847042079215e-08
, O 0 6.725596746193219e-10
is O 0 2.6103361139284686e-10
a O 0 1.4595820108098678e-09
novel O 0 8.63261373496016e-09
mutation O 0 9.425675795426969e-10
, O 0 4.743416215369223e-10
while O 0 8.945335583376846e-10
the O 0 5.728228558155024e-09
second O 0 6.648463823921702e-08
, O 0 6.5061671605803895e-09
1936delG O 0 4.770140549226198e-07
in O 0 8.080254687570232e-09
exon O 0 9.532462996730828e-08
12 O 0 1.537198990320121e-08
, O 0 2.9706437310039746e-09
has O 0 7.091867648689743e-10
been O 0 1.0438307995741525e-09
described O 0 3.035920848049045e-09
before O 0 3.3537475019329577e-09
to O 0 4.906477890642691e-09
cause O 0 2.73013097285002e-06
C6D B-Disease 1 0.9999997615814209
in O 0 3.580685969950537e-08
an O 0 1.9932777650666367e-09
unrelated O 0 5.703613936702823e-08
African O 0 1.1635537333631873e-07
- O 0 6.310748403848265e-07
American O 0 4.465211986826034e-07
individual O 0 8.045088151220625e-08
. O 0 7.15694966402225e-07

Both O 0 2.8188696887809783e-07
mutations O 0 1.288902353735466e-07
result O 0 3.540948156910417e-08
in O 0 2.5009901705175253e-08
premature O 0 2.4966232103906805e-06
termination O 0 8.240100578404963e-05
codons O 0 1.3071829016553238e-05
and O 0 8.206554298340052e-07
C6 O 0 0.027414364740252495
null O 0 8.579468158131931e-06
alleles O 0 8.444937975582434e-07
. O 0 6.1791456573701e-07

Allele O 0 5.3859575928072445e-06
- O 0 5.631833914776507e-07
specific O 0 1.0026812269359198e-08
PCR O 0 7.589684969389054e-07
indicated O 0 4.044730061991686e-08
that O 0 1.60917024150109e-09
the O 0 1.7588945411262102e-08
probands O 0 1.5353638445958495e-05
two O 0 2.2258271670239083e-08
brothers O 0 1.3804261470795609e-05
also O 0 2.0253171584272422e-08
inherited O 0 4.050748611916788e-05
the O 0 4.952664767188253e-07
1195delC O 0 1.4166899973133695e-06
mutation O 0 4.437336276197357e-09
from O 0 1.3437839729846246e-09
their O 0 7.264506773907442e-10
heterozygous O 0 4.5489980671220565e-09
mother O 0 5.209963571672915e-09
and O 0 1.0829163121783836e-09
the O 0 1.0413276463339116e-08
1936delG O 0 7.009431328697246e-07
mutation O 0 5.909656319857959e-09
from O 0 3.2036309161043164e-09
their O 0 3.1650939646965526e-09
homozygous O 0 9.74488472138546e-08
father O 0 5.729514782615297e-07
. O 0 1.8245626165480644e-07
. O 0 1.3758216255155276e-06

PAX6 O 1 0.9606040120124817
mutations O 0 5.8531786635285243e-05
reviewed O 0 5.690161924576387e-05
. O 0 1.0740965080913156e-05

Mutations O 0 9.309738743468188e-06
in O 0 3.9753714986545674e-07
PAX6 O 1 0.9294039607048035
are O 0 1.9749096580312653e-08
responsible O 0 8.898359737941064e-08
for O 0 3.238448442743902e-08
human O 0 5.778584181825863e-06
aniridia B-Disease 1 1.0
and O 0 1.956573669303907e-06
have O 0 3.3074127880894366e-09
also O 0 1.3291472367171764e-09
been O 0 3.3438585234080165e-10
found O 0 1.52653861773544e-10
in O 0 6.917388190030849e-11
patients O 0 8.734434286949977e-10
with O 0 9.0553903264734e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.247715080258786e-07
with O 0 0.007075374014675617
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.897517740726471
with O 0 0.0001844434009399265
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 4.305051390929293e-07
and O 0 7.150755720886082e-08
with O 0 4.302465583805315e-07
isolated B-Disease 1 0.9999998807907104
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.04056717827916145

No O 0 4.136368715990102e-06
locus O 0 1.9759361293836264e-06
other O 0 1.2536683691166672e-08
than O 0 5.8225202437256485e-09
chromosome O 0 5.516525192206245e-08
11p13 O 0 7.763417215755908e-07
has O 0 6.9694152671218035e-09
been O 0 2.654176656236018e-09
implicated O 0 6.222622062068695e-08
in O 0 1.7989441047916443e-08
aniridia B-Disease 1 1.0
, O 0 4.196126468514194e-08
and O 0 4.7185157114881804e-08
PAX6 O 1 0.9999990463256836
is O 0 2.742774540820392e-08
clearly O 0 9.872302086932905e-09
the O 0 3.0468616518675162e-09
major O 0 5.514420919894292e-08
, O 0 8.169231957566581e-10
if O 0 2.912195762316827e-10
not O 0 9.361778713357083e-11
only O 0 3.6454317342560216e-10
, O 0 1.4812048254597698e-09
gene O 0 1.1470084437803507e-08
responsible O 0 8.894236458445448e-08
. O 0 1.0929976497209282e-06

Twenty O 0 7.359709707088768e-05
- O 0 1.0408320122223813e-05
eight O 0 2.1757227841590066e-07
percent O 0 3.2091307389237045e-08
of O 0 1.285730721889422e-08
identified O 0 1.296060077038419e-07
PAX6 O 0 0.0002583234163466841
mutations O 0 4.522872742995787e-08
are O 0 5.4995026310677986e-09
C O 0 1.877602880995255e-05
- O 0 1.683545997366309e-05
T O 0 3.416598474359489e-06
changes O 0 3.499821232821887e-08
at O 0 4.33662350474151e-08
CpG O 0 1.6343800268714404e-07
dinucleotides O 0 1.9278297713754e-07
, O 0 1.3162153589263426e-09
20 O 0 7.170990468097216e-10
% O 0 1.2185213948967544e-10
are O 0 8.06706368372545e-11
splicing O 0 2.2060890003672284e-08
errors O 0 5.914620615499189e-08
, O 0 1.7192374190955206e-09
and O 0 1.2959031625570105e-09
more O 0 2.5443197548824514e-10
than O 0 3.987216945500194e-10
30 O 0 4.0229086728515995e-09
% O 0 7.686309366761179e-10
are O 0 5.364568234078604e-10
deletion O 0 2.3179666186479153e-08
or O 0 9.64857793661622e-09
insertion O 0 4.919384082313627e-07
events O 0 8.454674826907649e-08
. O 0 1.9101132409105048e-07

There O 0 5.953595518803922e-07
is O 0 7.625264686339506e-08
a O 0 1.0357994284504457e-07
noticeably O 0 8.084362889348995e-06
elevated O 0 3.453745011938736e-05
level O 0 1.4218940691534954e-07
of O 0 1.1014567924405583e-08
mutation O 0 4.698773370392928e-09
in O 0 1.3929554176783654e-09
the O 0 2.745259131131661e-09
paired O 0 9.510067400242406e-09
domain O 0 3.232960343879654e-09
compared O 0 3.946300508594902e-10
with O 0 1.2610487654107772e-10
the O 0 4.257539654162201e-09
rest O 0 9.510288379033227e-08
of O 0 1.1020539858463962e-07
the O 0 1.5144588871862652e-07
gene O 0 2.8427155029930873e-07
. O 0 2.5770657430257415e-07

Increased O 0 7.066798843879951e-07
mutation O 0 3.377939776783023e-07
in O 0 2.8958753617303046e-08
the O 0 3.21154303151161e-08
homeodomain O 0 1.2558335583889857e-05
is O 0 4.573793788154035e-09
accounted O 0 4.202500125671804e-09
for O 0 3.65354108078364e-10
by O 0 1.1297528468290352e-09
the O 0 4.958902977136859e-08
hypermutable O 0 0.00017684746126178652
CpG O 0 2.1647545509040356e-05
dinucleotide O 0 6.76631407259265e-06
in O 0 6.230270344076416e-08
codon O 0 4.288410764274886e-07
240 O 0 4.894376388620003e-07
. O 0 3.205442737908015e-07

Very O 0 1.3928798807683052e-06
nearly O 0 5.32542578923767e-08
all O 0 1.4447417706620058e-09
mutations O 0 4.464059788489294e-09
appear O 0 3.296227735205548e-09
to O 0 1.5197992864202092e-09
cause O 0 2.527418700992712e-07
loss O 0 1.2123870874347631e-05
of O 0 1.05240951597807e-06
function O 0 2.1823471030302244e-08
of O 0 2.7909822009064555e-08
the O 0 6.162406140930443e-09
mutant O 0 2.634184648186988e-09
allele O 0 4.020114241498618e-10
, O 0 1.0072384593051709e-10
and O 0 2.79862383267826e-10
more O 0 1.2450075692616025e-10
than O 0 3.924150726586362e-10
80 O 0 5.290313520589507e-09
% O 0 1.1413033851326304e-09
of O 0 1.5813794718155805e-08
exonic O 0 1.5156480230871239e-06
substitutions O 0 7.241659716328286e-08
result O 0 1.101057645058745e-08
in O 0 9.149283997089697e-09
nonsense O 0 1.1849698466903646e-06
codons O 0 9.296272196479549e-07
. O 0 3.21278747605902e-07

In O 0 4.872246108789113e-07
a O 0 6.67566979473122e-08
gene O 0 1.0327767974160906e-08
with O 0 7.115389388800963e-10
such O 0 4.44997372284206e-09
extraordinarily O 0 3.6031824492965825e-06
high O 0 3.0865268740853935e-07
sequence O 0 1.1229668750445398e-08
conservation O 0 5.422239990338085e-09
throughout O 0 2.6535476593814167e-10
evolution O 0 1.904779889372321e-09
, O 0 2.827511280667494e-10
there O 0 3.551042238036928e-10
are O 0 8.96140495143527e-10
presumed O 0 2.4975686301331734e-06
undiscovered O 0 8.666915528010577e-05
missense O 0 5.910442268941551e-07
mutations O 0 1.3227645645486064e-08
, O 0 1.2053991138571973e-09
these O 0 2.8462654455552183e-10
are O 0 4.915317597387059e-10
hypothesized O 0 5.379790124493411e-08
to O 0 3.3592535420012837e-09
exist O 0 1.2884507682997537e-08
in O 0 1.5055157120968943e-08
as O 0 7.498989162968428e-08
- O 0 2.395462104232138e-07
yet O 0 1.9166286335803306e-08
unidentified O 0 5.331575181344306e-08
phenotypes O 0 1.6081040143944847e-07
. O 0 1.3821688682469357e-08
. O 0 2.1568958175066655e-07

Genetic O 0 3.508828012854792e-05
heterogeneity O 0 1.610053368494846e-05
and O 0 1.3698473821932566e-07
penetrance O 0 1.0719516467361245e-05
analysis O 0 7.104600996399313e-08
of O 0 8.217434555035652e-08
the O 0 1.4862831676509813e-07
BRCA1 O 0 3.0930380034988048e-06
and O 0 9.921119925593302e-08
BRCA2 O 0 2.006543036259245e-05
genes O 0 2.3651777780742123e-07
in O 0 7.540267432659675e-08
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999990463256836
families O 0 2.964568921015598e-06
. O 0 4.512551186053315e-06

The O 0 0.0005226911744102836
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.4120998978614807
Consortium O 0 0.00011969361366936937
. O 0 2.4054324967437424e-06

The O 0 1.053453729582543e-06
contribution O 0 5.331392003427027e-07
of O 0 1.2134095186411287e-06
BRCA1 O 0 7.605823611811502e-06
and O 0 1.9400062001295737e-07
BRCA2 O 0 6.137800664873794e-05
to O 0 1.4198305962054292e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.015753787010908127
assessed O 0 4.757319871373511e-08
by O 0 4.938284225985967e-10
linkage O 0 2.3011301308883958e-08
and O 0 7.293606829605892e-10
mutation O 0 5.248200207752518e-10
analysis O 0 9.017351865203693e-10
in O 0 3.834352280129849e-10
237 O 0 4.594078006903146e-09
families O 0 6.574060185116082e-10
, O 0 1.6081937170842053e-10
each O 0 3.777986604114325e-11
with O 0 2.6788418705514516e-10
at O 0 8.21301160414123e-09
least O 0 1.7759978210296623e-10
four O 0 1.9347895507948465e-10
cases O 0 3.7831229815488143e-10
of O 0 7.364571530388275e-08
breast B-Disease 1 0.9998776912689209
cancer I-Disease 0 0.00012610101839527488
, O 0 3.855222807658265e-10
collected O 0 2.9560989767141166e-10
by O 0 2.1465487720639942e-10
the O 0 6.892270221214858e-08
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0007860107580199838
Consortium O 0 7.651621672266629e-06
. O 0 4.1594012145651504e-07

Families O 0 7.912566957202216e-07
were O 0 6.934200769137533e-08
included O 0 2.1187364751540372e-08
without O 0 8.198534295900117e-09
regard O 0 4.4684064448574645e-08
to O 0 3.6724137064680917e-09
the O 0 6.083251236077558e-09
occurrence O 0 1.677476006989309e-07
of O 0 5.96281279285904e-05
ovarian B-Disease 1 1.0
or I-Disease 0 3.853429916489404e-06
other I-Disease 0 4.778026436724758e-07
cancers I-Disease 1 0.9995546936988831
. O 0 4.520114543993259e-06

Overall O 0 3.3015621738741174e-05
, O 0 1.121117634284019e-06
disease O 1 0.9956722259521484
was O 0 4.278992855688557e-05
linked O 0 1.4977737919252831e-05
to O 0 7.378279320846559e-08
BRCA1 O 0 9.007730454868579e-07
in O 0 3.4709948248945466e-09
an O 0 4.238755735297417e-10
estimated O 0 4.944240572513081e-10
52 O 0 4.851387735982371e-09
% O 0 7.276154678770297e-10
of O 0 6.876627711704941e-09
families O 0 6.248940476183407e-09
, O 0 1.66331270978759e-09
to O 0 4.498608596747999e-09
BRCA2 O 0 1.7190291146107484e-07
in O 0 3.688869210094481e-09
32 O 0 6.2784497600887335e-09
% O 0 2.7522831236304057e-10
of O 0 1.3306614699004626e-09
families O 0 6.700028309936101e-10
, O 0 4.74260186678066e-10
and O 0 6.896366255837449e-10
to O 0 8.393257200367543e-10
neither O 0 9.29410859384916e-09
gene O 0 2.7662416801632617e-09
in O 0 1.1804802690917882e-09
16 O 0 5.394172220007931e-09
% O 0 5.947602410572017e-10
( O 0 1.4751037058502448e-09
95 O 0 8.646475890827787e-08
% O 0 1.3108195417999013e-08
confidence O 0 8.662014465699031e-07
interval O 0 5.867965455763624e-07
[ O 0 1.2103884046155144e-06
CI O 0 3.164342342643067e-05
] O 0 1.7853523104349733e-07
6 O 0 6.47308340262498e-08
% O 0 2.519585429183735e-09
- O 0 1.3091105088847144e-08
28 O 0 9.964621128233375e-09
% O 0 7.961990511340389e-10
) O 0 1.2075690447588272e-09
, O 0 1.3723593372816367e-09
suggesting O 0 2.3977996477242414e-08
other O 0 1.175257580143807e-08
predisposition O 0 1.597118898644112e-05
genes O 0 1.1778470252465922e-06
. O 0 7.340211709561117e-07

The O 0 1.8782693587127142e-06
majority O 0 9.549569313094253e-08
( O 0 1.8679603641658105e-08
81 O 0 2.1931258231688844e-07
% O 0 4.7485690934934155e-09
) O 0 1.4591199359870188e-09
of O 0 1.9155578456775402e-08
the O 0 4.259124125383096e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1944484512582676e-08
were O 0 1.934982396534224e-09
due O 0 5.488876908543716e-09
to O 0 1.9735530987219363e-09
BRCA1 O 0 1.57353241547753e-08
, O 0 4.5610723531375186e-10
with O 0 1.6228732246936772e-10
most O 0 6.2860228133843066e-09
others O 0 7.937037693750426e-09
( O 0 2.2319182058083697e-09
14 O 0 1.3933148856892785e-08
% O 0 1.5350534177116515e-09
) O 0 2.1451336262856557e-09
due O 0 1.2350814415640343e-07
to O 0 2.479439160651964e-07
BRCA2 O 0 4.105459083802998e-05
. O 0 2.4955352273536846e-06

Conversely O 0 2.180137380491942e-05
, O 0 1.7556877196511778e-07
the O 0 4.0889126751153526e-08
majority O 0 1.0823097973400309e-08
of O 0 2.350435401865525e-08
families O 0 7.751135733258252e-09
with O 0 1.3136070009522882e-09
male B-Disease 0 3.840430906620895e-08
and I-Disease 0 1.0183390131146552e-08
female I-Disease 0 5.938902631896781e-07
breast I-Disease 1 0.9999611377716064
cancer I-Disease 1 0.9982512593269348
were O 0 7.47449959703772e-08
due O 0 1.339416257906123e-06
to O 0 2.451618854593107e-07
BRCA2 O 0 4.636016001313692e-06
( O 0 2.356059702890434e-08
76 O 0 7.712676506343996e-07
% O 0 3.581232377314336e-08
) O 0 7.65364944754765e-08
. O 0 5.343333668861305e-07

The O 0 1.1817439371952787e-05
largest O 0 1.4256595477490919e-06
proportion O 0 5.610391795585201e-08
( O 0 9.039553106049425e-09
67 O 0 7.750931985128773e-08
% O 0 1.041410624402772e-09
) O 0 3.8057609841324336e-10
of O 0 5.263420366219407e-09
families O 0 3.977238538510619e-09
due O 0 3.1546328216336406e-08
to O 0 2.563982803849285e-09
other O 0 6.813395958538138e-10
genes O 0 1.6689375437195508e-09
was O 0 3.968463779813192e-09
found O 0 4.693548882883647e-10
in O 0 1.0608649375631884e-10
families O 0 1.1156089940733693e-10
with O 0 1.3998049941399415e-10
four O 0 1.2957943607005973e-09
or O 0 2.1520267790009484e-09
five O 0 1.9347314861306586e-09
cases O 0 1.6613246334173937e-09
of O 0 1.9574233078856196e-07
female O 0 1.0462596947036218e-05
breast B-Disease 1 0.9993411898612976
cancer I-Disease 0 0.20992545783519745
only O 0 2.2881235395288968e-07
. O 0 3.2146431294677313e-06

These O 0 6.1180804777905e-07
estimates O 0 2.755125478870468e-07
were O 0 1.8749922503502603e-08
not O 0 2.4085886618507857e-09
substantially O 0 5.6610851117966376e-08
affected O 0 4.732971348175852e-09
either O 0 2.4360180539417797e-09
by O 0 3.838361850583283e-10
changing O 0 9.551132329477241e-09
the O 0 5.439019901132269e-09
assumed O 0 7.484756991971153e-08
penetrance O 0 4.760310901019693e-07
model O 0 9.008640944330182e-09
for O 0 1.2013112726805275e-09
BRCA1 O 0 9.691719426996315e-09
or O 0 5.251745149870146e-10
by O 0 3.545357618595091e-10
including O 0 3.222217603848776e-09
or O 0 3.7961807919373314e-08
excluding O 0 9.268864573641622e-07
BRCA1 O 0 7.652947715541814e-07
mutation O 0 5.188724472304784e-08
data O 0 8.654016170339673e-08
. O 0 3.0507510473398725e-07

Among O 0 2.234331532235956e-06
those O 0 5.250888790442332e-08
families O 0 1.1202392791176408e-08
with O 0 4.7906625333382635e-09
disease O 0 0.00017989176558330655
due O 0 1.4864492641208926e-06
to O 0 5.204782382861595e-08
BRCA1 O 0 3.505330710140697e-07
that O 0 7.350699493535728e-10
were O 0 1.0198040190090296e-09
tested O 0 1.590750531299534e-09
by O 0 6.259085610915704e-11
one O 0 2.4646615304213526e-10
of O 0 1.6454778650754065e-09
the O 0 1.3308569801750991e-09
standard O 0 9.120153521280372e-09
screening O 0 8.934677997451956e-10
methods O 0 8.825534192347106e-10
, O 0 8.488692387897956e-11
mutations O 0 2.70295952287114e-10
were O 0 8.644076565644809e-10
detected O 0 6.9570109673122715e-09
in O 0 8.237010518108434e-10
the O 0 4.455077640130867e-09
coding O 0 8.878049584382097e-08
sequence O 0 4.7012833626070005e-09
or O 0 3.209153387473407e-09
splice O 0 3.744562206975388e-07
sites O 0 1.1024656743074956e-08
in O 0 6.26553864346846e-10
an O 0 1.3089195005644427e-10
estimated O 0 5.204617847809345e-10
63 O 0 2.9354985997542826e-08
% O 0 4.29231583609635e-09
( O 0 6.732967516853705e-09
95 O 0 4.612764712419448e-07
% O 0 1.1187322002115252e-07
CI O 0 6.394867523340508e-05
51 O 0 5.755763936576841e-07
% O 0 1.4255078895075712e-08
- O 0 1.0415784856832033e-07
77 O 0 1.0165908292947279e-07
% O 0 7.904556120763573e-09
) O 0 1.3431542100761362e-08
. O 0 1.399951088387752e-07

The O 0 1.3836322523275157e-06
estimated O 0 5.1289980262936297e-08
sensitivity O 0 3.1472441719415656e-07
was O 0 6.593341339566905e-08
identical O 0 5.1946829060511845e-09
for O 0 9.635809927743821e-10
direct O 0 9.321714955490279e-09
sequencing O 0 1.5199108815977525e-07
and O 0 5.18504128521613e-09
other O 0 4.088816840663867e-09
techniques O 0 2.4206622128986055e-06
. O 0 7.656217917428876e-07

The O 0 7.487207312806277e-06
penetrance O 0 0.0002579139545559883
of O 0 5.180811513127992e-06
BRCA2 O 0 4.54806286143139e-05
was O 0 6.929705023139832e-07
estimated O 0 3.7098817351477464e-09
by O 0 9.41985267566281e-10
maximizing O 0 1.1017345968866721e-07
the O 0 6.422219200885593e-08
LOD O 1 0.9999262094497681
score O 0 3.2473790270159952e-06
in O 0 3.361369849130824e-08
BRCA2 O 0 8.669609883327212e-07
- O 0 1.0473756617557228e-07
mutation O 0 4.108642759348413e-09
families O 0 2.3498829548884714e-09
, O 0 5.444788508945919e-10
over O 0 6.552278719595961e-10
all O 0 6.743863245617376e-10
possible O 0 3.5836031031522e-08
penetrance O 0 8.93915057531558e-06
functions O 0 4.6114013230180717e-07
. O 0 4.5268427584232995e-07

The O 0 2.0462205156945856e-06
estimated O 0 6.209947400748206e-08
cumulative O 0 1.8049712480205926e-07
risk O 0 4.819166861125268e-07
of O 0 1.8255929035149165e-06
breast B-Disease 1 0.9995774626731873
cancer I-Disease 1 0.7395849227905273
reached O 0 1.7267892644667882e-06
28 O 0 1.8961686976126657e-07
% O 0 6.844320221688349e-09
( O 0 3.481649857306479e-09
95 O 0 1.0592226828975981e-07
% O 0 3.629644496072615e-08
CI O 0 1.5503273971262388e-05
9 O 0 1.1462390148153645e-07
% O 0 4.641400597193979e-09
- O 0 9.708518433626523e-09
44 O 0 4.605316128447612e-09
% O 0 4.1634598546558266e-10
) O 0 6.960056142535365e-11
by O 0 8.350650032573625e-11
age O 0 1.053887421775812e-09
50 O 0 2.006353305716857e-09
years O 0 1.0973713049367007e-09
and O 0 1.2582432873387006e-09
84 O 0 1.6000871738697242e-08
% O 0 1.5411819598298848e-09
( O 0 2.496737483426159e-09
95 O 0 9.787187593701674e-08
% O 0 2.2735406446372508e-08
CI O 0 4.006220933661098e-06
43 O 0 8.607725021647639e-08
% O 0 4.931547170627937e-09
- O 0 2.7221048526371305e-08
95 O 0 3.0303105802431674e-08
% O 0 8.246442417814137e-10
) O 0 1.7859100309713938e-10
by O 0 1.0288650487133566e-10
age O 0 3.1155602542298766e-09
70 O 0 2.4204345194789312e-08
years O 0 3.4462193099216165e-08
. O 0 1.6036337058267236e-07

The O 0 9.78788739303127e-06
corresponding O 0 0.20722955465316772
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0005451727192848921
were O 0 9.277911772187508e-07
0 O 0 1.287227178181638e-06
. O 0 7.740530350019981e-07

4 O 0 1.1524022738740314e-05
% O 0 1.37468433081267e-07
( O 0 2.5820639848461724e-08
95 O 0 2.5179565454891417e-07
% O 0 2.9094506359683692e-08
CI O 0 1.1414971595513634e-05
0 O 0 5.8237784372749957e-08
% O 0 3.5484237770333493e-09
- O 0 1.5349137072462327e-08
1 O 0 7.582853456256089e-09
% O 0 3.135655346486743e-10
) O 0 6.760421389362392e-11
by O 0 4.4358936662769466e-11
age O 0 9.024165303905818e-10
50 O 0 2.1003394579111045e-09
years O 0 1.7196242207973e-09
and O 0 7.956616476789691e-10
27 O 0 4.3122971860043435e-09
% O 0 5.230911259701543e-10
( O 0 1.098707458346837e-09
95 O 0 4.4382105102158675e-08
% O 0 7.825499359626065e-09
CI O 0 1.9491540115268435e-06
0 O 0 2.2052983439380114e-08
% O 0 1.5723735646844261e-09
- O 0 7.979630289867146e-09
47 O 0 9.944723267096833e-09
% O 0 4.4457887371507354e-10
) O 0 2.3023309647651757e-10
by O 0 1.2303386087708645e-10
age O 0 7.75878294945187e-09
70 O 0 5.918209211586145e-08
years O 0 8.68800285047655e-08
. O 0 3.963571941767441e-07

The O 0 2.427963408990763e-06
lifetime O 0 3.96145878767129e-06
risk O 0 3.2903301416808972e-06
of O 0 4.246628122928087e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9998468160629272
appears O 0 8.059555511863437e-08
similar O 0 3.133151960099667e-09
to O 0 2.7485809184213394e-09
the O 0 1.944936833808697e-08
risk O 0 3.7431698274303926e-07
in O 0 3.5757703464867063e-09
BRCA1 O 0 1.9640571835566334e-08
carriers O 0 3.4881437738221166e-09
, O 0 3.86843695965311e-10
but O 0 2.193537296246717e-10
there O 0 5.734489549880095e-10
was O 0 3.845119778134176e-09
some O 0 6.260458818019288e-11
suggestion O 0 3.342227605784842e-09
of O 0 3.143759030876936e-09
a O 0 6.783432482393437e-09
lower O 0 3.0113781690488395e-07
risk O 0 1.523828245808545e-07
in O 0 9.044140547587176e-09
BRCA2 O 0 7.694134751545789e-08
carriers O 0 1.3181654878735571e-08
< O 0 2.594331931504712e-07
50 O 0 1.798820470355622e-08
years O 0 1.3157239742156435e-08
of O 0 3.969063655517857e-08
age O 0 2.6082366844093485e-07
. O 0 3.9796313444639964e-07

Eye B-Disease 1 0.9999948740005493
movement I-Disease 0 0.00022611679742112756
abnormalities I-Disease 0 0.0005850125453434885
correlate O 0 4.0072958995551744e-07
with O 0 1.6897001131610523e-08
genotype O 0 5.565878018387593e-05
in O 0 1.726264144963352e-07
autosomal O 0 0.15079043805599213
dominant O 1 0.999995231628418
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 0.00032059341901913285

We O 0 2.5888305117405253e-06
compared O 0 1.2748029121212312e-06
horizontal O 0 9.445690920983907e-06
eye O 0 0.000564542890060693
movements O 0 2.1447458493639715e-06
( O 0 4.0914412124948285e-07
visually O 0 1.0977905731124338e-06
guided O 0 6.02943964622682e-06
saccades O 0 0.0021715250331908464
, O 0 1.1930485754874098e-07
antisaccades O 0 2.427976141916588e-05
, O 0 1.6240205624740156e-08
and O 0 8.307066146073794e-09
smooth O 0 2.1842880926215003e-07
pursuit O 0 1.72787645169592e-06
) O 0 7.425246195680302e-09
in O 0 4.24459933867638e-09
control O 0 9.466076988928762e-08
subjects O 0 1.4240097812034946e-07
( O 0 4.1346641665995776e-09
n O 0 1.3914372765100325e-08
= O 0 2.354702743900816e-08
14 O 0 4.1290371122215674e-09
) O 0 5.016318471717796e-10
and O 0 5.781351508638011e-10
patients O 0 1.7496420978702076e-09
with O 0 2.580682612052243e-10
three O 0 8.104854010149154e-10
forms O 0 1.4855854324480333e-08
of O 0 6.418607085834083e-07
autosomal O 0 1.4551107597071677e-05
dominant O 0 0.0001357264118269086
cerebellar B-Disease 1 0.9999089241027832
ataxias I-Disease 0 0.0011668918887153268
type I-Disease 0 2.270307595608756e-05
I I-Disease 0 0.0008130833157338202
spinocerebellar B-Disease 1 0.9822190999984741
ataxias I-Disease 0 0.0006116042495705187
1 I-Disease 0 5.00926773838728e-07
and I-Disease 0 4.665304942363946e-08
2 I-Disease 0 5.344643341231858e-07
( O 0 8.093029180145095e-08
SCA1 B-Disease 0 0.0037908414378762245
, O 0 4.329325875573886e-08
n O 0 6.762417115169228e-08
= O 0 4.849475132573389e-08
11 O 0 3.948502680373167e-08
; O 0 1.533503279915749e-08
SCA2 B-Disease 0 2.2606718630413525e-05
, O 0 1.7844305588710085e-08
n O 0 3.3317270720090164e-08
= O 0 6.088697546147159e-08
10 O 0 1.2444343333584129e-08
) O 0 4.484336013632628e-09
and O 0 2.9545859092650062e-08
SCA3 B-Disease 1 1.0
/ O 0 3.776458106585778e-05
Machado B-Disease 0 3.05811113321397e-06
- I-Disease 0 7.967586270751781e-07
Joseph I-Disease 0 6.473564280895516e-05
disease I-Disease 1 0.9653398394584656
( O 0 2.0616271001472342e-07
MJD B-Disease 1 1.0
) O 0 4.2411539169506796e-08
( O 0 8.93969431814412e-09
n O 0 6.636074090238253e-08
= O 0 1.544365915151502e-07
16 O 0 1.5254552465648885e-07
) O 0 5.6418006266767406e-08
. O 0 5.032212584410445e-07

In O 0 5.342647455108818e-06
SCA1 B-Disease 0 0.0020472907926887274
, O 0 2.513414756322163e-07
saccade O 0 1.5527097275480628e-05
amplitude O 0 1.6755315073169186e-06
was O 0 8.009566698774506e-08
significantly O 0 1.3897610173785324e-08
increased O 0 9.662169730972892e-09
, O 0 3.1077793671840936e-09
resulting O 0 1.1453681736384169e-07
in O 0 1.4831327632691682e-07
hypermetria B-Disease 0 0.0001587792212376371
. O 0 8.439430985163199e-07

The O 0 1.3227780073066242e-05
smooth O 0 2.97288552246755e-05
pursuit O 0 5.4637715948047116e-05
gain O 0 1.009981679089833e-05
was O 0 3.4238298667332856e-06
decreased O 0 2.225599473604234e-06
. O 0 1.9373505892872345e-06

In O 0 8.509001418133266e-06
SCA2 B-Disease 0 0.005727296229451895
, O 0 7.15295129793958e-07
saccade O 0 3.366985765751451e-05
velocity O 0 9.984674761653878e-06
was O 0 5.0682556320680305e-06
markedly O 0 1.5063111277413554e-05
decreased O 0 5.434570539364358e-06
. O 0 2.560930852268939e-06

The O 0 4.2070200834132265e-06
percentage O 0 1.0991734598064795e-06
of O 0 2.0289483870783442e-07
errors O 0 1.1083765457442496e-05
in O 0 2.649353518791031e-07
antisaccades O 1 0.9898059964179993
was O 0 1.1290187558188336e-06
greatly O 0 8.989385946733819e-08
increased O 0 1.1724812232216664e-08
and O 0 7.340531293920094e-09
was O 0 1.518678693912534e-08
significantly O 0 3.7232654737096027e-09
correlated O 0 3.3821021538926743e-09
with O 0 2.9211189023214956e-10
age O 0 1.6741223518579318e-08
at O 0 1.1406046951378812e-07
disease O 0 1.7402478988515213e-05
onset O 1 0.9184511303901672
. O 0 4.9787331590778194e-06

In O 0 3.138632962418342e-07
addition O 0 5.374713296646405e-08
, O 0 8.203836721065727e-09
a O 0 6.620773707055605e-09
correlation O 0 1.4622271393704978e-08
between O 0 2.4183997027193982e-08
smooth O 0 7.285319725269801e-07
pursuit O 0 4.8993115342454985e-06
gain O 0 1.8826870018529007e-07
and O 0 4.967713795878126e-09
the O 0 5.3778275166394e-09
number O 0 2.361808526529785e-09
of O 0 4.6108734608196755e-08
trinucleotide O 0 0.0007548601715825498
repeats O 0 5.924804895585112e-07
was O 0 1.5311540835227788e-07
found O 0 2.835085233243717e-08
. O 0 9.373172815685393e-08

In O 0 2.309386218257714e-05
SCA3 B-Disease 1 1.0
, O 0 8.149976565619e-06
gaze B-Disease 0 0.0020540945697575808
- I-Disease 0 0.000215572101296857
evoked I-Disease 0 0.00034178540227003396
nystagmus I-Disease 0 0.461858332157135
was O 0 1.2951398957739002e-06
often O 0 4.639904904735204e-09
present O 0 4.752103155425402e-09
as O 0 1.3217808181309465e-08
was O 0 1.0016741924800954e-07
saccade O 0 4.2884003050858155e-06
hypometria O 0 1.0152641152672004e-05
and O 0 4.957522392601277e-08
smooth O 0 1.1121820762127754e-06
pursuit O 0 1.583756420586724e-05
gain O 0 7.309995453397278e-06
was O 0 4.055339559272397e-06
markedly O 0 9.936951755662449e-06
decreased O 0 3.805115738941822e-06
. O 0 1.7754630334820831e-06

Three O 0 1.2057121239195112e-06
major O 0 5.191080845179386e-07
criteria O 0 2.1317022458333668e-07
, O 0 1.6728487040040818e-08
saccade O 0 1.8697196537686978e-06
amplitude O 0 2.2395744281311636e-07
, O 0 2.999040793483232e-09
saccade O 0 3.986712329151487e-07
velocity O 0 5.965399907381652e-08
, O 0 2.8139119923054068e-09
and O 0 1.0596319377498276e-09
presence O 0 1.649431702333004e-08
of O 0 3.6905115052832116e-07
gaze B-Disease 0 0.002993029309436679
- I-Disease 0 2.436823706375435e-05
evoked I-Disease 0 4.629662726074457e-06
nystagmus I-Disease 0 2.2841607005830156e-06
, O 0 2.6767239535985254e-09
permitted O 0 1.883428746296545e-09
the O 0 1.9760202363272583e-09
correct O 0 5.798626023789666e-09
assignment O 0 6.205255864699666e-09
of O 0 2.5534168113239275e-09
90 O 0 2.0415475976420794e-09
% O 0 3.2147637329948964e-10
of O 0 2.6260580376913367e-09
the O 0 1.2343920552382315e-08
SCA1 B-Disease 0 5.00783535244409e-05
, O 0 4.566819811202549e-09
90 O 0 4.4131209797626525e-09
% O 0 4.503018791179869e-10
of O 0 4.980949430688497e-09
the O 0 1.8016567793210925e-08
SCA2 B-Disease 0 0.00029831635765731335
, O 0 2.7508886280003253e-09
and O 0 1.8324798345403792e-09
93 O 0 1.157714635269258e-08
% O 0 3.8432484972261705e-10
of O 0 2.739359183934198e-09
the O 0 5.142719139428209e-09
patients O 0 6.307246280812251e-08
with O 0 1.2933703885664727e-08
SCA3 B-Disease 1 1.0
to O 0 1.5952146270592493e-08
their O 0 3.6861684815647777e-09
genetically O 0 2.3854877184703582e-08
confirmed O 0 5.281561854530992e-09
patient O 0 2.1884746459477356e-08
group O 0 8.292008746302315e-10
and O 0 7.588970007965656e-10
, O 0 7.017993963742697e-10
therefore O 0 8.225334191536149e-09
, O 0 4.0314653837469905e-09
may O 0 2.134873255954517e-08
help O 0 7.707853910687845e-08
orient O 0 5.972919097985141e-06
diagnoses O 0 1.853045978350565e-05
of O 0 4.192409505776595e-06
SCA1 B-Disease 1 0.999998927116394
, O 0 1.2896104806259245e-07
SCA2 B-Disease 1 0.9591872692108154
, O 0 6.247417871918515e-08
and O 0 2.183288501100833e-07
SCA3 B-Disease 1 1.0
at O 0 7.972116122800799e-07
early O 0 1.1791536280725268e-07
clinical O 0 1.9507479009917006e-07
stages O 0 1.233577080483883e-07
of O 0 5.574115391482337e-08
the O 0 1.7214718184277444e-07
diseases O 1 0.9998466968536377
. O 0 2.6970764110956225e-07
. O 0 7.98183918959694e-07

Genetic O 0 3.875578386214329e-06
basis O 0 2.1159422658456606e-07
and O 0 2.2568720225990546e-08
molecular O 0 1.9835040632187884e-07
mechanism O 0 1.4904151157679735e-06
for O 0 1.306301442127733e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9998050332069397

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 1.683430491539184e-05
more O 0 1.8235061460813995e-08
than O 0 1.7849641764655644e-09
300 O 0 4.102988615528602e-09
, O 0 6.505803118450615e-10
000 O 0 6.931381690833405e-09
sudden O 0 5.9127259532942844e-08
deaths O 0 1.3307460022815576e-08
each O 0 1.2811719463101667e-09
year O 0 4.887647175877419e-09
in O 0 1.0794564353489022e-08
the O 0 1.8628001896559e-07
USA O 0 4.2963906707882416e-06
alone O 0 5.326223799784202e-07
. O 0 4.0820407321007224e-07

In O 0 9.218089758178394e-07
approximately O 0 7.07599809857129e-08
5 O 0 1.195131460463017e-07
- O 0 1.2630377455025155e-07
12 O 0 5.806705338784468e-09
% O 0 2.2917195918736866e-10
of O 0 7.703789828283902e-10
these O 0 1.421981560278951e-10
cases O 0 4.5931644598873334e-10
, O 0 2.0365099884234183e-10
there O 0 2.322177033997619e-10
are O 0 1.4629648881214763e-10
no O 0 4.422668009596009e-09
demonstrable O 0 0.0004150488239247352
cardiac O 1 0.999964714050293
or O 0 2.123101012330153e-06
non O 0 0.21488571166992188
- O 1 0.9994632601737976
cardiac O 1 0.9999815225601196
causes O 0 1.896685972724299e-07
to O 0 1.8508086174762184e-09
account O 0 7.669000434695761e-10
for O 0 9.20360787581842e-10
the O 0 9.994733929374888e-09
episode O 0 7.864106521537906e-08
, O 0 5.513931533585037e-10
which O 0 9.584079363467168e-11
is O 0 1.2260421844434433e-10
therefore O 0 1.4595570307918138e-09
classified O 0 1.1403768596096597e-08
as O 0 4.081954330104054e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999940395355225
IVF B-Disease 1 1.0
) O 0 1.6791211692179786e-06
. O 0 1.820807710828376e-06

A O 0 5.319291176419938e-06
distinct O 0 3.249233202495816e-07
group O 0 8.805265139244511e-08
of O 0 1.6767863826316898e-06
IVF B-Disease 1 1.0
patients O 1 0.7700369954109192
has O 0 8.050133892822942e-09
been O 0 7.715465488722373e-10
found O 0 3.0322849786657e-10
to O 0 1.2976586472035478e-10
present O 0 1.2876246735515906e-09
with O 0 2.1729134047632215e-09
a O 0 6.524486906300808e-08
characteristic O 0 3.2549319257668685e-06
electrocardiographic O 0 0.0007411727565340698
pattern O 0 1.6444439097540453e-05
. O 0 2.47585967372288e-06

Because O 0 1.4039839015822508e-06
of O 0 8.774916864240367e-07
the O 0 8.41175946675321e-08
small O 0 7.029330895136354e-09
size O 0 4.223988714358029e-09
of O 0 9.133469980326936e-09
most O 0 4.176242907050209e-09
pedigrees O 0 9.359720820611983e-08
and O 0 1.8989105843303378e-09
the O 0 3.881284182938316e-09
high O 0 9.174784310062023e-08
incidence O 0 1.4747985233043437e-07
of O 0 3.1787081411494e-08
sudden B-Disease 0 1.0928850997515838e-06
death I-Disease 0 2.7767050596594345e-06
, O 0 2.5680844117914603e-09
however O 0 4.173296819232064e-09
, O 0 5.76793557360844e-10
molecular O 0 4.418738708267256e-09
genetic O 0 4.2939043431999835e-09
studies O 0 2.887110550631178e-09
of O 0 6.070064273444586e-08
IVF B-Disease 1 1.0
have O 0 4.2375315700837746e-08
not O 0 6.787768125349203e-09
yet O 0 3.217300204028106e-08
been O 0 1.5197770153463352e-08
done O 0 4.919008489423504e-08
. O 0 8.236908399794629e-08

Because O 0 8.151893416652456e-05
IVF B-Disease 1 1.0
causes O 1 0.6080389022827148
cardiac O 1 1.0
rhythm O 1 1.0
disturbance O 1 0.9999816417694092
, O 0 1.4817119620147423e-07
we O 0 7.557440895311629e-09
investigated O 0 3.20503232842384e-08
whether O 0 5.1523998401137305e-09
malfunction O 0 0.0014126638416200876
of O 0 1.047231847906005e-07
ion O 0 1.4974081750551704e-05
channels O 0 5.519692081179528e-07
could O 0 4.234911088474291e-09
cause O 0 6.580414435575221e-08
the O 0 1.1908656283310393e-08
disorder O 0 3.778058044190402e-07
by O 0 4.979721635045564e-10
studying O 0 4.128848374307381e-09
mutations O 0 8.181144650620809e-10
in O 0 3.6873054609642963e-10
the O 0 5.8651883350080425e-09
cardiac O 0 0.004065718036144972
sodium O 0 2.6748612071969546e-05
channel O 0 3.743644583664718e-06
gene O 0 2.52757047292107e-07
SCN5A O 0 3.980017208959907e-05
. O 0 7.15850546839647e-07

We O 0 1.8241256611872814e-06
have O 0 2.5366563960460553e-08
now O 0 1.2176584185397132e-08
identified O 0 8.26736101799952e-09
a O 0 5.186010287872023e-09
missense O 0 1.615155582612715e-07
mutation O 0 1.5893682814294152e-08
, O 0 5.844305928093263e-09
a O 0 2.2150066669723856e-08
splice O 0 9.39220808504615e-06
- O 0 1.8441011206959956e-07
donor O 0 8.811847251877225e-09
mutation O 0 2.3721016262356898e-09
, O 0 4.565580691284765e-10
and O 0 1.6596936047719169e-09
a O 0 2.181448266469488e-08
frameshift O 0 7.796144245730829e-07
mutation O 0 1.0942493133825337e-08
in O 0 1.8925609968079016e-09
the O 0 6.316345668722079e-09
coding O 0 1.9800586414930876e-07
region O 0 2.3311081065457984e-08
of O 0 7.944431246187378e-08
SCN5A O 1 0.9999754428863525
in O 0 5.1621707797266936e-08
three O 0 1.2875791810529336e-07
IVF B-Disease 1 0.9999998807907104
families O 0 3.835040445210325e-07
. O 0 4.4436106350076443e-07

We O 0 2.1379107693064725e-06
show O 0 6.82318130884596e-08
that O 0 1.7354931935997797e-09
sodium O 0 9.885250307206661e-08
channels O 0 4.26379962448209e-08
with O 0 3.771092049742464e-10
the O 0 3.3390863407589677e-09
missense O 0 4.6403408759942977e-07
mutation O 0 4.44119976350521e-08
recover O 0 8.840771101858991e-07
from O 0 3.747634025330626e-08
inactivation O 0 0.00011874877964146435
more O 0 9.219807695082238e-10
rapidly O 0 4.361282002207645e-09
than O 0 5.254107218743975e-11
normal O 0 2.430410595000154e-10
and O 0 9.737198547465908e-11
that O 0 2.747854721540932e-11
the O 0 1.0999152699753267e-09
frameshift O 0 1.0895222146700689e-07
mutation O 0 1.2581784503140625e-09
causes O 0 2.417171574009558e-09
the O 0 2.63946553502592e-09
sodium O 0 2.3018640149530256e-07
channel O 0 6.508366112711883e-08
to O 0 9.605496398279456e-10
be O 0 2.0076396101131877e-09
non O 0 1.4101561873758328e-07
- O 0 4.985143959856941e-07
functional O 0 9.38127243443887e-07
. O 0 5.465436743179453e-07

Our O 0 5.0847256716224365e-06
results O 0 7.335789575790841e-08
indicate O 0 2.902295115347897e-08
that O 0 2.511869601207195e-09
mutations O 0 1.9591968936083504e-08
in O 0 1.2116903924663802e-08
cardiac O 0 0.005672416649758816
ion O 0 0.0017171971267089248
- O 1 0.6764926910400391
channel O 0 6.225589572750323e-07
genes O 0 7.742634866581e-10
contribute O 0 1.3706320800555005e-10
to O 0 2.4855606461926527e-10
the O 0 3.3985660952140506e-09
risk O 0 5.8695778903938844e-08
of O 0 1.8007675350872887e-07
developing O 0 0.00011984036973444745
IVF B-Disease 1 1.0
. O 0 2.7383842393646773e-07
. O 0 2.4686801225470845e-07

Molecular O 0 6.797004607506096e-05
heterogeneity O 0 0.00015007461479399353
in O 0 3.030345169463544e-06
mucopolysaccharidosis B-Disease 1 0.9718570113182068
IVA I-Disease 1 1.0
in O 0 3.601405751396669e-07
Australia O 0 4.436263978391253e-08
and O 0 5.564053662254764e-09
Northern O 0 5.676633563211908e-08
Ireland O 0 5.7997350921823454e-08
: O 0 3.4008613702951607e-09
nine O 0 6.926491824543746e-09
novel O 0 1.0680532902540563e-08
mutations O 0 3.0059015276862056e-09
including O 0 2.1312023257280543e-09
T312S O 0 1.7643397995925625e-06
, O 0 4.351518700929091e-09
a O 0 1.135207572389163e-08
common O 0 9.747282803118651e-08
allele O 0 3.7416061360318054e-08
that O 0 1.860212095472491e-09
confers O 0 2.1632797597703757e-07
a O 0 8.167649667711885e-08
mild O 0 0.0003809057525359094
phenotype O 0 0.00015664084639865905
. O 0 3.6752155665453756e-06

Mucopolysaccharidosis B-Disease 1 0.9999535083770752
IVA I-Disease 1 1.0
( O 0 0.0006898955325596035
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 6.301210078163422e-07
is O 0 2.6735362368413007e-08
an O 0 1.3043848667848579e-08
autosomal B-Disease 0 0.045293547213077545
recessive I-Disease 1 0.9999885559082031
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.015088946558535099
by O 0 9.778268150739677e-08
a O 0 3.843879312626086e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.921173619251931e-07
N O 0 4.39251380157657e-05
- O 0 1.3655232578457799e-05
acetylgalactosamine O 0 0.0003390757483430207
- O 0 3.784725777222775e-06
6 O 0 3.3494200124550844e-06
- O 0 4.782302767125657e-06
sulfate O 0 0.00015477073611691594
sulfatase O 0 0.3905365467071533
( O 0 1.1561410246940795e-06
GALNS O 0 0.12831328809261322
) O 0 2.762769213404681e-07
. O 0 3.84511508855212e-07

Previous O 0 2.1711721274186857e-06
studies O 0 1.8692118430863047e-07
of O 0 6.612106062675593e-08
patients O 0 1.2532623827610223e-07
from O 0 2.2058745940967128e-08
a O 0 5.292243798749041e-08
British O 0 2.1955252123007085e-06
- O 0 4.2241867959091906e-06
Irish O 0 4.0263194023282267e-07
population O 0 3.807285875456756e-10
showed O 0 5.704609007395334e-10
that O 0 5.564132835034208e-11
the O 0 8.191184397432494e-10
I113F O 0 9.233102105099533e-08
mutation O 0 1.1892737905583317e-09
is O 0 2.2705914926035575e-10
the O 0 1.0528787841579401e-09
most O 0 5.499573574319072e-10
common O 0 2.004188592863443e-09
single O 0 3.0933731132165576e-09
mutation O 0 1.000047333832299e-08
among O 0 2.4104878093567095e-08
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 1 0.9768692851066589
and O 0 1.6783624801064434e-07
produces O 0 4.2361250507383374e-08
a O 0 3.434905693211476e-08
severe O 0 3.153773650410585e-05
clinical O 0 0.002763851545751095
phenotype O 0 0.00020635656255763024
. O 0 1.367084905723459e-06

We O 0 1.019290152726171e-06
studied O 0 1.0668579761841102e-06
mutations O 0 9.801459555092151e-08
in O 0 1.0931394456292765e-08
the O 0 2.6465851732382362e-08
GALNS O 0 0.0003044782788492739
gene O 0 2.1811569439478262e-08
from O 0 7.81920306280881e-09
23 O 0 1.5109728579432158e-08
additional O 0 3.222631406174514e-08
MPS B-Disease 1 0.9999926090240479
IVA I-Disease 1 1.0
patients O 0 0.0010856764856725931
( O 0 2.5172905537829138e-08
15 O 0 2.4155459854569017e-08
from O 0 5.240780698301251e-09
Australia O 0 4.717163548662029e-09
, O 0 9.276252543877206e-10
8 O 0 5.841285677377073e-09
from O 0 1.4424481609154327e-09
Northern O 0 9.991894422967107e-09
Ireland O 0 6.504045302335726e-09
) O 0 4.353733484840916e-10
, O 0 1.3321818648215356e-10
with O 0 6.766871785135464e-11
various O 0 1.2724680198417104e-09
clinical O 0 9.382417260894726e-07
phenotypes O 0 5.459276053443318e-06
( O 0 5.4849657260547247e-08
severe O 1 0.8290754556655884
, O 0 9.127970201916469e-08
16 O 0 2.475820970460063e-08
cases O 0 1.9591137601082664e-09
; O 0 1.855566367225947e-09
intermediate O 0 2.289173437475256e-07
, O 0 9.137768874900587e-10
4 O 0 5.301890038111878e-09
cases O 0 1.311233899237152e-09
; O 0 5.0218544878077864e-09
mild O 0 8.110000635497272e-05
, O 0 3.494205103038439e-08
3 O 0 2.116555890552263e-07
cases O 0 3.2387696080604655e-08
) O 0 6.669267804682022e-08
. O 0 4.529636612460308e-07

We O 0 1.0705944077926688e-06
found O 0 3.001892423526442e-08
two O 0 6.230137294949145e-09
common O 0 1.0075544842891304e-08
mutations O 0 4.519938645586308e-09
that O 0 2.956082323368747e-10
together O 0 1.0114838966401862e-09
accounted O 0 6.718010148176745e-09
for O 0 2.507829277575979e-09
32 O 0 2.9270005086345918e-08
% O 0 2.2961135215382455e-09
of O 0 7.509850519227257e-09
the O 0 1.2005468619236126e-08
44 O 0 2.1864760668677263e-08
unrelated O 0 1.6886659182091535e-08
alleles O 0 2.258360831675077e-09
in O 0 5.80794301541232e-10
these O 0 2.9562641223890296e-09
patients O 0 2.2088055118274497e-07
. O 0 3.1987181614567817e-07

One O 0 5.971660925752076e-07
is O 0 3.7155064802618654e-08
the O 0 2.4543107102203976e-08
T312S O 0 4.721279935893108e-07
mutation O 0 9.837303416304621e-09
, O 0 8.538189599782697e-10
a O 0 2.765503159807281e-09
novel O 0 4.788563856550354e-08
mutation O 0 9.874712603163971e-09
found O 0 2.8323272616148643e-09
exclusively O 0 6.796836871103551e-09
in O 0 3.5739837755954795e-09
milder O 0 0.11482320725917816
patients O 1 0.6059725880622864
. O 0 6.457794370362535e-06

The O 0 1.9944745872635394e-06
other O 0 5.775239841909752e-08
is O 0 6.192415913375271e-09
the O 0 7.201656604394202e-09
previously O 0 3.3924148823416544e-08
described O 0 5.304654138171827e-08
I113F O 0 8.305294727506407e-07
that O 0 1.446567088336792e-09
produces O 0 1.9959951913506302e-08
a O 0 5.399187585908294e-08
severe O 0 0.00888149905949831
phenotype O 0 0.019070923328399658
. O 0 1.1410944352974184e-05

The O 0 7.354425633820938e-06
I113F O 0 7.04833073541522e-05
and O 0 3.52917282953058e-07
T312S O 0 3.2295281471306225e-06
mutations O 0 3.730802689005941e-08
accounted O 0 2.6922341689328277e-08
for O 0 8.559146280617824e-09
8 O 0 1.2964791551439703e-07
( O 0 7.542794833170774e-09
18 O 0 1.4815953797153725e-08
% O 0 1.1539772470925413e-09
) O 0 6.108163974616332e-10
and O 0 2.1048229825737508e-09
6 O 0 5.696036708968677e-08
( O 0 1.792664794386667e-09
14 O 0 6.7282690530134914e-09
% O 0 2.794079412282713e-10
) O 0 2.6305080336186393e-10
of O 0 2.2347765860075697e-09
44 O 0 2.1568725472320693e-08
unrelated O 0 5.8376578238039656e-08
alleles O 0 7.890335496085754e-09
, O 0 8.343429946933156e-09
respectively O 0 1.0364713176613805e-07
. O 0 5.607149091702013e-07

The O 0 2.7587723252509022e-06
relatively O 0 2.58091245086689e-06
high O 0 2.966240344903781e-06
residual O 0 4.545817137113772e-05
GALNS O 0 0.009419714100658894
activity O 0 9.263318645480467e-08
seen O 0 2.8380068073374787e-08
when O 0 3.993299912963266e-09
the O 0 1.2058112730528592e-08
T312S O 0 9.305301773565589e-07
mutant O 0 2.5410591319996456e-07
cDNA O 0 5.501572104549268e-07
is O 0 3.8785903377913655e-09
overexpressed O 0 6.654400976913166e-07
in O 0 4.829728172950354e-09
mutant O 0 4.914441120718038e-08
cells O 0 2.9387015043624842e-09
provides O 0 3.211037546968498e-10
an O 0 2.3414381544739626e-11
explanation O 0 1.0268462746765294e-09
for O 0 2.818927868908361e-10
the O 0 1.9425927533234244e-09
mild O 0 1.5125757272471674e-05
phenotype O 0 1.413575091646635e-06
in O 0 1.2044498731711428e-09
patients O 0 3.583362273573698e-09
with O 0 5.681588532979731e-10
this O 0 6.37178843021502e-09
mutation O 0 2.903320250879915e-07
. O 0 6.090382385082194e-07

The O 0 3.793438168031571e-07
distribution O 0 3.3742942662229325e-08
and O 0 4.638046835481191e-09
relative O 0 5.5092588269189946e-08
frequencies O 0 6.293991106076646e-08
of O 0 1.800743021362905e-08
the O 0 2.0510405818185973e-08
I113F O 0 7.847180540920817e-07
and O 0 2.1149087814364975e-08
T312S O 0 5.678137995346333e-07
mutations O 0 6.08096550891446e-09
in O 0 1.4829404371141663e-09
Australia O 0 2.513652619384743e-09
corresponded O 0 3.5194602787669282e-09
to O 0 3.409198756632037e-10
those O 0 5.069045183603293e-10
observed O 0 3.5672276244014256e-09
in O 0 9.091422059626098e-10
Northern O 0 3.607365428592857e-08
Ireland O 0 4.172853351747108e-08
and O 0 3.0156754871057956e-09
are O 0 1.4899029232573469e-10
unique O 0 7.525604583946688e-10
to O 0 2.4246554763962536e-10
these O 0 2.542156207763213e-10
two O 0 2.987478042726366e-10
populations O 0 7.223236453413051e-10
, O 0 4.6186759972144387e-10
suggesting O 0 2.692535749915237e-09
that O 0 3.376067758686929e-10
both O 0 1.959506112925169e-09
mutations O 0 5.051962848057201e-09
were O 0 1.49387098247189e-08
probably O 0 3.148225147242556e-08
introduced O 0 1.4782477464336807e-08
to O 0 8.306080823139439e-10
Australia O 0 1.2213654532189366e-09
by O 0 3.340339671531467e-10
Irish O 0 6.71344011493602e-08
migrants O 0 1.1003522537578192e-08
during O 0 2.3114678171509695e-08
the O 0 3.8928519074943324e-08
19th O 0 4.8525789679843e-06
century O 0 1.470375900680665e-05
. O 0 2.57384840551822e-06

Haplotype O 0 6.503926852019504e-05
analysis O 0 5.655569452756026e-07
using O 0 4.841887175643933e-07
6 O 0 1.340397602689336e-06
RFLPs O 0 1.4258866940508597e-05
provides O 0 2.534296683620596e-08
additional O 0 2.321018044426637e-09
data O 0 1.478362543494427e-09
that O 0 1.1656545173543975e-10
the O 0 2.221355988041296e-09
I113F O 0 1.3564599044002534e-07
mutation O 0 2.4586528368786276e-09
originated O 0 5.642992739751662e-09
from O 0 8.023396391720894e-10
a O 0 3.979909735107867e-09
common O 0 1.1510380915069618e-07
ancestor O 0 4.42680211563129e-05
. O 0 2.644385631356272e-06

The O 0 2.0290310658310773e-06
other O 0 7.284938874363434e-08
9 O 0 2.1207564770975296e-07
novel O 0 7.264208790047633e-08
mutations O 0 6.673057661998882e-09
identified O 0 5.815261605590649e-09
in O 0 7.507554578012332e-10
these O 0 9.326459604608317e-10
23 O 0 5.63845574674815e-08
patients O 0 2.6333772495945595e-08
were O 0 1.8249596278607783e-09
each O 0 2.38728758983342e-10
limited O 0 1.2209228072990186e-09
to O 0 1.231052815242606e-09
a O 0 3.2138959937810796e-08
single O 0 1.40271353643584e-07
family O 0 6.145788233880012e-07
. O 0 4.838752829527948e-07

These O 0 3.5571611078921705e-07
data O 0 1.2752900602208683e-07
provide O 0 2.6199456826248024e-08
further O 0 2.0274274703524497e-08
evidence O 0 4.835574429762346e-08
for O 0 9.954135293810396e-09
extensive O 0 3.611607155562524e-07
allelic O 0 4.762145636050263e-06
heterogeneity O 0 8.629441254015546e-06
in O 0 1.9632916803402622e-07
MPS B-Disease 1 0.9700490832328796
IVA I-Disease 1 1.0
in O 0 3.1795752875041217e-07
British O 0 4.735050879389746e-06
- O 0 5.167636572878109e-06
Irish O 0 7.657035894226283e-07
patients O 0 6.048832545957339e-08
and O 0 1.3276573174181294e-09
provide O 0 1.0520075921505168e-09
evidence O 0 1.13546532176656e-08
for O 0 2.718964164927229e-09
their O 0 2.027086276612522e-09
transmission O 0 1.5464453895219776e-07
to O 0 3.268194381789158e-09
Australia O 0 4.487305194089686e-09
by O 0 1.7115484585161767e-09
British O 0 1.2065909231750993e-06
- O 0 9.515148349237279e-07
Irish O 0 4.239617226176051e-07
migrants O 0 2.4510407925504296e-08
. O 0 1.3581214375335549e-08
. O 0 7.851636496525316e-08

Identification O 0 5.94980338064488e-06
of O 0 3.261843176005641e-06
constitutional O 0 4.892067954642698e-05
WT1 O 1 0.9999988079071045
mutations O 0 3.8086011500126915e-06
, O 0 4.781983165003112e-08
in O 0 6.528455109844344e-09
patients O 0 8.850643240521094e-08
with O 0 1.2201319954385781e-08
isolated O 0 0.14174441993236542
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 7.886397668244172e-08
and O 0 2.381404184959024e-09
analysis O 0 6.436675192844632e-09
of O 0 2.0639005171574354e-08
genotype O 0 8.485484613629524e-06
/ O 0 1.6604785741947126e-06
phenotype O 0 5.6835240513919416e-08
correlations O 0 4.377316287218491e-09
by O 0 5.863359103797094e-11
use O 0 2.075307481419486e-09
of O 0 2.2114312159260407e-08
a O 0 4.478705406540939e-08
computerized O 0 9.63706611400994e-07
mutation O 0 6.313372580279974e-08
database O 0 1.3604891080376547e-07
. O 0 1.4838713013887173e-07

Constitutional O 0 7.84167514211731e-06
mutations O 0 7.5439561442181e-07
of O 0 4.998263420930016e-07
the O 0 1.7174888000681676e-07
WT1 O 0 0.0008442875114269555
gene O 0 5.4649888170388294e-08
, O 0 2.6338480285659216e-09
encoding O 0 3.849098817454433e-08
a O 0 6.615891123828987e-08
zinc O 0 0.005356160458177328
- O 0 0.00032189040211960673
finger O 0 0.000313039607135579
transcription O 0 3.689503500936553e-05
factor O 0 2.3008668748047967e-08
involved O 0 9.714464788146415e-09
in O 0 7.6946600202632e-09
renal O 1 0.9999988079071045
and O 0 6.036478339410678e-07
gonadal O 1 0.9895884990692139
development O 0 4.412001089804107e-06
, O 0 4.852747981232142e-09
are O 0 2.3825752482053986e-10
found O 0 1.4994482322450153e-09
in O 0 6.796211371451477e-10
most O 0 7.414048264209327e-10
patients O 0 5.99539662360371e-09
with O 0 9.637818543239973e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00015203113434836268
DDS B-Disease 1 1.0
) O 0 1.78306365228309e-07
, O 0 8.389484662529867e-09
or O 0 2.8120092565586674e-07
diffuse B-Disease 1 0.9999991655349731
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.0032876578625291586
DMS B-Disease 1 1.0
) O 0 2.25400711428847e-08
associated O 0 2.8415382047342064e-08
with O 0 2.0316779369977667e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.028381004492985e-06
/ O 1 0.6472991108894348
or O 0 5.8089943195227534e-05
Wilms B-Disease 1 1.0
tumor I-Disease 0 0.3544125556945801
( O 0 7.293654675777361e-07
WT B-Disease 1 0.9999998807907104
) O 0 2.1197554644913907e-07
. O 0 3.5669785347636207e-07

Most O 0 1.0331697239962523e-06
mutations O 0 1.1010114349119249e-06
in O 0 2.671008871857339e-07
DDS B-Disease 1 1.0
patients O 1 0.9998683929443359
lie O 0 5.13288177899085e-05
in O 0 7.871294371852855e-08
exon O 0 5.34529590368038e-07
8 O 0 5.812492176460182e-08
or O 0 7.181903516340071e-09
exon O 0 1.6076961628641584e-07
9 O 0 3.613460108908839e-08
, O 0 2.3783990332759686e-09
encoding O 0 1.9950957153014315e-07
zinc O 0 0.00020255448180250823
finger O 0 6.230243161553517e-05
2 O 0 2.2506060304294806e-06
or O 0 3.4702293305599596e-07
zinc O 0 0.003284424776211381
finger O 0 1.1096278285549488e-05
3 O 0 4.266028952315537e-07
, O 0 4.202596048941132e-09
respectively O 0 4.909829431909429e-09
, O 0 1.4941836656845453e-09
with O 0 1.3951197974648721e-09
a O 0 9.106632603561593e-08
hot O 0 6.509158265544102e-05
spot O 0 1.6152955595316598e-06
( O 0 1.362456902853637e-08
R394W O 0 4.27429540650337e-07
) O 0 5.597946994839731e-09
in O 0 1.3685357735937487e-08
exon O 0 2.2533336050400976e-06
9 O 0 1.5172563507803716e-06
. O 0 5.180942252991372e-07

We O 0 5.684547659257078e-07
analyzed O 0 1.9247563898261433e-07
a O 0 2.057957004808486e-08
series O 0 2.9940128598582305e-08
of O 0 1.1815735057041366e-08
24 O 0 8.18258740764577e-08
patients O 0 1.4608492904244486e-07
, O 0 5.191771013102198e-09
10 O 0 8.521794825355755e-09
with O 0 5.478386633228638e-09
isolated B-Disease 0 0.000525171693880111
DMS I-Disease 1 1.0
( O 0 1.042913822857372e-06
IDMS B-Disease 1 0.9998795986175537
) O 0 1.3047581681746578e-08
, O 0 1.7608271507540962e-09
10 O 0 6.149290854295941e-09
with O 0 7.454520556393618e-09
DDS B-Disease 1 1.0
, O 0 1.6648534995056252e-07
and O 0 3.889964617087571e-08
4 O 0 2.2587350656522176e-07
with O 0 2.6885500048479116e-08
urogenital B-Disease 1 0.9999938011169434
abnormalities I-Disease 1 0.9999994039535522
and O 0 0.00017155666137114167
/ O 1 0.9999891519546509
or O 0 0.09401319921016693
WT B-Disease 1 1.0
. O 0 7.865837687859312e-06

We O 0 3.6836863728240132e-06
report O 0 1.1393004797355388e-06
WT1 O 0 0.001305033452808857
heterozygous O 0 5.21677861797798e-07
mutations O 0 2.900314122200598e-08
in O 0 7.742772645258356e-09
16 O 0 6.496980375914063e-08
patients O 0 1.9930511996335554e-07
, O 0 1.6410655945264807e-08
4 O 0 2.7572102112571883e-07
of O 0 3.7543276221185806e-07
whom O 0 6.854552339063957e-07
presented O 0 8.386078320654633e-07
with O 0 2.619329393382941e-07
IDMS B-Disease 1 1.0
. O 0 6.374732765834779e-05

One O 0 2.6979535050486447e-06
male O 0 3.92676071214737e-07
and O 0 3.7708655753476705e-08
two O 0 3.267260950678974e-08
female O 0 6.224604476301465e-07
IDMS B-Disease 1 1.0
patients O 0 0.00010850220132851973
with O 0 1.7839595329860458e-06
WT1 O 1 1.0
mutations O 0 0.00025363400345668197
underwent O 1 0.8428261876106262
normal O 0 1.34692227220512e-05
puberty O 0 7.025247032288462e-05
. O 0 1.0106032277690247e-06

Two O 0 6.21430729097483e-07
mutations O 0 2.9632948894686706e-07
associated O 0 8.9425626015327e-08
with O 0 1.6449231310389223e-08
IDMS B-Disease 1 0.9999997615814209
are O 0 5.630865107519867e-09
different O 0 2.8092892456754726e-09
from O 0 8.188032474265583e-09
those O 0 2.819316113900072e-09
described O 0 7.306994831424163e-08
in O 0 6.752054559910903e-08
DDS B-Disease 1 1.0
patients O 1 0.999833345413208
. O 0 1.0042057510872837e-05

No O 0 1.5294075637939386e-05
WT1 O 0 0.22105565667152405
mutations O 0 4.3657706783051253e-07
were O 0 4.586305735188034e-08
detected O 0 8.57298942946727e-08
in O 0 2.848526303722565e-09
the O 0 1.4730435538012898e-08
six O 0 6.224225046480569e-08
other O 0 9.508638498800792e-08
IDMS B-Disease 1 1.0
patients O 0 0.004228193312883377
, O 0 1.1988763759518406e-08
suggesting O 0 8.921897176605853e-08
genetic O 0 4.3421445639069134e-07
heterogeneity O 0 1.3205042250774568e-06
of O 0 2.434236705539661e-07
this O 0 9.026927472177704e-08
disease O 1 0.9999778270721436
. O 0 2.923758529504994e-06

We O 0 2.998567424583598e-06
analyzed O 0 1.5525350818279549e-06
genotype O 0 7.462229405064136e-06
/ O 0 2.402401605650084e-06
phenotype O 0 2.9443987159538665e-07
correlations O 0 1.278943955185241e-07
, O 0 4.5084180833043774e-09
on O 0 5.3316027148753165e-09
the O 0 1.1820100453974192e-09
basis O 0 6.368981786408767e-09
of O 0 8.473979740131199e-09
the O 0 6.326002832679478e-09
constitution O 0 2.3009973926235716e-09
of O 0 1.8185774663947996e-08
a O 0 6.516539485801331e-08
WT1 O 0 3.899394141626544e-05
mutation O 0 1.7569499632941188e-08
database O 0 1.1337751182338707e-08
of O 0 1.3233928619627022e-08
84 O 0 8.034106144805264e-07
germ O 1 1.0
- O 0 0.2963556945323944
line O 0 2.4101925646391464e-06
mutations O 0 5.890098631056162e-09
, O 0 6.06631966881821e-10
to O 0 3.34277439062447e-10
compare O 0 3.4586762343025157e-09
the O 0 1.6206068709223587e-09
distribution O 0 1.392934212418595e-09
and O 0 3.618360056023562e-10
type O 0 5.129376923207474e-09
of O 0 8.255857331107563e-09
mutations O 0 1.594727017106834e-09
, O 0 2.201450549632611e-10
according O 0 1.6250414902607702e-10
to O 0 7.725125539259636e-10
the O 0 3.4877447596670663e-09
different O 0 7.979888749787278e-09
symptoms O 0 6.992802082095295e-05
. O 0 2.9176753741921857e-06

This O 0 7.863797009122209e-07
demonstrated O 0 1.1668300885503413e-06
( O 0 6.465654678322608e-08
1 O 0 1.5159835697886592e-07
) O 0 4.3795709281369e-09
the O 0 1.5456661728308063e-08
association O 0 9.933557088004363e-09
between O 0 8.046542099293674e-09
mutations O 0 1.1596593907370334e-08
in O 0 9.41518685237952e-09
exons O 0 5.41443910151429e-07
8 O 0 1.360282908535737e-07
and O 0 1.4840928486137273e-08
9 O 0 1.868181840336547e-07
and O 0 7.105549570951553e-08
DMS B-Disease 1 0.9999994039535522
; O 0 3.933327263894171e-07
( O 0 1.0618826706831896e-07
2 O 0 9.653667802922428e-07
) O 0 2.9366955534015915e-09
among O 0 2.4151853850185034e-09
patients O 0 9.554921298615682e-09
with O 0 1.983712527575676e-09
DMS B-Disease 1 0.9830930233001709
, O 0 9.72837099766366e-09
a O 0 4.1859724575488144e-09
higher O 0 1.080301004208195e-08
frequency O 0 1.2564020934746623e-08
of O 0 5.307110306773666e-09
exon O 0 3.3883541306067855e-08
8 O 0 5.8056643936765795e-09
mutations O 0 1.0910601311309165e-09
among O 0 8.594788769578088e-10
46 O 0 4.209176296399164e-08
, O 0 1.409408234565035e-08
XY O 1 0.7957330346107483
patients O 0 1.4631598332925932e-06
with O 0 6.2619336382852e-09
female O 0 2.7266986890595035e-08
phenotype O 0 4.148284205029995e-08
than O 0 6.644553796064656e-10
among O 0 1.2113361425036828e-09
46 O 0 3.7140750919206766e-08
, O 0 1.0998948418716736e-08
XY O 1 0.7624644637107849
patients O 0 1.7359914750159078e-07
with O 0 8.546613972093553e-10
sexual O 0 2.955418576533475e-09
ambiguity O 0 4.297913491768668e-08
or O 0 2.3434196805283136e-09
male O 0 6.099606930654033e-10
phenotype O 0 1.2712405572656849e-09
; O 0 1.8866604112321994e-10
and O 0 8.442725962787279e-10
( O 0 1.6744471365015556e-09
3 O 0 2.774930862869951e-08
) O 0 5.077404607867209e-10
statistically O 0 2.977222079980635e-10
significant O 0 4.929626151728428e-10
evidence O 0 4.253773777662673e-09
that O 0 2.7568436422598097e-10
mutations O 0 2.321735248500545e-09
in O 0 5.425488502908138e-09
exons O 0 1.0748298109319876e-06
8 O 0 1.1815129852266182e-07
and O 0 2.3491223188898402e-08
9 O 0 5.007872516671341e-08
preferentially O 0 2.224082962243301e-08
affect O 0 2.930450992977285e-09
amino O 0 3.7256948637320875e-09
acids O 0 1.6952195203145948e-09
with O 0 1.1523446086236788e-10
different O 0 7.529007417517164e-10
functions O 0 9.53144141391249e-09
. O 0 1.8879617869060894e-08
. O 0 1.8702193926856125e-07

The O 0 9.529837370791938e-06
185delAG O 0 7.066123362164944e-05
BRCA1 O 0 1.049801198860223e-06
mutation O 0 2.3290635198236487e-08
originated O 0 2.0377243004077172e-08
before O 0 3.6146645676637945e-09
the O 0 1.307635000280527e-09
dispersion O 0 4.617905702275493e-08
of O 0 3.623750899350853e-08
Jews O 0 1.0909237602163557e-07
in O 0 3.192365038984235e-09
the O 0 3.942691062519543e-09
diaspora O 0 5.163113492301363e-09
and O 0 1.200683663604707e-09
is O 0 5.219589205296415e-10
not O 0 4.849646240145944e-10
limited O 0 1.1441831482272846e-08
to O 0 3.290908523467806e-08
Ashkenazim O 0 0.00016435273573733866
. O 0 2.2976144009589916e-06

The O 0 3.9642859519517515e-06
185delAG O 0 2.0234221665305085e-05
mutation O 0 3.363105349762918e-07
in O 0 1.4884101950940476e-08
BRCA1 O 0 9.25967995613064e-08
is O 0 1.2564878026921633e-09
detected O 0 1.0705945463485023e-08
in O 0 9.60458046428414e-10
Ashkenazi O 0 1.7899685644806596e-06
Jews O 0 8.477636725956472e-08
both O 0 2.655412112417821e-09
in O 0 4.7032382433087605e-09
familial B-Disease 1 0.9982327222824097
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.959344899660209e-06
in O 0 1.1339243322083803e-08
the O 0 2.015644362529656e-08
general O 0 1.1806694288907238e-07
population O 0 8.524915884322581e-09
. O 0 2.0730543326408224e-07

All O 0 5.778192075922561e-07
tested O 0 7.55421467601991e-07
Ashkenazi O 0 3.749297093236237e-06
mutation O 0 5.994849772150701e-08
carriers O 0 4.765002969975285e-08
share O 0 2.2906556651491883e-08
the O 0 8.707823795361946e-09
same O 0 1.3191765901865438e-08
allelic O 0 1.3453728797685471e-06
pattern O 0 5.279254082779516e-07
at O 0 1.943678427096529e-07
the O 0 7.362998388771302e-08
BRCA1 O 0 1.148496721725678e-06
locus O 0 1.7351054566461244e-06
. O 0 4.923504661746847e-07

Our O 0 5.280993264022982e-06
previous O 0 5.884626261831727e-07
study O 0 1.664747983909365e-08
showed O 0 3.1955449397713664e-09
that O 0 6.600139185186649e-11
this O 0 1.4036656559301974e-10
Ashkenazi O 0 9.017374509312504e-07
mutation O 0 8.987684374517357e-09
also O 0 9.550179536077508e-10
occurs O 0 1.2556443662603556e-09
in O 0 3.6274538928182665e-10
Iraqi O 0 1.957613093850341e-08
Jews O 0 9.970362313538317e-09
with O 0 5.203684705357148e-10
a O 0 2.3842310348243245e-09
similar O 0 1.5379702844597887e-08
allelic O 0 3.3692508623062167e-06
pattern O 0 2.537279442549334e-06
. O 0 8.117917218442017e-07

We O 0 2.3057800717651844e-06
extended O 0 1.386158828609041e-06
our O 0 1.065648405074171e-07
analysis O 0 8.164095177676245e-09
to O 0 3.1623244023393227e-09
other O 0 2.8321762712835152e-09
non O 0 1.0430456143240008e-07
- O 0 1.5292336286165664e-07
Ashkenazi O 0 1.8429053625368397e-06
subsets O 0 9.256430644200009e-08
354 O 0 2.9213895302859783e-08
of O 0 4.313679191625397e-09
Moroccan O 0 4.4386929687334487e-08
origin O 0 2.2682984379684967e-09
, O 0 2.7868209961923185e-09
200 O 0 6.192699686380365e-09
Yemenites O 0 1.0287600389347062e-06
and O 0 1.1049202441881789e-08
150 O 0 6.80342822079183e-08
Iranian O 0 6.545439532601449e-07
Jews O 0 1.2414825505402405e-06
. O 0 1.079767343981075e-06

Heteroduplex O 0 0.0001444467925466597
analysis O 0 4.5135050186217995e-07
complemented O 0 5.785062739960267e-07
by O 0 1.9094650305362393e-09
direct O 0 3.7733478563950484e-08
DNA O 0 1.3965880896193994e-07
sequencing O 0 2.483241985373752e-07
of O 0 6.268664520803213e-08
abnormally O 0 1.260773046851682e-06
migrating O 0 1.7958831222131266e-07
bands O 0 1.2853205078044994e-07
were O 0 3.9664978856990274e-08
employed O 0 6.074731686567247e-07
. O 0 9.643059684094624e-07

Four O 0 1.4601545217374223e-06
of O 0 4.4514874275591865e-07
Moroccan O 0 2.4072132873698138e-06
origin O 0 4.784948259839439e-08
( O 0 6.408303665494941e-09
1 O 0 3.8405335800462126e-08
. O 0 3.5950893373382087e-09
1 O 0 2.3312502150929504e-08
% O 0 1.6847113704088201e-09
) O 0 9.381374566075351e-10
and O 0 2.6175517309212637e-09
none O 0 6.376654226869505e-08
of O 0 6.402210317446588e-08
the O 0 1.3207102256274084e-07
Yemenites O 0 5.057855560153257e-06
or O 0 2.0594725924638624e-08
Iranians O 0 1.8342012353400605e-08
was O 0 6.5497829382366035e-09
a O 0 1.3058678582922312e-09
carrier O 0 7.855168959736147e-09
of O 0 5.901489963378026e-09
the O 0 5.807594405382588e-08
185delAG O 0 2.445545533191762e-06
mutation O 0 2.9126331924089754e-07
. O 0 3.858515356114367e-07

BRCA1 O 0 4.5787695853505284e-05
allelic O 0 9.931598469847813e-06
patterns O 0 2.0159332336788793e-07
were O 0 3.416518978838212e-08
determined O 0 1.880848721214079e-08
for O 0 3.539251336448501e-09
four O 0 4.687753296650499e-09
of O 0 5.908664668652364e-09
these O 0 4.62002408552209e-10
individuals O 0 1.3896747641517493e-10
and O 0 1.2673668781104652e-09
for O 0 1.830635310007267e-09
12 O 0 1.1697649959785394e-08
additional O 0 1.1296694246709649e-08
non O 0 1.7150566122836608e-07
- O 0 1.4457505415066407e-07
Ashkenazi O 0 4.5528807390837756e-07
185delAG O 0 7.938857748968076e-08
mutation O 0 9.892578978210054e-10
carriers O 0 3.1641163023010677e-09
who O 0 4.816076870639563e-09
had O 0 2.826226364049944e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.274691936094314e-05

Six O 0 1.0882436981773935e-05
non O 0 7.293861017387826e-06
- O 0 2.0062909698026488e-06
Ashkenazi O 0 1.1518972087287693e-06
individuals O 0 1.3620016225956988e-09
shared O 0 1.3437641221969443e-08
the O 0 2.9756794805990694e-09
common O 0 2.6041375278396117e-08
Ashkenazi O 0 4.396104031911818e-06
haplotype O 0 2.176113866880769e-06
, O 0 6.3433165387039026e-09
four O 0 5.3424340507035595e-09
had O 0 1.3805327547800061e-08
a O 0 2.1330079924553047e-09
closely O 0 3.2123625981483883e-09
related O 0 9.360770825139753e-09
pattern O 0 1.084562697428737e-07
, O 0 1.3003408128042793e-08
and O 0 1.659840087597786e-08
the O 0 1.265071460920808e-07
rest O 0 6.555522418238979e-07
( O 0 1.7685561459757082e-08
n O 0 8.075558355358226e-08
= O 0 6.79805864933769e-08
6 O 0 3.479049581756044e-08
) O 0 2.0778980758251464e-09
displayed O 0 1.3654747554880942e-08
a O 0 2.288699008090589e-08
distinct O 0 1.496847943371904e-07
BRCA1 O 0 1.3731541912420653e-06
allelic O 0 3.2875386750674807e-06
pattern O 0 2.7208805022382876e-06
. O 0 1.374059252157167e-06

We O 0 1.2670276419157744e-06
conclude O 0 7.540640467595949e-07
that O 0 8.346979107898278e-09
the O 0 2.7542919056600113e-08
185delAG O 0 3.08054427478055e-06
BRCA1 O 0 1.9143239171626192e-07
mutation O 0 7.792999134892398e-09
occurs O 0 3.061547459992653e-09
in O 0 5.350588860864036e-10
some O 0 7.424874048922447e-10
non O 0 4.8016421061447545e-08
- O 0 1.66568256076971e-07
Ashkenazi O 0 1.1709702221196494e-06
populations O 0 2.831274104053705e-09
at O 0 2.197009685289686e-09
rates O 0 1.0519894955152154e-09
comparable O 0 5.177817286039499e-09
with O 0 3.636570489184976e-10
that O 0 1.8105367205478728e-09
of O 0 5.196162646825542e-07
Ashkenazim O 0 0.04416251927614212
. O 0 4.01151601181482e-06

The O 0 1.2371048114800942e-06
majority O 0 8.784430605146554e-08
of O 0 8.361499936881955e-08
Jewish O 0 1.6278825398785557e-07
185delAG O 0 4.099534010038042e-07
mutation O 0 1.2558869499912362e-08
carriers O 0 6.284368136988405e-09
have O 0 5.057552709963886e-10
a O 0 4.387782137627028e-09
common O 0 2.4621595429152876e-08
allelic O 0 7.12790551915532e-07
pattern O 0 1.7580786959570105e-07
, O 0 3.3719635972317974e-09
supporting O 0 1.1331395377567333e-08
the O 0 5.3882622808032465e-08
founder O 0 2.726545062614605e-05
effect O 0 1.565032015093948e-08
notion O 0 1.186408837838826e-07
, O 0 7.752713471198547e-10
but O 0 2.481401750742407e-10
dating O 0 2.8384927741598176e-09
the O 0 4.6253759156122953e-10
mutations O 0 1.5996462487954943e-10
origin O 0 2.580874680635503e-10
to O 0 4.256969499127905e-10
an O 0 3.7270436736847046e-10
earlier O 0 1.3018944144960187e-08
date O 0 1.0433818431465625e-07
than O 0 8.809931451025932e-09
currently O 0 9.256762467657609e-09
estimated O 0 1.210826194864012e-08
. O 0 2.1668786587270006e-07

However O 0 1.9436706679698545e-06
, O 0 1.1517254705495361e-07
the O 0 2.9817030622325547e-08
different O 0 1.1958526613398135e-08
allelic O 0 1.6691951714165043e-06
pattern O 0 6.953808906473569e-07
at O 0 3.1832556146582647e-07
the O 0 6.608273395158903e-08
BRCA1 O 0 5.043806368121295e-07
locus O 0 1.2150591999215976e-07
even O 0 3.758441557977221e-09
in O 0 2.98542190968476e-10
some O 0 1.228094848038097e-10
Jewish O 0 2.2770243468528406e-09
mutation O 0 8.765275727462551e-10
carriers O 0 3.2256244342221407e-09
, O 0 5.643290834633774e-10
might O 0 2.537690724224717e-09
suggest O 0 4.363795103046186e-09
that O 0 9.195694206098892e-10
the O 0 4.7231418776050305e-09
mutation O 0 6.603470659172217e-09
arose O 0 3.4435185369829924e-08
independently O 0 2.1791983328967035e-08
. O 0 1.6366268340561874e-08
. O 0 3.2332337696061586e-07

Crystal O 0 0.0005768528208136559
structure O 0 1.8699958673096262e-05
of O 0 2.3178148694569245e-05
the O 0 0.00011143684241687879
hemochromatosis B-Disease 1 1.0
protein O 0 0.0006622421205975115
HFE O 1 0.9999864101409912
and O 0 6.79730618458052e-08
characterization O 0 1.1272156825725688e-06
of O 0 7.39666816684803e-08
its O 0 1.8905344845165928e-08
interaction O 0 1.4177669527271064e-07
with O 0 3.372750256858126e-08
transferrin O 0 0.0003939691814593971
receptor O 0 4.617272225004854e-06
. O 0 4.2628241203601647e-07

HFE O 1 0.9981052875518799
is O 0 1.4355222219819552e-06
an O 0 9.342669216039212e-08
MHC O 0 0.011611320078372955
- O 0 2.5527484467602335e-05
related O 0 4.179432835371699e-07
protein O 0 4.728227764871917e-08
that O 0 2.759416029007866e-10
is O 0 4.3718154096872297e-10
mutated O 0 1.77522068156577e-08
in O 0 2.4543609367100316e-09
the O 0 1.2341054400621942e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.36078354716300964

HFE O 1 0.766090452671051
binds O 0 1.9678725948324427e-05
to O 0 1.235179752256954e-06
transferrin O 0 0.00043864938197657466
receptor O 0 2.133702537321369e-06
( O 0 3.104167234369015e-08
TfR O 0 7.89052683103364e-06
) O 0 9.363610331547534e-09
and O 0 5.0403747842153734e-09
reduces O 0 1.0773033665145704e-07
its O 0 1.6093860466526166e-08
affinity O 0 8.383185701177354e-08
for O 0 2.843002100405556e-08
iron O 0 0.00028011910035274923
- O 0 1.1355018614267465e-06
loaded O 0 9.117161994254275e-07
transferrin O 0 2.2821075617684983e-05
, O 0 6.024974652518722e-08
implicating O 0 3.059072696487419e-05
HFE O 1 1.0
in O 0 2.264877548441291e-05
iron O 1 0.9999998807907104
metabolism O 0 0.00047658628318458796
. O 0 2.2151727989694336e-06

The O 0 4.719182470580563e-05
2 O 0 8.73952594702132e-05
. O 0 1.5215629900922067e-05

6 O 0 5.5327502195723355e-05
A O 0 1.228741166414693e-05
crystal O 0 6.715305789839476e-05
structure O 0 1.191564297187142e-05
of O 0 1.0380564162915107e-05
HFE O 1 1.0
reveals O 0 3.846376330329804e-06
the O 0 2.5302201223098564e-08
locations O 0 5.969929617322123e-08
of O 0 4.357650880137953e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 1.002815224637743e-06
and O 0 3.840372286845195e-08
a O 0 1.001893963348266e-07
patch O 1 0.9889435768127441
of O 0 9.04159969650209e-05
histidines O 1 0.999495267868042
that O 0 6.35531849368931e-09
could O 0 1.078032685342123e-08
be O 0 1.500435220513907e-09
involved O 0 3.57937324224622e-09
in O 0 2.9259774603218602e-09
pH O 0 2.5011436264321674e-06
- O 0 1.7900881630339427e-06
dependent O 0 1.4645249279965356e-07
interactions O 0 8.704041931650863e-08
. O 0 2.543478672123456e-07

We O 0 3.539588306011865e-06
also O 0 1.5973267863955698e-07
demonstrate O 0 1.7984231703849218e-07
that O 0 8.567003106918492e-09
soluble O 0 1.2363933819869999e-05
TfR O 0 0.0509793758392334
and O 0 3.6176223261463747e-07
HFE O 1 0.9950864911079407
bind O 0 5.818048975925194e-07
tightly O 0 2.1454953014199418e-07
at O 0 8.517049288059297e-09
the O 0 1.0579920273201537e-09
basic O 0 2.0825014601655312e-08
pH O 0 6.36441797041698e-08
of O 0 2.1542783557038092e-08
the O 0 6.998294388438353e-09
cell O 0 9.018081925660226e-08
surface O 0 8.780808080643965e-09
, O 0 2.413254596156378e-10
but O 0 1.7105686311857937e-10
not O 0 2.762043649351398e-10
at O 0 4.0305887516467465e-09
the O 0 3.691205785472107e-09
acidic O 0 5.150192237124429e-07
pH O 0 1.0654822517608409e-06
of O 0 5.473605142469751e-07
intracellular O 0 3.063634039790486e-06
vesicles O 0 6.035721980879316e-06
. O 0 3.495922840102139e-07

TfR O 0 0.015131565742194653
HFE O 0 0.0329827181994915
stoichiometry O 0 9.964142373064533e-05
( O 0 1.0891175179494894e-06
2 O 0 1.3510264125216054e-06
1 O 0 3.432594439800596e-07
) O 0 8.910176596543806e-09
differs O 0 1.051723614864386e-07
from O 0 3.394622183350293e-08
TfR O 0 2.000804670387879e-05
transferrin O 0 1.7552405552123673e-05
stoichiometry O 0 9.091930337490339e-07
( O 0 2.382413732959776e-08
2 O 0 6.987400524849363e-08
2 O 0 3.10115488844076e-08
) O 0 5.013142678755855e-10
, O 0 5.423375082358461e-10
implying O 0 2.4434916312543464e-09
a O 0 8.099306225695102e-10
different O 0 2.1547198747473573e-10
mode O 0 8.984650357035662e-09
of O 0 1.3964109868425112e-09
binding O 0 2.426710832281742e-09
for O 0 3.1622036100742434e-09
HFE O 0 0.0032952604815363884
and O 0 9.286156910093268e-08
transferrin O 0 1.24236466945149e-05
to O 0 1.866471777134393e-08
TfR O 0 1.620577859284822e-05
, O 0 7.663272683089417e-09
consistent O 0 3.017552430151227e-08
with O 0 2.877336147122378e-09
our O 0 4.482610904688045e-08
demonstration O 0 5.0868127488001846e-08
that O 0 1.2822867212491929e-09
HFE O 0 0.0007906846003606915
, O 0 2.1447217335435198e-08
transferrin O 0 7.705009920755401e-06
, O 0 1.1783370723605913e-08
and O 0 1.029686735876112e-08
TfR O 0 8.645271918794606e-06
form O 0 6.75742768407872e-08
a O 0 2.389500082244922e-07
ternary O 0 1.708743911876809e-05
complex O 0 4.956778138875961e-05
. O 0 3.2301195460604504e-06

Identification O 0 2.9096004254824948e-06
of O 0 7.76101899191417e-07
three O 0 6.111257278007542e-08
novel O 0 1.279295389622348e-07
mutations O 0 8.099882542467185e-09
and O 0 2.6847359890780353e-09
a O 0 3.3593046122604164e-09
high O 0 4.656362051491669e-08
frequency O 0 2.7372189848051676e-08
of O 0 6.5743765986781e-09
the O 0 8.318466804269065e-09
Arg778Leu O 0 1.914975200634217e-06
mutation O 0 5.339520381397733e-09
in O 0 2.574165325341937e-09
Korean O 0 1.5488084272874403e-06
patients O 0 3.0634648595651015e-08
with O 0 7.225265719057461e-09
Wilson B-Disease 0 2.61720906564733e-05
disease I-Disease 1 0.6304872035980225
. O 0 5.037185928813415e-06

Four O 0 6.185469828778878e-06
mutations O 0 1.2731626384265837e-06
- O 0 2.935660859293421e-06
- O 0 3.060217522943276e-06
R778L O 0 1.3992551430419553e-05
, O 0 8.749415769671032e-08
A874V O 0 2.2839756184112048e-06
, O 0 2.3164815843301767e-08
L1083F O 0 8.318675099872053e-07
, O 0 6.2797913535916905e-09
and O 0 1.246776903940372e-08
2304delC O 0 1.9539556888048537e-06
- O 0 8.445180128546781e-07
- O 0 4.021319170988136e-07
in O 0 4.6324948321796455e-09
the O 0 1.326660648004463e-08
copper O 0 4.5248918922879966e-07
- O 0 6.21804261413672e-08
transporting O 0 4.0967503167621544e-08
enzyme O 0 8.36984082042136e-09
, O 0 3.410969506845163e-09
P O 0 7.392999918920395e-07
- O 0 2.9800838774463045e-07
type O 0 1.0189130534854485e-06
ATPase O 0 7.972283242452249e-07
( O 0 8.58036308670762e-09
ATP7B O 0 4.497513600654202e-06
) O 0 9.80971859299018e-10
, O 0 2.4133836595829905e-10
were O 0 1.0039666875627518e-09
identified O 0 2.159699530324133e-09
in O 0 1.1316960701890366e-09
Korean O 0 1.191390310850693e-06
Patients O 0 2.2193667348346935e-08
with O 0 3.898972700255854e-09
Wilson B-Disease 0 8.226753379858565e-06
disease I-Disease 0 0.13203133642673492
. O 0 2.5741283025126904e-06

Arg778Leu O 0 0.03322608396410942
, O 0 5.698078666682704e-07
the O 0 9.290248925708511e-08
most O 0 1.2393817527822648e-08
frequently O 0 4.975480027979984e-09
reported O 0 8.181238464466389e-10
mutation O 0 4.831162692120472e-10
of O 0 1.8205791318948172e-09
this O 0 5.603690844679932e-10
enzyme O 0 1.2021324380384613e-08
, O 0 2.874516402684435e-09
was O 0 1.2823949901985543e-08
found O 0 6.436536303944251e-10
in O 0 2.0043786075341075e-10
six O 0 2.1326258536902287e-09
of O 0 8.882721225234036e-09
eight O 0 2.0081383667047703e-08
unrelated O 0 3.349542865294097e-08
patients O 0 8.990564737132445e-09
studied O 0 1.1549466272242626e-08
, O 0 3.1176627945939117e-10
an O 0 1.6141615821751998e-10
allele O 0 3.0824478525204313e-09
frequency O 0 1.914403569003298e-08
of O 0 5.646645462320521e-08
37 O 0 9.430742693439242e-07
. O 0 1.453610366297653e-06

5 O 0 2.275845872645732e-06
% O 0 8.411936391894415e-08
, O 0 1.0116522730641009e-08
which O 0 2.1553623330561322e-09
is O 0 1.7212781200370841e-09
considerably O 0 9.117547250525604e-08
higher O 0 4.308755663373631e-08
than O 0 7.807708923834866e-10
those O 0 8.051895816763022e-10
in O 0 8.815036478537763e-10
other O 0 2.7150566239697582e-09
Asian O 0 3.493918754315928e-08
populations O 0 1.5957411392264476e-08
. O 0 5.601281927170021e-08

The O 0 3.1036281598062487e-06
novel O 0 1.976840849238215e-06
single O 0 1.0992953747290812e-07
nucleotide O 0 1.4225587108285254e-07
deletion O 0 4.939363051903456e-08
, O 0 2.3637147794630664e-09
2304delC O 0 2.854040417332726e-07
, O 0 6.167956367875149e-09
was O 0 6.748230418907042e-08
found O 0 5.678493231187076e-09
in O 0 4.999939129390896e-09
one O 0 2.5023929595135996e-08
patient O 0 1.6265926205960568e-06
. O 0 1.9863048237311887e-06

Since O 0 1.7988570562010864e-06
a O 0 2.4065354864433175e-07
mutation O 0 1.306292460867553e-07
at O 0 1.6359877008653712e-07
cDNA O 0 1.0112993322763941e-06
nucleotide O 0 7.305969802473555e-07
2302 O 0 3.452427336014807e-05
( O 0 2.1287577922635137e-08
2302insC O 0 6.16460738456226e-07
) O 0 4.803856867852119e-09
had O 0 5.314454654126166e-09
been O 0 1.7207333335989006e-09
previously O 0 3.0174935883309217e-09
described O 0 1.8961454628652064e-09
, O 0 1.759214995900038e-10
this O 0 9.637166065168401e-11
region O 0 5.590061746829633e-09
of O 0 2.6399703756396775e-08
the O 0 3.881064571942261e-07
ATP7B O 1 1.0
gene O 0 8.729879397151308e-08
may O 0 3.482945043487007e-09
be O 0 7.447567562657298e-10
susceptible O 0 6.007458637213858e-07
to O 0 1.5451121271325974e-08
gene O 0 1.9405367766012205e-06
rearrangements O 0 0.006591063924133778
causing O 0 0.0004754956462420523
Wilson B-Disease 0 0.21697556972503662
disease I-Disease 1 0.9997513890266418
. O 0 5.872321708011441e-06

Disruption O 0 0.0004129736335016787
of O 0 7.677893336222041e-06
splicing O 0 1.0714284144341946e-05
regulated O 0 2.7829295845549495e-07
by O 0 1.1755916240474562e-08
a O 0 7.724145945076089e-08
CUG O 0 0.00571786891669035
- O 0 2.672552909643855e-06
binding O 0 2.7717391049009166e-07
protein O 0 1.120779870689148e-06
in O 0 2.7610886377260613e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0008245092467404902

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8818442821502686
DM B-Disease 1 1.0
) O 0 1.351914420411049e-06
is O 0 1.290689155553082e-08
caused O 0 3.444516849526735e-08
by O 0 1.9425334674139094e-09
a O 0 3.944303017533457e-08
CTG O 0 2.4997914806590416e-05
expansion O 0 3.213431227777619e-07
in O 0 7.529125767291589e-09
the O 0 1.1039237968191173e-08
3 O 0 5.0290839936906195e-08
untranslated O 0 0.000115989227197133
region O 0 6.387585926859174e-08
of O 0 6.286456510906646e-08
the O 0 1.1019548082913388e-06
DM B-Disease 1 1.0
gene O 0 1.3655805560119916e-05
. O 0 1.343503754469566e-06

One O 0 1.0118917543877615e-06
model O 0 5.381882601795951e-07
of O 0 2.4913549623306608e-06
DM B-Disease 1 1.0
pathogenesis O 1 1.0
suggests O 0 1.991866838579881e-06
that O 0 7.733886420169256e-09
RNAs O 0 4.5890621436228685e-07
from O 0 3.308851415084746e-09
the O 0 3.4316687269608792e-09
expanded O 0 1.0047201293161834e-08
allele O 0 5.882834219761435e-09
create O 0 4.570340550458241e-09
a O 0 7.382992439630698e-09
gain O 0 7.91200989169738e-08
- O 0 1.1747335548761839e-07
of O 0 2.8229443671534682e-08
- O 0 4.1951743412482756e-08
function O 0 2.6581573053796603e-10
mutation O 0 1.0077879503134213e-10
by O 0 1.944132875519866e-11
the O 0 3.7620542792105027e-10
inappropriate O 0 2.9325870620766636e-09
binding O 0 1.8233871079686992e-09
of O 0 3.5801925868383933e-09
proteins O 0 1.0563466767976593e-09
to O 0 2.9958164837751156e-09
the O 0 1.0286016305371959e-07
CUG O 1 0.9869763255119324
repeats O 0 3.663821189547889e-05
. O 0 1.7762048400982167e-06

Data O 0 5.7074125834333245e-06
presented O 0 1.7504142988400417e-06
here O 0 1.3642517160405987e-07
indicate O 0 3.7819219755874656e-08
that O 0 3.215298916003917e-09
the O 0 2.76055054371227e-08
conserved O 0 2.1258227889120462e-07
heterogeneous O 0 1.7725059251461062e-06
nuclear O 0 0.00023656374833080918
ribonucleoprotein O 0 0.00022458398598246276
, O 0 4.220222038497923e-08
CUG O 0 8.642354077892378e-05
- O 0 3.694962629197107e-07
binding O 0 3.173467888473169e-08
protein O 0 3.7798667307242795e-08
( O 0 4.950546195203742e-09
CUG O 0 0.0002945376036223024
- O 0 1.641603034840955e-06
BP O 0 9.99219082586933e-06
) O 0 5.848275197450903e-09
, O 0 5.48273515477149e-09
may O 0 2.1332695609999064e-08
mediate O 0 1.7605445918889018e-06
the O 0 6.008025934534089e-07
trans O 0 8.656351383251604e-06
- O 0 3.284768126832205e-06
dominant O 0 4.061893719153886e-07
effect O 0 2.549029076703846e-08
of O 0 3.073836651878992e-08
the O 0 5.897577182167879e-08
RNA O 0 3.8348061934811994e-06
. O 0 1.1449979098188123e-07

CUG O 1 0.9999979734420776
- O 1 0.8870903253555298
BP O 0 0.001462770625948906
was O 0 7.18841533853265e-07
found O 0 4.397987307669382e-09
to O 0 1.2098698709550604e-09
bind O 0 6.753906767187345e-09
to O 0 3.997781217179863e-09
the O 0 2.873399829184109e-08
human O 0 2.313807044629357e-06
cardiac O 1 1.0
troponin O 1 0.9999998807907104
T O 1 0.8347301483154297
( O 0 8.74990035981682e-08
cTNT O 0 1.3070093700662255e-06
) O 0 4.705714928832094e-09
pre O 0 1.122519165619451e-06
- O 0 4.6189055069589813e-07
messenger O 0 2.2932901799777028e-07
RNA O 0 2.0297535741065076e-07
and O 0 1.4294114780710743e-09
regulate O 0 7.2243016013828765e-09
its O 0 2.787480246624341e-09
alternative O 0 5.144228225617553e-07
splicing O 0 5.233659067016561e-06
. O 0 3.3918010444722313e-07

Splicing O 0 5.7020959502551705e-05
of O 0 4.350793005869491e-06
cTNT O 0 0.00090269825886935
was O 0 1.2711590898106806e-05
disrupted O 0 5.6490713177481666e-05
in O 0 8.940327234085998e-07
DM B-Disease 1 1.0
striated O 1 0.9999983310699463
muscle O 0 0.007905137725174427
and O 0 2.2158818069328845e-07
in O 0 7.777777533135577e-09
normal O 0 7.110009647703919e-08
cells O 0 6.580238220976753e-08
expressing O 0 2.9070154283772354e-08
transcripts O 0 6.860346957182628e-08
that O 0 1.4945485959927396e-09
contain O 0 1.5957721188897267e-07
CUG O 0 0.3352104127407074
repeats O 0 1.402806447003968e-05
. O 0 1.2092589258827502e-06

Altered O 0 2.5801995434449054e-05
expression O 0 2.9632035420945613e-06
of O 0 8.589533990743803e-07
genes O 0 3.977627898166247e-07
regulated O 0 2.420384248580376e-07
posttranscriptionally O 0 3.217980520275887e-06
by O 0 1.8427291692546532e-08
CUG O 1 0.9999997615814209
- O 0 0.26888391375541687
BP O 0 0.00032507642754353583
therefore O 0 2.5167434358763785e-08
may O 0 6.203291658124499e-09
contribute O 0 8.885873370445552e-09
to O 0 4.740336834174741e-08
DM B-Disease 1 1.0
pathogenesis O 1 1.0
. O 0 1.0901910627580946e-06
. O 0 9.59998942562379e-07

Identification O 0 2.1741038835898507e-06
of O 0 4.957248620485188e-07
a O 0 1.4239377321700886e-07
novel O 0 3.895853240010183e-07
nonsense O 0 7.336068961194542e-07
mutation O 0 2.0167210124100166e-08
and O 0 2.2443105152092357e-09
a O 0 2.5463939845593586e-09
missense O 0 6.754708437028967e-08
substitution O 0 1.0851668719169538e-07
in O 0 1.3034596513250563e-08
the O 0 3.301451911852382e-08
vasopressin O 0 2.5292320060543716e-06
- O 0 4.587276976053545e-07
neurophysin O 0 6.533953182952246e-06
II O 1 0.9999984502792358
gene O 0 2.5288017013735953e-08
in O 0 1.9399528650154707e-09
two O 0 1.555478301717983e-09
Spanish O 0 1.0337881661826032e-07
kindreds O 0 1.5163477655733004e-06
with O 0 1.7935171570115926e-08
familial B-Disease 1 0.7803765535354614
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 7.278572593349963e-05

Familial B-Disease 1 0.9999994039535522
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.8754871487617493
FNDI B-Disease 1 1.0
) O 0 4.900111889583059e-07
is O 0 1.3493116846063913e-08
an O 0 4.441654599673939e-09
autosomal B-Disease 1 0.999028205871582
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.045307327061891556
by O 0 1.7334684798697708e-07
deficiency O 1 1.0
in O 0 1.0741867129127058e-07
the O 0 1.3534017853089608e-06
antidiuretic O 0 0.00017418571223970503
hormone O 0 1.3853210703018703e-06
arginine O 0 5.743108886235859e-07
vasopressin O 0 1.5598784557369072e-06
( O 0 2.3289391748448907e-08
AVP O 0 3.001666300406214e-06
) O 0 1.4864037778394845e-09
encoded O 0 1.4245802315571154e-09
by O 0 6.937581620292121e-10
the O 0 4.7754479481909584e-08
AVP O 0 6.293017941061407e-05
- O 0 2.3635752768313978e-06
neurophysin O 0 0.00047995991189964116
II O 1 1.0
( O 0 3.781197392527247e-06
AVP O 0 0.07373645156621933
- O 0 5.643324584525544e-06
NPII O 0 9.898826101562008e-05
) O 0 2.0533265754352215e-08
gene O 0 2.412737032386758e-08
on O 0 7.194149276301687e-08
chromosome O 0 4.5701989392910036e-07
20p13 O 0 1.949626130226534e-05
. O 0 2.6501468255446525e-06

In O 0 4.029280944450875e-07
this O 0 5.172851924584165e-09
study O 0 5.0997890355120035e-09
, O 0 1.0799832139696264e-09
we O 0 6.147224396180206e-10
analyzed O 0 2.1526425086904055e-09
two O 0 3.9454878253408765e-10
families O 0 8.255160999226518e-10
with O 0 1.94830707123117e-09
FNDI B-Disease 1 1.0
using O 0 7.27795281818544e-08
direct O 0 8.957704977774483e-08
automated O 0 2.7934328272749553e-07
fluorescent O 0 8.787162641965551e-08
, O 0 2.697398526763095e-09
solid O 0 6.491789861229336e-08
phase O 0 5.158145768291433e-07
, O 0 9.555778390790692e-09
single O 0 1.5674995523795587e-08
- O 0 3.8468897400889546e-08
stranded O 0 3.740635534654757e-08
DNA O 0 5.5402367138412956e-09
sequencing O 0 6.625523685244161e-09
of O 0 4.091500915848201e-09
PCR O 0 2.5303852453362197e-06
- O 0 5.176672857487574e-06
amplified O 0 1.9212997358408757e-05
AVP O 0 0.001790264854207635
- O 0 1.0778686373669188e-05
NPII O 0 0.0003502996114548296
DNA O 0 5.423165475804126e-06
. O 0 4.113695410978835e-07

In O 0 9.748953289090423e-07
one O 0 4.8702293753422055e-08
of O 0 5.472614006407639e-08
the O 0 2.2435884261540195e-08
families O 0 6.257575790868941e-09
, O 0 1.0931514582424029e-09
affected O 0 1.00531194480169e-09
individuals O 0 3.306666607194586e-10
presented O 0 2.1607926115052578e-08
a O 0 1.4012329074830632e-08
novel O 0 4.543650433674884e-08
nonsense O 0 1.127065729633614e-07
mutation O 0 4.993877311676442e-09
in O 0 1.053071518875015e-09
exon O 0 2.1769093194734523e-08
3 O 0 3.6399030456379933e-09
of O 0 2.1554362739095723e-09
the O 0 2.5162909533804623e-09
gene O 0 1.8133878842974127e-09
, O 0 3.7217867676631045e-10
consisting O 0 2.3341144572697203e-09
in O 0 2.2162351953625148e-09
a O 0 1.3600604198416022e-08
G O 0 1.408621415066591e-06
to O 0 3.581239127470326e-08
T O 0 1.221735237777466e-05
transition O 0 2.021347881964175e-06
at O 0 6.394131446540996e-08
nucleotide O 0 4.1509750303703186e-08
2101 O 0 2.6674703690332535e-07
, O 0 2.1953412698838548e-10
which O 0 8.259219697048792e-11
produces O 0 4.888689453252937e-10
a O 0 1.561298312857673e-09
stop O 0 9.02191565899102e-09
signal O 0 2.4652663910273986e-07
in O 0 1.0918267179249597e-08
codon O 0 7.577593663654625e-08
82 O 0 5.900614610254706e-07
( O 0 1.063786214672291e-07
Glu O 0 0.00016981149383354932
) O 0 6.781689165791249e-08
of O 0 5.140859116181673e-07
NPII O 1 0.9993680119514465
. O 0 5.366054665500997e-06

The O 0 6.454777576436754e-06
premature O 0 1.1954080036957748e-05
termination O 0 2.0641289665945806e-05
eliminates O 0 3.907726295437897e-06
part O 0 7.107189503585687e-08
of O 0 2.6380828188621308e-08
the O 0 1.5739857417429448e-08
C O 0 5.0884905249404255e-06
- O 0 5.13185568706831e-07
terminal O 0 4.3437179897409806e-07
domain O 0 6.576496236476714e-09
of O 0 2.7939475177873874e-09
NPII O 0 6.0075149121985305e-06
, O 0 1.6322989626615936e-09
including O 0 5.779896006252727e-10
a O 0 2.648199659560646e-09
cysteine O 0 1.6574956518411454e-08
residue O 0 3.681279991951669e-08
in O 0 9.69642921511138e-10
position O 0 9.874712603163971e-09
85 O 0 2.850516978014639e-08
, O 0 1.8257325651305223e-09
which O 0 3.8395775447952474e-10
could O 0 2.1429746865919697e-09
be O 0 7.679407665328597e-10
involved O 0 1.5989423118867307e-09
in O 0 1.2510401603549326e-09
the O 0 5.772868849618362e-09
correct O 0 1.4373782164511795e-07
folding O 0 5.942295615568582e-07
of O 0 1.503378541656275e-07
the O 0 8.952347343438305e-07
prohormone O 0 0.4233666956424713
. O 0 9.110712198889814e-06

In O 0 2.0233615032339003e-06
the O 0 5.910358140681637e-07
second O 0 1.3350471590456436e-06
family O 0 2.3362720469322085e-07
, O 0 9.08269104371584e-09
a O 0 1.297684804058008e-08
G279A O 0 3.421841370254697e-07
substitution O 0 1.943550387295545e-07
at O 0 9.144978463382358e-08
position O 0 1.455666165384173e-07
- O 0 8.073741497582887e-08
1 O 0 2.0680852585996945e-08
of O 0 6.054255763388028e-09
the O 0 6.115977946308249e-09
signal O 0 2.4267683329526335e-07
peptide O 0 2.3635671198007913e-08
was O 0 7.478945462935371e-09
observed O 0 1.3133113485608305e-09
in O 0 4.3000897287370776e-10
all O 0 4.002791986756904e-10
affected O 0 6.181960277018561e-09
individuals O 0 3.582227847687136e-09
. O 0 1.9076901480730157e-07

This O 0 6.436653166019823e-07
missense O 0 5.105317995912628e-06
mutation O 0 1.0234411007559174e-07
, O 0 1.931708837332735e-08
which O 0 1.0776400216627735e-08
replaces O 0 0.00019689550390467048
Ala O 0 0.21902865171432495
with O 0 2.255710107590403e-08
Thr O 0 0.036236222833395004
, O 0 6.660367368738207e-09
is O 0 1.0371843384149315e-09
frequent O 0 1.753247502733757e-08
among O 0 7.805645907410508e-08
FNDI B-Disease 1 1.0
patients O 0 0.2755275368690491
and O 0 8.710851062687652e-08
is O 0 6.950538367078707e-09
thought O 0 1.6416823456211205e-08
to O 0 1.4445928897544036e-09
reduce O 0 1.2297039830855283e-08
the O 0 9.938426970279579e-09
efficiency O 0 2.69510707084919e-07
of O 0 2.176996538594267e-08
cleavage O 0 1.4322155550416937e-07
by O 0 4.014354182402258e-09
signal O 0 1.4285993756857351e-06
peptidases O 0 6.508082151412964e-06
. O 0 6.327646673298659e-08
. O 0 4.047069239732082e-07

Genetic O 0 3.6650024412665516e-05
heterogeneity O 0 7.032498251646757e-05
of O 0 6.219824717845768e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.2305540404186104e-08
due O 0 5.010567178942438e-07
to O 0 4.8270784702708625e-08
TWIST O 1 0.8335477113723755
and O 0 1.9481542494759196e-06
FGFR O 1 0.9999961853027344
mutations O 0 8.35518858366413e-06
. O 0 1.6802664504211862e-06

Thirty O 0 9.787906310521066e-05
- O 0 1.2481740668590646e-05
two O 0 2.4583210134210276e-08
unrelated O 0 7.483615149794787e-08
patients O 0 8.684039265460797e-09
with O 0 4.903294437141881e-10
features O 0 2.9814131607963645e-08
of O 0 1.3584890439233277e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.6196319275205724e-09
a O 0 2.540208932089172e-09
common O 0 9.540062819723971e-07
autosomal B-Disease 0 6.900854350533336e-05
dominant I-Disease 0 0.016753805801272392
condition I-Disease 0 0.22848118841648102
of O 0 0.044219620525836945
craniosynostosis B-Disease 1 1.0
and O 0 0.031044503673911095
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9920992851257324
, O 0 2.291652521080323e-07
were O 0 1.3190928882522712e-07
screened O 0 3.7176263845140056e-07
for O 0 1.146299855037114e-08
mutations O 0 2.0376699438884316e-08
in O 0 1.2645233304908743e-08
TWIST O 0 0.01958550699055195
, O 0 3.4945060178870335e-07
FGFR2 O 1 0.999946117401123
, O 0 1.7392012807704305e-07
and O 0 5.217106604504806e-07
FGFR3 O 1 0.9999741315841675
. O 0 6.100000973674469e-06

Nine O 0 6.232817668205826e-06
novel O 0 1.5797565993125318e-06
and O 0 7.092428688793007e-08
three O 0 5.8199251640189686e-08
recurrent O 0 5.356621477403678e-05
TWIST O 1 0.5510328412055969
mutations O 0 2.535467444886308e-07
were O 0 2.949282063013925e-08
found O 0 1.133385918450358e-08
in O 0 7.458318407316256e-09
12 O 0 1.4351125798839348e-07
families O 0 2.2615157035943412e-07
. O 0 6.762416546735039e-07

Seven O 0 5.49679180039675e-06
families O 0 7.173445482067109e-08
were O 0 2.009525523760658e-08
found O 0 4.504756123679954e-09
to O 0 1.343194555580851e-09
have O 0 2.227898754370017e-09
the O 0 2.734516080238336e-08
FGFR3 O 1 0.9655189514160156
P250R O 0 3.2404989269707585e-06
mutation O 0 8.467210044216245e-09
, O 0 1.4128633818444314e-09
and O 0 1.462826193510125e-09
one O 0 8.054031330750888e-10
individual O 0 5.022139371035905e-10
was O 0 3.025552075541782e-08
found O 0 2.3449131525410394e-09
to O 0 1.4238250578557654e-09
have O 0 3.3043228153673e-09
an O 0 1.046041564478628e-08
FGFR2 O 0 0.11864089220762253
VV269 O 0 5.661772229359485e-05
- O 0 6.090491297072731e-06
270 O 0 1.5024800177343423e-06
deletion O 0 1.8801349597197259e-06
. O 0 5.677336503140396e-07

To O 0 4.244452043167257e-07
date O 0 9.59548515311326e-07
, O 0 2.1013942586023404e-08
our O 0 2.076349936430688e-08
detection O 0 8.51854622396786e-07
rate O 0 1.541221017475891e-08
for O 0 3.1156435209567235e-09
TWIST O 0 5.4602242016699165e-06
or O 0 5.753723542056832e-08
FGFR O 0 0.008399463258683681
mutations O 0 8.811510632256159e-09
is O 0 1.092955392856254e-09
68 O 0 2.681185939934494e-08
% O 0 1.415879413713128e-09
in O 0 2.227915851804596e-09
our O 0 1.3631151318804768e-07
Saethre B-Disease 1 0.9999905824661255
- I-Disease 1 0.9978169202804565
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 6.646511110375286e-07
, O 0 3.3115157282992413e-09
including O 0 7.9153732457371e-09
our O 0 1.09842346773803e-07
five O 0 4.466003744596492e-08
patients O 0 1.0918375181745432e-07
elsewhere O 0 2.6222053861602035e-08
reported O 0 7.281212521803582e-09
with O 0 5.248903978127828e-09
TWIST O 0 0.0008309396216645837
mutations O 0 1.3471666306941188e-06
. O 0 8.455197075818432e-07

More O 0 9.052272531562267e-08
than O 0 4.888001559066879e-09
35 O 0 1.2072012722796899e-08
different O 0 1.1607629302190503e-09
TWIST O 0 7.567929856122646e-07
mutations O 0 6.7057590591446115e-09
are O 0 4.156136546029643e-10
now O 0 2.1356298951502595e-09
known O 0 9.940399614549733e-09
in O 0 2.015082101181065e-09
the O 0 1.77595556039023e-08
literature O 0 1.5030146016670187e-07
. O 0 2.2014785372448387e-07

The O 0 1.6456203866255237e-06
most O 0 4.842081224865069e-08
common O 0 5.974816019715945e-08
phenotypic O 0 1.995980483116e-07
features O 0 1.6225282450932355e-08
, O 0 1.225234025348243e-09
present O 0 3.0199118761231603e-09
in O 0 1.4163979988879305e-09
more O 0 1.9146720320328825e-10
than O 0 2.1405713312994123e-10
a O 0 8.268492557306217e-10
third O 0 1.254436110542656e-08
of O 0 1.1563793478330808e-08
our O 0 2.6414713971689707e-08
patients O 0 2.0477765261261993e-08
with O 0 1.1171490399419781e-09
TWIST O 0 4.44729630544316e-06
mutations O 0 9.21546927656891e-09
, O 0 1.093818813302505e-09
are O 0 4.998725322558073e-10
coronal B-Disease 0 0.00034434886765666306
synostosis I-Disease 0 0.008222943171858788
, O 0 3.703287632106367e-08
brachycephaly B-Disease 0 0.0002025583089562133
, O 0 5.213068021703293e-08
low B-Disease 0 0.01864415779709816
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 5.231565296526242e-07
facial B-Disease 1 0.6759762167930603
asymmetry I-Disease 0 0.11909371614456177
, O 0 4.209698545309948e-07
ptosis B-Disease 1 0.9999047517776489
, O 0 1.982081130336155e-06
hypertelorism B-Disease 1 0.9999991655349731
, O 0 2.813291303027654e-06
broad B-Disease 1 0.9292725324630737
great I-Disease 1 0.9999997615814209
toes I-Disease 1 0.9999974966049194
, O 0 5.872186648048228e-07
and O 0 1.908488457047497e-06
clinodactyly B-Disease 1 0.9993391633033752
. O 0 4.724045720649883e-05

Significant O 0 5.9446043451316655e-05
intra O 0 0.00773336086422205
- O 0 0.0025953673757612705
and O 0 1.1334072951285634e-06
interfamilial O 0 0.00010971198207698762
phenotypic O 0 2.0861962184426375e-06
variability O 0 1.192094714497216e-06
is O 0 6.700912713597518e-09
present O 0 1.0078120560308435e-08
for O 0 7.947626556870091e-09
either O 0 1.057569321005758e-07
TWIST O 0 0.0032809984404593706
mutations O 0 8.069451382652915e-07
or O 0 2.453263050483656e-07
FGFR O 1 0.8855428099632263
mutations O 0 2.076462578770588e-06
. O 0 8.922890515350446e-07

The O 0 1.6332019185938407e-06
overlap O 0 5.971945711280569e-07
in O 0 2.06842454275602e-08
clinical O 0 3.0019674568393384e-07
features O 0 4.5526110881155546e-08
and O 0 3.734966114166127e-09
the O 0 3.1646474329960483e-09
presence O 0 3.519997404666242e-09
, O 0 1.9845147747332703e-09
in O 0 2.648627428492034e-10
the O 0 5.520182089213677e-10
same O 0 2.6195032254427986e-10
genes O 0 4.679470144708375e-10
, O 0 8.766926073988657e-11
of O 0 1.1054256399134488e-09
mutations O 0 1.4330339137558212e-09
for O 0 1.7613914771175132e-09
more O 0 4.739635905970374e-10
than O 0 1.4754357735569101e-09
one O 0 2.8295303877712286e-09
craniosynostotic B-Disease 0 3.213014281300275e-07
condition I-Disease 0 2.5232856160073425e-07
- O 0 8.780209981296139e-08
such O 0 8.15948730803484e-09
as O 0 5.5930616582600123e-08
Saethre B-Disease 0 2.755857349256985e-05
- I-Disease 0 8.626598742011993e-07
Chotzen I-Disease 0 1.6942518413998187e-05
, I-Disease 0 2.086684247615267e-08
Crouzon I-Disease 0 2.2719837943441235e-05
, I-Disease 0 3.155294692192001e-08
and I-Disease 0 1.3112651231494965e-07
Pfeiffer I-Disease 1 0.9790367484092712
syndromes I-Disease 1 1.0
- O 0 0.019868632778525352
support O 0 1.146885665548325e-06
the O 0 1.3013536204198317e-07
hypothesis O 0 2.706927659801295e-07
that O 0 1.3423392397626799e-09
TWIST O 0 2.521842588976142e-06
and O 0 8.203149270968879e-09
FGFRs O 0 1.6714570847398136e-06
are O 0 3.648436830427926e-10
components O 0 2.366914664264641e-08
of O 0 2.5553184457294265e-08
the O 0 4.648958107367207e-09
same O 0 3.9211074387424105e-09
molecular O 0 5.290094051701999e-08
pathway O 0 1.284960937653068e-08
involved O 0 3.315634711231752e-10
in O 0 9.450369653496438e-11
the O 0 1.7387137285496124e-09
modulation O 0 6.44712145003723e-07
of O 0 2.2862238324705686e-07
craniofacial O 1 1.0
and O 0 9.509537449048366e-06
limb O 1 1.0
development O 0 0.00038168829632923007
in O 0 3.8945749736285507e-08
humans O 0 1.4250531421566848e-07
. O 0 3.059324882315195e-08
. O 0 1.9435245235399634e-07

Mutation O 0 1.6563159306315356e-06
analysis O 0 4.5122484948478814e-07
of O 0 2.318030055903364e-06
UBE3A O 1 1.0
in O 1 0.9896135926246643
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 1.0
. O 0 3.131652920274064e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.7675585746765137
AS B-Disease 1 1.0
) O 0 8.876357071585517e-08
is O 0 3.959784056206672e-09
caused O 0 2.7418277426249915e-08
by O 0 3.815560756237346e-09
chromosome O 0 1.560762257213355e-07
15q11 O 0 2.138954869224108e-06
- O 0 4.896523932984564e-07
q13 O 0 7.723945714133151e-07
deletions O 0 5.148659809606215e-08
of O 0 8.831331221870187e-09
maternal O 0 3.6141287296231894e-08
origin O 0 8.790762784371964e-09
, O 0 2.1754014145614065e-09
by O 0 3.592423025722269e-09
paternal O 0 0.00010784964251797646
uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999997615814209
( O 0 3.1222865800373256e-05
UPD B-Disease 1 1.0
) O 0 5.3837009517110346e-08
15 O 0 3.156547023763778e-08
, O 0 2.0686721224905114e-09
by O 0 3.268967319058902e-09
imprinting O 0 0.0004073220188729465
defects O 0 0.3633979260921478
, O 0 7.908175447823851e-09
and O 0 2.84901524594261e-09
by O 0 1.8618947494886129e-09
mutations O 0 1.4790204616588198e-08
in O 0 1.0564137120638861e-08
the O 0 3.027820980605611e-07
UBE3A O 1 0.9852724671363831
gene O 0 3.7574293401121395e-06
. O 0 7.774145842631697e-07

UBE3A O 0 0.03335493057966232
encodes O 0 2.6606498067849316e-05
a O 0 1.9202127532480517e-06
ubiquitin O 0 1.1850867849716451e-05
- O 0 2.941924549304531e-06
protein O 0 1.2638678015264304e-07
ligase O 0 3.819371272584249e-07
and O 0 2.6478776504745838e-08
shows O 0 4.7381583101469005e-08
brain O 0 5.075491571915336e-06
- O 0 3.0762180358578917e-07
specific O 0 1.4471756060174812e-07
imprinting O 0 1.874860026873648e-05
. O 0 9.85642373052542e-07

Here O 0 7.519838163716486e-06
we O 0 2.789482209664129e-07
describe O 0 1.9905071440007305e-06
UBE3A O 0 0.1259019374847412
coding O 0 4.426270606927574e-05
- O 0 3.482446800262551e-06
region O 0 5.27755688040088e-08
mutations O 0 1.8832574610883057e-08
detected O 0 1.915437231048145e-08
by O 0 1.4273654480589926e-09
SSCP O 0 0.00010294924868503585
analysis O 0 3.176150187300664e-08
in O 0 5.701609850916611e-09
13 O 0 8.180028743254297e-08
AS B-Disease 1 0.507899284362793
individuals O 0 1.801972127069007e-09
or O 0 4.8057653856403704e-08
families O 0 7.517018474345605e-08
. O 0 3.5785390650744375e-07

Two O 0 1.750596311467234e-06
identical O 0 2.427815161354374e-06
de O 0 1.560547752887942e-05
novo O 0 0.00010311431105947122
5 O 0 7.930992978799623e-06
- O 0 1.3999945622344967e-05
bp O 0 5.632249212794704e-06
duplications O 0 1.4071002851778758e-06
in O 0 3.131199832751008e-08
exon O 0 3.7528812413256674e-07
16 O 0 3.4439651130924176e-08
were O 0 1.7569330879041445e-08
found O 0 4.304033041080402e-08
. O 0 2.677279837826063e-07

Among O 0 2.9518762403313303e-06
the O 0 2.2422841539082583e-07
other O 0 3.511964763447395e-08
11 O 0 4.6595420855055636e-08
unique O 0 1.0178962561724347e-08
mutations O 0 1.8278450752973185e-08
, O 0 5.458079765929824e-09
8 O 0 6.788961570691754e-08
were O 0 1.618806599879008e-08
small O 0 1.1090881990583057e-08
deletions O 0 8.365391579445713e-08
or O 0 2.9106496768349643e-08
insertions O 0 1.0420667422295082e-06
predicted O 0 1.887377152343106e-07
to O 0 5.1446518156694765e-09
cause O 0 1.5850141608098056e-06
frameshifts O 1 0.9913739562034607
, O 0 3.338712417644274e-08
1 O 0 6.601433000241741e-08
was O 0 1.9417417007616677e-08
a O 0 1.206790778418565e-09
mutation O 0 3.498409895108523e-10
to O 0 3.6213979037746924e-10
a O 0 2.9367517306866375e-09
stop O 0 1.1430205226758972e-08
codon O 0 1.5489835192283863e-08
, O 0 4.373327477935618e-09
1 O 0 4.7753474063938484e-08
was O 0 3.5294917211103893e-08
a O 0 6.061025903392192e-09
missense O 0 2.4815273391709525e-08
mutation O 0 1.0626313162731549e-09
, O 0 6.257476758975145e-10
and O 0 2.74129297039849e-09
1 O 0 1.7028982313149754e-07
was O 0 2.418688325178664e-07
predicted O 0 4.5583547603200714e-08
to O 0 1.4731074138296663e-09
cause O 0 2.2383439102213742e-08
insertion O 0 2.2577359004571917e-07
of O 0 5.346656806182182e-08
an O 0 3.146956917277066e-09
isoleucine O 0 3.522168867675646e-07
in O 0 6.276414055150781e-09
the O 0 1.0108421655274924e-08
hect O 0 1.1672641448967624e-06
domain O 0 2.5959696614563654e-08
of O 0 8.922608429884349e-09
the O 0 2.5932974878628556e-08
UBE3A O 0 0.00018446891044732183
protein O 0 7.357677844765931e-08
, O 0 9.928911026690912e-10
which O 0 3.916366952960715e-10
functions O 0 4.157359789758175e-09
in O 0 9.508163145710569e-09
E2 O 0 5.996044819767121e-06
binding O 0 7.451127004287628e-08
and O 0 2.658388176257631e-08
ubiquitin O 0 1.3988529872221989e-06
transfer O 0 2.489462076482596e-06
. O 0 1.8643992234501638e-06

Eight O 0 1.4165278798827785e-06
of O 0 1.0279367756993452e-07
the O 0 9.823671653919064e-09
cases O 0 2.943997490234551e-09
were O 0 3.1002898026599723e-09
familial O 0 4.097618671039527e-07
, O 0 2.9768034703892e-09
and O 0 3.896772238221047e-09
five O 0 5.495162103130724e-09
were O 0 1.249214420795397e-08
sporadic O 0 3.423581802053377e-06
. O 0 2.1953369468974415e-06

In O 0 4.2884721551672556e-07
two O 0 2.903912132978803e-08
familial O 0 1.3208052678237436e-06
cases O 0 5.536236002967598e-08
and O 0 1.7002912855446084e-08
one O 0 2.753460570659172e-09
sporadic O 0 1.574728116793267e-07
case O 0 2.0006915235626366e-07
, O 0 1.2458688303240706e-08
mosaicism O 0 0.0003917283611372113
for O 0 1.132894666966422e-07
UBE3A O 1 0.8863824009895325
mutations O 0 1.0496435010054483e-07
was O 0 1.209602089602413e-07
detected O 0 1.544263561470416e-08
in O 0 7.356436015903967e-10
the O 0 2.2525532550332628e-09
mother O 0 1.9530780548393523e-08
of O 0 4.566891931290229e-08
three O 0 7.491512121760024e-08
AS B-Disease 1 0.9999998807907104
sons O 0 0.0732942447066307
, O 0 3.6919802770540855e-09
in O 0 9.868269534862861e-10
the O 0 4.75202144301079e-09
maternal O 0 2.8440226174097916e-07
grandfather O 0 6.6585671447683126e-06
of O 0 2.583089155905327e-07
two O 0 1.1423017554079706e-07
AS B-Disease 1 0.999998927116394
first O 0 4.44008605882118e-07
cousins O 0 1.108275137085002e-05
, O 0 9.93306503715985e-09
and O 0 4.79250861218361e-09
in O 0 4.49262360646685e-09
the O 0 1.5873023784251927e-08
mother O 0 4.1220676649800225e-08
of O 0 5.012976345142306e-08
an O 0 3.343581056469702e-08
AS B-Disease 1 0.9999998807907104
daughter O 0 0.0030700035858899355
. O 0 1.999194864765741e-05

The O 0 1.2415890751071856e-06
frequencies O 0 4.1021775132321636e-07
with O 0 7.712644745083708e-09
which O 0 2.9284283886710227e-09
we O 0 1.2271003102526379e-09
detected O 0 4.991220770023119e-09
mutations O 0 1.8476802310374296e-09
were O 0 3.205030463249159e-09
5 O 0 1.7741848878927158e-08
( O 0 3.5135780951378592e-09
14 O 0 8.033016030140061e-09
% O 0 6.6044752999872e-10
) O 0 6.257919182850458e-10
of O 0 7.70310304432087e-09
35 O 0 2.6136966368994763e-08
in O 0 1.2954137762477558e-09
sporadic O 0 2.52047112070386e-08
cases O 0 6.449837108846168e-09
and O 0 6.079295733485424e-09
8 O 0 2.1178029996349323e-08
( O 0 1.0105969394658132e-09
80 O 0 1.9377819349131187e-09
% O 0 2.9786420552291304e-10
) O 0 2.688854972010546e-10
of O 0 2.8080247016504245e-09
10 O 0 5.6864268849210475e-09
in O 0 1.405584537650384e-09
familial O 0 1.856318334603202e-07
cases O 0 1.4810981774360243e-08
. O 0 3.0466772216186655e-08
. O 0 2.694356453503133e-07

The O 0 9.394231892656535e-05
hemochromatosis B-Disease 1 0.9999997615814209
845 O 0 0.00024703776580281556
G O 0 4.148886364419013e-05
- O 0 4.676504431699868e-06
- O 0 5.141613996784145e-07
> O 0 1.7478659231073834e-07
A O 0 4.7568299521572044e-08
and O 0 3.6309306672421826e-09
187 O 0 5.3349289430570934e-09
C O 0 1.5013326049029274e-07
- O 0 1.1770706009883725e-07
- O 0 2.1024293062055222e-07
> O 0 1.0063562285722583e-06
G O 0 1.910928858706029e-06
mutations O 0 6.673554153735495e-09
: O 0 2.7602911067958757e-09
prevalence O 0 1.0613278789151082e-07
in O 0 9.344091722596204e-09
non O 0 4.3874078414773976e-07
- O 0 2.176769612560747e-06
Caucasian O 0 1.7504560219094856e-06
populations O 0 1.6365650878924498e-07
. O 0 3.4125369552384655e-07

Hemochromatosis B-Disease 1 1.0
, O 0 5.595895800070139e-06
the O 0 1.690557473921217e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999579191207886
, O 0 5.75148497716782e-08
leads O 0 6.662338591922889e-07
, O 0 1.6544035474908014e-08
if O 0 1.6405655856033263e-07
untreated O 1 0.9999990463256836
, O 0 2.2628034912486328e-07
to O 0 6.325377626126283e-07
progressive O 1 1.0
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 2.49950335273752e-06
premature B-Disease 0 9.376475645694882e-05
death I-Disease 0 7.58674941607751e-05
. O 0 6.701108759443741e-06

The O 0 8.941453415900469e-05
hemochromatosis B-Disease 1 1.0
gene O 0 7.985578122315928e-06
, O 0 2.9974302151458687e-07
HFE O 1 1.0
, O 0 1.5750661077618133e-06
recently O 0 1.3838777022101567e-06
has O 0 2.8982445332559337e-09
been O 0 5.482826415104114e-10
identified O 0 9.538947409737375e-10
, O 0 1.7443498034896976e-10
and O 0 4.819106780296067e-10
characterization O 0 2.864754264919611e-07
of O 0 4.107265993980036e-08
this O 0 1.0462964938895425e-09
gene O 0 6.403257923892625e-09
has O 0 2.1182573750611056e-10
shown O 0 8.667912915205633e-11
that O 0 2.597937143189455e-11
it O 0 4.613162282729455e-11
contains O 0 2.1178170328539636e-10
two O 0 1.8710108462549613e-10
mutations O 0 3.982383034450976e-10
that O 0 2.1376418690710608e-10
result O 0 5.556565874087482e-09
in O 0 2.071933735692255e-09
amino O 0 5.1836472891864105e-09
acid O 0 5.814595915865084e-09
substitutions O 0 3.910384549499213e-08
- O 0 6.978277156122203e-08
cDNA O 0 2.58818857901133e-07
nucleotides O 0 3.813656590523351e-08
845 O 0 1.7138613372935652e-07
G O 0 4.4339421378936095e-07
- O 0 2.2364156393450685e-07
- O 0 2.9881258001296374e-07
> O 0 2.2755847339794855e-07
A O 0 2.072945619602251e-07
( O 0 1.0058955446368145e-08
C282Y O 0 2.3208626487303263e-07
) O 0 1.3933486586736876e-09
and O 0 1.1346420469848795e-09
187 O 0 4.791466334808092e-09
C O 0 2.4000630105547316e-07
- O 0 2.1414928141894052e-07
- O 0 3.757211004540295e-07
> O 0 1.4533957255480345e-06
G O 0 1.4456003555096686e-05
( O 0 1.6733424956782983e-07
H63D O 0 0.0005055799847468734
) O 0 2.1614670231429045e-07
. O 0 2.647272481226537e-07

Although O 0 0.0003831129870377481
hemochromatosis B-Disease 1 1.0
is O 0 3.408760846923542e-07
common O 0 3.4002442816927214e-07
in O 0 1.4366855261016553e-08
Caucasians O 0 1.6021753026507213e-06
, O 0 1.804015781203816e-08
affecting O 0 2.4186348923649348e-08
> O 0 1.1792013765443699e-06
= O 0 3.7942305652904906e-07
1 O 0 1.2178215058611386e-07
/ O 0 4.506958717342968e-08
300 O 0 1.0922593940421166e-09
individuals O 0 5.1817144325339015e-11
of O 0 2.621303840655287e-09
northern O 0 4.923821350644175e-09
European O 0 2.354306305463183e-09
origin O 0 7.486820052804433e-10
, O 0 2.1008111916742678e-10
it O 0 6.741660701914398e-11
has O 0 7.261759943366641e-11
not O 0 2.030086689031041e-11
been O 0 1.0637218189613051e-10
recognized O 0 3.451952057531571e-10
in O 0 6.683295583620463e-10
other O 0 2.2564836665850407e-09
populations O 0 3.052225849842216e-08
. O 0 2.5579669227226987e-07

The O 0 1.1393091199352057e-06
present O 0 6.659124807129047e-08
study O 0 9.316828197825089e-09
used O 0 7.712644745083708e-09
PCR O 0 5.680640242644586e-07
and O 0 9.3805923029322e-09
restriction O 0 2.6798565144758868e-08
- O 0 3.637267553813217e-08
enzyme O 0 6.2726801530743614e-09
digestion O 0 1.4772556511388757e-08
to O 0 3.96040839012457e-10
analyze O 0 3.0537616879655616e-09
the O 0 1.41276368381682e-09
frequency O 0 1.0876862077680016e-08
of O 0 9.864058014841248e-09
the O 0 1.7839507648886865e-08
845 O 0 3.307941653929447e-07
G O 0 4.1587506416362885e-07
- O 0 1.1262599031169884e-07
- O 0 9.848345428054017e-08
> O 0 7.30748297428363e-08
A O 0 3.6934402203314676e-08
and O 0 2.8015731956543277e-09
187 O 0 5.870291808207639e-09
C O 0 6.077861058884082e-08
- O 0 6.379404027256896e-08
- O 0 1.3093581685552635e-07
> O 0 3.3123262710432755e-07
G O 0 6.43272585421073e-07
mutations O 0 1.7617786340906605e-08
in O 0 6.967793897416641e-09
HLA O 0 2.977351130084571e-07
- O 0 5.861276974883367e-08
typed O 0 1.2951947070405367e-08
samples O 0 1.113572900557358e-09
from O 0 1.418290374033404e-09
non O 0 3.681912019715128e-08
- O 0 1.6523355839126452e-07
Caucasian O 0 1.7952119435449276e-07
populations O 0 8.132762907564484e-09
, O 0 3.670158843505078e-09
comprising O 0 3.99785005100739e-09
Australian O 0 5.3263605082065624e-08
Aboriginal O 0 6.52101590503662e-08
, O 0 1.909945757105902e-09
Chinese O 0 2.2972622915062857e-08
, O 0 7.2535168982312825e-09
and O 0 4.5126270720174944e-08
Pacific O 0 1.568392508488614e-05
Islanders O 0 0.00015153038839343935
. O 0 3.0943658657633932e-06

Results O 0 9.261759259970859e-06
showed O 0 1.1670036883515422e-06
that O 0 2.2709532032649804e-08
the O 0 1.0938386196812644e-07
845 O 0 3.1715396744402824e-06
G O 0 8.478188647131901e-06
- O 0 3.0293599593278486e-06
- O 0 1.250012587661331e-06
> O 0 2.2047100856070756e-07
A O 0 2.3746107302713426e-08
mutation O 0 2.038648583280178e-09
was O 0 4.100047412691765e-09
present O 0 4.40498665321698e-10
in O 0 2.498632134528833e-10
these O 0 1.0374410358560127e-10
populations O 0 1.8056661721388423e-10
( O 0 6.867301866053666e-11
allele O 0 3.305695439603795e-10
frequency O 0 1.8046686367512166e-09
0 O 0 7.997331685771769e-10
. O 0 1.0867520078283732e-10
32 O 0 1.0672137618072952e-09
% O 0 1.5898700411742794e-10
) O 0 2.167237639350006e-10
, O 0 4.050377255815363e-10
and O 0 6.940705232771904e-10
, O 0 6.680567765648959e-10
furthermore O 0 6.7463625796904125e-09
, O 0 8.479181801135383e-10
it O 0 4.10878192580455e-10
was O 0 3.264538861458277e-08
always O 0 7.1804517887130714e-09
seen O 0 3.5187486258081435e-09
in O 0 4.805302267207878e-10
conjunction O 0 4.071991188681068e-09
with O 0 2.1783577164313783e-09
HLA O 0 9.359054274682421e-06
haplotypes O 0 3.065756857267843e-07
common O 0 1.0746970247055287e-07
in O 0 6.690466403114215e-09
Caucasians O 0 1.4847827856101503e-07
, O 0 2.7210653730236345e-09
suggesting O 0 1.2182763242662986e-08
that O 0 2.7377136113670986e-09
845 O 0 3.2518681791771087e-07
G O 0 2.698295702430187e-06
- O 0 1.2716749324681587e-06
- O 0 1.8679836557566887e-06
> O 0 1.372163183077646e-06
A O 0 3.067810041557095e-07
may O 0 2.1935772309689128e-08
have O 0 5.401283309502958e-10
been O 0 6.677141062283454e-10
introduced O 0 1.5408763154312055e-09
into O 0 4.552884735886664e-10
these O 0 1.226364981787853e-10
populations O 0 6.797092333421517e-10
by O 0 9.558963620648342e-10
Caucasian O 0 1.0397567393738427e-06
admixture O 0 8.840957889333367e-06
. O 0 2.391192310824408e-06

187 O 0 6.893031695653917e-06
C O 0 8.821838491712697e-06
- O 0 2.878111672544037e-06
- O 0 6.91865068347397e-07
> O 0 7.123759360183612e-07
G O 0 6.665312639597687e-07
was O 0 3.3829813617103355e-08
present O 0 3.4642220203551233e-09
at O 0 2.5121764668512014e-09
an O 0 5.689404503073092e-11
allele O 0 4.842455325615447e-10
frequency O 0 2.924197550768781e-09
of O 0 2.3420893668912868e-08
2 O 0 5.409308982962102e-07
. O 0 4.341564761034533e-07

68 O 0 4.1602492274250835e-05
% O 0 1.3274103594085318e-07
in O 0 2.6323577984044277e-08
the O 0 2.1538099304052594e-08
two O 0 5.144809023249763e-09
populations O 0 7.485824404795949e-09
analyzed O 0 1.2221141432178229e-08
( O 0 3.3420493039670873e-09
Australian O 0 1.1139031386164788e-07
Aboriginal O 0 2.6344454795435013e-07
and O 0 1.795769577483952e-08
Chinese O 0 1.7204592950292863e-07
) O 0 2.7216014331088445e-08
. O 0 4.3863661858267733e-07

In O 0 2.249917315566563e-06
the O 0 6.188457746247877e-07
Australian O 0 1.480339278714382e-06
Aboriginal O 0 2.6253087526129093e-07
samples O 0 4.4294554690793575e-09
, O 0 1.8793955280926866e-09
187 O 0 7.928382395050448e-09
C O 0 2.8771762572432635e-07
- O 0 5.344235773918626e-07
- O 0 9.34116940243257e-07
> O 0 1.8971829831571085e-06
G O 0 4.835021172766574e-06
was O 0 2.0030546110660907e-08
found O 0 3.610748922078244e-10
to O 0 1.1605764960176401e-10
be O 0 1.5835206756964482e-10
associated O 0 6.532640650647181e-09
with O 0 7.799704881961134e-09
HLA O 0 0.00013714235683437437
haplotypes O 0 7.893422662164085e-07
common O 0 9.328655892204551e-08
in O 0 6.692508325301105e-09
Caucasians O 0 1.877560720231486e-07
, O 0 1.013873207611482e-09
suggesting O 0 3.3133098487070356e-09
that O 0 1.892156015204094e-10
it O 0 2.9631722076040035e-10
was O 0 3.408433313367709e-09
introduced O 0 1.7034390564774071e-09
by O 0 2.1329216171039889e-10
recent O 0 6.023088250373121e-09
admixture O 0 8.207015866901202e-07
. O 0 3.482017518763314e-07

In O 0 2.413253923805314e-06
the O 0 5.601655175269116e-07
Chinese O 0 2.7448268724583613e-07
samples O 0 9.681649260073755e-09
analyzed O 0 8.88990747682783e-09
, O 0 1.6204677599773731e-09
187 O 0 1.0576980180587725e-08
C O 0 3.719612493569002e-07
- O 0 3.057674575757119e-07
- O 0 3.085741298036737e-07
> O 0 5.875967872270849e-07
G O 0 2.038087814071332e-06
was O 0 3.016051053350566e-08
present O 0 1.5030503508484117e-09
in O 0 7.452213846015354e-10
association O 0 6.731423196626451e-10
with O 0 1.3972761836456016e-10
a O 0 2.152043210301713e-09
wide O 0 8.974888388024738e-09
variety O 0 5.742317732426727e-09
of O 0 2.1196177257820636e-08
HLA O 0 7.804575034242589e-06
haplotypes O 0 2.777942142984102e-07
, O 0 1.8343121466202206e-09
showing O 0 1.3966906520224143e-09
this O 0 2.3985977093410327e-10
mutation O 0 8.721265931654898e-10
to O 0 6.95469848377428e-10
be O 0 6.457169243745398e-10
widespread O 0 4.5878632448648204e-08
and O 0 7.169434823595111e-09
likely O 0 1.6012290160460907e-08
to O 0 3.197069053939572e-09
predate O 0 1.5641313666492351e-06
the O 0 5.084542920030799e-08
more O 0 3.841894358203035e-09
genetically O 0 3.4182658481540784e-08
restricted O 0 1.0194195709800624e-08
845 O 0 2.2237931318613846e-07
G O 0 1.249111733159225e-06
- O 0 1.7041733144651516e-06
- O 0 1.076290459423035e-06
> O 0 8.186832474166295e-07
A O 0 7.45951524550037e-07
mutation O 0 1.3404842036379705e-07
. O 0 1.0179976328572593e-07

Genotype O 0 0.0011800593929365277
- O 0 0.00010252172069158405
phenotype O 0 1.2195839190098923e-05
correlations O 0 6.852500519016758e-06
in O 0 4.929913188789214e-07
attenuated B-Disease 1 0.9999871253967285
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.010545791126787663

Germ O 1 0.999990701675415
- O 0 0.0007487935363315046
line O 0 3.804063453571871e-06
mutations O 0 1.2401827120811504e-07
of O 0 4.481704607428583e-08
the O 0 7.48377217973939e-08
tumor B-Disease 0 0.0007705090683884919
suppressor O 0 0.00039638380985707045
APC O 0 1.4344287819767487e-06
are O 0 3.2615312672845675e-09
implicated O 0 2.3607742605236126e-07
in O 0 4.1738402956070786e-08
attenuated B-Disease 1 0.9999858140945435
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.0006049131625331938
AAPC B-Disease 1 1.0
) O 0 3.090661593319055e-08
, O 0 3.302483175815496e-09
a O 0 1.0260989391497333e-08
variant O 0 1.5063628779898863e-05
of O 0 0.0004630533803720027
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.8706055283546448
FAP B-Disease 1 0.9987303614616394
) O 0 2.0953284547431394e-06
. O 0 2.905546807596693e-06

AAPC B-Disease 1 1.0
is O 0 2.7424928816799365e-07
recognized O 0 2.5801883296594497e-08
by O 0 1.4295260530872156e-09
the O 0 3.690551197976788e-09
occurrence O 0 1.2622099809789233e-08
of O 0 8.344548518834927e-08
< O 0 4.322289896663278e-06
100 O 0 8.123495831569016e-08
colonic B-Disease 0 4.728859130409546e-05
adenomas I-Disease 0 4.248402547091246e-06
and O 0 2.125863707291842e-09
a O 0 1.9842765208721858e-09
later O 0 2.3003929428000447e-08
onset O 1 0.9925472140312195
of O 1 0.9999843835830688
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.4264481979230368e-08
age O 0 1.5179576706714215e-08
> O 0 1.0188445997982853e-07
40 O 0 1.680181149765758e-08
years O 0 1.293330864626796e-08
) O 0 1.1799383692334686e-08
. O 0 1.4773746670471155e-07

The O 0 1.6440595800304436e-06
aim O 0 1.0404005479358602e-06
of O 0 5.459529361928617e-08
this O 0 1.6652998979793665e-09
study O 0 3.785954660884272e-09
was O 0 6.7518715063386026e-09
to O 0 1.384965364614743e-09
assess O 0 1.0782161297129278e-07
genotype O 0 2.0582418073900044e-05
- O 0 5.3229700824886095e-06
phenotype O 0 1.6787479353297385e-06
correlations O 0 2.222151124442462e-06
in O 0 3.701741775330447e-07
AAPC B-Disease 1 1.0
families O 0 4.5131064325687476e-06
. O 0 2.734787813096773e-06

By O 0 6.052353000995936e-07
protein O 0 1.9773310668824706e-06
- O 0 1.424985271114565e-06
truncation O 0 5.479859282786492e-06
test O 0 6.902912446093978e-07
( O 0 6.026606769182763e-08
PTT O 0 2.0042887172166957e-06
) O 0 3.362060851941351e-09
assay O 0 7.242115884764644e-08
, O 0 6.290304277456471e-09
the O 0 1.3251255204238532e-08
entire O 0 5.714089112984766e-08
coding O 0 4.712211421065149e-07
region O 0 3.505981638340927e-08
of O 0 2.698305578974214e-08
the O 0 3.602634990329534e-08
APC B-Disease 0 5.434666832115909e-07
gene O 0 4.116300544865226e-08
was O 0 9.085033525479957e-08
screened O 0 4.870238967669138e-08
in O 0 7.279208902311041e-10
affected O 0 1.1611217543006092e-09
individuals O 0 5.503361655279093e-10
from O 0 5.6232689615853815e-08
11 O 0 3.787696550716646e-05
AAPC B-Disease 1 1.0
kindreds O 1 0.9999580383300781
, O 0 3.668872849971194e-08
and O 0 4.011361909306288e-09
their O 0 2.981258129253206e-09
phenotypic O 0 6.475824676499542e-08
differences O 0 4.211183934899054e-08
were O 0 4.107093332095246e-08
examined O 0 7.868687816880993e-07
. O 0 7.320379040720582e-07

Five O 0 5.208921265875688e-06
novel O 0 6.0292559282970615e-06
germ O 1 0.9981556534767151
- O 0 0.00012493204849306494
line O 0 5.761570264439797e-06
APC B-Disease 0 1.1716851986420806e-06
mutations O 0 1.348699285586008e-08
were O 0 3.0584481613971093e-09
identified O 0 1.6554894344267268e-08
in O 0 9.507672871222894e-09
seven O 0 4.490543972224259e-07
kindreds O 0 0.0005254190764389932
. O 0 1.6149966768352897e-06

Mutations O 0 3.2155508051801007e-06
were O 0 4.6947087639637175e-07
located O 0 1.4220961475075455e-07
in O 0 6.45525277676029e-09
three O 0 2.0893755614537213e-09
different O 0 6.923595585739406e-10
regions O 0 5.818612702768178e-09
of O 0 2.2862035820025994e-08
the O 0 3.409592252978655e-08
APC B-Disease 0 8.972975251708704e-08
gene O 0 3.6342977516312658e-09
( O 0 7.770463716916254e-10
1 O 0 9.709648196576381e-09
) O 0 1.3636053397547698e-09
at O 0 1.8106273813600637e-08
the O 0 6.849909528483522e-09
5 O 0 4.306710010837378e-08
end O 0 8.425536179856863e-08
spanning O 0 1.645664582383688e-07
exons O 0 1.228433887945357e-07
4 O 0 1.743034339085625e-08
and O 0 1.7530793483544471e-09
5 O 0 9.383419374842106e-09
, O 0 1.2037792984642692e-09
( O 0 2.6838757882785558e-09
2 O 0 7.638803367626679e-08
) O 0 1.941566685204066e-09
within O 0 1.2474952626462255e-08
exon O 0 5.451611073681306e-08
9 O 0 1.09467519493478e-08
, O 0 5.908965539092037e-10
and O 0 9.958175395397006e-10
( O 0 1.2866598897431913e-09
3 O 0 3.2725996135241076e-08
) O 0 3.260200331922647e-09
at O 0 1.8317154015790038e-08
the O 0 7.207894725524966e-09
3 O 0 5.8362214616636265e-08
distal O 0 6.602074904549227e-07
end O 0 2.9676985491278174e-07
of O 0 1.0304023589924327e-07
the O 0 1.3207292681727267e-07
gene O 0 3.883693295847479e-07
. O 0 3.2791800208542554e-07

Variability O 0 5.122515358380042e-05
in O 0 1.5055766766636225e-07
the O 0 4.607365511333228e-08
number O 0 2.665908205301548e-08
of O 0 7.927134720375761e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9999920129776001
most O 0 8.97033984870177e-08
apparent O 0 7.741105605418852e-07
in O 0 6.832577836846099e-10
individuals O 0 5.251822587926114e-11
with O 0 1.3145587396401481e-10
mutations O 0 2.9658993039305415e-09
in O 0 6.341949632115984e-09
region O 0 5.167500489733357e-07
1 O 0 1.3571547242463566e-05
, O 0 2.8986328004521056e-08
and O 0 2.3683784888817172e-07
upper O 1 0.9999939203262329
- O 1 0.9995317459106445
gastrointestinal O 1 0.999896764755249
manifestations O 0 0.22088488936424255
were O 0 7.136898005910552e-08
more O 0 9.409257817338812e-10
severe O 0 1.9981414425274124e-06
in O 0 1.7792681106243435e-08
them O 0 3.7562788435252514e-08
. O 0 4.216826425817999e-07

In O 0 4.953231496074295e-07
individuals O 0 6.377418149128289e-09
with O 0 5.739646091740269e-09
mutations O 0 2.233022122766215e-08
in O 0 6.875749303247858e-09
either O 0 4.4335486393265455e-08
region O 0 6.041062192707614e-07
2 O 0 1.7859819081422756e-06
or O 0 7.492569409350835e-08
region O 0 9.565538761080461e-08
3 O 0 2.2834585422515374e-07
, O 0 2.949201771684784e-09
the O 0 3.1656131049828673e-09
average O 0 3.812069326869505e-09
number O 0 1.8597544615417405e-09
of O 0 3.450639241009412e-08
adenomas B-Disease 0 0.009033934213221073
tended O 0 1.4647764601249946e-07
to O 0 3.6291927241194344e-09
be O 0 2.524347397780957e-09
lower O 0 1.4301926398729847e-07
than O 0 5.251985513154978e-10
those O 0 1.860193388214526e-10
in O 0 1.3639922524788517e-10
individuals O 0 1.0957179608084289e-11
with O 0 7.38763356045169e-11
mutations O 0 7.090650844254753e-10
in O 0 7.945575863921306e-10
region O 0 9.983379456457442e-09
1 O 0 4.058516722693639e-08
, O 0 7.144573266337773e-10
although O 0 1.1517474751698842e-09
age O 0 3.741690068892467e-09
at O 0 1.0097303437817118e-08
diagnosis O 0 1.969801388668202e-07
was O 0 5.23622709636129e-08
similar O 0 3.907804924097036e-08
. O 0 3.2201063504544436e-07

In O 0 1.1124398042738903e-05
all O 0 3.7870761389058316e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.002532835816964507
, O 0 8.110645666192795e-08
a O 0 4.64181049153467e-08
predominance O 0 3.413326703594066e-05
of O 0 0.00011025145067833364
right O 1 0.9999982118606567
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999995231628418
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999997615814209
sparing O 0 0.00010172669863095507
was O 0 2.6304917355446378e-06
observed O 0 5.067059305474686e-07
. O 0 7.608236956002656e-07

No O 0 0.00024047498300205916
desmoid B-Disease 1 0.9999994039535522
tumors I-Disease 1 1.0
were O 0 4.4718214553540747e-07
found O 0 3.2031746144411954e-08
in O 0 9.200260109309966e-09
these O 0 9.132376277420917e-08
kindreds O 0 0.0025937692262232304
. O 0 3.02020112030732e-06

Our O 0 4.3363279473851435e-06
data O 0 2.3822509831461502e-07
suggest O 0 4.2643364395189565e-08
that O 0 3.209214671784366e-09
, O 0 1.723065956582559e-08
in O 0 1.0849827702941184e-07
AAPC B-Disease 1 1.0
families O 0 2.1606797417916823e-07
, O 0 2.0837320757749467e-09
the O 0 1.3032600554296891e-09
location O 0 3.957543270871611e-08
of O 0 4.826857491480041e-08
the O 0 1.0550427731459422e-07
APC B-Disease 0 8.428384717262816e-06
mutation O 0 1.6731478069687e-07
may O 0 1.1045203507364931e-07
partially O 0 1.3011193686907063e-06
predict O 0 1.967801779301226e-07
specific O 0 1.6233029498380347e-07
phenotypic O 0 2.933900304924464e-06
expression O 0 1.1538741091499105e-06
. O 0 5.704125101146929e-07

This O 0 4.557898307666619e-07
should O 0 8.646905058640186e-08
help O 0 3.907342716047424e-08
in O 0 3.0396984929126347e-09
the O 0 2.989799963160067e-09
design O 0 4.5640533130608674e-08
of O 0 8.986484445472342e-09
tailored O 0 6.304865252104719e-08
clinical O 0 1.007126115837309e-06
- O 0 5.295677283356781e-07
management O 0 8.103099702339023e-08
protocols O 0 5.268686322779104e-07
in O 0 1.9042785126544004e-09
this O 0 2.5359284117065783e-10
subset O 0 6.834210974915322e-09
of O 0 1.0847691633841805e-08
FAP B-Disease 0 8.247051482612733e-06
patients O 0 2.677568602393876e-07
. O 0 3.282558580508521e-08
. O 0 3.408428881357395e-07

Wilms B-Disease 1 0.9999997615814209
' I-Disease 0 0.488345205783844
tumor I-Disease 0 0.0004578561056405306
1 O 0 4.6671393647557124e-06
and O 0 6.894149464642396e-07
Dax O 0 0.026101356372237206
- O 0 9.226302609022241e-06
1 O 0 9.899587212203187e-07
modulate O 0 7.704934432695154e-07
the O 0 2.7769488042395096e-07
orphan O 0 4.820416961592855e-06
nuclear O 0 1.1903831364179496e-05
receptor O 0 6.495455977528763e-07
SF O 0 0.0008627474890090525
- O 0 4.538275959475868e-07
1 O 0 2.169692514542021e-08
in O 0 5.907850320063801e-10
sex O 0 6.530992413544823e-10
- O 0 2.407651633618002e-09
specific O 0 8.065945134028141e-10
gene O 0 7.889869202415412e-09
expression O 0 2.358037676231106e-08
. O 0 1.709659329662827e-07

Products O 0 4.111888847546652e-05
of O 0 1.2988658454560209e-05
steroidogenic O 1 0.9999279975891113
factor O 0 1.9639692254713736e-05
1 O 0 4.383933628560044e-06
( O 0 1.3689853517462325e-07
SF O 1 0.9999980926513672
- O 0 7.382709554804023e-06
1 O 0 2.4570044843130745e-07
) O 0 6.7617436094735694e-09
and O 0 2.4092972950029434e-08
Wilms B-Disease 1 0.999977707862854
tumor I-Disease 0 0.00014959799591451883
1 O 0 1.4725821984029608e-06
( O 0 1.3092720507756894e-07
WT1 O 0 0.006538149435073137
) O 0 3.6505825029564676e-09
genes O 0 1.4990935159886476e-09
are O 0 1.1277350581151424e-10
essential O 0 7.744633379047627e-09
for O 0 2.716020075510528e-09
mammalian O 0 1.2494499515014468e-06
gonadogenesis O 0 3.8428532889156486e-07
prior O 0 1.0941783479267997e-08
to O 0 1.938147864422035e-09
sexual O 0 1.1014021694677467e-08
differentiation O 0 6.990412657614797e-07
. O 0 3.7133318642190716e-07

In O 0 6.014016094013641e-07
males O 0 1.1171670877274664e-07
, O 0 3.005387441135099e-07
SF O 1 1.0
- O 0 0.12015067785978317
1 O 0 1.7966076484299265e-06
participates O 0 1.6043992800973683e-08
in O 0 3.941095227943947e-10
sexual O 0 1.7761976611740948e-10
development O 0 5.259804813917413e-10
by O 0 6.95750748680446e-11
regulating O 0 1.5025860555795134e-09
expression O 0 1.17401788291005e-09
of O 0 3.9564924669832635e-09
the O 0 4.049099189273875e-08
polypeptide O 0 6.8803819885943085e-06
hormone O 0 3.179402767727879e-07
Mullerian O 0 4.5122927986085415e-05
inhibiting O 0 2.704821895349596e-07
substance O 0 1.2777103108874144e-07
( O 0 6.654921946847026e-08
MIS O 0 0.0039012215565890074
) O 0 1.6339778596830001e-07
. O 0 7.120513032532472e-07

Here O 0 1.0268104233546183e-05
, O 0 4.488874196795223e-07
we O 0 5.6681077609255226e-08
show O 0 4.898886984960882e-08
that O 0 2.0355257035475915e-08
WT1 O 1 0.9817754030227661
- O 0 0.0003833530063275248
KTS O 1 0.9998964071273804
isoforms O 0 2.5307376745331567e-06
associate O 0 6.337224363051064e-07
and O 0 2.4258836717194754e-08
synergize O 0 5.589633929048432e-06
with O 0 2.071016922400304e-07
SF O 1 1.0
- O 0 0.07127126306295395
1 O 0 2.0503402993199416e-06
to O 0 5.186211282648401e-08
promote O 0 7.717878816038137e-07
MIS O 1 0.9924532771110535
expression O 0 1.2392172266117996e-06
. O 0 4.988796149518748e-07

In O 0 1.788248709999607e-06
contrast O 0 3.261270649090875e-06
, O 0 8.887112130651076e-07
WT1 O 1 0.9950752854347229
missense O 0 4.225688462611288e-05
mutations O 0 2.567981027823407e-07
, O 0 1.6673665115263248e-08
associated O 0 4.5355545097436334e-08
with O 0 2.1821097817564805e-08
male B-Disease 0 3.7912784591753734e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 5.212203291193873e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.0140041695194668e-06
fail O 0 4.039074610773241e-06
to O 0 1.4184513474901905e-07
synergize O 0 0.0007948193233460188
with O 0 4.202287982479902e-06
SF O 1 1.0
- O 1 0.9998251795768738
1 O 0 8.649980009067804e-05
. O 0 2.048770738838357e-06

Additionally O 0 6.609649972233456e-06
, O 0 2.2601896887408657e-07
the O 0 7.162426385320941e-08
X O 0 2.688112363102846e-05
- O 0 4.75238675790024e-06
linked O 0 1.8397813619230874e-06
, O 0 1.1300099522770779e-08
candidate O 0 2.3745927890672647e-08
dosage O 0 1.123790525525692e-06
- O 0 4.421632979756396e-07
sensitive O 0 2.0197434480451193e-07
sex O 0 4.670893893887751e-09
- O 0 1.4464077935372188e-08
reversal O 0 3.2348307144047794e-08
gene O 0 9.482264751170533e-09
, O 0 7.219535635982766e-09
Dax O 0 3.3590033126529306e-05
- O 0 1.0840441291293246e-06
1 O 0 5.878316642338177e-07
, O 0 4.605573167282273e-08
antagonizes O 0 4.0978593460749835e-06
synergy O 0 2.3643124222871847e-06
between O 0 3.131573578230018e-07
SF O 1 0.999997615814209
- O 0 2.434903535686317e-06
1 O 0 6.971385602128066e-08
and O 0 8.608312285218744e-09
WT1 O 0 9.993937419494614e-05
, O 0 4.276878406983542e-09
most O 0 1.382674419403429e-09
likely O 0 4.774844519772614e-09
through O 0 8.612610624680883e-10
a O 0 6.374860639368762e-10
direct O 0 2.2803057220244227e-09
interaction O 0 7.626658415915699e-09
with O 0 1.5706479672417117e-08
SF O 1 0.9999997615814209
- O 0 0.00010623895650496706
1 O 0 4.65245648229029e-06
. O 0 1.2073852531102602e-06

We O 0 2.1601267690130044e-06
propose O 0 1.8020954257735866e-06
that O 0 8.751385394134559e-08
WT1 O 0 0.004920600447803736
and O 0 2.809285433613695e-06
Dax O 1 0.9999555349349976
- O 0 0.00014489388559013605
1 O 0 1.0983183074131375e-06
functionally O 0 5.584969926530903e-07
oppose O 0 4.0302218451415683e-08
each O 0 9.101345788131709e-10
other O 0 1.1212539785532272e-09
in O 0 1.568979390853542e-09
testis O 0 2.5629728384046757e-07
development O 0 7.668316648334894e-09
by O 0 2.1080692746977547e-09
modulating O 0 3.4834699818020454e-06
SF O 1 0.9999881982803345
- O 0 1.291588068852434e-05
1 O 0 9.660280966272694e-07
- O 0 1.0641509788911208e-06
mediated O 0 5.798423899250338e-06
transactivation O 0 2.0962734197382815e-05
. O 0 6.893479564951122e-08
. O 0 1.9824111063826422e-07

A O 0 4.426245141075924e-05
mouse O 0 1.0718658813857473e-05
model O 0 2.859813719169324e-07
for O 0 6.366944376168249e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999997615814209
centre O 0 0.001319038332439959
mutations O 0 2.0809607121918816e-06
. O 0 5.345158342606737e-07

Imprinting O 0 0.0002915053628385067
in O 0 9.96234234662552e-07
the O 0 6.49610683467472e-07
15q11 O 0 4.454106237972155e-05
- O 0 4.096675183973275e-06
q13 O 0 2.144661948477733e-06
region O 0 5.829123850276119e-08
involves O 0 7.212010189050488e-08
an O 0 4.923220053854038e-09
imprinting O 0 1.3492032167050638e-06
centre O 0 1.1742624792532297e-06
( O 0 1.3078401472910173e-08
IC O 0 2.6015692128567025e-05
) O 0 6.778556382869283e-09
, O 0 3.172056173283977e-09
mapping O 0 2.1214580314676823e-08
in O 0 1.7687979969593925e-09
part O 0 2.947812882680978e-09
to O 0 1.6229577681770024e-09
the O 0 1.0471235434295068e-08
promoter O 0 1.5290950159396743e-06
and O 0 1.4846053275618942e-08
first O 0 2.5329628172698904e-08
exon O 0 5.828022722198511e-07
of O 0 2.7774919431067246e-07
SNRPN O 1 0.6884930729866028
. O 0 3.913253294740571e-06

Deletion O 0 1.4677936633233912e-05
of O 0 9.055551117853611e-07
this O 0 1.0663234917274167e-07
IC O 0 0.00036790946614928544
abolishes O 0 1.8050237486022525e-05
local O 0 1.1730475790727724e-07
paternally O 0 3.7138525499358366e-07
derived O 0 1.713751096588112e-08
gene O 0 5.134888070301713e-09
expression O 0 4.3051149312134385e-09
and O 0 1.7198342749935591e-09
results O 0 8.67493454848045e-09
in O 0 1.859727518649379e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 3.7103040085639805e-05
. O 0 4.209556664136471e-06

We O 0 1.2247882068550098e-06
have O 0 1.562371565455578e-08
created O 0 3.9659763473309795e-08
two O 0 1.4015268945399839e-08
deletion O 0 2.498583171473001e-07
mutations O 0 4.2555125645549197e-08
in O 0 3.61269325566127e-09
mice O 0 1.156090903009499e-07
to O 0 9.178858562108871e-09
understand O 0 1.5094459740794264e-05
PWS B-Disease 1 1.0
and O 0 2.4299256438098382e-06
the O 0 9.258690880642462e-08
mechanism O 0 2.556949993959279e-07
of O 0 4.3840032049047295e-08
this O 0 1.3968140422093711e-08
IC O 0 0.0002622683241497725
. O 0 1.7569233250469551e-06

Mice O 0 0.0004739717405755073
harbouring O 0 0.00044800693285651505
an O 0 6.576160558324773e-07
intragenic O 0 0.0004979920340701938
deletion O 0 1.7267120711039752e-05
in O 0 1.2710938790405635e-07
Snrpn O 0 0.0006772535853087902
are O 0 1.1431295909858363e-08
phenotypically O 0 4.277307743905112e-05
normal O 0 1.7980320876631595e-07
, O 0 5.517532208898501e-09
suggesting O 0 1.1186741311064452e-08
that O 0 4.945221454555337e-10
mutations O 0 1.3632264206364653e-08
of O 0 1.7014437503348745e-07
SNRPN O 1 0.999983549118042
are O 0 2.718093083942108e-09
not O 0 9.747701534834619e-10
sufficient O 0 3.77972249054892e-08
to O 0 5.3346266071230275e-08
induce O 0 0.00012525077909231186
PWS B-Disease 1 1.0
. O 0 0.0016785445623099804

Mice O 0 7.699647539993748e-06
with O 0 3.152262806338513e-08
a O 0 5.6359393596494556e-08
larger O 0 5.534409552865327e-08
deletion O 0 2.993259613504051e-07
involving O 0 3.9731766321438045e-08
both O 0 2.2724957915443156e-08
Snrpn O 0 3.545457366271876e-05
and O 0 9.09281752115021e-08
the O 0 1.9984472032774647e-07
putative O 1 0.6676427125930786
PWS O 1 1.0
- O 1 0.9999607801437378
IC O 1 0.9985673427581787
lack O 0 2.2438318865170004e-06
expression O 0 4.93186966821213e-08
of O 0 2.2089142959202945e-08
the O 0 1.6831544158435463e-08
imprinted O 0 1.3673334819941374e-07
genes O 0 3.4247786828700555e-08
Zfp127 O 0 6.234470220078947e-06
( O 0 4.7642576106454726e-08
mouse O 0 2.334226110178861e-06
homologue O 0 1.3491513527696952e-05
of O 0 2.2935242327548622e-07
ZNF127 O 1 0.9999233484268188
) O 0 1.0842586561921053e-07
, O 0 7.7114712837556e-08
Ndn O 0 0.0007471014396287501
and O 0 8.117439165289397e-08
Ipw O 0 3.018335519300308e-05
, O 0 2.4068860682291415e-08
and O 0 1.500570512291688e-08
manifest O 0 1.689098354518137e-07
several O 0 2.2334651461619615e-08
phenotypes O 0 6.218896260179463e-07
common O 0 2.052382797046448e-06
to O 0 2.469671926519368e-06
PWS B-Disease 1 1.0
infants O 1 0.9999998807907104
. O 0 5.276743104332127e-05

These O 0 2.580710827260191e-07
data O 0 1.561523106374807e-07
demonstrate O 0 2.526362230526047e-08
that O 0 1.6911630984495218e-09
both O 0 4.040811241168285e-09
the O 0 7.71338015681522e-09
position O 0 1.41795638342046e-07
of O 0 6.838516242169135e-08
the O 0 3.746304599872019e-08
IC O 0 0.00015077428543008864
and O 0 4.554381316523859e-09
its O 0 2.5924156155099354e-09
role O 0 1.003038985203375e-08
in O 0 3.709766660531244e-10
the O 0 3.5681652077457215e-10
coordinate O 0 1.4601110320811017e-09
expression O 0 2.5930189107015167e-09
of O 0 2.5980586570995e-09
genes O 0 1.6386251244782102e-09
is O 0 3.778954649202859e-10
conserved O 0 1.1779236253062209e-08
between O 0 6.610754610392178e-09
mouse O 0 2.3487422140533454e-07
and O 0 1.5368520900338467e-09
human O 0 4.320348967468135e-09
, O 0 1.728859055916132e-09
and O 0 1.2091015966220198e-09
indicate O 0 2.635099471959279e-09
that O 0 8.977178445057632e-10
the O 0 1.6592132112691615e-08
mouse O 0 6.318842338259856e-08
is O 0 3.758023614519601e-10
a O 0 3.2872354838175966e-10
suitable O 0 1.4891145205808698e-08
model O 0 8.788851424412769e-09
system O 0 2.3951074012984463e-08
in O 0 4.4602871396293153e-10
which O 0 7.940481605572813e-11
to O 0 2.0367549313782263e-10
investigate O 0 1.138911298603773e-09
the O 0 1.0494783930781182e-09
molecular O 0 2.364658335807235e-08
mechanisms O 0 6.050609613339475e-08
of O 0 8.497302417254105e-09
imprinting O 0 4.170809120296326e-07
in O 0 1.3617106331409445e-09
this O 0 2.960663936235619e-10
region O 0 5.3615227812997546e-09
of O 0 1.3505836449212438e-08
the O 0 2.251128350394538e-08
genome O 0 4.964941169305348e-08
. O 0 1.1167299085457216e-08
. O 0 2.0840241177211283e-07

Mutations O 0 1.6342613662345684e-06
of O 0 6.147558906377526e-07
the O 0 2.485516574779467e-07
ATM O 0 1.6146263078553602e-05
gene O 0 8.831200659642491e-08
detected O 0 6.943015051774637e-08
in O 0 8.908816795383245e-09
Japanese O 0 0.21975979208946228
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
: O 0 6.722678591586373e-08
possible O 0 1.2600503396242857e-07
preponderance O 0 0.000131675842567347
of O 0 1.1005625566440358e-07
the O 0 2.2534567989396237e-08
two O 0 1.1595554738619285e-08
founder O 0 3.587475475796964e-06
mutations O 0 9.804863054796442e-08
4612del165 O 0 3.981422651122557e-06
and O 0 2.712408786464948e-07
7883del5 O 0 5.7781981013249606e-05
. O 0 2.3423517632181756e-06

The O 0 1.0006094271375332e-05
ATM O 0 0.0002124716411344707
( O 0 1.6664181430314784e-06
A O 1 0.9999991655349731
- O 1 0.9999934434890747
T O 1 1.0
, O 0 3.94837478268073e-08
mutated O 0 8.692129682685845e-08
) O 0 3.899672140761368e-09
gene O 0 1.3197630543970718e-08
on O 0 1.4595382680226976e-08
human O 0 4.644467210823677e-08
chromosome O 0 9.318436013927567e-07
11q22 O 0 2.8128564736107364e-05
. O 0 1.797728486963024e-06

3 O 0 2.327239235455636e-05
has O 0 1.6561912730139738e-07
recently O 0 7.752646524750162e-08
been O 0 3.5696441358368247e-09
identified O 0 1.984000075339054e-09
as O 0 6.342091851685439e-10
the O 0 5.75158864979386e-10
gene O 0 1.538441707360505e-09
responsible O 0 1.8646275634637277e-09
for O 0 9.925219535134033e-10
the O 0 9.123702682245494e-09
human O 0 3.364885969858733e-07
recessive B-Disease 0 0.05622270703315735
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999957084655762
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.3065724639745895e-06
. O 0 5.149532626091968e-06

In O 0 6.492087436527072e-07
order O 0 1.6877038433449343e-07
to O 0 1.411431149733744e-08
define O 0 2.513558072791966e-08
the O 0 5.745648401500603e-09
types O 0 2.8028894760723233e-08
of O 0 9.86707249239771e-08
disease O 1 0.9856573343276978
- O 0 1.9960921235906426e-06
causing O 0 1.7756988768269366e-07
ATM O 0 3.7867907849431504e-06
mutations O 0 5.756903398435043e-09
in O 0 2.1427701835108337e-09
Japanese O 0 1.4539415133185685e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.003061870578676462
as O 0 5.003938952086173e-08
well O 0 9.013486845788066e-09
as O 0 3.5653231478249836e-09
to O 0 1.4241618995214367e-09
look O 0 1.3163665713022965e-08
for O 0 5.559629645546238e-09
possible O 0 1.7995743917254003e-07
mutational O 0 6.291337194852531e-05
hotspots O 0 1.731734869281354e-06
, O 0 3.460318920289751e-09
reverse O 0 3.534059089815855e-08
- O 0 3.5823390476252825e-08
transcribed O 0 1.7158704679332004e-08
RNA O 0 1.5922902107945447e-08
derived O 0 1.0131966377002755e-09
from O 0 1.377118419298995e-09
ten O 0 6.281611675262866e-09
patients O 0 6.801661012190152e-09
belonging O 0 1.4335760134542852e-08
to O 0 5.9814162511884206e-09
eight O 0 6.752260617304273e-08
unrelated O 0 8.079469466792943e-07
Japanese O 0 0.2661471366882324
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 5.5104258933624806e-08
was O 0 2.6854337420445518e-08
analyzed O 0 1.381045500181699e-09
for O 0 2.3488153089168406e-10
mutations O 0 3.676701165744589e-10
by O 0 4.830167932290408e-10
the O 0 1.682091976817901e-08
restriction O 0 1.2240649027717154e-07
endonuclease O 0 1.6782502143541933e-06
fingerprinting O 0 2.9890091468587343e-07
method O 0 3.4851206009989255e-07
. O 0 3.963329788803094e-07

As O 0 3.4277895792911295e-06
has O 0 4.186820845575312e-08
been O 0 2.8010707087133824e-09
reported O 0 5.645821588018407e-10
by O 0 1.1437172042771948e-10
others O 0 1.5439152178942095e-09
, O 0 5.636793809493668e-10
mutations O 0 1.5688805810043505e-09
that O 0 6.996262458258684e-10
lead O 0 9.808042733538969e-08
to O 0 1.509837765922839e-08
exon O 0 1.7541826764500001e-06
skipping O 0 9.765258823790646e-08
or O 0 1.0903741021195401e-08
premature O 0 7.485841990728659e-08
protein O 0 2.7453964435153466e-08
truncation O 0 6.02106922542589e-07
were O 0 4.817512433419324e-08
also O 0 3.4100345658316655e-08
predominant O 0 2.5305612325610127e-06
in O 0 7.107203003897666e-08
our O 0 1.2172912420282955e-06
mutants O 0 2.0416697225300595e-05
. O 0 1.472978283345583e-06

Six O 0 5.996017193865555e-07
different O 0 7.208348584697433e-09
mutations O 0 1.1079507089561957e-08
were O 0 2.28530416812589e-09
identified O 0 9.494064201476249e-09
on O 0 6.710365152429176e-09
12 O 0 6.246819506117163e-09
of O 0 9.229347952555145e-09
the O 0 4.182367163707568e-08
16 O 0 1.436555976397358e-07
alleles O 0 2.7840279415158875e-08
examined O 0 4.769867700815666e-07
. O 0 3.714922343078797e-07

Four O 0 1.2483233149396256e-06
were O 0 8.623796787787796e-08
deletions O 0 2.731274548750662e-07
involving O 0 4.26253095042739e-08
a O 0 2.3921947089888818e-08
loss O 0 3.218773940716346e-07
of O 0 2.0080597096239217e-06
a O 0 3.8322508544297307e-07
single O 0 1.5019084287359874e-07
exon O 0 7.328237643378088e-07
exon O 0 1.3308809343470784e-07
7 O 0 5.51143486404726e-08
, O 0 6.37172803408248e-09
exon O 0 1.1838839242273025e-07
16 O 0 9.643908782663857e-08
, O 0 3.3318926284664485e-08
exon O 0 1.4770042753298185e-06
33 O 0 5.500994575413642e-07
or O 0 2.460500923007203e-07
exon O 0 7.3312967288075015e-06
35 O 0 2.228364564871299e-06
. O 0 1.4390298019861802e-06

The O 0 3.2253913104796084e-06
others O 0 4.210533575133013e-07
were O 0 1.5465884928289597e-07
minute O 0 7.776533266223851e-07
deletions O 0 5.602728947451396e-07
, O 0 3.890788136118317e-08
4649delA O 0 1.905171529870131e-06
in O 0 2.1973711739065038e-08
exon O 0 1.2397669024721836e-06
33 O 0 3.926566023437772e-07
and O 0 7.580209882007694e-08
7883del5 O 0 8.755742783250753e-06
in O 0 1.357053918127349e-07
exon O 0 4.321919277572306e-06
55 O 0 1.5811401681276038e-06
. O 0 9.936135256793932e-07

The O 0 3.5105097140331054e-06
mutations O 0 1.513262191110698e-06
4612del165 O 0 7.435449333570432e-06
and O 0 7.367999899088318e-08
7883del5 O 0 1.7799727629608242e-06
were O 0 1.4456301045129294e-08
found O 0 2.020990486073515e-09
in O 0 6.360808546546082e-10
more O 0 1.0093731406257689e-10
than O 0 8.954258862159392e-11
two O 0 2.839194990222893e-10
unrelated O 0 4.571595990654487e-09
families O 0 6.757150949887603e-10
; O 0 4.884979643016152e-10
44 O 0 7.95713628320982e-09
% O 0 1.1373764152722288e-09
( O 0 2.167846568923437e-09
7 O 0 4.150025390003975e-08
of O 0 4.3502680568963115e-08
16 O 0 4.573464806867378e-08
) O 0 1.4300250983367846e-09
of O 0 6.117342632450118e-09
the O 0 6.58847421064479e-09
mutant O 0 1.0677436712569488e-08
alleles O 0 4.215029159038153e-10
had O 0 9.004650913801981e-10
one O 0 2.583154801172327e-10
of O 0 2.2796968757177183e-09
the O 0 1.3070296844830409e-08
two O 0 2.194263437615973e-08
mutations O 0 2.910500711550412e-07
. O 0 4.7068127173588437e-07

The O 0 5.993163085804554e-06
4612del165 O 0 2.251963633170817e-05
mutations O 0 1.8300974602425413e-07
in O 0 9.513931864546521e-09
three O 0 1.4313349394612374e-09
different O 0 4.0585901306400274e-10
families O 0 1.0910392589380535e-09
were O 0 9.636104136845347e-10
all O 0 3.4712444030304823e-10
ascribed O 0 1.7706486943325217e-08
to O 0 3.662313119434657e-09
the O 0 1.5561113286821637e-08
same O 0 9.506131881664714e-09
T O 0 1.3002560308450484e-06
- O 0 1.952141985839262e-07
- O 0 1.1618982398431399e-07
> O 0 6.220937365242207e-08
A O 0 2.3684952665803394e-08
substitution O 0 3.345335386484294e-08
at O 0 1.6793096691003484e-08
the O 0 3.060350639572107e-09
splice O 0 4.268698603482335e-07
donor O 0 1.2531854665098763e-08
site O 0 2.8527033180125727e-08
in O 0 8.137883256154055e-09
intron O 0 1.5229073142108973e-05
33 O 0 3.7636482375091873e-06
. O 0 1.2988953130843583e-06

Microsatellite O 0 0.005617982242256403
genotyping O 0 0.0002423199184704572
around O 0 4.198888916562282e-07
the O 0 1.3218014771609887e-07
ATM O 0 1.8831027773558162e-05
locus O 0 3.619699953105737e-07
also O 0 1.6320810258818597e-09
indicated O 0 2.2305095548347253e-09
that O 0 1.5729847979706335e-10
a O 0 1.6320188533924807e-09
common O 0 2.537880838815454e-08
haplotype O 0 1.7661006950220326e-06
was O 0 4.193838165633679e-08
shared O 0 4.298058353668921e-09
by O 0 2.7333138530316603e-10
the O 0 3.5490126393256105e-09
mutant O 0 4.293399058497016e-08
alleles O 0 7.276741875728021e-09
in O 0 2.6478761405712703e-09
both O 0 9.657157740150524e-09
mutations O 0 3.1744428952151793e-07
. O 0 1.1704275948432041e-06

This O 0 1.2282288253118168e-07
suggests O 0 5.83766883721637e-08
that O 0 3.8338401897597407e-10
these O 0 5.325979102188683e-10
two O 0 2.5450974661112014e-09
founder O 0 6.1633941186300945e-06
mutations O 0 2.63206665351845e-08
may O 0 1.8966817449950213e-08
be O 0 4.634332917419215e-09
predominant O 0 4.016572802356677e-06
among O 0 4.613697157651586e-08
Japanese O 0 1.8929611087514786e-06
ATM O 0 9.33151659410214e-06
mutant O 0 4.6359267003026616e-07
alleles O 0 1.701586427316215e-07
. O 0 2.1943309036487335e-07

W474C O 0 6.968856905587018e-05
amino O 0 8.309191912303504e-07
acid O 0 1.0930232008377061e-07
substitution O 0 7.149514402726709e-08
affects O 0 8.020707653599857e-09
early O 0 1.8694858994194874e-08
processing O 0 2.3427954687349484e-08
of O 0 6.4048459869070484e-09
the O 0 6.405456609570592e-09
alpha O 0 2.323286985017603e-08
- O 0 2.1048469633910827e-09
subunit O 0 2.19018536640192e-09
of O 0 1.7663301932202558e-09
beta O 0 1.1940111122044073e-08
- O 0 1.76410228647228e-08
hexosaminidase O 0 1.1404002009385295e-07
A O 0 1.1431775526205001e-08
and O 0 8.458441169700848e-10
is O 0 4.584271851015842e-10
associated O 0 2.2240014274643727e-09
with O 0 4.035928036216774e-09
subacute O 1 0.9999991655349731
G B-Disease 1 0.9991440773010254
( I-Disease 0 1.8416350258121383e-06
M2 I-Disease 0 0.00025966030079871416
) I-Disease 0 2.9340665719246317e-07
gangliosidosis I-Disease 0 8.170267392415553e-05
. O 0 1.334326611868164e-06

Mutations O 0 6.710937668685801e-06
in O 0 5.373534008867864e-07
the O 0 4.7137078240666597e-07
HEXA O 0 0.0004052024451084435
gene O 0 7.320637962493493e-08
, O 0 3.180222307719305e-09
encoding O 0 3.7265213137516184e-08
the O 0 2.636719464987891e-08
alpha O 0 7.18034485203134e-08
- O 0 1.7970235077768848e-08
subunit O 0 8.899747605539687e-09
of O 0 5.4254365444705854e-09
beta O 0 6.732521029562122e-08
- O 0 7.736723262041778e-08
hexosaminidase O 0 5.5263399190153e-07
A O 0 1.19420519695268e-07
( O 0 7.683923719525865e-09
Hex O 0 2.564109706781892e-07
A O 0 3.858581010263151e-08
) O 0 1.7648418282334433e-09
, O 0 9.414410362396097e-10
that O 0 1.3202331450301585e-09
abolish O 0 1.3255140629553352e-07
Hex O 0 1.0306425792805385e-06
A O 0 9.280650203891128e-08
enzyme O 0 2.8752968006529045e-08
activity O 0 2.1898022950495033e-08
cause O 0 9.975632565328851e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
( O 0 5.427974656413426e-07
TSD B-Disease 1 0.9999973773956299
) O 0 1.9778386928237524e-08
, O 0 4.1141716700110464e-09
the O 0 1.585595654773897e-08
fatal O 0 6.096849119785475e-06
infantile B-Disease 0 2.421659701212775e-06
form I-Disease 0 5.298425165278786e-08
of I-Disease 0 3.441185981500894e-06
G I-Disease 0 0.001154666650108993
( I-Disease 0 1.2739542398776393e-07
M2 I-Disease 0 7.942740012367722e-06
) I-Disease 0 2.011227984155539e-08
gangliosidosis I-Disease 0 2.294049863849068e-06
, I-Disease 0 1.3375759166933676e-08
Type I-Disease 0 1.167364416687633e-06
1 I-Disease 0 3.548362428773544e-06
. O 0 1.0065155038319062e-06

Less O 0 8.83377742866287e-06
severe O 0 0.11171663552522659
, O 0 2.8139295409346232e-06
subacute O 1 1.0
( O 0 3.264418774051592e-05
juvenile O 1 0.9999828338623047
- O 0 3.309076782898046e-05
onset O 1 0.9999982118606567
) O 0 9.23276743947099e-08
and O 0 6.793327145260264e-08
chronic O 1 0.9999853372573853
( O 0 9.189512439888858e-08
adult O 0 1.0842757092177635e-06
- O 0 5.411837378233031e-07
onset O 0 0.00011980516865151003
) O 0 2.2678485755989186e-09
variants O 0 6.488148240890723e-09
are O 0 6.762588405928582e-11
characterized O 0 1.4919681046166033e-09
by O 0 1.1572320879338349e-10
a O 0 2.418601097176065e-09
broad O 0 4.751615989562197e-08
spectrum O 0 3.5953522115050873e-07
of O 0 9.188948268956665e-09
clinical O 0 3.803777133271069e-07
manifestations O 0 1.0499149539100472e-05
and O 0 8.561122477601657e-09
are O 0 2.462983705875388e-10
associated O 0 1.2005003657833413e-09
with O 0 2.032389118111766e-10
residual O 0 3.4256484582328994e-07
levels O 0 4.4224506723367085e-08
of O 0 2.9370722742783073e-08
Hex O 0 1.0773645726658287e-06
A O 0 3.199660625341494e-07
enzyme O 0 9.006513579379316e-08
activity O 0 9.825830460385987e-08
. O 0 2.703127961467544e-07

We O 0 3.269722810728126e-06
identified O 0 9.977021591112134e-07
a O 0 4.025213797831384e-07
1422 O 0 9.251001029042527e-05
G O 0 3.140293119940907e-05
- O 0 5.409750428952975e-06
- O 0 7.22253957974317e-07
> O 0 3.5043643720200635e-07
C O 0 1.992330993516589e-07
( O 0 9.65376445449806e-10
amino O 0 1.1763423568567077e-09
acid O 0 1.8302861448660224e-09
W474C O 0 8.101395998494354e-09
) O 0 5.54755894000003e-11
substitution O 0 2.13282924654834e-09
in O 0 9.52249612495848e-10
the O 0 2.4581792157363225e-09
first O 0 2.176862468061813e-09
position O 0 2.3852420483194692e-08
of O 0 2.2383780162726907e-08
exon O 0 2.0907185671603656e-07
13 O 0 2.035184110127375e-08
of O 0 2.810834409672225e-08
HEXA O 0 0.0008314948645420372
of O 0 3.279945985923405e-07
a O 0 1.569232352949257e-07
non O 0 3.2131737270901795e-07
- O 0 4.5616033617079665e-07
Jewish O 0 1.0068114164596409e-07
proband O 0 5.6924527598312125e-06
who O 0 1.8107794375055164e-08
manifested O 0 6.393339191390623e-08
a O 0 3.621581257107209e-08
subacute O 1 0.9600288271903992
variant O 0 0.0242230873554945
of O 0 0.0018895510584115982
G B-Disease 1 0.9999352693557739
( I-Disease 0 2.115233201038791e-06
M2 I-Disease 0 0.0002745266247075051
) I-Disease 0 2.9950612656648445e-07
gangliosidosis I-Disease 0 5.250541653367691e-05
. O 0 1.1003260169673013e-06

On O 0 7.5998054853698704e-06
the O 0 4.3277822214804473e-07
second O 0 8.702927516424097e-07
maternally O 0 2.726886350501445e-06
inherited O 0 2.2575020466319984e-06
allele O 0 7.310772787150199e-08
, O 0 4.6904817807558175e-09
we O 0 2.685791145040639e-09
identified O 0 6.902686422449733e-09
the O 0 6.517631323532669e-09
common O 0 6.000735538691515e-06
infantile O 1 0.9999973773956299
disease O 1 0.9999998807907104
- O 0 3.2011648727348074e-05
causing O 0 2.3542099825135665e-06
4 O 0 4.7583002924511675e-06
- O 0 1.4518523130391259e-06
bp O 0 7.841135811759159e-07
insertion O 0 2.5252307978007593e-07
, O 0 1.2379901548342787e-08
+ O 0 3.3970258073168225e-07
TATC O 0 0.00014298009045887738
1278 O 0 6.578875036211684e-05
, O 0 5.3063441640688325e-08
in O 0 2.7013490111471583e-08
exon O 0 1.6601208017164026e-06
11 O 0 8.118861387629295e-07
. O 0 4.71276422331357e-07

Pulse O 0 0.0007400434697046876
- O 0 4.159991294727661e-05
chase O 0 3.0456540116574615e-06
analysis O 0 6.934293139693182e-08
using O 0 9.960558600141667e-08
proband O 0 6.638531431235606e-06
fibroblasts O 0 9.374742830914329e-07
revealed O 0 1.447904480755824e-07
that O 0 2.358675255109688e-09
the O 0 1.4170634443644303e-08
W474C O 0 5.082584948468138e-07
- O 0 3.310708862613865e-08
containing O 0 4.411008891480606e-09
alpha O 0 3.1513192055854233e-08
- O 0 1.498162660595881e-08
subunit O 0 1.04799067202066e-08
precursor O 0 1.5975500033960088e-08
was O 0 3.866240660954645e-09
normally O 0 5.929615132238553e-10
synthesized O 0 4.8993142875985995e-09
, O 0 2.0183237026127898e-10
but O 0 2.220312822487358e-10
not O 0 1.9577604815079752e-10
phosphorylated O 0 1.809916128081568e-08
or O 0 1.7775373395423344e-09
secreted O 0 1.577931674212607e-09
, O 0 5.027084304387586e-10
and O 0 1.4510825874225475e-09
the O 0 1.1374334363267735e-08
mature O 0 8.359474179542303e-08
lysosomal O 0 3.894726887665456e-06
alpha O 0 1.9474374823857943e-07
- O 0 5.3509822350861214e-08
subunit O 0 4.1895528823943096e-08
was O 0 2.5743041476289363e-08
not O 0 2.27726326684774e-09
detected O 0 1.4913777590663813e-07
. O 0 1.5163782052241004e-07

When O 0 5.307889296091162e-06
the O 0 1.4707379705214407e-06
W474C O 0 1.0918060070252977e-05
- O 0 6.021115268595167e-07
containing O 0 7.108558719437497e-08
alpha O 0 2.930864297923108e-07
- O 0 8.5797616122818e-08
subunit O 0 5.0704812792901066e-08
was O 0 1.2301607910103485e-07
transiently O 0 4.399122417453327e-07
co O 0 1.7161855225822364e-07
- O 0 3.388509028923181e-08
expressed O 0 6.6693166544951055e-09
with O 0 1.0126827154621765e-09
the O 0 7.778385935353072e-09
beta O 0 3.254225333648719e-08
- O 0 1.3610050864087953e-08
subunit O 0 3.043283847148359e-09
to O 0 4.517609064613737e-10
produce O 0 1.2744993505009461e-08
Hex O 0 5.706714887310227e-07
A O 0 2.709750788199017e-07
( O 0 2.7443180172781467e-08
alphabeta O 0 4.140903911320493e-06
) O 0 1.583238429248013e-08
in O 0 1.4845996432200081e-08
COS O 0 0.00025875557912513614
- O 0 7.985219099282403e-07
7 O 0 1.0935403338407923e-07
cells O 0 3.240388579683895e-08
, O 0 2.0406325518251833e-09
the O 0 4.6723021007721854e-09
mature O 0 1.0106725234493297e-08
alpha O 0 3.258224978708313e-08
- O 0 1.0188675680922188e-08
subunit O 0 5.225837984568216e-09
was O 0 3.0130078432222263e-09
present O 0 2.322035203006223e-10
, O 0 2.7382501821549e-10
but O 0 2.476040761312248e-10
its O 0 1.2762598755600152e-09
level O 0 1.8231306242455503e-08
was O 0 1.5351067972346755e-08
much O 0 3.0679014884071876e-09
lower O 0 5.078182763185168e-09
than O 0 7.882295510741599e-11
that O 0 3.070649984282525e-11
from O 0 3.4490035827339227e-10
normal O 0 4.2043919457057655e-09
alpha O 0 1.8131814272237534e-08
- O 0 6.240484129449442e-09
subunit O 0 4.877812820325289e-09
transfections O 0 6.755507087063961e-08
, O 0 2.40912040316843e-10
although O 0 4.451431445673393e-10
higher O 0 5.519110946039518e-09
than O 0 3.8385816747421586e-10
in O 0 2.436732482458126e-10
those O 0 2.3764662460123986e-10
cells O 0 4.065045633439013e-09
transfected O 0 1.024060054533038e-07
with O 0 1.9496294856313767e-10
an O 0 6.211943737177705e-10
alpha O 0 3.38982140135613e-08
- O 0 2.4542451626530237e-08
subunit O 0 2.46048834640078e-08
associated O 0 1.0368861325105172e-08
with O 0 1.5793476748626745e-08
infantile O 0 0.00038495377521030605
TSD B-Disease 1 0.9993939399719238
. O 0 4.754476321977563e-06

Furthermore O 0 1.0449135515955277e-05
, O 0 3.26209971035496e-07
the O 0 1.3272888566007168e-07
precursor O 0 2.8219781142979627e-06
level O 0 4.6189890667847067e-07
of O 0 1.6833253368986334e-07
the O 0 3.920518665267991e-08
W474C O 0 5.903642659177422e-07
alpha O 0 8.957601949077798e-08
- O 0 1.1686588585746449e-08
subunit O 0 4.946506759750946e-09
was O 0 3.3100884255787832e-09
found O 0 4.493718175346828e-10
to O 0 5.881092279835798e-10
accumulate O 0 2.7244007938520554e-08
in O 0 1.7188241940857552e-09
comparison O 0 1.0125131844063162e-08
to O 0 5.009991532745062e-09
the O 0 1.1093971075126774e-08
normal O 0 8.54248227710741e-08
alpha O 0 2.6357599836046575e-07
- O 0 6.791578499587558e-08
subunit O 0 1.471738215741425e-07
precursor O 0 3.5325973612998496e-07
levels O 0 1.318568365604733e-07
. O 0 2.53596084576202e-07

We O 0 2.3759439500281587e-06
conclude O 0 1.3735588026975165e-06
that O 0 2.994869419126189e-08
the O 0 9.170830139737518e-08
1422 O 0 4.3105825170641765e-05
G O 0 3.910073792212643e-05
- O 0 5.69961775909178e-06
- O 0 7.535493296018103e-07
> O 0 1.3582787516952521e-07
C O 0 1.7903015248066367e-07
mutation O 0 1.4624996769185827e-09
is O 0 1.1486907952606984e-10
the O 0 6.209018299507818e-10
cause O 0 1.089696333167467e-08
of O 0 1.2818367167710676e-07
Hex B-Disease 0 0.00025284444564022124
A I-Disease 0 0.0007852456765249372
enzyme I-Disease 1 0.9999901056289673
deficiency I-Disease 1 0.9999998807907104
in O 0 2.6817177811722104e-08
the O 0 2.1817608342189487e-07
proband O 0 4.9479989684186876e-05
. O 0 1.0721455510065425e-06

The O 0 2.8011156700813444e-06
resulting O 0 3.4736635825538542e-06
W474C O 0 1.7404337995685637e-05
substitution O 0 1.412689698554459e-06
clearly O 0 2.413430308934039e-07
interferes O 0 1.1522165266342199e-07
with O 0 5.8558882187753625e-09
alpha O 0 8.118276184632123e-08
- O 0 1.5000267694631475e-08
subunit O 0 4.531902852988878e-09
processing O 0 3.939955028897657e-09
, O 0 1.3312523305941681e-10
but O 0 1.2984484321076906e-10
because O 0 1.8427975811974306e-10
the O 0 4.6203327275229356e-10
base O 0 1.0013471829495302e-08
substitution O 0 3.008243254498666e-08
falls O 0 2.7798370183518273e-07
at O 0 8.948752849846642e-09
the O 0 1.3967332845865599e-09
first O 0 2.389439091032841e-09
position O 0 3.299903283959793e-08
of O 0 2.876689997322046e-08
exon O 0 1.257071318150338e-07
13 O 0 1.3093951700682283e-08
, O 0 1.3322690728401199e-09
aberrant O 0 4.124820307538357e-08
splicing O 0 1.910031102170251e-07
may O 0 5.117191115289188e-09
also O 0 1.003491956197422e-09
contribute O 0 1.1533940469377058e-09
to O 0 1.2781704583630926e-08
Hex B-Disease 0 0.0012641744688153267
A I-Disease 0 0.0009983525378629565
deficiency I-Disease 1 0.9999946355819702
in O 0 5.415741455294665e-08
this O 0 1.3476603832884848e-08
proband O 0 1.4096270206209738e-05
. O 0 4.218121674171016e-08
. O 0 1.3459488457101543e-07

Two O 0 1.243176711795968e-06
frequent O 0 3.761487960218801e-06
missense O 0 4.4262407755013555e-05
mutations O 0 4.082253326487262e-06
in O 0 1.5936825548124034e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0009007740300148726

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.947842065419536e-06
an O 0 2.1676796677638777e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.7275497317314148
by O 0 4.134950160050721e-08
early O 1 0.5171998739242554
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 1 0.9999783039093018

A O 0 7.536710654676426e-06
century O 0 4.519519734458299e-06
after O 0 7.187415462794888e-08
its O 0 3.60983487546207e-09
recognition O 0 2.7134946734008736e-08
as O 0 1.4877376663946507e-08
a O 0 3.219454924874299e-08
syndrome O 0 3.728016235982068e-05
by O 0 3.07460301662843e-09
Vaughan O 0 5.113699444336817e-06
Pendred O 0 0.025701304897665977
, O 0 1.1399810873058414e-08
the O 0 3.475057042123808e-08
disease O 0 8.19256529211998e-05
gene O 0 1.0194821697950829e-07
( O 0 3.487121347234279e-08
PDS O 0 0.39561963081359863
) O 0 6.627801241165798e-08
was O 0 7.089087716849463e-07
mapped O 0 5.343460998119554e-07
to O 0 5.849572559668559e-08
chromosome O 0 1.00962745364086e-06
7q22 O 0 5.222566323936917e-05
- O 0 3.1556934118270874e-05
q31 O 0 7.64656942919828e-05
. O 0 1.6113690435304306e-06

1 O 0 9.219907951774076e-06
and O 0 1.4726607844295359e-07
, O 0 2.8987599876018066e-08
recently O 0 7.626603348853678e-08
, O 0 2.4741722004506528e-09
found O 0 1.1068771454958437e-09
to O 0 1.3440351054327948e-09
encode O 0 2.3892306799666585e-08
a O 0 4.5755236044442427e-08
putative O 0 2.83531189779751e-05
sulfate O 0 0.03663600608706474
transporter O 1 0.8870580196380615
. O 0 5.721172783523798e-06

We O 0 8.046865218602761e-07
performed O 0 1.4649859281234967e-07
mutation O 0 1.1614988970620743e-08
analysis O 0 6.0555720438060234e-09
of O 0 1.8710410998323823e-08
the O 0 4.9428027892872706e-08
PDS B-Disease 0 0.3938746452331543
gene O 0 9.770251097052096e-08
in O 0 4.466563563454429e-09
patients O 0 1.0595782384825725e-07
from O 0 3.7226353555297464e-08
14 O 0 1.8398920076379e-07
Pendred B-Disease 0 0.0002608734939713031
families O 0 1.70434990565127e-08
originating O 0 3.5085570004866895e-08
from O 0 2.9548434810067192e-09
seven O 0 2.5003115133870324e-09
countries O 0 1.5190189384117758e-10
and O 0 1.9682451224412034e-09
identified O 0 1.2682671801655943e-08
all O 0 1.1295876234385105e-08
mutations O 0 1.770561652847391e-07
. O 0 2.869687136808352e-07

The O 0 2.084013203784707e-06
mutations O 0 2.468705986302666e-07
include O 0 1.1458149629106629e-07
three O 0 3.699990358541072e-08
single O 0 2.77634963907758e-08
base O 0 7.481801276298938e-07
deletions O 0 7.521851443925698e-07
, O 0 1.5029824496082256e-08
one O 0 6.841200939078362e-09
splice O 0 1.663940679463849e-06
site O 0 5.17311136150056e-08
mutation O 0 4.499638439625642e-09
and O 0 4.401259801056767e-09
10 O 0 8.636998671818219e-08
missense O 0 6.752486569894245e-06
mutations O 0 8.763425967117655e-07
. O 0 1.2871216767962324e-06

One O 0 2.692501993806218e-06
missense O 0 7.190868927864358e-06
mutation O 0 9.095904829337087e-08
( O 0 2.1138038874823906e-08
L236P O 0 1.4485344763670582e-06
) O 0 5.239141565027694e-09
was O 0 3.930716729882988e-08
found O 0 2.4653585839473635e-09
in O 0 1.1029803737017119e-09
a O 0 4.038669398909178e-09
homozygous O 0 8.211414659342609e-09
state O 0 1.1126515264692216e-09
in O 0 8.778643922902063e-10
two O 0 2.779325880553074e-09
consanguineous O 0 2.6424525003676536e-06
families O 0 1.0624050084118153e-08
and O 0 5.5913731422663204e-09
in O 0 2.7906295052559926e-09
a O 0 6.891636150641034e-09
heterozygous O 0 3.8698115822910495e-09
state O 0 6.46024955752722e-10
in O 0 5.887400011950206e-10
five O 0 1.0004150841069759e-09
additional O 0 8.126514572381893e-09
non O 0 8.598434533269028e-07
- O 0 6.4318141994590405e-06
consanguineous O 0 7.10233289282769e-05
families O 0 3.2653738912813424e-07
. O 0 5.706421006834717e-07

Another O 0 7.872419701016042e-06
missense O 0 1.6641039110254496e-05
mutation O 0 3.6854606833003345e-07
( O 0 5.054953788885541e-08
T416P O 0 2.7111670988233527e-06
) O 0 9.148166668637714e-09
was O 0 5.332937647040126e-08
found O 0 1.970840823872777e-09
in O 0 1.0740465183900483e-09
a O 0 2.290208689359474e-09
homozygous O 0 3.635753920150364e-09
state O 0 8.123875461230057e-10
in O 0 8.091014525035689e-10
one O 0 3.111450652681924e-09
family O 0 8.751781521709745e-09
and O 0 1.9756696278960817e-09
in O 0 1.9990040733830483e-09
a O 0 1.339730815175244e-08
heterozygous O 0 4.967477096329276e-09
state O 0 1.1523100251764617e-09
in O 0 1.8993344674811397e-09
four O 0 1.1480634221072705e-08
families O 0 4.863128211241019e-08
. O 0 2.824415616942133e-07

Pendred B-Disease 1 0.9774237275123596
patients O 0 0.0001673850347287953
in O 0 3.494315876650944e-07
three O 0 2.1199414845796127e-07
non O 0 9.765780305315275e-06
- O 0 3.1233561458066106e-05
consanguineous O 0 0.0015138981398195028
families O 0 5.79585304194552e-08
were O 0 5.192899443784427e-09
shown O 0 2.1744805955847823e-09
to O 0 9.825221747306045e-10
be O 0 3.2411657802100535e-09
compound O 0 6.751217824785272e-07
heterozygotes O 0 5.934734872425906e-07
for O 0 4.08872544710448e-08
L236P O 0 4.970871941623045e-06
and O 0 2.3191125819721492e-07
T416P O 0 2.2800193619332276e-05
. O 0 1.6578773056608043e-06

In O 0 2.8263744411560765e-07
total O 0 8.947882434995336e-09
, O 0 3.6544840487096053e-09
one O 0 7.271424018462369e-10
or O 0 8.318828403908185e-10
both O 0 4.4692630152276536e-10
of O 0 1.4135480563837177e-09
these O 0 4.379819562583265e-10
mutations O 0 9.31234589440777e-10
were O 0 7.157844872374142e-10
found O 0 7.814487390511715e-10
in O 0 5.778573175518886e-10
nine O 0 7.159227433106707e-09
of O 0 2.6621684412475588e-08
the O 0 8.237238802166758e-08
14 O 0 1.38215355605098e-07
families O 0 4.042215806521199e-08
analyzed O 0 1.879769797596964e-07
. O 0 2.744570508639299e-07

The O 0 5.881299784959992e-07
identification O 0 2.3914037683425704e-07
of O 0 1.0930898497463204e-07
two O 0 1.9314436272566127e-08
frequent O 0 3.6660475188909913e-07
PDS B-Disease 0 0.005695282947272062
mutations O 0 3.265529002760559e-08
will O 0 2.083366368310635e-09
facilitate O 0 1.0326605348609519e-08
the O 0 1.0970370389884465e-08
molecular O 0 8.73698127179523e-07
diagnosis O 1 0.9825887680053711
of O 0 0.10883565992116928
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.695501072797924e-05

Insertional O 0 0.00024330406449735165
mutation O 0 5.71201837828994e-07
by O 0 2.991170333643822e-08
transposable O 0 2.1160554751986638e-05
element O 0 2.0397599200805416e-06
, O 0 1.888495262392098e-07
L1 O 0 0.0007450127159245312
, O 0 3.182881869179255e-08
in O 0 9.241502674228741e-09
the O 0 1.2204863253373333e-07
DMD B-Disease 1 1.0
gene O 0 2.5332775521746953e-07
results O 0 1.6595741669789277e-08
in O 0 2.3483696764969864e-08
X B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999991655349731
linked I-Disease 1 0.9999992847442627
dilated I-Disease 1 0.9999995231628418
cardiomyopathy I-Disease 1 1.0
. O 0 0.0003887184720952064

X B-Disease 1 0.9999939203262329
- I-Disease 1 0.99992835521698
linked I-Disease 1 0.997646152973175
dilated I-Disease 1 0.999992847442627
cardiomyopathy I-Disease 1 1.0
( O 0 4.171484033577144e-05
XLDCM B-Disease 1 1.0
) O 0 2.3660659209667756e-08
is O 0 1.3433432144438484e-09
a O 0 2.8378213112745243e-09
clinical O 0 3.95161492861007e-07
phenotype O 0 1.966690888366429e-06
of O 0 5.775095814897213e-07
dystrophinopathy B-Disease 0 0.026494085788726807
which O 0 1.8226394837839166e-09
is O 0 3.11309922285119e-10
characterized O 0 2.496070905522174e-09
by O 0 4.918487284122364e-10
preferential O 0 6.815714641561499e-07
myocardial B-Disease 1 0.9998923540115356
involvement I-Disease 0 3.1285080126508547e-07
without O 0 1.5892227978042683e-08
any O 0 4.721520507899868e-09
overt O 0 4.7010349391030104e-08
clinical O 0 3.2804308602862875e-07
signs O 0 2.357840287459112e-07
of O 0 9.696744200482499e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9928386807441711

To O 0 2.3909635160634934e-07
date O 0 9.254688393411925e-07
, O 0 1.2220698231146798e-08
several O 0 2.4613460158917633e-09
mutations O 0 1.21361010130272e-08
in O 0 8.833437092903296e-09
the O 0 5.058344072494947e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9342730641365051
, O 0 9.273814612242859e-06
DMD O 1 1.0
, O 0 2.9659631763934158e-06
have O 0 1.5994341850955607e-08
been O 0 1.1317527359722135e-08
identified O 0 6.301700494759643e-09
in O 0 3.989986119279365e-10
patients O 0 3.4246594449172107e-09
with O 0 2.2842103764020294e-09
XLDCM B-Disease 1 1.0
, O 0 3.8933940516017174e-08
but O 0 4.872447334491881e-09
a O 0 6.162488741523475e-09
pathogenic O 0 2.1137635641821362e-08
correlation O 0 2.716206592978665e-09
of O 0 3.8175262950801425e-09
these O 0 2.7220878884293143e-09
cardiospecific O 0 1.8623343294166261e-06
mutations O 0 7.325425599447044e-09
in O 0 2.4352098115798526e-09
DMD O 1 1.0
with O 0 2.223179684790466e-08
the O 0 6.217603640834568e-07
XLDCM B-Disease 1 0.9999202489852905
phenotype O 0 1.883895265564206e-06
has O 0 1.4360717948136426e-08
remained O 0 5.467126129587996e-08
to O 0 2.7013475900616868e-09
be O 0 1.5019393728721298e-08
elucidated O 0 5.6863482313929126e-05
. O 0 1.6636265627312241e-06

We O 0 1.1220824944757624e-06
report O 0 1.5784824825004762e-07
here O 0 2.6301195887867834e-08
the O 0 5.2200896938359165e-09
identification O 0 9.21784248930635e-09
of O 0 1.4493848787822117e-08
a O 0 1.4556404970278436e-08
unique O 0 9.008969925616839e-08
de O 0 1.4095392089075176e-06
novo O 0 1.5918785720714368e-05
L1 O 0 7.247039320645854e-05
insertion O 0 9.005248671201116e-07
in O 0 1.55272257273964e-08
the O 0 1.1574341485243167e-08
muscle O 0 2.998951131871763e-08
exon O 0 2.940503804893524e-07
1 O 0 4.130425423909401e-08
in O 0 8.868771494974226e-09
DMD O 1 1.0
in O 0 1.5109174000826897e-07
three O 0 1.434581804460322e-07
XLDCM B-Disease 1 0.9998906850814819
patients O 0 3.007423288181599e-07
from O 0 2.6346382853148498e-08
two O 0 1.0764424018816499e-08
unrelated O 0 4.330969716193067e-07
Japanese O 0 9.929192856361624e-06
families O 0 1.9784806681855116e-07
. O 0 7.369087597908219e-07

The O 0 1.9867900391545845e-06
insertion O 0 3.24947950502974e-06
was O 0 1.2592782923093182e-06
a O 0 4.8594010593205894e-08
5 O 0 8.787514360619753e-08
- O 0 3.346248078628378e-08
truncated O 0 2.6748111281449383e-08
form O 0 1.0105723369235875e-08
of O 0 3.679391724631387e-08
human O 0 4.482320292709119e-08
L1 O 0 2.425850425424869e-06
inversely O 0 2.2699535406900395e-07
integrated O 0 6.255800144572277e-07
in O 0 8.1625692871512e-09
the O 0 2.908524088240938e-08
5 O 0 1.2012860395316238e-07
- O 0 5.665135631716112e-07
untranslated O 1 0.8354711532592773
region O 0 3.179975749389996e-07
in O 0 6.707818300810686e-09
the O 0 1.2697582540965868e-08
muscle O 0 6.419548981284606e-08
exon O 0 1.0838389385980918e-07
1 O 0 1.9602810041874363e-08
, O 0 2.769080242881472e-10
which O 0 1.3970577472655066e-10
affected O 0 2.40521424998974e-09
the O 0 1.672099081417855e-08
transcription O 0 1.0949590887321392e-06
or O 0 1.542403182952512e-08
the O 0 2.6059414182100227e-08
stability O 0 1.7686121509541408e-06
of O 0 1.6427151194875478e-07
the O 0 5.787468637663551e-08
muscle O 0 4.527688801658769e-08
form O 0 1.089633983042404e-08
of O 0 6.9249487921752e-08
dystrophin O 0 2.6726038413471542e-06
transcripts O 0 5.396654501055309e-08
but O 0 3.14506531928771e-10
not O 0 4.6785932766857385e-11
that O 0 6.668699620293594e-11
of O 0 3.897240752337439e-09
the O 0 8.299341658357662e-08
brain O 0 0.002287451643496752
or O 0 8.081829605544044e-08
Purkinje O 0 0.0056342254392802715
cell O 0 3.386866637811181e-06
form O 0 2.4534026366040962e-08
, O 0 1.1150824263950199e-08
probably O 0 2.811247838963027e-07
due O 0 3.089365634423302e-07
to O 0 1.3348769201115829e-08
its O 0 1.1034670066578656e-08
unique O 0 4.547803200694034e-08
site O 0 1.2249033431999123e-07
of O 0 6.779102079690347e-08
integration O 0 1.5174616692092968e-06
. O 0 9.11556298888172e-07

We O 0 7.660505048079358e-07
speculate O 0 1.4641688039773726e-07
that O 0 9.449003801620393e-10
this O 0 3.9267339380089084e-10
insertion O 0 6.437549160409617e-08
of O 0 1.9269396744903133e-08
an O 0 2.2855615178229982e-09
L1 O 0 1.462748286940041e-06
sequence O 0 1.5062310509961208e-08
in O 0 4.2137688893717495e-09
DMD O 1 1.0
is O 0 1.0586183485372658e-08
responsible O 0 5.12213205183798e-09
for O 0 4.503430961477761e-10
some O 0 2.6222127247343963e-10
of O 0 3.901063472255828e-09
the O 0 1.7395297424727119e-09
population O 0 8.733629791590758e-11
of O 0 1.91241000813136e-09
Japanese O 0 3.268106070208887e-07
patients O 0 2.7503968880182583e-08
with O 0 7.690874603838438e-09
XLDCM B-Disease 1 0.6908715963363647
. O 0 1.9372865267541783e-07
. O 0 9.55466703089769e-07

Severe O 0 0.3891238570213318
early O 0 0.18811477720737457
- O 1 0.9995548129081726
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 7.902621291577816e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.15848584473133087
red O 1 0.999373733997345
hair O 0 0.015057926066219807
pigmentation O 1 0.9274119734764099
caused O 0 6.607482646359131e-05
by O 0 3.229886829103634e-07
POMC O 1 1.0
mutations O 0 3.494729980957345e-06
in O 0 1.0371516623308707e-07
humans O 0 2.695199327718001e-06
. O 0 6.742106961610261e-07

Sequential O 0 3.353328429511748e-05
cleavage O 0 2.8774351449101232e-05
of O 0 3.061478537347284e-06
the O 0 3.779456392294378e-07
precursor O 0 4.384660769574111e-06
protein O 0 4.055468707520049e-07
pre O 0 3.8602597669523675e-06
- O 0 2.1244113668217324e-06
pro O 0 1.0646326700225472e-05
- O 0 6.5500876189616974e-06
opiomelanocortin O 0 9.486865747021511e-05
( O 0 1.50002165355545e-07
POMC O 0 0.0013295630924403667
) O 0 1.2257816095484486e-08
generates O 0 1.8424374914616237e-08
the O 0 3.490129074634751e-08
melanocortin O 0 3.580699922167696e-05
peptides O 0 5.951636694589979e-07
adrenocorticotrophin O 0 7.985638148966245e-06
( O 0 3.06029939167729e-08
ACTH O 0 6.849952569609741e-06
) O 0 3.6091822863681955e-08
, O 0 5.974588646040502e-08
melanocyte O 0 0.004353121854364872
- O 0 1.9691302441060543e-05
stimulating O 0 4.4131149934401037e-07
hormones O 0 4.251010210509776e-08
( O 0 5.617177389893868e-09
MSH O 0 1.1334473128954414e-05
) O 0 4.071152304163661e-09
alpha O 0 2.1001081762506146e-08
, O 0 5.364548250064161e-10
beta O 0 3.68394004190975e-09
and O 0 6.347537495621225e-10
gamma O 0 6.393860996212197e-09
as O 0 1.1274688960227763e-09
well O 0 1.4712711049469362e-09
as O 0 1.874433719351032e-09
the O 0 3.959950145571156e-09
opioid O 0 4.3604612187664316e-07
- O 0 2.7336980679137923e-07
receptor O 0 5.126552693468511e-08
ligand O 0 2.3900335577309306e-07
beta O 0 4.3697943397091876e-07
- O 0 1.0982502089973423e-06
endorphin O 0 5.390549995354377e-05
. O 0 9.918185241986066e-07

While O 0 1.2909607676192536e-06
a O 0 1.375801588210379e-07
few O 0 2.566929957481534e-08
cases O 0 8.903312753716364e-09
of O 0 2.2036421398752282e-07
isolated O 1 0.9988596439361572
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
have O 0 3.5061020753346384e-08
been O 0 9.397425060342357e-09
reported O 0 8.073907764583055e-09
( O 0 2.1795599991492054e-08
OMIM O 0 0.37931692600250244
201400 O 0 2.0687202777480707e-05
) O 0 4.268581932365123e-09
, O 0 2.5098629841124875e-09
an O 0 7.686489666980378e-09
inherited O 1 0.9999986886978149
POMC O 1 1.0
defect O 1 1.0
has O 0 1.7435256438602664e-07
not O 0 2.1856159104771677e-09
been O 0 3.6032652417361533e-09
described O 0 8.619056579561857e-09
so O 0 4.7058947849620836e-09
far O 0 6.564981447354512e-08
. O 0 1.6871085506409145e-07

Recent O 0 2.47341267822776e-06
studies O 0 2.3930189740895e-07
in O 0 1.394732151993594e-08
animal O 0 3.4372124702031215e-08
models O 0 1.9352563995767014e-08
elucidated O 0 3.3937469652300933e-06
a O 0 8.127494055543139e-08
central O 0 8.947407792447848e-08
role O 0 1.188396225870747e-07
of O 0 5.334664365364006e-06
alpha O 0 0.0007004303624853492
- O 0 4.3993339204462245e-05
MSH O 0 0.3636050224304199
in O 0 3.751429833442899e-09
the O 0 2.976740853810611e-09
regulation O 0 1.3525892406107687e-08
of O 0 1.3636469731181933e-09
food O 0 2.5662334479648052e-09
intake O 0 5.741943032155916e-10
by O 0 2.240860795532651e-11
activation O 0 2.4430255596286088e-09
of O 0 3.044980800837038e-08
the O 0 9.97456979234812e-08
brain O 0 1.2687865819316357e-05
melanocortin O 0 0.0007733042584732175
- O 0 9.889905641102814e-07
4 O 0 3.015188667632174e-07
- O 0 1.9568317100038257e-07
receptor O 0 6.464002666461965e-08
( O 0 1.5778303108504588e-08
MC4 O 0 0.0005167957278899848
- O 0 1.5512963500441401e-06
R O 0 2.2563872335013002e-06
; O 0 1.3550320865363119e-08
refs O 0 1.111010647036892e-06
3 O 0 7.37574694653631e-08
- O 0 3.432528217217623e-08
5 O 0 3.5347247351324995e-09
) O 0 3.0906879833203504e-10
and O 0 3.9246672578485686e-10
the O 0 2.3614752375777925e-09
linkage O 0 2.886220897835301e-07
of O 0 2.0612175077872052e-08
human O 0 2.5324465013909503e-07
obesity B-Disease 1 0.9563989639282227
to O 0 1.5160420474558123e-08
chromosome O 0 4.880709525423299e-08
2 O 0 1.228081316639873e-07
in O 0 1.0169435071816224e-08
close O 0 1.1685546041917405e-07
proximity O 0 9.987932116928278e-07
to O 0 3.599640052698305e-08
the O 0 2.7384209033698426e-07
POMC O 1 0.9983652234077454
locus O 0 4.4888571437695646e-07
, O 0 1.4964254280158684e-09
led O 0 4.021443178459094e-09
to O 0 6.317486533902184e-10
the O 0 2.64593746912567e-09
proposal O 0 1.5185831259145743e-08
of O 0 6.396812857190071e-09
an O 0 1.2362858514691766e-09
association O 0 8.043104848809435e-09
of O 0 9.269575684811571e-08
POMC O 1 0.9999954700469971
with O 0 2.721656642279413e-07
human O 0 0.00021313269098754972
obesity B-Disease 1 1.0
. O 0 1.0270474376739003e-05

The O 0 3.011047510881326e-06
dual O 0 3.3252124467253452e-06
role O 0 2.2367321435012855e-06
of O 0 8.554647138225846e-06
alpha O 0 0.037526462227106094
- O 0 0.004852975253015757
MSH O 1 0.9999926090240479
in O 0 5.368688604789895e-08
regulating O 0 6.254403928096508e-08
food O 0 5.083980170184077e-08
intake O 0 2.237157303852655e-08
and O 0 1.944030936229524e-09
influencing O 0 1.1466293869943911e-07
hair O 0 9.147244099949603e-07
pigmentation O 0 0.00020758163009304553
predicts O 0 2.481471312876238e-07
that O 0 5.826561455535284e-10
the O 0 3.3652429731745315e-09
phenotype O 0 2.8943349050791767e-08
associated O 0 1.6546426451213847e-09
with O 0 3.070358689516439e-10
a O 0 2.1033631725231317e-08
defect O 0 1.995473212446086e-05
in O 0 3.7509739314600665e-08
POMC O 1 0.9999988079071045
function O 0 2.0882250595377627e-08
would O 0 5.3123772048024875e-09
include O 0 1.6328750973571005e-07
obesity B-Disease 1 1.0
, O 0 9.721582650001892e-09
alteration O 0 1.0495235983398743e-05
in O 0 9.424371683053323e-08
pigmentation O 1 0.9908239841461182
and O 0 1.42229591801879e-05
ACTH B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999996423721313
. O 0 6.16575152889709e-06

The O 0 1.675108251220081e-06
observation O 0 1.4172387636790518e-05
of O 0 3.7810031017215806e-07
these O 0 4.333175951387602e-08
symptoms O 0 0.04803520813584328
in O 0 3.710449547611461e-08
two O 0 2.954563171897462e-08
probands O 0 5.7057124649873e-05
prompted O 0 1.5403327324747806e-07
us O 0 1.703881835624088e-08
to O 0 2.3675004179324333e-09
search O 0 2.5181167373489188e-08
for O 0 3.4075493537955026e-09
mutations O 0 8.493461933767321e-09
within O 0 4.1249382576324933e-08
their O 0 1.4564493255875277e-07
POMC O 1 0.9999639987945557
genes O 0 2.559416998337838e-06
. O 0 5.513962832992547e-07

Patient O 0 0.0001538657961646095
1 O 0 3.4383911042823456e-06
was O 0 1.844642696369192e-07
found O 0 4.2226515617471705e-09
to O 0 5.692501470200284e-10
be O 0 6.44867714783004e-10
a O 0 4.659797880890437e-09
compound O 0 1.5676033626732533e-07
heterozygote O 0 9.947626722350833e-07
for O 0 2.5815602988643604e-09
two O 0 1.1493181961697019e-09
mutations O 0 1.4002008441593716e-09
in O 0 2.888101979792168e-09
exon O 0 1.2505378776950238e-07
3 O 0 4.6965357825001774e-08
( O 0 2.6811999287446042e-09
G7013T O 0 4.5052226482766855e-07
, O 0 4.9119646128303884e-09
C7133delta O 0 2.3659949874854647e-06
) O 0 1.6171639583006936e-09
which O 0 4.1049277865745637e-10
interfere O 0 2.32268315691897e-09
with O 0 1.7612258873533904e-10
appropriate O 0 7.05256386623887e-09
synthesis O 0 1.509642686414736e-07
of O 0 3.205912690873447e-08
ACTH O 0 5.108970981382299e-06
and O 0 2.3976585339369194e-07
alpha O 0 1.2179520126665011e-05
- O 0 1.3807039977109525e-05
MSH O 0 0.0022189144510775805
. O 0 1.9514454834279604e-06

Patient O 0 0.00014129152987152338
2 O 0 8.32603018352529e-06
was O 0 7.340134970945655e-07
homozygous O 0 6.575345423698309e-08
for O 0 3.1103648545638407e-09
a O 0 6.198217938901962e-09
mutation O 0 9.075123763579995e-09
in O 0 1.4610924914393308e-08
exon O 0 5.483521476890019e-07
2 O 0 2.1498006219644594e-07
( O 0 1.6387383894311824e-08
C3804A O 0 8.819684467198385e-07
) O 0 1.4756054156350729e-08
which O 0 4.306020073840955e-08
abolishes O 0 3.06464426103048e-05
POMC O 1 0.8310369253158569
translation O 0 1.1674461347865872e-05
. O 0 1.7494212443125434e-06

These O 0 2.6777419748214015e-07
findings O 0 6.72721895966788e-08
represent O 0 1.2744021837818309e-08
the O 0 1.0301739017393174e-08
first O 0 4.715715373748708e-09
examples O 0 3.98789801181465e-08
of O 0 1.839437686612655e-07
a O 0 5.260849320620764e-07
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999653100967407
within O 0 9.13847415517921e-08
the O 0 1.0228126967604112e-07
POMC O 1 0.737628698348999
gene O 0 2.1403367966854603e-08
and O 0 3.6741654163563453e-09
define O 0 1.0623847579438461e-08
a O 0 2.729232484455224e-08
new O 0 4.955696567776613e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9897320866584778
resulting O 0 9.62144554250699e-07
in O 0 1.6548897363577453e-08
early O 0 4.673450348491315e-06
- O 0 5.4194963013287634e-05
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 9.224921086570248e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.00037203356623649597
red O 0 0.21888117492198944
hair O 0 5.896023503737524e-05
pigmentation O 0 0.004559105262160301
. O 0 5.707613013328228e-07
. O 0 1.3052655276624137e-06

A O 0 7.288381766556995e-06
European O 0 1.2206811561554787e-06
multicenter O 0 8.338520274264738e-05
study O 0 2.2836110247226316e-07
of O 0 2.0640422008000314e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.261410838234951e-08
classification O 0 3.7043690781501937e-07
of O 0 7.70481136669332e-08
105 O 0 1.1679295397470923e-07
mutations O 0 1.7421394327143958e-09
and O 0 7.698928161659069e-10
a O 0 1.8422714465060608e-09
general O 0 3.181273555696862e-08
system O 0 1.0968533104005473e-07
for O 0 3.752138599821819e-09
genotype O 0 6.632632221226231e-08
- O 0 1.1965485491316485e-08
based O 0 3.3008582533966546e-09
prediction O 0 2.2155732892770175e-07
of O 0 1.1297387914055435e-07
metabolic O 1 0.5579923987388611
phenotype O 0 6.876486168039264e-06
. O 0 2.504057476926391e-07

Phenylketonuria B-Disease 1 0.9999524354934692
( O 0 1.3593024050351232e-05
PKU B-Disease 1 0.9999561309814453
) O 0 2.098687161833368e-07
and O 0 3.2219432455349306e-07
mild B-Disease 1 1.0
hyperphenylalaninemia I-Disease 1 1.0
( O 1 1.0
MHP B-Disease 1 1.0
) O 0 6.624529305554461e-06
are O 0 3.280862159726894e-08
allelic B-Disease 0 0.2508217990398407
disorders I-Disease 1 0.9837908148765564
caused O 0 5.3840501834656607e-08
by O 0 6.675243691134369e-10
mutations O 0 4.897576566520456e-09
in O 0 1.587979747696977e-09
the O 0 9.4299963393496e-09
gene O 0 3.099522771776719e-08
encoding O 0 2.210879301856039e-07
phenylalanine O 0 5.228111604083097e-06
hydroxylase O 0 0.00031123831286095083
( O 0 3.143622507195687e-06
PAH O 1 1.0
) O 0 2.4793262127786875e-06
. O 0 1.8525455516282818e-06

Previous O 0 2.0682964532170445e-06
studies O 0 9.831304481622283e-08
have O 0 2.4729738257178724e-09
suggested O 0 5.087489540755996e-09
that O 0 5.489104726308369e-10
the O 0 4.4711581104195375e-09
highly O 0 1.4604745501856087e-07
variable O 0 8.395488180212851e-07
metabolic O 1 0.9997492432594299
phenotypes O 0 0.002764949342235923
of O 1 0.6662372350692749
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 6.915519770700485e-05
with O 0 5.1202728172938805e-06
PAH O 1 1.0
genotypes O 1 0.9998315572738647
. O 0 6.67134963805438e-06

We O 0 4.676620051213831e-07
identified O 0 8.496577663663629e-08
both O 0 1.2490904310880069e-08
causative O 0 1.3463521781886811e-06
mutations O 0 2.3660396664126893e-07
in O 0 1.875994115607682e-08
686 O 0 3.5818407923216e-05
patients O 0 1.6523383237654343e-05
from O 0 1.3788911701340112e-07
seven O 0 1.703936334251921e-07
European O 0 6.902096174599137e-07
centers O 0 2.5858250864985166e-06
. O 0 9.642102440921008e-07

On O 0 1.9594999685068615e-06
the O 0 5.70532208143959e-08
basis O 0 5.287985871404999e-08
of O 0 3.245441959620621e-08
the O 0 2.4932599984595072e-08
phenotypic O 0 1.4349552657222375e-07
characteristics O 0 7.93116825548168e-08
of O 0 9.172335069251858e-08
297 O 0 3.1101117770049314e-07
functionally O 0 8.761689969105646e-06
hemizygous O 0 7.843803177820519e-05
patients O 0 1.256833996876594e-07
, O 0 1.5225731786472352e-09
105 O 0 2.9178144345110013e-08
of O 0 1.0087813251402622e-08
the O 0 5.568512317921659e-09
mutations O 0 9.349631069355269e-10
were O 0 4.3824602280473357e-10
assigned O 0 2.6451656420789504e-09
to O 0 1.3319895186825192e-09
one O 0 1.9187675892595735e-09
of O 0 7.898889542445886e-09
four O 0 7.573486726641931e-09
arbitrary O 0 4.772406470010537e-08
phenotype O 0 3.562817312285915e-07
categories O 0 1.1274420330664725e-07
. O 0 1.1712299397004244e-07

We O 0 5.332927344170457e-07
proposed O 0 5.445380111268605e-07
and O 0 3.16449195736368e-08
tested O 0 3.37244117076807e-08
a O 0 3.077759824776649e-09
simple O 0 3.367053746927695e-09
model O 0 2.8123987583228427e-09
for O 0 5.036595585039549e-10
correlation O 0 2.9283280245095966e-09
between O 0 4.513511786541358e-09
genotype O 0 1.9417682040057116e-07
and O 0 1.3688621791629885e-08
phenotypic O 0 3.2647233183524804e-07
outcome O 0 5.409742129813822e-07
. O 0 4.2573151404212695e-07

The O 0 1.968285232578637e-06
observed O 0 3.405793904676102e-07
phenotype O 0 1.2240711839694995e-06
matched O 0 2.375970638013314e-07
the O 0 3.1948395928793616e-08
predicted O 0 1.661709632116981e-07
phenotype O 0 3.7103160366314114e-07
in O 0 4.0338732354427975e-09
79 O 0 3.0128653349947854e-08
% O 0 5.727427976331967e-10
of O 0 1.768096447030132e-09
the O 0 1.338519517446457e-09
cases O 0 1.2587496600602321e-09
, O 0 8.119088734659385e-10
and O 0 6.596744817066735e-10
in O 0 4.190236213563736e-10
only O 0 2.0543350354174095e-10
5 O 0 1.3091997486114337e-09
of O 0 1.48770562535816e-09
184 O 0 1.447301922752331e-08
patients O 0 5.537228631169455e-08
was O 0 7.998955453558665e-08
the O 0 4.29563273840472e-09
observed O 0 3.2302664987327034e-09
phenotype O 0 1.052658493705394e-08
more O 0 1.5170645295548013e-10
than O 0 2.404240695419446e-10
one O 0 1.0419868301525526e-09
category O 0 2.771707974247306e-09
away O 0 4.4569472557043355e-09
from O 0 1.3725529601771314e-09
that O 0 9.254603750008528e-10
expected O 0 1.7064878932160354e-07
. O 0 7.802385084687558e-07

Among O 0 2.514486823201878e-06
the O 0 2.1913028547260183e-07
seven O 0 3.6248085422130316e-08
contributing O 0 1.41503235795426e-08
centers O 0 2.3071907051530616e-08
, O 0 1.0197924726895735e-09
the O 0 1.2015634043294199e-09
proportion O 0 1.4703901429768962e-09
of O 0 9.999196137755462e-09
patients O 0 5.838091965415515e-08
for O 0 3.781292612359266e-09
whom O 0 3.795442182763509e-08
the O 0 1.1506808839101268e-08
observed O 0 7.283017744441622e-09
phenotype O 0 1.205746880117431e-08
did O 0 8.421544017700455e-10
not O 0 4.2008227452150493e-10
match O 0 8.871783307995429e-09
the O 0 1.2359564927066913e-08
predicted O 0 5.8391833590576425e-08
phenotype O 0 1.1819683010116933e-07
was O 0 9.757922470043923e-08
4 O 0 2.450479819060547e-08
% O 0 2.6778677053584943e-09
- O 0 3.9414075558852346e-08
23 O 0 4.12971665753048e-08
% O 0 4.189071312055148e-09
( O 0 7.729271445100494e-09
P O 0 2.6137597615161212e-06
< O 0 4.3642967284540646e-07
. O 0 3.7094998184272754e-09
0001 O 0 4.118091965210624e-07
) O 0 3.4202318754950056e-10
, O 0 1.4748498256000886e-10
suggesting O 0 8.242039273298474e-10
that O 0 6.469667163111481e-11
differences O 0 8.344078761268747e-10
in O 0 1.1553200063296742e-10
methods O 0 2.449866309817139e-09
used O 0 5.541533898423268e-10
for O 0 1.3301126866593904e-10
mutation O 0 2.996410675137895e-09
detection O 0 1.8273694877279922e-06
or O 0 3.5719136093348425e-08
phenotype O 0 1.6211043885050458e-07
classification O 0 3.386092828350229e-08
may O 0 1.0977606601514367e-09
account O 0 2.3021684558699462e-10
for O 0 4.697857103330705e-10
a O 0 1.8384977984453599e-09
considerable O 0 1.1764641705269696e-08
proportion O 0 5.763297394878464e-09
of O 0 3.5321718883096764e-08
genotype O 0 7.62736817705445e-06
- O 0 7.1536046561959665e-06
phenotype O 0 2.967134378195624e-06
inconsistencies O 0 2.103176484524738e-06
. O 0 8.334779408869508e-07

Our O 0 6.114142252044985e-06
data O 0 2.3019364903120731e-07
indicate O 0 2.6403430553045837e-08
that O 0 6.830965570969738e-09
the O 0 2.554173761382117e-07
PAH O 1 1.0
- O 0 0.00014740209735464305
mutation O 0 3.508597501422628e-08
genotype O 0 5.845301132012537e-08
is O 0 4.641000084237845e-10
the O 0 5.650087619990529e-10
main O 0 2.3547432448367545e-08
determinant O 0 1.7449679035053123e-07
of O 0 1.1346786976673684e-07
metabolic O 1 0.99972003698349
phenotype O 0 2.8956408186786575e-06
in O 0 2.470371462948151e-09
most O 0 2.483164118771697e-09
patients O 0 2.287307694359697e-07
with O 0 2.5082094907702412e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.002761509269475937

In O 0 2.905924532115023e-07
the O 0 2.2755319406542185e-08
present O 0 7.607945384791037e-09
study O 0 2.502821505601105e-09
, O 0 7.024582582282335e-10
the O 0 1.1372225383610157e-09
classification O 0 3.3423951606437186e-08
of O 0 3.822038650014292e-07
105 O 1 0.667201578617096
PAH O 1 1.0
mutations O 0 6.068200377740141e-07
may O 0 9.936684364220127e-09
allow O 0 3.562040218341167e-09
the O 0 4.411833121054087e-09
prediction O 0 2.2304729441202653e-07
of O 0 1.7826241816010224e-08
the O 0 1.2944809668624657e-08
biochemical O 0 2.7525493351276964e-07
phenotype O 0 9.325363947709775e-08
in O 0 1.1826302159789748e-09
> O 0 2.062936310665009e-08
10 O 0 3.286998895291049e-09
, O 0 8.642889737231485e-10
000 O 0 9.429204972377647e-09
genotypes O 0 1.250473502523164e-07
, O 0 2.2081678707763785e-09
which O 0 4.6413897725194886e-10
may O 0 1.5452232826618229e-09
be O 0 3.54258622436987e-10
useful O 0 2.4146693533566577e-09
for O 0 2.866302750703653e-10
the O 0 2.4299762202417696e-09
management O 0 9.652944754634518e-08
of O 0 2.0661245514475013e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.766522217394595e-07
newborns O 0 1.5302416613849346e-06
. O 0 6.368559297698084e-07

Somatic O 0 0.0007417444139719009
instability O 0 0.00048037641681730747
of O 0 1.1961800737481099e-05
the O 0 9.00226859812392e-06
CTG O 1 0.9999908208847046
repeat O 0 2.0654206309700385e-05
in O 0 1.0574441944299906e-07
mice O 0 3.3525219578223187e-07
transgenic O 0 3.090927691573597e-07
for O 0 3.418681338018814e-09
the O 0 3.6303381421021186e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 1 0.9953953623771667
is O 0 6.863526635925155e-08
age O 0 7.231953258468593e-09
dependent O 0 1.6982096839868177e-09
but O 0 1.6246602674296895e-10
not O 0 4.202431458377731e-11
correlated O 0 1.2931427040285826e-09
to O 0 7.627846687618955e-10
the O 0 6.4086340678670695e-09
relative O 0 3.219852942493162e-06
intertissue O 0 0.006683663465082645
transcription O 0 3.919894425052917e-06
levels O 0 1.1812662847887623e-07
and O 0 5.644480793876028e-08
proliferative O 0 0.04913279041647911
capacities O 0 0.0001292069355258718
. O 0 5.96434665567358e-06

A O 0 0.00010065217065857723
( O 0 3.2982031825667946e-06
CTG O 0 0.0006142667261883616
) O 0 1.945742411635365e-07
nexpansion O 0 1.6366777344956063e-05
in O 0 2.660219244887685e-08
the O 0 5.7847980627911966e-08
3 O 0 5.92776643770776e-07
- O 0 1.5115097085072193e-06
untranslated O 1 0.9999796152114868
region O 0 1.337185267402674e-06
( O 0 1.3467051473980973e-07
UTR O 1 0.9999945163726807
) O 0 1.7816995878661146e-08
of O 0 7.20120567621052e-08
the O 0 4.031414277960721e-07
DM O 1 1.0
protein O 0 1.4675885040560388e-06
kinase O 0 4.2002784539363347e-07
gene O 0 1.007650674011984e-08
( O 0 2.4101003415211153e-09
DMPK O 0 4.603032721206546e-05
) O 0 3.2456259901891826e-09
is O 0 7.901205245630649e-10
responsible O 0 3.737795406522082e-09
for O 0 5.978713080168063e-09
causing O 0 5.888314626645297e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9921544194221497
DM B-Disease 1 1.0
) O 0 3.4905863230960676e-06
. O 0 1.875360908343282e-06

Major O 0 5.646776480716653e-05
instability O 0 0.0004941053921356797
, O 0 4.937987796438392e-08
with O 0 3.6960670080077307e-09
very O 0 9.619617991063478e-09
large O 0 1.5502248373877592e-08
expansions O 0 2.931051881205349e-07
between O 0 1.8111455446501168e-08
generations O 0 2.190563179738092e-07
and O 0 2.5650981338998236e-09
high O 0 2.3314592922929478e-08
levels O 0 7.089329123743937e-09
of O 0 8.115020655452554e-09
somatic O 0 8.098214721030672e-07
mosaicism O 0 6.987159395066556e-06
, O 0 9.808408529821122e-10
is O 0 3.1634628250287733e-10
observed O 0 2.846114899313079e-09
in O 0 2.406659982412407e-09
patients O 0 2.2624065820764372e-07
. O 0 4.248408629337064e-07

There O 0 7.333201210713014e-07
is O 0 5.962237281664784e-08
a O 0 1.7107824490381063e-08
good O 0 2.4561275679957362e-08
correlation O 0 1.2203973831503845e-08
between O 0 1.1921836851058742e-08
repeat O 0 8.895067793446287e-08
size O 0 1.0061449451370663e-08
( O 0 3.026260353422572e-09
at O 0 6.755903836364041e-09
least O 0 1.9734541778504422e-10
in O 0 3.2272964856083775e-10
leucocytes O 0 1.2644213143175875e-07
) O 0 4.1864492428267397e-10
, O 0 3.056394026756948e-10
clinical O 0 1.9806133622068955e-08
severity O 0 3.2042064503912115e-06
and O 0 3.520388602851199e-08
age O 0 4.7475118947204464e-08
of O 0 1.8906973764387658e-07
onset O 1 0.9875257015228271
. O 0 8.78722858033143e-06

The O 0 0.00010584943083813414
trinucleotide O 1 0.9999877214431763
repeat O 0 7.678237307118252e-05
instability O 0 9.852914809016511e-05
mechanisms O 0 1.1028064363927115e-05
involved O 0 9.02239989386544e-08
in O 0 1.307895587387975e-07
DM B-Disease 1 1.0
and O 0 1.4876859495416284e-06
other O 0 4.157108079994032e-08
human O 0 1.8687392184801865e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.0312611209428724e-08
unknown O 0 1.0767770390884834e-06
. O 0 4.659320325117733e-07

We O 0 4.331533091317397e-06
studied O 0 3.721418806890142e-06
somatic O 0 3.183465378242545e-05
instability O 0 5.621259788313182e-06
by O 0 4.807167997000761e-08
measuring O 0 1.3973996146887657e-06
the O 0 7.163750979088945e-07
CTG O 0 0.00438665971159935
repeat O 0 4.157172099894524e-07
length O 0 3.772333201368383e-08
at O 0 1.7153730880181683e-08
several O 0 7.076950137019367e-10
ages O 0 4.261146990813813e-09
in O 0 5.593248086910307e-10
various O 0 3.5540659304444944e-09
tissues O 0 1.889159904067128e-07
of O 0 3.4417757888149936e-07
transgenic O 0 9.360241165268235e-06
mice O 0 9.05921666571885e-08
carrying O 0 7.788912625983357e-09
a O 0 2.6528013563620334e-08
( O 0 8.711033672170743e-08
CTG O 0 0.000459369650343433
) O 0 5.574636574579017e-08
55expansion O 0 4.099606485397089e-06
surrounded O 0 2.1012725426317047e-07
by O 0 1.27209920375293e-09
45 O 0 2.3271807592095684e-08
kb O 0 3.997456019533274e-07
of O 0 3.241031620859758e-08
the O 0 3.968102291196374e-08
human O 0 6.909010608069366e-07
DM B-Disease 1 1.0
region O 0 6.468615083576879e-07
, O 0 3.974584217303345e-09
using O 0 9.939128631231142e-09
small O 0 4.390102859019862e-08
- O 0 3.1452128723685746e-07
pool O 0 4.307433130179561e-07
PCR O 0 9.662146112532355e-06
. O 0 7.34931745682843e-07

These O 0 4.824234565603547e-06
mice O 0 8.727564818400424e-06
have O 0 1.6972585115127004e-08
been O 0 1.1351122708447292e-08
shown O 0 7.249312261592422e-09
to O 0 2.7946138736467674e-09
reproduce O 0 8.062492184990333e-08
the O 0 4.7463803554137485e-08
intergenerational O 0 1.2278007943677949e-06
and O 0 1.6621717335851827e-08
somatic O 0 1.8139581925424864e-06
instability O 0 6.460415988840396e-07
of O 0 8.735825929306884e-08
the O 0 7.837601856408583e-08
55 O 0 8.248383096542966e-07
CTG O 0 6.76381605444476e-05
repeat O 0 1.2116930747652077e-07
suggesting O 0 1.182967057644646e-08
that O 0 4.479879800456388e-10
surrounding O 0 1.0081427248564978e-08
sequences O 0 5.6872946352370946e-09
and O 0 1.1795012744286737e-09
the O 0 1.7385080042231493e-09
chromatin O 0 8.091192427173155e-08
environment O 0 8.677913498900125e-09
are O 0 2.7249799638973116e-10
involved O 0 3.158351802312609e-09
in O 0 5.283305348768863e-09
instability O 0 7.324657417484559e-06
mechanisms O 0 0.0005702368798665702
. O 0 3.4334627798671136e-06

As O 0 5.939179459346633e-07
observed O 0 4.8135813557337315e-08
in O 0 1.721750964023272e-09
some O 0 4.629012173573699e-10
of O 0 3.738529485985964e-09
the O 0 3.1385647414339246e-09
tissues O 0 1.7874323532396375e-07
of O 0 3.0037535907467827e-06
DM B-Disease 1 1.0
patients O 1 0.964836597442627
, O 0 7.51185602609894e-09
there O 0 1.093364176973921e-09
is O 0 3.4134278736885904e-10
a O 0 9.652071364385506e-10
tendency O 0 5.489798393654155e-09
for O 0 8.795874029132733e-10
repeat O 0 1.9797822048417402e-08
length O 0 1.35201672080143e-08
and O 0 9.385531463124153e-09
somatic O 0 1.068863184627844e-06
mosaicism O 0 3.406061068744748e-06
to O 0 1.0540602835007462e-09
increase O 0 3.8280092984344094e-10
with O 0 3.9109324112551747e-10
the O 0 7.86431364474538e-09
age O 0 1.8001452772864468e-08
of O 0 9.392662292384557e-08
the O 0 2.9886786023780587e-07
mouse O 0 9.650046195019968e-06
. O 0 4.471604029276932e-07

Furthermore O 0 1.0527956874284428e-05
, O 0 1.6277954273391515e-07
we O 0 7.348950781249641e-09
observed O 0 9.212077323184076e-09
no O 0 4.2274379552509345e-09
correlation O 0 7.937158486015505e-09
between O 0 1.9798871431220277e-09
the O 0 5.204481290377316e-09
somatic O 0 8.139095371006988e-07
mutation O 0 1.4752564503339727e-08
rate O 0 1.1720787007618583e-08
and O 0 6.2146368051685386e-09
tissue O 0 1.0499593372514937e-06
proliferation O 0 6.392526847776026e-05
capacity O 0 1.4575487057300052e-06
. O 0 1.0003317356677144e-06

The O 0 3.502771505736746e-06
somatic O 0 4.110175359528512e-05
mutation O 0 5.417130068963161e-07
rates O 0 8.047973665270547e-08
in O 0 1.4729838460070255e-09
different O 0 5.752641696332716e-10
tissues O 0 2.028998693504036e-07
were O 0 7.515868816199145e-09
also O 0 1.3675618415476265e-09
not O 0 1.602941668288338e-10
correlated O 0 6.883491110443174e-09
to O 0 1.702198493269691e-09
the O 0 2.4638838524992934e-08
relative O 0 6.173885049065575e-05
inter O 1 0.9937833547592163
- O 0 7.898762851255015e-05
tissue O 0 7.810663760210446e-07
difference O 0 1.592627363322663e-08
in O 0 4.561020172655361e-10
transcriptional O 0 1.2594852272229673e-08
levels O 0 1.7105107330550595e-09
of O 0 1.7203001245746918e-09
the O 0 1.4632113298773675e-09
three O 0 1.8244584731874625e-09
genes O 0 3.7865901525435675e-09
( O 0 3.2543849837196603e-09
DMAHP O 0 0.0028571535367518663
, O 0 6.250957085285336e-08
DMPK O 0 0.11225968599319458
and O 0 9.070713957726184e-08
59 O 0 2.2322626591630979e-07
) O 0 4.2828864899036034e-09
surrounding O 0 5.7392988139781664e-08
the O 0 4.473318426789774e-08
repeat O 0 2.1016474249790917e-07
. O 0 4.303819522988306e-08
. O 0 2.0592671035046806e-07

A O 0 1.3507646144717e-05
novel O 0 6.401663540600566e-06
missense O 0 5.952629180683289e-06
mutation O 0 1.881534643644045e-07
in O 0 1.6250215395530176e-08
patients O 0 2.7413946668275457e-07
from O 0 3.514484703259768e-08
a O 0 2.8630390147554863e-07
retinoblastoma B-Disease 1 0.9999880790710449
pedigree O 0 0.0009651036816649139
showing O 0 9.146757662392702e-08
only O 0 7.852292149834739e-09
mild O 0 2.668621345947031e-05
expression O 0 2.0470881167966581e-07
of O 0 3.2823649576130265e-07
the O 0 5.511886342901562e-07
tumor B-Disease 0 0.00019298156257718801
phenotype O 0 8.032719051698223e-06
. O 0 4.237131463469268e-07

We O 0 1.4537380366164143e-06
have O 0 4.63419382867869e-08
used O 0 6.237487326643532e-08
single O 0 6.311073263987055e-08
strand O 0 1.2697599061084475e-07
conformation O 0 1.088938006432727e-08
polymorphism O 0 8.488198588452178e-09
analysis O 0 1.6276016090444045e-09
to O 0 3.555352401374279e-10
study O 0 7.973997018240198e-10
the O 0 3.901785117221834e-09
27 O 0 5.3161095081577514e-08
exons O 0 7.983361456354032e-07
of O 0 7.880156971395991e-08
the O 0 1.0290647622923643e-07
RB1 O 0 0.005809732712805271
gene O 0 1.0795018212661489e-08
in O 0 2.6517463225239624e-10
individuals O 0 5.350014875560305e-11
from O 0 1.7256304163382197e-09
a O 0 1.0835449870683078e-08
family O 0 5.5139480537036434e-08
showing O 0 2.022175138449711e-08
mild O 0 6.312201730906963e-05
expression O 0 5.59192983473622e-07
of O 0 1.5696798527642386e-06
the O 0 2.3273553324543172e-06
retinoblastoma B-Disease 1 0.9096896648406982
phenotype O 0 0.00010038101027021185
. O 0 2.2536130472872173e-06

In O 0 5.89794240113406e-07
this O 0 3.4684092042880366e-08
family O 0 7.227750131733046e-08
affected O 0 3.3964404622111033e-09
individuals O 0 3.211307331163482e-10
developed O 0 1.138443622039631e-06
unilateral B-Disease 0 0.20931749045848846
tumors I-Disease 1 1.0
and O 0 1.0981321793224197e-05
, O 0 8.641443116630398e-09
as O 0 2.2031949598044775e-09
a O 0 9.267763778630922e-10
result O 0 1.8050404504421635e-09
of O 0 4.266986763923342e-09
linkage O 0 3.983040386401626e-08
analysis O 0 3.863808384352296e-09
, O 0 5.580300665997129e-10
unaffected O 0 1.9420232533207127e-08
mutation O 0 1.978452734974212e-09
carriers O 0 5.201405084420685e-09
were O 0 3.298969986076372e-09
also O 0 3.3646141428533838e-09
identified O 0 8.963102260395317e-09
within O 0 2.2969906865455414e-08
the O 0 2.0557959601319453e-07
pedigree O 0 1.867657556431368e-05
. O 0 6.864941042294959e-07

A O 0 8.369943316210993e-06
single O 0 4.0099490661305026e-07
band O 0 4.182088275683782e-07
shift O 0 1.910712512653845e-07
using O 0 4.781189488767268e-08
SSCP O 0 0.00011474108032416552
was O 0 1.2182535158444807e-07
identified O 0 5.86415893621961e-09
in O 0 1.935687388154861e-09
exon O 0 6.099472926734961e-08
21 O 0 3.873910081608756e-09
which O 0 1.807713284618373e-10
resulted O 0 1.576846386797115e-08
in O 0 3.68574659681542e-09
a O 0 1.605608446197948e-08
missense O 0 2.2407024857784563e-07
mutation O 0 1.195015908450614e-08
converting O 0 2.055486305607701e-07
a O 0 4.953023591269812e-08
cys O 0 2.2006857761880383e-05
- O 0 3.4444628909113817e-06
- O 0 1.9391825389902806e-06
> O 0 1.0757875088529545e-06
arg O 0 9.198787438435829e-07
at O 0 1.850163755534595e-08
nucleotide O 0 9.688004176666709e-09
position O 0 2.733535708898671e-08
28 O 0 2.935924037217319e-08
in O 0 8.26368751205564e-09
the O 0 1.4750263233054284e-07
exon O 0 1.1017341421393212e-05
. O 0 8.117839911392366e-07

The O 0 3.408179736652528e-06
mutation O 0 1.5164563365033246e-06
destroyed O 0 7.463667316187639e-06
an O 0 7.082358166599079e-08
NdeI O 0 3.3491483918624e-05
restriction O 0 1.0456843710926478e-06
enzyme O 0 4.872236445407907e-07
site O 0 5.135752871865407e-07
. O 0 2.723476484334242e-07

Analysis O 0 1.553562924527796e-06
of O 0 1.5404913256134023e-06
all O 0 5.13718276806685e-08
family O 0 7.9160855648297e-08
members O 0 2.5370907597022097e-09
demonstrated O 0 1.2069916621726406e-08
that O 0 5.34938482399383e-10
the O 0 1.1381126263643182e-08
missense O 0 6.057977657292213e-07
mutation O 0 1.0232575675672706e-07
co O 0 2.7204756406717934e-05
- O 0 5.772751592303393e-06
segregated O 0 1.033102279279774e-07
with O 0 1.0835112806972802e-09
patients O 0 9.271255407838908e-08
with O 0 1.7949956188090255e-08
tumors B-Disease 1 1.0
or O 0 0.11206579208374023
who O 0 6.8673766691063065e-06
, O 0 5.674876568662057e-09
as O 0 3.0128353145641995e-09
a O 0 1.7875023683444624e-09
result O 0 3.5046028301621845e-09
of O 0 1.8632277942742803e-08
linkage O 0 1.4274171178385586e-07
analysis O 0 6.920060968695907e-09
had O 0 7.86318832268762e-09
been O 0 1.3109587859716498e-09
predicted O 0 7.935039292306101e-09
to O 0 9.692361357949153e-10
carry O 0 1.0745572431858363e-08
the O 0 4.713802326250516e-08
predisposing O 0 1.2270935258129612e-05
mutation O 0 1.0216540431429166e-06
. O 0 8.298778197968204e-07

These O 0 2.2515497732911172e-07
observations O 0 5.298051632962597e-07
point O 0 1.3347462868296134e-07
to O 0 1.6712373707150618e-09
another O 0 3.63243368717292e-09
region O 0 2.350592431810128e-08
of O 0 2.2389359344288096e-07
the O 0 9.144138743977237e-07
RB1 O 1 0.9977625608444214
gene O 0 1.2920832404006433e-08
where O 0 5.101177813493507e-10
mutations O 0 3.0600805223102157e-10
only O 0 7.045659888849087e-11
modify O 0 2.9979199123175704e-09
the O 0 1.9253698635424144e-09
function O 0 6.073543890039446e-10
of O 0 3.4877583043879667e-09
the O 0 1.904907120930943e-09
gene O 0 4.107773232675527e-09
and O 0 8.885631119781578e-10
raise O 0 3.5928890973480065e-09
important O 0 1.789446812949791e-09
questions O 0 1.403527183363451e-09
for O 0 3.523031311125635e-10
genetic O 0 8.334507306528849e-09
counseling O 0 7.218406317122117e-09
in O 0 7.524323525354149e-11
families O 0 6.236764577005616e-11
with O 0 5.6562844685803526e-11
these O 0 8.679613694440036e-10
distinctive O 0 3.005035011938162e-07
phenotypes O 0 2.0955162653990556e-06
. O 0 1.3000821752484626e-07
. O 0 1.2334387520240853e-06

Maternal B-Disease 0 0.0013669512700289488
disomy I-Disease 0 0.4364705979824066
and O 0 0.00010166666470468044
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.5891274213790894
with O 0 4.054084286053694e-07
gamete O 0 2.93559623969486e-05
complementation O 0 6.395166565198451e-05
in O 0 1.2323313924866852e-08
a O 0 1.7921015782462746e-08
case O 0 2.9745290675009528e-08
of O 0 6.622948944823293e-08
familial O 0 1.0828469385160133e-05
translocation O 0 3.996535724581918e-06
( O 0 1.6945898906328694e-08
3 O 0 6.012668762878093e-08
; O 0 8.544581042713162e-09
15 O 0 3.8015862457996263e-08
) O 0 5.646577871942782e-09
( O 0 1.21629355476216e-08
p25 O 0 1.7833422134572174e-06
; O 0 2.4124011233084275e-08
q11 O 0 7.234665986288746e-07
. O 0 7.589654238415733e-09
2 O 0 1.1813315836661786e-07
) O 0 3.2370280678151175e-08
. O 0 2.4953754973466857e-07

Maternal B-Disease 1 0.5495961308479309
uniparental I-Disease 1 0.9999996423721313
disomy I-Disease 1 0.9999946355819702
( I-Disease 0 8.407601853832603e-05
UPD I-Disease 1 1.0
) I-Disease 0 2.7195133611712663e-07
for I-Disease 0 4.5894207545416066e-08
chromosome I-Disease 0 5.2094502933641706e-08
15 I-Disease 0 1.7656912376651235e-08
is O 0 1.4931410552421198e-09
responsible O 0 5.587173390608768e-09
for O 0 1.2418278627635004e-09
an O 0 3.575768570129867e-10
estimated O 0 3.3980718239234875e-10
30 O 0 8.938018658533053e-10
% O 0 2.4983273783085735e-10
of O 0 2.3925263992197188e-09
cases O 0 8.54562376417789e-09
of O 0 1.4815213944530115e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9068067669868469
PWS B-Disease 1 1.0
) O 0 7.179685326264007e-06
. O 0 2.9294187697814777e-06

We O 0 8.956181432040466e-07
report O 0 5.3695284663035636e-08
on O 0 2.1927196058868503e-08
an O 0 4.05993738628041e-10
unusual O 0 6.017599307739374e-09
case O 0 1.244985092796469e-08
of O 0 3.660387193349379e-08
maternal B-Disease 0 5.012645851820707e-05
disomy I-Disease 1 0.9767900109291077
15 I-Disease 0 7.846963399060769e-07
in O 0 1.0840870601214192e-07
PWS B-Disease 1 1.0
that O 0 1.2291933160213375e-07
is O 0 1.3362423167961879e-08
most O 0 2.7567554905516545e-09
consistent O 0 6.294180732169252e-09
with O 0 1.3960301803450648e-09
adjacent O 0 3.32059414631658e-07
- O 0 3.475144012554665e-07
1 O 0 6.900083349137276e-08
segregation O 0 4.110565399173538e-08
of O 0 4.485927629360731e-09
a O 0 3.9809573415539035e-09
paternal O 0 7.224193865340567e-08
t O 0 4.7829590954506784e-08
( O 0 3.0427846908764877e-09
3 O 0 2.7303363125952274e-08
; O 0 4.405274367513812e-09
15 O 0 1.6803667790554755e-08
) O 0 5.3883413286826e-09
( O 0 1.2277892480483388e-08
p25 O 0 8.513446232427668e-07
; O 0 5.402769787110628e-09
q11 O 0 1.924178434364876e-07
. O 0 1.21153709287114e-09
2 O 0 4.515767759727396e-09
) O 0 1.2992808218204033e-10
with O 0 1.208437100386206e-10
simultaneous O 0 1.7559917964149463e-08
maternal O 0 1.949992565641878e-06
meiotic O 0 0.0002170890074921772
nondisjunction O 0 7.66850498621352e-05
for O 0 7.462504925115354e-08
chromosome O 0 2.87083139483002e-07
15 O 0 1.8759480724384048e-07
. O 0 3.56931280975914e-07

The O 0 3.5095993098366307e-06
patient O 0 6.2428593992081005e-06
( O 0 1.027954397159192e-07
J O 0 5.580659035331337e-06
. O 0 2.1524998672362017e-08
B O 0 2.754586887476762e-07
. O 0 2.370821761132902e-09
) O 0 8.623031733101527e-10
, O 0 1.3604281035028976e-09
a O 0 7.882394292835215e-09
17 O 0 3.776911938757621e-08
- O 0 4.9511911015542864e-08
year O 0 1.6035702543604202e-08
- O 0 3.0442495813076675e-07
old O 0 5.411733923210704e-07
white O 0 2.288864919819389e-08
male O 0 1.4298723316485962e-09
with O 0 4.944353815261593e-10
PWS B-Disease 1 1.0
, O 0 2.3804862792076165e-07
was O 0 9.27171186049236e-07
found O 0 7.078897468204559e-09
to O 0 2.0091948105260826e-09
have O 0 1.4709007345459213e-09
47 O 0 1.6651258150091053e-08
chromosomes O 0 3.033015394393601e-09
with O 0 1.0658568472265983e-09
a O 0 9.53555456817412e-08
supernumerary O 0 0.0003271835157647729
, O 0 2.187060132996521e-08
paternal O 0 3.4853640045184875e-06
der O 0 0.00016444208449684083
( O 0 1.9269801754262517e-08
15 O 0 1.7627568738021182e-08
) O 0 5.721826901172733e-10
consisting O 0 5.5961533185211465e-09
of O 0 1.3140536658795554e-08
the O 0 1.5278715181921143e-08
short O 0 7.191446371734855e-08
arm O 0 3.5742041859521123e-07
and O 0 7.627269482668453e-09
the O 0 2.1989475129657876e-08
proximal O 0 4.9961676268139854e-05
long O 0 2.2426827399613103e-06
arm O 0 3.061618599531357e-06
of O 0 9.730527494866692e-08
chromosome O 0 5.562082705523608e-08
15 O 0 3.3647953756599236e-08
, O 0 7.963452119952308e-09
and O 0 1.2065915200309973e-07
distal O 1 0.8638290762901306
chromosome O 0 0.00025760772405192256
arm O 1 0.8807607889175415
3p O 1 0.9999943971633911
. O 0 3.543611819623038e-05

The O 0 1.39359926834004e-05
t O 0 4.6515865506080445e-06
( O 0 2.5230541211840318e-08
3 O 0 5.4633627399880424e-08
; O 0 4.161675448699498e-09
15 O 0 1.4343746634892796e-08
) O 0 1.6813727077291674e-09
was O 0 3.103557588701733e-08
present O 0 3.287951910735387e-09
in O 0 1.6176329165062953e-09
the O 0 2.7077338149439356e-09
balanced O 0 4.956366428388037e-09
state O 0 2.0605628314740443e-10
in O 0 2.0023344093900164e-10
the O 0 7.828734327475217e-10
patients O 0 5.130237568096163e-09
father O 0 1.2740646582187765e-07
and O 0 2.1026412611035994e-08
a O 0 5.638648303829541e-07
sister O 0 5.004621925763786e-05
. O 0 7.066354100970784e-06

Fluorescent O 0 6.435059185605496e-05
in O 0 2.0716254311992088e-07
situ O 0 9.387623322254512e-06
hybridization O 0 5.777498017778271e-07
analysis O 0 5.947972070430296e-08
demonstrated O 0 4.432398625908718e-08
that O 0 2.017258804443145e-09
the O 0 7.218601894010135e-08
PWS B-Disease 1 1.0
critical O 0 0.00015296599303837866
region O 0 1.1659691381282755e-06
resided O 0 7.928890113362286e-07
on O 0 1.8273709656568826e-08
the O 0 2.739672710916352e-09
derivative O 0 3.254870861724157e-08
chromosome O 0 1.2613242894587984e-08
3 O 0 7.0420926867598155e-09
and O 0 3.351917077232258e-10
that O 0 1.6285103821012115e-10
there O 0 1.869057131287377e-09
was O 0 4.2292064961202414e-08
no O 0 2.4508197693506872e-09
deletion O 0 9.548728030495113e-09
of O 0 5.6081104204963594e-09
the O 0 2.358923900658283e-08
PWS B-Disease 1 1.0
region O 0 6.829977792222053e-07
on O 0 9.143234080966067e-08
the O 0 8.646686922020308e-09
normal O 0 8.252362349026043e-09
pair O 0 3.51126843156635e-08
of O 0 1.7394642171097985e-08
15s O 0 4.309382347855717e-06
present O 0 2.9657039135599916e-07
in O 0 2.6583458634377166e-07
J O 0 0.0064720045775175095
. O 0 3.5471512092044577e-06

B O 0 0.002589221578091383
. O 0 4.2507545003900304e-05

Methylation O 0 7.870220542827155e-06
analysis O 0 7.325638193833584e-07
at O 0 3.502690617551707e-07
exon O 0 8.634607411295292e-07
alpha O 0 1.4664871628156106e-07
of O 0 2.183696246049749e-08
the O 0 2.7201586760838836e-08
small O 0 1.1051735526734774e-07
nuclear O 0 2.462210613884963e-05
ribonucleoprotein O 0 0.00015005543536972255
- O 0 9.410133543497068e-07
associated O 0 7.855052075456115e-08
polypeptide O 0 9.616932175049442e-07
N O 0 1.9193710443232703e-07
( O 0 5.5300066748031895e-09
SNRPN O 0 7.077414466039045e-06
) O 0 1.3822261113460854e-09
gene O 0 1.3586182179281536e-09
showed O 0 3.6488681520729926e-10
a O 0 1.9341808710215957e-10
pattern O 0 3.6597991304176958e-09
characteristic O 0 8.713272769966807e-09
of O 0 9.757361141282672e-09
only O 0 7.045824479412488e-10
the O 0 3.792502756283511e-09
maternal O 0 1.070333581765226e-07
chromosome O 0 1.8816345814798296e-08
15 O 0 2.056120784743598e-08
in O 0 2.9514316324252832e-08
J O 0 0.0004982518148608506
. O 0 5.294846232573036e-06

B O 0 0.004774710163474083
. O 0 0.00014658886357210577

Maternal B-Disease 0 0.0008264906937256455
disomy I-Disease 0 0.0019113746238872409
was O 0 1.1448563554949942e-06
confirmed O 0 5.607802933127459e-08
by O 0 2.297528389760828e-09
polymerase O 0 1.7474587821197929e-06
chain O 0 1.5735646741177334e-07
reaction O 0 1.1907110852860114e-08
analysis O 0 1.6765124399853448e-08
of O 0 3.0454803123802776e-08
microsatellite O 0 2.4090597889880883e-06
repeats O 0 1.1804431210293842e-07
at O 0 1.263288940123175e-08
the O 0 3.5078728810589155e-09
gamma O 0 5.43377609574236e-08
- O 0 1.25544204365724e-07
aminobutyric O 0 2.1144505808479153e-06
acid O 0 2.1968435248709284e-07
receptor O 0 1.0598228072922211e-07
beta3 O 0 1.0443898190715117e-06
subunit O 0 1.9972810605395352e-07
( O 0 4.004644083011044e-08
GABRB3 O 0 6.64176041027531e-05
) O 0 1.3294956602294405e-07
locus O 0 2.173668463001377e-06
. O 0 3.117431788268732e-07

A O 0 3.4332242648815736e-05
niece O 0 7.944238313939422e-05
( O 0 8.431034359546175e-08
B O 0 1.2914409808217897e-06
. O 0 8.038212762073726e-09
B O 0 1.401153184588111e-07
. O 0 9.074789808494188e-10
) O 0 1.0712961767689322e-10
with O 0 1.487565903790511e-10
45 O 0 3.470451925835505e-09
chromosomes O 0 2.683128608182983e-09
and O 0 1.2132345128534894e-09
the O 0 2.1800370397784263e-09
derivative O 0 3.662887593236519e-08
3 O 0 1.1321931836505428e-08
but O 0 3.9162026399530703e-10
without O 0 1.727896492553782e-09
the O 0 7.4385990700420734e-09
der O 0 5.230258466326632e-07
( O 0 1.6776120492778546e-09
15 O 0 3.977344675831773e-09
) O 0 5.753201248737128e-10
demonstrated O 0 4.284030463708177e-09
a O 0 3.545048254949279e-09
phenotype O 0 1.2488522216358433e-08
consistent O 0 8.097688741770526e-09
with O 0 4.170223333321843e-10
that O 0 4.871460457245291e-10
reported O 0 6.2136416012492646e-09
for O 0 6.2895004759866424e-09
haploinsufficiency O 0 5.143544967722846e-06
of O 0 3.703471804783476e-07
distal O 0 0.0002929357287939638
3 O 0 3.1873722036834806e-05
p O 0 3.0769439035793766e-05
. O 0 1.8068830058837193e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999995231628418
associated O 0 1.161652289738413e-05
with O 0 2.966920362723613e-07
unbalanced O 0 1.813137532735709e-05
segregation O 0 4.730632099381182e-06
of O 0 2.0033530745422468e-07
non O 0 1.2290636277612066e-06
- O 0 2.694741851883009e-06
Robertsonian O 0 4.5793549361405894e-05
translocations O 0 9.78547632257687e-07
has O 0 9.913701859431967e-09
been O 0 1.0081576684584093e-09
reported O 0 6.365213911507794e-10
previously O 0 2.1250001758232884e-09
but O 0 5.909416289640035e-10
has O 0 2.2806177779610692e-10
not O 0 1.175920055773716e-10
, O 0 1.715744352148718e-10
to O 0 2.5098137457213454e-10
our O 0 3.853063201830764e-09
knowledge O 0 1.0036114161948717e-07
, O 0 1.3793817199569958e-09
been O 0 5.393182012092268e-10
observed O 0 1.043617747775727e-09
in O 0 5.694412164025664e-10
a O 0 4.763455851986009e-09
case O 0 1.8194904782831145e-07
of O 0 5.719274213333847e-06
PWS B-Disease 1 1.0
. O 0 0.0014838112983852625

Furthermore O 0 1.4993271179264411e-05
, O 0 2.2886342776473612e-07
our O 0 7.151997039045455e-08
findings O 0 3.211978238937263e-08
are O 0 1.375850322560268e-09
best O 0 2.4390878650137893e-08
interpreted O 0 3.753156363472954e-08
as O 0 2.1595193189227757e-08
true O 0 3.5147735388818546e-07
gamete O 0 8.059821084316354e-06
complementation O 0 6.497678259620443e-05
resulting O 0 9.021985079016304e-07
in O 0 1.6928332513543864e-07
maternal B-Disease 1 0.7183108329772949
UPD I-Disease 1 1.0
15 I-Disease 0 0.00039954204112291336
and O 0 0.00010782373283291236
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9996398687362671
- I-Disease 1 0.9999716281890869
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 4.6746336010983214e-05
2 I-Disease 0 7.539492344221799e-06
and O 0 2.8423033882063464e-07
Stuve B-Disease 1 0.9999932050704956
- I-Disease 1 0.9984616041183472
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 1.6182601925152085e-08
a O 0 7.106386590294278e-09
case O 0 1.4553406479933528e-08
for O 0 4.501853112515164e-09
" O 0 5.6997428998784017e-08
lumping O 0 4.999732254873379e-07
" O 0 2.482531726855086e-07
. O 0 3.375434403096733e-07

Recent O 0 1.3943271142125013e-06
studies O 0 2.193527421923136e-07
demonstrated O 0 1.830783418199644e-07
the O 0 1.4046232621467425e-08
existence O 0 5.1859839089729576e-08
of O 0 6.390534679212578e-08
a O 0 9.623619234844227e-09
genetically O 0 2.801975362842768e-08
distinct O 0 4.225116256861838e-09
, O 0 7.385129729975404e-10
usually O 0 6.430867505180515e-10
lethal O 0 1.2709211461015002e-08
form O 0 2.9895261821621943e-09
of O 0 4.151988974854248e-08
the O 0 8.797492512258032e-08
Schwartz B-Disease 0 0.041314709931612015
- I-Disease 0 0.21746888756752014
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.492050500928599e-06
SJS B-Disease 1 0.9999998807907104
) O 0 8.015465624566787e-08
of O 0 4.427888143254677e-06
myotonia B-Disease 1 1.0
and O 0 1.3801207387587056e-05
skeletal B-Disease 1 0.9999998807907104
dysplasia I-Disease 1 1.0
, O 0 6.137810260042897e-07
which O 0 6.420994225209142e-08
we O 0 2.2837809865450254e-07
called O 0 4.7864818952803034e-06
SJS B-Disease 1 0.9996739625930786
type I-Disease 0 3.752012344193645e-05
2 I-Disease 0 2.4476301405229606e-05
. O 0 1.7656241197983036e-06

This O 0 9.282736073146225e-07
disorder O 0 0.19343599677085876
is O 0 5.1686932067696034e-08
reminiscent O 0 2.884682544390671e-05
of O 0 1.3212130056672322e-07
another O 0 1.827656781472342e-08
rare O 0 7.532375434493588e-08
condition O 0 6.985374056966975e-07
, O 0 1.0929685601013261e-08
the O 0 1.1761740381643904e-07
Stuve B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999953508377075
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00020176629186607897
SWS B-Disease 1 0.9999997615814209
) O 0 4.1951661700068144e-08
, O 0 8.687981889465846e-09
which O 0 4.214010029812698e-09
comprises O 0 2.9886724206562576e-08
campomelia B-Disease 0 4.5477527237380855e-06
at O 0 7.70964803109564e-08
birth O 0 7.764958809275413e-08
with O 0 2.5167192774233627e-08
skeletal B-Disease 1 0.9999991655349731
dysplasia I-Disease 1 1.0
, O 0 1.4837391972832847e-05
contractures B-Disease 1 1.0
, O 0 8.226073191508476e-07
and O 0 3.09074493998196e-07
early B-Disease 0 1.6733180018491112e-05
death I-Disease 0 8.042413537623361e-05
. O 0 3.974366336478852e-06

To O 0 3.799665933001961e-07
test O 0 2.3480187394397944e-07
for O 0 1.7350638259472362e-08
possible O 0 3.000230037741858e-07
nosologic O 0 0.005133259110152721
identity O 0 7.361987286458316e-08
between O 0 1.7559381504383964e-08
these O 0 7.033301052672414e-09
disorders O 0 0.016144417226314545
, O 0 1.7677828090256753e-09
we O 0 7.513656918867184e-10
reviewed O 0 2.4721060754018254e-09
the O 0 3.2109337411156957e-10
literature O 0 8.038407717236851e-10
and O 0 5.210296777358181e-11
obtained O 0 1.0798632127384522e-10
a O 0 2.1554022455738675e-10
follow O 0 8.69434357841925e-10
- O 0 1.2820868811047603e-08
up O 0 2.7770472588173334e-09
of O 0 2.7948003911149044e-09
the O 0 1.9510180138126998e-09
only O 0 3.619947674948776e-10
two O 0 8.346768831657414e-10
surviving O 0 2.2522027620652807e-07
patients O 0 1.809957517195926e-08
, O 0 2.3199380194682817e-09
one O 0 3.109742019447026e-09
with O 0 1.5810234899049647e-08
SJS B-Disease 1 0.9201894402503967
type I-Disease 0 1.6603851690888405e-05
2 I-Disease 0 5.163873083802173e-06
at O 0 8.89311664309389e-08
age O 0 3.161136241658369e-09
10 O 0 1.5365474448358896e-09
years O 0 1.2131188276143234e-09
and O 0 6.322971590755344e-10
another O 0 2.2907942209826615e-09
with O 0 7.833190096562248e-09
SWS B-Disease 0 0.01429953146725893
at O 0 1.4572579232208227e-07
age O 0 4.5993584052439473e-08
7 O 0 1.630931194540608e-07
years O 0 1.2319134157223743e-07
. O 0 5.16201851041842e-07

Patients O 0 6.20699065621011e-05
reported O 0 2.733932547016593e-07
as O 0 4.156663990784182e-08
having O 0 4.2111921061405155e-08
either O 0 1.7358867125949473e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.6837172508239746
SWS B-Disease 1 0.9999756813049316
presented O 0 6.316324174804322e-08
a O 0 4.550681609316598e-09
combination O 0 3.4662594572409944e-08
of O 0 2.4672273113424126e-08
a O 0 1.2707951135837448e-08
severe O 0 5.7154280511895195e-05
, O 0 5.074757325473911e-08
prenatal O 0 0.07958418130874634
- O 0 0.1375923454761505
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 2.0783376442068402e-07
with O 0 7.907210601842962e-07
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.6494765281677246
feeding O 0 0.010735142044723034
difficulties O 0 0.000964501581620425
, O 0 4.211424808886477e-08
tendency O 0 2.1422670215542894e-07
to O 0 4.076080273307525e-08
hyperthermia B-Disease 1 1.0
, O 0 5.679059356111793e-08
and O 0 1.0410416528827682e-08
frequent O 0 1.4899845268701029e-07
death O 0 3.507478140818421e-06
in O 0 5.897396704312996e-08
infancy O 0 1.2129284186812583e-05
) O 0 1.5706951295157978e-09
with O 0 6.227068860553686e-10
a O 0 1.1300874902531177e-08
distinct O 0 4.784309339811443e-07
campomelic B-Disease 1 0.9999492168426514
- I-Disease 1 0.993333637714386
metaphyseal I-Disease 1 0.9999947547912598
skeletal I-Disease 1 0.9999990463256836
dysplasia I-Disease 1 1.0
. O 0 0.0001335602719336748

The O 0 7.021487817837624e-07
similarity O 0 1.2169824685770436e-06
of O 0 6.370175356096297e-07
the O 0 7.059780671170302e-08
clinical O 0 5.243661234999308e-06
and O 0 4.2009475009763264e-08
radiographic O 0 0.00766710052266717
findings O 0 6.869190656288993e-07
is O 0 5.609040787390995e-09
so O 0 6.000816510365325e-10
extensive O 0 6.177292455333827e-09
that O 0 3.042898988336873e-10
these O 0 2.748365979243772e-09
disorders O 0 0.014567333273589611
appear O 0 6.359249482557061e-08
to O 0 8.611038104788804e-09
be O 0 8.260425232720081e-09
a O 0 4.041537593479916e-08
single O 0 1.0059111588134328e-07
entity O 0 5.348574632080272e-07
. O 0 1.420916987626697e-06

The O 0 2.3070647330314387e-06
follow O 0 7.154363288464083e-07
- O 0 7.552760052931262e-07
up O 0 2.110331287497047e-08
observation O 0 1.1631099994247052e-07
of O 0 8.866843259625057e-09
an O 0 3.83735182518663e-10
identical O 0 5.955551607428333e-09
and O 0 2.176513635987476e-09
unique O 0 9.644899101601823e-09
pattern O 0 1.589212814678831e-07
of O 0 3.468406930551282e-06
progressive O 1 0.9999998807907104
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 2.1619968038066872e-07
the O 0 2.426254468446132e-07
two O 0 2.8024830456274685e-08
patients O 0 2.37218955589924e-07
( O 0 1.2076665001359288e-08
one O 0 6.2911440501522975e-09
with O 0 1.652719383571366e-08
SJS B-Disease 1 0.9988383650779724
type I-Disease 0 5.3345011110650375e-06
2 I-Disease 0 1.4393290257430635e-06
, O 0 3.837280271312693e-09
one O 0 1.7068507718320802e-09
with O 0 4.3690251416705905e-09
SWS B-Disease 0 0.0002477891102898866
) O 0 1.2829723949892013e-08
surviving O 0 7.580349119962193e-06
beyond O 0 2.752359932856052e-06
infancy O 0 4.551935489871539e-06
adds O 0 2.7430411719819858e-08
to O 0 9.62535828819e-10
the O 0 1.896087509223321e-09
evidence O 0 9.017098179242566e-09
in O 0 2.3589405984125733e-09
favor O 0 6.846738642707351e-08
of O 0 8.155569730661227e-08
identity O 0 3.366934038240288e-07
. O 0 4.783351528203639e-07

The O 0 4.0954641917778645e-06
hypothesis O 0 1.2976723155588843e-05
that O 0 1.6546867698252754e-07
SWS B-Disease 1 0.9954361319541931
and O 0 1.8634179923537886e-06
SJS B-Disease 1 1.0
type I-Disease 0 0.00012768137094099075
2 I-Disease 0 1.1777369763876777e-06
are O 0 1.0277202422415144e-09
the O 0 1.0268037087257653e-08
same O 0 1.840825269994184e-08
disorder O 0 4.585214628605172e-05
should O 0 6.083529680012134e-09
be O 0 1.3291496792078306e-09
testable O 0 1.5802335440184834e-08
by O 0 1.1718048753550647e-10
molecular O 0 4.9832111770342635e-09
methods O 0 2.4455818703472687e-08
. O 0 2.0332208805484697e-08
. O 0 1.4883285359701404e-07

A O 0 3.3648000680841506e-05
mouse O 0 4.084917236468755e-06
model O 0 5.202032937745571e-08
of O 0 1.1533477817238236e-07
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999998807907104
defects O 1 1.0
in O 0 8.390589982809615e-07
hemostasis O 1 0.9999972581863403
and O 0 2.225318348791916e-05
thrombosis B-Disease 1 1.0
. O 0 0.000217657710891217

von B-Disease 1 0.9999985694885254
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9951543807983398
( I-Disease 0 0.00038698845310136676
vWf I-Disease 1 0.9999998807907104
) I-Disease 0 7.495321915484965e-05
deficiency I-Disease 1 1.0
causes O 1 0.8593548536300659
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.6593737602233887
humans O 0 0.005834429059177637
. O 0 2.3279526430997066e-06

We O 0 9.029317880049348e-07
generated O 0 1.587186346796443e-07
a O 0 3.859346620060933e-08
mouse O 0 7.695367543192333e-08
model O 0 3.076456644990344e-09
for O 0 4.354397675765398e-10
this O 0 4.074677262266846e-10
disease O 0 6.757710480087553e-08
by O 0 5.721695894855827e-10
using O 0 8.960110875477767e-09
gene O 0 3.824721517275975e-08
targeting O 0 1.2384619196836866e-07
. O 0 2.373490701756964e-07

vWf B-Disease 1 0.9999641180038452
- I-Disease 1 0.9999994039535522
deficient I-Disease 1 0.9999985694885254
mice O 0 2.3708584194537252e-05
appeared O 0 2.915400898473308e-07
normal O 0 4.0950318691557186e-08
at O 0 3.3532121079815624e-08
birth O 0 2.190926196021792e-08
; O 0 2.833483669917314e-09
they O 0 2.46134135295506e-09
were O 0 1.6350231391015768e-08
viable O 0 3.6637441098719137e-06
and O 0 1.635240636232993e-07
fertile O 0 4.0876369894249365e-05
. O 0 4.7487711185567605e-07

Neither O 0 0.00039229527465067804
vWf O 0 0.0074773854576051235
nor O 0 0.00029897232889197767
vWf O 0 0.002461725613102317
propolypeptide O 0 0.0013599679805338383
( O 0 1.2037198757752776e-06
von B-Disease 1 0.9974732995033264
Willebrand I-Disease 1 1.0
antigen O 1 0.9999710321426392
II O 1 1.0
) O 0 2.2834846902242134e-07
were O 0 2.372799734473574e-08
detectable O 0 2.0266993772111164e-07
in O 0 2.3562203299576367e-09
plasma O 0 4.923748875285128e-08
, O 0 9.675849010903903e-10
platelets O 0 1.2127334514389077e-07
, O 0 2.9302387183349765e-09
or O 0 1.531293492007535e-08
endothelial O 0 5.985550615150714e-07
cells O 0 7.262061529900166e-08
of O 0 5.373462741431467e-08
the O 0 9.118451771428226e-08
homozygous O 0 1.3337872815100127e-06
mutant O 0 4.059031198266894e-06
mice O 0 1.660849193285685e-06
. O 0 2.1090562540848623e-07

The O 0 6.157856114441529e-05
mutant O 0 0.06210146099328995
mice O 0 0.00011615777475526556
exhibited O 0 1.5595512650179444e-06
defects O 1 0.7213970422744751
in O 0 7.711736316196038e-08
hemostasis O 1 0.508661150932312
with O 0 1.446010600147929e-08
a O 0 1.454586424642912e-07
highly O 0 9.8161171990796e-06
prolonged O 1 0.9999908208847046
bleeding O 1 0.9968343377113342
time O 0 9.23329537272366e-08
and O 0 1.9687417918134997e-08
spontaneous O 0 7.886472275231426e-08
bleeding O 0 2.2843457827548264e-06
events O 0 2.9808600032765753e-09
in O 0 5.804222102945289e-10
approximately O 0 5.101303823806802e-10
10 O 0 2.073163196669725e-09
% O 0 2.1244817016707884e-09
of O 0 5.965559068954462e-08
neonates O 0 2.0009458239655942e-05
. O 0 3.4837887596950168e-06

As O 0 1.1612661410254077e-06
in O 0 3.320283425978232e-08
the O 0 1.9041488386051242e-08
human O 0 5.646117884339219e-08
disease O 0 6.835583008069079e-06
, O 0 6.384282436044941e-09
the O 0 1.544245797902022e-08
factor O 0 1.6062509189396224e-07
VIII O 1 1.0
level O 0 0.24875155091285706
in O 0 5.455872642556869e-09
these O 0 6.46227071854355e-10
mice O 0 5.7111879669946575e-09
was O 0 6.63404331469053e-10
reduced O 0 2.057178871694987e-09
strongly O 0 2.3422623840474444e-09
as O 0 1.5510994710865589e-09
a O 0 9.102457121379359e-10
result O 0 2.4353399297183387e-09
of O 0 2.322591363679294e-08
the O 0 9.792505473171786e-09
lack O 0 5.62402000525708e-08
of O 0 1.1308163294643236e-08
protection O 0 9.134240031016816e-08
provided O 0 3.172142370999609e-08
by O 0 1.2121595283076658e-08
vWf O 0 1.653414983593393e-05
. O 0 1.001904138320242e-06

Defective O 1 0.9976638555526733
thrombosis B-Disease 1 1.0
in O 0 1.3440915608953219e-05
mutant O 0 0.0001681196881690994
mice O 0 2.3033228444546694e-06
was O 0 8.876713053496132e-08
also O 0 3.4477296573243166e-09
evident O 0 4.3294168250440634e-08
in O 0 2.0070651807202466e-09
an O 0 4.215350568603782e-10
in O 0 1.1425622670202529e-09
vivo O 0 3.040488749661563e-08
model O 0 1.0528873772841507e-08
of O 0 4.765043684074044e-07
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.0012899977155029774

In O 0 3.3482851335975283e-07
this O 0 8.077973845388442e-09
model O 0 2.362990336735038e-08
, O 0 6.1093792247390866e-09
the O 0 2.6380071460607724e-08
exteriorized O 0 0.0002316999016329646
mesentery O 0 0.0016774485120549798
was O 0 1.3072760793875204e-06
superfused O 0 2.6910695396509254e-06
with O 0 1.0518075299614793e-08
ferric O 0 0.22861185669898987
chloride O 0 8.92909611138748e-06
and O 0 6.368996707806218e-08
the O 0 8.69473311126967e-08
accumulation O 0 1.6053443232522113e-06
of O 0 1.983181846298976e-06
fluorescently O 0 0.007472793105989695
labeled O 0 3.003793835887336e-06
platelets O 0 4.397952011458983e-07
was O 0 7.59336415967482e-08
observed O 0 1.7124701656712205e-08
by O 0 7.152948899857847e-09
intravital O 0 8.682884072186425e-06
microscopy O 0 5.434529157355428e-06
. O 0 1.8241310044686543e-06

We O 0 1.3403005141299218e-06
conclude O 0 8.823369626043132e-07
that O 0 3.560817418701845e-09
these O 0 9.349012231041343e-09
mice O 0 2.652409989423177e-07
very O 0 5.520321977314779e-09
closely O 0 2.8303359655978966e-08
mimic O 0 2.0559053155011497e-05
severe O 1 0.9999982118606567
human O 1 0.9999997615814209
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.01005503162741661
will O 0 9.124747180067061e-09
be O 0 6.359619497686708e-10
very O 0 3.921172830878561e-10
useful O 0 9.33108590395193e-10
for O 0 1.4098208711565974e-10
investigating O 0 3.444283469544729e-10
the O 0 8.795303374498076e-10
role O 0 9.658189803474215e-09
of O 0 1.213421825241312e-07
vWf O 0 0.0007440623012371361
in O 0 9.923084576257679e-09
normal O 0 6.462055068823247e-08
physiology O 0 2.787907646961685e-07
and O 0 2.2671824417841435e-09
in O 0 2.2569914825965043e-09
disease O 0 1.3843674651070614e-06
models O 0 5.6283983695948336e-08
. O 0 1.4606082743284787e-07
. O 0 1.3435280834528385e-06

Oral O 0 0.0031731578055769205
contraceptives O 0 0.15023134648799896
and O 0 1.2336064969531435e-07
the O 0 6.713222688858878e-08
risk O 0 2.8183178528706776e-06
of O 0 0.02455279603600502
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00012586245429702103

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 0.054483022540807724
Study O 0 1.4156782981444849e-06
Group O 0 3.307459053303319e-07
. O 0 3.980656515523151e-07

BACKGROUND O 0 2.986148865602445e-05
Women O 0 3.8508321864583195e-08
with O 0 3.0731137634631978e-09
mutations O 0 5.95659699342832e-09
in O 0 8.205382484582913e-10
either O 0 8.11144662549168e-09
the O 0 6.785363382277865e-08
BRCA1 O 0 3.227762022106617e-07
or O 0 1.955747030990551e-08
the O 0 3.6592076924080175e-08
BRCA2 O 0 3.305579525658686e-07
gene O 0 4.946430820496062e-09
have O 0 5.607283526387619e-10
a O 0 3.3763465356884126e-09
high O 0 3.943212902868254e-07
lifetime O 0 1.6981949784167227e-06
risk O 0 3.1266848964150995e-05
of O 1 0.9680382609367371
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.068832666031085e-05

Oral O 0 0.44565531611442566
contraceptives O 1 0.9999983310699463
protect O 1 0.934440016746521
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.407948577840216e-08
general O 0 9.73203100329556e-08
, O 0 8.688442187931855e-10
but O 0 1.6576301442583485e-10
it O 0 4.298382136336265e-11
is O 0 3.425178543570162e-11
not O 0 2.5145659859893144e-11
known O 0 1.202315247361696e-09
whether O 0 3.985331509248624e-10
they O 0 7.392401690786699e-10
also O 0 3.408745286037629e-09
protect O 0 2.9115435395965505e-08
against O 0 3.757834576845198e-07
hereditary B-Disease 1 1.0
forms I-Disease 1 0.9208851456642151
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.675530984357465e-05

METHODS O 0 7.024362275842577e-05
We O 0 7.805138579897175e-07
enrolled O 0 2.727461492213479e-07
207 O 0 1.040180706013416e-07
women O 0 1.426703977180921e-09
with O 0 1.2161334161930881e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.965869493389619e-07
161 O 0 1.286310151726866e-07
of O 0 5.4443887620436726e-08
their O 0 2.8930212891964402e-08
sisters O 0 1.038662412611302e-05
as O 0 4.903056094462954e-08
controls O 0 2.8579921718119294e-07
in O 0 5.8683662373937295e-09
a O 0 2.4968912271106092e-08
case O 0 3.101611127931392e-07
- O 0 6.081728542994824e-07
control O 0 2.3755265488034638e-07
study O 0 3.177725815817212e-08
. O 0 1.1900645802143117e-07

All O 0 3.332210951612069e-07
the O 0 5.9477674341223974e-08
patients O 0 5.058647900568758e-08
carried O 0 9.390705990597326e-09
a O 0 3.104882129179032e-09
pathogenic O 0 5.8266337532586476e-08
mutation O 0 1.6575242511862598e-08
in O 0 4.9360826537281355e-09
either O 0 2.603864501793396e-08
BRCA1 O 0 1.3356108752304863e-07
( O 0 3.5416147792233232e-09
179 O 0 3.27614699813239e-08
women O 0 1.7681504038691287e-09
) O 0 2.8250812800223457e-09
or O 0 3.733308417963599e-08
BRCA2 O 0 3.873546575050568e-06
( O 0 1.0451565657376705e-07
28 O 0 1.6880046587175457e-06
women O 0 3.9451453659467006e-08
) O 0 1.0687404028431047e-07
. O 0 7.585097705486987e-07

The O 0 1.3194027815188747e-05
control O 0 8.635368430987e-06
women O 0 1.1969754076801564e-08
were O 0 6.469155433563856e-09
enrolled O 0 5.9169198429742664e-09
regardless O 0 2.183749181483563e-09
of O 0 3.638251255821956e-09
whether O 0 1.0071504741304693e-09
or O 0 2.4794064579225505e-09
not O 0 1.0758014479250733e-09
they O 0 5.476554765238006e-10
had O 0 4.740849490758592e-09
either O 0 8.436290777069644e-09
mutation O 0 1.0457966226340432e-07
. O 0 1.476656308341262e-07

Lifetime O 0 6.17796104052104e-05
histories O 0 7.051254215184599e-06
of O 0 6.055875019228552e-07
oral O 0 0.0002101249701809138
- O 0 6.107638455432607e-06
contraceptive O 0 4.097878900211072e-06
use O 0 5.977618400265783e-09
were O 0 6.704949928604265e-10
obtained O 0 5.044719642022244e-10
by O 0 2.2940330191012492e-10
interview O 0 1.262074444952077e-09
or O 0 2.1307949849003194e-10
by O 0 1.1209498607112067e-10
written O 0 4.766034233938399e-10
questionnaire O 0 1.0903152825036955e-09
and O 0 6.003243457897156e-10
were O 0 6.812316821758202e-10
compared O 0 1.9004107176812113e-09
between O 0 8.581475974267505e-09
patients O 0 9.790825288291671e-07
and O 0 4.981750123533857e-08
control O 0 5.59027171220805e-07
women O 0 6.11548478524071e-10
, O 0 3.0393146333018706e-10
after O 0 1.146837180776572e-09
adjustment O 0 4.0467038608937855e-09
for O 0 3.67935987233281e-10
year O 0 3.8647937627978024e-10
of O 0 4.351684790293575e-09
birth O 0 1.9361931435923907e-07
and O 0 8.200149181902816e-08
parity O 0 4.287758656573715e-06
. O 0 7.740242153886356e-07

RESULTS O 0 1.1864277439599391e-05
The O 0 7.654502383047657e-07
adjusted O 0 5.949230512669601e-07
odds O 0 1.1299557627353352e-05
ratio O 0 7.391505505438545e-07
for O 0 3.488736183498986e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 6.34939567589754e-08
with O 0 6.909651184550114e-10
any O 0 2.6523798712929647e-09
past O 0 2.5998532215965042e-09
use O 0 2.0055994642831365e-09
of O 0 8.192079015145737e-09
oral O 0 7.947089102344762e-07
contraceptives O 0 3.0825529393041506e-05
was O 0 1.0159429848499713e-06
0 O 0 4.037270002754667e-07
. O 0 3.1715379122942977e-07

5 O 0 6.656122877757298e-06
( O 0 1.1828016255321927e-07
95 O 0 1.016892952065973e-06
percent O 0 1.0081623713631416e-07
confidence O 0 2.054817827001898e-07
interval O 0 7.986943018067905e-08
, O 0 5.6269890968962955e-09
0 O 0 8.727077727144206e-09
. O 0 1.1539199595844707e-09
3 O 0 9.83985604108284e-09
to O 0 2.421620015624626e-09
0 O 0 2.041860014401209e-08
. O 0 3.971538209412984e-09
8 O 0 1.1613930439580145e-07
) O 0 3.3936967014369657e-08
. O 0 2.4003742282729945e-07

The O 0 3.1220331493386766e-06
risk O 0 8.539335567547823e-07
decreased O 0 7.093146336956124e-08
with O 0 9.838161396658052e-10
increasing O 0 3.4130909210006166e-09
duration O 0 9.249176713410634e-08
of O 0 1.423592266291962e-08
use O 0 1.2129296678153878e-08
( O 0 4.36088276600799e-09
P O 0 3.311372438474791e-07
for O 0 2.5986532925514894e-09
trend O 0 8.605652190851742e-09
, O 0 9.61301038771012e-10
< O 0 1.7845021460516364e-08
0 O 0 5.4239466251715385e-09
. O 0 4.400133035709075e-10
001 O 0 4.066901482246976e-08
) O 0 6.449461104063303e-11
; O 0 6.648302741663059e-11
use O 0 5.911321432350292e-10
for O 0 4.6484860405371364e-10
six O 0 1.0491582047578163e-09
or O 0 5.241097555952479e-10
more O 0 1.0333727623601519e-10
years O 0 8.199078083137579e-10
was O 0 1.4408231274742889e-09
associated O 0 2.2727318638171567e-10
with O 0 1.1777674668866922e-10
a O 0 1.1911353015037207e-09
60 O 0 4.768473171878895e-09
percent O 0 1.829246198958856e-09
reduction O 0 2.610916460810131e-08
in O 0 1.2599152832137861e-08
risk O 0 9.071845283870061e-07
. O 0 8.004172968867351e-07

Oral O 0 0.002094225026667118
- O 0 0.00014567091420758516
contraceptive O 0 5.0817478040698916e-05
use O 0 2.431162613447668e-07
protected O 0 7.444454240612686e-05
against O 1 0.9982280135154724
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 9.17427289692796e-09
for O 0 6.973214783378978e-10
carriers O 0 1.612303957010397e-09
of O 0 8.334300360957059e-09
the O 0 1.644358604835361e-08
BRCA1 O 0 4.15393763830707e-08
mutation O 0 1.5840652123344512e-09
( O 0 1.110416869565256e-09
odds O 0 6.992932810589991e-08
ratio O 0 4.60256766032785e-09
, O 0 9.320875182794452e-10
0 O 0 2.7739133212634215e-09
. O 0 6.613626868379185e-10
5 O 0 2.20530549377429e-09
; O 0 1.679571370871713e-09
95 O 0 7.191130890760178e-08
percent O 0 1.6537599734078867e-08
confidence O 0 8.114498228906086e-08
interval O 0 1.9361721115274122e-08
, O 0 2.6791908691592425e-09
0 O 0 5.600274910477765e-09
. O 0 7.487391817662115e-10
3 O 0 3.839887074974513e-09
to O 0 1.2800630555531711e-09
0 O 0 4.407258114014212e-09
. O 0 4.250608476308315e-10
9 O 0 3.394885927932023e-09
) O 0 1.4267333148243466e-10
and O 0 2.2161242285712035e-10
for O 0 2.51525300587474e-10
carriers O 0 4.04364053352424e-09
of O 0 1.2601580223758901e-08
the O 0 1.8107344956774796e-08
BRCA2 O 0 8.189989131324182e-08
mutation O 0 3.1875277972659433e-09
( O 0 1.2061924792305945e-09
odds O 0 6.546313358057887e-08
ratio O 0 4.805616349301545e-09
, O 0 8.883987434593621e-10
0 O 0 1.5944078279872542e-09
. O 0 5.955458348694265e-10
4 O 0 9.668713829569242e-09
; O 0 3.228449729775207e-09
95 O 0 1.891404366460847e-07
percent O 0 2.3541414151395657e-08
confidence O 0 5.013234272155387e-08
interval O 0 2.4434834600128852e-08
, O 0 2.018297751149589e-09
0 O 0 4.289213872965547e-09
. O 0 3.965911765657637e-10
2 O 0 2.5152928628813243e-09
to O 0 8.08613953573456e-10
1 O 0 2.2031036550629324e-08
. O 0 2.9719584571097357e-09
1 O 0 6.541408481552935e-08
) O 0 2.3841867147211815e-08
. O 0 2.3482179756229016e-07

CONCLUSIONS O 0 0.00010538594506215304
Oral O 0 0.0067945062182843685
- O 0 0.0001251049106940627
contraceptive O 0 2.4690012651262805e-05
use O 0 4.651603902061652e-08
may O 0 6.879737224352311e-09
reduce O 0 9.32176913437388e-09
the O 0 4.866716807327975e-09
risk O 0 2.975601319121779e-06
of O 1 0.9999905824661255
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.379535122391644e-09
women O 0 5.263796690191391e-11
with O 0 1.557887673031555e-11
pathogenic O 0 7.13798442575353e-09
mutations O 0 6.954436582162771e-09
in O 0 1.7840180444039788e-09
the O 0 5.198511843218512e-08
BRCA1 O 0 3.302943468952435e-06
or O 0 1.496826484981284e-06
BRCA2 O 0 0.00011300473124720156
gene O 0 2.3887969291536137e-05

A O 0 5.165703987586312e-05
Japanese O 0 0.00011183263268321753
family O 0 9.250285302186967e-07
with O 0 1.010617083352372e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.49024229915085e-08
a O 0 1.561274416417291e-07
codon O 0 2.0455131277685723e-07
291 O 0 5.00537069569873e-08
deletion O 0 4.322230040543218e-08
: O 0 8.209186108665278e-10
a O 0 1.5989302104557623e-09
clinical O 0 1.4746971999102243e-07
, O 0 5.804236202777702e-09
biochemical O 0 1.282189623452723e-05
, O 0 3.4141216076477576e-08
pathological O 0 3.861228105961345e-05
, O 0 1.3888759475833012e-08
and O 0 1.4428698236201853e-08
genetic O 0 2.7049843538407004e-06
report O 0 1.2786171055267914e-07
. O 0 3.713962257734238e-07

We O 0 9.209671816279297e-07
report O 0 6.133480212611175e-08
a O 0 5.2470245037739005e-08
Japanese O 0 2.3058416900312295e-06
family O 0 1.6783239686901652e-07
with O 0 1.00450392892526e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.8208228349685669
ALD B-Disease 1 1.0
) O 0 9.411169088480165e-08
with O 0 6.161783527858233e-09
a O 0 2.4985014945855255e-08
three O 0 1.89846254272652e-08
base O 0 4.947632419316506e-07
pair O 0 2.1594252075374243e-07
deletion O 0 2.3544654936813458e-07
( O 0 1.1936696076020326e-08
delGAG O 0 1.3483387419910287e-06
291 O 0 2.9353307340329593e-08
) O 0 1.6853958229035015e-09
in O 0 5.035896588623245e-09
the O 0 1.9095811865099677e-07
ALD B-Disease 1 1.0
gene O 0 2.4487417249474674e-05
. O 0 1.0789233328978298e-06

A O 0 4.15551767218858e-06
variety O 0 4.667663802138122e-07
of O 0 1.2866229326391476e-07
phenotypes O 0 9.838693131314358e-07
were O 0 1.605072696975185e-08
observed O 0 9.369201414699546e-09
within O 0 8.87506690361306e-09
this O 0 8.876928525580752e-09
family O 0 2.2169132307681139e-07
. O 0 2.812572574839578e-07

While O 0 3.144431957480265e-06
the O 0 1.5264200783349224e-06
proband O 0 0.00012350500037427992
( O 0 1.8710595384163753e-07
patient O 0 2.1866069346287986e-06
1 O 0 6.966865839785896e-07
) O 0 1.0714361842190101e-08
was O 0 4.5271708160044e-08
classified O 0 9.475937368108589e-09
as O 0 1.892207501796861e-09
having O 0 1.587592057816778e-09
a O 0 2.6359185945068475e-09
rare O 0 1.1610603145584264e-08
intermediate O 0 7.09881646798749e-08
type O 0 5.96651474893406e-08
of O 0 1.7857864520465228e-07
adult O 0 7.000326149864122e-07
cerebral O 0 1.381851325277239e-05
and O 0 3.2777322189758706e-07
cerebello O 1 0.9977867603302002
- O 0 0.0006169480038806796
brain O 0 3.3829023777798284e-06
stem O 0 7.708736404765659e-08
forms O 0 1.0003812889181063e-08
, O 0 2.5457578267662484e-09
his O 0 1.8813187452337843e-08
younger O 0 1.0578814908512868e-06
brother O 0 5.516626515600365e-06
( O 0 2.850679869936812e-08
patient O 0 2.5928579816536512e-06
2 O 0 1.1170099014634616e-06
) O 0 6.50862430617849e-09
and O 0 2.9253538258444678e-08
nephew O 0 0.16379940509796143
( O 0 6.699343657601275e-08
patient O 0 2.6778830942930654e-05
3 O 0 1.4599833093598136e-06
) O 0 9.312048021570263e-09
had O 0 7.554057646075307e-08
a O 0 1.5954633170167654e-07
childhood O 0 0.2816949784755707
ALD B-Disease 1 1.0
type O 1 0.9995118379592896
. O 0 2.9153416107874364e-05

Another O 0 1.4350895980896894e-05
nephew O 0 0.0021925338078290224
( O 0 3.0257976391112607e-07
patient O 0 3.4826994124159683e-06
4 O 0 6.340391678349988e-07
) O 0 5.528804525312125e-09
of O 0 5.213983200746952e-08
patient O 0 1.3171223145036492e-05
1 O 0 3.311364253022475e-06
was O 0 5.284104531710909e-07
classified O 0 1.6313256523403652e-08
as O 0 2.706153745535289e-09
having O 0 7.1243011490196295e-09
an O 0 2.1389887638889604e-09
adolescent O 0 1.2341007504801382e-07
form O 0 1.0933568006521455e-07
. O 0 9.945501915353816e-07

The O 0 1.002016961137997e-05
tau O 0 1.7156147805508226e-05
level O 0 5.696405764865631e-07
in O 0 1.9464659217760527e-08
the O 0 1.996490262001771e-08
cerebrospinal O 0 1.780944387519412e-07
fluid O 0 1.598352383780366e-07
( O 0 6.622835257985571e-08
CSF O 1 0.928558349609375
) O 0 1.918958680846572e-08
in O 0 1.3063194082008067e-08
patient O 0 3.7169497772993054e-06
1 O 0 2.572891162344604e-06
was O 0 5.907078275413369e-07
as O 0 7.73751640537057e-09
high O 0 4.327724312247483e-08
as O 0 3.957848770941297e-10
that O 0 5.2726996380147995e-11
of O 0 2.6984223744364044e-09
patients O 0 4.12228757795674e-08
with O 0 3.068464948796645e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
( O 0 3.70945286931601e-07
AD B-Disease 0 2.86340327875223e-05
) O 0 1.3567704115757806e-07
. O 0 3.0189752919795865e-07

His O 0 3.891429878422059e-05
brain O 0 0.0002257695305161178
magnetic O 0 1.8153763448935933e-05
resonance O 0 1.3251062227936927e-05
image O 0 3.6469000406214036e-06
( O 0 3.1065130201568536e-07
MRI O 0 0.0005498186219483614
) O 0 1.102789894957823e-07
showed O 0 1.1357721518834296e-07
abnormalities B-Disease 0 1.0896467756538186e-05
in I-Disease 0 1.0836318509177545e-08
the I-Disease 0 1.723757065974496e-07
bilateral I-Disease 0 0.1361205130815506
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9948569536209106
and O 0 3.223662815798889e-06
brain O 0 9.533441334497184e-05
stem O 0 6.903267717461858e-07
, O 0 3.6201981412631312e-09
but O 0 2.5005693071733504e-09
not O 0 2.2787838283022666e-09
in O 0 3.379529323055408e-09
the O 0 3.335669518378381e-08
cerebral O 0 3.2682692108210176e-05
white O 0 1.265532318939222e-07
matter O 0 1.2154330875091546e-08
, O 0 4.055610847153446e-10
where O 0 3.2473518318809624e-10
marked O 0 5.5368456486348805e-09
reductions O 0 1.245963119345106e-07
of O 0 1.8526874612234678e-07
the O 0 3.8085320852587756e-07
cerebral O 0 0.009651310741901398
blood O 0 8.668934015076957e-08
flow O 0 1.865183385518776e-08
and O 0 3.3445808345078376e-09
oxygen O 0 8.412305163574274e-08
metabolism O 0 6.581920786175033e-08
were O 0 4.625201999175488e-09
clearly O 0 7.2020136521189215e-09
demonstrated O 0 1.2298001728083818e-08
by O 0 1.6136268987665403e-09
positron O 0 1.594807628180206e-07
emission O 0 1.2566613349918043e-07
tomography O 0 4.83102951420733e-07
( O 0 5.9555208764550116e-08
PET O 0 6.938156730029732e-06
) O 0 1.0656362547933895e-07
. O 0 7.418829000016558e-07

In O 0 1.513943402642326e-06
patients O 0 1.562551005918067e-06
2 O 0 4.6634369255116326e-07
and O 0 1.615983791225517e-08
3 O 0 1.4408352910777467e-07
, O 0 8.315976351980225e-09
the O 0 1.336938204588023e-08
autopsy O 0 2.9167583193157043e-07
findings O 0 3.3797050491557457e-08
showed O 0 2.287084654994942e-08
massive O 0 1.5037027196740382e-06
demyelination B-Disease 1 1.0
of I-Disease 1 0.6072762608528137
the I-Disease 0 0.00014450658636633307
cerebral I-Disease 0 0.07315361499786377
white I-Disease 0 1.0198789368587313e-07
matter I-Disease 0 4.655285046339941e-09
with O 0 2.2472737559731115e-10
sparing O 0 7.155271930514573e-08
of O 0 3.224451745609258e-07
the O 0 1.5264435205608606e-05
U O 1 1.0
- O 0 0.04037650302052498
fibers O 0 3.4088232041540323e-06
, O 0 4.445248613649255e-09
compatible O 0 3.9551554209538153e-07
with O 0 1.1200677052514152e-09
the O 0 4.6047010648919695e-09
findings O 0 1.6075512476732e-08
of O 0 4.400498312406853e-07
childhood O 1 0.9685702919960022
ALD B-Disease 1 1.0
. O 0 0.00040068820817396045

Oleic O 0 0.010621048510074615
and O 0 5.3272315199137665e-06
erucic O 1 0.8878490328788757
acids O 0 3.82045300284517e-06
( O 0 2.008516304385921e-07
Lorenzos O 0 9.450748621020466e-05
Oil O 0 1.2435300504876068e-06
) O 0 2.335374782447275e-09
were O 0 2.578312674472727e-09
administered O 0 5.1588213700881624e-09
to O 0 9.269920386856256e-10
patients O 0 1.1429769131154899e-08
1 O 0 3.152142724616169e-08
and O 0 4.222844740553455e-09
4 O 0 4.6715559420817954e-08
, O 0 1.0787973847570242e-09
but O 0 3.254209401948316e-10
sufficient O 0 8.433604037350051e-09
effectiveness O 0 5.771969568968416e-08
was O 0 1.7147646858006738e-08
not O 0 1.2031365903553137e-09
obtained O 0 2.2565492585613356e-08
. O 0 9.554579349924097e-08

The O 0 1.504891997683444e-06
findings O 0 3.4043293339891534e-07
in O 0 1.4434176520694564e-08
this O 0 2.0868902161907954e-09
family O 0 1.180588959925899e-08
suggest O 0 2.7033475458182465e-09
that O 0 3.9996017608956436e-10
delGAG291 O 0 9.267825618053394e-08
is O 0 1.2372294300178055e-09
part O 0 2.14058881731205e-09
of O 0 1.7012384390113766e-08
the O 0 2.2465558302542377e-08
cause O 0 1.1289714620943414e-06
of O 0 4.826829808735056e-06
Japanese O 1 0.9996798038482666
ALD B-Disease 1 1.0
with O 0 7.517190283579112e-07
phenotypic O 0 1.0200758879364002e-05
variations O 0 9.399018381373025e-06
. O 0 2.4752673652983503e-06

Moreover O 0 8.34170168673154e-06
, O 0 5.135301961445293e-08
although O 0 9.456941896246462e-09
the O 0 8.440523835417935e-09
scale O 0 3.083448874008354e-08
of O 0 6.8544845355233974e-09
the O 0 1.1458161086608243e-09
study O 0 3.14118037136879e-10
is O 0 4.837744441155145e-11
limited O 0 2.0238478948275684e-10
, O 0 1.165825769255946e-10
there O 0 1.834339347084324e-10
is O 0 5.399779512416103e-10
a O 0 1.9940837869825145e-09
possibility O 0 2.3208066579627484e-08
that O 0 1.4834468098356979e-09
PET O 0 6.052607091078244e-07
can O 0 4.148551280280799e-09
detect O 0 1.9013801022538246e-07
an O 0 1.0041089737455877e-08
insidious B-Disease 0 0.004898437298834324
lesion I-Disease 0 0.09700929373502731
which O 0 9.2998542200462e-09
is O 0 1.741464972226936e-09
undetectable O 0 2.9805775625391107e-08
by O 0 3.0084010282926954e-10
computed O 0 9.91283233275908e-09
tomogram O 0 1.2364607755444013e-06
( O 0 1.4661704739182824e-08
CT O 0 4.9762205890147015e-05
) O 0 1.4914758317274845e-09
or O 0 1.7683932096446142e-09
MRI O 0 4.967725786286792e-08
analysis O 0 2.884039229655855e-09
, O 0 4.646633355864793e-10
and O 0 4.514267015753859e-10
that O 0 8.127699208104744e-11
the O 0 1.7268948493409653e-09
higher O 0 2.0420898749762273e-08
level O 0 2.32468764238547e-08
of O 0 8.295477194053547e-09
tau O 0 2.229387696672802e-08
reflects O 0 1.194534360315913e-09
the O 0 3.491856526149917e-10
process O 0 1.938373461740639e-09
of O 0 3.3639931729112504e-08
neuronal B-Disease 0 0.00013888291141483933
degeneration I-Disease 1 1.0
in O 0 5.562078058574116e-06
ALD B-Disease 1 1.0
. O 0 0.00020149307965766639

Lorenzos O 0 0.002869965508580208
Oil O 0 1.1026013453374617e-05
should O 0 3.6451154983296874e-08
be O 0 1.943185834463179e-09
given O 0 1.9306396481511e-09
in O 0 1.7471408764180296e-09
the O 0 5.1698334502248144e-09
early O 0 1.275583230153643e-07
stage O 0 2.2715279612839367e-07
. O 0 4.351637272748121e-08
. O 0 1.9382160587610997e-07

Nonsense O 0 0.00011236291175009683
mutation O 0 1.7029808532242896e-06
in O 0 1.7376345340380794e-07
exon O 0 2.115374400091241e-06
4 O 0 1.778770126747986e-07
of O 0 3.3146516642545976e-08
human O 0 2.8458774892214933e-08
complement O 0 1.145217879638949e-06
C9 O 1 0.9999942779541016
gene O 0 1.0913566228509808e-07
is O 0 2.03140171350924e-09
the O 0 2.7313140638085542e-09
major O 0 3.261899905737664e-08
cause O 0 3.7335578895181243e-07
of O 0 1.1439602758400724e-06
Japanese O 0 0.07170668244361877
complement B-Disease 0 0.01461646519601345
C9 I-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.0895393390674144e-05

Deficiency B-Disease 1 0.9999523162841797
of I-Disease 0 3.8938425859669223e-05
the I-Disease 0 4.444540536496788e-06
ninth I-Disease 0 0.10605425387620926
component I-Disease 0 3.98317342842347e-06
of I-Disease 0 8.58413216064946e-08
human I-Disease 0 1.506147562224669e-08
complement I-Disease 0 1.5152015464536817e-07
( O 0 5.631845567677374e-08
C9 O 1 0.9999994039535522
) O 0 1.3201431059428614e-08
is O 0 8.031756371096321e-10
the O 0 1.5344329140631885e-09
most O 0 9.786469412631504e-10
common O 0 1.1029477775537089e-07
complement B-Disease 1 0.9999967813491821
deficiency I-Disease 1 1.0
in O 0 2.2009196243288898e-08
Japan O 0 1.4446631269038335e-07
but O 0 7.830182613410841e-10
is O 0 6.470904367894548e-10
rare O 0 7.911342692068501e-09
in O 0 5.182587137220196e-10
other O 0 8.232392545437506e-10
countries O 0 3.420814298493724e-09
. O 0 2.896293267440342e-07

We O 0 4.614331032826158e-07
studied O 0 1.4683512006286037e-07
the O 0 5.516722190179735e-09
molecular O 0 2.9608591134433482e-08
basis O 0 5.549832238216368e-08
of O 0 1.7849092728283722e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.917307129901019e-07
four O 0 1.8054859651783772e-07
Japanese O 0 0.00011332424764987081
C9 B-Disease 1 1.0
- I-Disease 1 0.9999812841415405
deficient I-Disease 1 0.9999963045120239
patients O 0 0.0013488938566297293
who O 0 1.994433489471703e-07
had O 0 3.469607179340528e-07
suffered O 1 0.7277786135673523
from O 0 4.289181742933579e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.037545633967966e-05

Direct O 0 9.06248897081241e-06
sequencing O 0 1.1508340321597643e-05
of O 0 2.6062255074066343e-06
amplified O 0 3.2746112992754206e-05
C9 O 0 0.1256139874458313
cDNA O 0 1.6919721019803546e-05
and O 0 6.246297346024221e-08
DNA O 0 2.4682350385774043e-07
revealed O 0 9.124244826352879e-08
a O 0 1.3858963754387332e-08
nonsense O 0 3.76799022205887e-07
substitution O 0 3.457708999121678e-07
( O 0 4.138476938919666e-08
CGA O 0 7.555060619779397e-06
- O 0 7.066906846375787e-07
- O 0 4.4057307491129905e-07
> O 0 5.775250428996515e-07
TGA O 0 5.1598854042822495e-06
) O 0 4.7254755664027925e-09
at O 0 7.135098734067924e-09
codon O 0 4.263276842664254e-09
95 O 0 3.9832077192158977e-08
in O 0 5.47411449502988e-09
exon O 0 8.209241286749602e-08
4 O 0 3.8334345475732334e-08
in O 0 1.4807302051167426e-09
the O 0 1.2774685309580036e-08
four O 0 1.3016067157423095e-07
C9 B-Disease 1 1.0
- I-Disease 1 0.700955331325531
deficient I-Disease 0 0.0002815818879753351
individuals O 0 5.0274344687295525e-08
. O 0 5.732186991735944e-07

An O 0 2.8695450282612e-07
allele O 0 6.153048275336914e-07
- O 0 9.666597833302149e-08
specific O 0 1.4516922774987506e-08
polymerase O 0 5.047562808613293e-06
chain O 0 4.3617006895146915e-07
reaction O 0 2.8648793559682417e-08
system O 0 8.099499382296926e-08
designed O 0 8.040823473720593e-08
to O 0 1.61933688680449e-09
detect O 0 3.933379488785249e-08
exclusively O 0 2.5320243679516352e-09
only O 0 2.3663659920458713e-10
one O 0 1.503531327218255e-10
of O 0 6.252383055738164e-10
the O 0 9.157538061188575e-10
normal O 0 3.5585703273000036e-09
and O 0 1.136827743053459e-09
mutant O 0 2.3021169415216036e-09
alleles O 0 1.145773961819252e-10
indicated O 0 3.987216945500194e-10
that O 0 3.9166114795818885e-11
all O 0 1.5047449397620483e-10
the O 0 8.017308483765362e-10
four O 0 8.090552117145933e-10
patients O 0 8.099229620306403e-10
were O 0 4.307625922628233e-10
homozygous O 0 9.474576678769608e-10
for O 0 3.192582309630154e-10
the O 0 1.0852321263854492e-09
mutation O 0 1.7543972941069796e-09
in O 0 2.0735351213829745e-09
exon O 0 2.2244309505481397e-08
4 O 0 5.694143823120612e-09
and O 0 2.515061214847236e-10
that O 0 9.132014588963955e-11
the O 0 2.0928374588891074e-09
parents O 0 3.220220756716685e-09
of O 0 2.3228260204177786e-08
patient O 0 1.6277130043818033e-06
2 O 0 3.6398121210368117e-06
were O 0 3.8201872598619957e-07
heterozygous O 0 3.3089227713389846e-07
. O 0 3.27552925227792e-07

The O 0 2.2674616957374383e-06
common O 0 6.286732627813763e-07
mutation O 0 2.027544070415388e-07
at O 0 1.707762606883989e-07
codon O 0 1.1564327451196732e-07
95 O 0 2.2769349072859768e-07
in O 0 2.4761090955394138e-08
exon O 0 5.880020808035624e-07
4 O 0 7.672299062733146e-08
might O 0 4.751287363546908e-09
be O 0 8.213760227526734e-10
responsible O 0 4.915470253052945e-09
for O 0 3.06259284599264e-09
most O 0 1.5849666468170653e-08
Japanese O 0 0.0001300831645494327
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999985694885254
. O 0 4.3600911681096477e-07
. O 0 8.93661024292669e-07

BRCA1 O 0 5.788578164356295e-06
required O 0 1.0186696641767412e-07
for O 0 8.337738677255402e-08
transcription O 0 6.148831744212657e-05
- O 0 3.86350839107763e-05
coupled O 0 5.7114237279165536e-05
repair O 0 0.021058717742562294
of O 0 7.034597615529492e-07
oxidative O 0 2.371692971792072e-05
DNA O 0 7.200380423455499e-06
damage O 0 1.3465780284604989e-05
. O 0 1.2976100833839155e-06

The O 0 3.354339423822239e-05
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9948284029960632
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9879043698310852
gene O 0 8.297551516989188e-07
BRCA1 O 0 2.6703364142122155e-07
encodes O 0 2.6409724185327832e-08
a O 0 1.773707758445653e-08
zinc O 0 3.5833893434755737e-06
finger O 0 1.2136467830714537e-06
protein O 0 1.4781709012368083e-07
of O 0 7.881946118004635e-08
unknown O 0 6.507355010398896e-07
function O 0 2.3143996941143996e-07
. O 0 4.3271879235362576e-07

Association O 0 6.1492032727983315e-06
of O 0 2.6872585294768214e-06
the O 0 7.05033357917273e-07
BRCA1 O 0 1.370350787510688e-06
protein O 0 4.992518043422933e-08
with O 0 1.8428020220895291e-09
the O 0 1.0860983223892617e-08
DNA O 0 4.6591303544119e-06
repair O 0 0.006412962917238474
protein O 0 1.961251655302476e-06
Rad51 O 0 5.24844335814123e-06
and O 0 1.9743022772189533e-09
changes O 0 7.002950996870538e-10
in O 0 6.176936184765225e-10
the O 0 1.5885127657710996e-09
phosphorylation O 0 1.4995348962543176e-08
and O 0 2.0926178567748366e-09
cellular O 0 4.4732161086358246e-08
localization O 0 5.241213330009487e-07
of O 0 2.0483625462475175e-08
the O 0 9.873356354717089e-09
protein O 0 3.00842692979586e-08
after O 0 7.024827386459265e-09
exposure O 0 2.8128294360385553e-08
to O 0 4.694124200455008e-09
DNA O 0 9.104858236241853e-07
- O 0 5.400937652666471e-07
damaging O 0 2.791744293517695e-07
agents O 0 4.0846392934668074e-09
are O 0 7.988241318424016e-11
consistent O 0 2.6107458417357066e-09
with O 0 1.4563111827570197e-10
a O 0 4.355595883964725e-09
role O 0 2.1972706321093938e-08
for O 0 1.4914965262846636e-08
BRCA1 O 0 5.448470687952067e-07
in O 0 2.8915041028199084e-08
DNA O 0 5.6921162467915565e-06
repair O 0 0.00043687233119271696
. O 0 3.0882276860211277e-06

Here O 0 4.229120349918958e-06
, O 0 7.100712906549234e-08
it O 0 2.6942670316998374e-09
is O 0 3.5224487771046142e-09
shown O 0 4.639400419392814e-09
that O 0 2.7573707761519017e-09
mouse O 0 2.6889761102211196e-06
embryonic O 0 6.978142664593179e-06
stem O 0 6.751115051883971e-06
cells O 0 1.6138934370246716e-05
deficient B-Disease 0 0.012366754934191704
in I-Disease 0 1.6356969112507613e-08
BRCA1 I-Disease 0 1.1511731656810298e-07
are O 0 1.275921590604412e-09
defective O 0 2.7454757400846574e-06
in O 0 7.753382824660093e-09
the O 0 1.0595313959527175e-08
ability O 0 6.3889111778792085e-09
to O 0 1.6372504463291193e-09
carry O 0 3.857858033029515e-09
out O 0 1.2563037721236014e-08
transcription O 0 3.573427648007055e-06
- O 0 7.551722660537052e-07
coupled O 0 1.643490577407647e-06
repair O 0 1.6259045878541656e-05
of O 0 8.999764844475067e-08
oxidative O 0 1.1901695415872382e-06
DNA O 0 9.952010486813379e-07
damage O 0 1.3990771776661859e-06
, O 0 3.5840390655295096e-09
and O 0 2.975452328968231e-09
are O 0 2.22765228485855e-09
hypersensitive O 0 4.3443747017590795e-06
to O 0 1.4378369606049546e-08
ionizing O 0 0.002419197466224432
radiation O 0 0.005991099402308464
and O 0 5.622379006808842e-08
hydrogen O 0 5.479496394400485e-07
peroxide O 0 3.947549885197077e-06
. O 0 9.999654366765753e-07

These O 0 3.443886953391484e-07
results O 0 8.722106059622092e-08
suggest O 0 7.305030891302522e-08
that O 0 4.9330615148335255e-09
BRCA1 O 0 3.4873548315772496e-07
participates O 0 1.4911835322095612e-08
, O 0 8.858150324364544e-10
directly O 0 1.363415491617559e-09
or O 0 1.8311171467999543e-09
indirectly O 0 1.5286934385017048e-08
, O 0 3.5582985447035753e-09
in O 0 7.552771741359265e-09
transcription O 0 0.0007758633582852781
- O 0 1.220021385961445e-05
coupled O 0 1.755227094690781e-05
repair O 0 0.00011564244778128341
of O 0 1.539417837648216e-07
oxidative O 0 3.283841124357423e-06
DNA O 0 2.5941242256521946e-06
damage O 0 1.8443048475091928e-06
. O 0 7.907318178013156e-08
. O 0 3.785852129567502e-07

Truncation O 0 0.000269266776740551
mutations O 0 4.632348009181442e-06
in O 0 1.5014786924893997e-07
the O 0 3.5901715023101133e-07
transactivation O 0 0.00025478770839981735
region O 0 7.460582196472387e-07
of O 0 3.7886798054387327e-06
PAX6 O 1 0.9999998807907104
result O 0 4.966597771272063e-06
in O 0 1.0955319851291279e-07
dominant O 0 0.00016159663209691644
- O 0 3.92349238609313e-06
negative O 0 9.776086073998158e-08
mutants O 0 3.928059413738083e-06
. O 0 3.514351192279719e-07

PAX6 O 0 0.27265965938568115
is O 0 8.118342975649284e-07
a O 0 2.8155568543297704e-07
transcription O 0 6.978529540901945e-07
factor O 0 4.477859860685385e-08
with O 0 2.0870414285667493e-09
two O 0 3.6161746930218897e-09
DNA O 0 1.0432484742750603e-07
- O 0 7.376633703870539e-08
binding O 0 1.6753041620631848e-08
domains O 0 3.8596855489458903e-08
( O 0 5.943341818692716e-09
paired O 0 1.0673449679643454e-07
box O 0 8.819407071314345e-07
and O 0 4.7727521490514846e-08
homeobox O 0 7.295168416021625e-06
) O 0 5.752403442471632e-09
and O 0 9.614189444562271e-09
a O 0 5.0510696070205086e-08
proline O 0 1.3157160765331355e-06
- O 0 7.558654147032939e-07
serine O 0 1.1477073940113769e-06
- O 0 7.560485073554446e-07
threonine O 0 7.117390055100259e-07
( O 0 2.963356315888177e-08
PST O 0 0.00022200128296390176
) O 0 8.360638759086214e-08
- O 0 8.445630896858347e-07
rich O 0 6.851950615782698e-07
transactivation O 0 3.7499299651244655e-05
domain O 0 1.267132802240667e-06
. O 0 2.8464211254686234e-07

PAX6 O 1 0.9999998807907104
regulates O 0 0.0003596452297642827
eye O 1 0.9209190011024475
development O 0 3.969483714172384e-06
in O 0 2.1559719343144934e-08
animals O 0 1.1086631168666372e-08
ranging O 0 5.4384212688773914e-08
from O 0 2.6631028049450833e-08
jellyfish O 0 5.715593687227738e-08
to O 0 6.234844196484346e-09
Drosophila O 0 2.0895066654702532e-07
to O 0 1.335368349231203e-08
humans O 0 1.299989548897429e-06
. O 0 8.071152706179419e-07

Heterozygous O 0 1.0573354302323423e-05
mutations O 0 5.422872959570668e-07
in O 0 3.093292377798207e-08
the O 0 3.313463281529039e-08
human O 0 2.0307022907672945e-07
PAX6 O 1 0.999847412109375
gene O 0 1.7179688427404471e-07
result O 0 1.5341527159762336e-08
in O 0 1.6129222402128107e-09
various O 0 2.788107522633254e-09
phenotypes O 0 9.430161185264296e-08
, O 0 1.932275228710978e-09
including O 0 1.4611593712743343e-08
aniridia B-Disease 1 1.0
, O 0 7.34262016521825e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 4.54228967328163e-07
autosomal B-Disease 0 0.000882837688550353
dominant I-Disease 1 0.9892696738243103
keratitis I-Disease 1 1.0
, O 0 4.906039976049215e-06
and O 0 1.603724194865208e-05
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9303073883056641

It O 0 2.657656352766935e-07
is O 0 2.2580174174891e-08
believed O 0 3.264121772872386e-08
that O 0 8.457311517773292e-10
the O 0 5.406872727320433e-09
mutated O 0 6.794999052317507e-08
allele O 0 6.672983943190047e-08
of O 0 1.2193031295737455e-07
PAX6 O 0 0.22796893119812012
produces O 0 7.162044113329102e-08
an O 0 4.480070536772018e-09
inactive O 0 1.7343747060749592e-07
protein O 0 1.8705100046645384e-07
and O 0 3.6718692086878946e-08
aniridia B-Disease 1 0.9999998807907104
is O 0 5.8160964044873253e-08
caused O 0 2.7395023494136694e-07
due O 0 4.461415414880321e-07
to O 0 5.634219846228916e-08
genetic O 0 5.684754796675406e-06
haploinsufficiency O 0 9.066914935829118e-05
. O 0 9.650658512327936e-07

However O 0 3.18017464451259e-06
, O 0 1.5052492585709842e-07
several O 0 3.2693680651618706e-08
truncation O 0 2.9900977551733376e-06
mutations O 0 4.185846691484585e-08
have O 0 3.720880270563498e-09
been O 0 2.0825161595183772e-09
found O 0 7.843516947048101e-10
to O 0 3.012236293731263e-10
occur O 0 9.998809558098287e-10
in O 0 2.9362474673888528e-09
the O 0 1.1888979578600356e-08
C O 0 4.149456071900204e-05
- O 0 2.350611566726002e-06
terminal O 0 9.632434512241161e-07
half O 0 1.0121888216474417e-08
of O 0 1.4195901343327932e-08
PAX6 O 1 0.9548969268798828
in O 0 1.183127196213718e-08
patients O 0 5.430336713629913e-08
with O 0 1.608069588598937e-08
Aniridia B-Disease 1 1.0
resulting O 0 3.666176780825481e-06
in O 0 4.0255507371966814e-08
mutant O 0 4.665118069624441e-08
proteins O 0 1.1845897596174382e-09
that O 0 2.5260227243251165e-10
retain O 0 2.019014821996734e-08
the O 0 1.6712828454501505e-08
DNA O 0 1.337919570687518e-07
- O 0 3.2517807113663366e-08
binding O 0 2.6802540187276236e-09
domains O 0 9.71984004394244e-09
but O 0 1.1703669144935702e-09
have O 0 1.6831567251074375e-09
lost O 0 7.913911304058274e-08
most O 0 5.196922447936458e-09
of O 0 4.416280319219368e-08
the O 0 1.8149361835639866e-07
transactivation O 0 0.0001547335705254227
domain O 0 3.2377959087170893e-06
. O 0 8.560617175135121e-07

It O 0 1.852832411941563e-07
is O 0 1.1040354408464736e-08
not O 0 1.6573021843768743e-09
clear O 0 1.7571709420849402e-08
whether O 0 3.93885013494355e-09
such O 0 2.8302117982548225e-08
mutants O 0 0.00011519979307195172
really O 0 3.312980254577269e-07
behave O 0 2.0476631945598456e-08
as O 0 6.931183627045812e-09
loss O 0 1.1306592995197207e-07
- O 0 1.1867182365676854e-06
of O 0 5.019251602789154e-06
- O 0 1.3361398487177212e-05
function O 0 2.1104360925505716e-08
mutants O 0 7.526099921051355e-08
as O 0 4.008998022442256e-09
predicted O 0 5.083088439050698e-08
by O 0 1.843165087223042e-08
haploinsufficiency O 0 0.00023643656459171325
. O 0 5.0596886467246804e-06

Contrary O 0 4.885049293079646e-06
to O 0 4.998406666345545e-08
this O 0 5.110129652763362e-09
theory O 0 1.553158455180892e-07
, O 0 7.087206377320854e-09
our O 0 1.3809408727638584e-08
data O 0 7.2458012922993476e-09
showed O 0 2.7042446060221437e-09
that O 0 1.5548931586728543e-10
these O 0 1.340267008487217e-09
mutants O 0 1.3389853847911581e-07
are O 0 1.597195820046693e-09
dominant O 0 2.93984635391098e-06
- O 0 4.118539607134153e-07
negative O 0 1.6134615421492526e-08
in O 0 3.254850833300793e-09
transient O 0 2.2054963721984677e-07
transfection O 0 2.7747885269491235e-06
assays O 0 5.750234421952882e-08
when O 0 5.552180049051003e-09
they O 0 8.994317513000283e-10
are O 0 5.756461418648939e-10
coexpressed O 0 4.2544741063466063e-07
with O 0 8.70745875403145e-09
wild O 0 1.4032515309736482e-06
- O 0 2.770341097857454e-06
type O 0 5.447455623652786e-05
PAX6 O 1 0.9999967813491821
. O 0 5.77370929022436e-06

We O 0 1.1069199672419927e-06
found O 0 3.507279089376425e-08
that O 0 3.0452464994112916e-09
the O 0 2.946201149711669e-08
dominant O 0 0.0009990003891289234
- O 0 1.0614878192427568e-05
negative O 0 1.9469782230885357e-08
effects O 0 1.7076665415061143e-07
result O 0 6.2995617611250054e-09
from O 0 3.6108884771124394e-09
the O 0 1.3402541299001314e-09
enhanced O 0 2.305101354238559e-08
DNA O 0 1.2616900413320309e-08
binding O 0 1.5417142007478901e-09
ability O 0 2.1429418239904408e-09
of O 0 7.820514902334708e-09
these O 0 1.1463654026044878e-08
mutants O 0 2.0456900529097766e-06
. O 0 2.3108556490569754e-07

Kinetic O 0 1.3169176781957503e-05
studies O 0 2.1708686404053879e-07
of O 0 4.4562185053109715e-08
binding O 0 3.4800052617356414e-08
and O 0 9.816348622848636e-09
dissociation O 0 2.3235357105022558e-07
revealed O 0 6.781689165791249e-08
that O 0 7.837639426355736e-10
various O 0 9.171333914537172e-09
truncation O 0 3.3820313092292054e-06
mutants O 0 4.122437928799627e-07
have O 0 8.072490231825213e-09
3 O 0 8.476860813289022e-08
- O 0 1.7585851708190603e-07
5 O 0 1.8454679207025038e-07
- O 0 1.8260824674598553e-07
fold O 0 5.645062728376615e-08
higher O 0 2.4925421726607055e-08
affinity O 0 6.0437335136498405e-09
to O 0 4.372090744997337e-10
various O 0 1.3262247966494556e-09
DNA O 0 2.8831994569600283e-08
- O 0 9.32434751632627e-09
binding O 0 1.7384019779242976e-09
sites O 0 1.6698545879378912e-09
when O 0 1.8985872596299913e-10
compared O 0 2.676850130445274e-10
with O 0 1.5569230626955033e-10
the O 0 3.9736294255021676e-09
wild O 0 2.0738156081279158e-07
- O 0 3.725057524661679e-07
type O 0 4.153140253038146e-06
PAX6 O 1 0.9996622800827026
. O 0 3.3552323657204397e-06

These O 0 3.0638540238214773e-07
results O 0 7.801449442013109e-08
provide O 0 4.3778360492297e-08
a O 0 2.1235994296375793e-08
new O 0 2.8116922123899712e-08
insight O 0 7.727210515895422e-08
into O 0 4.900417405195867e-09
the O 0 1.6532103463973158e-09
role O 0 1.701225471606449e-08
of O 0 9.701081893354058e-08
mutant O 0 1.3958485396869946e-05
PAX6 O 1 0.9999891519546509
in O 0 2.1149800488728943e-07
causing O 0 1.8380085748503916e-05
aniridia B-Disease 1 1.0
. O 0 1.1862045994348591e-06
. O 0 8.138785005940008e-07

Reversal O 0 0.00028601434314623475
of O 0 5.429935845313594e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.999861478805542
excellent O 1 0.9995844960212708
neuropsychologic O 1 0.9977624416351318
outcome O 0 2.320366729691159e-05
in O 0 5.0107200166849e-08
very B-Disease 0 8.195583234282822e-08
- I-Disease 0 3.951716962546925e-07
long I-Disease 0 4.108998155061272e-07
- I-Disease 0 4.1832967667687626e-07
chain I-Disease 0 3.2653676385052677e-07
acyl I-Disease 0 4.594798781454301e-07
- I-Disease 0 1.9389740657516086e-07
coenzyme I-Disease 0 4.3305445274199883e-07
A I-Disease 0 1.6385220078518614e-05
dehydrogenase I-Disease 0 0.0002579921274445951
deficiency I-Disease 0 0.0008107673493213952
. O 0 8.68909467044432e-07

Very B-Disease 0 1.977067040570546e-05
- I-Disease 0 1.3377209143072832e-05
long I-Disease 0 1.025343635774334e-06
- I-Disease 0 2.3848602381804085e-07
chain I-Disease 0 1.1404686972582567e-07
acyl I-Disease 0 9.90319719562649e-08
- I-Disease 0 2.991672332086637e-08
coenzyme I-Disease 0 2.8351339054211167e-08
A I-Disease 0 1.5863116686887224e-07
dehydrogenase I-Disease 0 1.0024833727584337e-06
( I-Disease 0 4.331159431103515e-08
VLCAD I-Disease 1 0.9998964071273804
) I-Disease 0 2.585203731086949e-07
deficiency I-Disease 0 0.41636934876441956
is O 0 1.0878812517489678e-08
a O 0 2.5659655733534237e-08
disorder O 0 3.0206565497792326e-05
of O 0 5.075513058727665e-07
fatty O 0 4.387714852782665e-06
acid O 0 5.535813940582557e-08
beta O 0 1.5675563957984195e-08
oxidation O 0 7.349511221832472e-09
that O 0 7.289560066681133e-10
reportedly O 0 5.706160521867787e-08
has O 0 2.4013684374324384e-09
high O 0 4.989871271732227e-08
rates O 0 1.4157828687189067e-08
of O 0 1.3868244330694779e-08
morbidity O 0 4.758327577292221e-06
and O 0 9.81447954018222e-08
mortality O 0 3.851474957627943e-06
. O 0 1.019382466438401e-06

We O 0 6.904597853463201e-07
describe O 0 3.134104247237701e-07
the O 0 6.732802404485483e-08
outcome O 0 4.626642464700126e-07
of O 0 1.8278211655342602e-07
a O 0 7.224221576507261e-08
5 O 0 8.75465815397547e-08
- O 0 5.352982768158654e-08
year O 0 1.4904841805218894e-08
- O 0 1.3417964339623722e-07
old O 0 6.622417458856944e-07
girl O 0 1.0120850646444524e-07
with O 0 1.837513785574174e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 5.053992572356947e-05
was O 0 1.8349521724303486e-06
first O 0 3.267878057044982e-08
seen O 0 2.201389825984279e-08
at O 0 1.3980827162640708e-08
5 O 0 2.989640313089126e-09
months O 0 2.0235015885106122e-09
of O 0 2.4410691246146143e-09
age O 0 4.9384936140484115e-09
with O 0 4.16267553760008e-09
severe O 1 0.9999847412109375
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999334812164307
hepatomegaly B-Disease 1 1.0
, O 1 0.9999706745147705
encephalopathy B-Disease 1 1.0
, O 0 1.6355289744751644e-06
and O 0 1.7111065972130746e-05
hypotonia B-Disease 1 1.0
. O 0 0.0015814541839063168

Biochemical O 0 0.0001592800981597975
studies O 0 4.062380867253523e-06
indicated O 0 0.0010721657890826464
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0010645317379385233
by O 0 3.9284532959982243e-08
a O 0 1.215925209407942e-07
stable O 0 1.682145466475049e-06
yet O 0 2.402148879809829e-07
inactive O 0 4.299628926673904e-06
enzyme O 0 1.153843300016888e-06
. O 0 3.335823066663579e-07

Molecular O 0 6.08063646723167e-06
genetic O 0 4.6326695724019373e-07
analysis O 0 9.511467879974589e-08
of O 0 2.2693777168569795e-07
her O 0 1.8489683384359523e-07
VLCAD O 1 0.9999427795410156
gene O 0 1.122045091506152e-06
revealed O 0 5.532414775188954e-07
a O 0 1.306542856127635e-07
T1372C O 0 6.633399152633501e-06
( O 0 7.640930732577544e-08
F458L O 0 3.67112420462945e-06
) O 0 1.3085363903542202e-08
missense O 0 3.553051897142723e-07
mutation O 0 1.5246079954067682e-08
and O 0 1.591777021303642e-08
a O 0 1.8139360236091306e-07
1668 O 0 0.03322291746735573
ACAG O 1 0.999995231628418
1669 O 0 0.022917073220014572
splice O 0 0.0006213211454451084
site O 0 4.229386377119226e-06
mutation O 0 4.6291407329590584e-07
. O 0 5.884328970751085e-07

After O 0 3.809865347648156e-06
initial O 0 8.313726311826031e-07
treatment O 0 2.2201811589184217e-06
with O 0 2.6151228738058307e-08
intravenous O 0 2.7413734642323107e-06
glucose O 0 4.103271749045234e-06
and O 0 3.04553857688461e-08
carnitine O 0 3.423147290959605e-06
, O 0 2.413303334947159e-08
the O 0 5.790737489519415e-08
patient O 0 3.3149347018479602e-06
has O 0 3.618087873746845e-08
thrived O 0 3.547157518823951e-07
on O 0 1.3425344391748695e-08
a O 0 5.027048999295403e-09
low O 0 3.405066593131778e-07
- O 0 2.1309114117684658e-07
fat O 0 2.234863529793074e-07
diet O 0 2.5738033926359094e-08
supplemented O 0 5.5241660135152415e-09
with O 0 8.533956319389802e-10
medium O 0 2.559411996116978e-06
- O 0 4.874495061812922e-06
chain O 0 3.438043449932593e-06
triglyceride O 0 9.044020430337696e-07
oil O 0 1.3922766584073543e-07
and O 0 4.982593448943362e-09
carnitine O 0 2.2140990552088624e-07
and O 0 6.44298880914107e-09
avoidance O 0 6.229822702152887e-06
of O 0 9.615611133995117e-07
fasting O 0 2.3550010155304335e-05
. O 0 1.0517914006413775e-06

Her O 0 6.168729305500165e-05
ventricular O 1 0.9999682903289795
hypertrophy O 1 0.9999890327453613
resolved O 0 0.0019472870044410229
significantly O 0 4.187965714663733e-06
over O 0 1.0644559722550184e-07
1 O 0 3.818700378133144e-08
year O 0 1.5092901373137124e-09
, O 0 7.298630588792321e-10
and O 0 2.690939027161221e-09
cognitively O 0 2.9159757104935125e-05
, O 0 8.170575327426377e-09
she O 0 1.7138482855116877e-09
is O 0 2.2784002462472586e-10
in O 0 1.9518991978273448e-10
the O 0 1.210991973366049e-09
superior O 0 9.963312095351284e-07
range O 0 3.9148628161456145e-07
for O 0 4.98816810079461e-08
age O 0 2.6119730023310694e-07
. O 0 6.79608717746305e-07

Clinical O 0 9.365895675728098e-05
recognition O 0 0.000172372892848216
of O 1 0.9999597072601318
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.2794999899342656e-07
important O 0 1.6839603489415822e-08
because O 0 8.327940559382796e-10
it O 0 1.3227884065880602e-10
is O 0 1.9232146430958608e-10
one O 0 1.5979445544545e-10
of O 0 2.6072723979808643e-09
the O 0 5.084443088776425e-09
few O 0 9.326428518363628e-09
directly O 0 2.365768203560492e-08
treatable O 1 0.9793546199798584
causes O 0 3.2140856092155445e-06
of O 0 0.03374835103750229
cardiomyopathy B-Disease 1 1.0
in O 0 6.995604053372517e-05
children O 0 3.273411834925355e-07
. O 0 5.0225946068849225e-08
. O 0 2.667958938218362e-07

Cloning O 0 3.510671740514226e-05
of O 0 6.89781927576405e-07
a O 0 1.447441917434844e-07
novel O 0 4.806581728189485e-07
member O 0 6.068894720101525e-08
of O 0 7.30968494622175e-08
the O 0 9.763023456343944e-08
low O 0 1.3161241440684535e-05
- O 0 6.678566251139273e-07
density O 0 6.432173194070856e-08
lipoprotein O 0 2.0472418327699415e-05
receptor O 0 1.6081514786492335e-06
family O 0 5.451069569062383e-07
. O 0 2.918986865552142e-07

A O 0 7.1860426942294e-06
gene O 0 2.3522031256106857e-07
encoding O 0 5.63603521186451e-07
a O 0 6.905889904373907e-08
novel O 0 3.2163438845600467e-07
transmembrane O 0 2.1663601046384429e-07
protein O 0 1.4283029869943675e-08
was O 0 6.253805473477314e-09
identified O 0 5.494635302305539e-10
by O 0 4.7154946614114124e-11
DNA O 0 2.679047650389066e-09
sequence O 0 4.818959675745305e-10
analysis O 0 3.320051733535223e-10
within O 0 6.313776723665399e-10
the O 0 8.943496609958856e-09
insulin B-Disease 0 0.001031639170832932
- I-Disease 0 8.756008901400492e-05
dependent I-Disease 0 0.0045439694076776505
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.5837851606193e-05
IDDM B-Disease 1 0.9949265718460083
) O 0 9.978413828548582e-08
locus O 0 1.0135546517631155e-06
IDDM4 O 0 2.2717109459335916e-05
on O 0 4.3196260435252043e-07
chromosome O 0 5.862730176886544e-07
11q13 O 0 1.3508148185792379e-05
. O 0 1.7967309986488544e-06

Based O 0 2.420373675704468e-06
on O 0 2.3287888950562774e-07
its O 0 2.0840431602664466e-08
chromosomal O 0 1.4209736320935917e-07
position O 0 1.116195846861956e-07
, O 0 1.9356911629131446e-09
this O 0 3.774704437908838e-10
gene O 0 1.4200363107619296e-09
is O 0 2.5324481400801346e-10
a O 0 5.605786390638912e-10
candidate O 0 5.026204785707478e-09
for O 0 2.811701316218773e-09
conferring O 0 1.9678611806739355e-06
susceptibility O 0 0.0015227231197059155
to O 0 1.5329848110923194e-06
diabetes B-Disease 1 1.0
. O 0 0.00027483070152811706

The O 0 2.3255713585967897e-06
gene O 0 4.3868973875760275e-07
, O 0 3.264171510863889e-08
termed O 0 1.0084024779644096e-06
low O 0 8.972554496722296e-06
- O 0 6.856853360659443e-07
density O 0 3.273249049584592e-08
lipoprotein O 0 1.816603457882593e-06
receptor O 0 3.164323203463937e-08
related O 0 8.362675885109638e-09
protein O 0 1.4252604429998428e-08
5 O 0 5.301970862348071e-09
( O 0 7.501900767259428e-10
LRP5 O 0 4.476067715586396e-06
) O 0 8.224639302945036e-10
, O 0 3.400768833206058e-10
encodes O 0 5.65415159137217e-10
a O 0 6.952762254819334e-10
protein O 0 1.6106073141841648e-09
of O 0 1.5886825188715648e-09
1615 O 0 7.364276655152935e-08
amino O 0 3.007817106492894e-09
acids O 0 1.7070591606938024e-09
that O 0 1.8146360802884232e-10
contains O 0 1.3755354633104844e-09
conserved O 0 1.9068528089860592e-08
modules O 0 2.0589856930541828e-08
which O 0 1.006746699894201e-10
are O 0 4.19672838147811e-11
characteristic O 0 2.5608450915370895e-09
of O 0 5.960938853633024e-09
the O 0 1.559578777232673e-08
low O 0 6.408410513358831e-07
- O 0 4.947613518879734e-08
density O 0 6.433434673880356e-09
lipoprotein O 0 6.301282837739564e-07
( O 0 2.3788084391185293e-08
LDL O 0 9.633926310925744e-06
) O 0 2.8190166645458703e-08
receptor O 0 4.5339845655689714e-07
family O 0 2.802649419209047e-07
. O 0 2.3242405688961298e-07

These O 0 6.666361969109857e-07
modules O 0 2.9246677968330914e-06
include O 0 5.769767952301663e-08
a O 0 6.340561498063835e-08
putative O 0 2.1629550701618427e-06
signal O 0 1.146170575339056e-06
peptide O 0 1.028623231036363e-07
for O 0 2.7171858096863843e-09
protein O 0 6.430502352827716e-09
export O 0 1.3871128246023545e-08
, O 0 1.6605896657750918e-09
four O 0 1.3573963286717117e-08
epidermal O 0 9.64763103183941e-07
growth O 0 1.8197884088522187e-08
factor O 0 2.484558336846021e-08
( O 0 2.3911134405807388e-08
EGF O 0 4.568983968056273e-06
) O 0 2.754900085832901e-09
repeats O 0 1.8322117156799322e-08
with O 0 1.1053664650262363e-09
associated O 0 1.1716920766957628e-08
spacer O 0 4.690618311542494e-07
domains O 0 4.135186415510361e-08
, O 0 1.7667007856658756e-09
three O 0 6.83383261090853e-09
LDL O 0 2.5894796635839157e-06
- O 0 9.714447060105158e-07
receptor O 0 6.11258670346615e-08
( O 0 8.953277230716594e-09
LDLR O 0 8.563429219066165e-06
) O 0 6.27603080616268e-09
repeats O 0 2.104615326459225e-08
, O 0 1.2389580472671469e-09
a O 0 3.0679014884071876e-09
single O 0 5.7967906030853555e-09
transmembrane O 0 4.3852239173247654e-08
spanning O 0 2.2186471326790524e-08
domain O 0 9.668474021395923e-09
, O 0 9.909538745134228e-10
and O 0 2.3560313699988455e-09
a O 0 2.585059988291505e-08
cytoplasmic O 0 6.872539302094083e-07
domain O 0 7.504539780711639e-07
. O 0 1.8400288581688073e-07

The O 0 1.4949077922210563e-06
encoded O 0 6.694917260574584e-07
protein O 0 1.2492159839894157e-07
has O 0 4.219640192815177e-09
a O 0 2.2642050456767038e-09
unique O 0 7.612561248038219e-09
organization O 0 1.4573017459440507e-08
of O 0 1.4483104848750372e-07
EGF O 1 0.8114720582962036
and O 0 2.924217028521525e-07
LDLR O 1 0.8348270654678345
repeats O 0 1.355077756670653e-07
; O 0 2.362853912529772e-09
therefore O 0 6.372821825806341e-09
, O 0 7.69288455160222e-09
LRP5 O 0 0.007048506755381823
likely O 0 6.17835524963084e-08
represents O 0 6.9397820823269285e-09
a O 0 3.815779248128592e-09
new O 0 5.20059151298824e-09
category O 0 7.089166587093132e-09
of O 0 1.499569179941318e-08
the O 0 1.6855500462042983e-07
LDLR O 1 0.9727485775947571
family O 0 2.269222704853746e-06
. O 0 3.891638300501654e-07

Both O 0 3.5469547583488747e-06
human O 0 2.4060657324298518e-06
and O 0 9.479118716626544e-07
mouse O 0 0.00021231124992482364
LRP5 O 1 0.9999549388885498
cDNAs O 0 0.004184449091553688
have O 0 1.6925064016959368e-08
been O 0 8.730141054513751e-09
isolated O 0 3.609382304148312e-08
and O 0 2.4099258144616442e-09
the O 0 2.3609751931275014e-09
encoded O 0 5.961279470056979e-09
mature O 0 6.538499075503523e-09
proteins O 0 2.3433202600564584e-10
are O 0 6.281665465568409e-11
95 O 0 5.790425472440575e-09
% O 0 4.48185460966144e-10
identical O 0 3.97033383947587e-09
, O 0 7.799507151240448e-10
indicating O 0 8.586224176099222e-09
a O 0 4.566332201250134e-09
high O 0 2.18506688298703e-08
degree O 0 4.099533157386759e-08
of O 0 9.025563407760728e-09
evolutionary O 0 6.145564412918247e-08
conservation O 0 1.875149813201915e-08
. O 0 4.116957885713646e-09
. O 0 4.687693433425011e-08

The O 0 6.872906396893086e-06
APC B-Disease 0 1.689513010205701e-05
variants O 0 9.99640269583324e-06
I1307K O 0 2.1852894860785455e-05
and O 0 4.3604359234450385e-08
E1317Q O 0 8.670287456880033e-07
are O 0 6.206270497521871e-10
associated O 0 7.627170361956814e-08
with O 0 5.4926287702983245e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0015771585749462247
but O 0 1.8950110813875654e-08
not O 0 1.0872459599298168e-09
always O 0 4.824461719010742e-09
with O 0 4.977034340214459e-10
a O 0 1.9137537776714453e-08
family O 0 1.7439265320717823e-07
history O 0 4.6644510121041094e-07
. O 0 3.224153601877333e-07

Classical O 0 0.01301357988268137
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.03917941451072693
FAP B-Disease 1 0.9998685121536255
) O 0 1.240915139533172e-07
is O 0 6.462261836759353e-09
a O 0 4.247476326213473e-08
high O 0 5.347673868527636e-05
- O 0 0.19930703938007355
penetrance O 1 0.9999446868896484
autosomal B-Disease 1 0.9991273283958435
dominant I-Disease 1 0.9999974966049194
disease I-Disease 1 0.9999959468841553
that O 0 1.9727787403667207e-08
predisposes O 0 2.9450400688801892e-05
to O 0 2.8934847406958397e-08
hundreds O 0 3.96714092687489e-08
or O 0 4.301505285297935e-08
thousands O 0 9.287627023013556e-08
of O 0 0.4282934069633484
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 7.75634305227868e-07
that O 0 1.562573404001455e-09
results O 0 1.4938902337391369e-09
from O 0 3.5284197785756533e-09
truncating O 0 1.9875771783972596e-07
mutations O 0 1.0296671071330366e-08
in O 0 4.517852758567642e-09
the O 0 5.513138034984877e-08
APC B-Disease 0 2.7815815428766655e-06
gene O 0 8.386102194890555e-07
. O 0 5.806763283544569e-07

A O 0 6.906086582603166e-06
variant O 0 3.972782360506244e-05
of O 0 3.1348445190815255e-06
FAP B-Disease 0 0.011454356834292412
is O 0 1.972708787434385e-06
attenuated B-Disease 1 0.9999842643737793
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 1.1098182994828676e-06
which O 0 9.470877415651557e-09
results O 0 1.0576071574064372e-08
from O 0 2.5651337054455325e-08
germ O 1 0.9997075200080872
- O 0 1.1918985364900436e-05
line O 0 4.6677931209160306e-07
mutations O 0 5.8157496596322744e-09
in O 0 6.947963315795391e-10
the O 0 2.299040957609577e-09
5 O 0 7.249312261592422e-09
and O 0 3.290712369263815e-09
3 O 0 4.1045954191076817e-08
regions O 0 8.255920391775362e-09
of O 0 1.4117603086560848e-07
the O 0 6.045038958291116e-07
APC B-Disease 0 3.421721203267225e-06
gene O 0 5.833940122101922e-07
. O 0 3.158649235501798e-07

Attenuated B-Disease 1 0.9999980926513672
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.99693763256073
have O 0 1.254498869229792e-07
" O 0 2.2760187334824877e-07
multiple O 0 2.3851658625062555e-05
" O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.8905383285527932e-06
typically O 0 2.7117096124129603e-08
fewer O 0 3.1703746294908797e-09
than O 0 6.568043886545638e-10
100 O 0 1.945574146233753e-09
) O 0 3.1523139654154875e-10
without O 0 3.0525271199621784e-09
the O 0 1.064482013646284e-08
florid O 0 2.0583122477546567e-06
phenotype O 0 3.727211321802315e-07
of O 0 4.92481930791655e-08
classical O 0 3.1243416742654517e-06
FAP B-Disease 0 3.0445096854236908e-05
. O 0 1.376891418658488e-06

Another O 0 2.123985950674978e-06
group O 0 9.011874624320626e-08
of O 0 9.390333843839471e-08
patients O 0 3.9363709447570727e-07
with O 0 8.487082148178615e-09
multiple O 0 8.65625188453123e-05
adenomas B-Disease 1 1.0
has O 0 6.23865403781565e-08
no O 0 4.541005349523175e-09
mutations O 0 1.8284089797759862e-09
in O 0 5.115900481023061e-10
the O 0 2.9943825197165097e-09
APC B-Disease 0 2.486098971132833e-08
gene O 0 2.420885714116139e-09
, O 0 5.480986220440798e-10
and O 0 1.0452871901378558e-09
their O 0 2.53044074582931e-09
phenotype O 0 2.389240307820728e-07
probably O 0 3.9004103058459805e-08
results O 0 1.1700500568423422e-09
from O 0 1.9784753835239144e-09
variation O 0 5.623161669632282e-08
at O 0 1.6711904748945017e-08
a O 0 5.9015685671681695e-09
locus O 0 1.0023791574553798e-08
, O 0 4.4382822417254886e-10
or O 0 8.194606659905901e-10
loci O 0 2.9248573341078554e-08
, O 0 2.7414184256002727e-09
elsewhere O 0 2.9403624424162444e-08
in O 0 7.468339724425732e-09
the O 0 6.486678927331013e-08
genome O 0 3.750140820102388e-07
. O 0 2.663103373379272e-07

Recently O 0 4.046265075885458e-06
, O 0 3.7785692796887815e-08
however O 0 2.355120543029443e-08
, O 0 6.482965275722563e-09
a O 0 1.3662223352639558e-08
missense O 0 8.245693265962473e-07
variant O 0 1.0764807484520134e-05
of O 0 1.779551530489698e-05
APC B-Disease 0 3.429863500059582e-05
( O 0 1.0484429679991081e-07
I1307K O 0 2.274175130878575e-06
) O 0 3.44628303672323e-09
was O 0 1.8518830913194506e-08
described O 0 3.6355249921626864e-09
that O 0 1.87733439904747e-10
confers O 0 1.8215873254234793e-08
an O 0 1.724902304323095e-10
increased O 0 2.3037025620453733e-09
risk O 0 2.0080355511709058e-07
of O 1 0.662131667137146
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.4399976180357044e-06
including O 0 6.863880486207563e-08
multiple O 0 1.3295682038005907e-05
adenomas B-Disease 1 0.9999953508377075
, O 0 9.732643491133786e-08
in O 0 2.0328840832917194e-07
Ashkenazim O 1 0.9642561674118042
. O 0 8.131251888698898e-06

We O 0 6.505784995169961e-07
have O 0 1.3963290967922148e-08
studied O 0 3.34910836841118e-08
a O 0 4.214878224217955e-09
set O 0 5.790093737800817e-09
of O 0 6.859166123973637e-09
164 O 0 1.2030022844555788e-07
patients O 0 6.209402414469878e-08
with O 0 2.058475168098539e-08
multiple O 1 0.9999994039535522
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998965263366699
/ I-Disease 1 1.0
or I-Disease 1 0.6926606893539429
carcinoma I-Disease 1 1.0
and O 0 1.3115689512233075e-07
analyzed O 0 1.3354350869576592e-07
codons O 0 1.3989688341098372e-07
1263 O 0 6.060744453861844e-06
- O 0 7.432836923726427e-07
1377 O 0 1.5933002941892482e-05
( O 0 9.795199673590105e-08
exon O 0 5.979001116429572e-07
15G O 0 6.277913371377508e-07
) O 0 1.153409479037748e-09
of O 0 9.068426898295456e-09
the O 0 3.185778751912949e-08
APC B-Disease 0 3.828137948858057e-07
gene O 0 2.999031067929536e-08
for O 0 1.7908373450836734e-08
germ O 1 0.9999123811721802
- O 0 0.00016574897745158523
line O 0 2.805435906338971e-05
variants O 0 1.5742547475383617e-05
. O 0 1.8194955373473931e-06

Three O 0 9.581302720107487e-07
patients O 0 2.130574188186074e-07
with O 0 6.1375731164048375e-09
the O 0 2.896184625456044e-08
I1307K O 0 6.765596367586113e-07
allele O 0 1.5398633479435375e-08
were O 0 2.0550925405871112e-09
detected O 0 1.0215586598860682e-08
, O 0 4.5489093047912377e-10
each O 0 1.450680547909755e-10
of O 0 1.1553564327471122e-08
Ashkenazi O 0 0.00012730351591017097
descent O 0 3.489253867883235e-05
. O 0 2.1157495666557224e-06

Four O 0 8.172032721631695e-06
patients O 0 4.008070391137153e-06
had O 0 3.221150848276011e-07
a O 0 2.862086319055379e-07
germ O 1 0.9971588850021362
- O 0 8.765131497057155e-05
line O 0 1.2274552318558563e-05
E1317Q O 0 3.3121950764325447e-06
missense O 0 3.684694434014091e-07
variant O 0 2.815798438859929e-07
of O 0 6.255573481439569e-08
APC O 0 2.722671865740267e-07
that O 0 2.1939359218237087e-09
was O 0 2.3792351200313533e-08
not O 0 1.6530675439607734e-10
present O 0 7.07597869187282e-10
in O 0 4.4634021478806574e-10
controls O 0 1.0598628641389496e-08
; O 0 1.0336413946987477e-09
one O 0 8.436512044518452e-10
of O 0 1.6273935532495898e-09
these O 0 3.1244554166143246e-10
individuals O 0 1.3323649128427206e-10
had O 0 2.257904307967351e-09
an O 0 2.1700710672867274e-10
unusually O 0 6.557482556956984e-09
large O 0 8.128804851459392e-10
number O 0 5.955139714686197e-10
of O 0 3.323919983699852e-08
metaplastic B-Disease 0 0.0006027001072652638
polyps I-Disease 0 2.8904216378577985e-05
of I-Disease 0 4.777087383445178e-07
the I-Disease 0 2.2259307570493547e-06
colorectum I-Disease 0 0.001074444386176765
. O 0 2.790804273899994e-06

There O 0 8.371758895009407e-07
is O 0 3.4409382010380796e-08
increasing O 0 1.388020542947288e-08
evidence O 0 1.4955302773955736e-08
that O 0 7.981894589725869e-10
there O 0 1.0922864834839174e-09
exist O 0 9.142585355448318e-09
germ O 0 0.49747610092163086
- O 0 1.0442882967254263e-06
line O 0 1.1760764806467705e-07
variants O 0 3.096686285175565e-08
of O 0 9.9952304211115e-09
the O 0 8.37851477086815e-09
APC B-Disease 0 5.6185950114695515e-08
gene O 0 3.1251958798605983e-09
that O 0 4.151224919368701e-10
predispose O 0 4.782211249221291e-08
to O 0 1.2666104831637881e-09
the O 0 6.937796559469689e-09
development O 0 6.14286932432151e-08
of O 0 7.328349056479055e-07
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999974966049194
carcinoma I-Disease 1 1.0
, O 0 3.834692563486897e-08
but O 0 2.026328438375913e-09
without O 0 6.961603293831331e-09
the O 0 7.419469927327782e-09
florid O 0 1.1354867410773295e-06
phenotype O 0 4.544820342289313e-08
of O 0 1.077274269789541e-08
classical O 0 3.222364455268689e-07
FAP B-Disease 0 1.9721671833394794e-06
, O 0 2.3951243210973416e-09
and O 0 7.503345722525978e-10
possibly O 0 4.430046995906878e-09
with O 0 9.696392577751567e-10
importance O 0 1.7518655113235582e-06
for O 0 0.4456785023212433
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.7488679885864258
in O 0 5.733016283926418e-09
the O 0 2.9844839932735567e-09
general O 0 1.2244286473617194e-08
population O 0 6.471620461745431e-10
. O 0 1.0945143458229722e-08
. O 0 2.1735409916345816e-07

Genomic O 0 2.7126850909553468e-05
structure O 0 1.165497678812244e-06
of O 0 4.7176115458569257e-07
the O 0 5.079623974779679e-07
human O 0 0.009370028972625732
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999825954437256
CLD B-Disease 1 1.0
) O 0 4.5331689761951566e-06
gene O 0 1.8472497913535335e-06
. O 0 8.517822607245762e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999977350234985
CLD B-Disease 1 1.0
) O 0 4.708536778252892e-07
is O 0 3.9876448809650356e-09
caused O 0 1.358310530719109e-08
by O 0 2.8852153999281427e-10
mutations O 0 2.569485735293142e-09
in O 0 5.637944000547179e-10
a O 0 2.101846252600126e-09
gene O 0 2.3032367124642406e-09
which O 0 5.851430451286888e-10
encodes O 0 7.505697396936739e-09
an O 0 2.0482286977596686e-09
intestinal O 0 2.5159446522593498e-05
anion O 0 1.4143439329927787e-05
transporter O 0 0.00016480343765579164
. O 0 1.272643089578196e-06

We O 0 1.7535018059788854e-06
report O 0 1.8850225558253442e-07
here O 0 4.2665572408395747e-08
the O 0 6.121264384262304e-09
complete O 0 2.2993008386151814e-08
genomic O 0 1.6459911478250433e-07
organization O 0 8.826397390748753e-09
of O 0 3.1520826837549976e-08
the O 0 6.104232852521818e-08
human O 0 8.7578700913582e-07
CLD B-Disease 1 0.9999997615814209
gene O 0 3.97188898659806e-07
which O 0 6.262590446226568e-09
spans O 0 5.071312969562314e-08
approximately O 0 1.6974487371257396e-09
39kb O 0 3.9155648323685455e-07
, O 0 3.4275737803568518e-09
and O 0 8.793076489155283e-09
comprises O 0 4.403025144483763e-08
21 O 0 1.0124477967110579e-06
exons O 0 3.749307870748453e-05
. O 0 1.758681833052833e-06

All O 0 1.3636468793265522e-05
exon O 0 8.905187132768333e-05
/ O 0 1.6198919183807448e-05
intron O 0 1.592297849128954e-05
boundaries O 0 1.9027551445560675e-07
conform O 0 4.797769648234862e-08
to O 0 3.070068999022624e-08
the O 0 1.244786176357593e-07
GT O 0 0.012133055366575718
/ O 0 0.1334807276725769
AG O 1 0.9998249411582947
rule O 0 3.5195116652175784e-05
. O 0 5.093316303828033e-06

An O 0 1.1232801000460313e-07
analysis O 0 8.302524889813867e-08
of O 0 8.986779675979051e-08
the O 0 7.153702341611279e-08
putative O 0 4.1344068449689075e-05
promoter O 0 4.7452482249354944e-05
region O 0 2.0610019646483124e-07
sequence O 0 7.885960684461679e-08
shows O 0 1.4958468241843548e-08
a O 0 1.4859339536599236e-08
putative O 0 5.441547546070069e-05
TATA O 1 0.9998074173927307
box O 0 4.227749741403386e-06
and O 0 2.9783441490849327e-08
predicts O 0 2.25695657718461e-07
multiple O 0 4.822991854780412e-07
transcription O 0 8.539795089745894e-06
factor O 0 1.927515569377647e-07
binding O 0 1.0704602004807384e-07
sites O 0 2.290201877030995e-07
. O 0 1.4649440061020869e-07

The O 0 3.2579694106971147e-06
genomic O 0 6.842078619229142e-06
structure O 0 7.930213996587554e-07
was O 0 2.620886050408444e-07
determined O 0 1.4685213933773866e-08
using O 0 3.757825162153949e-09
DNA O 0 1.6444213102317917e-08
from O 0 7.145540825703733e-10
several O 0 3.6145661463926615e-10
sources O 0 3.6998473174065794e-09
including O 0 1.0952008189235585e-09
multiple O 0 3.5349760452163537e-08
large O 0 2.710267779093556e-07
- O 0 2.220934902652516e-06
insert O 0 9.85393285191094e-07
libaries O 0 2.8190950160933426e-06
and O 0 7.766852050394846e-09
genomic O 0 6.532992102847857e-08
DNA O 0 9.689061641893204e-08
from O 0 3.7827515342314655e-08
Finnish O 0 0.0010225625010207295
CLD B-Disease 1 1.0
patients O 1 0.9745284914970398
and O 0 3.532004711814807e-06
controls O 0 6.160164775792509e-05
. O 0 2.5322344754385995e-06

Exon O 0 0.0001542940444778651
- O 0 5.647857960866531e-06
specific O 0 6.921066386667007e-08
primers O 0 2.034134240602725e-06
developed O 0 1.3916714181050338e-07
in O 0 1.7557565401560282e-09
this O 0 2.9137181556393443e-10
study O 0 7.807842705709334e-10
will O 0 9.851150450934654e-11
facilitate O 0 1.6134730218553273e-09
mutation O 0 1.5812759990296854e-09
screening O 0 2.0344765871982418e-09
studies O 0 1.8611445717908737e-10
of O 0 3.0593219624286405e-10
patients O 0 2.2430526325223354e-09
with O 0 8.894007197390863e-10
the O 0 4.111773819204245e-07
disease O 1 0.9999401569366455
. O 0 4.5234523895487655e-06

Genomic O 0 2.4834818759700283e-05
sequencing O 0 5.746249826188432e-06
of O 0 9.063517154572764e-07
a O 0 3.7429808799060993e-06
BAC O 1 1.0
clone O 1 0.9999998807907104
H O 1 1.0
_ O 0 2.8316483167145634e-06
RG364P16 O 0 3.0205699204088887e-06
revealed O 0 4.939947118032251e-08
the O 0 1.2021547091123352e-09
presence O 0 1.2495855461480687e-09
of O 0 4.208917214754138e-09
another O 0 6.4691798584703974e-09
, O 0 7.102832766392453e-10
highly O 0 3.747381960295115e-09
homologous O 0 4.520265939333967e-09
gene O 0 1.130104232416329e-09
3 O 0 3.44221007253509e-09
of O 0 7.965305748314222e-09
the O 0 5.633746980038268e-08
CLD B-Disease 1 0.9996374845504761
gene O 0 4.6826180266634765e-08
, O 0 1.0718484988458954e-09
with O 0 2.0199142358734434e-10
a O 0 1.2961502982022921e-09
similar O 0 2.872581728041723e-09
genomic O 0 9.950551316251222e-08
structure O 0 3.601240194939237e-08
, O 0 2.0323978056069336e-09
recently O 0 4.191452962487574e-09
identified O 0 2.1684172235580945e-09
as O 0 3.011720650647476e-09
the O 0 2.0062746841631451e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.614136292322655e-06
( O 0 1.3937952303422207e-07
PDS B-Disease 0 0.00417301757261157
) O 0 1.2335875965163723e-07
. O 0 1.6810521685783897e-07
. O 0 1.5959107031449093e-06

The O 0 7.185083177319029e-06
APCI1307K O 0 0.004920950625091791
allele O 0 3.655493856058456e-06
and O 0 6.891217481097556e-07
cancer B-Disease 1 0.7246119379997253
risk O 0 1.5329716234191437e-06
in O 0 1.4401588366297347e-08
a O 0 3.2365960578317754e-08
community O 0 1.0593637078670781e-08
- O 0 1.296393392635764e-08
based O 0 1.4083808563825073e-09
study O 0 7.734236584511223e-10
of O 0 4.511626627845544e-09
Ashkenazi O 0 5.442381734610535e-06
Jews O 0 1.7139296915047453e-06
. O 0 8.729010687602567e-07

Mutations O 0 6.320762167888461e-06
in O 0 2.0887554796900076e-07
APC O 0 2.6666716621548403e-06
are O 0 4.9395390000483985e-09
classically O 0 2.5118959001702024e-06
associated O 0 1.7090530946006766e-07
with O 0 1.7171777244584518e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9751778841018677
FAP B-Disease 1 0.996537446975708
) O 0 3.784714408539003e-08
, O 0 3.784351498836713e-09
a O 0 3.2095101687446004e-08
highly O 0 0.06680236756801605
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.48890578746795654
by O 0 5.0633875758876457e-08
multiple O 0 0.0002664265630301088
intestinal O 1 1.0
polyps B-Disease 0 0.025201288983225822
and O 0 3.112236157676307e-08
, O 0 4.757408245126271e-09
without O 0 2.7296490401340634e-08
surgical O 1 0.9997135996818542
intervention O 1 0.703170120716095
, O 0 1.895719847766486e-08
the O 0 6.974309130214351e-09
development O 0 1.5147378462643246e-07
of O 0 0.333784282207489
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.000991053064353764
CRC B-Disease 0 0.009954583831131458
) O 0 1.4021530603258725e-07
. O 0 4.654754661714833e-07

APC B-Disease 0 7.993738108780235e-05
is O 0 6.071998086554231e-07
a O 0 1.1576569249882596e-06
tumour O 1 1.0
- O 0 1.1042965525120962e-05
suppressor O 0 4.188752427580766e-06
gene O 0 5.772054390007497e-09
, O 0 5.189313423414887e-10
and O 0 2.523639741625061e-09
somatic O 0 3.3041640563169494e-05
loss O 0 1.1448332770669367e-05
occurs O 0 2.0553306967485696e-06
in O 0 5.311467816682125e-07
tumours B-Disease 1 1.0
. O 0 4.5941860662424006e-06

The O 0 2.917928395618219e-05
germline O 0 0.00013123748067300767
T O 0 5.6619559472892433e-05
- O 0 2.5680642465886194e-06
to O 0 7.36429086600765e-08
- O 0 4.7478653186772135e-07
A O 0 3.4827482409127697e-07
transversion O 0 3.43854208040284e-06
responsible O 0 1.2641278246405818e-08
for O 0 4.241855755537927e-09
the O 0 2.2763263274327983e-08
APC O 0 4.2101601138710976e-07
I1307K O 0 5.37779897058499e-07
allele O 0 1.122975401557369e-08
converts O 0 2.4858572089669906e-08
the O 0 2.8447906252893063e-09
wild O 0 1.5398281760781174e-08
- O 0 7.731865814264438e-09
type O 0 4.79858197621752e-09
sequence O 0 3.720468599865967e-09
to O 0 2.1049513243553974e-09
a O 0 3.4631668199835985e-08
homopolymer O 0 0.0005967480828985572
tract O 0 4.693411756306887e-05
( O 0 5.4946720950965755e-08
A8 O 0 6.812245828768937e-06
) O 0 2.3560584594406464e-09
that O 0 5.448528295204369e-10
is O 0 6.454686118928521e-09
genetically O 0 1.3825492715113796e-06
unstable O 0 0.0001256709365407005
and O 0 2.6470124225852487e-07
prone O 0 2.121889338013716e-05
to O 0 1.6213873266224255e-07
somatic O 0 6.213007873157039e-05
mutation O 0 1.451367893423594e-06
. O 0 7.277701570274075e-07

The O 0 5.744967438658932e-06
I1307K O 0 2.049816794169601e-05
allele O 0 7.243828008540731e-07
was O 0 2.3696797768479883e-07
found O 0 2.3608592414348095e-08
in O 0 2.3707009688678227e-08
6 O 0 1.5571316680507152e-06
. O 0 2.636222461660509e-06

1 O 0 8.395332770305686e-06
% O 0 1.2593548603945237e-07
of O 0 1.6015856374451687e-07
unselected O 0 0.00011894325143657625
Ashkenazi O 0 2.4715645849937573e-05
Jews O 0 2.4502887185917643e-07
and O 0 3.350346222674716e-09
higher O 0 2.7690937542956817e-08
proportions O 0 7.817342151383855e-08
of O 0 5.14281026653407e-08
Ashkenazim O 0 2.619241422507912e-05
with O 0 7.031637938581525e-09
family O 0 6.809296593246472e-08
or O 0 1.1906657881866067e-08
personal O 0 1.045055341819534e-06
histories O 0 5.435218554339372e-06
of O 0 0.00014906686556059867
CRC B-Disease 1 0.9999986886978149
( O 0 3.845287210424431e-06
ref O 1 0.8154956102371216
. O 0 1.2814395233817777e-07
2 O 0 8.233230914811429e-07
) O 0 8.551938179834906e-08
. O 0 4.013989496343129e-07

To O 0 5.569433483287867e-07
evaluate O 0 5.571457108999311e-07
the O 0 9.066216932751558e-08
role O 0 1.6299873095704243e-07
of O 0 1.869570240842222e-07
I1307K O 0 5.8833302318817005e-05
in O 0 2.2300085333881725e-08
cancer B-Disease 0 7.968782301759347e-05
, O 0 3.903593892573554e-09
we O 0 6.553256604036051e-09
genotyped O 0 4.070528575539356e-06
5 O 0 7.72746062693841e-08
, O 0 1.5849304091375416e-08
081 O 0 4.523270399658941e-05
Ashkenazi O 0 6.356521771522239e-05
volunteers O 0 2.0871266315225512e-07
in O 0 1.0730518695822866e-08
a O 0 3.2734615018625846e-08
community O 0 1.710362340645588e-07
survey O 0 9.319318650113928e-08
. O 0 1.7528370221953082e-07

Risk O 0 1.6509306078660302e-05
of O 0 4.750646439788397e-06
developing O 1 0.9959325194358826
colorectal B-Disease 1 1.0
, I-Disease 0 0.2629605233669281
breast I-Disease 1 1.0
and I-Disease 0 3.387964852663572e-06
other I-Disease 0 2.0374159248603974e-07
cancers I-Disease 1 0.9999313354492188
were O 0 1.3204345350459334e-07
compared O 0 1.5208794934551406e-07
between O 0 2.4712406343496696e-07
genotyped O 0 0.008284641429781914
I1307K O 0 4.804106993105961e-06
carriers O 0 6.472836133752935e-08
and O 0 1.4815389803857215e-08
non O 0 7.643933486178867e-08
- O 0 7.040819838266543e-08
carriers O 0 1.7753967185285546e-08
and O 0 2.31027219577129e-09
their O 0 1.2465669607664154e-09
first O 0 8.053036459898522e-09
- O 0 5.355985877031344e-08
degree O 0 5.975774115540844e-07
relatives O 0 5.342823783394124e-07
. O 0 1.3812470456286974e-07

Sperm O 0 1.1752640602935571e-06
DNA O 0 3.0755700208828785e-07
analysis O 0 2.7680693293063996e-08
in O 0 9.858378113847266e-09
a O 0 8.243792137818673e-08
Friedreich B-Disease 1 0.9999997615814209
ataxia I-Disease 1 1.0
premutation O 1 1.0
carrier O 1 0.9092382788658142
suggests O 0 4.100044407095993e-06
both O 0 6.955050224632942e-08
meiotic O 0 7.62101772124879e-05
and O 0 1.9581196397666645e-07
mitotic O 0 6.285057224886259e-06
expansion O 0 2.4751468572503654e-06
in O 0 5.4101768398595595e-08
the O 0 1.8412505653486733e-07
FRDA B-Disease 0 0.045223165303468704
gene O 0 1.3047974789515138e-06
. O 0 3.357827154104598e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 5.587299256148981e-06
usually O 0 3.435751523284125e-07
caused O 0 9.211202467440671e-08
by O 0 8.399951290094521e-10
an O 0 1.021456808025789e-09
expansion O 0 1.9045960186758748e-07
of O 0 7.382206490547105e-07
a O 0 1.9488861653371714e-06
GAA O 0 0.001150278141722083
trinucleotide O 1 0.8338858485221863
repeat O 0 1.4926170024409657e-06
in O 0 4.760551419735748e-08
intron O 0 1.0765844308480155e-05
1 O 0 1.326413183733166e-07
of O 0 5.98693148390339e-08
the O 0 2.563828331858531e-07
FRDA B-Disease 1 0.9955226182937622
gene O 0 2.8354099868010962e-06
. O 0 1.0389707085778355e-06

Occasionally O 0 3.929805643565487e-06
, O 0 1.6350487896943378e-07
a O 0 3.8702562932257933e-08
fully O 0 4.402941655712311e-08
expanded O 0 3.934700032459659e-08
allele O 0 1.9763339409450964e-08
has O 0 1.7059329504576226e-09
been O 0 5.007934622547339e-10
found O 0 4.0377429177951285e-10
to O 0 2.853663694235564e-10
arise O 0 1.0301857145122995e-08
from O 0 1.4070660192544437e-08
a O 0 3.991946329051643e-08
premutation O 0 4.809176516573643e-06
of O 0 6.018807141572324e-08
100 O 0 1.9547178098378026e-08
or O 0 1.7563401399911527e-08
less O 0 8.299991094418147e-08
triplet O 0 5.968079221929656e-06
repeats O 0 3.192146323272027e-06
. O 0 8.27860560548288e-07

We O 0 1.2377090570225846e-06
have O 0 2.4219446004281053e-08
examined O 0 1.4010275606324285e-07
the O 0 1.0993411514448326e-08
sperm O 0 2.0450247717462844e-08
DNA O 0 6.537504049219933e-08
of O 0 3.310456264671302e-08
a O 0 2.3284403027901135e-07
premutation O 0 0.0011332824360579252
carrier O 0 4.908605478703976e-05
. O 0 2.9688096674362896e-06

This O 0 4.423756308824522e-06
mans O 0 8.456602517981082e-05
leucocyte O 0 2.8852880859631114e-05
DNA O 0 7.682819500587357e-07
showed O 0 3.024784689387161e-08
one O 0 1.265936688810143e-09
normal O 0 4.293928768106525e-09
allele O 0 8.029218179217423e-09
and O 0 2.7879056840873773e-09
one O 0 1.2882880318088041e-09
allele O 0 4.883276893963284e-09
of O 0 1.0360578173163049e-08
approximately O 0 9.900323227896024e-09
100 O 0 8.909398729883833e-08
repeats O 0 4.849743504564685e-07
. O 0 3.803697552484664e-07

His O 0 8.668685950397048e-06
sperm O 0 7.516889013459149e-07
showed O 0 4.73735397577002e-08
an O 0 6.189130319356195e-10
expanded O 0 1.0397677385753923e-08
allele O 0 1.7144833108773128e-08
in O 0 3.43542794212226e-09
a O 0 1.7067115720692527e-08
tight O 0 6.550209832312248e-07
range O 0 2.1662381755049864e-07
centering O 0 8.710051702109922e-07
on O 0 2.760882544805554e-08
a O 0 6.155698617504868e-09
size O 0 4.401209618976054e-09
of O 0 1.0726671106908725e-08
approximately O 0 2.2326643644987598e-08
320 O 0 2.606953444228566e-07
trinucleotide O 0 0.00010943363304249942
repeats O 0 3.8007128750905395e-06
. O 0 1.0475719136593398e-06

His O 0 1.0650328476913273e-05
affected O 0 4.812223323824583e-06
son O 0 0.1792762279510498
has O 0 1.2240087698955904e-07
repeat O 0 1.834350484841707e-07
sizes O 0 7.808340996007246e-08
of O 0 1.1615713191304167e-07
1040 O 0 5.263766979624052e-06
and O 0 1.95508008005163e-07
540 O 0 3.2800976441649254e-06
. O 0 7.233334713419026e-07

These O 0 2.172330795247035e-07
data O 0 1.0903599445555301e-07
suggest O 0 2.496062556645029e-08
that O 0 1.8715471394870065e-09
expansion O 0 5.7746564863236927e-08
occurs O 0 3.348237909150953e-09
in O 0 4.716657620029707e-10
two O 0 2.7927685164463867e-10
stages O 0 5.201722164116518e-09
, O 0 3.6116923340934193e-10
the O 0 6.238148331227933e-10
first O 0 1.06120956466782e-09
during O 0 2.0251154086992074e-09
meiosis O 0 3.8984375727579845e-09
followed O 0 3.5906557727116706e-09
by O 0 3.0973687503710323e-10
a O 0 1.2653242897897599e-08
second O 0 1.2530257720300142e-07
mitotic O 0 2.7598193810263183e-06
expansion O 0 9.513274562777951e-06
. O 0 3.141931756545091e-06

We O 0 3.945984190067975e-06
also O 0 3.8366246712939756e-07
show O 0 1.2774928670467034e-08
that O 0 4.674688414141315e-10
in O 0 6.782613914957381e-10
all O 0 6.345891034875706e-10
informative O 0 6.681233788441432e-09
carrier O 0 1.8385724942504567e-08
father O 0 2.8154380160572146e-08
to O 0 2.571500790082837e-09
affected O 0 8.983691124342386e-09
child O 0 5.551928694558228e-08
transmissions O 0 2.1396432714482216e-07
, O 0 8.537684448306493e-10
with O 0 4.1074654788531006e-10
the O 0 2.9298363735108524e-09
notable O 0 1.1293677992796347e-08
exception O 0 1.5873053982318197e-08
of O 0 1.675128302736084e-08
the O 0 2.1509032777089487e-08
premutation O 0 1.9323151718708687e-06
carrier O 0 9.937900813383749e-08
, O 0 4.78193484809708e-09
the O 0 8.16473377796001e-09
expansion O 0 2.981936972901167e-07
size O 0 3.288242211851866e-08
decreases O 0 3.85253642321004e-08
. O 0 1.7405062280317907e-08
. O 0 1.56063876488588e-07

The O 0 3.225950877094874e-06
R496H O 0 1.4000826922710985e-05
mutation O 0 2.7889504394806863e-07
of O 0 2.39239824395554e-07
arylsulfatase O 0 0.003442435758188367
A O 0 2.9920659017079743e-06
does O 0 5.283882131834616e-08
not O 0 3.687337368774024e-08
cause O 0 0.00451040780171752
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 4.3141764763277024e-05

Deficiency B-Disease 1 0.9999873638153076
of I-Disease 0 7.166803698055446e-05
arylsulfatase I-Disease 1 0.9993124008178711
A I-Disease 0 0.00045805456466041505
( O 0 2.738598368523526e-06
ARSA O 1 0.9999926090240479
) O 0 4.298159339555241e-08
enzyme O 0 9.375658294175082e-08
activity O 0 2.6125404062327107e-08
causes O 0 9.995002301366185e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.5479457943001762e-05
MLD B-Disease 1 1.0
) O 0 1.871000222308794e-06
. O 0 1.4224381175154122e-06

A O 0 4.541381713352166e-06
number O 0 1.94526762697933e-07
of O 0 7.033665383460175e-07
ARSA O 1 0.9933363199234009
gene O 0 3.3750512784536113e-07
mutations O 0 6.42408153339602e-08
responsible O 0 1.1336263128214341e-07
for O 0 1.4411321558327472e-07
MLD B-Disease 1 1.0
have O 0 1.419711452399497e-06
been O 0 8.89849616214633e-08
identified O 0 1.2124662873702619e-07
. O 0 2.0766158570495463e-07

Recently O 0 1.0176099749514833e-05
, O 0 1.763892782946641e-07
the O 0 6.128323093435029e-08
R496H O 0 1.8292107597517315e-06
mutation O 0 9.457324523509669e-08
of O 0 2.3584522068631486e-07
ARSA O 1 0.9999905824661255
was O 0 5.699155281035928e-07
proposed O 0 1.4483346966187582e-08
to O 0 1.4260754799266806e-09
be O 0 7.485763675596502e-10
a O 0 4.0020307068289185e-09
cause O 0 3.284463048203179e-07
of O 0 4.112748229090357e-06
MLD B-Disease 1 1.0
( O 0 4.650273695006035e-06
Draghia O 0 7.692586950724944e-05
et O 0 1.7039344584190985e-06
al O 0 5.409308982962102e-07
. O 0 4.0214662710980065e-09
, O 0 5.105940115157637e-09
1997 O 0 5.004664416219384e-08
) O 0 7.255830780650285e-08
. O 0 1.0937839078906109e-06

We O 0 1.4745454564035754e-06
have O 0 3.22666586782816e-08
investigated O 0 1.314406432584292e-07
the O 0 2.585267111498979e-08
R496H O 0 3.7017028375885275e-07
mutation O 0 5.290353932707603e-09
and O 0 5.040660666644214e-10
found O 0 1.350206196848447e-10
this O 0 5.752529008695717e-11
mutation O 0 6.265168384089748e-10
at O 0 2.60953592068347e-09
a O 0 6.173402344877843e-10
relatively O 0 3.1787181775655426e-09
high O 0 1.3768039153205791e-08
frequency O 0 9.494897312833928e-09
in O 0 4.819621368667981e-10
an O 0 1.244701286484684e-10
African O 0 1.237380531371457e-09
American O 0 1.7997943135839023e-09
population O 0 6.693548493252877e-11
( O 0 3.490791267157789e-10
f O 0 1.4255160607490325e-08
= O 0 1.5440280165535114e-08
0 O 0 1.072564881354765e-08
. O 0 2.1349699785844223e-09
09 O 0 3.654764313409942e-08
, O 0 3.549188498652711e-09
n O 0 4.230683003925151e-08
= O 0 1.207435360583986e-07
61 O 0 2.887321954858635e-07
subjects O 0 2.648029919782857e-07
) O 0 4.786353713370772e-08
. O 0 3.782084831982502e-07

The O 0 3.6089684726903215e-05
ARSA O 1 0.9999669790267944
enzyme O 0 8.716483534954023e-07
activity O 0 5.362977972822591e-08
in O 0 1.4682154381162604e-09
subjects O 0 6.535731067458528e-09
with O 0 3.463044295770601e-10
and O 0 1.309004904470612e-09
without O 0 7.205311014502058e-09
the O 0 1.2272085569975388e-08
R496H O 0 5.493890853358607e-07
mutation O 0 6.2042855297761434e-09
was O 0 8.558934894153936e-09
determined O 0 4.260310326742456e-09
and O 0 1.5732135594248575e-09
found O 0 1.072797517487345e-09
to O 0 1.7411296848734992e-09
be O 0 7.613170538434133e-09
normal O 0 4.855296538153198e-07
. O 0 5.048652269579179e-07

It O 0 4.2057578752974223e-07
is O 0 3.108984358846101e-08
therefore O 0 2.3623998757216214e-08
concluded O 0 2.7442972339031257e-08
that O 0 5.443625550327624e-10
the O 0 3.6407430403784247e-09
R496H O 0 5.716933628718834e-07
mutation O 0 3.296361583693397e-08
of O 0 4.231982586588856e-07
ARSA O 1 0.9999997615814209
does O 0 4.6528903396847454e-08
not O 0 3.462828024325404e-09
negatively O 0 4.429717481713169e-09
influence O 0 9.475304096895343e-09
the O 0 2.4792741193380152e-09
activity O 0 3.182783148147905e-09
of O 0 2.3851555397413904e-08
ARSA O 1 0.9999966621398926
and O 0 7.975734739318341e-09
is O 0 8.953033314718084e-10
not O 0 3.51974033252489e-10
a O 0 1.0228162317105216e-08
cause O 0 1.1759132121369475e-06
of O 0 0.00022182631073519588
MLD B-Disease 1 1.0

Down O 0 0.0002527704637032002
- O 0 1.5802108464413323e-05
regulation O 0 1.3106840697219013e-06
of O 0 1.607549080517856e-07
transmembrane O 0 1.6865822090039728e-06
carbonic O 0 0.0009014210081659257
anhydrases O 0 0.041584961116313934
in O 0 1.7698943111099652e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 0 0.024149524047970772
lines O 0 6.216630765720765e-08
by O 0 1.7627256321262053e-09
wild O 0 9.953265589501825e-08
- O 0 1.3929926012679061e-07
type O 0 1.498534743404889e-06
von B-Disease 1 0.9999926090240479
Hippel I-Disease 1 1.0
- I-Disease 1 0.999910831451416
Lindau I-Disease 1 0.9988051652908325
transgenes O 0 0.00033266356331296265
. O 0 2.2245767468120903e-06

To O 0 1.3707795005757362e-06
discover O 0 7.4393250315552e-07
genes O 0 9.738585760032947e-08
involved O 0 4.379573681490001e-08
in O 0 4.130362185605918e-08
von B-Disease 1 0.9752259850502014
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Lindau I-Disease 1 1.0
( O 0 1.2330494882917264e-06
VHL B-Disease 1 0.9999996423721313
) O 0 7.028763775451807e-07
- O 0 2.183077231165953e-05
mediated O 0 0.30807167291641235
carcinogenesis O 1 0.9999922513961792
, O 0 1.2895965184611669e-08
we O 0 3.5042952983843634e-09
used O 0 4.5554952521342784e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.920738160610199
lines O 0 1.2294623275010963e-06
stably O 0 3.4017759844573447e-06
transfected O 0 1.2099671948817559e-06
with O 0 6.871999413959884e-09
wild O 0 1.1484332844702294e-06
- O 0 3.2979041861835867e-06
type O 0 0.0002599887957330793
VHL O 1 1.0
- O 1 0.8776882290840149
expressing O 0 2.0534971554297954e-05
transgenes O 0 0.0005958252004347742
. O 0 4.421542143973056e-06

Large O 0 8.55874259286793e-06
- O 0 1.1965953490289394e-05
scale O 0 3.8011114611435914e-06
RNA O 0 4.930721843265928e-06
differential O 0 8.848219295032322e-07
display O 0 1.1327693272278339e-07
technology O 0 3.5837749123857066e-07
applied O 0 1.4120773883519178e-08
to O 0 1.3108187868482446e-09
these O 0 1.0563224739357224e-09
cell O 0 1.6541976322059782e-07
lines O 0 5.917630829799236e-09
identified O 0 1.4657447477972596e-09
several O 0 5.381713963359402e-10
differentially O 0 4.601411163207558e-08
expressed O 0 2.6486846049778023e-09
genes O 0 1.6934549318392556e-09
, O 0 3.0577468335124536e-10
including O 0 6.992419976370456e-10
an O 0 2.406008059452347e-09
alpha O 0 3.45804522794424e-07
carbonic O 0 1.263421836483758e-05
anhydrase O 0 4.610777250491083e-05
gene O 0 1.6514218259544577e-07
, O 0 3.131671633127553e-08
termed O 0 6.709792160108918e-06
CA12 O 1 0.9897603392601013
. O 0 7.423460374411661e-06

The O 0 2.744868652371224e-06
deduced O 0 2.2985129817243433e-06
protein O 0 8.637311310621953e-08
sequence O 0 2.684491562376934e-08
was O 0 2.3594548537175797e-08
classified O 0 5.7974869349664004e-09
as O 0 1.6774776012695725e-09
a O 0 3.164864592619665e-09
one O 0 8.37854674529126e-09
- O 0 3.92514351688078e-07
pass O 0 7.891104587542941e-07
transmembrane O 0 1.1887401569765643e-06
CA O 0 8.406079814449186e-07
possessing O 0 4.272005327266015e-08
an O 0 5.316796780618915e-09
apparently O 0 5.032615604250168e-07
intact O 0 1.2016759001198807e-06
catalytic O 0 1.938922196131898e-07
domain O 0 6.062034429987762e-08
in O 0 3.2067550836956116e-09
the O 0 3.046880792112461e-08
extracellular O 0 8.184302942026989e-07
CA O 0 0.00011323977378197014
module O 0 0.0002889908500947058
. O 0 2.917335905294749e-06

Reintroduced O 0 0.00012774394417647272
wild O 0 2.4479102648911066e-05
- O 0 7.016486051725224e-06
type O 0 3.55035604115983e-06
VHL B-Disease 1 0.9999991655349731
strongly O 0 1.0112579502674635e-06
inhibited O 0 3.4053101671815966e-07
the O 0 2.5747068477244284e-08
overexpression O 0 3.519422477893386e-07
of O 0 3.6102843381513594e-08
the O 0 2.8494188342165216e-08
CA12 O 0 0.0005476261721923947
gene O 0 1.139741989675258e-08
in O 0 4.3849351927249813e-10
the O 0 4.332173730858813e-09
parental O 0 5.864502782060299e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999783039093018
lines O 0 1.6254874935839325e-05
. O 0 9.6502162705292e-07

Similar O 0 8.165326903508685e-07
results O 0 1.0450848009213587e-07
were O 0 2.082747663223472e-08
obtained O 0 1.9201230827547988e-08
with O 0 6.423098497521096e-09
CA9 O 0 0.11897019296884537
, O 0 3.828611738754262e-08
encoding O 0 6.244856081139005e-07
another O 0 4.301620322166855e-07
transmembrane O 0 1.1638361456789426e-06
CA O 0 2.8839920673817687e-07
with O 0 1.7084990089344387e-09
an O 0 9.819868473925908e-09
intact O 0 3.792045163208968e-06
catalytic O 0 6.522377589135431e-07
domain O 0 7.666344572498929e-07
. O 0 2.8912347715959186e-07

Although O 0 2.468635784680373e-06
both O 0 1.7892092785132263e-07
domains O 0 4.0354299812861427e-07
of O 0 3.95870642933005e-07
the O 0 5.417104489424673e-07
VHL B-Disease 1 1.0
protein O 0 7.034939812911034e-07
contribute O 0 7.482598540775598e-09
to O 0 4.957274146732971e-09
regulation O 0 4.155483850354358e-07
of O 0 1.815607788557827e-07
CA12 O 1 0.9974857568740845
expression O 0 8.80771722222562e-08
, O 0 2.8189506284803656e-09
the O 0 3.153277639000862e-09
elongin O 0 4.235810422414943e-07
binding O 0 9.801306433132595e-09
domain O 0 2.1363316449196645e-08
alone O 0 4.3735273180800505e-09
could O 0 5.490803367536046e-09
effectively O 0 9.740517725731479e-08
regulate O 0 3.109456372385466e-07
CA9 O 1 0.9752629399299622
expression O 0 6.00667863182025e-06
. O 0 2.028614972005016e-06

We O 0 1.0142073733732104e-05
mapped O 0 4.012004501419142e-05
CA12 O 1 0.9948651194572449
and O 0 3.20370804729464e-06
CA9 O 1 0.9999903440475464
loci O 0 7.882275895099156e-06
to O 0 1.0436545494485472e-07
chromosome O 0 1.2920567371565994e-07
bands O 0 5.388420731833321e-07
15q22 O 0 4.837756023334805e-06
and O 0 2.0219289353917702e-07
17q21 O 0 3.09344868583139e-05
. O 0 1.3697040230908897e-06

2 O 0 2.1630337869282812e-05
respectively O 0 9.703613841338665e-07
, O 0 5.114539902706383e-08
regions O 0 1.9955407992711116e-07
prone O 0 1.78187638084637e-05
to O 0 1.1255233545170995e-07
amplification O 0 0.002065473236143589
in O 0 1.334787746998245e-08
some O 0 4.115309426566682e-09
human O 0 1.1390273613187674e-07
cancers B-Disease 0 0.3548681139945984
. O 0 1.6395658803958213e-06

Additional O 0 1.6563001281610923e-06
experiments O 0 1.4730485418112949e-06
are O 0 1.089340972981745e-08
needed O 0 9.763582653476988e-08
to O 0 8.760048686440314e-09
define O 0 4.4144446320615316e-08
the O 0 2.6616605808271743e-08
role O 0 1.0133173589110811e-07
of O 0 1.3763951756118331e-06
CA O 0 0.14184395968914032
IX O 1 1.0
and O 0 0.0001234648225363344
CA O 0 0.0012012915685772896
XII O 1 0.9996999502182007
enzymes O 0 5.057904672867153e-08
in O 0 1.067828714340635e-09
the O 0 8.040018095734069e-10
regulation O 0 7.492695353050749e-09
of O 0 2.5306339246355947e-09
pH O 0 1.635523005916184e-07
in O 0 4.826946842229063e-09
the O 0 1.1310061331926136e-08
extracellular O 0 1.1594961080163557e-07
microenvironment O 0 2.431258280921611e-06
and O 0 5.064408448163249e-09
its O 0 5.211156395290573e-09
potential O 0 5.075870745940847e-08
impact O 0 1.1075369599211626e-07
on O 0 3.6665579727923614e-07
cancer B-Disease 0 0.2482379674911499
cell O 0 3.2043906685430557e-05
growth O 0 3.11635858452064e-07
. O 0 8.600813430348353e-07

A O 0 4.6743730308662634e-06
gene O 0 3.6872958730782557e-07
encoding O 0 4.4192807990839356e-07
a O 0 1.168775227711194e-07
transmembrane O 0 4.966897222402622e-07
protein O 0 1.6079500397836455e-08
is O 0 3.6449449014597235e-10
mutated O 0 6.663543494767055e-09
in O 0 4.0636483067402196e-10
patients O 0 5.878361619693351e-08
with O 0 2.783057198030292e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999997615814209
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.0325994708182407e-06
. O 0 9.253135431208648e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.019784364849328995
WFS B-Disease 1 1.0
; O 0 1.5951734894770198e-05
OMIM O 1 0.9999946355819702
222300 O 0 9.383318683831021e-05
) O 0 8.311219268364312e-09
is O 0 2.1012049877811023e-09
an O 0 7.627429354783999e-09
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 1.6153079513969715e-06
by O 0 1.585033260198543e-08
young O 0 4.279357312952925e-07
- O 0 8.328237527166493e-06
onset O 1 1.0
non O 1 1.0
- O 1 1.0
immune O 1 1.0
insulin B-Disease 1 1.0
- I-Disease 1 0.590857982635498
dependent I-Disease 0 0.10828858613967896
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.999237060546875
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999997615814209
. O 0 7.100138464011252e-05

Linkage O 0 0.00011690997052937746
to O 0 1.1452506214482128e-06
markers O 0 2.9359352993196808e-06
on O 0 3.4596220643834386e-07
chromosome O 0 9.058349519364128e-07
4p O 1 0.9771425724029541
was O 0 1.9482117750158068e-06
confirmed O 0 8.255845784788107e-08
in O 0 9.2305452170649e-09
five O 0 5.1447823778971724e-08
families O 0 4.477125514767977e-08
. O 0 5.304381147652748e-07

On O 0 2.141636969099636e-06
the O 0 8.786089722434554e-08
basis O 0 1.4392587388556422e-07
of O 0 2.588479901532992e-07
meiotic O 1 0.9999785423278809
recombinants O 1 0.9999992847442627
and O 0 1.7502439959571348e-06
disease O 1 0.9492434859275818
- O 0 7.39934819193877e-07
associated O 0 6.029492283232685e-08
haplotypes O 0 1.5491157228098018e-06
, O 0 8.960828523640885e-09
the O 0 7.812974445187137e-08
WFS B-Disease 1 0.9997922778129578
gene O 0 2.3408685478898406e-07
was O 0 1.234989497334027e-07
localized O 0 1.2927739589940757e-07
to O 0 1.3216648220293337e-08
a O 0 3.973972866333497e-07
BAC O 1 0.9995415210723877
/ O 0 0.0075477235950529575
P1 O 0 0.0004991930327378213
contig O 0 6.33540275885025e-06
of O 0 3.652806412901555e-08
less O 0 1.4475228127253104e-08
than O 0 5.7640892059396265e-09
250 O 0 8.168039045131081e-08
kb O 0 4.338660801295191e-06
. O 0 4.5966922357365547e-07

Mutations O 0 4.800360784429358e-06
in O 0 1.3763673223365913e-07
a O 0 1.1791401988148209e-07
novel O 0 4.679091318848805e-07
gene O 0 1.0477092615701622e-07
( O 0 3.704636952761575e-08
WFS1 O 0 0.0008774138987064362
) O 0 6.140081154626387e-08
encoding O 0 4.300521254663181e-07
a O 0 2.0520977273008612e-07
putative O 0 4.294088739698054e-06
transmembrane O 0 3.072963465911016e-07
protein O 0 1.2329497423024804e-08
were O 0 1.0221876678428998e-09
found O 0 6.297227739260336e-10
in O 0 6.9357952714455e-10
all O 0 4.806585685024345e-10
affected O 0 1.3184313640834944e-09
individuals O 0 3.6709971173998213e-10
in O 0 4.964152644504338e-09
six O 0 3.5278233667668246e-07
WFS B-Disease 1 0.9999996423721313
families O 0 1.853413067465226e-08
, O 0 9.98516380690262e-10
and O 0 3.5412617283014924e-10
these O 0 3.6759509325356987e-10
mutations O 0 1.6169388050712996e-09
were O 0 1.4125615122040358e-09
associated O 0 6.777625571885437e-09
with O 0 3.157099248696227e-09
the O 0 3.3739055993464717e-07
disease O 1 0.9953901767730713
phenotype O 0 0.00014783903316129
. O 0 2.3569236873299815e-06

WFS1 O 1 0.963846743106842
appears O 0 5.640306881105062e-06
to O 0 5.833483385231375e-08
function O 0 3.484428390265748e-08
in O 0 7.775226684714198e-09
survival O 0 4.775372508447617e-05
of O 0 8.77825641509844e-07
islet O 1 0.6151596903800964
beta O 0 4.3029594962717965e-06
- O 0 8.595450253778836e-07
cells O 0 3.549136096125949e-08
and O 0 5.7976525802416745e-09
neurons O 0 8.487555192004947e-08
. O 0 3.002499227022781e-08
. O 0 2.2102994989836589e-07

Stable O 0 0.0001047829064191319
interaction O 0 7.62727836445265e-07
between O 0 4.757873384164668e-08
the O 0 1.617865130754126e-08
products O 0 1.0137194550452477e-07
of O 0 5.3382397169343676e-08
the O 0 5.618937848339556e-08
BRCA1 O 0 5.419408921625291e-07
and O 0 2.7823398696114054e-08
BRCA2 O 0 2.102215603372315e-06
tumor B-Disease 0 1.1106727470178157e-05
suppressor O 0 7.3420146691205446e-06
genes O 0 2.007648092217096e-08
in O 0 2.325662107338644e-09
mitotic O 0 6.121231876932143e-07
and O 0 1.2059335574576835e-07
meiotic O 0 0.02384078875184059
cells O 0 0.00014691686374135315
. O 0 1.7813567865232471e-06

BRCA1 O 0 0.00017777409811969846
and O 0 6.3456303678322e-07
BRCA2 O 0 9.90471562545281e-07
account O 0 6.928909890291379e-09
for O 0 1.4212013788039712e-09
most O 0 7.999222950694218e-10
cases O 0 1.2331959897693423e-09
of O 0 5.559576798930266e-09
familial O 0 2.6502125365368556e-06
, O 0 6.0298011028692144e-09
early O 0 3.713827823048632e-07
onset O 1 0.9999998807907104
breast B-Disease 1 0.9999959468841553
and I-Disease 0 6.896841659909114e-05
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.0330636491271434e-07
encode O 0 2.0132583600229736e-08
products O 0 8.57249844443686e-08
that O 0 5.38288469353887e-10
each O 0 4.917370954871103e-10
interact O 0 1.695264706391697e-09
with O 0 3.558115357904512e-09
hRAD51 O 0 7.445369192282669e-06
. O 0 7.562114205938997e-07

Results O 0 4.015354988951003e-06
presented O 0 5.274756858852925e-06
here O 0 3.6348757248561014e-07
show O 0 3.001789394829757e-08
that O 0 5.157286597778921e-09
BRCA1 O 0 7.655050353605475e-07
and O 0 1.0644134107451464e-07
BRCA2 O 0 5.2816820243606344e-05
coexist O 0 1.9296505797683494e-06
in O 0 1.1971329705318112e-08
a O 0 1.804865767951469e-08
biochemical O 0 4.019676907773828e-06
complex O 0 2.7407356810726924e-06
and O 0 5.496212907019071e-08
colocalize O 0 3.0245648304116912e-05
in O 0 1.745622846271999e-08
subnuclear O 0 2.6960095055983402e-05
foci O 0 4.206329776934581e-06
in O 0 3.789241365126372e-09
somatic O 0 2.206060401022114e-07
cells O 0 2.058911086066928e-08
and O 0 1.5890401217077965e-09
on O 0 2.9108866428373403e-09
the O 0 1.5772155803617238e-09
axial O 0 1.1806587707496874e-08
elements O 0 3.764383649240699e-08
of O 0 1.2715145203401335e-07
developing O 0 1.2934000551467761e-05
synaptonemal O 0 0.0012441397411748767
complexes O 0 1.0753530659712851e-05
. O 0 1.0183359790971735e-06

Like O 0 3.396853571757674e-05
BRCA1 O 0 5.769212657469325e-05
and O 0 1.5665752925997367e-06
RAD51 O 1 0.9999939203262329
, O 0 9.864453431873699e-07
BRCA2 O 0 3.353133433847688e-05
relocates O 0 8.398072168347426e-06
to O 0 1.6050826445734856e-07
PCNA O 1 0.5869299173355103
+ O 0 6.424694447559887e-07
replication O 0 3.430244177593522e-08
sites O 0 1.4600944897580348e-09
following O 0 8.577396570785822e-10
exposure O 0 2.556590672497805e-08
of O 0 2.0951389956280764e-08
S O 0 5.896536094951443e-06
phase O 0 2.5815893422986846e-06
cells O 0 1.0840911812692866e-07
to O 0 5.676089376294158e-09
hydroxyurea O 0 2.556777189965942e-06
or O 0 5.980072614875098e-08
UV O 0 0.0077868117950856686
irradiation O 0 0.00012428281479515135
. O 0 2.454967216181103e-06

Thus O 0 7.83370796852978e-06
, O 0 5.2275555617598e-07
BRCA1 O 0 8.52169875997788e-07
and O 0 4.114354013040611e-08
BRCA2 O 0 3.351946418206353e-07
participate O 0 4.46958070554615e-09
, O 0 2.930518050447972e-09
together O 0 1.3420832223332013e-09
, O 0 1.7884095315778836e-09
in O 0 2.2128858745418256e-09
a O 0 4.074129478226496e-08
pathway O 0 6.229604423424462e-07
( O 0 5.167871908184907e-09
s O 0 7.265178680881945e-08
) O 0 5.064773045404536e-10
associated O 0 4.723447855070617e-09
with O 0 6.251226203346505e-10
the O 0 1.6463671315136708e-08
activation O 0 8.45783532099631e-08
of O 0 8.160549214153434e-08
double O 0 3.8690612313985184e-07
- O 0 1.4136344361759257e-06
strand O 0 3.467027056558436e-07
break O 0 6.336076552315717e-08
repair O 0 6.086782491365739e-07
and O 0 3.070080722977764e-08
/ O 0 1.196872403852467e-06
or O 0 6.109591055292185e-08
homologous O 0 3.025713795068441e-07
recombination O 0 3.0925374971957353e-07
. O 0 2.1586778586879518e-07

Dysfunction O 1 0.9315895438194275
of O 0 4.666115728468867e-06
this O 0 6.819200137897496e-08
pathway O 0 1.6745490256653284e-06
may O 0 7.162341386646176e-09
be O 0 6.372368743789991e-10
a O 0 1.2154162121191803e-09
general O 0 1.880149191890723e-08
phenomenon O 0 3.026532979788499e-08
in O 0 4.2227943364281373e-10
the O 0 3.0101343639898914e-10
majority O 0 1.5208773129771203e-10
of O 0 4.692770061431872e-10
cases O 0 1.5182927137757929e-09
of O 0 1.1098356367256201e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
and I-Disease 0 0.08484648168087006
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.0444170988630503e-06
. O 0 2.1182611362746684e-06

A O 0 3.5042728995904326e-05
novel O 0 1.0383553671999834e-05
Arg362Ser O 0 5.323068762663752e-05
mutation O 0 2.0158410052317777e-07
in O 0 1.539672567218986e-08
the O 0 3.5127687425529075e-08
sterol O 0 5.308649178914493e-06
27 O 0 1.2287483741602045e-06
- O 0 1.77533445366862e-06
hydroxylase O 0 6.14892560406588e-05
gene O 0 1.244865757143998e-07
( O 0 2.5622632904287457e-08
CYP27 O 0 0.4122922122478485
) O 0 1.5245150919440675e-08
: O 0 5.396436186799747e-09
its O 0 5.996219964998772e-09
effects O 0 2.917331300977821e-07
on O 0 7.586878325582802e-08
pre O 0 1.5267229400706128e-06
- O 0 1.7586538092473347e-07
mRNA O 0 7.03398796986221e-08
splicing O 0 5.131875013830722e-08
and O 0 1.9040498067113276e-09
enzyme O 0 2.5567274519744387e-08
activity O 0 2.6262595653747667e-08
. O 0 1.5345192139193387e-07

A O 0 1.3297812984092161e-05
novel O 0 1.5801272184035042e-06
C O 0 2.7171515739610186e-06
to O 0 2.8093067427903406e-08
A O 0 1.5325886693062785e-07
mutation O 0 1.805943483645933e-08
in O 0 7.428901493966578e-09
the O 0 1.8095432707809778e-08
sterol O 0 2.1248004031804157e-06
27 O 0 5.206529749557376e-07
- O 0 4.798868644684262e-07
hydroxylase O 0 1.457316193409497e-05
gene O 0 6.714105893479427e-08
( O 0 9.574441683923851e-09
CYP27 O 0 0.00014862263924442232
) O 0 4.478848403266511e-09
was O 0 1.1531174237688901e-08
identified O 0 2.2786450504241884e-09
by O 0 4.2362827135100645e-10
sequencing O 0 1.0297068087083971e-07
amplified O 0 2.3366953882941743e-07
CYP27 O 0 7.646216545253992e-06
gene O 0 1.5125992902653707e-08
products O 0 1.58210351486332e-08
from O 0 4.126675001714375e-09
a O 0 2.1169590525005333e-08
patient O 0 9.817033514991635e-07
with O 0 2.108760526198239e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 7.81023936724523e-06
CTX B-Disease 1 0.9999978542327881
) O 0 7.714044159001787e-07
. O 0 1.5487227074117982e-06

The O 0 3.787726200243924e-06
mutation O 0 9.993782441597432e-07
changed O 0 9.400769727108127e-07
the O 0 2.0263225053440692e-07
adrenodoxin O 0 1.6778529243310913e-05
cofactor O 0 7.432134907503496e-07
binding O 0 6.37610710896297e-08
residue O 0 2.5719833729453967e-07
362Arg O 0 5.90373304021341e-07
to O 0 1.7031215548968248e-08
362Ser O 0 2.9728444133070298e-06
( O 0 1.456767364516054e-07
CGT O 0 0.0004812451370526105
362Arg O 0 2.3622664230060764e-05
to O 0 3.5159737876711006e-07
AGT O 1 0.9940949082374573
362Ser O 0 5.289502041705418e-06
) O 0 7.905912369210455e-09
, O 0 1.5946844955649908e-09
and O 0 2.411866262264084e-09
was O 0 6.582472167337983e-08
responsible O 0 3.373727963662532e-08
for O 0 2.4257913011638266e-08
deficiency O 1 0.7507205009460449
in O 0 2.661264808523356e-08
the O 0 7.621819264613805e-08
sterol O 0 4.189447736280272e-06
27 O 0 3.728213471276831e-07
- O 0 3.42255276564174e-07
hydroxylase O 0 1.8482222685634042e-06
activity O 0 6.785930484198843e-09
, O 0 5.659395174717474e-10
as O 0 6.77612299604391e-10
confirmed O 0 1.605454658104577e-09
by O 0 6.583144585015077e-10
expression O 0 2.2063584736997655e-08
of O 0 8.54147188533716e-08
mutant O 0 3.7432482713484205e-07
cDNA O 0 1.1404941915316158e-06
into O 0 8.963190367694551e-08
COS O 0 0.00020243476319592446
- O 0 3.004957306984579e-06
1 O 0 1.145771648225491e-06
cells O 0 1.1660758900688961e-06
. O 0 2.9377792998275254e-07

Quantitative O 0 5.184311248740414e-06
analysis O 0 2.4580896251791273e-07
showed O 0 4.033898193256391e-08
that O 0 7.373643917674144e-10
the O 0 4.5261501213644806e-09
expression O 0 1.979631214510391e-08
of O 0 5.933841507044235e-08
CYP27 O 0 9.605998639017344e-05
gene O 0 1.944699334899269e-08
mRNA O 0 2.3967158924165233e-08
in O 0 8.812346963260609e-10
the O 0 5.360162980139194e-09
patient O 0 1.1447456671476175e-07
represented O 0 8.478656354782288e-08
52 O 0 3.824718532996485e-06
. O 0 2.008373940043384e-06

5 O 0 2.3640959625481628e-06
% O 0 7.674553614833712e-08
of O 0 1.256663750837106e-07
the O 0 9.378913290447599e-08
normal O 0 7.760412472634926e-07
level O 0 4.001409706688719e-06
. O 0 6.297761956375325e-07

As O 0 6.316167286968266e-07
the O 0 8.96011371764871e-08
mutation O 0 6.814064335003422e-08
occurred O 0 2.3729000986350002e-07
at O 0 6.363617188753778e-08
the O 0 1.568887419978182e-08
penultimate O 0 1.2201667232147884e-06
nucleotide O 0 1.6196580077121325e-07
of O 0 7.868337803529357e-08
exon O 0 6.20540049567353e-07
6 O 0 1.1832653257215497e-07
( O 0 5.913693090775496e-09
- O 0 6.60288108633722e-08
2 O 0 1.1702217506126544e-07
position O 0 1.743710242863017e-07
of O 0 2.2443873604061082e-07
exon O 0 1.336672767138225e-06
6 O 0 7.17241903203103e-07
- O 0 6.200212965268292e-07
intron O 0 1.0707644833019003e-05
6 O 0 4.139286886584159e-07
splice O 0 1.6927150454648654e-06
site O 0 4.1857351362750705e-08
) O 0 6.561808318927831e-10
of O 0 2.8665556595086628e-09
the O 0 4.708812895160008e-09
gene O 0 7.879718211256659e-09
, O 0 1.4928591696161675e-09
we O 0 1.408456129503577e-09
hypothesized O 0 3.543765458857706e-08
that O 0 6.284125442235222e-10
the O 0 6.478169556345392e-09
mutation O 0 1.2084452549743219e-08
may O 0 1.172669072957433e-08
partially O 0 9.358613795029669e-08
affect O 0 5.600873098643433e-09
the O 0 2.961253020572485e-09
normal O 0 7.915327948637696e-09
splicing O 0 7.354520903390949e-08
efficiency O 0 1.899940293981217e-08
in O 0 7.040531491142588e-10
exon O 0 2.3271452320727803e-08
6 O 0 5.116781220948496e-09
and O 0 4.892569682724002e-10
cause O 0 7.207564767242047e-09
alternative O 0 7.209190755474992e-08
splicing O 0 5.878630560118836e-08
elsewhere O 0 2.55792587111614e-09
, O 0 6.699743537730285e-11
which O 0 6.5050055619853e-11
resulted O 0 6.807813424103415e-09
in O 0 1.5590605473292385e-09
decreased O 0 3.2183621101467e-08
transcript O 0 1.9825186825528363e-07
in O 0 2.3429014284204186e-09
the O 0 1.0379250348080404e-08
patient O 0 5.598354846370057e-07
. O 0 6.918123176546942e-07

Transfection O 0 0.0046899220906198025
of O 0 1.9451172192930244e-05
constructed O 0 0.0001665866730036214
minigenes O 0 0.00010693985677789897
, O 0 1.2041196484346983e-08
with O 0 1.2440847241279585e-09
or O 0 3.1326559124522646e-09
without O 0 1.0138176520513298e-08
the O 0 6.661205809166404e-09
mutation O 0 2.9418758540344925e-09
, O 0 1.2675409610807264e-09
into O 0 3.192573316823655e-08
COS O 1 0.9719083309173584
- O 0 4.763530796481064e-06
1 O 0 5.171454020569399e-08
cells O 0 7.70932029325877e-09
confirmed O 0 1.852768938270799e-09
that O 0 1.3979212232229088e-10
the O 0 3.2720550713349894e-09
mutant O 0 6.015031317474495e-08
minigene O 0 2.849533586868347e-07
was O 0 9.453082761012865e-09
responsible O 0 1.6674865932486682e-09
for O 0 7.776660981839711e-10
a O 0 4.846855805595851e-09
mRNA O 0 1.154726358976177e-08
species O 0 2.4078017357709314e-10
alternatively O 0 7.744573871093507e-09
spliced O 0 1.406305898399296e-07
at O 0 1.890797740600192e-08
an O 0 1.9685906238464668e-09
activated O 0 8.821972414807533e-07
cryptic O 0 3.737722636287799e-06
5 O 0 3.704284381456091e-07
splice O 0 5.8997479754907545e-06
site O 0 1.3505172091754503e-07
88 O 0 1.264111375576249e-07
bp O 0 1.7432613219625637e-07
upstream O 0 1.976047414586901e-08
from O 0 1.4168655138036002e-09
the O 0 5.310796691304631e-09
3 O 0 4.6532363739970606e-08
end O 0 2.1396556348918239e-07
of O 0 4.2618199813659885e-07
exon O 0 6.347752332658274e-06
6 O 0 1.150452476395003e-06
. O 0 4.606487209457555e-07

Our O 0 6.777932867407799e-06
data O 0 1.9374417092876683e-07
suggest O 0 2.568595114382788e-08
that O 0 1.1466796401293777e-09
the O 0 4.7860955199041655e-09
C O 0 2.504203280295769e-07
to O 0 5.171905126388765e-09
A O 0 3.343593846238946e-08
mutation O 0 4.3453898257439505e-09
at O 0 9.301522219118397e-09
the O 0 3.1011770929012528e-09
penultimate O 0 1.9521661442922777e-07
nucleotide O 0 1.9778536142212033e-08
of O 0 8.517211824710103e-09
exon O 0 6.118605710980773e-08
6 O 0 2.843826329979038e-08
of O 0 8.196110456992756e-09
the O 0 2.1086977497475345e-08
CYP27 O 0 0.0013296769466251135
gene O 0 5.491872290264155e-09
not O 0 1.4676714010786185e-10
only O 0 2.2139609590077214e-10
causes O 0 2.2564201174191112e-08
the O 0 3.637850554127908e-08
deficiency B-Disease 0 0.29670700430870056
in I-Disease 0 1.708920294163363e-08
the I-Disease 0 2.7900561860860762e-08
sterol I-Disease 0 1.195575350720901e-06
27 I-Disease 0 1.8258873524246155e-07
- I-Disease 0 1.7168812860290927e-07
hydroxylase I-Disease 0 3.1313009003497427e-06
activity I-Disease 0 1.0601297617540695e-08
, O 0 1.0838896447040725e-09
but O 0 1.282071449004718e-09
also O 0 5.6996309893975194e-09
partially O 0 6.044853506637082e-08
leads O 0 1.9200205869651654e-08
to O 0 1.723762022010078e-09
alternative O 0 1.4627606503836432e-07
pre O 0 6.973739345994545e-07
- O 0 1.3106874519053235e-07
mRNA O 0 2.9216790764508005e-08
splicing O 0 2.2934797172524668e-08
of O 0 1.7118292339191044e-09
the O 0 7.230132492708208e-09
gene O 0 3.594837494347303e-08
. O 0 1.0961527152630879e-07

To O 0 8.669146609463496e-07
our O 0 2.9098680442984914e-07
knowledge O 0 6.26575911155669e-07
, O 0 7.726926654072486e-09
this O 0 6.666108220976241e-10
is O 0 8.12184541842953e-10
the O 0 1.4260973513202657e-09
first O 0 2.918135733054328e-09
report O 0 7.030131476959411e-10
regarding O 0 7.4216779388791565e-09
effects O 0 1.066990762410569e-07
on O 0 4.799389685672395e-08
pre O 0 4.142237060023035e-07
- O 0 4.337657699693409e-08
mRNA O 0 2.088384576381941e-08
splicing O 0 1.1768681140722492e-08
of O 0 6.3854482812431e-10
a O 0 3.6058073193956375e-10
mutation O 0 4.927445118596552e-10
at O 0 3.2764766455528616e-09
the O 0 5.0640220905506794e-09
- O 0 4.9765741749752124e-08
2 O 0 5.168683259171303e-08
position O 0 1.260918196521743e-07
of O 0 6.119294226891725e-08
a O 0 1.8260909939726844e-07
5 O 0 1.1343113328621257e-06
splice O 0 2.6500043531996198e-05
site O 0 1.3509734344552271e-06
. O 0 2.9433459758365643e-07

ATM O 0 0.0007076550973579288
germline O 0 7.591886969748884e-05
mutations O 0 4.292391508897708e-07
in O 0 5.8765234456359394e-08
classical O 0 0.002246621297672391
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
in O 0 2.578171915956773e-07
the O 0 1.585801925330088e-07
Dutch O 0 3.2370023745897925e-06
population O 0 1.0632199121118902e-08
. O 0 2.3267133997251221e-07

Germline O 0 0.0004489499842748046
mutations O 0 6.81110748246283e-07
in O 0 2.5114589519148467e-08
the O 0 2.013254452037927e-08
ATM O 0 1.4367479934662697e-06
gene O 0 3.714909269092459e-09
are O 0 8.250654326413809e-11
responsible O 0 3.546698268408477e-09
for O 0 6.5356315914755214e-09
the O 0 1.6652451449772343e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999169111251831
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.309777457616292e-05
. O 0 2.2280471966951154e-05

In O 0 1.050864966600784e-06
our O 0 2.3116336933526327e-07
study O 0 1.829233120531626e-08
, O 0 2.4622899275072996e-09
we O 0 9.484503182832782e-10
have O 0 2.583440683601168e-10
determined O 0 3.776189583248879e-09
the O 0 5.0183119881808125e-09
ATM O 0 3.9262550899366033e-07
mutation O 0 8.97043861414204e-09
spectrum O 0 9.244150334097867e-08
in O 0 1.9404746698370445e-09
19 O 0 2.2404666566444575e-08
classical O 0 6.43259113530803e-07
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 1.302455302720773e-06
, O 0 8.818534236176845e-10
including O 0 3.6110725520899223e-10
some O 0 1.4802042924699776e-10
immigrant O 0 1.0553939944202284e-09
populations O 0 1.6576331973716663e-10
, O 0 1.5655379770329603e-10
as O 0 3.986464214289498e-10
well O 0 7.157530679258173e-10
as O 0 1.7893341253127915e-09
12 O 0 4.376147444418166e-09
of O 0 1.6370826472211775e-08
Dutch O 0 3.677252493616834e-07
ethnic O 0 5.4836659657553355e-09
origin O 0 8.53909369880057e-08
. O 0 2.1162973951049935e-07

Both O 0 1.2553094848044566e-06
the O 0 4.612016937244334e-07
protein O 0 2.3247459068898024e-07
truncation O 0 3.4711201806203462e-06
test O 0 4.844792442781909e-07
( O 0 9.127500533168131e-08
PTT O 0 4.155160695518134e-06
) O 0 7.261629075827614e-09
and O 0 9.520049637501415e-09
the O 0 5.356966426006693e-08
restriction O 0 2.889029815378308e-07
endonuclease O 0 2.875159907489433e-06
fingerprinting O 0 4.038814154228021e-07
( O 0 1.934060911423785e-08
REF O 0 5.613534540316323e-06
) O 0 8.048134381155592e-10
method O 0 4.0419827485038695e-09
were O 0 5.281680093283114e-10
used O 0 1.6481980225080406e-09
and O 0 8.350335423124022e-10
compared O 0 1.9645094440079447e-09
for O 0 1.2427259221681197e-09
their O 0 1.2993037756814374e-09
detection O 0 1.0394730907137273e-06
efficiency O 0 1.1902847774081238e-07
, O 0 1.6738660457704668e-09
identifying O 0 4.735327685523316e-09
76 O 0 1.8716622918191206e-08
% O 0 7.319639894198815e-10
and O 0 1.068556021444067e-09
60 O 0 2.9594573458524565e-09
% O 0 5.899697397282466e-10
of O 0 4.014492294146521e-09
the O 0 3.984892416042385e-09
mutations O 0 5.032632088841638e-09
, O 0 4.025549227293368e-09
respectively O 0 8.494535563841055e-08
. O 0 3.389987170976383e-07

Most O 0 2.2980746052780887e-06
patients O 0 1.0652252058207523e-06
were O 0 1.8306641536014467e-08
found O 0 8.953294106106569e-09
to O 0 7.98879806751529e-09
be O 0 2.703503554357667e-08
compound O 0 2.954474803118501e-05
heterozygote O 0 0.005512145813554525
. O 0 4.998996246285969e-06

Seventeen O 0 9.608465006749611e-06
mutations O 0 1.3126914666372613e-07
were O 0 1.0425360130739136e-08
distinct O 0 9.740997342078117e-09
, O 0 4.390845909085783e-09
of O 0 2.1669132266310953e-08
which O 0 4.81940309882134e-09
10 O 0 8.717196742225042e-09
were O 0 3.714441865199092e-09
not O 0 2.0265837896715766e-09
reported O 0 3.573583029492511e-08
previously O 0 4.2670379230003164e-07
. O 0 5.00921032653423e-07

Mutations O 0 2.7078106086264597e-06
are O 0 1.532614390953313e-08
small O 0 2.265566934056551e-08
deletions O 0 7.6951022265348e-07
or O 0 2.8719321676362597e-07
point O 0 3.5792838843917707e-06
mutations O 0 1.6215793152696278e-07
frequently O 0 1.56015076413496e-07
affecting O 0 1.664602677919902e-07
splice O 0 5.776666512247175e-05
sites O 0 1.7149336599686649e-06
. O 0 6.221661124072853e-07

Moreover O 0 2.2452797566074878e-05
, O 0 8.957684372035146e-07
a O 0 6.70039128181088e-07
16 O 0 3.474617642496014e-06
. O 0 3.24085112879402e-06

7 O 0 5.796842378913425e-05
- O 0 1.1033954251615796e-05
kb O 0 5.926052836002782e-06
genomic O 0 5.832314968756691e-07
deletion O 0 7.669812163157985e-08
of O 0 2.652325648000442e-08
the O 0 9.900096742399e-09
3 O 0 1.788925629853111e-08
end O 0 2.30003340817575e-08
of O 0 6.379656802835143e-09
the O 0 3.759624167543052e-09
gene O 0 1.4331241748877233e-09
, O 0 1.8218217212595533e-10
most O 0 1.441017444259174e-10
likely O 0 1.4773449130700556e-09
a O 0 5.641655476118501e-10
result O 0 1.889509659847022e-09
of O 0 6.230362892267749e-09
recombination O 0 7.530735146588086e-09
between O 0 2.2864989901449917e-09
two O 0 1.4408890747219516e-09
LINE O 0 2.846149698143563e-07
elements O 0 4.423699451194807e-08
, O 0 7.820321279439213e-09
was O 0 5.716029605196127e-08
identified O 0 9.268833167652701e-08
. O 0 3.5604057302407455e-07

The O 0 1.608519596629776e-06
most O 0 3.906836099076827e-08
frequently O 0 9.136902789919077e-09
found O 0 9.88269799329089e-10
mutation O 0 1.5348425863592752e-09
, O 0 5.716503381769655e-10
identified O 0 6.639591099144582e-09
in O 0 2.6188848867292336e-09
three O 0 6.916524242228661e-09
unrelated O 0 4.06461396096347e-07
Turkish O 0 6.548094097524881e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999963045120239
T I-Disease 1 1.0
individuals O 0 9.754569596509555e-09
, O 0 1.3691284550532146e-08
was O 0 1.7327099044450733e-07
previously O 0 3.287489747094696e-08
described O 0 5.108472755921412e-09
to O 0 6.30078378360821e-10
be O 0 4.5701112338925043e-10
a O 0 6.695572540849071e-09
Turkish O 0 1.5582205605824129e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999972581863403
T I-Disease 1 1.0
founder O 0 0.008012834936380386
mutation O 0 1.9712608718691627e-06
. O 0 6.227799076441443e-07

The O 0 1.1175127383467043e-06
presence O 0 1.472742212627054e-07
of O 0 2.909257261762832e-07
a O 0 2.1917418280281709e-07
founder O 0 0.00010788399958983064
mutation O 0 5.7484356830173056e-08
among O 0 6.457937296033833e-09
relatively O 0 1.5204641101718153e-08
small O 0 1.3718672864371229e-09
ethnic O 0 3.009066329440202e-10
population O 0 2.4287225008912117e-11
groups O 0 4.1173463943833255e-11
in O 0 2.1781655645813913e-10
Western O 0 6.06480980991364e-08
Europe O 0 1.0146091966589665e-07
could O 0 3.752024024805678e-09
indicate O 0 2.273062627011768e-09
a O 0 3.8611780439623544e-09
high O 0 1.6908284550254393e-08
carrier O 0 7.797101631012993e-09
frequency O 0 1.0089141078140074e-08
in O 0 1.123349746556812e-09
such O 0 4.5174219920340875e-09
communities O 0 5.118560508776682e-08
. O 0 5.019012974116777e-07

In O 0 5.216335239310865e-07
patients O 0 8.638066901767161e-07
of O 0 1.358375953941504e-07
Dutch O 0 1.4120956848273636e-06
ethnic O 0 2.329915593790588e-09
origin O 0 4.422617383426086e-09
, O 0 6.621351245073015e-10
however O 0 1.1350901329976182e-09
, O 0 4.032724709723823e-10
no O 0 9.746531359766664e-10
significant O 0 1.97198115614583e-08
founder O 0 2.3938364392961375e-05
effect O 0 5.4218496359226265e-08
could O 0 1.3389720443512942e-08
be O 0 1.652523984319032e-08
identified O 0 2.0753093110670306e-07
. O 0 3.923047700027382e-07

The O 0 1.2622372196346987e-06
observed O 0 3.0750859991712787e-07
genetic O 0 2.713914568630571e-07
heterogeneity O 0 6.608544254049775e-07
including O 0 2.3086743183853287e-08
the O 0 4.191023350585965e-08
relative O 0 6.5903009272005875e-06
high O 0 3.9818358345655724e-05
percentage O 0 1.3902626960771158e-07
of O 0 4.311164758519226e-08
splice O 0 3.234065297874622e-05
- O 0 1.463197463635879e-06
site O 0 3.0881690094020087e-08
mutations O 0 2.2923107856342995e-09
had O 0 2.3976016727544902e-09
no O 0 2.2384025744059954e-09
reflection O 0 5.3132513500031564e-08
on O 0 7.473088459164501e-08
the O 0 6.392266271859626e-08
phenotype O 0 2.126109620803618e-06
. O 0 3.621436519551935e-07

All O 0 1.8077585082210135e-06
patients O 0 1.7265981568925781e-06
manifested O 0 3.1563956781610614e-06
classical O 0 7.075326720951125e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999994158744812
T I-Disease 1 1.0
and O 0 6.83807286350202e-08
increased O 0 8.718281208075496e-08
cellular O 0 4.2216271367578884e-07
radioresistant O 0 1.0240908068226418e-06
DNA O 0 4.0386987620877335e-07
synthesis O 0 9.80490654001187e-07
. O 0 2.0367924946640414e-07

Determination O 0 2.6461859306436963e-05
of O 0 1.6784694025773206e-06
the O 0 1.1878920247454516e-07
genomic O 0 6.042871518729953e-07
structure O 0 6.979714584076646e-08
of O 0 2.0102961073575898e-08
the O 0 1.1564941004849061e-08
COL4A4 O 0 0.0012482324382290244
gene O 0 1.1680215017406681e-08
and O 0 1.1784443421092305e-09
of O 0 1.6800848712250627e-08
novel O 0 1.0593494152999483e-06
mutations O 0 2.3616262296854984e-06
causing O 0 1.724567664496135e-05
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0007274750387296081

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.545678272435907e-06
a O 0 7.240212653414346e-06
progressive O 1 0.9999998807907104
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9996895790100098
by O 0 2.0814429717574967e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 0 0.001009096042253077
abnormalities I-Disease 0 8.85821646079421e-05
and O 0 3.70821240380792e-09
associated O 0 2.636186380300387e-08
with O 0 6.5299001761331965e-09
mutations O 0 1.773163944562839e-07
in O 0 5.6988188390505456e-08
either O 0 3.3836627721939294e-07
the O 0 5.096607083032723e-07
COL4A3 O 1 0.9997939467430115
or O 0 3.9962813502825156e-08
the O 0 2.1874230426988106e-08
COL4A4 O 0 1.7448162907385267e-05
gene O 0 1.0975309550076418e-08
, O 0 3.5383990182324965e-10
which O 0 2.734398540926719e-10
encode O 0 8.30358182213331e-09
the O 0 1.6638370681221204e-08
alpha3 O 0 8.19622800918296e-06
and O 0 3.274835336242177e-08
alpha4 O 0 1.018815873976564e-05
type O 0 5.944023996562464e-06
IV O 1 1.0
collagen O 1 0.9999548196792603
chains O 0 0.0002498022804502398
, O 0 1.711060519937746e-07
respectively O 0 9.003882723845891e-07
. O 0 1.7288701883444446e-06

To O 0 3.0021246288924885e-07
date O 0 9.088722663364024e-07
, O 0 1.4694096606149287e-08
mutation O 0 6.052304435399947e-09
screening O 0 1.7444012456735436e-08
in O 0 8.239209869920217e-10
the O 0 1.8326266060242347e-09
two O 0 2.3572541696381677e-09
genes O 0 8.784627247848675e-09
has O 0 1.5282057841403685e-09
been O 0 1.528599358202598e-09
hampered O 0 2.0158652205282124e-06
by O 0 2.4505253382045566e-09
the O 0 1.2934394000296834e-08
lack O 0 3.8158327697601635e-07
of O 0 1.0864965815926553e-07
genomic O 0 3.7737873981313896e-07
structure O 0 9.697529890217993e-08
information O 0 6.981285594065412e-08
. O 0 2.3670325788316404e-07

We O 0 1.347877173429879e-06
report O 0 1.208134534635974e-07
here O 0 3.1152289636793284e-08
the O 0 6.6756546956980856e-09
complete O 0 2.2916344377676978e-08
characterization O 0 2.70498986765233e-07
of O 0 3.967890549461117e-08
the O 0 2.4062524417445275e-08
48 O 0 8.862417644195375e-08
exons O 0 4.6993315550025727e-07
of O 0 3.0254941663088175e-08
the O 0 5.17696072677154e-08
COL4A4 O 0 0.00013292173389345407
gene O 0 1.2126660564604208e-08
, O 0 9.074426210453623e-10
a O 0 1.722956666228015e-09
comprehensive O 0 3.0597565370271695e-08
gene O 0 1.1961081902711612e-08
screen O 0 6.794713414137732e-08
, O 0 1.0715746068257204e-09
and O 0 1.036565389078703e-09
the O 0 1.3066849824383553e-09
subsequent O 0 3.9543515129025764e-08
detection O 0 3.010062528119306e-06
of O 0 4.343916515381352e-08
10 O 0 5.605318875723242e-09
novel O 0 9.464971917338971e-09
mutations O 0 1.1148288958651165e-09
in O 0 1.9977451637398502e-10
eight O 0 5.746645825865926e-09
patients O 0 1.4849726426291454e-07
diagnosed O 0 2.2891217668075114e-05
with O 0 1.9497251457778475e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.05021117627620697

Furthermore O 0 6.246861630643252e-06
, O 0 1.049595468316511e-07
we O 0 9.60835944141536e-09
identified O 0 1.4610256116043274e-08
a O 0 3.303774809282345e-09
glycine O 0 2.4320918612374953e-08
to O 0 3.276158011544794e-09
alanine O 0 7.925785183715561e-08
substitution O 0 2.415357585050515e-07
in O 0 1.0325777566322358e-08
the O 0 2.241898755528382e-08
collagenous O 0 1.4364889466378372e-05
domain O 0 1.6333897789877483e-08
that O 0 2.2273750899248768e-10
is O 0 4.1443101728155796e-10
apparently O 0 1.9516404492492256e-08
silent O 0 9.41729183523421e-08
in O 0 1.974419072681144e-09
the O 0 4.1327483657482844e-09
heterozygous O 0 4.98141483618042e-09
carriers O 0 4.368600148296764e-09
, O 0 2.1746797695954e-09
in O 0 1.0077620515858143e-08
11 O 0 7.539151738455985e-07
. O 0 2.6620016342349118e-06

5 O 0 2.625684601298417e-06
% O 0 5.948403014599535e-08
of O 0 5.6962864647402967e-08
all O 0 4.449982160537047e-09
control O 0 3.1735527983300926e-08
individuals O 0 7.30503713075592e-10
, O 0 1.8679950919420207e-09
and O 0 2.090268402810125e-09
in O 0 1.495920276539664e-09
one O 0 5.017888327074616e-10
control O 0 3.5900669104194094e-09
individual O 0 6.092220478093324e-11
homozygous O 0 2.2867026328032836e-10
for O 0 7.800723261786047e-11
this O 0 2.6916463502502097e-10
glycine O 0 2.4421323630008374e-08
substitution O 0 3.1426731084138737e-07
. O 0 9.108229050980299e-07

There O 0 1.2962408391103963e-06
has O 0 7.47018091828977e-08
been O 0 9.390920929774893e-09
no O 0 1.489670609089444e-09
previous O 0 5.08312458791238e-09
finding O 0 1.257317805425373e-08
of O 0 3.782302471222465e-09
a O 0 3.961581729328145e-09
glycine O 0 8.585716138043153e-09
substitution O 0 8.111013194422867e-09
that O 0 2.392561704311902e-10
is O 0 1.4879092402608762e-10
not O 0 3.914236643143276e-11
associated O 0 4.2821085566302486e-10
with O 0 1.3034036350223488e-10
any O 0 3.5632294892451455e-09
obvious O 0 3.229572484997334e-07
phenotype O 0 4.120940104712645e-07
in O 0 3.2233118396618465e-09
homozygous O 0 4.605626102716087e-08
individuals O 0 8.71480221320553e-09
. O 0 2.7242612077316153e-07

Founder O 1 0.9775263071060181
BRCA1 O 0 0.00012659681669902056
and O 0 1.321873810411489e-06
BRCA2 O 0 8.726333362574223e-06
mutations O 0 1.017586086504707e-07
in O 0 1.5043074341747342e-08
French O 0 8.988852641778067e-06
Canadian O 1 0.9494376182556152
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.645423955982551e-05
. O 0 2.710298304009484e-06

We O 0 7.622253974659543e-07
have O 0 1.4110866253247423e-08
identified O 0 1.4327449449069718e-08
four O 0 1.7940295915508386e-09
mutations O 0 1.0498828473259891e-09
in O 0 3.030134199111245e-10
each O 0 1.4520784574756362e-10
of O 0 1.6998406238144526e-08
the O 0 1.1114917697341298e-06
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
- O 0 0.00045007289736531675
susceptibility O 0 8.641909516882151e-06
genes O 0 2.3806242310797643e-08
, O 0 2.32868035965339e-09
BRCA1 O 0 5.2087841595493956e-08
and O 0 6.7338281617423945e-09
BRCA2 O 0 6.067598974368593e-07
, O 0 6.96003699118819e-09
in O 0 6.710735966919401e-09
French O 0 4.9073501031671185e-06
Canadian O 0 0.0008487695595249534
breast B-Disease 1 0.9999985694885254
cancer I-Disease 1 0.9999731779098511
and O 0 8.159755816450343e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.1556583596502605e-07
from O 0 1.405533680554072e-07
Quebec O 0 5.298943051457172e-06
. O 0 1.2045375115121715e-06

To O 0 2.5239503429475008e-06
identify O 0 4.333533524913946e-06
founder O 0 0.0004015011654701084
effects O 0 0.00028030533576384187
, O 0 1.4206796095095342e-07
we O 0 1.537735627721304e-08
examined O 0 3.51136897336346e-08
independently O 0 8.998233269608136e-09
ascertained O 0 7.579848926297927e-08
French O 0 2.793262297018373e-07
Canadian O 0 1.3890781929148943e-06
cancer B-Disease 0 4.030557829537429e-05
families O 0 2.2006332311974575e-09
for O 0 4.339391068697296e-10
the O 0 5.767308852711039e-10
distribution O 0 1.2903142998510475e-09
of O 0 2.596394210740982e-09
these O 0 1.879334687870937e-09
eight O 0 3.9395658291141444e-08
mutations O 0 5.8595222895974075e-08
. O 0 1.4873013753913256e-07

Mutations O 0 2.369838512095157e-06
were O 0 1.5295077560040227e-07
found O 0 3.04286729146952e-08
in O 0 1.2370036550635177e-08
41 O 0 3.63651196266801e-07
of O 0 3.871534488553152e-07
97 O 0 4.4289216020843014e-05
families O 0 9.519323498352605e-07
. O 0 1.740850279929873e-06

Six O 0 2.334136979698087e-06
of O 0 5.6241799484269e-07
eight O 0 1.0620548351880643e-07
mutations O 0 1.0761672442072268e-08
were O 0 1.0937068140037809e-08
observed O 0 2.4975770784863016e-08
at O 0 4.291335642392369e-08
least O 0 8.341616286600129e-09
twice O 0 1.62427070904414e-07
. O 0 2.774540064365283e-07

The O 0 1.791904833225999e-05
BRCA1 O 0 1.8458285921951756e-05
C4446T O 0 9.174709703074768e-06
mutation O 0 9.160270764141387e-08
was O 0 1.6647089751131716e-07
the O 0 6.140922437225527e-09
most O 0 1.299031215928892e-09
common O 0 2.8067452806368465e-09
mutation O 0 7.102480825693647e-10
found O 0 5.369082956008242e-10
, O 0 1.9868011402746077e-10
followed O 0 1.9768306991352347e-09
by O 0 1.245804015503893e-09
the O 0 7.414493552460044e-08
BRCA2 O 0 1.110466200771043e-05
8765delAG O 0 8.016618266992737e-06
mutation O 0 6.479753551502654e-07
. O 0 5.681052357431327e-07

Together O 0 1.3330217143447953e-06
, O 0 4.1831491159882717e-08
these O 0 4.144209864165305e-09
mutations O 0 9.601763828470666e-09
were O 0 2.769821039194653e-09
found O 0 1.4832176598034152e-09
in O 0 9.963133651424982e-10
28 O 0 2.2297619750588638e-08
of O 0 4.587915469755899e-08
41 O 0 3.66899257642217e-07
families O 0 4.266913489203716e-09
identified O 0 4.2100576358450326e-09
to O 0 2.162799717098096e-09
have O 0 2.8697615395145704e-09
a O 0 4.32403624017752e-08
mutation O 0 2.756947310444957e-07
. O 0 3.7822761100869684e-07

The O 0 3.5755003864323953e-06
odds O 0 1.0203103556705173e-05
of O 0 1.5756370430608513e-07
detection O 0 6.256430879147956e-06
of O 0 8.417954688866303e-08
any O 0 1.0629602975598118e-08
of O 0 2.6541123077095108e-08
the O 0 1.5616654636119165e-08
four O 0 1.3292239309237175e-08
BRCA1 O 0 5.081964005171358e-08
mutations O 0 1.148050188248817e-08
was O 0 2.3053482323120988e-07
18 O 0 3.612185821566527e-07
. O 0 1.2413025842761272e-06

7x O 1 0.9825829267501831
greater O 0 7.887419087637682e-06
if O 0 1.2056000286975177e-07
one O 0 8.85457396293532e-09
or O 0 1.7383489092637205e-09
more O 0 1.836397700571979e-10
cases O 0 2.1981034770135466e-09
of O 0 8.535348570148926e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 8.794825134827988e-08
also O 0 1.4013177285221445e-09
present O 0 1.174542130222278e-09
in O 0 1.9651766880457444e-09
the O 0 2.911521335136058e-08
family O 0 4.0525767985855055e-07
. O 0 2.232524423106952e-07

The O 0 2.219258021796122e-06
odds O 0 5.809438334836159e-06
of O 0 8.866052780831524e-08
detection O 0 6.211941581568681e-06
of O 0 7.048976158330333e-08
any O 0 2.1953853845957383e-08
of O 0 5.933332047902695e-08
the O 0 4.467119651963003e-08
four O 0 2.4358614680863866e-08
BRCA2 O 0 2.2803965293860529e-07
mutations O 0 3.320105790294292e-08
was O 0 3.383175339877198e-07
5 O 0 4.1512851112202043e-07
. O 0 7.857237278585671e-07

3x O 0 0.0005475818179547787
greater O 0 1.74278397935268e-06
if O 0 4.071286241469352e-08
there O 0 7.480886132782416e-09
were O 0 8.314961164046508e-09
at O 0 2.1607380329413672e-09
least O 0 8.75270758649016e-11
five O 0 8.828021647033779e-11
cases O 0 2.2848410663467433e-10
of O 0 2.859872871852076e-08
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999972581863403
in O 0 8.125881834075699e-08
the O 0 6.01699355229357e-07
family O 0 1.1962413282162743e-06
. O 0 4.426653958944371e-07

Interestingly O 0 5.137240350450156e-06
, O 0 6.913019490184524e-08
the O 0 1.7295921139748316e-08
presence O 0 1.1719535564225225e-08
of O 0 8.617515590003677e-08
a O 0 2.023620737645615e-07
breast B-Disease 1 0.9111435413360596
cancer I-Disease 0 0.005655830726027489
case O 0 1.0300977493216124e-07
< O 0 5.160960085959232e-07
36 O 0 3.661602576698897e-08
years O 0 3.002692317011224e-09
of O 0 4.096107897311185e-09
age O 0 8.99274343879597e-09
was O 0 7.53883977466785e-09
strongly O 0 6.821809228618747e-10
predictive O 0 3.16307224856871e-09
of O 0 1.9041841436973073e-09
the O 0 1.082073874947298e-09
presence O 0 1.3338811166718756e-09
of O 0 3.139241311345131e-09
any O 0 2.0613972750993526e-09
of O 0 1.83448118917795e-08
the O 0 1.933234905493464e-08
eight O 0 2.4979200929919898e-08
mutations O 0 3.429210337912991e-08
screened O 0 4.921960226056399e-07
. O 0 2.785739070532145e-07

Carriers O 0 2.9617938253068132e-06
of O 0 3.916188688890543e-07
the O 0 2.195226223022928e-08
same O 0 2.782009511648198e-09
mutation O 0 1.973026186874449e-09
, O 0 2.456593817257158e-10
from O 0 2.370607876667208e-10
different O 0 1.8076615204698498e-10
families O 0 1.1100060870461448e-09
, O 0 2.5084498367355934e-10
shared O 0 1.972205954103856e-09
similar O 0 3.021974670502914e-09
haplotypes O 0 2.144615791621618e-07
, O 0 2.679722221898828e-09
indicating O 0 9.784887566866018e-09
that O 0 6.048065936958835e-10
the O 0 4.454975499612601e-09
mutant O 0 7.885747166369583e-09
alleles O 0 3.1722843796266886e-10
were O 0 3.712357365959207e-10
likely O 0 1.296165175190822e-09
to O 0 4.228556949037454e-10
be O 0 1.8818478719762055e-10
identical O 0 1.3610874649572224e-09
by O 0 2.5745763854168047e-10
descent O 0 3.75784097172982e-08
for O 0 1.6683135983797115e-09
a O 0 5.3308806258201e-09
mutation O 0 3.8535779012249805e-09
in O 0 2.1081818513124517e-09
the O 0 2.5467791431310616e-08
founder O 0 1.2324744602665305e-05
population O 0 1.2963389472986364e-08
. O 0 2.415228550489701e-07

The O 0 2.454142702390527e-07
identification O 0 2.2332206128794496e-07
of O 0 2.1245926973278983e-07
common O 0 1.3238671272119973e-05
BRCA1 O 0 3.908761209459044e-05
and O 0 2.6231663241560454e-07
BRCA2 O 0 1.468212872168806e-06
mutations O 0 1.6832924387699677e-08
will O 0 3.1622338081405132e-09
facilitate O 0 4.685700005779836e-08
carrier O 0 5.090705030852405e-07
detection O 0 3.2833700970513746e-05
in O 0 2.400119569756498e-08
French O 0 1.231140117852192e-06
Canadian O 0 2.8975695386179723e-05
breast B-Disease 1 0.9982567429542542
cancer I-Disease 1 0.9962006211280823
and O 0 0.00016912280989345163
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.017515261191875e-06
. O 0 1.2454860325306072e-06

Are O 0 1.5902892300800886e-06
Dp71 O 0 0.001858323230408132
and O 0 1.396387119712017e-06
Dp140 O 0 0.010191304609179497
brain O 0 0.002199350157752633
dystrophin O 0 6.209879938978702e-05
isoforms O 0 7.944095727907552e-07
related O 0 1.1069329985957665e-07
to O 0 1.6319138040898906e-08
cognitive B-Disease 1 0.8765633702278137
impairment I-Disease 1 1.0
in O 0 0.008739016950130463
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999994039535522

Molecular O 0 5.084687018097611e-06
study O 0 1.2800812498880987e-07
and O 0 5.198776964476792e-09
neuropsychological O 0 2.5769281819520984e-07
analysis O 0 1.98931360273491e-08
were O 0 9.298932290846551e-09
performed O 0 9.058504168990567e-09
concurrently O 0 3.2227788437921845e-08
on O 0 2.5956429894335997e-08
49 O 0 1.1237429475841054e-07
patients O 0 1.0034373332246105e-07
with O 0 1.8208825736110157e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999996423721313
DMD B-Disease 1 1.0
) O 0 1.9424757624619815e-07
in O 0 5.003258696234525e-09
order O 0 4.690418720088019e-09
to O 0 9.7243602059649e-10
find O 0 1.2356705658689293e-09
a O 0 3.716870422554308e-10
molecular O 0 1.937748850266985e-09
explanation O 0 2.3804140880656632e-09
for O 0 5.582174722462696e-10
the O 0 7.218970754507836e-09
cognitive B-Disease 0 1.3736212167714257e-05
impairment I-Disease 0 6.401412974810228e-06
observed O 0 3.266251624722827e-08
in O 0 6.723509748951528e-09
most O 0 1.1810567457359866e-07
DMD B-Disease 1 1.0
patients O 0 0.05472453311085701
. O 0 4.4575890569831245e-06

Complete O 0 2.0003606095997384e-06
analysis O 0 3.9048549638209806e-07
of O 0 1.807949985277446e-07
the O 0 1.5216890858482657e-07
dystrophin O 0 2.3501015675719827e-05
gene O 0 3.586581556191959e-07
was O 0 3.40629100037404e-07
performed O 0 2.2525886933522088e-08
to O 0 3.6550276139024618e-09
define O 0 3.67460835093425e-08
the O 0 3.3191689396971924e-08
localization O 0 2.5867899239528924e-05
of O 0 6.230626325987032e-08
deletions O 0 2.0576770509705966e-07
and O 0 1.0968445707248975e-08
duplications O 0 4.680135532453278e-07
in O 0 1.151294948265047e-09
relation O 0 9.014862634160181e-09
to O 0 3.947582261076832e-09
the O 0 4.079868176631862e-08
different O 0 6.843160917924251e-07
DMD B-Disease 1 1.0
promoters O 0 0.11207226663827896
. O 0 2.72594502348511e-06

Qualitative O 0 6.523206593556097e-06
analysis O 0 6.320553893601755e-07
of O 0 5.010925860915449e-07
the O 0 1.6782024658823502e-07
Dp71 O 0 0.00011269599781371653
transcript O 0 1.4292220384959364e-06
and O 0 3.93177224111696e-09
testing O 0 4.097467254382536e-09
for O 0 3.2198446686670934e-10
the O 0 7.75494668481258e-10
specific O 0 1.943234018142448e-09
first O 0 1.5284193466413853e-08
exon O 0 1.1665413524042378e-07
of O 0 1.104570479526501e-08
Dp140 O 0 3.2963058060886397e-07
were O 0 1.1686922540832256e-08
also O 0 2.436613133482979e-09
carried O 0 5.740215414107297e-09
out O 0 2.5464293784693837e-08
. O 0 1.8522740674598026e-07

Neuropsychological O 0 0.00015491720114368945
analysis O 0 1.1896190699189901e-06
assessed O 0 9.945539432010264e-07
verbal O 0 1.047475052473601e-06
and O 0 2.5085773813771084e-07
visuospatial O 0 0.00016696308739483356
intelligence O 0 2.605400368338451e-06
, O 0 2.3277578975466895e-08
verbal O 0 1.1868789897562237e-06
memory O 1 0.9999990463256836
, O 0 4.2969665514647204e-07
and O 0 4.0332983530788624e-07
reading O 0 8.725867701286916e-06
skills O 0 6.850421777926385e-05
. O 0 2.3017967123450944e-06

Comparison O 0 4.0477048059983645e-06
of O 0 8.143956051753776e-07
molecular O 0 3.5915320495405467e-06
and O 0 1.004795180392648e-07
psychometric O 0 6.39658683212474e-05
findings O 0 1.7924166684224474e-07
demonstrated O 0 9.640745446404253e-08
that O 0 1.5359173932694148e-09
deletions O 0 8.112161964390907e-08
and O 0 4.96429475305149e-09
duplications O 0 3.4888250866060844e-07
that O 0 1.269578331353216e-09
were O 0 3.4685458949468284e-09
localized O 0 5.792814405936042e-08
in O 0 1.7531596174791275e-09
the O 0 3.4724909614425314e-09
distal O 0 8.328573812832474e-07
part O 0 1.4503416245759126e-08
of O 0 2.0413811085973066e-08
the O 0 1.7954613795723162e-08
gene O 0 3.136466020237094e-08
seemed O 0 2.4016580724151027e-08
to O 0 7.421079861735791e-10
be O 0 9.322048688531481e-10
preferentially O 0 2.2328602966581457e-08
associated O 0 2.5787025847989753e-08
with O 0 3.5579812873720584e-08
cognitive B-Disease 1 0.9955964684486389
impairment I-Disease 1 0.9998152852058411
. O 0 3.287681465735659e-05

Two O 0 5.169908945390489e-06
altered O 0 5.529278041649377e-06
Dp71 O 0 0.0001583114790264517
transcripts O 0 1.8565250456958893e-06
and O 0 4.5319225705497956e-08
two O 0 1.1148229894786255e-08
deleted O 0 5.280376313976376e-08
Dp140 O 0 1.54014614395237e-07
DNA O 0 1.4976484052908745e-08
sequences O 0 1.490764955924817e-09
were O 0 4.034786671436308e-10
found O 0 4.772128248120566e-10
in O 0 3.4192795816956334e-10
four O 0 2.8915743133239857e-09
patients O 0 7.386206846149435e-08
with O 0 4.586436830322782e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.00021223592921160161

These O 0 3.7778994510517805e-07
findings O 0 1.0792716409468994e-07
suggest O 0 2.5589910634948865e-08
that O 0 5.257116408863283e-10
some O 0 2.6696811428195133e-10
sequences O 0 2.8886637526426284e-09
located O 0 3.5747065307845105e-09
in O 0 3.278056437405752e-10
the O 0 1.2611840460863277e-09
distal O 0 4.717539923149161e-07
part O 0 1.2188434261872771e-08
of O 0 1.2674014726599125e-08
the O 0 2.417420486011679e-09
gene O 0 1.4984247176386134e-09
and O 0 6.472780644806164e-10
, O 0 2.0561892466464116e-10
in O 0 1.3329241876913756e-10
particular O 0 3.2775582248234514e-09
, O 0 7.356927289592363e-10
some O 0 1.7319681244742924e-09
DMD B-Disease 1 1.0
isoforms O 0 1.4831045973551227e-06
expressed O 0 6.023365983764961e-08
in O 0 4.721997903800457e-09
the O 0 4.9177042882320166e-08
brain O 0 4.132309550186619e-05
may O 0 3.3963625245547746e-09
be O 0 5.824628002137899e-10
related O 0 1.0474171752150596e-08
to O 0 2.5610014109389567e-09
the O 0 4.1335777467566004e-08
cognitive B-Disease 0 0.009166231378912926
impairment I-Disease 0 0.00017655009287409484
associated O 0 6.561689360751188e-07
with O 0 3.659135074940423e-07
DMD B-Disease 1 1.0
. O 0 1.102053647628054e-05
. O 0 3.0478388453047955e-06

I1307K O 0 0.00055681262165308
APC O 0 3.65658852388151e-05
and O 0 2.5654085789028613e-07
hMLH1 O 0 5.618863724521361e-06
mutations O 0 8.321453748294516e-08
in O 0 1.6362804444725043e-08
a O 0 2.8375414018455558e-08
non O 0 5.301519081513106e-07
- O 0 8.713407737559464e-07
Jewish O 0 9.354616281598283e-08
family O 0 1.1215028017375062e-08
with O 0 8.257964312363697e-10
hereditary B-Disease 1 0.9999879598617554
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9994199275970459

We O 0 9.547379704599734e-07
describe O 0 1.2448828101696563e-06
a O 0 2.778789962576411e-07
French O 0 4.91309128847206e-06
Canadian O 0 2.598318678792566e-05
hereditary B-Disease 1 1.0
non I-Disease 1 0.9999998807907104
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9986899495124817
HNPCC B-Disease 1 1.0
) O 0 4.135203539590293e-07
kindred O 0 9.063111065188423e-05
which O 0 5.461245233817635e-09
carries O 0 6.759734105798998e-08
a O 0 1.658270498694492e-08
novel O 0 7.771033949666162e-08
truncating O 0 7.334446081586066e-07
mutation O 0 7.233018095575972e-08
in O 0 6.55162182283675e-08
hMLH1 O 0 1.7623435269342735e-05
. O 0 1.750656338117551e-06

Interestingly O 0 3.0502926165354438e-05
, O 0 6.010707807035942e-07
the O 0 3.9664001860728604e-07
I1307K O 0 2.406381827313453e-05
APC O 0 2.1659730009560008e-06
polymorphism O 0 5.045879447607149e-07
, O 0 3.307778717598353e-09
associated O 0 2.7686062331611083e-09
with O 0 2.6697014043897127e-10
an O 0 1.3825682265711237e-10
increased O 0 3.932792314031985e-09
risk O 0 3.9382067029691825e-07
of O 1 0.9902194142341614
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.328213544293249e-07
is O 0 2.2181552150613015e-09
also O 0 8.724311273411445e-10
present O 0 1.0696999952486408e-09
in O 0 1.42038303341252e-09
this O 0 5.096210564659032e-09
family O 0 1.4516028556954552e-07
. O 0 2.8633559168156353e-07

The O 0 6.968048637645552e-06
I1307K O 0 3.386461685295217e-05
polymorphism O 0 3.6563585581461666e-06
has O 0 4.1492338453963384e-08
previously O 0 1.190404574913373e-08
only O 0 4.5506970414166403e-10
been O 0 8.356963454581035e-10
identified O 0 1.1419216683350442e-09
in O 0 2.9558339109669873e-10
individuals O 0 1.0390391325110215e-10
of O 0 4.834043920709519e-08
self O 0 4.879197149421088e-06
- O 0 7.384977379842894e-06
reported O 0 4.2257230603581775e-08
Ashkenazi O 0 1.3913835346102132e-06
Jewish O 0 7.655840050801999e-08
origins O 0 3.8166695048857946e-07
. O 0 1.7774983973595226e-07

In O 0 3.0753324153920403e-07
addition O 0 6.870089208632635e-08
, O 0 7.68257635286318e-09
in O 0 1.0320181376144433e-09
this O 0 8.442966881183622e-10
family O 0 1.504479563152472e-08
, O 0 9.643348342081026e-10
there O 0 4.583590174078722e-10
appears O 0 5.70919489462085e-09
to O 0 8.35894020667638e-10
be O 0 1.3500215390038761e-09
no O 0 4.012448595602791e-09
relationship O 0 1.0283247142695018e-08
between O 0 1.8314079142101036e-08
the O 0 3.103142987015417e-08
I1307K O 0 3.190382642515033e-07
polymorphism O 0 1.524614035020022e-08
and O 0 8.129718565008659e-10
the O 0 9.710551251984612e-10
presence O 0 3.5227241124147213e-09
or O 0 9.984979065791322e-09
absence O 0 1.5306284240068635e-06
of O 0 3.690691073643393e-06
cancer B-Disease 1 0.9816903471946716
. O 0 1.7065870849819476e-07
. O 0 5.652539698530745e-07

Identification O 0 1.7688111029201536e-06
of O 0 5.906199476157781e-07
a O 0 1.0115041959579685e-07
novel O 0 1.8143200009035354e-07
mutation O 0 2.289546152667299e-08
of O 0 3.2298249408313495e-08
the O 0 1.9783919924520887e-07
CPO O 0 1.70630773936864e-05
gene O 0 4.8409638964130863e-08
in O 0 4.667127129209803e-09
a O 0 6.705671751205955e-08
Japanese O 0 0.0003374948282726109
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
family O 0 3.220602957298979e-05
. O 0 1.4278257367550395e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
( O 0 0.00013850057439412922
HCP B-Disease 1 1.0
) O 0 2.0758832874889777e-07
is O 0 2.6945922826371316e-08
an O 0 1.4809822701522535e-08
autosomal B-Disease 1 0.9999880790710449
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 1.699065433058422e-05
by O 0 8.878807911116837e-09
a O 0 1.322525235991634e-07
deficiency B-Disease 1 0.9999405145645142
of I-Disease 0 0.01834969036281109
coproporphyrinogen I-Disease 1 0.9999997615814209
oxidase I-Disease 0 1.4807621482759714e-05
( O 0 8.344102297996869e-08
CPO O 0 2.6139516648981953e-06
) O 0 3.4729019660062477e-09
caused O 0 7.639032517658961e-09
by O 0 1.026305818108142e-09
a O 0 8.983897181735756e-09
mutation O 0 8.110610849598743e-09
in O 0 3.7078728976069897e-09
the O 0 3.1539226341692483e-08
CPO O 0 1.9364164472790435e-05
gene O 0 9.016290505314828e-07
. O 0 4.333308254445001e-07

Only O 0 2.749542602487054e-07
11 O 0 1.228858081958606e-07
mutations O 0 1.0215839729710297e-08
of O 0 9.827701319409243e-09
the O 0 1.722438369711199e-08
gene O 0 1.6765190125056506e-08
have O 0 1.3670897747175559e-09
been O 0 4.280257037692081e-09
reported O 0 1.4972540540725277e-08
in O 0 4.235753792158903e-08
HCP B-Disease 1 1.0
patients O 1 0.9346005320549011
. O 0 1.7063368431990966e-05

We O 0 4.984720476386428e-07
report O 0 3.938799864044995e-08
another O 0 8.512794913428934e-09
mutation O 0 1.4069238218894498e-08
in O 0 6.498142912647609e-09
a O 0 6.857180778752081e-08
Japanese O 0 6.017008126946166e-05
family O 0 2.9766799798380816e-06
. O 0 1.387114821227442e-06

Polymerase O 0 0.0002686454390641302
chain O 0 1.8100588931702077e-05
reaction O 0 9.44727901242004e-07
- O 0 1.3043520539213205e-06
single O 0 5.321669505065074e-08
strand O 0 1.1914067954421625e-07
conformational O 0 1.0489466184537832e-08
polymorphism O 0 8.185456756848453e-09
and O 0 7.232791032762975e-10
direct O 0 2.2130546284415686e-09
sequence O 0 2.5568527295405374e-09
analyses O 0 4.846319345830352e-09
demonstrated O 0 5.27878230016654e-09
a O 0 2.9980111726501946e-09
C O 0 1.0810228445734538e-07
to O 0 3.1858684579333385e-09
T O 0 1.3622054950701568e-07
substitution O 0 5.9111584960191976e-08
in O 0 4.9928581269398364e-09
exon O 0 4.41609557810807e-08
1 O 0 7.586122841019005e-09
of O 0 2.730085046920294e-09
the O 0 7.175043670315517e-09
CPO O 0 4.963492870047048e-07
gene O 0 9.331125205847002e-09
at O 0 6.427534948727498e-09
nucleotide O 0 1.3215842642466669e-08
position O 0 1.5778812922917496e-08
85 O 0 2.4965292055867394e-08
, O 0 3.219993605085847e-09
which O 0 3.1326139460219338e-09
lies O 0 1.1972875313404074e-07
in O 0 6.179484923762857e-09
the O 0 2.298410706202958e-08
putative O 0 1.2088795529052732e-06
presequence O 0 2.540412424423266e-06
for O 0 6.278354280908616e-09
targeting O 0 5.238164746401708e-08
to O 0 5.612660913811851e-08
mitochondria O 0 5.6022927310550585e-06
. O 0 2.5544084110151744e-06

This O 0 5.346901588154651e-08
mutation O 0 1.9681710483610004e-08
changes O 0 3.1047282522678188e-09
the O 0 2.0757984220409753e-09
codon O 0 8.651058536202072e-09
for O 0 8.10384981342338e-10
glutamine O 0 1.2165765284066765e-08
to O 0 6.284520681631989e-10
a O 0 2.8281974540078636e-09
termination O 0 1.2418171024819458e-07
codon O 0 3.235731682593723e-08
at O 0 8.632975223576977e-09
amino O 0 2.8532078921728043e-09
acid O 0 6.895791049288391e-09
position O 0 4.4128956488975746e-08
29 O 0 4.651639358144166e-07
. O 0 5.102876343698881e-07

MaeI O 0 0.0003389338671695441
restriction O 0 4.1702205066940223e-07
analysis O 0 7.669636659102252e-08
showed O 0 2.446967428682001e-08
two O 0 2.966295209461123e-09
other O 0 1.3774151819134772e-09
carriers O 0 4.4624446360330694e-08
in O 0 1.4718191110318912e-08
the O 0 1.1767103558213421e-07
family O 0 1.5580853869323619e-06
. O 0 5.070399424766947e-07

The O 0 5.3724916142527945e-06
C O 0 0.00021038037084508687
- O 0 7.981764065334573e-05
T O 0 7.81907783675706e-06
mutation O 0 2.104434670968658e-08
is O 0 1.5579250112196519e-09
located O 0 3.045571572712902e-09
within O 0 2.0224906194243886e-09
a O 0 4.261586195042355e-09
recently O 0 1.1572090841127647e-08
proposed O 0 1.2113344993736064e-08
putative O 0 9.907996911806549e-08
alternative O 0 6.099112681567931e-08
translation O 0 2.6312635625913572e-08
initiation O 0 2.5235401324152917e-08
codon O 0 1.136182348204784e-08
( O 0 2.806311627523428e-09
TIC O 0 1.4724528796250524e-07
- O 0 2.882720906427494e-08
1 O 0 1.2788874848013165e-08
) O 0 1.0060293709202028e-09
, O 0 9.473871687148971e-10
supporting O 0 5.828687310582836e-09
that O 0 3.257415670532282e-09
TIC O 0 1.9088361113972496e-06
- O 0 4.349256244040589e-07
1 O 0 1.9335949730248103e-07
is O 0 1.1356839912934902e-08
the O 0 4.1368590331103405e-08
real O 0 5.139192467140674e-07
TIC O 0 9.240075655725377e-07
rather O 0 1.3227165140961006e-08
than O 0 6.447893774463864e-09
TIC O 0 7.89062312378519e-07
- O 0 3.089730853389483e-07
2 O 0 2.0310295667513856e-07
. O 0 4.5732726050573547e-08
. O 0 1.8914006716386211e-07

Human B-Disease 0 3.1646297884435626e-06
complement I-Disease 0 1.594984860275872e-05
factor I-Disease 0 0.0017169014317914844
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
associated O 0 2.2878906747791916e-05
with O 0 0.0001252516231033951
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.999994158744812

This O 0 1.0276328765712606e-07
study O 0 3.974040296839121e-08
reports O 0 1.914575342709668e-08
on O 0 9.932893618724847e-09
six O 0 2.3213455602189015e-09
cases O 0 7.079383301800135e-09
of O 0 5.236606739345007e-07
deficiency B-Disease 1 1.0
in I-Disease 0 1.4385011581907747e-07
the I-Disease 0 4.7530210878221624e-08
human I-Disease 0 1.5714929801902144e-08
complement I-Disease 0 4.567980838032781e-08
regulatory I-Disease 0 2.1114632886565232e-07
protein I-Disease 0 3.879746657275973e-08
Factor I-Disease 0 5.109635381472799e-08
H I-Disease 1 0.8761305809020996
( O 0 3.520039371096573e-08
FH O 0 3.315238245704677e-06
) O 0 4.8101994609695e-10
in O 0 1.8178923644196487e-10
the O 0 1.9334467360465624e-10
context O 0 1.3701518808417745e-09
of O 0 2.0356567542734183e-09
an O 0 7.340853258597235e-09
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00010815676796482876

Five O 0 1.1369895673851715e-06
of O 0 1.096872139783045e-07
the O 0 1.3565965240047717e-08
cases O 0 5.752622378452088e-09
were O 0 1.5622843019258426e-09
observed O 0 1.9039589904679133e-09
in O 0 2.6367719119235744e-10
children O 0 1.6254134149740196e-10
presenting O 0 2.2229920126903835e-09
with O 0 1.493070556080056e-08
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.00022249376343097538
. O 0 1.458862425351981e-05

Two O 0 6.104716590016324e-07
of O 0 4.496934025155497e-07
the O 0 2.54329933113695e-07
children O 0 4.235850781242334e-08
exhibited O 0 1.029966085752676e-07
a O 0 8.245852711752377e-08
homozygous O 0 2.5644496872700984e-06
deficiency O 1 0.6571099758148193
characterized O 0 7.271291906363331e-07
by O 0 1.0625427648847108e-08
the O 0 4.890596727591401e-08
absence O 0 5.700350698134571e-07
of O 0 2.651891577443166e-07
the O 0 7.065627016800136e-08
150 O 0 1.1824392132098183e-08
- O 0 1.4448031215863466e-08
kD O 0 4.0514009924663696e-08
form O 0 1.481063494068735e-09
of O 0 2.243083585540262e-08
Factor O 0 9.782894494492211e-08
H O 1 0.9980362057685852
and O 0 5.008347958579407e-09
the O 0 2.2232973240221554e-09
presence O 0 1.0838421271586185e-09
, O 0 3.904701562085222e-10
upon O 0 3.594602615564213e-09
immunoblotting O 0 1.738688695240853e-07
, O 0 1.035591057352292e-09
of O 0 5.652601497985188e-09
the O 0 2.3455852371512265e-08
42 O 0 8.800630979521884e-08
- O 0 8.496058256923789e-08
kD O 0 8.279639587271959e-07
Factor O 0 1.7253063333555474e-07
H O 1 0.7395137548446655
- O 0 1.2391806194500532e-06
like O 0 7.130557833079365e-08
protein O 0 6.659988827095731e-08
1 O 0 6.775727712238222e-08
( O 0 1.3221061578860827e-08
FHL O 0 0.00010939419007627293
- O 0 8.490605409861018e-07
1 O 0 4.9907281862715536e-08
) O 0 1.2469331123199368e-09
and O 0 1.2859606712822824e-09
other O 0 3.0990898736149575e-09
FH O 0 4.576344963425072e-06
- O 0 1.5825054333618027e-07
related O 0 6.064914259695797e-08
protein O 0 9.188268279558542e-08
( O 0 8.07190581042505e-09
FHR O 0 0.00011817833728855476
) O 0 5.4465807863834925e-08
bands O 0 1.9395042727410328e-06
. O 0 1.3898559245717479e-06

Southern O 0 5.7451332395430654e-05
blot O 0 3.294146517873742e-05
and O 0 8.592780886829132e-08
PCR O 0 8.258268735517049e-07
analysis O 0 1.616813172233833e-08
of O 0 6.773567928775037e-09
DNA O 0 7.171502858227541e-08
of O 0 1.5834739741649173e-08
one O 0 4.89898743794015e-09
patient O 0 1.0269354078218385e-07
with O 0 5.462641006204194e-09
homozygous O 0 1.927439825522015e-06
deficiency O 1 0.9989820122718811
ruled O 0 2.935142765636556e-05
out O 0 1.96175093947204e-08
the O 0 2.3265052107035444e-09
presence O 0 8.628164849255882e-10
of O 0 2.8290985110146494e-09
a O 0 1.300796470538046e-09
large O 0 2.136795185236906e-09
deletion O 0 3.4719878083677713e-09
of O 0 4.696622646349624e-09
the O 0 1.4802537862124154e-08
FH O 0 3.777614665523288e-06
gene O 0 2.253177378008786e-08
as O 0 2.813117516708985e-09
the O 0 8.129289241765036e-09
underlying O 0 8.19120614323765e-05
defect O 0 0.00011368629202479497
for O 0 1.0826302343502903e-07
the O 0 6.487943210231606e-06
deficiency O 1 0.9999995231628418
. O 0 1.7332056813756935e-05

The O 0 1.8818141143128742e-06
other O 0 4.3706776864382846e-08
four O 0 1.3428673284465731e-08
children O 0 3.603829012988058e-09
presented O 0 2.07499972759706e-08
with O 0 1.1504767805092797e-08
heterozygous O 0 2.340047558391234e-06
deficiency O 1 0.9992818236351013
and O 0 1.2426937701093266e-07
exhibited O 0 1.4705288720051612e-07
a O 0 4.5554255478919004e-08
normal O 0 2.4448968360957224e-07
immunoblotting O 0 2.6756413262774004e-06
pattern O 0 2.7985731065882646e-08
of O 0 1.578372099686476e-08
proteins O 0 3.347829347077891e-09
of O 0 2.7505540955985452e-08
the O 0 3.4517520930421597e-07
FH O 0 0.009617569856345654
family O 0 1.591554678270768e-06
. O 0 3.572786795302818e-07

Factor B-Disease 1 0.9988246560096741
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 9.961470226471647e-08
the O 0 2.6015461784822946e-08
only O 0 1.2233384971693795e-08
complement B-Disease 1 0.9846888780593872
deficiency I-Disease 1 1.0
associated O 0 2.9719230951741338e-06
with O 0 5.692305649063201e-07
HUS B-Disease 1 1.0
. O 0 0.00019067639368586242

These O 0 2.7374653654987924e-07
observations O 0 2.8079654157409095e-07
suggest O 0 4.0971880110873826e-08
a O 0 1.3169265677959174e-08
role O 0 3.011205151892682e-08
for O 0 1.3774237750396878e-08
FH O 0 0.15126749873161316
and O 0 4.7378648559970316e-07
/ O 0 0.0004409915709402412
or O 0 2.9211008722995757e-07
FH O 0 0.0003559375472832471
receptors O 0 2.0796276700707494e-08
in O 0 3.486007316144679e-10
the O 0 1.4819028226753517e-09
pathogenesis O 0 6.531598046422005e-05
of O 0 1.079818844118563e-06
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 5.235481876297854e-05
. O 0 2.9919917778897798e-06

Further O 0 2.6846203127206536e-07
evidence O 0 1.230567931997939e-07
for O 0 8.318196798029476e-09
a O 0 8.83123085770876e-09
major O 0 3.449783747555557e-08
ancient O 0 2.0488334939727793e-06
mutation O 0 6.8599470068875235e-06
underlying O 1 0.9999721050262451
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 3.020206895598676e-05
linkage O 0 0.00012582405179273337
disequilibrium O 0 6.521173781948164e-05
studies O 0 7.605351015627093e-08
in O 0 8.063657297441296e-09
the O 0 3.1685324586305796e-08
Japanese O 0 2.508661737010698e-06
population O 0 1.562478857408678e-08
. O 0 2.8299913878981897e-07

The O 0 0.0003937155706807971
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.012389174662530422
DM B-Disease 1 1.0
) O 0 5.442851147563488e-07
mutation O 0 7.632308296479096e-08
is O 0 8.83540884899503e-09
an O 0 4.640170470082694e-09
unstable O 0 4.855342922382988e-06
( O 0 1.3345884042337275e-07
CTG O 0 0.00045842782128602266
) O 0 1.8078770480656203e-08
n O 0 2.495301032467978e-08
repeat O 0 1.8565550874427572e-08
, O 0 7.058939544002385e-10
present O 0 1.2343019939464739e-09
at O 0 6.7814012183475825e-09
a O 0 7.719440642262043e-10
copy O 0 1.95510452272174e-09
number O 0 2.524288555960652e-10
of O 0 3.859021102670113e-09
5 O 0 4.940964970501227e-08
- O 0 1.683429644572243e-07
37 O 0 1.2458241371859913e-07
repeats O 0 1.7756075010311179e-07
on O 0 2.0704217007505576e-08
normal O 0 4.416244703264738e-09
chromosomes O 0 2.5779829382344133e-09
but O 0 1.068751642741006e-09
amplified O 0 2.1094619384598445e-08
to O 0 2.907934559814862e-09
50 O 0 2.8600309676107827e-08
- O 0 9.666080558190515e-08
3000 O 0 7.356820930226604e-08
copies O 0 1.8655462952210655e-08
on O 0 1.3257164255264797e-07
DM B-Disease 1 0.9999754428863525
chromosomes O 0 1.4017856528880657e-06
. O 0 8.886756290849007e-07

Previous O 0 6.7859205046261195e-06
findings O 0 4.430480089467892e-07
in O 0 4.655509400208757e-08
Caucasian O 0 4.5147106675358373e-07
populations O 0 2.636387641530291e-08
of O 0 1.0514007442452566e-07
a O 0 4.164729944022838e-06
DM B-Disease 1 1.0
founder O 1 0.9999983310699463
chromosome O 0 4.954946462021326e-07
raise O 0 6.8698238209208284e-09
a O 0 1.932979332153195e-09
question O 0 2.5860646957198696e-09
about O 0 1.220926970635361e-10
the O 0 5.700432348376694e-10
molecular O 0 1.126609650015098e-08
events O 0 5.126293278756577e-10
involved O 0 1.1742172789652727e-09
in O 0 7.148799330281008e-10
the O 0 5.8955382797876155e-09
expansion O 0 7.707793656663853e-07
mutation O 0 4.301390674754657e-07
. O 0 4.20370867004749e-07

To O 0 5.124466042616405e-07
investigate O 0 2.2998541737706546e-07
whether O 0 3.5376064744241376e-08
a O 0 5.796859525730724e-08
founder O 0 3.149251597278635e-06
chromosome O 0 3.644761292775911e-08
for O 0 4.8932813356827864e-09
the O 0 1.5405618114527897e-07
DM B-Disease 1 1.0
mutation O 0 1.735289600901524e-07
exists O 0 1.3440923041230235e-08
in O 0 4.882901860625566e-10
the O 0 5.780138589983608e-10
Japanese O 0 1.608161603883218e-08
population O 0 7.299170295960167e-11
, O 0 4.006366627340441e-10
we O 0 9.257658528660784e-10
genotyped O 0 3.3262958254454134e-07
families O 0 1.0413748752213792e-09
using O 0 3.247316637811082e-09
polymorphic O 0 9.726223026973457e-08
markers O 0 1.581331616762327e-07
near O 0 4.0164326264857664e-07
the O 0 1.0773383962714433e-07
( O 0 1.250468812941108e-07
CTG O 0 0.00012948320363648236
) O 0 2.702214452199314e-08
n O 0 1.0986916976207795e-07
repeat O 0 7.792110068294278e-08
region O 0 2.7833907623175946e-08
and O 0 2.9845708127140824e-08
constructed O 0 1.1375144822522998e-05
haplotypes O 0 1.546682688058354e-05
. O 0 1.0354552841818077e-06

Six O 0 1.0919683290921967e-06
different O 0 5.0594874068110585e-08
haplotypes O 0 1.6625924672553083e-06
were O 0 2.7252584189341178e-08
found O 0 1.8021653502842128e-08
and O 0 8.550159691367298e-08
DM B-Disease 1 1.0
alleles O 0 1.5744143411211553e-06
were O 0 3.2280331652145833e-07
always O 0 1.0324379218218382e-06
haplotype O 0 1.6440862964373082e-05
A O 0 5.18380647918093e-06
. O 0 1.788547251635464e-06

To O 0 2.893160058192734e-07
find O 0 1.0432246000391387e-07
an O 0 1.7694931075951104e-09
origin O 0 1.0096552038874052e-08
of O 0 5.4100734558915065e-08
the O 0 2.2844170644020778e-07
( O 0 1.1874558936142421e-07
CTG O 0 0.000749585684388876
) O 0 2.3925961656345862e-08
n O 0 2.1573868025370757e-08
repeat O 0 1.7927716200460964e-08
mutation O 0 1.3472434279293566e-09
and O 0 5.873401764944219e-10
to O 0 4.875522208180882e-10
investigate O 0 1.7524375284239113e-09
the O 0 2.954939404276047e-09
mechanism O 0 3.369509471440324e-08
of O 0 1.4466836617543777e-08
the O 0 6.996506041190287e-09
expansion O 0 2.712113200686872e-08
mutation O 0 1.5821629562040584e-09
in O 0 4.867271585773381e-10
the O 0 1.067293142753556e-09
Japanese O 0 2.892811501453707e-08
population O 0 8.406213919398553e-11
we O 0 2.1034494979144114e-10
have O 0 1.0397330219014123e-10
studied O 0 3.813603655089537e-09
90 O 0 8.937614204285182e-09
Japanese O 0 1.794374838937074e-06
DM B-Disease 1 1.0
families O 0 3.430977102425459e-08
comprising O 0 5.251167056741224e-09
190 O 0 7.71850139358321e-09
affected O 0 4.206325066036243e-09
and O 0 6.137432784214525e-09
130 O 0 1.1532179655660002e-07
unaffected O 0 1.7663398921285989e-06
members O 0 6.831241705640423e-08
. O 0 5.553749815589981e-07

The O 0 2.33935816140729e-06
results O 0 1.1533246890849114e-07
suggest O 0 4.811295895024159e-08
that O 0 2.049314939966962e-09
a O 0 1.1753695794425312e-08
few O 0 1.2062920440314429e-08
common O 0 3.6212842502436615e-08
ancestral O 0 2.771620074781822e-06
mutations O 0 2.0150062951529435e-08
in O 0 3.025816042168117e-09
both O 0 2.731897819074902e-09
Caucasian O 0 5.252311439107871e-07
and O 0 7.54338884689787e-08
Japanese O 0 1.2143427738919854e-05
populations O 0 1.0221375745800287e-08
have O 0 1.1811875921807768e-09
originated O 0 6.797679752423846e-09
by O 0 3.361450007233202e-10
expansion O 0 2.3255390502185946e-08
of O 0 1.5811682629873758e-08
an O 0 4.377032514213397e-09
ancestral O 0 9.620337948490487e-08
n O 0 1.780836633713534e-08
= O 0 1.827245377228337e-08
5 O 0 1.0326566268759052e-08
repeat O 0 1.6329101626411102e-08
to O 0 6.227641957678998e-09
n O 0 5.114383583304516e-08
= O 0 1.895940897611581e-07
19 O 0 2.627457718062942e-07
- O 0 3.7905016370132216e-07
37 O 0 3.9243798255483853e-07
copies O 0 1.0965396057827093e-07
. O 0 3.1375614639728155e-07

These O 0 2.432134351693094e-07
data O 0 1.4071255804992688e-07
support O 0 3.815461013800814e-08
multistep O 0 1.5806939472895465e-06
models O 0 1.180127924271801e-07
of O 0 3.0599468914260797e-07
triplet O 0 8.41226865304634e-05
repeat O 0 7.657576475139649e-07
expansion O 0 2.1560218499416806e-07
that O 0 4.223825178506502e-10
have O 0 1.4096164513421883e-10
been O 0 2.0134752198863737e-10
proposed O 0 5.070978637000678e-10
for O 0 3.097132272866787e-10
both O 0 5.048553131103972e-09
DM B-Disease 1 1.0
and O 0 1.9053060213991557e-06
Friedreichs B-Disease 1 0.9829170107841492
ataxia I-Disease 1 0.9998164772987366
. O 0 1.9602980501076672e-06
. O 0 3.897372607752914e-06

The O 0 1.0299655741619063e-06
molecular O 0 1.4017468856764026e-06
basis O 0 8.119527592498343e-07
of O 0 0.14916513860225677
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.831633250683808e-07
the O 0 4.134642495046137e-08
western O 0 2.753746457528905e-07
Cape O 0 5.174108537175925e-07
, O 0 5.8640807765186764e-09
South O 0 1.4089089006574795e-07
Africa O 0 3.2852901199476037e-07
. O 0 6.074187126614561e-07

Deficiency B-Disease 1 0.99977046251297
of I-Disease 0 2.165840851375833e-05
the I-Disease 0 2.4043911253102124e-06
sixth I-Disease 0 0.0006039905129000545
component I-Disease 0 4.042527507408522e-06
of I-Disease 0 6.140678721067161e-08
human I-Disease 0 2.672791588054224e-08
complement I-Disease 0 3.824642078598117e-07
( O 0 5.239774054643931e-07
C6 O 1 0.9999997615814209
) O 0 1.4297039996336025e-08
has O 0 2.6706603595272327e-09
been O 0 1.6065635488615726e-09
reported O 0 6.524916162931049e-10
in O 0 4.362661065737683e-10
a O 0 3.3920621866911915e-10
number O 0 8.993643330068579e-11
of O 0 1.1155776302729237e-09
families O 0 5.733122310225269e-10
from O 0 1.3537861942580776e-09
the O 0 8.350625968489567e-09
western O 0 1.2504663970958063e-07
Cape O 0 1.0468079381098505e-06
, O 0 1.4265441272698354e-08
South O 0 1.6583548756443633e-07
Africa O 0 2.620895998006745e-07
. O 0 5.981875688121363e-07

Meningococcal B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999980926513672
is O 0 1.7454338774314238e-07
endemic O 0 1.7179834799208038e-07
in O 0 3.201413578679535e-09
the O 0 7.376869337605285e-09
Cape O 0 1.9566785169899958e-07
and O 0 1.0243462744696785e-09
almost O 0 6.033640254088368e-10
all O 0 3.5229574812944975e-10
pedigrees O 0 2.489700712260401e-08
of O 0 2.3227819667681615e-08
total O 0 8.438562417723006e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.9723099740076577e-06
C6Q0 O 1 0.9980667233467102
) O 0 3.025042660809163e-09
have O 0 3.352466915185204e-10
been O 0 1.1654750498024669e-09
ascertained O 0 2.660929787623445e-08
because O 0 1.2569744134438565e-09
of O 0 5.385683365943805e-08
recurrent O 1 0.9811656475067139
disease O 1 0.9999995231628418
. O 0 1.1901538528036326e-05

We O 0 6.137207719802973e-07
have O 0 1.514230163479624e-08
sequenced O 0 6.387744377889248e-08
the O 0 9.100951103846455e-09
expressed O 0 2.860462089415705e-08
exons O 0 1.217288968291541e-06
of O 0 1.168612513424705e-07
the O 0 1.9864363309807231e-07
C6 O 1 0.9987683892250061
gene O 0 8.53158521607611e-09
from O 0 8.182299282566419e-10
selected O 0 9.293644187557959e-10
cases O 0 9.222498320582417e-10
and O 0 1.0791925131314883e-09
have O 0 5.132868019508408e-10
found O 0 1.5671161035513137e-09
three O 0 4.318470470110469e-09
molecular O 0 2.1273277525324374e-05
defects O 1 0.9964720010757446
leading O 0 9.185980047732301e-07
to O 0 6.748601233397267e-09
total O 0 1.778440150701499e-08
deficiency O 1 0.9999886751174927
879delG O 0 0.0001183459025924094
, O 0 6.7641692247377705e-09
which O 0 6.881019642968056e-10
is O 0 5.906002353839312e-10
the O 0 3.961037720046079e-09
common O 0 8.000267825991614e-08
defect O 0 1.5809864635230042e-06
in O 0 4.018598342980795e-09
the O 0 1.1539601274535016e-08
Cape O 0 3.629876914601482e-07
and O 0 5.318784523922204e-09
hitherto O 0 1.1255168885782041e-07
unreported O 0 3.2101347358093335e-08
, O 0 1.3457666092620002e-09
and O 0 3.950655358408994e-09
1195delC O 0 3.247476740853017e-07
and O 0 2.1798676641537895e-08
1936delG O 0 1.0718163139245007e-06
, O 0 8.342635027247525e-09
which O 0 1.3285946787178204e-09
have O 0 1.5128350794313405e-09
been O 0 5.10669995179569e-09
previously O 0 1.802141369466881e-08
reported O 0 2.2378903175024334e-09
in O 0 2.2937673982426077e-09
African O 0 2.761856876531965e-08
- O 0 3.291763164270378e-07
Americans O 0 1.5198007474737096e-07
. O 0 6.389010991370014e-07

We O 0 4.367862857179716e-06
also O 0 2.0339990669526742e-07
show O 0 1.5446140366748295e-08
that O 0 4.046069035368305e-10
the O 0 6.494722981642553e-09
879delG O 0 1.3682848702956107e-06
and O 0 7.589830630649885e-08
1195delC O 0 7.941314106574282e-05
defects O 0 6.72547030262649e-05
are O 0 1.6985530759683343e-09
associated O 0 2.454928704764825e-08
with O 0 2.4782682572777048e-08
characteristic O 1 0.999414324760437
C6 O 1 1.0
/ O 1 1.0
C7 O 1 0.9999618530273438
region O 0 2.949423674181162e-07
DNA O 0 7.310584351216676e-07
marker O 0 1.8194418771599885e-07
haplotypes O 0 9.396138267447895e-08
, O 0 1.4378442880769171e-09
although O 0 3.776845058922618e-09
small O 0 1.0375925008077047e-08
variations O 0 6.076910352703635e-08
were O 0 5.567984473486831e-08
observed O 0 2.1351243617573346e-07
. O 0 1.1577398026929586e-06

The O 0 9.094965207623318e-06
1936delG O 0 0.00020579104602802545
defect O 0 0.00027103727916255593
was O 0 1.7715441344989813e-06
observed O 0 4.5837872164611326e-08
only O 0 7.174838501100567e-09
once O 0 2.283157485294396e-08
in O 0 1.656796366766855e-09
the O 0 3.858262598299689e-09
Cape O 0 2.3753180755647918e-07
, O 0 5.970561822721265e-10
but O 0 2.5151811189338957e-10
its O 0 1.3547316601858483e-09
associated O 0 1.9815503904396792e-08
haplotype O 0 1.113794155571668e-06
could O 0 2.269437793245288e-08
be O 0 1.9301326759091353e-08
deduced O 0 1.9371937014511786e-06
. O 0 6.836233410467685e-07

The O 0 1.8756148847387522e-06
data O 0 2.310428186547142e-07
from O 0 3.9504914894905596e-08
the O 0 2.7698911608808885e-08
haplotypes O 0 7.089980158525577e-07
indicate O 0 1.2303678964542542e-08
that O 0 4.4290476841624127e-10
these O 0 8.763971770520129e-10
three O 0 5.770249167369457e-09
molecular O 0 3.9871912349553895e-07
defects O 0 5.888640544071677e-07
account O 0 1.499253721171101e-09
for O 0 4.762764849175483e-09
the O 0 4.5370862267191114e-07
defects O 1 0.9984694123268127
in O 0 1.7911926164515535e-08
all O 0 3.9839425092225156e-09
the O 0 9.700429792758314e-09
38 O 0 7.218946507236979e-08
unrelated O 0 1.198899752807847e-07
C6Q0 O 0 9.058963041752577e-05
individuals O 0 1.1848948489046052e-09
we O 0 3.0932492123270094e-09
have O 0 4.814127430030624e-10
studied O 0 1.1200149252488245e-08
from O 0 4.962656952045563e-09
the O 0 3.755082644829599e-08
Cape O 0 3.673757873912109e-06
. O 0 4.1609641243667284e-07

We O 0 1.2041355148539878e-06
have O 0 4.2461238081159536e-08
also O 0 1.9185343091976392e-08
observed O 0 2.0809846290603673e-08
the O 0 3.790175995277423e-08
879delG O 0 6.690106602036394e-06
defect O 0 7.902983270469122e-06
in O 0 9.169273340603468e-08
two O 0 2.5572938966433867e-07
Dutch O 1 0.9999992847442627
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.07094421237707138
, O 0 2.2507290253770407e-08
but O 0 3.5435607781408862e-09
the O 0 1.4345032717244521e-08
879delG O 0 2.6991731374437222e-06
defect O 0 1.8294201709068147e-06
in O 0 1.451753206538342e-08
the O 0 7.4747276812559e-08
Cape O 0 2.727890205278527e-06
probably O 0 1.2187892650672438e-07
did O 0 4.730949410003404e-09
not O 0 7.697268378237254e-10
come O 0 3.3518163800039247e-09
from O 0 3.93511845331318e-09
The O 0 4.421388410946747e-08
Netherlands O 0 8.0453463624508e-07
. O 0 1.1937702026898478e-07
. O 0 9.198419093081611e-07

Complement B-Disease 1 1.0
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.023639459977858e-07
seven O 0 3.576508689207003e-08
further O 0 9.540280565545345e-09
molecular O 0 1.1599257732086699e-06
defects O 0 1.4571854990208521e-05
and O 0 3.3002036659013356e-09
their O 0 8.563065811983961e-09
associated O 0 9.334864898846718e-07
marker O 0 2.9788621759507805e-05
haplotypes O 0 0.00011302617349429056
. O 0 2.6892171263170894e-06

Seven O 0 2.2227741283131763e-06
further O 0 1.1227231766497425e-07
molecular O 0 9.607380206944072e-07
bases O 0 2.734886948019266e-06
of O 0 0.006536267232149839
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.664097221189877e-07
described O 0 1.7275041273023817e-06
. O 0 7.894009854680917e-07

All O 0 2.9386143296505907e-07
these O 0 1.94779534723466e-08
new O 0 3.0211577239924736e-08
molecular O 0 2.703256711811264e-07
defects O 0 1.012762595564709e-06
involve O 0 2.062755477538758e-08
single O 0 8.794976480430705e-08
- O 0 5.536256821869756e-07
nucleotide O 0 1.0840788178256844e-07
events O 0 2.309272106870708e-09
, O 0 5.491178067806857e-10
deletions O 0 9.246440058063854e-09
and O 0 2.3124808734564795e-09
substitutions O 0 7.75853408185867e-08
, O 0 2.68654409829594e-09
some O 0 1.005864280756441e-09
of O 0 1.666539795053268e-08
which O 0 3.2132572158616313e-09
alter O 0 1.002593634780169e-07
splice O 0 1.706453531369334e-06
sites O 0 1.0183409671071786e-08
, O 0 1.1541753108801345e-09
and O 0 3.552968141917745e-09
others O 0 6.160446019976007e-08
codons O 0 4.662397259380668e-06
. O 0 1.9847673229378415e-06

They O 0 3.0355698754647165e-07
are O 0 5.538842273722366e-09
distributed O 0 4.367158634721591e-09
along O 0 8.997341538474757e-09
the O 0 1.2643858404715047e-08
C7 O 0 5.969719495624304e-05
gene O 0 9.125860067626945e-09
, O 0 7.761990494792315e-10
but O 0 6.327640633685405e-10
predominantly O 0 9.718907900690965e-10
towards O 0 6.686065034955391e-09
the O 0 1.1608213057456851e-08
3 O 0 1.3220763150911807e-07
end O 0 5.634971103063435e-07
. O 0 9.447036291021504e-07

All O 0 3.865129940550105e-07
were O 0 6.020150067342911e-08
found O 0 1.9605950640766423e-08
in O 0 8.148833607890538e-09
compound O 0 5.908148636990518e-07
heterozygous O 0 1.6723772944260418e-07
individuals O 0 9.969506997720146e-09
. O 0 2.9515115329559194e-07

The O 0 0.00024467380717396736
C6 O 1 1.0
/ O 1 0.999794065952301
C7 O 1 0.9989247918128967
marker O 0 4.2806536839634646e-06
haplotypes O 0 1.3224890835772385e-06
associated O 0 8.212546021013623e-08
with O 0 1.992100528980245e-08
most O 0 1.7855758414953016e-05
C7 B-Disease 1 1.0
defects I-Disease 1 1.0
are O 0 1.1050660475575569e-07
tabulated O 0 3.222471889330336e-07
. O 0 9.027977654341157e-08
. O 0 8.15167254586413e-07

A O 0 4.078618803760037e-05
genome O 0 4.049195013067219e-06
- O 0 1.0976502835546853e-06
wide O 0 1.9940645756832964e-07
search O 0 7.504483789944061e-08
for O 0 1.0427706698123984e-08
chromosomal O 0 4.179148618277395e-06
loci O 0 3.148170662825578e-06
linked O 0 1.4479210221907124e-05
to O 0 1.3789595243451913e-07
mental O 1 1.0
health O 1 0.9972972273826599
wellness O 1 0.8460199236869812
in O 0 1.0131584460282284e-08
relatives O 0 3.4855851538395655e-08
at O 0 3.497510725480879e-09
high O 0 1.4552519189692248e-08
risk O 0 7.340450025594691e-08
for O 0 3.6577290529749007e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.0002083430445054546
the O 0 1.7664611959844478e-06
Old O 0 9.24924279388506e-06
Order O 0 2.9951722808618797e-06
Amish O 0 2.7494441383169033e-05
. O 0 9.831338729782146e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999994039535522
BPAD B-Disease 1 1.0
; O 1 1.0
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.210497657666565e-07
is O 0 3.7196881130796555e-09
characterized O 0 3.117880353897817e-08
by O 0 2.2264334820221166e-09
episodes O 0 9.109644452109933e-07
of O 0 2.2701642592437565e-06
mania B-Disease 1 0.9999953508377075
and O 0 1.0177001286137966e-06
/ O 1 0.8971953392028809
or O 0 5.4841361816215795e-06
hypomania B-Disease 1 0.9982274174690247
interspersed O 0 1.9584877009037882e-07
with O 0 9.51363654522197e-10
periods O 0 1.0289907095284434e-06
of O 0 1.2255943602212938e-06
depression B-Disease 1 0.9815334677696228
. O 0 4.011359123978764e-06

Compelling O 0 6.6137358771811705e-06
evidence O 0 7.22293975741195e-07
supports O 0 1.4166965911499574e-07
a O 0 1.3004449961329101e-08
significant O 0 1.4031264150560219e-08
genetic O 0 2.812017498854402e-07
component O 0 5.802544933430909e-07
in O 0 4.109371953830987e-09
the O 0 3.224260680667612e-08
susceptibility O 0 9.263501124223694e-05
to O 0 1.4763182321075874e-07
develop O 1 0.7598243355751038
BPAD B-Disease 1 1.0
. O 0 0.00030581682221964

To O 0 4.612395230196853e-07
date O 0 1.2634836821234785e-06
, O 0 1.9691622554773858e-08
however O 0 1.4139748039099231e-08
, O 0 3.777010704197892e-09
linkage O 0 9.87439605637519e-08
studies O 0 2.3376565128074844e-09
have O 0 2.9694977032868053e-10
attempted O 0 1.7588577705396347e-08
only O 0 1.2587425546328745e-09
to O 0 3.468016762653292e-09
identify O 0 1.3846074864432012e-07
chromosomal O 0 1.8569251551525667e-05
loci O 0 1.2390706842779764e-06
that O 0 3.3575751068326554e-09
cause O 0 4.7342288667096e-07
or O 0 2.7519185152868886e-08
increase O 0 7.508704769065844e-09
the O 0 2.265376863874735e-08
risk O 0 1.4704728812375834e-07
of O 0 3.6641881706600543e-07
developing O 0 0.0004399750614538789
BPAD B-Disease 1 1.0
. O 0 1.4833543900749646e-05

To O 0 2.786985362490668e-07
determine O 0 1.2357259038253687e-07
whether O 0 4.00179587245475e-08
there O 0 8.032955634007521e-09
could O 0 1.1773283681293378e-08
be O 0 3.134574599883422e-09
protective O 0 8.507553275194368e-07
alleles O 0 1.1901684970894166e-08
that O 0 5.532050928458432e-10
prevent O 0 1.1394028831546166e-08
or O 0 1.237423585820352e-08
reduce O 0 4.2498673025193057e-08
the O 0 1.1906225338975673e-08
risk O 0 5.5846403057557836e-08
of O 0 4.513806217687488e-08
developing O 0 7.649602048331872e-05
BPAD B-Disease 1 1.0
, O 0 1.1805411093135376e-09
similar O 0 3.131549186630167e-10
to O 0 2.432683221531562e-10
what O 0 1.5366405370365044e-10
is O 0 1.4622898725225042e-10
observed O 0 3.241133195164281e-10
in O 0 2.0162614633445486e-10
other O 0 6.578943168022988e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.5685134968634884e-08
we O 0 5.1714117432766216e-09
used O 0 9.302622743234679e-07
mental O 1 0.9999990463256836
health O 0 0.0041087171994149685
wellness O 0 0.0002918307145591825
( O 0 5.33026023319394e-09
absence O 0 9.923505217557249e-08
of O 0 1.1487417594935323e-07
any O 0 5.197233008402691e-07
psychiatric B-Disease 1 1.0
disorder I-Disease 0 0.04417145997285843
) O 0 4.463310609992277e-09
as O 0 7.241283572767543e-09
the O 0 1.43722269640989e-08
phenotype O 0 2.3075720889664808e-07
in O 0 1.1366656949007847e-08
our O 0 7.018616088316776e-08
genome O 0 1.0051094534446747e-07
- O 0 6.759218962315572e-08
wide O 0 8.209194390929042e-08
linkage O 0 5.369148539102753e-07
scan O 0 1.300166587725471e-07
of O 0 2.944234900326137e-08
several O 0 1.3667853515642037e-08
large O 0 2.9008564439436668e-08
multigeneration O 0 1.799268829927314e-06
Old O 0 3.786325066812424e-07
Order O 0 1.0485669577064982e-07
Amish O 0 1.3105141078995075e-06
pedigrees O 0 2.2706505831138202e-07
exhibiting O 0 6.8972116906707015e-09
an O 0 8.765476677830009e-10
extremely O 0 2.1664504856744315e-08
high O 0 5.172282726562116e-07
incidence O 0 4.11445798818022e-05
of O 0 0.00019860680913552642
BPAD B-Disease 1 1.0
. O 0 0.0001897972251754254

We O 0 9.062410981641733e-07
have O 0 1.438742192050313e-08
found O 0 3.280216098744404e-09
strong O 0 7.026221382488984e-09
evidence O 0 5.661668467382697e-08
for O 0 2.0419651747261014e-08
a O 0 7.484671016300126e-08
locus O 0 4.988996238353138e-07
on O 0 1.8226288034384197e-07
chromosome O 0 3.3886584560605115e-07
4p O 0 0.0027754290495067835
at O 0 1.1279985301371198e-06
D4S2949 O 0 1.8060180764223333e-06
( O 0 2.977327540065744e-08
maximum O 0 4.93879326768365e-07
GENEHUNTER O 0 0.0006178716430440545
- O 0 2.239370132883778e-06
PLUS O 0 1.5562677617708687e-06
nonparametric O 0 1.3373052070164704e-06
linkage O 0 3.941595991818758e-07
score O 0 5.033335170878672e-08
= O 0 3.265890313741693e-08
4 O 0 2.426938827682079e-08
. O 0 4.306609291404584e-09
05 O 0 5.935685862823448e-07
, O 0 2.859250969322602e-08
P O 0 1.864331807155395e-06
= O 0 2.3993626996343664e-07
5 O 0 8.682884100608135e-08
. O 0 6.565066712482803e-09
22 O 0 4.619438342956528e-08
x O 0 7.095256648881332e-08
10 O 0 4.2369656227947416e-08
( O 0 1.2760512646536881e-08
- O 0 7.601464346862485e-08
4 O 0 7.908027299663445e-08
) O 0 4.340924508738908e-09
; O 0 3.112283408768235e-08
SIBPAL O 0 5.396309643401764e-05
Pempirical O 0 4.309103132982273e-06
value O 0 6.306272126721524e-08
< O 0 1.8947262958590727e-07
3 O 0 5.7362239402891646e-08
x O 0 4.408739684436114e-08
10 O 0 2.397465870274118e-08
( O 0 3.9027527876100976e-09
- O 0 3.739750908948736e-08
5 O 0 1.367776381044905e-08
) O 0 1.0735631272851265e-09
) O 0 6.117235051839032e-10
and O 0 5.082094745034738e-10
suggestive O 0 6.912264538527779e-09
evidence O 0 4.935612363254904e-09
for O 0 1.8079761021638774e-09
a O 0 1.3744267057802517e-08
locus O 0 1.2042350761021225e-07
on O 0 2.856514491611506e-08
chromosome O 0 4.528950015014743e-08
4q O 0 5.139925633557141e-06
at O 0 1.5978127976268297e-07
D4S397 O 0 1.056463929671736e-06
( O 0 1.9990659794189014e-08
maximum O 0 3.116920481716079e-07
GENEHUNTER O 0 0.0015646034153178334
- O 0 1.5417052736665937e-06
PLUS O 0 8.655895840092853e-07
nonparametric O 0 6.115362793934764e-07
linkage O 0 2.2972191970893618e-07
score O 0 2.6911919803751516e-08
= O 0 2.1627181823191677e-08
3 O 0 2.1087098289740425e-08
. O 0 2.038228696932265e-09
29 O 0 5.631039812215022e-08
, O 0 5.4596513976434835e-09
P O 0 5.206023843129515e-07
= O 0 6.725820611563904e-08
2 O 0 4.442800971560246e-08
. O 0 1.3353830263795885e-09
57 O 0 1.823812212364828e-08
x O 0 2.1792731175196423e-08
10 O 0 1.8389933131857106e-08
( O 0 3.644933244117965e-09
- O 0 4.0061031825189275e-08
3 O 0 2.6050864576632193e-08
) O 0 2.0946586687387025e-09
; O 0 1.448821063121386e-08
SIBPAL O 0 2.2542906663147733e-05
Pempirical O 0 2.226202241217834e-06
value O 0 2.4124105379996763e-08
< O 0 5.503020972241757e-08
1 O 0 2.9749658736477613e-08
x O 0 3.0685470164826256e-08
10 O 0 9.886925056434848e-09
( O 0 4.540347209314177e-09
- O 0 4.784464380236386e-08
3 O 0 2.0901218533708743e-08
) O 0 4.457234026311596e-10
) O 0 1.7953021014260884e-10
that O 0 8.866530426532293e-11
are O 0 6.086091630663759e-10
linked O 0 2.773352036911092e-07
to O 0 9.301169967557144e-08
mental O 1 0.9999465942382812
health O 0 0.05590460076928139
wellness O 0 0.07313007116317749
. O 0 3.7975969462422654e-06

These O 0 4.892528409072838e-07
findings O 0 2.4349515115318354e-07
are O 0 1.771343738354858e-09
consistent O 0 1.233173119175035e-08
with O 0 7.53734075154e-10
the O 0 5.1237738496467955e-09
hypothesis O 0 6.872723190554098e-08
that O 0 1.8215645658514745e-10
certain O 0 1.2363472468024383e-09
alleles O 0 3.996660336014202e-09
could O 0 2.69849476097761e-09
prevent O 0 8.562885511764762e-09
or O 0 4.8576653810528114e-09
modify O 0 2.6366590688553515e-08
the O 0 7.124015599657696e-09
clinical O 0 1.7990304002069024e-07
manifestations O 0 3.4511434932937846e-05
of O 0 0.00010667709284462035
BPAD B-Disease 1 1.0
and O 0 5.7359720528893376e-08
perhaps O 0 2.3779557878356172e-08
other O 0 3.944375936981714e-09
related O 0 1.1081408956670202e-05
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.001105290139093995

Segregation O 0 0.003860329743474722
distortion O 0 0.022877607494592667
in O 0 2.136676266673021e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.008380231447517872

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9210638403892517
DM B-Disease 1 1.0
) O 0 7.966917792145978e-07
is O 0 1.2900000179172366e-08
an O 0 4.6819454979640796e-09
autosomal B-Disease 0 6.415489042410627e-05
dominant I-Disease 1 0.9981393814086914
disease I-Disease 1 0.9999986886978149
which O 0 3.188082686733651e-08
, O 0 5.6908429080237966e-09
in O 0 1.8446343341693705e-09
the O 0 1.3550992328248412e-08
typical O 0 3.5786550256489136e-07
pedigree O 0 2.4338146431546193e-06
, O 0 4.812513942908936e-09
shows O 0 4.740976056183399e-09
a O 0 1.372281399625308e-08
three O 0 6.464002666461965e-08
generation O 0 0.0015619895420968533
anticipation O 0 0.00011044127313653007
cascade O 0 0.0022474706638604403
. O 0 4.463429377210559e-06

This O 0 1.2173870800324949e-07
results O 0 1.7044092714968428e-07
in O 0 1.4939087122911587e-07
infertility B-Disease 1 0.9999984502792358
and O 0 0.28574851155281067
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9736440181732178
CDM B-Disease 1 0.9823992252349854
) O 0 7.1405854562556215e-09
with O 0 1.362110646496717e-09
the O 0 1.579588726485781e-08
disappearance O 0 5.021761353418697e-07
of O 0 7.406863915093709e-06
DM B-Disease 1 1.0
in O 0 1.6652758176860516e-06
that O 0 5.30640491547274e-08
pedigree O 0 7.434257895511109e-06
. O 0 3.754553290491458e-07

The O 0 2.2154665657581063e-06
concept O 0 2.719910071391496e-06
of O 0 5.019242621528974e-07
segregation O 0 4.220425580570009e-06
distortion O 0 2.9980644740135176e-06
, O 0 2.1242059222714715e-09
where O 0 7.494220799486584e-10
there O 0 2.514341790327279e-10
is O 0 1.9756084268518492e-10
preferential O 0 8.263199013924805e-09
transmission O 0 2.117084285657711e-08
of O 0 6.150698617091166e-09
the O 0 3.644516022305311e-09
larger O 0 6.3254717019844975e-09
allele O 0 5.181897577699601e-09
at O 0 8.535653961416756e-09
the O 0 1.9285796071244476e-08
DM B-Disease 1 0.9999998807907104
locus O 0 5.559303417612682e-07
, O 0 5.825086191180162e-09
has O 0 1.5381131923675184e-09
been O 0 2.332418924666513e-09
put O 0 1.320102871460449e-08
forward O 0 2.2960577439334884e-08
to O 0 1.1015491629962071e-08
explain O 0 3.765776668274157e-08
partially O 0 1.1969986246640474e-07
the O 0 1.691170403717024e-08
maintenance O 0 7.221325631689979e-06
of O 0 2.9652192097273655e-06
DM B-Disease 1 1.0
in O 0 1.2701910634405067e-07
the O 0 7.603828322544359e-08
population O 0 6.981402567163286e-09
. O 0 1.2417579853263305e-07

In O 0 1.0528229950068635e-06
a O 0 1.8195633799678035e-07
survey O 0 2.2624577766805487e-08
of O 0 1.4905629086570116e-07
DM B-Disease 1 1.0
in O 0 1.8306559468328487e-07
Northern O 0 8.441894578936626e-07
Ireland O 0 2.3557007011731912e-07
, O 0 2.5747658227714965e-08
59 O 0 3.141202000733756e-07
pedigrees O 0 8.16730562291923e-07
were O 0 5.79345496021233e-08
ascertained O 0 4.472402451938251e-06
. O 0 8.893250651453855e-07

Sibships O 0 0.0005288462270982563
where O 0 2.747775624811766e-07
the O 0 4.2316678161569143e-08
status O 0 2.495167628069339e-08
of O 0 3.348073818187913e-08
all O 0 2.1896633395357412e-09
the O 0 1.499453894382441e-09
members O 0 1.9809437423745635e-10
had O 0 9.210404106063663e-10
been O 0 3.808549586814536e-10
identified O 0 4.0015019076022895e-10
were O 0 2.233999790712815e-10
examined O 0 2.8269302454475564e-09
to O 0 4.055881464015698e-10
determine O 0 2.5015041149600847e-09
the O 0 7.857506645336798e-09
transmission O 0 2.04126692437967e-07
of O 0 1.0490530399920317e-07
the O 0 2.669962100299017e-07
DM B-Disease 1 1.0
expansion O 0 7.242251740535721e-05
from O 0 4.8881627634500546e-08
affected O 0 8.679402974109962e-09
parents O 0 3.500093326280762e-09
to O 0 1.3806188414733356e-09
their O 0 1.1188918236371137e-08
offspring O 0 1.5938543356242008e-06
. O 0 6.70625979637407e-07

Where O 0 2.8892275167891057e-06
the O 0 8.751207474233524e-07
transmitting O 0 2.033818600466475e-05
parent O 0 1.3552383961723535e-06
was O 0 5.36808386186749e-07
male O 0 1.9688887675783917e-07
, O 0 7.437184024183807e-08
58 O 0 2.337431396881584e-06
. O 0 1.7132825860244338e-06

3 O 0 3.161770109727513e-06
% O 0 5.0271470541929375e-08
of O 0 9.403525069728857e-08
the O 0 2.67308220003315e-08
offspring O 0 1.6228725030487112e-07
were O 0 2.9137530166423176e-09
affected O 0 1.3590951697395326e-09
, O 0 6.365480920145217e-10
and O 0 8.752662483679785e-10
in O 0 6.30506369336814e-10
the O 0 1.9477275348123158e-09
case O 0 7.289855386005684e-09
of O 0 9.045158400056152e-09
a O 0 1.4764049538484869e-08
female O 0 1.1663206400669424e-08
transmitting O 0 1.924725268054317e-07
parent O 0 5.8434395100448455e-08
, O 0 3.269293102903248e-08
68 O 0 6.683086212433409e-06
. O 0 4.9569162001716904e-06

7 O 0 3.177278267685324e-05
% O 0 6.427071639336646e-07
were O 0 3.0050605914766493e-07
affected O 0 1.0982345202137367e-06
. O 0 2.418719304841943e-06

Studies O 0 4.3257336983515415e-06
on O 0 1.6168460206245072e-06
meiotic O 0 9.09549999050796e-05
drive O 0 9.726101779961027e-06
in O 0 7.440673357450578e-07
DM B-Disease 1 1.0
have O 0 6.285149822815583e-08
shown O 0 5.4822648642982585e-09
increased O 0 1.899131518712238e-09
transmission O 0 7.829634718348188e-09
of O 0 1.4370958867360173e-09
the O 0 1.1409767575187857e-09
larger O 0 3.254261082830112e-09
allele O 0 4.2648546916268515e-09
at O 0 7.666006496265254e-09
the O 0 1.402767857427989e-08
DM B-Disease 1 0.9999921321868896
locus O 0 6.418717362066673e-07
in O 0 1.1181471748500371e-08
non O 0 2.8933200724168273e-07
- O 0 1.0805310012074187e-05
DM O 1 1.0
heterozygotes O 0 4.715736213256605e-05
for O 0 4.876899311057059e-07
CTGn O 0 0.0003230829897802323
. O 0 2.7797250368166715e-06

This O 0 2.0027628977459244e-07
study O 0 4.1705533249114524e-08
provides O 0 1.175903285854929e-08
further O 0 3.6169955919262975e-09
evidence O 0 7.851244099299493e-09
that O 0 2.2458950255099808e-09
the O 0 1.0822896001627669e-07
DM B-Disease 1 1.0
expansion O 0 0.02773616649210453
tends O 0 1.152123559222673e-06
to O 0 1.4851604390742068e-08
be O 0 1.1694927692929014e-08
transmitted O 0 1.5990369206519972e-07
preferentially O 0 5.179519462217286e-07
. O 0 2.9295316039679165e-07

Diagnosis O 1 0.9999990463256836
of O 1 0.9945637583732605
hemochromatosis B-Disease 1 1.0
. O 0 0.005020780488848686

If O 0 4.210523184156045e-05
untreated O 1 0.9999997615814209
, O 0 4.664374137064442e-05
hemochromatosis B-Disease 1 1.0
can O 0 4.429240107128862e-06
cause O 1 0.9328297972679138
serious O 1 0.9990444779396057
illness O 1 0.9999983310699463
and O 0 1.996931864312046e-08
early B-Disease 0 1.0017105722681663e-07
death I-Disease 0 1.54956040887555e-07
, O 0 1.2661008907954852e-09
but O 0 1.2816119276948257e-09
the O 0 1.4100266731986721e-08
disease O 0 0.2209099531173706
is O 0 1.014264494614281e-08
still O 0 1.4286626104365041e-08
substantially O 0 2.6452082124706067e-07
under O 0 1.6646768926875666e-05
- O 1 0.9835243225097656
diagnosed O 1 0.824630081653595
. O 0 3.42737439495977e-06

The O 0 8.112089744827244e-06
cornerstone O 0 0.0026630153879523277
of O 0 1.2492498626670567e-06
screening O 0 5.090782906336244e-07
and O 0 9.84524373137674e-09
case O 0 1.693284445991594e-08
detection O 0 8.973049148153223e-07
is O 0 1.0359901825296447e-09
the O 0 1.7191127410498552e-09
measurement O 0 1.1955350487369287e-07
of O 0 1.3733109938129928e-07
serum O 0 3.827500040642917e-05
transferrin O 0 0.0011346375104039907
saturation O 0 1.5327977962442674e-06
and O 0 1.0989344545464519e-08
the O 0 2.5413443793809165e-08
serum O 0 2.422909346933011e-06
ferritin O 0 6.903646135469899e-05
level O 0 1.923988975249813e-06
. O 0 3.941182455946546e-07

Once O 0 1.1680141142278444e-05
the O 0 4.719326227586862e-07
diagnosis O 0 0.0005647746147587895
is O 0 3.263262726704852e-08
suspected O 0 1.7149957329820609e-06
, O 0 1.1422402579341906e-08
physicians O 0 2.5041100570888375e-07
must O 0 1.0092047197929332e-08
use O 0 1.7225639226126077e-07
serum O 0 0.006031157914549112
ferritin O 1 0.9996726512908936
levels O 0 1.858810492194607e-06
and O 0 3.89688977975311e-07
hepatic O 1 1.0
iron O 1 0.9999998807907104
stores O 0 5.781444087915588e-07
on O 0 4.921589180639785e-08
liver O 0 8.513908369423007e-07
biopsy O 0 3.622299260541695e-08
specimens O 0 4.864359581802091e-09
to O 0 1.003289118450823e-09
assess O 0 2.85787713494301e-08
patients O 0 2.1288843754518894e-07
for O 0 8.950647334415862e-09
the O 0 8.263045003786829e-08
presence O 0 2.899811875067826e-07
of O 0 5.0120252126362175e-05
iron B-Disease 1 1.0
overload I-Disease 1 0.7904524803161621
. O 0 2.2658623493043706e-06

Liver O 1 0.9978688955307007
biopsy O 0 0.0010260619455948472
is O 0 1.397110196421636e-07
also O 0 1.0313516263238398e-08
used O 0 7.1296977210977275e-09
to O 0 3.673926940450656e-09
establish O 0 4.877256998270241e-08
the O 0 9.95193261132954e-09
presence O 0 7.931271639449733e-09
or O 0 1.1501740893038459e-08
absence O 0 8.415929642069386e-07
of O 0 1.5169760445132852e-05
cirrhosis B-Disease 1 1.0
, O 0 7.94570453876986e-08
which O 0 2.3024198103627214e-09
can O 0 3.250724800452076e-09
affect O 0 5.5480118277273505e-08
prognosis O 1 0.9999550580978394
and O 0 1.7084530554711819e-06
management O 0 0.00010978816862916574
. O 0 2.283881940456922e-06

A O 0 4.2958499761880375e-06
DNA O 0 1.4102922705205856e-06
- O 0 2.2634078788996703e-07
based O 0 1.1889069284620746e-08
test O 0 1.4365430622831354e-08
for O 0 2.0099537589857164e-09
the O 0 8.906268611497126e-09
HFE O 0 0.008969707414507866
gene O 0 2.2275981947927903e-08
is O 0 4.77666350917616e-10
commercially O 0 5.952394577235509e-09
available O 0 3.0787092319961573e-10
, O 0 1.1566385349492947e-10
but O 0 1.4828294148117038e-10
its O 0 3.691549288475926e-10
place O 0 4.816223864168023e-09
in O 0 1.4145129512144194e-10
the O 0 1.1071558114750246e-09
diagnosis O 0 1.3119198229105677e-05
of O 0 3.0509681891999207e-06
hemochromatosis B-Disease 1 1.0
is O 0 3.154699470542255e-07
still O 0 6.665262475280542e-08
being O 0 8.972290288511431e-08
evaluated O 0 3.3122756804004894e-07
. O 0 4.7133710268099094e-07

Currently O 0 1.2808521887563984e-06
, O 0 6.408660624401818e-08
the O 0 2.2692947965197163e-08
most O 0 3.2381439751816288e-09
useful O 0 1.656140113936999e-08
role O 0 7.0483952008260076e-09
for O 0 4.741715908807009e-10
this O 0 1.7256954198963115e-10
test O 0 5.182747564447254e-09
is O 0 3.459677544448425e-10
in O 0 2.1640363112584993e-10
the O 0 1.3692531553033405e-09
detection O 0 8.029333912418224e-06
of O 0 2.2167239421833074e-06
hemochromatosis B-Disease 1 1.0
in O 0 5.949151571371658e-08
the O 0 3.6034389694350466e-08
family O 0 6.1720282218402645e-09
members O 0 2.3164968554478804e-10
of O 0 1.899653101489207e-09
patients O 0 5.262095204017214e-09
with O 0 9.577669768390251e-10
a O 0 2.386830288969577e-08
proven O 0 0.00011029435700038448
case O 0 5.784836503153201e-07
of O 0 4.4995118742008344e-07
the O 0 1.9437188711890485e-06
disease O 1 0.9982534050941467
. O 0 1.561578187647683e-06

It O 0 3.0672103434881137e-07
is O 0 5.7472188785823164e-08
crucial O 0 6.293763590292656e-07
to O 0 8.003335949524626e-08
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.9999997615814209
because O 0 2.4207743990700692e-05
phlebotomy O 1 1.0
therapy O 1 0.9988096952438354
can O 0 1.1067429994682243e-07
avert O 1 0.9992632269859314
serious O 1 0.9999998807907104
chronic O 1 1.0
disease O 1 1.0
and O 0 6.199367135195644e-07
can O 0 7.74702701988872e-09
even O 0 3.266781334332336e-08
lead O 0 8.276546736851742e-08
to O 0 4.191580860180011e-09
normal O 0 7.9278265729954e-08
life O 0 7.225572318247941e-08
expectancy O 0 1.2987797504138143e-07
. O 0 1.5932807073681943e-08
. O 0 1.4268046300003334e-07

Prevalence O 0 2.9482547688530758e-05
of O 0 1.8768191694107372e-06
the O 0 4.456924500573223e-07
I1307K O 0 4.729950887849554e-06
APC B-Disease 0 2.83624359553869e-07
gene O 0 6.744406810810233e-09
variant O 0 7.579111382938208e-08
in O 0 1.9273502793737407e-09
Israeli O 0 4.4853308622805343e-08
Jews O 0 1.910923330683545e-08
of O 0 1.9004431361935303e-09
differing O 0 1.7957960674053197e-09
ethnic O 0 4.0180600513473053e-10
origin O 0 1.3064008763663537e-09
and O 0 2.3846584706888052e-09
risk O 0 8.563281994611316e-08
for O 0 1.6526065564903547e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.005578719545155764

BACKGROUND O 0 0.00014773265866097063
& O 0 5.686440636054613e-05
AIMS O 0 7.973287097229331e-07
Israeli O 0 3.2345042200176977e-07
Jews O 0 1.0132439598464771e-07
of O 0 3.549230953581173e-08
European O 0 3.037109763681656e-08
birth O 0 9.175046500331518e-08
, O 0 4.153650312588297e-09
i O 0 3.2338052236013937e-09
. O 0 3.621867805669865e-10
e O 0 6.765171756129007e-10
. O 0 3.4795502590334593e-10
, O 0 7.821227554494214e-10
Ashkenazim O 0 2.888957396862679e-06
, O 0 2.8436080157234755e-09
have O 0 1.0984539944303151e-09
the O 0 5.2027772312612797e-08
highest O 1 0.999966025352478
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0011237378930673003
of O 0 2.8330106260909815e-07
any O 0 3.2274108718866046e-08
Israeli O 0 4.4890580852552375e-07
ethnic O 0 2.8835899001933285e-08
group O 0 5.380251977271655e-08
. O 0 2.0802353617455083e-07

The O 0 1.2431112736521754e-05
I1307K O 0 5.211025199969299e-05
APC B-Disease 0 2.9952520890219603e-06
gene O 0 1.2486800926581054e-07
variant O 0 3.2995999390550423e-06
was O 0 1.332038095824828e-06
found O 0 2.7716090755802725e-08
in O 0 3.652876046089659e-08
6 O 0 2.147893837900483e-06
. O 0 3.0654634883831022e-06

1 O 0 2.545442157497746e-06
% O 0 6.251541861956866e-08
of O 0 4.638712880478124e-08
American O 0 3.0757774993617204e-08
Jews O 0 2.9412602131628773e-08
, O 0 2.2502943952673604e-09
28 O 0 1.0080966283965154e-08
% O 0 5.575502837196211e-10
of O 0 3.936634573875608e-09
their O 0 2.6742704051230248e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 9.221147593052592e-06
, O 0 7.936507451233865e-09
but O 0 7.443534677520347e-10
not O 0 3.6845917983363563e-10
in O 0 1.4344943011224132e-09
non O 0 1.0553205243013508e-07
- O 0 4.869403369411884e-07
Jews O 0 4.119124810131325e-07
. O 0 4.963029027749144e-07

We O 0 2.367220758969779e-06
assessed O 0 1.5118081364562386e-06
the O 0 1.0491390867173322e-07
I1307K O 0 1.9727237940969644e-06
prevalence O 0 3.792635254740162e-07
in O 0 1.519567360830365e-09
Israeli O 0 3.644941770630794e-08
Jews O 0 1.369091862102323e-08
of O 0 1.4594372377274567e-09
differing O 0 1.4052253805019177e-09
ethnic O 0 2.995118042470324e-10
origin O 0 5.401138980509756e-10
and O 0 1.2015770600726228e-09
risk O 0 7.16144299417465e-08
for O 0 9.297593805968063e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0010163452243432403

METHODS O 0 2.755024252110161e-05
DNA O 0 3.4287540984223597e-06
samples O 0 6.873902691495459e-08
from O 0 9.962131564122956e-09
500 O 0 3.4417833028044242e-09
unrelated O 0 1.4864017572335797e-08
Jews O 0 2.6416829612685433e-08
of O 0 3.011101767924629e-08
European O 0 9.571596848445552e-08
or O 0 4.421995569714454e-08
non O 0 5.65709115107893e-08
- O 0 1.665135407336038e-08
European O 0 1.96997262946752e-09
origin O 0 6.94899748854283e-10
, O 0 1.1563208723863738e-10
with O 0 5.724858434530411e-11
or O 0 1.4622681954179484e-09
without O 0 4.272687537110187e-09
a O 0 7.004383739683817e-09
personal O 0 1.9932052452986682e-07
and O 0 1.1668328880887202e-07
/ O 0 0.047728851437568665
or O 0 3.002041637500952e-07
family O 0 9.054361527205401e-08
history O 0 3.361652289868289e-08
of O 0 1.9856818411767563e-08
neoplasia B-Disease 0 0.002416431438177824
, O 0 5.180780693336828e-09
were O 0 4.1193932709404635e-09
examined O 0 1.125898574372286e-08
for O 0 1.1317047299286287e-09
the O 0 5.103408806661491e-09
I1307K O 0 6.684334152851079e-08
variant O 0 1.0987227128111954e-08
by O 0 3.59907353919553e-10
the O 0 3.5103426831994966e-09
allele O 0 3.106659152152247e-09
- O 0 7.152867187443235e-09
specific O 0 4.7488590837474476e-09
oligonucleotide O 0 2.029344386755838e-06
( O 0 8.304868259756404e-08
ASO O 0 3.913240652764216e-05
) O 0 2.4326206826685848e-08
method O 0 8.441757586297172e-07
. O 0 8.141478815559822e-07

RESULTS O 0 6.2877793425286654e-06
In O 0 8.598076561838752e-08
persons O 0 1.1552550915894244e-08
at O 0 1.9710411081064194e-08
average O 0 4.29092406051268e-09
risk O 0 1.535288518539346e-08
for O 0 1.817879251575505e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.0248440958093852e-05
I1307K O 0 0.00011322358477627859
was O 0 2.635433133946208e-07
found O 0 4.112939766542922e-09
in O 0 3.144862814608018e-09
5 O 0 1.177539914465342e-07
. O 0 2.920365602676611e-07

0 O 0 2.868124283850193e-06
% O 0 5.2021619012521114e-08
of O 0 9.578354820405366e-08
120 O 0 1.2570473018058692e-07
European O 0 1.6608144903784705e-07
and O 0 1.7451941403123783e-07
1 O 0 4.266689757059794e-06
. O 0 1.5181551589193987e-06

6 O 0 1.6467838577227667e-05
% O 0 2.1259181437471852e-07
of O 0 1.7715329647671751e-07
188 O 0 2.9495251396838285e-07
non O 0 3.298918898053671e-07
- O 0 3.0202738798834616e-07
European O 0 7.758134756841173e-08
Jews O 0 7.858528050519453e-08
( O 0 1.058905141348987e-08
P O 0 8.518204595020507e-07
= O 0 8.587079491917393e-08
0 O 0 9.437625791974824e-09
. O 0 1.3529859455019277e-09
08 O 0 4.934212327611931e-08
) O 0 1.0722171595034524e-08
. O 0 1.8110527832959633e-07

It O 0 9.065764743354521e-07
occurred O 0 3.0498133583023446e-06
in O 0 1.318505553626892e-07
15 O 0 7.338126124523114e-07
. O 0 1.0600305131447385e-06

4 O 0 6.41515725874342e-06
% O 0 4.5050679631231105e-08
of O 0 4.5707260198923905e-08
52 O 0 1.558812101620788e-07
Ashkenazi O 0 9.675484307081206e-07
Israelis O 0 7.697217796476252e-08
with O 0 2.341721927479057e-09
familial O 0 1.8075653542837244e-06
cancer B-Disease 0 0.0011355760507285595
( O 0 1.9763490399782313e-08
P O 0 2.993344651258667e-06
= O 0 7.854273320617722e-08
0 O 0 1.043938802069988e-08
. O 0 1.1368537222722352e-09
02 O 0 5.775537204044667e-08
) O 0 6.780945249751369e-10
and O 0 2.764827922163704e-09
was O 0 3.5878777282505325e-08
not O 0 6.541065467047247e-10
detected O 0 2.5610612297555235e-08
in O 0 3.1801374866802234e-09
51 O 0 3.5384836394314334e-08
non O 0 1.471738215741425e-07
- O 0 1.8602543150336714e-07
European O 0 5.289125581953158e-08
Jews O 0 9.819666502153268e-08
at O 0 3.285928684704231e-08
increased O 0 4.205661596756727e-08
cancer B-Disease 0 1.1975201232417021e-05
risk O 0 1.4081768995310995e-06
. O 0 8.701367164576368e-07

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999998807907104
occurred O 0 0.002043244196102023
personally O 0 9.644433703215327e-06
or O 0 9.378269538729e-08
in O 0 7.855422978764182e-09
the O 0 4.48048043111271e-09
families O 0 1.9880683765904905e-09
of O 0 1.1891905238314848e-08
13 O 0 2.890098116381523e-08
of O 0 5.090384291861483e-08
20 O 0 6.263859120281268e-08
Ashkenazi O 0 1.483374830968387e-06
I1307K O 0 3.095322824719915e-07
carriers O 0 8.798864747916468e-09
, O 0 1.8368119247824666e-09
8 O 0 1.6338509212232566e-08
of O 0 2.1871100486237083e-08
whom O 0 3.7466946878339513e-07
also O 0 4.452904889262754e-08
had O 0 5.047226991905518e-08
a O 0 1.7813734487504007e-08
personal O 0 2.164049419661751e-07
or O 0 3.699786077504541e-08
family O 0 7.960449011079618e-08
history O 0 1.1608249650407743e-07
of O 0 4.995318363398837e-07
noncolonic O 1 0.8055868148803711
neoplasia B-Disease 1 0.9999961853027344
. O 0 7.409827958326787e-05

CONCLUSIONS O 0 4.05215541832149e-05
The O 0 3.0658318337373203e-06
I1307K O 0 4.936640107189305e-05
APC O 0 3.6028250178787857e-06
variant O 0 6.8770496000070125e-06
may O 0 3.4084738587125685e-08
represent O 0 5.388464785482938e-09
a O 0 1.4431203787523827e-08
susceptibility O 0 1.963203430932481e-06
gene O 0 5.658515789264129e-08
for O 0 7.57901048586973e-08
colorectal B-Disease 1 1.0
, I-Disease 0 8.462759069516324e-06
or I-Disease 0 2.8857082270405954e-06
other I-Disease 0 8.146925978280706e-08
, I-Disease 0 1.840045982248739e-08
cancers I-Disease 0 0.005203606560826302
in O 0 3.881772681069151e-09
Ashkenazi O 0 1.9839060769299977e-05
Jews O 0 2.2247752440307522e-07
, O 0 3.817468119393652e-09
and O 0 3.705256990116368e-09
partially O 0 1.0367600822291934e-07
explains O 0 9.79738068451752e-09
the O 0 1.980347885677247e-09
higher O 0 1.6138061553760963e-08
incidence O 0 8.838562735036248e-07
of O 1 0.5005597472190857
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.953590059310955e-07
European O 0 6.955897902116703e-07
Israelis O 0 5.336082153917232e-07
. O 0 3.72221677480411e-07

Systematic O 0 5.223922698860406e-07
analysis O 0 2.4878360704860825e-07
of O 0 3.3266670129705744e-07
coproporphyrinogen O 0 0.0008396606426686049
oxidase O 0 0.0001252574729733169
gene O 0 1.5248896488628816e-05
defects O 0 0.0006372467614710331
in O 0 3.373779478010874e-08
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999996423721313
and O 0 9.940021072907257e-07
mutation O 0 4.4348936967253394e-07
update O 0 3.159391781082377e-06
. O 0 8.569913347855618e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999890327453613
( O 0 5.2983418754593e-06
HC B-Disease 1 0.9999986886978149
) O 0 2.926532260971726e-07
is O 0 2.2572551827693133e-08
an O 0 3.520858626870904e-08
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.00011565204476937652
autosomal O 1 0.999998927116394
dominant O 1 0.9999896287918091
inheritance O 0 0.02498868852853775
caused O 0 1.0299037057848182e-05
by O 0 2.02352943290407e-08
deficient B-Disease 0 1.1131698556710035e-05
activity I-Disease 0 8.463838696570747e-08
of I-Disease 0 2.7802241220342694e-07
coproporphyrinogen I-Disease 0 0.08494149893522263
III I-Disease 1 1.0
oxidase I-Disease 0 5.9140547818969935e-05
( O 0 7.34007187475072e-07
CPO O 0 2.715278424147982e-05
) O 0 1.023718354531411e-07
. O 0 6.26368034772895e-07

Clinical O 0 0.0003138210449833423
manifestations O 1 0.9939661622047424
of O 0 0.10228230804204941
the O 0 4.387590161059052e-05
disease O 1 0.9995301961898804
are O 0 2.816949729034235e-10
characterized O 0 1.0570485819982878e-08
by O 0 4.5366571610472306e-10
acute O 1 0.9999979734420776
attacks O 0 0.3890751004219055
of O 1 1.0
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.796503508761816e-07
precipitated O 0 3.406271673611627e-07
by O 0 4.776900541791917e-10
drugs O 0 2.5088352728630525e-08
, O 0 1.0575587516825635e-08
fasting O 0 9.462868911214173e-05
, O 0 1.4397309655578283e-07
cyclical O 0 0.10264938324689865
hormonal O 0 0.02434120513498783
changes O 0 1.3892844208385213e-07
, O 0 3.099522771776719e-08
or O 0 3.9244994809450873e-07
infectious B-Disease 1 0.9999979734420776
diseases I-Disease 1 0.9999996423721313
. O 0 5.542243798117852e-06

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 0.0005849121953360736
also O 0 6.270325911827968e-07
be O 0 4.574459211426074e-08
present O 0 3.780797612762399e-07
. O 0 1.6051882312240195e-06

The O 0 9.562503691995516e-06
seven O 0 2.714178435780923e-06
exons O 0 4.2854244384216145e-06
, O 0 2.543099597573928e-08
the O 0 5.993901197598461e-08
exon O 0 1.555003677822242e-06
/ O 0 8.052945759118302e-07
intron O 0 1.3727901659876807e-06
boundaries O 0 1.62249733648423e-08
and O 0 4.1102263814707385e-09
part O 0 1.0285090112915896e-08
of O 0 2.6882831960506337e-08
3 O 0 1.1790097431685354e-07
noncoding O 0 1.1494040563775343e-06
sequence O 0 7.532917400965289e-09
of O 0 1.645823921592182e-08
the O 0 3.408877091715112e-08
CPO O 0 2.2605524918617448e-06
gene O 0 9.467987283073853e-09
were O 0 3.3691607281838287e-09
systematically O 0 4.233215555871084e-09
analyzed O 0 1.9267880624340705e-09
by O 0 3.4697483775048e-10
an O 0 1.3615263361188568e-09
exon O 0 1.0394747107511648e-07
- O 0 5.989775075931902e-08
by O 0 1.8960234271503396e-08
- O 0 1.3208278915044502e-06
exon O 0 2.50432299253589e-06
denaturing O 0 2.0703939298982732e-05
gradient O 0 3.137572321065818e-06
gel O 0 4.844723093810899e-07
electrophoresis O 0 3.867608029395342e-07
( O 0 2.2621772899356074e-08
DGGE O 0 2.3997086827876046e-05
) O 0 2.5646089696351737e-09
strategy O 0 2.120078512746204e-08
followed O 0 1.1265554045181148e-09
by O 0 5.174504574823047e-11
direct O 0 9.755420915524837e-10
sequencing O 0 1.5584488366471305e-08
in O 0 7.256364398244841e-10
seven O 0 6.441796873701833e-09
unrelated O 0 9.120817168195572e-08
heterozygous O 0 3.377095225687299e-08
HC B-Disease 0 1.838376556406729e-05
patients O 0 4.6450699642264226e-07
from O 0 1.0834007468929485e-07
France O 0 1.6446762174382457e-07
, O 0 2.604450699550398e-08
Holland O 0 2.3076324850990204e-06
, O 0 1.6663268098682238e-08
and O 0 4.092720473636291e-08
Czech O 0 1.857136157923378e-05
Republic O 0 0.0001844945945776999
. O 0 0.0008926066802814603

Seven O 0 6.01521469434374e-06
novel O 0 1.3836613561579725e-06
mutations O 0 8.250714245150448e-08
and O 0 2.7480318465222808e-08
two O 0 1.3574947388406144e-08
new O 0 8.825274022683516e-08
polymorphisms O 0 2.249859335279325e-06
were O 0 2.0805747169561073e-07
detected O 0 4.6761388148297556e-06
. O 0 1.7803937453209073e-06

Among O 0 6.342780807244708e-07
these O 0 1.8345055252666498e-08
mutations O 0 1.9230258274660628e-08
two O 0 2.6984432466292674e-09
are O 0 1.2100775936829677e-09
missense O 0 4.974277771907509e-07
( O 0 2.114146546716711e-08
G197W O 0 5.610548214463051e-06
, O 0 1.8800058398937836e-08
W427R O 0 5.585257554230338e-07
) O 0 1.0591266752513206e-09
, O 0 8.284594121832356e-10
two O 0 1.1418432865895056e-09
are O 0 9.57894874531462e-10
nonsense O 0 5.38651420356473e-07
( O 0 1.8094501896825932e-08
Q306X O 0 3.298852675470698e-07
, O 0 2.7885649345193997e-09
Q385X O 0 1.6486366405388253e-07
) O 0 7.706053017919601e-10
, O 0 4.931506869532143e-10
two O 0 8.958294661631783e-10
are O 0 4.700492217679653e-10
small O 0 4.326451197300685e-09
deletions O 0 9.910983322924949e-08
( O 0 1.2487474165823187e-08
662de14bp O 0 8.340425097230764e-07
; O 0 2.2095717255865566e-08
1168del3bp O 0 4.1839975892798975e-06
removing O 0 3.00963819199751e-07
a O 0 3.6819400861531904e-08
glycine O 0 6.828479826026523e-08
at O 0 1.3515474073244604e-08
position O 0 7.480286612349119e-09
390 O 0 1.0650973436554523e-08
) O 0 2.6885985104918575e-10
, O 0 2.0567698932882905e-10
and O 0 5.98899319026458e-10
one O 0 1.901389490299721e-09
is O 0 9.54165857436351e-10
a O 0 5.027681382330229e-09
splicing O 0 7.157291292969603e-08
mutation O 0 5.331643126993413e-09
( O 0 4.094662831022333e-09
IVS1 O 0 1.6601872630417347e-05
- O 0 4.772793431584432e-07
15c O 0 3.7187612633715617e-06
- O 0 4.526704628915468e-07
- O 0 2.609866385228088e-07
> O 0 2.3297441487102333e-07
g O 0 3.72160577910563e-08
) O 0 5.092010701979177e-10
which O 0 1.5181586543455694e-10
creates O 0 2.9578659521689588e-09
a O 0 9.453906546497137e-10
new O 0 2.18753437586372e-09
acceptor O 0 6.270335806135563e-09
splice O 0 7.604515985804028e-07
site O 0 1.4578084517324896e-07
. O 0 7.544107916146459e-08

The O 0 3.0559128845197847e-06
pathological O 0 2.6669293220038526e-05
significance O 0 2.953385319415247e-06
of O 0 7.483128570129338e-07
the O 0 2.77810642046461e-07
point O 0 5.581412665378593e-07
mutations O 0 1.6788611389984e-08
G197W O 0 5.689423119292769e-07
, O 0 7.795139644883875e-09
W427R O 0 1.0830015071405796e-06
, O 0 7.819829228594699e-09
and O 0 1.0939696259981702e-08
the O 0 4.870470959872364e-08
in O 0 3.906925272190165e-08
- O 0 7.518752909163595e-07
frame O 0 7.247911639751692e-07
deletion O 0 1.6164793237294361e-07
390delGly O 0 1.3618391392355989e-07
were O 0 1.5068221115299707e-09
assessed O 0 7.298731841132167e-09
by O 0 3.489299960079961e-10
their O 0 1.6908922040315133e-09
respective O 0 2.7905032951025532e-08
expression O 0 1.7284577324971906e-08
in O 0 2.682227995265407e-09
a O 0 3.96769950228304e-09
prokaryotic O 0 7.08257417159075e-08
system O 0 7.652482025832796e-08
using O 0 1.754746214999159e-08
site O 0 8.650138028087895e-08
- O 0 1.5518318718932278e-07
directed O 0 1.6295133775656723e-07
mutagenesis O 0 2.4622011551400647e-05
. O 0 8.564651352571673e-07

These O 0 1.2950518168963754e-07
mutations O 0 1.2379859981592745e-07
resulted O 0 1.581960731300569e-07
in O 0 1.1971832414303663e-08
the O 0 1.812240846277291e-08
absence O 0 4.836367679672549e-07
or O 0 3.8483943143319266e-08
a O 0 2.256024167479609e-08
dramatic O 0 2.2287910894647212e-07
decrease O 0 1.7805521679292724e-07
of O 0 2.7093371954833856e-06
CPO O 0 0.0006691913004033267
activity O 0 1.1600673133216333e-06
. O 0 1.1888409972016234e-06

The O 0 2.3065763343765866e-06
two O 0 1.4134401737919688e-07
polymorphisms O 0 1.5397569086417207e-06
were O 0 6.744910763245571e-08
localized O 0 1.1641868695733137e-06
in O 0 3.666941950086766e-08
noncoding O 0 7.811744580976665e-06
part O 0 3.368025147665321e-08
of O 0 4.152131438672768e-08
the O 0 1.373297386919603e-08
gene O 0 4.623702754003034e-09
1 O 0 8.330804490697119e-09
) O 0 7.822839043214458e-10
a O 0 6.514051964501277e-09
C O 0 3.854370334011037e-06
/ O 0 2.6534041808190523e-06
G O 0 3.552604994183639e-06
polymorphism O 0 1.5077148418640718e-07
in O 0 4.763673899788046e-09
the O 0 1.330060772630759e-08
promotor O 0 6.5063572947110515e-06
region O 0 1.77034564785572e-07
, O 0 3.15808854622901e-08
142 O 0 5.431076033346471e-07
bp O 0 7.893995075392013e-07
upstream O 0 9.466997852314307e-08
from O 0 5.404089176153093e-09
the O 0 7.27076221451739e-09
transcriptional O 0 5.735457193623006e-07
initiation O 0 2.4385954588979075e-07
site O 0 8.661777428642381e-08
( O 0 4.518498908367974e-09
- O 0 5.104501710206932e-08
142C O 0 7.885237209848128e-07
/ O 0 1.2818330219488416e-07
G O 0 2.508288048375107e-07
) O 0 3.1323987847997614e-09
, O 0 2.5643984713497048e-09
and O 0 6.62748256274881e-09
2 O 0 1.0067365252552918e-07
) O 0 4.63615412726881e-09
a O 0 3.478671217749252e-08
6 O 0 3.9133922768996854e-07
bp O 0 4.759398564146977e-07
deletion O 0 2.3740717836062686e-08
polymorphism O 0 1.700129104165171e-08
in O 0 1.1384725384644412e-09
the O 0 1.6339312125523975e-09
3 O 0 2.4228503647805155e-08
noncoding O 0 8.042086392379133e-07
part O 0 1.55247956712401e-08
of O 0 4.4061167159270553e-08
the O 0 5.039195016820486e-08
CPO O 0 2.044767370534828e-06
gene O 0 2.240103569306484e-08
, O 0 7.0735799440058145e-09
574 O 0 3.030935431524995e-07
bp O 0 5.395449989009649e-07
downstream O 0 5.4626127621304477e-08
of O 0 7.775152965905363e-09
the O 0 9.218264374055707e-09
last O 0 1.2242768576697927e-08
base O 0 6.241890559977037e-08
of O 0 9.779607346160901e-09
the O 0 4.054908853134975e-09
normal O 0 1.6050879736440038e-08
termination O 0 3.103285450833937e-07
codon O 0 9.754238305959007e-08
( O 0 2.2017340839397548e-08
+ O 0 3.428982324749086e-07
574 O 0 1.0399401162430877e-06
delATTCTT O 0 6.325145932351006e-06
) O 0 8.997036360369748e-08
. O 0 5.936240654591529e-07

Five O 0 2.9615612220368348e-05
intragenic O 0 0.0019091080175712705
dimorphisms O 0 0.00021446587925311178
are O 0 1.0218802692918416e-08
now O 0 8.384237304426279e-09
well O 0 2.328520487537844e-09
characterized O 0 1.953212169780727e-08
and O 0 3.210243182394379e-09
the O 0 3.6750762433257478e-09
high O 0 7.921735090121729e-08
degree O 0 1.2738011889723566e-07
of O 0 3.273517279467342e-08
allelic O 0 9.897312338580377e-07
heterogeneity O 0 1.6509209217474563e-06
in O 0 2.708375745896774e-08
HC B-Disease 1 0.9629819393157959
is O 0 1.3097252349325572e-07
demonstrated O 0 1.2370416868634493e-07
with O 0 1.8711365790125e-09
seven O 0 4.7335850794638645e-09
new O 0 1.2166572194161063e-09
different O 0 2.407140597959767e-10
mutations O 0 2.867746595747178e-10
making O 0 5.394323876473095e-10
a O 0 6.539194186139241e-10
total O 0 3.528034253630352e-10
of O 0 1.401970717296308e-08
nineteen O 0 5.182612312637502e-07
CPO O 0 1.7043688785634004e-05
gene B-Disease 0 4.2299490132791107e-07
defects I-Disease 0 1.9318508748256136e-06
reported O 0 1.1780966424623784e-08
so O 0 6.933219331983764e-09
far O 0 3.583863161793488e-08
. O 0 3.26483160506541e-08
. O 0 2.440847879370267e-07

Coincidence O 0 1.5933397662593052e-05
of O 0 1.7106800669353106e-06
two O 0 1.6670395552864647e-07
novel O 0 1.669293737904809e-06
arylsulfatase O 0 9.330964530818164e-06
A O 0 2.7124397661282273e-07
alleles O 0 2.743224314372128e-08
and O 0 8.073245183481959e-09
mutation O 0 2.1016790086036963e-08
459 O 0 5.449811624202994e-07
+ O 0 9.49638263136876e-07
1G O 0 5.673256600857712e-05
> O 0 3.854944168324437e-07
A O 0 4.916729068327186e-08
within O 0 3.796519099097395e-09
a O 0 4.535396502802769e-09
family O 0 8.66362359630557e-09
with O 0 2.6565265542899397e-09
metachromatic B-Disease 1 0.9999958276748657
leukodystrophy I-Disease 1 1.0
: O 0 1.0366033365016847e-08
molecular O 0 4.223088367893979e-08
basis O 0 1.3684288369120168e-08
of O 0 6.780368977388207e-08
phenotypic O 0 5.736016191804083e-06
heterogeneity O 0 7.111542799975723e-05
. O 0 3.5008881695830496e-06

In O 0 1.3571577710536076e-06
a O 0 2.119880946338526e-07
family O 0 3.6624683730224206e-08
with O 0 2.3921657987813205e-09
three O 0 6.398826357667531e-09
siblings O 0 3.53525990703929e-07
, O 0 3.6035125994260397e-09
one O 0 3.883135146764971e-09
developed O 0 4.811433882423444e-07
classical O 0 8.970500857685693e-06
late O 0 0.0019916496239602566
infantile O 1 0.9999796152114868
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 6.525544904434355e-07
MLD B-Disease 1 1.0
) O 0 5.743701692040304e-08
, O 0 8.893943359566947e-09
fatal O 0 1.2235623216838576e-06
at O 0 8.699660014599431e-08
age O 0 1.2311966557376763e-08
5 O 0 1.0116542270566242e-08
years O 0 4.327309621743325e-09
, O 0 1.2016206918374905e-09
with O 0 4.084249827229769e-09
deficient O 0 0.0066147721372544765
arylsulfatase O 0 0.010345219634473324
A O 0 7.927280421426985e-06
( O 0 4.858446231992275e-07
ARSA O 1 0.9959585070610046
) O 0 1.243255187688419e-08
activity O 0 6.740985547537548e-09
and O 0 3.5645617568746957e-09
increased O 0 1.8796974643464637e-08
galactosylsulfatide O 0 0.00010162148828385398
( O 0 3.3685591915855184e-07
GS O 1 0.9999983310699463
) O 0 1.2111235037082224e-07
excretion O 0 7.428677122334193e-07
. O 0 2.693262217690062e-07

The O 0 2.713024287004373e-06
two O 0 1.413209531619941e-07
other O 0 2.230382811774234e-08
siblings O 0 1.3607814253191464e-06
, O 0 3.2991795961834214e-08
apparently O 0 7.905160259724653e-07
healthy O 0 3.596168198782834e-07
at O 0 9.882045759468383e-08
12 O 0 2.4209748872294767e-08
( O 0 2.773310248116445e-09
1 O 0 2.1955449369670532e-07
/ O 0 1.1985720220764051e-06
2 O 0 4.668269468766084e-07
) O 0 2.2041910519021712e-09
and O 0 3.900609613083361e-09
15 O 0 5.975566264027066e-09
years O 0 5.941188430114153e-09
, O 0 4.899368133415294e-10
respectively O 0 2.007206845178189e-09
, O 0 4.04986766344706e-10
and O 0 2.4591487179925764e-10
their O 0 9.829458358368015e-10
father O 0 2.1436525798890216e-07
, O 0 1.1134503097309789e-08
apparently O 0 1.6617762810255954e-07
healthy O 0 3.1922812837592573e-08
as O 0 3.2320046639000566e-09
well O 0 6.522816953236088e-09
, O 0 5.618645104732423e-09
presented O 0 7.585213097627275e-07
ARSA O 1 1.0
and O 0 4.051736596011324e-06
GS O 1 1.0
values O 0 6.789091600012398e-08
within O 0 8.297408093937975e-09
the O 0 4.8919188699869665e-09
range O 0 1.0659615412578205e-07
of O 0 4.2460834492885624e-07
MLD B-Disease 1 1.0
patients O 0 0.004591396078467369
. O 0 2.480359626133577e-06

Mutation O 0 1.989569682336878e-06
screening O 0 9.408922210241144e-07
and O 0 2.055077885643186e-08
sequence O 0 1.3755991012942559e-08
analysis O 0 5.9719091893839504e-09
disclosed O 0 7.143230362771646e-08
the O 0 4.9859303352661755e-09
involvement O 0 5.903125455120062e-08
of O 0 3.129760628439726e-08
three O 0 1.784719927400147e-08
different O 0 2.6090546612067556e-08
ARSA O 1 0.9018546938896179
mutations O 0 1.1881521544410134e-08
being O 0 4.415233956223119e-09
the O 0 1.1132225141707863e-09
molecular O 0 9.049973215269347e-09
basis O 0 2.1172093411792048e-08
of O 0 1.1322585180550959e-07
intrafamilial O 0 0.00017544603906571865
phenotypic O 0 1.3630499779537786e-05
heterogeneity O 0 6.597490573767573e-05
. O 0 2.495949502190342e-06

The O 0 4.165158770774724e-06
late O 0 8.516827801940963e-05
infantile O 0 0.08278301358222961
patient O 0 1.1525660738698207e-05
inherited O 0 0.0032060942612588406
from O 0 2.429706853490643e-07
his O 0 5.485174483510491e-07
mother O 0 4.211071882309625e-07
the O 0 3.778209034521751e-08
frequent O 0 1.2599230103660375e-07
0 O 0 1.1314769210457598e-07
- O 0 1.0609210931988855e-07
type O 0 9.729173200412333e-08
mutation O 0 4.632461525488907e-08
459 O 0 2.5398622938155313e-07
+ O 0 1.8577316041046288e-07
1G O 0 2.6064938083436573e-06
> O 0 4.9582787653434934e-08
A O 0 2.0294780966878534e-08
, O 0 9.869473016621555e-10
and O 0 4.052185809122477e-10
from O 0 2.5518152035886033e-09
his O 0 1.431384699657201e-08
father O 0 8.94382452543141e-08
a O 0 1.200530785894216e-08
novel O 0 2.5603336339941052e-08
, O 0 2.3945032623373663e-09
single O 0 1.597860865842904e-08
basepair O 0 1.63441097811301e-06
microdeletion O 0 1.9104879811493447e-06
of O 0 6.846099154245167e-08
guanine O 0 3.9070377511052357e-07
at O 0 9.069884043810816e-08
nucleotide O 0 5.07723605380761e-08
7 O 0 7.426098846963214e-08
in O 0 1.2442301411397239e-08
exon O 0 6.872879794173059e-07
1 O 0 2.075281599900336e-07
( O 0 2.2905332741629536e-08
7delG O 0 1.6274615290967631e-06
) O 0 8.557861264080202e-08
. O 0 5.168905090613407e-07

The O 0 4.306522896513343e-06
two O 0 5.449832087833784e-07
clinically O 0 0.0008548459736630321
unaffected O 0 6.493472028523684e-05
siblings O 0 3.05454341287259e-06
carried O 0 3.1527200405889744e-08
the O 0 1.8735052620399983e-08
maternal O 0 2.906583915773808e-07
mutation O 0 9.010671675468984e-08
459 O 0 8.008663030523167e-07
+ O 0 6.203761699907773e-07
1G O 0 1.6448391761514358e-05
> O 0 1.116568384418315e-07
A O 0 2.1119177517903154e-08
and O 0 1.1996100779398944e-09
, O 0 6.219590953371323e-10
on O 0 1.0192519050988835e-09
their O 0 2.2278169586886776e-10
paternal O 0 1.316904008064057e-08
allele O 0 6.057605528297927e-09
, O 0 4.673618714257088e-10
a O 0 3.521756664071063e-09
novel O 0 6.791292861407783e-08
cytosine O 0 2.1864515531433426e-07
to O 0 2.1464076738197946e-08
thymidine O 0 4.3859618017449975e-06
transition O 0 2.2747067305317614e-06
at O 0 1.7537399799039122e-07
nucleotide O 0 1.6492342069795995e-07
2435 O 0 7.19636409485247e-06
in O 0 4.837620082298599e-09
exon O 0 7.169232674186787e-08
8 O 0 7.473712315686498e-09
, O 0 3.84069082093319e-10
resulting O 0 2.1919992487795525e-09
in O 0 1.151303830049244e-09
substitution O 0 2.3834274998080218e-08
of O 0 2.3001824445145758e-08
alanine O 0 5.0802292150819994e-08
464 O 0 1.422933166850271e-07
by O 0 9.512118204213493e-09
valine O 0 1.5064686067489674e-06
( O 0 4.788581975390116e-08
A464V O 0 8.922796951083e-06
) O 0 9.924337263100824e-08
. O 0 5.728121550419019e-07

The O 0 1.510927813797025e-05
fathers O 0 1.7133092114818282e-05
genotype O 0 7.69106100051431e-06
thus O 0 9.420954256711411e-07
was O 0 3.3909871035575634e-06
7delG O 0 7.589454617118463e-05
/ O 0 6.748803571099415e-05
A464V O 0 0.00010308234777767211
. O 0 4.0424697544949595e-06

Mutation O 0 1.2127664376748726e-05
A464V O 0 3.8220143323997036e-05
was O 0 4.2779416276061966e-07
not O 0 3.74718922557804e-09
found O 0 6.431876364842992e-09
in O 0 2.0943629053249424e-09
18 O 0 8.291304709473479e-08
unrelated O 0 9.655656322138384e-05
MLD B-Disease 1 1.0
patients O 1 0.9973438382148743
and O 0 4.613156363575399e-07
50 O 0 4.200707053314545e-07
controls O 0 3.078788267885102e-06
. O 0 1.1746320751626627e-06

A464V O 0 0.00013984020915813744
, O 0 3.4649119129426253e-07
although O 0 1.9437396758803516e-07
clearly O 0 5.823256401527033e-07
modifying O 0 8.22057427285472e-06
ARSA O 1 1.0
and O 0 8.624044312455226e-06
GS O 1 1.0
levels O 0 2.7051030428992817e-06
, O 0 1.3558800304735996e-08
apparently O 0 8.078686164481041e-08
bears O 0 4.6571081213642174e-08
little O 0 8.880146395995325e-09
significance O 0 1.5825319721329834e-08
for O 0 1.7028803922514157e-09
clinical O 0 4.2021378021672717e-07
manifestation O 0 0.0813167467713356
of O 0 0.013474252074956894
MLD B-Disease 1 1.0
, O 0 4.2321036630710296e-07
mimicking O 0 8.008937584236264e-07
the O 0 9.707466830377598e-08
frequent O 0 1.8785219708661316e-06
ARSA O 1 0.985066294670105
pseudodeficiency O 0 0.0001746047637425363
allele O 0 4.556200565275503e-06
. O 0 1.372163183077646e-06

Our O 0 1.157126735051861e-05
results O 0 5.393047217694402e-07
demonstrate O 0 2.613757033032016e-07
that O 0 4.7341450759574855e-09
in O 0 2.1890786960909736e-09
certain O 0 1.0514565218500138e-08
genetic O 0 3.148820439946576e-07
conditions O 0 9.383936230733525e-06
MLD B-Disease 1 1.0
- O 1 0.9999996423721313
like O 0 4.3398547859396785e-05
ARSA O 1 1.0
and O 0 1.5867650290601887e-05
GS O 1 1.0
values O 0 8.216901647983832e-08
need O 0 4.816444576505319e-09
not O 0 1.6238640987431552e-10
be O 0 1.093086315906433e-10
paralleled O 0 3.0606541745470395e-09
by O 0 7.369493210118705e-11
clinical O 0 2.0565782676840172e-07
disease O 0 2.1393310817074962e-05
, O 0 9.100651343629806e-10
a O 0 1.2532948012733414e-09
finding O 0 7.205915864005874e-09
with O 0 1.0449523468736288e-09
serious O 0 2.3731534781745722e-07
diagnostic O 0 0.016080623492598534
and O 0 1.8502256580177345e-06
prognostic O 1 0.9999992847442627
implications O 0 0.0008085222798399627
. O 0 9.687297279015183e-06

Moreover O 0 1.2640075510716997e-05
, O 0 4.256243357758649e-07
further O 0 8.375312745556585e-07
ARSA O 1 0.9833260774612427
alleles O 0 6.543410790982307e-07
functionally O 0 9.300883903051727e-07
similar O 0 3.8084809972360745e-08
to O 0 2.8780622329804828e-08
A464V O 0 7.84707663115114e-06
might O 0 3.7804145591735505e-08
exist O 0 6.419742515362259e-09
which O 0 1.2000241911280796e-09
, O 0 5.179464079851925e-10
together O 0 2.980528879259481e-10
with O 0 7.351709241376625e-10
0 O 0 6.365328886204225e-08
- O 0 9.821783208963097e-08
type O 0 1.532740583343184e-07
mutations O 0 4.792858376845288e-08
, O 0 3.1085498619631835e-09
may O 0 7.502265475523018e-08
cause O 0 0.09377038478851318
pathological O 1 0.9999998807907104
ARSA O 1 1.0
and O 0 2.497478135410347e-06
GS O 1 1.0
levels O 0 1.3229806938852562e-07
, O 0 4.811189779907465e-10
but O 0 9.517116261736902e-11
not O 0 9.721832366915706e-11
clinical O 0 2.3849599628533724e-08
outbreak O 0 1.0354931845313331e-07
of O 0 8.047973665270547e-08
the O 0 1.4055872554763482e-07
disease O 0 0.0031312662176787853
. O 0 6.051025280839895e-08
. O 0 3.038103670860437e-07

Human O 1 0.971578061580658
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.9990328550338745
to O 0 4.450104825082235e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 0.00011585016181925312
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.8340721130371094
1 I-Disease 0 0.0009494671830907464
. O 0 5.97131293034181e-06

Heterozygous O 0 7.84362418926321e-05
germ O 1 0.9510319828987122
- O 0 0.0001096818596124649
line O 0 2.6510367661103373e-06
mutations O 0 4.537397657600195e-08
in O 0 5.812755610179465e-09
the O 0 1.2716874664420175e-08
DNA O 0 2.7411667815613328e-06
mismatch O 0 0.017437361180782318
repair O 0 0.009952145628631115
genes O 0 1.1498498508899502e-07
lead O 0 1.5409511888719862e-07
to O 0 9.911890685998515e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.42634379863739014

The O 0 1.1773555343097541e-05
disease O 0 0.3968023955821991
susceptibility O 0 0.00016533701273147017
of O 0 1.2431328286766075e-06
individuals O 0 4.532674680035598e-08
who O 0 1.0169704864892992e-06
constitutionally O 0 6.946896064619068e-06
lack O 0 1.2508863619586919e-05
both O 0 7.053777295595864e-08
wild O 0 2.1484703438545694e-07
- O 0 2.8285120023952004e-08
type O 0 3.403458848083574e-08
alleles O 0 9.11399666847501e-09
is O 0 6.682469688712445e-09
unknown O 0 1.8394410972177866e-07
. O 0 2.650940587045625e-07

We O 0 6.279577746681753e-07
have O 0 1.9688393138039828e-08
identified O 0 2.4108096852160088e-08
three O 0 2.7574864613910677e-09
offspring O 0 4.25929655989421e-08
in O 0 3.756807309684973e-09
a O 0 6.761436566193879e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9772344827651978
who O 0 2.301651136349392e-07
developed O 0 6.8491162892314605e-06
hematological B-Disease 1 0.9999998807907104
malignancy I-Disease 1 1.0
at O 0 1.033337048284011e-05
a O 0 1.7721218270594363e-08
very O 0 3.645391766227135e-09
early O 0 7.599812335001843e-08
age O 0 7.238425414612948e-09
, O 0 1.011717376542265e-09
and O 0 1.5548731191472598e-09
at O 0 3.6174785389420094e-09
least O 0 1.3737046222761506e-10
two O 0 1.0323404631140676e-10
of O 0 6.440687427833325e-10
them O 0 6.260151286241467e-10
displayed O 0 1.3190659231554491e-08
signs O 0 3.6191782015748686e-08
of O 0 2.5290580651926575e-07
neurofibromatosis B-Disease 1 0.9999839067459106
type I-Disease 0 0.0007947534904815257
1 I-Disease 0 5.229433736531064e-05
( O 0 4.99907855555648e-07
NF1 B-Disease 0 0.299823135137558
) O 0 3.309345686375309e-07
. O 0 7.992106816345768e-07

DNA O 0 2.832934114849195e-06
sequence O 0 6.766597238083705e-08
analysis O 0 1.6185472517804556e-08
and O 0 4.119903529442581e-09
allele O 0 1.7565678689379638e-08
- O 0 1.1227655249967938e-08
specific O 0 4.149785848284182e-09
amplification O 0 4.871930059380247e-07
in O 0 6.143570097094653e-09
two O 0 1.2594371767704615e-08
siblings O 0 8.858798992150696e-07
revealed O 0 2.755490982053743e-07
a O 0 2.5095346245507244e-07
homozygous O 0 1.2618363598448923e-06
MLH1 O 0 0.000869482581038028
mutation O 0 3.3069008509301057e-07
( O 0 5.085639287472077e-08
C676T O 0 8.327181603817735e-06
- O 0 5.891780801903224e-06
- O 0 5.099751433590427e-06
> O 0 8.436280040768906e-06
Arg226Stop O 0 4.58753238490317e-05
) O 0 1.0674344963490512e-07
. O 0 3.5244269724898913e-07

Thus O 0 4.226129021844827e-06
, O 0 2.1865474764126702e-07
a O 0 2.1775038305804628e-07
homozygous O 0 2.938329998869449e-06
germ O 1 0.9999997615814209
- O 0 0.14792269468307495
line O 0 0.0004995714989490807
MLH1 O 1 0.9999996423721313
mutation O 0 7.856532988625986e-07
and O 0 8.448419919204753e-08
consequent O 0 0.4074692726135254
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 1.247877605692338e-07
in O 0 1.3846438662312721e-08
a O 0 2.594578774051115e-08
mutator O 0 0.0124514764174819
phenotype O 0 2.3841170104788034e-07
characterized O 0 2.060140502635477e-08
by O 0 1.4311110074771705e-09
leukemia B-Disease 1 1.0
and O 0 0.01072363369166851
/ O 1 1.0
or O 1 0.9999992847442627
lymphoma B-Disease 1 1.0
associated O 0 3.1528088584309444e-05
with O 0 1.092081234332909e-07
neurofibromatosis B-Disease 1 0.9999773502349854
type I-Disease 0 7.179074600571766e-05
1 I-Disease 0 4.103721494175261e-06
. O 0 1.2431537754764577e-07
. O 0 5.66080359476473e-07

Missense O 0 0.00019179652736056596
mutations O 0 1.3847728723703767e-06
in O 0 6.358048665333627e-08
the O 0 3.612116472595517e-08
most O 0 4.0671941370362674e-09
ancient O 0 5.397457769618086e-08
residues O 0 4.549443133328168e-08
of O 0 2.435285395563369e-08
the O 0 5.940420777506006e-08
PAX6 O 1 0.9997780919075012
paired O 0 1.6437930980828241e-06
domain O 0 3.2690692819414835e-07
underlie O 0 7.926312264316948e-07
a O 0 5.5898620843208846e-08
spectrum O 0 9.682624295237474e-06
of O 0 1.899359062917938e-06
human O 1 0.9999470710754395
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9937830567359924

Mutations O 0 2.6148993583774427e-06
of O 0 5.213008762439131e-07
the O 0 2.4260091890937474e-07
human O 0 1.2796813280147035e-06
PAX6 O 1 0.9999998807907104
gene O 0 0.00010105590627063066
underlie O 1 0.999998927116394
aniridia B-Disease 1 1.0
( O 1 0.9949609041213989
congenital B-Disease 1 1.0
absence I-Disease 1 0.9986559152603149
of I-Disease 1 0.9398307800292969
the I-Disease 0 4.062756852363236e-05
iris I-Disease 0 6.008144191582687e-05
) O 0 1.0821033846752925e-08
, O 0 2.5991588881169037e-09
a O 0 6.132977148354257e-08
rare O 0 0.0003599947667680681
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 0.9999997615814209
the I-Disease 1 0.9999979734420776
eye I-Disease 1 1.0
. O 0 0.00013060167839284986

The O 0 3.5680914152180776e-06
spectrum O 0 2.597040293039754e-05
of O 0 1.8487281749912654e-06
PAX6 O 1 0.9999966621398926
mutations O 0 7.387696769001195e-06
in O 0 4.806205424756627e-07
aniridia B-Disease 1 1.0
patients O 0 0.0007674094522371888
is O 0 1.1621525963789736e-08
highly O 0 1.6341532571573225e-08
biased O 0 1.292388862594862e-08
, O 0 4.0149647495546503e-10
with O 0 1.2888329292692902e-10
92 O 0 5.4972403518149804e-08
% O 0 1.4611418741594662e-09
of O 0 9.034744508085168e-09
all O 0 1.4460815878081235e-09
reported O 0 9.757510355257182e-09
mutations O 0 4.776556483676586e-09
leading O 0 1.73524252744528e-08
to O 0 7.281791281066319e-10
premature O 0 1.2156434081589396e-07
truncation O 0 5.155045528226765e-06
of O 0 2.5507321765871893e-07
the O 0 3.0790765492838545e-08
protein O 0 1.5844589640323647e-08
( O 0 7.530817081047303e-10
nonsense O 0 3.620310451424302e-08
, O 0 8.29585289352508e-10
splicing O 0 2.570584989314284e-08
, O 0 1.4470639131403118e-09
insertions O 0 1.2120278114480243e-08
and O 0 3.4532183779134584e-09
deletions O 0 2.9067937390436782e-08
) O 0 2.054441949894681e-09
and O 0 4.75815253864198e-09
just O 0 1.972052743326458e-08
2 O 0 3.7947472719679354e-08
% O 0 9.657594723933016e-10
leading O 0 4.304654854792034e-09
to O 0 8.053919337003279e-11
substitution O 0 5.381111112257031e-09
of O 0 5.677486036859136e-09
one O 0 1.6601495733681304e-09
amino O 0 1.1168699298735874e-09
acid O 0 1.2256593517889769e-09
by O 0 1.4673355586136694e-10
another O 0 4.711552481495573e-09
( O 0 1.5660262420169602e-08
missense O 0 8.201234322768869e-07
) O 0 5.118834067729949e-08
. O 0 2.904203881826106e-07

The O 0 9.273090881833923e-07
extraordinary O 0 3.649057020993496e-07
conservation O 0 2.6835684252546343e-07
of O 0 4.185535473766322e-08
the O 0 4.51888872987638e-08
PAX6 O 1 0.815625011920929
protein O 0 1.34657028638685e-07
at O 0 5.424619420324461e-09
the O 0 6.133076269065896e-10
amino O 0 4.254268493042446e-09
acid O 0 1.6771968702755657e-08
level O 0 1.630283641418373e-08
amongst O 0 1.3575652246800018e-07
vertebrates O 0 4.912970439363562e-07
predicts O 0 2.7111459743878186e-08
that O 0 7.960000991680261e-10
pathological O 0 2.872014590593608e-07
missense O 0 2.324541839016092e-07
mutations O 0 5.740872222048665e-09
should O 0 1.4448574559011718e-09
in O 0 3.55190932221916e-10
fact O 0 1.1448789694057382e-09
be O 0 3.891385547127868e-10
common O 0 5.444998674164481e-09
even O 0 2.9192377404285708e-09
though O 0 1.3888010741425205e-09
they O 0 3.172944129659072e-10
are O 0 3.83430814876462e-10
hardly O 0 1.5838824651837058e-07
ever O 0 5.7753830162710074e-08
seen O 0 1.0124982452452969e-07
in O 0 7.613565600195216e-08
aniridia B-Disease 1 1.0
patients O 0 0.0007657645619474351
. O 0 3.907319751306204e-06

This O 0 9.963637381815715e-08
indicates O 0 1.0188056620563657e-07
that O 0 1.1752053774571891e-09
there O 0 1.9157322395102483e-09
is O 0 8.517662686280403e-10
a O 0 4.50316717248711e-09
heavy O 0 2.300065261806594e-06
ascertainment O 0 0.03570638969540596
bias O 0 7.281367402356409e-07
in O 0 2.469655369097268e-09
the O 0 1.0709944042730513e-09
selection O 0 3.6664644653683354e-09
of O 0 3.9225738213133354e-09
patients O 0 1.796406756682245e-08
for O 0 2.047783276282189e-09
PAX6 O 0 3.952904080506414e-05
mutation O 0 3.6090430644009075e-09
analysis O 0 9.181130855573372e-10
and O 0 4.706987577485222e-10
that O 0 3.951075300268059e-10
the O 0 1.2913367264388853e-08
missing O 0 4.677753622672753e-06
PAX6 O 1 0.9999994039535522
missense O 0 0.00012383116700220853
mutations O 0 7.09804453435936e-07
frequently O 0 6.638061478270174e-08
may O 0 8.193801193101535e-08
underlie O 0 2.0225075786584057e-05
phenotypes O 0 1.2964489542355295e-05
distinct O 0 4.69856075824282e-07
from O 0 2.1673479011496966e-07
textbook O 0 5.5336582590825856e-05
aniridia B-Disease 1 0.9999891519546509
. O 0 4.62328262074152e-06

Here O 0 3.6854291920462856e-06
we O 0 5.668097102784486e-08
present O 0 5.885979703634803e-08
four O 0 3.480788635101817e-08
novel O 0 7.226763614198717e-07
PAX6 O 0 0.11770512163639069
missense O 0 4.404824721859768e-06
mutations O 0 6.58936869513127e-08
, O 0 4.6346158022458894e-09
two O 0 2.2518142905880723e-09
in O 0 3.028460371368169e-09
association O 0 6.973963184719878e-09
with O 0 2.760823125669276e-09
atypical O 0 0.0011259553721174598
phenotypes O 1 0.9955251812934875
ectopia B-Disease 1 0.9999957084655762
pupillae I-Disease 1 0.8237165212631226
( O 0 3.065153819648003e-08
displaced B-Disease 0 1.6642655253917837e-08
pupils I-Disease 0 1.9560156161446685e-08
) O 0 1.140355099238377e-08
and O 0 1.8833334536338953e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999749660491943
( O 0 9.650428864915739e-07
searching B-Disease 0 1.3314145235199248e-06
gaze I-Disease 0 1.3074183016215102e-06
) O 0 1.7233872107169645e-09
, O 0 8.356070835269236e-10
and O 0 2.2658770415517893e-09
two O 0 3.7216467685396992e-09
in O 0 3.6772009881502754e-09
association O 0 5.633163713270051e-09
with O 0 8.736266710052121e-10
more O 0 7.988127492808417e-09
recognizable O 0 4.7860950871836394e-05
aniridia B-Disease 1 1.0
phenotypes O 0 0.00015005558088887483
. O 0 4.1373036765435245e-06

Strikingly O 0 9.545540524413809e-05
, O 0 3.0310829401969386e-07
all O 0 1.2652856540285029e-08
four O 0 7.65639107669358e-09
mutations O 0 4.48308767886374e-09
are O 0 3.6147454474111385e-10
located O 0 6.484028425290944e-09
within O 0 2.0941321565715043e-08
the O 0 7.87881972996729e-08
PAX6 O 1 0.9893785119056702
paired O 0 2.2054102544188936e-07
domain O 0 1.6322935891821544e-08
and O 0 5.858052376517264e-10
affect O 0 1.1461024351788751e-09
amino O 0 2.003133658945444e-09
acids O 0 8.982522503586665e-10
which O 0 1.023525639243239e-10
are O 0 7.065185936294682e-11
highly O 0 5.991452667331032e-09
conserved O 0 1.115529180140129e-08
in O 0 1.1551664069742174e-09
all O 0 6.978710387350873e-10
known O 0 2.0352540985868472e-08
paired O 0 4.6909850226484195e-08
domain O 0 6.623908888059304e-08
proteins O 0 1.909750046991121e-08
. O 0 5.964830762650308e-08

Our O 0 5.2798404794884846e-06
results O 0 1.284625739117473e-07
support O 0 5.1706059878142696e-08
the O 0 2.006729538095442e-08
hypothesis O 0 5.841812367179955e-08
that O 0 3.490364941516333e-10
the O 0 1.77869041717571e-09
under O 0 1.7983333933102585e-08
- O 0 2.183508840403192e-08
representation O 0 2.3676629545832384e-09
of O 0 7.0194703383208434e-09
missense O 0 4.82354380437755e-07
mutations O 0 8.484362545857493e-09
is O 0 4.879848192196334e-10
caused O 0 8.386620287126334e-09
by O 0 5.497259092379636e-09
ascertainment O 0 0.1355857104063034
bias O 0 1.2461251799322781e-06
and O 0 7.762142928413596e-09
suggest O 0 3.4748630639569456e-09
that O 0 2.024303363823421e-10
a O 0 9.475860096586075e-10
substantial O 0 1.6793160639849702e-08
burden O 0 6.86344151290541e-07
of O 0 7.193544888650649e-07
PAX6 B-Disease 1 1.0
- I-Disease 0 0.022064806893467903
related I-Disease 0 1.4268634004110936e-05
disease I-Disease 1 0.9974300265312195
remains O 0 2.4451185254292795e-06
to O 0 3.6504015366034537e-09
be O 0 7.503722088131326e-09
uncovered O 0 1.0942596873064758e-06
. O 0 5.5963162992611615e-08
. O 0 2.8479198022068886e-07

The O 0 1.1777100326071377e-06
chromosomal O 0 2.184376626246376e-06
order O 0 3.242324169150379e-07
of O 0 5.906334763494669e-07
genes O 0 2.975653501380293e-07
controlling O 0 6.313107974165177e-07
the O 0 9.999790506753925e-08
major O 0 1.0291594662703574e-05
histocompatibility O 1 0.9999998807907104
complex O 0 3.646350887720473e-05
, O 0 6.432121946176039e-09
properdin O 0 4.623334461939521e-07
factor O 0 1.0708335551612436e-08
B O 0 3.427648493925517e-07
, O 0 2.4933397568815963e-09
and O 0 5.5117679309546475e-09
deficiency B-Disease 0 0.2446087747812271
of I-Disease 0 3.6414658097783104e-05
the I-Disease 0 2.2295041617326206e-06
second I-Disease 0 1.5403047655127011e-06
component I-Disease 0 9.85021301858069e-07
of I-Disease 0 1.834011129631108e-07
complement I-Disease 0 1.707211936263775e-06
. O 0 3.042548087250907e-06

The O 0 8.58851819884876e-07
relationship O 0 3.8854381045894115e-07
of O 0 2.744918390362727e-07
the O 0 5.8237894506874e-08
genes O 0 3.110218216306748e-08
coding O 0 1.9626251912541193e-07
for O 0 7.257239698077456e-09
HLA O 0 9.228653539139486e-07
to O 0 4.05907218947732e-09
those O 0 4.339741010994658e-09
coding O 0 1.2162905704826699e-07
for O 0 3.743803045352934e-09
properdin O 0 1.681834305600205e-06
Factor O 0 3.4105941182360766e-08
B O 0 4.3547925088205375e-07
allotypes O 0 6.05465061198629e-07
and O 0 2.0501360609159747e-09
for O 0 1.3742530446947399e-09
deficiency B-Disease 0 1.4070777979213744e-05
of I-Disease 0 2.645303709414293e-07
the I-Disease 0 7.468158003121061e-08
second I-Disease 0 8.311317856168898e-08
component I-Disease 0 5.993889828914689e-08
of I-Disease 0 1.638204061293891e-08
complement I-Disease 0 1.0012367823719615e-07
( O 0 1.9263884709630474e-08
C2 O 0 1.7987540559261106e-06
) O 0 2.9270044166196385e-09
was O 0 1.8282459990359712e-08
studied O 0 3.69720898341086e-09
in O 0 1.25906854386848e-10
families O 0 4.5791506697590023e-10
of O 0 1.8606983731572768e-09
patients O 0 5.1214218643735876e-08
with O 0 5.287511584128879e-08
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 9.087741636903957e-05

Patients O 0 7.869246474001557e-05
were O 0 3.6911870893163723e-07
selected O 0 9.569151160349065e-08
because O 0 1.6899225130373452e-08
they O 0 2.9521509681273983e-09
were O 0 9.808150736034804e-09
heterozygous O 0 2.4658348252160067e-08
or O 0 6.606745817094861e-09
homozygous O 0 2.9471013363036036e-07
for O 0 5.385035137805971e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.9105805879225954e-05

12 O 0 4.515672117122449e-06
families O 0 5.7242232287535444e-08
with O 0 5.578633111014142e-09
15 O 0 9.747896712042348e-08
matings O 0 4.992536105419276e-06
informative O 0 4.798941404260404e-07
for O 0 3.75083828885181e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 6.016741167513828e-07
found O 0 1.4049078345124144e-07
. O 0 2.153477680622018e-07

Of O 0 1.2282655006856658e-05
57 O 0 9.333670277555939e-06
informative O 0 1.1886370430147508e-06
meioses O 0 1.3269791452330537e-05
, O 0 2.946414490168081e-08
two O 0 3.719049734840496e-09
crossovers O 0 1.8615439856262128e-08
were O 0 4.6853667612367644e-09
noted O 0 8.039822141370223e-09
between O 0 2.103459451063827e-08
the O 0 1.7431229935027659e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 4.177525880777466e-09
and O 0 7.051672579194701e-10
the O 0 2.149081579361223e-09
HLA O 0 1.3242872398677719e-07
- O 0 3.045091290232449e-08
B O 0 5.901278754549821e-08
gene O 0 1.3755774297408152e-09
, O 0 1.246789754771882e-10
with O 0 8.916661853319852e-11
a O 0 2.1107084968718937e-09
recombinant O 0 3.901422118701703e-08
fraction O 0 4.175337053879957e-08
of O 0 1.7352201098219666e-07
0 O 0 9.647143315305584e-07
. O 0 4.7468873276557133e-07

035 O 1 0.7516870498657227
. O 0 0.00025657477090135217

A O 0 2.3726703147985972e-05
lod O 0 0.0003206771216355264
score O 0 2.1146845483599463e-06
of O 0 5.518113539437763e-07
13 O 0 3.778310428970144e-07
was O 0 1.2348471045697806e-07
calculated O 0 2.7652196976646337e-08
for O 0 1.475616606683161e-08
linkage O 0 9.467045856581535e-06
between O 0 6.443177881010342e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 3.895704594469862e-07
HLA O 0 3.4982381293957587e-06
- O 0 2.0947840084772906e-07
B O 0 1.5099710992672044e-07
at O 0 2.3229753676190512e-09
a O 0 2.671973475809608e-10
maximum O 0 1.0908977055024138e-09
likelihood O 0 1.949939321121974e-09
value O 0 6.505977423465481e-10
of O 0 2.2910127128739077e-09
the O 0 3.849243590536844e-09
recombinant O 0 3.388871050447051e-08
fraction O 0 1.6341999753421987e-08
of O 0 3.787314284409149e-08
0 O 0 2.1104163749896543e-07
. O 0 3.5431915534900327e-07

04 O 0 0.03994251415133476
. O 0 0.00031871095416136086

18 O 0 3.4655370200198377e-06
families O 0 1.354262622044189e-07
with O 0 1.7509917071834025e-08
21 O 0 1.56828363628847e-07
informative O 0 9.571378001282937e-08
matings O 0 3.243449668843823e-07
for O 0 7.55530749074751e-09
both O 0 1.5857045454481522e-08
properdin O 0 1.1492547855596058e-05
Factor O 0 3.946734352666681e-07
B O 0 2.0863476493104827e-06
allotype O 0 4.147361778450431e-06
and O 0 5.2572225683888973e-08
HLA O 0 2.614774302855949e-06
- O 0 5.946666874478979e-07
B O 0 1.5479135981877334e-06
were O 0 2.8057939971404267e-08
found O 0 4.215781146399422e-08
. O 0 7.883795660745818e-08

Of O 0 3.435965845710598e-05
72 O 0 4.2682782805059105e-05
informative O 0 2.8589404337253654e-06
meioses O 0 3.450459553278051e-05
, O 0 4.757338345484641e-08
three O 0 3.8248892053616146e-08
recombinants O 0 6.491495696536731e-06
were O 0 1.625408962979691e-08
found O 0 3.7371394867591334e-09
, O 0 7.683216840526086e-10
giving O 0 2.4256141539780174e-09
a O 0 4.249621543550575e-09
recombinant O 0 6.007555697351563e-08
fraction O 0 3.544414539646823e-08
of O 0 2.1161037011552253e-07
0 O 0 1.5272033806468244e-06
. O 0 7.388827043541824e-07

042 O 0 0.034189872443675995
. O 0 0.00034783969749696553

A O 0 2.010944990615826e-05
lod O 0 0.00023059795785229653
score O 0 1.937086608450045e-06
of O 0 4.2429988411640807e-07
16 O 0 4.189920446151518e-07
between O 0 8.399366890898818e-08
HLA O 0 3.6241908674128354e-06
- O 0 2.532721907755331e-07
B O 0 2.7807942615254433e-07
and O 0 2.14805306875121e-09
Factor O 0 1.3088882866441054e-08
B O 0 1.3896529083012865e-07
allotypes O 0 5.162801244296134e-07
was O 0 1.9745781898450332e-08
calculated O 0 1.565278906490164e-09
at O 0 1.7934206342218317e-09
a O 0 4.977148138074483e-10
maximum O 0 1.7406647234707862e-09
likelihood O 0 4.480642523674305e-09
value O 0 1.5742941394947252e-09
of O 0 3.89788734622698e-09
the O 0 3.459533992611341e-09
recombinant O 0 2.3081899058752242e-08
fraction O 0 6.362498528034166e-09
of O 0 2.6011342413312377e-08
0 O 0 2.0943943468409998e-07
. O 0 1.7654309658610146e-07

04 O 0 0.02565188705921173
. O 0 0.0002055602235486731

A O 0 1.970813718799036e-05
crossover O 0 6.6943830461241305e-06
was O 0 4.723477502466267e-07
shown O 0 6.922199258241335e-09
to O 0 1.848712960494936e-09
have O 0 7.851958527815839e-10
occurred O 0 1.3168989454470648e-08
between O 0 1.968140095343074e-09
genes O 0 8.702954468198243e-10
for O 0 5.995668406200139e-10
Factor O 0 9.346747376071107e-09
B O 0 7.384488753814367e-08
and O 0 9.005719725507788e-09
HLA O 0 9.15295061076904e-07
- O 0 5.528922883968335e-07
D O 0 2.4411976937699364e-06
, O 0 5.928600721460953e-09
in O 0 1.9420778318846033e-09
which O 0 1.440240593453268e-09
HLA O 0 3.413099989302282e-07
- O 0 1.377897405063777e-07
D O 0 6.042906193215458e-07
segregared O 0 3.594138604512409e-07
with O 0 1.6943918490497367e-09
HLA O 0 1.2319504776314716e-06
- O 0 1.0473996781001915e-07
A O 0 1.4515917712287774e-07
and O 0 6.135807950613525e-08
B O 0 1.1825803994724993e-05
. O 0 8.302475293930911e-07

These O 0 1.195319470070899e-07
studies O 0 2.975215629419381e-08
suggest O 0 6.658969819994809e-09
that O 0 2.1530929816826472e-10
the O 0 7.861669093500723e-10
genes O 0 8.877838464371735e-10
for O 0 5.512165168752858e-10
Factor O 0 8.810724949626092e-08
B O 1 0.9168612957000732
and O 0 0.03368246927857399
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.266416997467104e-09
located O 0 7.1938037748964234e-09
outside O 0 1.0042157105871752e-09
those O 0 5.574139066988337e-11
for O 0 3.4701919116031377e-10
HLA O 0 1.6026673677060899e-07
, O 0 5.454496299073242e-10
that O 0 2.778751950760494e-10
the O 0 3.4414746608035784e-09
order O 0 9.299641057225472e-09
of O 0 1.0604517086676424e-07
genese O 0 2.446508915454615e-06
is O 0 9.368915421248403e-09
HLA O 0 8.646558313785135e-08
- O 0 1.7087996795339677e-08
A O 0 2.2201625426987448e-08
, O 0 2.2524326848127885e-09
- O 0 8.047585708936822e-09
B O 0 7.840906590672603e-08
, O 0 3.830976869068081e-09
- O 0 6.891691839427949e-08
D O 0 4.205060122330906e-07
, O 0 2.9654581013005554e-09
Factor O 0 2.672863175234852e-08
B O 0 3.481337898847414e-06
allotype O 0 0.001946189091540873
, O 0 1.1865416809087037e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.231624828321401e-09
that O 0 5.552452386758944e-10
the O 0 4.165646494413977e-09
genes O 0 1.4937029391148826e-08
coding O 0 4.560959609989368e-07
for O 0 5.364133670582305e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.3889626870877692e-07
Factor O 0 8.73229382136742e-08
B O 0 8.604422987446014e-07
allotypes O 0 1.0320973160560243e-06
are O 0 8.366436987650161e-10
approximately O 0 9.790651622765267e-10
3 O 0 1.6965140403613077e-08
- O 0 4.562408051356215e-08
- O 0 1.1298595126163491e-07
5 O 0 1.0350213131005148e-07
centimorgans O 0 9.294056440012355e-07
from O 0 1.1271684918767733e-08
the O 0 1.2006796445973578e-08
HLA O 0 5.165707079868298e-07
- O 0 2.7812999903176205e-08
A O 0 1.318396858351889e-08
and O 0 8.422399666585534e-09
HLA O 0 4.184003046248108e-07
- O 0 4.1134907036166624e-08
B O 0 6.325136325813219e-08
loci O 0 3.0489659685883908e-09
, O 0 1.2345462152563158e-10
and O 0 8.324696487704841e-11
that O 0 6.106087857560283e-11
the O 0 1.4240858492442499e-09
apparent O 0 2.5179778617712145e-07
lack O 0 2.204318860776766e-07
of O 0 4.7799677105331284e-08
recombinants O 0 3.6969365169170487e-07
between O 0 1.7170219690498811e-09
the O 0 1.5328123215141432e-09
Factor O 0 1.6695240745434603e-08
B O 0 6.198640676302603e-07
gene O 0 1.6016880977076653e-07
and O 0 4.518867626757128e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.1672558031250446e-07
suggests O 0 7.143623026450996e-09
that O 0 1.4616233223740949e-10
these O 0 2.5063456865481726e-10
two O 0 1.0811785911002403e-09
genes O 0 8.199426027033496e-09
lie O 0 6.759321991012257e-08
in O 0 5.153471427377099e-09
close O 0 1.5672101483232836e-07
proximity O 0 2.3594918729941128e-06
to O 0 2.2084847728365276e-08
one O 0 4.14671816884038e-08
another O 0 1.3042833302279178e-07
. O 0 6.101637950450822e-07

Distribution O 0 2.7970954761258326e-06
of O 0 4.7417702262464445e-06
emerin O 0 0.033306993544101715
and O 0 3.654754721083009e-07
lamins O 1 0.9599721431732178
in O 0 5.766984401134323e-08
the O 0 1.5160297550664836e-07
heart O 0 0.00035954787745140493
and O 0 2.9976355619965034e-08
implications O 0 6.864089527880424e-07
for O 0 5.4058443055282623e-08
Emery B-Disease 1 0.9439936280250549
- I-Disease 1 0.9999980926513672
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9096736311912537

Emerin O 0 0.0023382361978292465
is O 0 1.0410734603283345e-06
a O 0 4.048879986839893e-07
nuclear O 0 6.24044287178549e-06
membrane O 0 1.0278877482505777e-07
protein O 0 1.2573441843244382e-08
which O 0 5.884345788409462e-10
is O 0 1.087864132109928e-09
missing O 0 5.385888357523072e-08
or O 0 4.528587282948138e-08
defective O 0 4.879120024270378e-05
in O 0 2.767956459592824e-07
Emery B-Disease 1 0.9914348721504211
- I-Disease 1 0.9999946355819702
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999933242797852
EDMD B-Disease 1 1.0
) O 0 2.56016446655849e-05
. O 0 6.12539452049532e-06

It O 0 2.7317798867443344e-07
is O 0 1.697724627547359e-08
one O 0 5.468416386378294e-09
member O 0 4.7065049635364176e-09
of O 0 1.9050133914788603e-08
a O 0 1.4767597811271571e-08
family O 0 2.615457006527322e-08
of O 0 8.170017906650173e-08
lamina O 1 0.9999979734420776
- O 0 0.03574998676776886
associated O 0 5.322120841810829e-07
proteins O 0 4.807183984212315e-09
which O 0 9.377224552409302e-10
includes O 0 7.310700045337626e-09
LAP1 O 0 0.01578213833272457
, O 0 6.778972760912438e-08
LAP2 O 0 0.3822295367717743
and O 0 5.19760476436204e-07
lamin O 0 0.001270446926355362
B O 0 0.0002938630059361458
receptor O 0 2.648817826411687e-06
( O 0 1.8498961651403079e-07
LBR O 0 0.0006419976125471294
) O 0 4.7111464596127917e-07
. O 0 2.2695430743624456e-06

A O 0 1.9697406969498843e-05
panel O 0 3.1345275601779576e-06
of O 0 4.5701904127781745e-07
16 O 0 3.362005713825056e-07
monoclonal O 0 1.3906594631407643e-06
antibodies O 0 5.694450351256819e-07
( O 0 1.3092008543935663e-07
mAbs O 0 3.0860766855767e-05
) O 0 2.0089430563530186e-08
has O 0 4.685608345766923e-09
been O 0 2.435409651724285e-09
mapped O 0 1.140755401252136e-08
to O 0 8.655460237427803e-10
six O 0 2.5588822172295522e-09
specific O 0 1.4191291475285084e-09
sites O 0 8.23081158785044e-09
throughout O 0 3.5109855023307546e-09
the O 0 4.933955466412954e-09
emerin O 0 4.6333363457051746e-07
molecule O 0 7.376180111151598e-09
using O 0 5.056397078817554e-09
phage O 0 1.3101201545850927e-07
- O 0 8.142793461729525e-08
displayed O 0 3.4294526329858854e-08
peptide O 0 1.8195044049207354e-07
libraries O 0 2.5999241870522383e-08
and O 0 3.880025634117601e-09
has O 0 9.61816404299043e-10
been O 0 4.0942155221657117e-10
used O 0 8.255444106097798e-10
to O 0 2.7780326927739907e-09
localize O 0 2.6212060220132116e-06
emerin O 0 6.161439523566514e-05
in O 0 1.017554662752218e-08
human O 0 2.8758124770433824e-08
and O 0 1.8110924315806187e-07
rabbit O 0 0.0007076843758113682
heart O 0 0.0007419317844323814
. O 0 2.0880474949080963e-06

Several O 0 5.090208560432075e-06
mAbs O 0 9.588885586708784e-05
against O 0 8.077651614257775e-07
different O 0 1.260211348608209e-07
emerin O 0 0.00030286284163594246
epitopes O 0 1.5360346878878772e-05
did O 0 4.920012486309133e-08
not O 0 4.913876416878793e-09
recognize O 0 4.2193043725546886e-08
intercalated O 0 3.159276820952073e-05
discs O 0 1.7820955690694973e-05
in O 0 1.0944371631183003e-08
the O 0 3.872205667221351e-08
heart O 0 1.711625372990966e-05
, O 0 4.039609091677221e-09
though O 0 2.1346930889620808e-09
they O 0 4.591412527954475e-10
recognized O 0 5.5070814575231e-09
cardiomyocyte O 0 4.1400647887712694e-07
nuclei O 0 1.1133827371168081e-07
strongly O 0 5.1806850365210266e-08
, O 0 8.424536623863332e-09
both O 0 1.2665363868791246e-08
at O 0 2.377013146315221e-07
the O 0 7.29350304595755e-08
rim O 0 7.532313247793354e-06
and O 0 2.4700620215867275e-08
in O 0 3.7346687520312116e-08
intranuclear O 0 0.00014486777945421636
spots O 0 1.2092001497876481e-06
or O 0 1.5766876515499462e-07
channels O 0 2.6508168957661837e-06
. O 0 4.038556369323487e-07

A O 0 0.00010670863412087783
polyclonal O 0 0.00336006423458457
rabbit O 0 0.0003750918840523809
antiserum O 0 0.00021514255786314607
against O 0 1.5225821698550135e-05
emerin O 1 0.9093762040138245
did O 0 3.4294239981136343e-07
recognize O 0 1.1147213996309802e-07
both O 0 3.7479914283267135e-08
nuclear O 0 1.0321630725229625e-05
membrane O 0 1.2296692375457496e-07
and O 0 4.856313129408818e-09
intercalated O 0 2.196579629298867e-07
discs O 0 1.0036325193141238e-07
but O 0 1.2800507320775978e-09
, O 0 6.433344967859966e-10
after O 0 2.9266640222402884e-09
affinity O 0 1.3075084126512593e-08
purification O 0 2.682004947018868e-07
against O 0 5.206628728160467e-08
a O 0 3.990477281945459e-08
pure O 0 2.3248130673891865e-06
- O 0 5.255458290776005e-07
emerin O 0 1.8359007754042977e-06
band O 0 8.668008177892261e-08
on O 0 4.9775303878618615e-09
a O 0 2.7708779715140963e-09
western O 0 4.7741089304054185e-08
blot O 0 1.4720429817316472e-06
, O 0 7.0966614806877715e-09
it O 0 1.6676583447505777e-09
stained O 0 9.547379704599734e-07
only O 0 5.57937784861906e-09
the O 0 2.37447039808103e-08
nuclear O 0 4.3912687033298425e-06
membrane O 0 5.03189596656739e-07
. O 0 1.8073913565785915e-07

These O 0 2.9387038580352964e-07
results O 0 7.28898328361538e-08
would O 0 1.3434514833932099e-08
not O 0 1.164941698661437e-09
be O 0 1.5106379480656074e-09
expected O 0 9.57539203483293e-09
if O 0 6.473327207601187e-09
immunostaining O 0 2.5794073735596612e-05
at O 0 1.1914158903891803e-07
intercalated O 0 3.495022440347384e-07
discs O 0 1.542359768791357e-07
were O 0 1.814553840517874e-09
due O 0 6.6973355750121755e-09
to O 0 1.5836151279202682e-09
a O 0 2.8382978189966934e-09
product O 0 9.208283024975117e-09
of O 0 1.7889050241137738e-08
the O 0 1.357629386689041e-08
emerin O 0 1.035036575558479e-06
gene O 0 2.1578880904371545e-09
and O 0 2.4591439995447217e-10
, O 0 2.90798857216501e-10
therefore O 0 3.1638627273622433e-09
, O 0 1.7381168726515739e-09
cast O 0 5.537447833603437e-09
some O 0 7.196599427494732e-10
doubt O 0 8.342762036761542e-09
upon O 0 2.734650283997553e-09
the O 0 2.086571804227333e-09
hypothesis O 0 2.8735753332398417e-08
that O 0 2.6627255955702367e-09
cardiac B-Disease 1 0.9999992847442627
defects I-Disease 1 0.9999997615814209
in O 0 4.356588760856539e-06
EDMD B-Disease 1 1.0
are O 0 1.9849018428885756e-08
caused O 0 5.8089458576660036e-08
by O 0 1.2541556682066357e-09
absence O 0 3.5679516940945177e-07
of O 0 9.820694231166271e-07
emerin O 0 0.062084268778562546
from O 0 6.776994041501894e-07
intercalated O 0 2.667341505002696e-05
discs O 0 4.596619328367524e-05
. O 0 3.062786618102109e-06

Although O 0 1.3330940419109538e-05
emerin O 0 0.0007173690828494728
was O 0 1.4811372466283501e-06
abundant O 0 5.717762974200014e-07
in O 0 1.0400374783614552e-08
the O 0 7.57091633829532e-09
membranes O 0 9.550170432248706e-08
of O 0 7.637797949655578e-08
cardiomyocyte O 0 7.331149390665814e-06
nuclei O 0 5.03820558606094e-07
, O 0 9.10558739519729e-09
it O 0 3.52530515890237e-09
was O 0 1.888102616476317e-07
absent O 0 1.451662541285259e-07
from O 0 6.312647737871657e-09
many O 0 6.06586025853062e-09
non O 0 3.759228945909854e-07
- O 0 4.202753189019859e-06
myocyte O 0 0.007934571243822575
cells O 0 1.293659579459927e-07
in O 0 5.804557279276423e-09
the O 0 5.8250556378425244e-08
heart O 0 7.836522127036005e-05
. O 0 1.7810152712627314e-06

This O 0 1.1378688924423841e-07
distribution O 0 1.5442185485881055e-07
of O 0 2.60570828913842e-07
emerin O 0 2.8545369787025265e-05
was O 0 7.46475450341677e-08
similar O 0 2.003003762851563e-09
to O 0 4.6300896450190976e-10
that O 0 3.508948409614021e-10
of O 0 3.136525705826898e-08
lamin O 0 1.919852729770355e-05
A O 0 2.8903249926770513e-07
, O 0 2.8549880237704883e-09
a O 0 2.6827242649574146e-09
candidate O 0 4.747581883179919e-09
gene O 0 2.063427206877577e-09
for O 0 7.209252639306385e-10
an O 0 8.115806360287081e-10
autosomal O 0 6.002562003004641e-08
form O 0 5.070510269433726e-07
of O 1 0.9898216724395752
EDMD B-Disease 1 1.0
. O 0 0.0011855383636429906

In O 0 1.5765929219924146e-06
contrast O 0 7.634397661604453e-06
, O 0 2.462207476128242e-06
lamin O 1 0.7824739217758179
B1 O 1 0.9999181032180786
was O 0 1.469473045290215e-05
absent O 0 1.9679623619595077e-06
from O 0 4.824574517670044e-08
cardiomyocyte O 0 7.408969395328313e-06
nuclei O 0 1.6487481389049208e-06
, O 0 3.1949614509585444e-08
showing O 0 4.606811998542071e-08
that O 0 2.879566629587771e-08
lamin O 1 0.9859108924865723
B1 O 1 0.9384782910346985
is O 0 7.962420056628616e-09
not O 0 4.790988716862898e-10
essential O 0 1.2687414674417141e-08
for O 0 3.008092441803001e-09
localization O 0 4.538186658464838e-06
of O 0 9.330612726898835e-08
emerin O 0 5.322295237419894e-06
to O 0 1.0321485888198367e-08
the O 0 7.930140100143035e-08
nuclear O 0 4.850986442761496e-05
lamina O 0 0.08468300104141235
. O 0 6.451934495999012e-06

Lamin O 1 0.9999761581420898
B1 O 1 0.9999892711639404
is O 0 1.4824513527855743e-06
also O 0 1.5800533503806946e-07
almost O 0 2.2317234282809295e-08
completely O 0 4.3794358361992636e-07
absent O 0 1.789811562957766e-06
from O 0 1.3624418215840706e-07
skeletal O 0 0.00010927533730864525
muscle O 0 2.1158559320610948e-05
nuclei O 0 0.005371948704123497
. O 0 2.3059401428326964e-05

In O 0 9.14536758500617e-06
EDMD B-Disease 1 1.0
, O 0 1.8788431077609857e-07
the O 0 2.0724209903733026e-08
additional O 0 1.7671332841473486e-08
absence O 0 3.615832326886448e-07
of O 0 3.402496304261149e-06
lamin O 1 0.9999996423721313
B1 O 1 0.9999998807907104
from O 0 2.007098601097823e-06
heart O 1 0.9991983771324158
and O 0 3.39748999067524e-06
skeletal O 1 0.9999994039535522
muscle O 0 0.25137442350387573
nuclei O 1 0.7144943475723267
which O 0 5.790604404865007e-07
already O 0 2.0182916671274143e-07
lack O 0 9.506917194812559e-06
emerin O 0 5.564853563555516e-05
may O 0 7.414560965202099e-09
offer O 0 4.7370622979769905e-09
an O 0 2.428482970273649e-10
alternative O 0 4.7101154088124986e-09
explanation O 0 4.875162051831694e-09
of O 0 2.3556674388913734e-09
why O 0 1.7915368077936478e-09
these O 0 2.523889153227543e-10
tissues O 0 2.147206146219105e-08
are O 0 2.855711223048729e-10
particularly O 0 1.4216386290399896e-08
affected O 0 7.952023040047607e-09
. O 0 3.2378430603330344e-08
. O 0 2.8800891982427856e-07

Genetic O 0 1.2600562513398472e-05
mapping O 0 2.4016594579734374e-06
of O 0 5.069678650215792e-07
the O 0 1.2995097904422437e-06
copper B-Disease 1 0.9676074385643005
toxicosis I-Disease 1 1.0
locus O 0 5.723833601223305e-05
in O 0 1.313811139880272e-07
Bedlington O 0 0.0006144298240542412
terriers O 0 1.8003975128522143e-05
to O 0 4.94718861432375e-08
dog O 0 1.5751758155602147e-06
chromosome O 0 5.545229697645482e-08
10 O 0 3.562836781156875e-08
, O 0 9.041657200725695e-09
in O 0 7.924150224880577e-09
a O 0 1.4264304581956821e-07
region O 0 1.4519894193654181e-06
syntenic O 0 0.0006007656338624656
to O 0 2.6266002706165636e-08
human O 0 6.673467112250364e-08
chromosome O 0 1.4189167529821134e-07
region O 0 1.780686318397784e-07
2p13 O 0 6.651572039118037e-05
- O 0 1.713985693641007e-05
p16 O 0 5.52491383132292e-06
. O 0 7.447559369211376e-07

Abnormal O 1 0.8620297312736511
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9844948649406433
accumulation I-Disease 0 0.00011331462155794725
is O 0 5.1973422898754507e-08
recognized O 0 2.824366340803408e-08
as O 0 1.740692212592876e-08
an O 0 1.4899980804727875e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 8.127778528432827e-06
man O 0 2.661959661054425e-05
, O 0 2.8122714823552997e-08
mouse O 0 5.770984444097849e-06
, O 0 9.813581414164219e-08
rat O 0 0.29149800539016724
and O 0 1.1260788141953526e-06
dog O 0 0.046619661152362823
. O 0 1.7136524547822773e-05

The O 0 3.117900178040145e-06
major O 0 6.704190127493348e-06
cause O 0 1.9913382857339457e-05
of O 0 0.00010660956468200311
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999977350234985
accumulation I-Disease 0 0.11211804300546646
in O 0 4.810149221157189e-07
man O 0 2.7062383196607698e-06
is O 0 1.2690076545140982e-08
a O 0 5.9172162281129204e-08
dysfunctional O 0 6.790497536712792e-06
ATP7B O 1 0.9950311183929443
gene O 0 2.1855176157714595e-07
, O 0 7.331045104308487e-09
causing O 0 1.577552438902785e-06
Wilson B-Disease 0 0.04019340127706528
disease I-Disease 1 0.9999988079071045
( O 0 1.9411256289458834e-05
WD B-Disease 1 1.0
) O 0 2.3753368623147253e-06
. O 0 2.0278703232179396e-06

Mutations O 0 6.3067082010093145e-06
in O 0 4.025497730708594e-07
the O 0 3.8987190009720507e-07
ATP7B O 1 0.9995530247688293
genes O 0 1.192693588336624e-07
have O 0 4.8040678102267975e-09
also O 0 3.0989242283396834e-09
been O 0 6.348146008861022e-09
demonstrated O 0 7.64839569455944e-08
in O 0 2.3303078577896486e-08
mouse O 0 7.666354576940648e-06
and O 0 2.0907285147586663e-07
rat O 0 0.00019513885490596294
. O 0 8.517034757460351e-07

The O 0 1.589754901942797e-05
ATP7B O 1 0.8050553202629089
gene O 0 1.1098669574494124e-06
has O 0 3.511576451842302e-08
been O 0 9.965799740996317e-09
excluded O 0 2.5235786793587067e-08
in O 0 1.7684708142340355e-09
the O 0 7.743510721525126e-09
much O 0 4.1644010906338735e-08
rarer O 1 0.5519627332687378
human O 0 9.03476211533416e-06
copper B-Disease 1 0.9998103976249695
overload I-Disease 1 0.9999861717224121
disease O 1 0.999007523059845
non B-Disease 0 8.40897064335877e-06
- I-Disease 0 1.233612806572637e-06
Indian I-Disease 0 2.6118087248505617e-07
childhood I-Disease 0 3.918095171684399e-05
cirrhosis I-Disease 1 0.9999998807907104
, O 0 4.9821682779338516e-08
indicating O 0 8.68655035901611e-07
genetic O 0 6.519954240502557e-06
heterogeneity O 0 4.9676571507006884e-05
. O 0 3.1118199785851175e-06

By O 0 1.4274293391736137e-07
investigating O 0 2.4668983655828924e-07
the O 0 5.382899814776465e-08
common O 0 4.020735104859341e-06
autosomal O 0 0.42854344844818115
recessive O 1 0.9800845384597778
copper B-Disease 1 0.9999997615814209
toxicosis I-Disease 1 1.0
( O 0 2.6461984816705808e-05
CT B-Disease 1 0.999962329864502
) O 0 1.6325590479482344e-07
in O 0 6.82932679296755e-08
Bedlington O 0 0.14318744838237762
terriers O 0 7.135135092539713e-05
, O 0 8.922999228389017e-09
we O 0 2.931161091623835e-09
have O 0 6.271600461182913e-10
identified O 0 2.811390453771878e-09
a O 0 5.164915606314935e-09
new O 0 1.0466742139669805e-08
locus O 0 5.37139257517083e-08
involved O 0 3.444061924540165e-09
in O 0 1.287031103913705e-08
progressive O 1 0.9999641180038452
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.4811804147902876e-05

We O 0 7.841098295102711e-07
examined O 0 6.441037498916558e-07
whether O 0 2.653995778700846e-08
the O 0 1.0138432315898172e-07
WD B-Disease 0 0.1413843035697937
gene O 0 8.325579869961075e-07
ATP7B O 1 0.5720906853675842
was O 0 6.844779250059219e-07
also O 0 1.3539521503957985e-08
causative O 0 1.5388556562356825e-07
for O 0 1.1759795803811812e-08
CT B-Disease 0 8.494334906572476e-06
by O 0 4.18225365450553e-09
investigating O 0 2.0195772165720882e-08
the O 0 3.387727076642477e-08
chromosomal O 0 1.1099060657215887e-06
co O 0 2.598105675133411e-05
- O 0 6.31796592642786e-06
localization O 0 0.0737304836511612
of O 0 1.521075319033116e-06
ATP7B O 1 0.9674627184867859
and O 0 5.0937643436554936e-08
C04107 O 0 2.9913704224782123e-07
, O 0 1.5015688692443518e-09
using O 0 4.2761687524262015e-09
fluorescence O 0 1.676166334618756e-07
in O 0 1.513975966815906e-08
situ O 0 2.463736791469273e-06
hybridization O 0 6.258544544834876e-07
( O 0 4.750655335783449e-08
FISH O 0 1.8911315464720246e-06
) O 0 6.599771040782798e-08
. O 0 3.1824208690522937e-07

C04107 O 0 0.0001552096800878644
is O 0 1.5502712358284043e-07
an O 0 1.589532061530008e-08
anonymous O 0 2.2162494417443668e-07
microsatellite O 0 1.4540052688971628e-05
marker O 0 7.660337359993719e-07
closely O 0 9.846355197851153e-08
linked O 0 2.8582423965417547e-06
to O 0 1.2926226418130682e-06
CT B-Disease 1 1.0
. O 0 0.0005691202240996063

However O 0 1.5005444765847642e-05
, O 0 5.625593075819779e-06
BAC O 1 0.9994379878044128
clones O 0 0.002199804177507758
containing O 0 1.365383241136442e-06
ATP7B O 1 0.9890663623809814
and O 0 2.484274830294453e-07
C04107 O 0 5.053130735177547e-06
mapped O 0 3.8370305333046417e-07
to O 0 1.7325536560974797e-08
the O 0 9.697399860897349e-08
canine O 0 1.9487564713926986e-05
chromosome O 0 2.6074235393025447e-07
regions O 0 4.744343584661692e-08
CFA22q11 O 0 0.00017324551299680024
and O 0 7.757957121157233e-08
CFA10q26 O 0 0.00024401287373621017
, O 0 1.6563674876124423e-08
respectively O 0 4.2094015384464e-08
, O 0 1.2385806158476953e-08
demonstrating O 0 3.9081701430632165e-08
that O 0 1.3351595384847315e-08
WD B-Disease 0 0.050491705536842346
cannot O 0 8.060954570510148e-08
be O 0 8.497318404465659e-09
homologous O 0 4.3420197215482403e-08
to O 0 2.54331293803034e-08
CT B-Disease 0 0.0005633168620988727
. O 0 3.209399210390984e-06

The O 0 1.0676136298570782e-05
copper O 0 6.502395262941718e-05
transport O 0 9.189237061946187e-06
genes O 0 2.325762352484162e-06
CTR1 O 1 0.9815733432769775
and O 0 5.967567631159909e-07
CTR2 O 1 0.999984622001648
were O 0 2.624525166083913e-07
also O 0 1.0285836182788444e-08
excluded O 0 1.0997920796285143e-08
as O 0 2.5839741457645005e-09
candidate O 0 4.6882631110634065e-09
genes O 0 1.588264408880491e-09
for O 0 1.3451122438112861e-09
CT B-Disease 0 0.0013886449160054326
since O 0 5.5168090540291814e-08
they O 0 2.649017893929795e-09
both O 0 9.5955030587902e-09
mapped O 0 8.560505904142701e-08
to O 0 1.543774708068213e-08
canine O 0 1.3443146599456668e-05
chromosome O 0 1.747987198541523e-06
region O 0 2.450008651067037e-06
CFA11q22 O 0 0.03900022432208061
. O 0 3.751872327484307e-06

2 O 0 0.0005761233041994274
- O 0 0.00015609960246365517
22 O 0 1.6761750885052606e-05
. O 0 3.5500274861988146e-06

5 O 0 0.00023892181343398988
. O 0 5.0661572458921e-05

A O 0 8.65279434947297e-06
transcribed O 0 6.68984284857288e-07
sequence O 0 2.938400278651443e-08
identified O 0 2.9310450955222223e-08
from O 0 9.556671010102491e-09
the O 0 4.129346464765149e-08
C04107 O 0 5.305591457727132e-06
- O 0 6.024239382895757e-07
containing O 0 7.090792308872551e-08
BAC O 0 0.0015522099565714598
was O 0 9.815845913863086e-08
found O 0 9.392152611198412e-10
to O 0 3.3477512428881084e-10
be O 0 4.847038326261099e-10
homologous O 0 2.7678090930294275e-09
to O 0 8.293067899067808e-10
a O 0 5.209308095999177e-09
gene O 0 5.764221100434952e-09
expressed O 0 5.309014117216293e-09
from O 0 1.9865076694713935e-08
human O 0 2.9036684168204374e-08
chromosome O 0 7.720493044871546e-08
2p13 O 0 9.874402167042717e-07
- O 0 1.291403748382436e-07
p16 O 0 2.802493703768505e-08
, O 0 8.693614161892071e-10
a O 0 2.6572968270244246e-09
region O 0 1.2206627708621909e-08
devoid O 0 5.454803044813161e-07
of O 0 1.5845193601649044e-08
any O 0 1.681322281399389e-08
positional O 0 3.7998104289727053e-06
candidate O 0 6.040981475052831e-07
genes O 0 2.5854600949060114e-07
. O 0 3.2866313404156244e-07

Molecular O 0 2.6512034310144372e-06
analysis O 0 2.967163368339243e-07
of O 0 2.020679801262304e-07
the O 0 9.62646780067189e-08
APC B-Disease 0 9.6232713531208e-07
gene O 0 3.1720457371875455e-08
in O 0 2.9040656546186483e-09
205 O 0 2.7228891141817257e-08
families O 0 5.259045199323964e-09
: O 0 3.913486423812174e-09
extended O 0 1.8836368553820648e-07
genotype O 0 6.775941983505618e-06
- O 0 1.217621047544526e-06
phenotype O 0 2.0820256452225294e-07
correlations O 0 9.777857457038408e-08
in O 0 2.8130693330297163e-09
FAP B-Disease 0 3.073570269407355e-07
and O 0 1.3131260523380206e-09
evidence O 0 4.882410920004077e-09
for O 0 1.3259667808185327e-09
the O 0 2.4469894999157304e-09
role O 0 5.722812002062483e-09
of O 0 1.617109290918961e-08
APC B-Disease 0 6.708153676981965e-08
amino O 0 9.167835379741973e-09
acid O 0 1.1427676582798085e-08
changes O 0 1.3913523666531091e-08
in O 0 1.3680318033948424e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 5.822793173138052e-05

BACKGROUND O 0 0.00013784405018668622
/ O 0 5.9389840316725895e-05
AIMS O 0 8.805112088339229e-07
The O 0 2.5427890903984007e-08
development O 0 2.671365280093596e-07
of O 0 0.001782280975021422
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.533876835604133e-08
a O 0 9.0915258654789e-10
variable O 0 6.400079910484635e-10
range O 0 8.978758181399371e-09
of O 0 3.084242905515566e-08
extracolonic O 0 6.056534402887337e-05
manifestations O 0 0.00044085245463065803
in O 0 2.112749371008249e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.4342755321195e-06
FAP B-Disease 0 8.198661089409143e-05
) O 0 3.297397466184293e-09
is O 0 3.8406614000230377e-10
the O 0 7.115334432761244e-10
result O 0 1.4427178340881142e-09
of O 0 1.515637393367797e-08
the O 0 3.4825081485223564e-08
dominant O 0 1.4208139873517212e-06
inheritance O 0 8.624246561339532e-07
of O 0 1.0613587164698401e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 3.6292613003752194e-06
APC B-Disease 0 2.431159737170674e-05
) O 0 1.4345202714594052e-07
gene O 0 7.624377076353994e-07
mutations O 0 8.248163112511975e-07
. O 0 1.3060985111224e-06

In O 0 2.3237130619691015e-07
this O 0 4.5670116577412045e-09
study O 0 1.992091824831732e-09
, O 0 4.017669252842637e-10
direct O 0 1.8885368824328452e-09
mutation O 0 1.110539771254082e-09
analysis O 0 3.86634413374054e-09
of O 0 9.503267506261182e-09
the O 0 3.03254239497619e-08
APC B-Disease 0 3.6788236457141466e-07
gene O 0 2.7668129121138918e-08
was O 0 5.023600735398759e-08
performed O 0 6.6938614651235184e-09
to O 0 7.914342514681039e-10
determine O 0 1.01961017406893e-08
genotype O 0 1.0042671192422858e-06
- O 0 2.2768111307414074e-07
phenotype O 0 7.972498394792638e-08
correlations O 0 2.7183434170297005e-08
for O 0 2.4469335446752893e-09
nine O 0 4.510312479055756e-08
extracolonic O 0 2.2543308659805916e-06
manifestations O 0 1.2750339237754815e-06
and O 0 1.1440937086604208e-08
to O 0 2.2995583215390525e-09
investigate O 0 5.474406705729962e-09
the O 0 5.5860862602230554e-09
incidence O 0 2.61417596902902e-07
of O 0 8.23133277094712e-08
APC B-Disease 0 8.205200288102787e-07
mutations O 0 3.187006569760342e-08
in O 0 1.1428854307382608e-08
non O 0 1.3060327546554618e-05
- O 1 0.9977832436561584
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.825528882676736e-05

METHODS O 0 3.97720214095898e-05
The O 0 3.160232608934166e-06
APC B-Disease 0 3.445773700150312e-06
gene O 0 1.3021158906667551e-07
was O 0 6.048717438034146e-08
analysed O 0 7.23864914675687e-08
in O 0 4.213929649665715e-09
190 O 0 2.9019853187151057e-08
unrelated O 0 2.625238550990616e-07
FAP B-Disease 0 1.0839710739674047e-05
and O 0 4.739242953633038e-08
15 O 0 3.135318138447474e-07
non O 0 0.0003018811985384673
- O 1 0.9999969005584717
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.010184107348322868
using O 0 2.5674299308775517e-07
denaturing O 0 3.520972313708626e-05
gradient O 0 1.1693878150254022e-06
gel O 0 9.254559074634017e-08
electrophoresis O 0 3.765547162970506e-08
, O 0 2.049338476695084e-09
the O 0 2.811497701316057e-09
protein O 0 1.1617138362396418e-08
truncation O 0 7.139730229255292e-08
test O 0 4.8510364614173795e-09
, O 0 6.985195200037708e-10
and O 0 1.59241397845733e-09
direct O 0 5.998693097808427e-08
sequencing O 0 1.2977424148630234e-06
. O 0 3.4336093790443556e-07

RESULTS O 0 2.8993246814934537e-05
Chain O 0 4.0405866457149386e-05
terminating O 0 4.368795998743735e-06
signals O 0 1.4881952665746212e-06
were O 0 1.9709171183990293e-08
only O 0 1.3923286967809645e-09
identified O 0 4.329571812178301e-09
in O 0 1.0919302129153152e-09
patients O 0 1.33817295022709e-08
belonging O 0 2.9855332428496695e-08
to O 0 9.834957737098193e-09
the O 0 1.8086484487866983e-07
FAP B-Disease 0 0.0008744006045162678
group O 0 9.954689517144288e-08
( O 0 1.472349797637662e-08
105 O 0 9.30492944917205e-07
patients O 0 1.211336439155275e-06
) O 0 1.8799168799432664e-07
. O 0 1.1679678664222592e-06

Amino O 0 7.244214543788985e-07
acid O 0 5.406834446830544e-08
changes O 0 3.473120457897494e-09
were O 0 1.8852401861835233e-09
identified O 0 2.6544095810265844e-09
in O 0 3.400626169547394e-10
four O 0 7.365548171378578e-10
patients O 0 5.4196549470475475e-09
, O 0 8.162285292101501e-10
three O 0 1.6790525636523057e-09
of O 0 4.840040901399334e-08
whom O 0 2.9065287776575133e-07
belonged O 0 2.636486669871374e-06
to O 0 1.3615425231705558e-08
the O 0 1.4168033146688686e-07
non O 0 2.750386784100556e-06
- O 0 5.280459845380392e-06
FAP O 0 1.0748383829195518e-05
group O 0 5.544563563830707e-08
of O 0 0.0001463790686102584
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9999783039093018
. O 0 8.970526323537342e-06

Genotype O 0 0.002387948567047715
- O 0 0.00010248164471704513
phenotype O 0 2.1357709556468762e-06
correlations O 0 3.338483622883359e-07
identified O 0 3.6327197250329846e-08
significant O 0 3.582571395099876e-08
differences O 0 1.7467860402575752e-07
in O 0 1.2693901041416211e-08
the O 0 1.3695619749398702e-08
nature O 0 1.4460216135603332e-08
of O 0 1.0482345658147096e-08
certain O 0 1.0676907358231347e-08
extracolonic O 0 8.780543794273399e-06
manifestations O 0 6.775767815270228e-06
in O 0 3.1015098045372724e-08
FAP B-Disease 0 2.164692705264315e-05
patients O 0 1.1618406148272697e-07
belonging O 0 3.0658554805995664e-08
to O 0 1.2785021041850086e-08
three O 0 3.344129595461709e-08
mutation O 0 2.7648093237075955e-07
subgroups O 0 2.5686351818876574e-06
. O 0 8.417824233220017e-07

CONCLUSIONS O 0 3.0326636988320388e-05
Extended O 0 9.09683876670897e-06
genotype O 0 3.4195560147054493e-05
- O 0 1.867167952696036e-06
phenotype O 0 1.7692805442948156e-07
correlations O 0 5.640316302901738e-08
made O 0 1.147262196354859e-08
in O 0 8.088977820897014e-10
this O 0 2.1526454230258452e-10
study O 0 1.8965071735266292e-09
may O 0 1.6477610387255481e-09
have O 0 4.1557560170879526e-10
the O 0 1.5908384609630843e-09
potential O 0 1.301283614196791e-08
to O 0 7.325841600014371e-10
determine O 0 1.9934298656210103e-09
the O 0 1.83364756711768e-09
most O 0 6.101084082388297e-10
appropriate O 0 4.3298520324697165e-09
surveillance O 0 4.387549878970276e-08
and O 0 1.5648877749185885e-09
prophylactic O 0 3.6042547435499728e-06
treatment O 0 0.002927709836512804
regimens O 0 0.00048443631385453045
for O 0 5.15959897029461e-09
those O 0 2.4525967923239023e-09
patients O 0 4.027998823374901e-09
with O 0 1.2718608111139673e-10
mutations O 0 1.6070906827536646e-09
associated O 0 5.2588244869866685e-09
with O 0 3.390615122000895e-09
life O 0 4.43601038568886e-07
threatening O 0 4.1124344534182455e-06
conditions O 0 0.00020586916070897132
. O 0 3.765414248846355e-06

This O 0 8.835361597903102e-08
study O 0 4.432483180494273e-08
also O 0 2.109179275677775e-09
provided O 0 3.199692288902156e-09
evidence O 0 4.916070217575452e-09
for O 0 2.7381574785323437e-09
the O 0 9.32497012939848e-09
pathological O 0 1.7849210962594952e-06
nature O 0 1.7210821212643168e-08
of O 0 6.147239162146434e-09
amino O 0 6.69880417802915e-09
acid O 0 2.858060899058046e-09
changes O 0 3.8379371902763637e-10
in O 0 4.831614552891494e-10
APC O 0 1.684573902593911e-08
associated O 0 2.7964053295193025e-09
with O 0 9.77740222118939e-10
both O 0 5.456871843279032e-09
FAP B-Disease 0 4.613399141817354e-06
and O 0 7.792942113837853e-08
non O 0 0.0006637150072492659
- O 1 0.9999986886978149
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.06095533445477486
. O 0 1.193001963883944e-07
. O 0 3.0604283551838307e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9999953508377075
cancer B-Disease 1 1.0
risk O 0 0.01727294921875
of O 0 2.6907488063443452e-05
the O 0 5.572776899498422e-06
APC O 0 0.00011420120426919311
I1307K O 0 7.116231427062303e-05
polymorphism O 0 1.7400074284523726e-05
. O 0 1.8795577716446132e-06

Germ O 1 0.9999953508377075
- O 0 0.0011876272037625313
line O 0 7.177001862146426e-06
and O 0 1.9112441407287406e-08
somatic O 0 5.699138796444458e-07
truncating O 0 5.961254032627039e-07
mutations O 0 1.4183560992364619e-08
of O 0 2.1689393392421152e-08
the O 0 4.423496946515115e-08
APC B-Disease 0 4.580304278078984e-07
gene O 0 9.135020739847732e-09
are O 0 4.6182707658104505e-10
thought O 0 3.467276021851262e-09
to O 0 2.639797713754888e-09
initiate O 0 1.7698133660815074e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9829978942871094
formation O 0 1.0023495633504353e-05
in O 0 1.3616017895401455e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.003276995150372386
sporadic O 1 0.999998927116394
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.1114345397800207e-05
respectively O 0 8.930066542234272e-06
. O 0 1.0831940016942099e-05

Recently O 0 1.6552121451240964e-05
, O 0 1.9287530506062467e-07
an O 0 2.8711317767715627e-08
isoleucine O 0 1.34361353048007e-05
- O 0 1.1981733223365154e-05
- O 0 5.5661325859546196e-06
> O 0 3.2073919555841712e-06
lysine O 0 7.047846111163381e-07
polymorphism O 0 4.551447929657115e-08
at O 0 1.3090905248702711e-08
codon O 0 1.121678128157555e-08
1307 O 0 1.340750486633624e-06
( O 0 1.1241562347663603e-08
I1307K O 0 6.688733265036717e-07
) O 0 2.2885933148586446e-09
of O 0 1.151888717743077e-08
the O 0 2.475599103490822e-08
APC B-Disease 0 2.2215355954813276e-07
gene O 0 9.794298705401161e-09
has O 0 1.4040626439282278e-09
been O 0 1.2260078507964067e-09
identified O 0 2.6309761036458212e-09
in O 0 1.3328078640739704e-09
6 O 0 2.7199250851595025e-08
% O 0 5.127176017083457e-09
- O 0 3.9754276315306925e-08
7 O 0 3.4017713090861434e-08
% O 0 1.6152127413349149e-09
of O 0 6.155475240632313e-09
the O 0 1.8272803714580732e-08
Ashkenazi O 0 9.713428426039172e-07
Jewish O 0 8.591585043404848e-08
population O 0 3.4461251630091283e-09
. O 0 8.402812312624519e-08

To O 0 6.863631369924406e-07
assess O 0 6.385551500898146e-07
the O 0 7.808207413972923e-08
risk O 0 2.2528772092300642e-07
of O 0 2.5544265369603636e-08
this O 0 2.513863561759422e-09
common O 0 7.210633867771321e-08
APC B-Disease 0 6.299179631241714e-07
allelic O 0 6.665452474408085e-07
variant O 0 2.1448977349791676e-05
in O 0 3.075432175592141e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 3.88860769362509e-07
we O 0 1.0292783514387338e-08
have O 0 1.1387244480687286e-09
analyzed O 0 2.27610819081292e-09
a O 0 6.683830711118333e-10
large O 0 1.224019441359303e-09
cohort O 0 4.7045329409911574e-08
of O 0 4.57561952771357e-08
unselected O 0 4.350944436737336e-05
Ashkenazi O 0 7.677958819840569e-06
Jewish O 0 8.094047387885439e-08
subjects O 0 5.1165791603580146e-08
with O 0 4.850508883436078e-09
adenomatous B-Disease 0 0.0003790245100390166
polyps I-Disease 0 5.2912248065695167e-05
and O 0 2.2298342727822273e-08
. O 0 3.5538644027610644e-08
or O 1 0.9992833733558655
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.934118464916537e-07
for O 0 2.688324229893624e-08
the O 0 6.49914909445215e-07
APC O 0 2.41977959376527e-05
I1307K O 0 3.1534127629129216e-05
polymorphism O 0 7.117673703760374e-06
. O 0 7.407418252114439e-07

The O 0 7.845894288038835e-06
APC O 0 1.3448378012981266e-05
I1307K O 0 5.467883966048248e-06
allele O 0 2.1430619767670578e-07
was O 0 7.517277111901421e-08
identified O 0 7.387189970842201e-09
in O 0 1.5665303498835215e-09
48 O 0 2.0709826742404402e-08
( O 0 1.9450101529372432e-09
10 O 0 5.898237898094294e-09
. O 0 2.203329518835062e-09
1 O 0 1.8904552590015555e-08
% O 0 1.001358218566395e-09
) O 0 1.2820666750457121e-09
of O 0 2.1222268387077747e-08
476 O 0 5.250215508567635e-06
patients O 0 8.376052392122801e-06
. O 0 1.6809267435746733e-06

Compared O 0 4.50185979161688e-07
with O 0 4.434569600419991e-09
the O 0 8.565254283610102e-09
frequency O 0 3.843802076630709e-08
in O 0 8.561411579677269e-10
two O 0 2.7524513224186364e-10
separate O 0 3.246150570568318e-10
population O 0 2.966609249921426e-11
control O 0 1.638634450351617e-09
groups O 0 1.0662649929660262e-10
, O 0 5.632644906050643e-10
the O 0 6.198962676506881e-09
APC O 0 1.5859077961977164e-07
I1307K O 0 2.2464902826868638e-07
allele O 0 1.4915185753139326e-09
is O 0 1.3632484030523528e-10
associated O 0 4.920861496060525e-10
with O 0 1.192974191654983e-10
an O 0 1.0651368675951289e-10
estimated O 0 2.1929977278567492e-10
relative O 0 3.695843275863808e-08
risk O 0 2.188704684158438e-07
of O 0 8.713424222150934e-07
1 O 0 7.407697466987884e-06
. O 0 1.9657024949992774e-06

5 O 0 6.874359678477049e-05
- O 0 5.4397420171881095e-05
1 O 0 1.1327912943670526e-05
. O 0 4.833932962355902e-06

7 O 0 2.9029017241555266e-05
for O 0 2.101668314935523e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
( O 0 3.2296973131451523e-06
both O 0 4.4564100676325324e-07
P O 0 0.00027905096067115664
= O 0 1.078699028767005e-06
. O 0 1.9732228295765708e-08
01 O 0 6.885042580506706e-07
) O 0 4.566116729165515e-08
. O 0 2.5240896661671286e-07

Furthermore O 0 7.030056167423027e-06
, O 0 1.787197305702648e-07
compared O 0 5.828801263874084e-08
with O 0 2.290887124445362e-08
noncarriers O 0 0.00019693982903845608
, O 0 2.1691676010959782e-07
APC O 0 4.285215709387558e-06
I1307K O 0 4.112869646633044e-06
carriers O 0 3.6674947523351875e-08
had O 0 5.570732763970909e-09
increased O 0 1.0530695204735707e-09
numbers O 0 4.2900627494901755e-10
of O 0 2.5619945276389444e-08
adenomas B-Disease 1 0.9999995231628418
and O 0 0.00020522867271210998
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999980926513672
per O 0 4.50627126724612e-08
patient O 0 4.947000320498773e-07
( O 0 4.252800334114681e-09
P O 0 7.618852464474912e-07
= O 0 3.094254097391058e-08
. O 0 1.425458195924989e-09
03 O 0 4.6089656535741597e-08
) O 0 2.5219787369579194e-10
, O 0 3.171727602779839e-10
as O 0 1.0553518059452927e-09
well O 0 1.7757684211971991e-09
as O 0 1.4455134866864228e-09
a O 0 3.4795588632619e-09
younger O 0 4.459228364339651e-08
age O 0 1.6501616073583136e-08
at O 0 6.166370525306775e-08
diagnosis O 0 6.593356374651194e-06
. O 0 4.3895838075513893e-07

We O 0 1.233891794072406e-06
conclude O 0 1.1693008445945452e-06
that O 0 8.808150653294433e-09
the O 0 5.2135852968149266e-08
APC O 0 1.7582173086339026e-06
I1307K O 0 4.077257472090423e-06
variant O 0 9.17976831260603e-06
leads O 0 2.0817932977479359e-07
to O 0 9.934864486638162e-09
increased O 0 3.4814365790225565e-07
adenoma B-Disease 1 1.0
formation O 0 5.476530350279063e-05
and O 0 2.2637382812717988e-07
directly O 0 1.1554313950057349e-08
contributes O 0 1.0264351590905108e-09
to O 0 3.1050817472788594e-10
3 O 0 3.29601412829561e-09
% O 0 7.310208549604624e-10
- O 0 7.845226690506024e-09
4 O 0 5.640840239351519e-09
% O 0 3.131250536636543e-10
of O 0 1.1188164839026626e-09
all O 0 2.1502131186679208e-09
Ashkenazi O 0 6.78190917824395e-06
Jewish O 0 5.1626797358039767e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.5928677587216953e-06

The O 0 7.947444942146831e-07
estimated O 0 3.8260861146000025e-08
relative O 0 3.499855552036024e-07
risk O 0 2.86593490272935e-07
for O 0 5.872150765640072e-09
carriers O 0 2.9749884333796217e-08
may O 0 4.031157629924564e-09
justify O 0 2.594851089554595e-08
specific O 0 2.6640769590358104e-09
clinical O 0 3.606677623224641e-08
screening O 0 8.306020760073807e-09
for O 0 4.3496745094628864e-10
the O 0 2.287310119086783e-09
360 O 0 5.3709417358049905e-08
, O 0 1.7254263573462936e-09
000 O 0 3.1662170663082634e-09
Americans O 0 9.186315041986859e-10
expected O 0 1.4700536343781323e-09
to O 0 1.438028141009795e-09
harbor O 0 6.599166795240308e-07
this O 0 1.5602971692452172e-10
allele O 0 5.447031714567174e-10
, O 0 1.3264619957986667e-10
and O 0 2.8786686923076843e-10
genetic O 0 2.2754613748787733e-09
testing O 0 3.6097453914862854e-09
in O 0 5.662191271404993e-10
the O 0 9.062232630974165e-10
setting O 0 1.1072324390681842e-08
of O 0 1.3202414272939222e-08
long O 0 7.332614160304729e-08
- O 0 7.773584087544805e-08
term O 0 4.433527749370114e-07
- O 0 1.886820939489553e-07
outcome O 0 2.3490686729132904e-08
studies O 0 2.2147055300791862e-09
may O 0 5.495987553949533e-10
impact O 0 1.517840964027073e-09
significantly O 0 7.054477180190588e-08
on O 0 8.998115845315624e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 1 0.9999868869781494
in O 0 6.4903269425542476e-09
this O 0 5.186977514171076e-10
population O 0 1.0766472158252327e-09
. O 0 4.960151755994957e-08

Localization O 0 0.0017044969135895371
of O 0 4.903542048850795e-06
human O 0 1.4106809658187558e-06
BRCA1 O 0 1.1130849770779605e-06
and O 0 1.4936828662825974e-08
its O 0 1.1967539848001252e-08
loss O 0 1.1177887699886924e-06
in O 0 9.127256817009766e-08
high O 0 5.987827535136603e-05
- O 0 2.290469183208188e-06
grade O 0 9.016393960337155e-07
, O 0 8.085280001068895e-09
non B-Disease 0 6.226409254850296e-07
- I-Disease 0 0.0017904217820614576
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 4.2298568587284535e-05

Although O 0 2.217193241449422e-06
the O 0 4.25769684397892e-07
link O 0 1.4220854609447997e-06
between O 0 9.70537499256352e-08
the O 0 1.8725715733580728e-07
BRCA1 O 0 0.00011795034515671432
tumour B-Disease 1 1.0
- O 0 2.1450388885568827e-05
suppressor O 0 1.812791742850095e-05
gene O 0 2.8060346934921654e-08
and O 0 1.799211801767342e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 5.657350143906115e-08
established O 0 2.3650057912050215e-08
, O 0 6.589928602807049e-10
the O 0 2.0492916252834448e-09
role O 0 8.731007916651379e-09
, O 0 6.440551980624321e-10
if O 0 4.974775591470859e-10
any O 0 1.4236186673954876e-09
, O 0 2.1185899701237076e-09
of O 0 3.91447407821488e-08
BRCA1 O 0 2.487503820702841e-07
in O 0 4.712460643929717e-09
non B-Disease 0 5.03556748299161e-06
- I-Disease 0 0.03898671269416809
familial I-Disease 1 0.8480973243713379
cancers I-Disease 1 0.9999986886978149
is O 0 1.8429616943649307e-07
unclear O 0 8.151508836817811e-07
. O 0 4.823056656277913e-07

BRCA1 O 0 5.985292591503821e-05
mutations O 0 4.902429964204202e-07
are O 0 8.784058813660067e-09
rare O 0 1.855061952937831e-07
in O 0 1.5620615911871027e-08
sporadic B-Disease 0 5.7988105254480615e-05
cancers I-Disease 1 1.0
, O 0 5.13899607312851e-08
but O 0 7.448935246401334e-09
loss O 0 1.4537311017193133e-06
of O 0 2.864914904421312e-06
BRCA1 O 0 1.3625073052025982e-06
resulting O 0 5.129946956117237e-08
from O 0 1.1722978143779983e-08
reduced O 0 3.4281967487004295e-08
expression O 0 1.651830672244614e-08
or O 0 9.659994582023046e-09
incorrect O 0 1.0642753522915882e-07
subcellular O 0 8.184255761989334e-07
localization O 0 1.6915694232011447e-06
is O 0 1.7077137481891214e-09
postulated O 0 4.072272474786587e-08
to O 0 9.416438739862087e-10
be O 0 1.1360821172701208e-09
important O 0 1.2270026772398523e-08
in O 0 4.602374481521565e-09
non B-Disease 0 1.1574074960662983e-06
- I-Disease 0 4.6672568714711815e-05
familial I-Disease 1 0.9975481629371643
breast I-Disease 1 1.0
and I-Disease 1 0.9999885559082031
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00042122177546843886

Epigenetic O 0 0.0008497029193677008
loss O 0 5.0868329708464444e-05
, O 0 9.104964959760764e-08
however O 0 7.042928729106279e-08
, O 0 5.051635110220332e-09
has O 0 5.785609213937448e-10
not O 0 5.4742762406467804e-11
received O 0 4.927388497222296e-10
general O 0 5.081903342585292e-09
acceptance O 0 4.8253841811174425e-08
due O 0 3.959098293648822e-08
to O 0 4.462076041988894e-09
controversy O 0 2.810276811260337e-08
regarding O 0 1.5253178275997925e-08
the O 0 6.079180270290863e-09
subcellular O 0 1.1558146297829808e-06
localization O 0 3.611866077335435e-06
of O 0 2.4211594507050904e-08
BRCA1 O 0 3.0569101028277146e-08
proteins O 0 5.184950246928111e-10
, O 0 3.079085320045749e-10
reports O 0 8.914965987649737e-10
of O 0 1.1966192481338567e-08
which O 0 4.497561434391173e-09
have O 0 1.236998170561776e-09
ranged O 0 5.72792586694959e-08
from O 0 2.397949394605803e-09
exclusively O 0 2.7314703832104215e-09
nuclear O 0 1.1790524467869545e-07
, O 0 9.891711894027821e-10
to O 0 1.5094340222177038e-09
conditionally O 0 2.0380572607336944e-07
nuclear O 0 1.2539120461951825e-06
, O 0 4.905785555564535e-09
to O 0 4.359876459858469e-09
the O 0 1.2778662039636401e-07
ER O 1 0.9998563528060913
/ O 0 8.165955478034448e-06
golgi O 0 2.927418790932279e-05
, O 0 1.576266051017683e-08
to O 0 9.932136002532843e-09
cytoplasmic O 0 4.3961949813819956e-07
invaginations O 0 2.8701026622002246e-06
into O 0 6.09446075827691e-08
the O 0 1.1088813067772207e-07
nucleus O 0 2.136736839020159e-06
. O 0 1.4558329439751105e-06

In O 0 1.4292207879407215e-06
an O 0 7.530249490628194e-08
attempt O 0 5.294293714541709e-07
to O 0 5.020075732886653e-08
resolve O 0 5.877862463421479e-07
this O 0 6.043756162199543e-09
issue O 0 2.6385610141232974e-08
, O 0 4.3756300804886905e-09
we O 0 1.17613596639643e-09
have O 0 5.380902945439914e-10
comprehensively O 0 4.489490379455674e-08
characterized O 0 5.0139895790835e-08
19 O 0 1.948955343777925e-07
anti O 0 1.4088072930462658e-05
- O 0 4.2942407162627205e-05
BRCA1 O 0 2.1955190732114716e-06
antibodies O 0 7.50382469050237e-07
. O 0 1.0233195553155383e-06

These O 0 8.456841555926076e-07
reagents O 0 1.710556898615323e-05
detect O 0 2.783311629173113e-06
a O 0 4.788317369275319e-07
220 O 0 7.448923042829847e-07
- O 0 1.3515804084818228e-06
kD O 0 5.929196049692109e-06
protein O 0 9.580766402450536e-08
localized O 0 1.5931902908050688e-07
in O 0 4.103059225712968e-09
discrete O 0 9.126890887500849e-08
nuclear O 0 1.5648818134650355e-06
foci O 0 4.1218243040930247e-07
in O 0 2.0393913224836524e-09
all O 0 8.591182765194105e-10
epithelial O 0 4.606179686561518e-07
cell O 0 2.397763694261812e-07
lines O 0 4.16670342673342e-09
, O 0 1.8003015744838535e-10
including O 0 2.0147275514581509e-10
those O 0 3.643457480162482e-10
derived O 0 6.895925963590344e-08
from O 0 4.141486442676978e-07
breast B-Disease 1 0.9833752512931824
malignancies I-Disease 1 0.9887500405311584
. O 0 5.3156400099396706e-06

Immunohistochemical O 0 0.0015953599940985441
staining O 0 0.00013373742694966495
of O 0 7.635927431692835e-06
human O 0 4.4464140955824405e-06
breast O 0 0.0020573569927364588
specimens O 0 7.116236133697385e-07
also O 0 8.7361918588158e-08
revealed O 0 1.4643617305409862e-06
BRCA1 O 0 1.061030343407765e-05
nuclear O 0 0.0012028217315673828
foci O 0 0.006408886983990669
in O 0 2.2170929980802612e-07
benign O 1 0.9999996423721313
breast O 1 1.0
, O 0 1.3756191037828103e-05
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 2.0309636965976097e-05
low B-Disease 1 0.9999920129776001
- I-Disease 1 0.9998980760574341
grade I-Disease 1 0.999991774559021
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.3147830941306893e-05

Conversely O 0 8.705830259714276e-05
, O 0 1.8599737359181745e-06
BRCA1 O 0 4.480526513361838e-06
expression O 0 4.719785238194163e-07
was O 0 2.3311065433517797e-07
reduced O 0 1.1739887639805602e-07
or O 0 2.2719714110053246e-08
undetectable O 0 4.886275064563961e-07
in O 0 2.6319146861908393e-09
the O 0 2.130243315079383e-09
majority O 0 9.584998350575802e-10
of O 0 1.9030885312076862e-08
high O 0 1.4450422440859256e-06
- O 0 5.383648726819956e-07
grade O 0 1.3390497315413086e-06
, O 0 7.497902032582715e-08
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.962899887075764e-08
suggesting O 0 1.5792091190292012e-08
that O 0 7.193676765382406e-10
absence O 0 8.251341796494671e-07
of O 0 7.846007065381855e-06
BRCA1 O 0 5.970994152448839e-06
may O 0 1.3649722241382278e-08
contribute O 0 1.0120146942682595e-09
to O 0 1.4343191079291273e-09
the O 0 6.324796686385525e-09
pathogenesis O 1 0.8171091675758362
of O 0 2.573426058916084e-07
a O 0 1.1269965405347193e-08
significant O 0 1.918819592106047e-08
percentage O 0 9.809180134823237e-09
of O 0 1.4413955362613251e-08
sporadic B-Disease 0 0.00013259942352306098
breast I-Disease 1 1.0
cancers I-Disease 1 0.9999886751174927
. O 0 4.041815770960966e-07
. O 0 1.005552235255891e-06

